data_4bf8_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 4bf8 _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 18.2 p . . . . . 0 N--CA 1.443 -0.79 0 CA-C-O 121.543 0.687 . . . . 1.27 110.896 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 284' ' ' LYS . . . . . 0.403 ' O ' ' HA ' ' A' ' 291' ' ' ILE . 41.8 mtmt -131.55 159.21 38.85 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.519 -0.764 . . . . 2.51 110.414 -174.407 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . 0.502 HD12 ' HA2' ' A' ' 289' ' ' GLY . 42.3 tp -111.93 127.07 55.75 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.217 -0.447 . . . . 1.52 111.987 -170.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.423 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 99.2 mt -108.32 -161.83 0.79 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.839 -0.618 . . . . 1.39 110.309 173.653 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -51.99 140.48 20.15 Favored 'General case' 0 N--CA 1.447 -0.591 0 C-N-CA 123.263 0.625 . . . . 2.64 112.301 179.293 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.472 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 70.4 -102.94 1.08 Allowed Glycine 0 N--CA 1.446 -0.69 0 CA-C-N 115.482 -0.781 . . . . 1.84 111.595 -177.63 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . 0.502 ' HA2' HD12 ' A' ' 285' ' ' LEU . . . -145.92 28.2 1.73 Allowed Glycine 0 N--CA 1.442 -0.948 0 N-CA-C 110.603 -0.999 . . . . 1.16 110.603 176.08 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 290' ' ' ILE . . . . . 0.423 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 75.4 mt -71.14 120.9 19.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.803 0.335 . . . . 1.16 110.733 -177.73 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . 0.403 ' HA ' ' O ' ' A' ' 284' ' ' LYS . 92.1 mt -103.72 138.53 27.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.274 -0.421 . . . . 1.6 110.171 178.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 292' ' ' ILE . . . . . 0.416 HG23 HG12 ' A' ' 360' ' ' ILE . 24.9 pt -124.46 128.21 73.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-O 121.3 0.571 . . . . 1.17 109.864 178.038 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 293' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -114.59 110.78 20.31 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.282 -0.872 . . . . 2.31 109.117 179.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 20.7 m-20 -83.83 103.75 13.37 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.386 0.612 . . . . 2.36 109.851 -173.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 295' ' ' ARG . . . . . . . . . . . . . 10.5 mmm180 -76.8 -49.4 15.95 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 114.809 -1.087 . . . . 3.99 110.663 -173.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . . . . . . . . . 97.9 t -118.66 130.09 73.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 115.662 -0.699 . . . . 1.31 110.358 -176.025 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 1.6 m -63.03 107.25 0.97 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.156 -0.475 . . . . 2.46 110.554 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -118.01 116.25 3.39 Favored Glycine 0 N--CA 1.445 -0.759 0 C-N-CA 120.802 -0.713 . . . . 1.04 112.402 -177.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 13.1 tptm -121.9 113.13 19.19 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.575 -0.528 . . . . 5.01 109.575 175.296 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -170.79 -153.71 9.04 Favored Glycine 0 N--CA 1.436 -1.304 0 N-CA-C 111.042 -0.823 . . . . 1.59 111.042 -178.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . 0.403 ' HB2' ' SD ' ' A' ' 391' ' ' MET . 36.8 Cg_exo -60.75 132.7 44.0 Favored 'Trans proline' 0 N--CA 1.461 -0.397 0 C-N-CA 122.6 2.2 . . . . 1.1 111.756 177.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 302' ' ' HIS . . . . . 0.417 ' HA ' ' O ' ' A' ' 352' ' ' MET . 37.3 m80 -88.82 138.44 31.41 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.207 -0.451 . . . . 1.85 110.786 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -85.68 117.37 24.53 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.897 -0.592 . . . . 1.17 111.25 -179.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 21.9 pttp -116.87 -178.54 3.46 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.045 -0.724 . . . . 3.26 109.045 173.15 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 51.4 mttm -68.13 142.4 55.77 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 110.119 -0.326 . . . . 3.21 110.119 176.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 85.29 -7.86 73.79 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 121.085 -0.578 . . . . 0.7 112.225 -175.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 307' ' ' THR . . . . . 0.451 ' O ' ' HA ' ' A' ' 335' ' ' LYS . 87.0 m -89.25 135.47 33.56 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.758 0.314 . . . . 1.07 111.119 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 308' ' ' ARG . . . . . 0.416 HH21 ' C ' ' A' ' 392' ' ' LYS . 73.1 mtm180 -94.24 102.34 14.35 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.687 -0.688 . . . . 3.98 109.903 -177.643 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.795 ' HB ' HD12 ' A' ' 388' ' ' LEU . 34.1 m -103.43 141.54 19.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 CA-C-O 121.426 0.631 . . . . 1.1 111.75 -177.679 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -115.51 121.66 5.34 Favored Glycine 0 N--CA 1.445 -0.759 0 N-CA-C 110.325 -1.11 . . . . 0.32 110.325 177.462 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 13.9 ptp -135.77 177.67 7.65 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.513 0.673 . . . . 1.55 112.304 -173.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -136.65 143.47 43.49 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 106.938 -1.504 . . . . 3.0 106.938 174.157 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 313' ' ' TYR . . . . . 0.499 ' CB ' HG13 ' A' ' 386' ' ' VAL . 18.2 p90 -157.52 157.49 33.92 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 113.39 0.885 . . . . 1.24 113.39 -170.245 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 58.0 t -124.34 120.94 60.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 114.795 -1.093 . . . . 1.09 109.219 173.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -97.86 110.29 3.99 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 120.959 -0.639 . . . . 0.32 112.573 -176.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 316' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -116.15 154.63 29.67 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.177 0.513 . . . . 2.61 110.929 -178.49 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 317' ' ' LEU . . . . . 0.537 HD13 ' HD3' ' A' ' 321' ' ' LYS . 80.1 mt -86.92 170.39 11.66 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.795 -0.639 . . . . 1.32 110.134 171.13 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 318' ' ' LYS . . . . . 0.432 ' HB2' ' HB3' ' A' ' 381' ' ' GLU . 57.7 tttp -59.07 -25.44 63.77 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.14 -0.482 . . . . 2.9 111.298 179.493 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 28.1 p-10 -87.7 -3.04 58.98 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 120.555 0.216 . . . . 2.39 111.267 -178.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 95.52 3.75 61.07 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.775 -0.726 . . . . 0.69 112.7 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 321' ' ' LYS . . . . . 0.537 ' HD3' HD13 ' A' ' 317' ' ' LEU . 53.4 tttp -75.18 113.55 12.65 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.751 0.31 . . . . 2.86 110.259 179.431 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . . . . . . . . . 4.7 p -85.52 119.52 34.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-O 121.287 0.565 . . . . 1.96 110.431 179.222 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 52.2 p90 -110.14 -27.13 9.3 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.072 -0.513 . . . . 0.56 111.284 -177.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -130.88 156.61 44.76 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 108.952 -0.758 . . . . 1.68 108.952 178.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 59.6 pttt -174.44 135.81 0.44 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.099 0.476 . . . . 2.55 111.525 -176.012 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 6.0 p30 -150.35 118.56 6.36 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.68 -0.691 . . . . 1.92 109.316 166.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 29.7 m -140.63 -46.8 0.41 Allowed 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.642 -0.708 . . . . 2.06 110.94 -175.451 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 83.9 mttt -79.66 92.55 5.38 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.79 -0.641 . . . . 3.15 111.259 -173.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.455 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 65.78 7.92 38.05 Favored Glycine 0 CA--C 1.52 0.391 0 CA-C-N 115.853 -0.612 . . . . 1.17 113.742 174.418 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 68.9 mmtt -103.93 100.4 20.26 Favored Pre-proline 0 C--N 1.324 -0.52 0 CA-C-N 116.688 0.244 . . . . 2.56 111.39 -177.29 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 331' ' ' PRO . . . . . 0.455 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 94.1 Cg_endo -88.38 129.54 2.3 Favored 'Trans proline' 0 N--CA 1.453 -0.895 0 C-N-CA 122.839 2.359 . . . . 0.73 112.298 173.199 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -103.74 118.89 37.77 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.956 -0.757 . . . . 0.76 108.956 174.208 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 56.7 t -112.15 125.87 69.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.904 0.383 . . . . 1.14 110.172 -177.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.732 ' HB2' HE22 ' A' ' 338' ' ' GLN . 29.8 p90 -147.31 156.38 42.86 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.835 -0.62 . . . . 0.48 109.511 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 335' ' ' LYS . . . . . 0.451 ' HA ' ' O ' ' A' ' 307' ' ' THR . 0.2 OUTLIER -111.08 142.12 43.65 Favored 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 120.034 -0.667 . . . . 3.11 110.508 177.709 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 9.3 mp -69.84 148.17 49.41 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.851 -0.613 . . . . 1.2 109.91 178.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 103.38 -8.3 52.24 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.7 -0.762 . . . . 1.02 112.942 -178.162 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 338' ' ' GLN . . . . . 0.732 HE22 ' HB2' ' A' ' 334' ' ' PHE . 30.1 pt20 -83.91 160.82 21.02 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.832 0.316 . . . . 3.1 110.215 179.367 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -107.32 21.63 30.59 Favored Glycine 0 CA--C 1.52 0.354 0 C-N-CA 120.485 -0.864 . . . . 0.98 114.307 -172.481 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -114.93 9.56 16.16 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 117.574 0.687 . . . . 2.09 111.093 178.47 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 27.3 m -116.11 146.55 20.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 108.341 -0.985 . . . . 1.27 108.341 172.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 11.4 pt -68.88 151.98 9.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 N-CA-C 109.743 -0.466 . . . . 1.08 109.743 -178.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 343' ' ' LYS . . . . . 0.49 ' HA ' ' HE2' ' A' ' 343' ' ' LYS . 6.2 mmpt? -61.85 -30.38 70.81 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 111.894 0.331 . . . . 3.46 111.894 -172.778 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -54.86 -31.4 54.68 Favored Glycine 0 CA--C 1.521 0.457 0 C-N-CA 120.878 -0.677 . . . . 0.32 112.343 173.647 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 9.3 m95 -77.48 -60.8 2.22 Favored 'General case' 0 C--O 1.22 -0.452 0 CA-C-O 120.531 0.205 . . . . 0.44 111.055 176.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -51.14 -28.87 11.93 Favored 'General case' 0 N--CA 1.47 0.544 0 N-CA-C 112.327 0.491 . . . . 1.75 112.327 -179.336 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 63.6 mt -91.19 -51.17 12.08 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.533 0 N-CA-C 111.946 0.35 . . . . 1.18 111.946 177.523 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -63.95 -31.1 79.68 Favored Glycine 0 CA--C 1.524 0.606 0 C-N-CA 121.282 -0.485 . . . . 0.37 113.758 -178.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 349' ' ' VAL . . . . . 0.536 ' O ' ' HB2' ' A' ' 352' ' ' MET . 90.8 t -79.7 -19.87 12.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 121.024 0.44 . . . . 1.08 110.645 179.704 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -64.6 113.64 3.86 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.373 -0.376 . . . . 1.09 110.132 178.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 97.07 15.17 39.79 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 121.035 -0.603 . . . . 0.45 112.11 -176.634 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 352' ' ' MET . . . . . 0.828 ' HE3' ' HG2' ' A' ' 358' ' ' ARG . 0.0 OUTLIER -77.12 154.9 32.78 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 109.296 -0.631 . . . . 1.3 109.296 175.264 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 353' ' ' ALA . . . . . . . . . . . . . . . -129.95 134.92 47.77 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.729 0.299 . . . . 1.33 111.166 -177.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 61.4 t -59.85 123.39 12.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.017 -0.538 . . . . 1.24 110.681 177.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 109.47 -12.36 33.2 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 121.136 -0.554 . . . . 0.44 112.022 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -104.89 150.9 17.2 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.761 -0.733 . . . . 0.37 112.737 -179.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 357' ' ' GLU . . . . . 0.426 ' CB ' ' HB3' ' A' ' 387' ' ' LYS . 40.0 tt0 -122.44 140.37 52.8 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.247 -0.649 . . . . 1.63 109.247 176.461 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 358' ' ' ARG . . . . . 0.828 ' HG2' ' HE3' ' A' ' 352' ' ' MET . 3.1 ptp180 -146.15 137.55 24.71 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.157 0.503 . . . . 1.53 111.178 175.425 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 359' ' ' ARG . . . . . . . . . . . . . 11.9 ttp180 -87.27 117.63 26.16 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.047 -0.723 . . . . 3.26 109.047 174.734 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 360' ' ' ILE . . . . . 0.416 HG12 HG23 ' A' ' 292' ' ' ILE . 65.1 mt -103.17 126.26 57.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-N 115.979 -0.555 . . . . 1.13 110.535 -175.125 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 361' ' ' VAL . . . . . . . . . . . . . 47.7 t -100.73 115.12 41.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 109.175 -0.676 . . . . 1.14 109.175 175.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 362' ' ' ILE . . . . . 0.401 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 60.5 mt -110.21 108.97 58.86 Favored Pre-proline 0 C--N 1.322 -0.603 0 CA-C-N 116.447 -0.342 . . . . 1.13 110.689 -175.456 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 363' ' ' PRO . . . . . 0.468 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 35.6 Cg_endo -65.51 162.03 35.75 Favored 'Trans proline' 0 C--O 1.239 0.541 0 C-N-CA 122.42 2.08 . . . . 1.05 111.613 175.432 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 364' ' ' ALA . . . . . . . . . . . . . . . -52.61 -48.89 88.87 Favored Pre-proline 0 CA--C 1.537 0.47 0 N-CA-C 113.85 1.055 . . . . 1.16 113.85 -173.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 365' ' ' PRO . . . . . 0.468 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 74.1 Cg_exo -52.14 -29.74 38.35 Favored 'Trans proline' 0 C--N 1.359 1.09 0 C-N-CA 122.501 2.134 . . . . 1.14 114.212 -175.505 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 366' ' ' TYR . . . . . 0.472 ' CE2' ' HA3' ' A' ' 288' ' ' GLY . 43.1 m-85 -101.05 10.16 41.35 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 112.196 0.443 . . . . 1.03 112.196 -175.75 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -125.39 -110.81 0.3 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.806 -0.179 . . . . 1.07 110.572 175.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -90.02 -22.17 22.01 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.991 0.424 . . . . 1.44 111.317 178.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 70.7 -95.87 0.56 Allowed Glycine 0 N--CA 1.448 -0.51 0 CA-C-N 115.996 -0.547 . . . . 0.65 113.761 175.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 23.4 pttm -109.17 8.12 25.76 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.622 0.248 . . . . 3.34 111.645 -171.625 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 6.3 tp-100 -89.48 120.25 30.63 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.864 0.364 . . . . 2.88 110.56 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 372' ' ' ALA . . . . . 0.714 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -92.47 93.71 8.71 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-O 121.436 0.636 . . . . 1.39 110.592 178.025 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 43.3 mt -81.97 162.99 55.4 Favored Pre-proline 0 C--N 1.318 -0.784 0 CA-C-N 115.373 -0.83 . . . . 1.55 109.079 176.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_exo -61.14 114.97 2.42 Favored 'Trans proline' 0 N--CA 1.462 -0.378 0 C-N-CA 121.478 1.452 . . . . 1.61 110.645 172.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 91.23 -26.63 11.01 Favored Glycine 0 CA--C 1.521 0.413 0 C-N-CA 121.086 -0.578 . . . . 0.96 112.525 -178.457 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 23.5 mt -126.62 81.94 67.66 Favored Pre-proline 0 CA--C 1.533 0.32 0 CA-C-O 120.638 0.256 . . . . 1.29 110.518 -177.118 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 377' ' ' PRO . . . . . 0.714 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 73.5 Cg_endo -80.17 167.85 19.28 Favored 'Trans proline' 0 N--CA 1.463 -0.322 0 C-N-CA 122.693 2.262 . . . . 1.08 113.156 -177.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 378' ' ' ALA . . . . . 0.401 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -49.12 147.25 3.04 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 115.572 -0.74 . . . . 1.52 111.862 178.834 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 379' ' ' ASN . . . . . 0.401 ' HB2' ' O ' ' A' ' 378' ' ' ALA . 42.2 m-80 67.75 33.31 4.94 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 115.712 -0.676 . . . . 1.97 110.688 -175.752 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 2.4 p -82.29 133.16 35.23 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.922 -0.581 . . . . 1.91 111.42 179.506 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 381' ' ' GLU . . . . . 0.432 ' HB3' ' HB2' ' A' ' 318' ' ' LYS . 32.1 tt0 -104.03 106.64 17.21 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.73 -0.668 . . . . 1.03 109.398 177.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 89.9 mt -86.83 139.97 30.15 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.832 0.349 . . . . 1.13 111.093 -177.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 33.4 m -117.89 117.51 29.49 Favored 'General case' 0 N--CA 1.446 -0.629 0 N-CA-C 109.153 -0.684 . . . . 1.12 109.153 175.645 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 33.9 m-85 -113.69 117.29 31.14 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.214 0.53 . . . . 0.4 111.784 -175.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 385' ' ' ASP . . . . . 0.414 ' O ' ' HA ' ' A' ' 313' ' ' TYR . 10.4 t70 -85.49 103.82 14.71 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 107.946 -1.131 . . . . 1.8 107.946 172.311 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 386' ' ' VAL . . . . . 0.499 HG13 ' CB ' ' A' ' 313' ' ' TYR . 35.3 m -130.29 141.17 47.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.65 0.738 . . . . 1.13 111.89 -173.159 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 387' ' ' LYS . . . . . 0.426 ' HB3' ' CB ' ' A' ' 357' ' ' GLU . 10.7 pttm -141.07 141.54 34.25 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.148 -0.933 . . . . 3.1 109.747 174.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 388' ' ' LEU . . . . . 0.795 HD12 ' HB ' ' A' ' 309' ' ' VAL . 16.9 tp -94.24 127.35 40.04 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.962 -0.755 . . . . 1.05 108.962 -176.656 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 34.2 m -125.92 -0.6 4.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 C-N-CA 120.897 -0.321 . . . . 1.2 111.056 -172.094 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 22.9 t -165.15 157.52 15.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.254 -0.43 . . . . 1.82 111.164 179.65 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 391' ' ' MET . . . . . 0.42 ' HE3' HG13 ' A' ' 309' ' ' VAL . 39.1 ttm -162.29 132.86 4.85 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.412 -0.813 . . . . 1.14 109.407 175.902 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 392' ' ' LYS . . . . . 0.416 ' C ' HH21 ' A' ' 308' ' ' ARG . 31.9 mmtp . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.496 -0.764 . . . . 5.51 110.408 -177.64 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.526 HG23 ' HG2' ' A' ' 293' ' ' GLU . 28.3 p . . . . . 0 N--CA 1.449 -0.497 0 CA-C-O 120.894 0.378 . . . . 1.27 111.377 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 43.4 mtpt -127.58 156.98 41.39 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.528 -0.545 . . . . 2.51 109.528 175.037 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 37.7 tp -112.47 119.24 37.53 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.373 -0.376 . . . . 1.52 110.087 -178.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.619 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 92.3 mt -99.37 -170.16 1.87 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.927 -0.579 . . . . 1.39 110.411 178.574 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -50.86 142.93 10.79 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.11 0.481 . . . . 2.64 111.554 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 73.08 -102.74 1.28 Allowed Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 121.069 -0.586 . . . . 1.84 111.9 -178.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . -146.44 28.04 1.65 Allowed Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 110.691 -0.964 . . . . 1.16 110.691 177.184 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 290' ' ' ILE . . . . . 0.619 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 66.2 mt -74.48 125.57 34.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 115.335 -0.432 . . . . 1.16 110.53 -175.702 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 8.1 mt -111.12 142.69 22.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 N-CA-C 109.384 -0.599 . . . . 1.6 109.384 -179.024 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 292' ' ' ILE . . . . . . . . . . . . . 18.5 pt -132.8 128.47 57.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 120.859 0.361 . . . . 1.17 111.222 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 293' ' ' GLU . . . . . 0.58 ' HB2' ' HB3' ' A' ' 359' ' ' ARG . 40.0 mt-10 -103.99 131.79 50.88 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.334 -0.848 . . . . 2.31 110.204 175.618 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -79.98 126.48 31.08 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.234 0.54 . . . . 2.36 109.966 175.492 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 295' ' ' ARG . . . . . 0.573 ' HA ' ' HE ' ' A' ' 295' ' ' ARG . 2.6 mmp_? -105.28 -59.23 1.79 Allowed 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.46 -0.57 . . . . 3.99 109.46 175.36 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.616 ' HB ' ' HG2' ' A' ' 357' ' ' GLU . 90.0 t -131.77 105.18 9.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.822 -0.626 . . . . 1.31 109.334 174.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 10.2 t -68.9 138.72 54.89 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.068 0.461 . . . . 2.46 109.827 178.013 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -128.47 161.82 22.17 Favored Glycine 0 N--CA 1.442 -0.959 0 C-N-CA 120.316 -0.945 . . . . 1.04 112.067 -175.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 23.3 tptm -127.26 110.96 13.39 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 109.799 -0.445 . . . . 5.01 109.799 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -171.43 -154.58 9.95 Favored Glycine 0 N--CA 1.441 -0.98 0 N-CA-C 111.381 -0.688 . . . . 1.59 111.381 -178.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . 0.542 ' O ' ' HA ' ' A' ' 353' ' ' ALA . 21.9 Cg_exo -65.12 133.73 36.64 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.988 2.459 . . . . 1.1 111.744 177.546 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 52.7 m80 -93.32 139.55 30.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.731 0.301 . . . . 1.85 110.35 -179.376 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -74.03 151.73 40.16 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.053 -0.522 . . . . 1.17 111.832 -179.153 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 304' ' ' LYS . . . . . 0.449 ' HG2' ' N ' ' A' ' 305' ' ' LYS . 25.6 ttpp -152.98 169.25 23.35 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 115.855 -0.611 . . . . 3.26 109.387 -178.602 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.449 ' N ' ' HG2' ' A' ' 304' ' ' LYS . 99.4 mttt -64.91 130.94 45.29 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 110.136 -0.32 . . . . 3.21 110.136 176.252 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 92.44 -11.8 71.23 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 121.094 -0.575 . . . . 0.7 111.852 -178.682 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 52.5 m -83.5 140.08 32.52 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 122.457 0.303 . . . . 1.07 110.57 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 50.7 mtt180 -100.68 104.74 16.05 Favored 'General case' 0 CA--C 1.516 -0.36 0 N-CA-C 109.002 -0.74 . . . . 3.98 109.002 -179.514 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.85 ' HB ' HD12 ' A' ' 388' ' ' LEU . 33.7 m -102.12 140.01 21.72 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.915 0 CA-C-O 121.276 0.56 . . . . 1.1 111.14 -176.719 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 310' ' ' GLY . . . . . 0.443 ' HA2' ' HA ' ' A' ' 333' ' ' VAL . . . -115.01 125.85 6.94 Favored Glycine 0 N--CA 1.441 -1.029 0 N-CA-C 110.136 -1.186 . . . . 0.32 110.136 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 13.4 ptp -134.07 177.04 8.05 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-O 121.459 0.647 . . . . 1.55 112.123 -173.75 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 312' ' ' ARG . . . . . 0.733 ' HE ' HG12 ' A' ' 389' ' ' VAL . 72.5 mtm180 -138.25 140.85 39.85 Favored 'General case' 0 C--N 1.317 -0.813 0 N-CA-C 106.995 -1.483 . . . . 3.0 106.995 172.351 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 313' ' ' TYR . . . . . 0.423 ' CE2' ' HH2' ' A' ' 345' ' ' TRP . 9.8 p90 -158.55 169.53 24.23 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 119.593 -0.843 . . . . 1.24 113.056 -167.404 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 26.2 t -129.42 108.07 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 CA-C-N 114.33 -1.305 . . . . 1.09 109.086 171.234 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -88.28 110.38 3.63 Favored Glycine 0 N--CA 1.447 -0.576 0 N-CA-C 111.761 -0.535 . . . . 0.32 111.761 -177.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 316' ' ' LYS . . . . . 0.834 ' HG2' HG23 ' A' ' 322' ' ' VAL . 51.0 mttp -115.81 164.38 14.46 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.175 0.512 . . . . 2.61 110.831 -176.331 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 94.1 mt -87.95 158.67 18.6 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 107.561 -1.274 . . . . 1.32 107.561 164.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 318' ' ' LYS . . . . . 0.78 ' HG2' ' HB3' ' A' ' 381' ' ' GLU . 0.1 OUTLIER -63.29 -8.76 9.25 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.011 0.434 . . . . 2.9 111.232 178.978 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 85.8 m-20 -81.16 -14.55 57.51 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.123 -0.489 . . . . 2.39 110.769 177.059 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 109.55 -18.53 29.79 Favored Glycine 0 CA--C 1.518 0.25 0 C-N-CA 120.806 -0.711 . . . . 0.69 112.853 179.148 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 55.2 mtpt -78.08 138.57 38.83 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.662 0.268 . . . . 2.86 111.249 -176.572 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.834 HG23 ' HG2' ' A' ' 316' ' ' LYS . 47.7 t -97.8 136.84 27.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.123 -0.489 . . . . 1.96 110.466 -176.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -118.21 -24.8 6.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.85 0.357 . . . . 0.56 111.164 179.416 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -140.27 146.83 39.1 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.469 -0.567 . . . . 1.68 109.469 177.173 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 21.0 ptmt -163.25 137.66 6.17 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.041 0.448 . . . . 2.55 111.48 -175.631 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 326' ' ' ASN . . . . . 0.412 ' HB2' ' HB2' ' A' ' 330' ' ' LYS . 5.8 p30 -154.58 128.9 9.05 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.796 -0.638 . . . . 1.92 110.279 170.145 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 327' ' ' THR . . . . . 0.447 ' HA ' ' HD2' ' A' ' 312' ' ' ARG . 7.6 t -163.07 -33.92 0.04 OUTLIER 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.676 -0.693 . . . . 2.06 110.573 -177.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 58.8 mttp -89.29 95.46 10.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.657 -0.247 . . . . 3.15 110.441 177.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.487 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 73.65 -10.33 7.01 Favored Glycine 0 CA--C 1.518 0.275 0 C-N-CA 121.137 -0.554 . . . . 1.17 113.439 177.234 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 330' ' ' LYS . . . . . 0.412 ' HB2' ' HB2' ' A' ' 326' ' ' ASN . 58.7 mttm -103.03 100.74 17.97 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 116.945 0.372 . . . . 2.56 111.291 -177.305 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 331' ' ' PRO . . . . . 0.487 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 87.5 Cg_endo -88.84 143.51 5.05 Favored 'Trans proline' 0 N--CA 1.452 -0.917 0 C-N-CA 122.7 2.267 . . . . 0.73 112.034 170.925 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 73.8 t80 -116.01 115.65 26.51 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.594 -0.521 . . . . 0.76 109.594 174.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 333' ' ' VAL . . . . . 0.443 ' HA ' ' HA2' ' A' ' 310' ' ' GLY . 42.7 t -114.73 117.08 54.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 120.559 0.218 . . . . 1.14 110.517 -175.375 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.503 ' HZ ' HG22 ' A' ' 349' ' ' VAL . 27.8 p90 -136.18 160.78 37.63 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 110.173 -0.306 . . . . 0.48 110.173 -178.749 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 335' ' ' LYS . . . . . 0.639 ' O ' ' HG2' ' A' ' 338' ' ' GLN . 6.0 ptmt -106.04 134.62 48.88 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.016 0.436 . . . . 3.11 111.513 -179.187 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 10.8 mp -68.82 117.8 10.98 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.332 -0.395 . . . . 1.2 110.174 177.452 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 128.86 -19.27 5.55 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.832 -0.699 . . . . 1.02 112.207 -179.279 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 338' ' ' GLN . . . . . 0.741 HE21 ' HB2' ' A' ' 340' ' ' GLU . 18.8 pt20 -72.53 138.55 47.0 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.836 0.35 . . . . 3.1 110.742 179.883 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -86.65 20.31 24.21 Favored Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 120.931 -0.652 . . . . 0.98 111.56 176.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 340' ' ' GLU . . . . . 0.741 ' HB2' HE21 ' A' ' 338' ' ' GLN . 11.5 mt-10 -89.22 -11.05 44.77 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.287 -0.635 . . . . 2.09 109.287 178.007 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 35.5 m -112.98 173.53 2.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.353 -0.84 . . . . 1.27 109.587 177.386 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 342' ' ' ILE . . . . . 0.552 HD13 ' HA ' ' A' ' 367' ' ' ALA . 8.7 pt -92.81 159.96 2.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 N-CA-C 109.736 -0.468 . . . . 1.08 109.736 178.322 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 343' ' ' LYS . . . . . 0.489 ' HA ' ' HE2' ' A' ' 343' ' ' LYS . 3.4 mmpt? -55.97 -35.73 67.06 Favored 'General case' 0 N--CA 1.467 0.377 0 N-CA-C 112.219 0.451 . . . . 3.46 112.219 -174.78 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 344' ' ' GLY . . . . . 0.428 ' HA3' HD11 ' A' ' 362' ' ' ILE . . . -56.18 -28.74 54.94 Favored Glycine 0 CA--C 1.521 0.446 0 C-N-CA 120.805 -0.712 . . . . 0.32 113.061 177.628 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 345' ' ' TRP . . . . . 0.423 ' HH2' ' CE2' ' A' ' 313' ' ' TYR . 11.2 m95 -79.01 -59.99 2.56 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 112.715 0.635 . . . . 0.44 112.715 -177.063 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 9.0 p-10 -63.92 -22.85 67.11 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 118.046 0.384 . . . . 1.75 111.268 -175.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 73.5 mt -86.52 -53.63 9.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.05 -0.523 . . . . 1.18 111.249 176.477 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -64.52 -32.61 84.78 Favored Glycine 0 CA--C 1.523 0.549 0 C-N-CA 121.184 -0.531 . . . . 0.37 113.894 -178.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 349' ' ' VAL . . . . . 0.503 HG22 ' HZ ' ' A' ' 334' ' ' PHE . 93.7 t -80.48 -14.4 12.91 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 CA-C-O 121.047 0.451 . . . . 1.08 111.242 -179.798 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.08 131.67 47.17 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.237 0.541 . . . . 1.09 110.632 178.531 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 79.89 16.15 77.68 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.821 -0.704 . . . . 0.45 112.387 -179.145 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 352' ' ' MET . . . . . 0.41 ' SD ' ' HG2' ' A' ' 358' ' ' ARG . 42.7 mmm -82.6 149.46 27.42 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.643 0.259 . . . . 1.3 110.53 174.238 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 353' ' ' ALA . . . . . 0.542 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -122.84 137.83 54.82 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.031 -0.531 . . . . 1.33 110.491 -179.56 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 354' ' ' VAL . . . . . 0.51 ' HB ' ' HD2' ' A' ' 301' ' ' PRO . 87.6 t -55.33 122.85 5.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.147 -0.479 . . . . 1.24 110.679 176.499 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 111.27 -16.1 27.37 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.927 -0.654 . . . . 0.44 112.175 -178.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -108.37 160.81 13.58 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.692 -0.766 . . . . 0.37 112.439 -178.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 357' ' ' GLU . . . . . 0.845 ' HB3' ' HB2' ' A' ' 387' ' ' LYS . 9.9 pt-20 -139.03 135.91 34.74 Favored 'General case' 0 C--O 1.238 0.462 0 CA-C-O 121.08 0.467 . . . . 1.63 111.171 178.573 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 358' ' ' ARG . . . . . 0.41 ' HG2' ' SD ' ' A' ' 352' ' ' MET . 4.9 ptp180 -132.17 140.46 48.75 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.83 -0.623 . . . . 1.53 109.931 177.445 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 359' ' ' ARG . . . . . 0.58 ' HB3' ' HB2' ' A' ' 293' ' ' GLU . 39.6 ttm180 -86.42 116.15 24.39 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.909 -0.587 . . . . 3.26 109.671 177.086 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 42.2 mt -99.42 117.77 45.05 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 CA-C-N 116.007 -0.542 . . . . 1.13 110.485 -177.536 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 361' ' ' VAL . . . . . . . . . . . . . 47.2 t -100.52 112.4 33.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 N-CA-C 108.714 -0.847 . . . . 1.14 108.714 175.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 362' ' ' ILE . . . . . 0.444 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 47.9 mt -110.59 109.37 58.04 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 116.073 -0.512 . . . . 1.13 111.67 -171.001 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 363' ' ' PRO . . . . . 0.457 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 13.8 Cg_endo -57.0 157.22 21.13 Favored 'Trans proline' 0 C--O 1.235 0.357 0 C-N-CA 123.098 2.532 . . . . 1.05 112.185 172.045 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 364' ' ' ALA . . . . . 0.566 ' CB ' ' HA ' ' A' ' 379' ' ' ASN . . . -47.0 -53.8 24.6 Favored Pre-proline 0 CA--C 1.538 0.482 0 N-CA-C 114.051 1.13 . . . . 1.16 114.051 -176.138 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 365' ' ' PRO . . . . . 0.457 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 27.3 Cg_endo -61.6 -15.32 40.98 Favored 'Trans proline' 0 C--N 1.358 1.049 0 C-N-CA 122.2 1.933 . . . . 1.14 114.207 -172.376 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 366' ' ' TYR . . . . . . . . . . . . . 12.2 m-85 -109.25 5.08 23.42 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.794 0.331 . . . . 1.03 111.387 -178.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 367' ' ' ALA . . . . . 0.552 ' HA ' HD13 ' A' ' 342' ' ' ILE . . . -119.52 -125.09 0.28 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.435 -0.348 . . . . 1.07 110.41 176.454 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 42.0 m-85 -68.9 -19.02 64.2 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-O 120.562 0.22 . . . . 1.44 111.297 179.232 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 74.96 -117.63 5.41 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.957 -0.639 . . . . 0.65 113.177 177.587 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 370' ' ' LYS . . . . . 0.454 ' HA ' ' HB2' ' A' ' 378' ' ' ALA . 0.0 OUTLIER -111.54 13.57 21.35 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.652 -0.274 . . . . 3.34 111.467 -173.931 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 51.0 tp60 -103.98 108.28 19.55 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.137 0.494 . . . . 2.88 110.875 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 372' ' ' ALA . . . . . 0.447 ' HB2' ' HA ' ' A' ' 377' ' ' PRO . . . -75.42 119.18 19.16 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-N 115.77 -0.65 . . . . 1.39 111.664 178.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 75.3 mt -90.68 160.07 39.48 Favored Pre-proline 0 C--N 1.32 -0.716 0 N-CA-C 108.975 -0.75 . . . . 1.55 108.975 174.309 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -59.6 114.18 1.94 Allowed 'Trans proline' 0 N--CA 1.461 -0.384 0 C-N-CA 121.326 1.351 . . . . 1.61 110.831 173.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 97.2 -29.5 10.65 Favored Glycine 0 CA--C 1.52 0.38 0 C-N-CA 121.129 -0.558 . . . . 0.96 112.768 -177.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 37.7 mt -126.7 94.23 40.56 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.66 0.23 . . . . 1.29 110.461 -178.237 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 377' ' ' PRO . . . . . 0.447 ' HA ' ' HB2' ' A' ' 372' ' ' ALA . 72.1 Cg_endo -75.47 167.36 26.76 Favored 'Trans proline' 0 N--CA 1.461 -0.418 0 C-N-CA 122.51 2.14 . . . . 1.08 112.839 -176.523 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 378' ' ' ALA . . . . . 0.454 ' HB2' ' HA ' ' A' ' 370' ' ' LYS . . . -57.82 152.13 16.45 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.842 -0.617 . . . . 1.52 111.42 178.656 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 379' ' ' ASN . . . . . 0.566 ' HA ' ' CB ' ' A' ' 364' ' ' ALA . 13.6 m120 72.12 14.25 5.68 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 115.714 -0.676 . . . . 1.97 111.962 179.072 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 33.7 m -70.45 112.43 6.74 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.187 0.517 . . . . 1.91 110.861 176.327 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 381' ' ' GLU . . . . . 0.78 ' HB3' ' HG2' ' A' ' 318' ' ' LYS . 40.9 tt0 -72.95 105.11 4.3 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.259 -0.882 . . . . 1.03 109.444 175.236 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 86.6 mt -82.67 148.99 27.61 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.025 -0.534 . . . . 1.13 111.569 -175.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 29.4 m -130.57 120.09 23.51 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.589 -0.522 . . . . 1.12 109.589 176.08 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 -121.39 110.45 16.1 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.757 0.313 . . . . 0.4 111.484 -174.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 23.2 m-20 -82.42 103.92 12.34 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 108.375 -0.972 . . . . 1.8 108.375 168.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 386' ' ' VAL . . . . . . . . . . . . . 28.2 m -118.28 128.33 75.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.256 0.551 . . . . 1.13 111.56 -175.533 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 387' ' ' LYS . . . . . 0.845 ' HB2' ' HB3' ' A' ' 357' ' ' GLU . 28.9 ttpt -120.58 131.11 54.49 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.621 -0.718 . . . . 3.1 109.756 175.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 388' ' ' LEU . . . . . 0.85 HD12 ' HB ' ' A' ' 309' ' ' VAL . 17.7 tp -87.43 130.29 34.73 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.33 -0.619 . . . . 1.05 109.33 -174.851 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 389' ' ' VAL . . . . . 0.733 HG12 ' HE ' ' A' ' 312' ' ' ARG . 17.6 m -121.08 -12.75 8.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 111.997 0.369 . . . . 1.2 111.997 -172.625 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 55.4 p -162.28 170.6 18.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.704 0.288 . . . . 1.82 110.8 -178.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 391' ' ' MET . . . . . 0.532 ' HE3' HG13 ' A' ' 309' ' ' VAL . 36.8 ttm -169.74 137.94 1.78 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.112 -0.495 . . . . 1.14 110.652 -179.053 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 99.2 mttt . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.35 -0.833 . . . . 5.51 110.265 177.587 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 20.8 p . . . . . 0 N--CA 1.446 -0.626 0 CA-C-O 120.741 0.305 . . . . 1.27 110.991 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 25.5 mtpp -129.98 135.38 48.24 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.879 -0.415 . . . . 2.51 109.879 170.651 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 47.7 tp -94.01 120.77 34.71 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.884 -0.598 . . . . 1.52 109.989 -177.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.59 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 88.3 mt -104.54 -171.95 2.02 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.554 -0.748 . . . . 1.39 110.308 178.433 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 287' ' ' GLU . . . . . 0.626 ' HG3' ' OH ' ' A' ' 366' ' ' TYR . 7.3 tp10 -61.31 145.32 51.83 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.634 -0.712 . . . . 2.64 111.377 -177.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 67.24 17.29 68.03 Favored Glycine 0 CA--C 1.521 0.439 0 C-N-CA 121.171 -0.537 . . . . 1.84 113.967 176.008 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 82.06 17.4 69.76 Favored Glycine 0 C--N 1.33 0.197 0 C-N-CA 120.512 -0.851 . . . . 1.16 113.179 178.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 290' ' ' ILE . . . . . 0.59 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 87.8 mt -69.62 126.47 29.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 109.813 -0.439 . . . . 1.16 109.813 176.759 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 10.5 mt -114.81 135.21 55.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 109.448 -0.575 . . . . 1.6 109.448 -179.771 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 292' ' ' ILE . . . . . . . . . . . . . 24.5 pt -124.19 129.64 74.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-O 121.019 0.438 . . . . 1.17 110.563 -177.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 293' ' ' GLU . . . . . . . . . . . . . 25.9 tt0 -107.7 121.18 44.18 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.403 -0.817 . . . . 2.31 109.367 178.033 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -83.19 120.85 26.32 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.352 0.596 . . . . 2.36 109.95 -179.624 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 295' ' ' ARG . . . . . 0.541 ' HD2' ' HB2' ' A' ' 359' ' ' ARG . 68.6 mtp180 -102.06 -50.77 3.56 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.37 -0.377 . . . . 3.99 110.312 -176.768 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.489 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 60.3 t -118.71 115.09 46.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 109.78 -0.452 . . . . 1.31 109.78 174.676 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 20.7 p -81.06 121.52 26.18 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.036 -0.529 . . . . 2.46 111.682 -177.507 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -134.99 173.71 21.46 Favored Glycine 0 N--CA 1.446 -0.654 0 N-CA-C 111.632 -0.587 . . . . 1.04 111.632 179.049 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -151.27 128.17 11.0 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.261 0.553 . . . . 5.01 109.892 174.572 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -172.92 -153.5 9.54 Favored Glycine 0 N--CA 1.443 -0.874 0 N-CA-C 110.869 -0.892 . . . . 1.59 110.869 -177.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_exo -56.64 133.36 57.53 Favored 'Trans proline' 0 N--CA 1.462 -0.372 0 C-N-CA 122.369 2.046 . . . . 1.1 111.017 173.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 302' ' ' HIS . . . . . 0.413 ' HA ' ' O ' ' A' ' 352' ' ' MET . 53.6 m80 -100.48 144.24 29.71 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.42 -0.355 . . . . 1.85 111.033 -176.604 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 303' ' ' ALA . . . . . 0.421 ' HB3' HG12 ' A' ' 309' ' ' VAL . . . -77.39 125.84 29.96 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.832 -0.622 . . . . 1.17 111.382 -179.239 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -133.21 179.47 6.18 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.717 -0.674 . . . . 3.26 109.922 176.472 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.917 ' HG3' ' HA3' ' A' ' 337' ' ' GLY . 87.0 tttt -67.39 130.99 44.82 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.839 0.352 . . . . 3.21 110.268 177.03 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 95.99 -26.02 22.7 Favored Glycine 0 N--CA 1.448 -0.542 0 N-CA-C 111.42 -0.672 . . . . 0.7 111.42 -177.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 307' ' ' THR . . . . . 0.62 ' O ' ' HA ' ' A' ' 335' ' ' LYS . 9.7 m -72.51 131.36 42.43 Favored 'General case' 0 N--CA 1.449 -0.52 0 CA-C-N 115.619 -0.291 . . . . 1.07 110.224 178.239 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 308' ' ' ARG . . . . . 0.63 ' HG2' ' HB3' ' A' ' 335' ' ' LYS . 49.6 mtp180 -102.18 104.37 14.95 Favored 'General case' 0 N--CA 1.452 -0.356 0 N-CA-C 108.651 -0.87 . . . . 3.98 108.651 -179.676 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.781 ' HB ' HD12 ' A' ' 388' ' ' LEU . 32.0 m -99.58 140.02 19.88 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-O 121.243 0.544 . . . . 1.1 111.267 -171.034 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -103.79 113.3 4.43 Favored Glycine 0 N--CA 1.442 -0.933 0 CA-C-N 114.956 -1.02 . . . . 0.32 110.646 179.508 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 13.3 ptp -133.62 176.89 8.15 Favored 'General case' 0 N--CA 1.441 -0.92 0 CA-C-O 121.92 0.867 . . . . 1.55 112.273 -173.516 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 49.4 mtp180 -135.46 145.16 46.91 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 113.81 -1.541 . . . . 3.0 106.976 177.174 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 313' ' ' TYR . . . . . 0.515 ' HA ' ' O ' ' A' ' 385' ' ' ASP . 44.9 p90 -161.42 155.63 22.57 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.461 0.648 . . . . 1.24 112.708 -170.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 57.7 t -122.48 120.01 59.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 114.756 -1.111 . . . . 1.09 109.45 175.263 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -101.37 115.23 5.21 Favored Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.83 -0.7 . . . . 0.32 112.461 -177.046 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 316' ' ' LYS . . . . . 0.493 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 62.7 mttm -112.29 151.09 30.08 Favored 'General case' 0 C--N 1.331 -0.221 0 O-C-N 123.946 0.439 . . . . 2.61 111.193 -179.278 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 317' ' ' LEU . . . . . 0.558 HD22 HG12 ' A' ' 376' ' ' ILE . 80.1 mt -84.95 -178.5 6.85 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.505 -0.771 . . . . 1.32 112.114 178.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 318' ' ' LYS . . . . . 0.506 ' HD3' ' H ' ' A' ' 381' ' ' GLU . 49.7 tptt -57.43 -32.59 67.03 Favored 'General case' 0 N--CA 1.461 0.111 0 CA-C-N 115.198 -0.91 . . . . 2.9 110.854 176.82 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 27.0 p-10 -92.7 6.9 45.78 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.078 -0.51 . . . . 2.39 111.368 -177.244 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 88.13 -8.22 79.02 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.638 -0.791 . . . . 0.69 112.641 178.155 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 28.7 tptp -66.25 114.19 5.14 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.028 0.442 . . . . 2.86 110.634 179.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.493 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 4.0 p -68.15 122.44 19.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-N 115.788 -0.642 . . . . 1.96 109.856 175.571 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 323' ' ' PHE . . . . . 0.455 ' HD1' ' HG ' ' A' ' 317' ' ' LEU . 43.1 p90 -100.83 -30.48 11.66 Favored 'General case' 0 C--N 1.322 -0.596 0 C-N-CA 120.738 -0.385 . . . . 0.56 110.794 -178.776 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -149.48 160.08 43.76 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.835 -0.346 . . . . 1.68 110.622 178.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 14.8 pttp -166.66 128.42 1.75 Allowed 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.129 -0.487 . . . . 2.55 110.505 -178.38 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -124.82 117.9 25.18 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.947 -0.76 . . . . 1.92 108.947 178.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 2.0 t -164.05 -45.04 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.47 -0.332 . . . . 2.06 111.278 -175.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 12.6 ptmm? -89.44 100.41 13.21 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.317 0.579 . . . . 3.15 110.84 -177.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.445 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 86.28 -26.76 6.03 Favored Glycine 0 N--CA 1.452 -0.292 0 CA-C-N 115.532 -0.758 . . . . 1.17 113.074 178.023 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -103.36 100.78 19.44 Favored Pre-proline 0 C--N 1.329 -0.309 0 N-CA-C 111.729 0.27 . . . . 2.56 111.729 -177.001 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 331' ' ' PRO . . . . . 0.445 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 84.2 Cg_endo -87.79 125.93 2.07 Favored 'Trans proline' 0 N--CA 1.45 -1.078 0 C-N-CA 122.35 2.034 . . . . 0.73 110.342 165.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 43.1 t80 -99.92 115.6 30.02 Favored 'General case' 0 C--N 1.321 -0.639 0 C-N-CA 120.486 -0.485 . . . . 0.76 110.107 -177.323 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 333' ' ' VAL . . . . . 0.636 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 47.5 t -111.94 113.17 43.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 116.032 -0.531 . . . . 1.14 109.939 -177.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 30.7 p90 -135.99 149.44 48.86 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.313 -0.403 . . . . 0.48 110.41 -178.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 335' ' ' LYS . . . . . 0.63 ' HB3' ' HG2' ' A' ' 308' ' ' ARG . 12.0 ptmt -92.84 139.22 30.77 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 116.181 -0.463 . . . . 3.11 111.133 177.577 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 9.8 mp -77.64 151.76 34.17 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 109.517 -0.549 . . . . 1.2 109.517 172.267 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 337' ' ' GLY . . . . . 0.917 ' HA3' ' HG3' ' A' ' 305' ' ' LYS . . . 90.78 40.36 5.62 Favored Glycine 0 N--CA 1.446 -0.687 0 C-N-CA 120.698 -0.763 . . . . 1.02 112.577 -177.662 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 338' ' ' GLN . . . . . 0.483 ' HB3' ' HE2' ' A' ' 335' ' ' LYS . 29.7 pt20 -148.26 157.63 43.61 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.454 -0.573 . . . . 3.1 109.454 176.179 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -89.73 20.1 37.3 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.756 -0.735 . . . . 0.98 112.352 -176.223 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -85.18 -15.07 44.92 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.301 0.572 . . . . 2.09 110.012 178.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 25.4 m -123.58 156.78 30.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.843 -0.617 . . . . 1.27 109.855 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 342' ' ' ILE . . . . . 0.433 HD13 ' HA ' ' A' ' 367' ' ' ALA . 11.3 pt -76.79 159.93 5.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 N-CA-C 110.203 -0.295 . . . . 1.08 110.203 -179.826 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 343' ' ' LYS . . . . . 0.459 ' HA ' ' CE ' ' A' ' 343' ' ' LYS . 4.7 mmpt? -63.14 -34.38 77.48 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.19 0.441 . . . . 3.46 112.19 -173.88 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 344' ' ' GLY . . . . . 0.424 ' HA3' HD11 ' A' ' 362' ' ' ILE . . . -54.19 -33.54 52.08 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.72 -0.753 . . . . 0.32 112.383 174.564 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 11.8 m95 -81.23 -59.83 2.5 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 120.584 0.231 . . . . 0.44 110.781 177.568 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 31.5 t70 -48.76 -31.11 6.44 Favored 'General case' 0 CA--C 1.537 0.463 0 CA-C-N 116.193 -0.458 . . . . 1.75 112.107 179.049 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 71.6 mt -93.2 -52.39 9.91 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.404 0 CA-C-N 116.626 -0.261 . . . . 1.18 111.69 178.323 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -63.8 -31.84 82.16 Favored Glycine 0 C--N 1.335 0.505 0 C-N-CA 121.318 -0.468 . . . . 0.37 113.767 -176.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 98.7 t -78.28 -20.52 13.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-O 120.984 0.421 . . . . 1.08 110.812 179.442 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -63.8 118.35 8.21 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.96 0.409 . . . . 1.09 110.163 178.185 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 100.2 0.61 55.89 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.69 -0.766 . . . . 0.45 112.397 -178.017 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 352' ' ' MET . . . . . 0.413 ' O ' ' HA ' ' A' ' 302' ' ' HIS . 58.0 mmm -68.69 139.97 55.42 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.673 0.273 . . . . 1.3 110.668 175.893 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 353' ' ' ALA . . . . . . . . . . . . . . . -109.69 137.19 47.86 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.877 -0.601 . . . . 1.33 110.819 -178.734 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 68.4 t -56.85 117.19 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.279 -0.419 . . . . 1.24 110.125 173.449 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 111.07 -6.08 28.91 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 121.229 -0.51 . . . . 0.44 112.477 -178.555 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -105.36 154.93 17.11 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.748 -0.739 . . . . 0.37 113.126 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 357' ' ' GLU . . . . . 0.489 ' HB3' ' HB ' ' A' ' 296' ' ' VAL . 25.8 tt0 -132.61 133.53 43.76 Favored 'General case' 0 C--N 1.329 -0.293 0 C-N-CA 122.944 0.498 . . . . 1.63 109.868 -179.486 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 358' ' ' ARG . . . . . . . . . . . . . 5.0 ptp180 -144.48 143.23 30.77 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.094 0.473 . . . . 1.53 111.063 177.598 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 359' ' ' ARG . . . . . 0.541 ' HB2' ' HD2' ' A' ' 295' ' ' ARG . 11.8 ttp180 -93.35 121.47 34.77 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.696 -0.684 . . . . 3.26 109.422 174.551 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 44.9 mt -106.07 127.64 61.06 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-N 116.134 -0.485 . . . . 1.13 110.577 -175.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 361' ' ' VAL . . . . . . . . . . . . . 58.8 t -107.16 109.24 27.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 N-CA-C 108.868 -0.79 . . . . 1.14 108.868 175.312 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 362' ' ' ILE . . . . . 0.431 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 51.5 mt -107.11 110.04 63.25 Favored Pre-proline 0 C--N 1.322 -0.598 0 CA-C-N 116.43 -0.35 . . . . 1.13 111.495 -174.255 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 363' ' ' PRO . . . . . 0.49 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 13.2 Cg_endo -57.45 152.83 44.7 Favored 'Trans proline' 0 N--CA 1.46 -0.487 0 C-N-CA 122.641 2.228 . . . . 1.05 111.18 170.4 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 364' ' ' ALA . . . . . 0.501 ' HB1' ' HA ' ' A' ' 379' ' ' ASN . . . -47.93 -49.86 56.59 Favored Pre-proline 0 CA--C 1.537 0.479 0 N-CA-C 113.913 1.079 . . . . 1.16 113.913 -173.87 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 365' ' ' PRO . . . . . 0.49 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 77.6 Cg_exo -49.5 -35.4 36.6 Favored 'Trans proline' 0 C--N 1.36 1.18 0 C-N-CA 122.564 2.176 . . . . 1.14 114.555 -173.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 366' ' ' TYR . . . . . 0.626 ' OH ' ' HG3' ' A' ' 287' ' ' GLU . 3.1 m-85 -101.23 13.82 33.91 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.481 -0.488 . . . . 1.03 112.234 -174.857 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 367' ' ' ALA . . . . . 0.433 ' HA ' HD13 ' A' ' 342' ' ' ILE . . . -116.58 -105.3 0.4 Allowed 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.306 -0.406 . . . . 1.07 109.926 172.539 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 76.4 m-85 -95.87 4.82 52.48 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.988 0.423 . . . . 1.44 111.158 175.232 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 61.35 -117.4 11.48 Favored Glycine 0 N--CA 1.45 -0.371 0 CA-C-N 115.829 -0.623 . . . . 0.65 113.34 174.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 95.4 mttt -103.14 14.32 32.04 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.686 -0.257 . . . . 3.34 110.778 -176.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 27.8 tp60 -87.27 103.92 15.9 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.355 -0.384 . . . . 2.88 110.773 -177.769 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 372' ' ' ALA . . . . . 0.553 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -74.84 104.15 5.35 Favored 'General case' 0 N--CA 1.45 -0.448 0 CA-C-O 121.077 0.465 . . . . 1.39 110.542 174.517 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 90.2 mt -94.34 162.75 25.22 Favored Pre-proline 0 C--N 1.321 -0.668 0 CA-C-N 115.796 -0.638 . . . . 1.55 109.44 176.589 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_endo -63.15 114.86 2.65 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 121.724 1.616 . . . . 1.61 110.606 170.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 93.83 -30.03 7.93 Favored Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 120.941 -0.647 . . . . 0.96 112.279 -176.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 376' ' ' ILE . . . . . 0.558 HG12 HD22 ' A' ' 317' ' ' LEU . 24.3 mt -128.36 79.92 73.28 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.668 0.27 . . . . 1.29 110.615 -178.524 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 377' ' ' PRO . . . . . 0.553 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 72.5 Cg_endo -75.44 167.96 25.52 Favored 'Trans proline' 0 N--CA 1.463 -0.276 0 C-N-CA 122.379 2.053 . . . . 1.08 112.313 -179.675 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 378' ' ' ALA . . . . . 0.447 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -55.96 146.14 23.15 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.362 -0.381 . . . . 1.52 111.01 178.588 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 379' ' ' ASN . . . . . 0.501 ' HA ' ' HB1' ' A' ' 364' ' ' ALA . 49.1 m-80 75.56 9.29 3.64 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 123.435 0.694 . . . . 1.97 112.138 179.723 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 62.2 m -72.02 107.03 4.52 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.32 0.581 . . . . 1.91 110.774 174.591 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 381' ' ' GLU . . . . . 0.506 ' H ' ' HD3' ' A' ' 318' ' ' LYS . 4.5 tt0 -77.01 99.62 5.35 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.02 -0.991 . . . . 1.03 109.153 177.628 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 83.2 mt -82.46 140.44 33.38 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.167 -0.47 . . . . 1.13 110.878 -173.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 25.5 m -117.66 120.57 38.42 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 109.622 -0.51 . . . . 1.12 109.622 178.779 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 92.3 m-85 -118.92 113.68 21.4 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.611 -0.268 . . . . 0.4 111.168 -176.66 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 385' ' ' ASP . . . . . 0.515 ' O ' ' HA ' ' A' ' 313' ' ' TYR . 23.3 t70 -83.19 104.98 13.79 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 108.428 -0.952 . . . . 1.8 108.428 171.495 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 386' ' ' VAL . . . . . . . . . . . . . 36.0 m -115.27 133.21 62.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-O 121.665 0.745 . . . . 1.13 111.469 -174.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 387' ' ' LYS . . . . . . . . . . . . . 3.3 ptpp? -129.6 126.39 38.35 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.085 -0.961 . . . . 3.1 109.841 176.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 388' ' ' LEU . . . . . 0.781 HD12 ' HB ' ' A' ' 309' ' ' VAL . 22.3 tp -91.64 127.99 37.3 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 108.279 -1.008 . . . . 1.05 108.279 -179.738 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 28.2 m -127.76 -6.18 4.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 C-N-CA 120.77 -0.372 . . . . 1.2 111.591 -171.248 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 13.4 p -167.98 171.08 10.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.381 -0.372 . . . . 1.82 110.534 179.167 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 391' ' ' MET . . . . . 0.517 ' HE3' HG13 ' A' ' 309' ' ' VAL . 31.7 ttm -164.45 143.72 7.37 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.9 0.381 . . . . 1.14 111.348 -178.232 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 3.2 tppp? . . . . . 0 C--O 1.251 1.133 0 CA-C-O 118.678 -0.677 . . . . 5.51 109.257 173.038 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.5 HG23 ' HB3' ' A' ' 293' ' ' GLU . 1.9 p . . . . . 0 N--CA 1.445 -0.7 0 N-CA-C 110.016 -0.365 . . . . 1.27 110.016 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 92.7 mttt -101.45 154.73 18.56 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 110.418 -0.215 . . . . 2.51 110.418 179.371 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 59.9 tp -110.43 112.73 24.86 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 109.722 -0.473 . . . . 1.52 109.722 176.129 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.72 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 89.4 mt -100.41 -170.97 1.94 Allowed 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.057 -0.52 . . . . 1.39 110.924 -178.132 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 287' ' ' GLU . . . . . 0.429 ' HB3' HD11 ' A' ' 347' ' ' ILE . 28.1 tt0 -50.32 136.74 19.64 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 116.011 -0.54 . . . . 2.64 111.788 -179.043 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 76.22 -99.42 1.3 Allowed Glycine 0 N--CA 1.445 -0.761 0 C-N-CA 120.755 -0.736 . . . . 1.84 111.561 -177.114 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . -151.17 31.91 0.96 Allowed Glycine 0 N--CA 1.447 -0.575 0 N-CA-C 110.736 -0.945 . . . . 1.16 110.736 175.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 290' ' ' ILE . . . . . 0.72 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 72.6 mt -74.38 121.94 26.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 110.127 -0.324 . . . . 1.16 110.127 -176.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 17.9 mt -115.1 139.86 39.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 109.307 -0.627 . . . . 1.6 109.307 -178.736 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 292' ' ' ILE . . . . . . . . . . . . . 22.0 pt -136.91 127.02 39.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 C-N-CA 120.816 -0.354 . . . . 1.17 110.637 -179.098 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 293' ' ' GLU . . . . . 0.5 ' HB3' HG23 ' A' ' 283' ' ' THR . 16.9 pt-20 -110.87 131.83 54.71 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.09 -0.505 . . . . 2.31 109.933 173.271 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -89.64 109.03 20.03 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.186 0.517 . . . . 2.36 109.69 -173.106 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 295' ' ' ARG . . . . . 0.767 ' HG3' HG21 ' A' ' 296' ' ' VAL . 21.6 tpt180 -77.89 -54.35 6.42 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.278 -0.874 . . . . 3.99 111.232 -173.807 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.767 HG21 ' HG3' ' A' ' 295' ' ' ARG . 65.0 t -128.63 106.68 14.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 N-CA-C 109.199 -0.667 . . . . 1.31 109.199 178.614 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 25.3 m -73.34 114.0 11.05 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.11 0.481 . . . . 2.46 111.739 -175.519 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -113.76 171.15 13.65 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.565 -0.743 . . . . 1.04 111.46 178.125 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 26.4 tptp -137.73 127.4 25.25 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.419 0.628 . . . . 5.01 111.111 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -170.98 -155.02 10.12 Favored Glycine 0 N--CA 1.44 -1.034 0 N-CA-C 109.966 -1.254 . . . . 1.59 109.966 176.202 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . 0.547 ' HB2' ' SD ' ' A' ' 391' ' ' MET . 11.5 Cg_endo -59.48 146.87 93.76 Favored 'Trans proline' 0 CA--C 1.53 0.297 0 C-N-CA 122.305 2.003 . . . . 1.1 110.974 170.342 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 29.1 m80 -106.75 139.09 41.72 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.067 0.46 . . . . 1.85 111.445 -178.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -73.68 142.28 46.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.408 -0.814 . . . . 1.17 112.438 -175.497 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 57.6 tttp -150.24 165.52 32.7 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 108.149 -1.056 . . . . 3.26 108.149 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 65.8 mttm -62.92 134.94 56.99 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-N 118.203 0.456 . . . . 3.21 109.929 174.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 92.23 -6.54 78.49 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 121.087 -0.578 . . . . 0.7 111.859 -174.174 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 24.7 m -102.65 145.95 28.91 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.975 -0.379 . . . . 1.07 109.975 179.414 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 308' ' ' ARG . . . . . 0.564 ' HB3' ' HG3' ' A' ' 335' ' ' LYS . 11.5 ptp85 -108.86 123.82 49.67 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 109.499 -0.556 . . . . 3.98 109.499 179.723 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.786 ' HB ' HD12 ' A' ' 388' ' ' LEU . 34.4 m -110.86 139.17 35.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-O 121.387 0.613 . . . . 1.1 111.649 179.477 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -111.05 115.84 4.08 Favored Glycine 0 N--CA 1.444 -0.772 0 N-CA-C 110.189 -1.165 . . . . 0.32 110.189 176.858 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 14.2 ptp -133.38 177.75 7.44 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-O 121.498 0.666 . . . . 1.55 111.879 -170.498 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 312' ' ' ARG . . . . . 0.412 ' HB3' ' CB ' ' A' ' 327' ' ' THR . 94.1 mtt180 -131.89 144.84 51.15 Favored 'General case' 0 C--N 1.319 -0.717 0 N-CA-C 107.182 -1.414 . . . . 3.0 107.182 175.431 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 313' ' ' TYR . . . . . 0.615 ' HB3' HG13 ' A' ' 386' ' ' VAL . 33.6 p90 -159.53 159.27 33.18 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 113.162 0.801 . . . . 1.24 113.162 -172.519 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 60.5 t -128.27 113.26 29.5 Favored 'Isoleucine or valine' 0 C--O 1.237 0.423 0 CA-C-N 114.782 -1.099 . . . . 1.09 109.024 171.652 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -93.36 116.28 5.14 Favored Glycine 0 C--O 1.239 0.454 0 C-N-CA 121.241 -0.504 . . . . 0.32 112.602 -176.44 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 316' ' ' LYS . . . . . 0.729 ' HG2' HG23 ' A' ' 322' ' ' VAL . 26.7 mttp -122.19 154.76 37.03 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-O 121.181 0.515 . . . . 2.61 110.885 -177.521 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 317' ' ' LEU . . . . . 0.604 HD22 HG12 ' A' ' 376' ' ' ILE . 69.5 mt -81.04 164.16 22.69 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.202 -0.908 . . . . 1.32 109.471 172.481 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 318' ' ' LYS . . . . . 0.45 ' HD3' ' HB3' ' A' ' 381' ' ' GLU . 53.2 tptt -60.8 -25.31 66.48 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.074 0.464 . . . . 2.9 110.072 175.333 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 74.7 m-20 -75.18 -0.85 20.73 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.82 -0.627 . . . . 2.39 111.196 -179.283 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 84.97 10.73 78.11 Favored Glycine 0 C--N 1.334 0.423 0 C-N-CA 120.902 -0.666 . . . . 0.69 112.592 178.307 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 321' ' ' LYS . . . . . 0.527 ' HB2' HD13 ' A' ' 317' ' ' LEU . 30.6 mmtp -95.71 125.04 40.01 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.276 -0.268 . . . . 2.86 110.276 -179.489 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.729 HG23 ' HG2' ' A' ' 316' ' ' LYS . 50.3 t -83.31 115.36 25.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 110.214 -0.291 . . . . 1.96 110.214 179.221 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 47.7 p90 -91.72 -30.82 16.07 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.919 -0.312 . . . . 0.56 111.131 -178.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -150.5 153.1 35.23 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 110.025 -0.361 . . . . 1.68 110.025 177.531 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 21.0 pttm -163.41 133.32 4.27 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.965 0.412 . . . . 2.55 110.438 -177.08 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 4.1 p30 -155.13 121.44 5.25 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.443 0.639 . . . . 1.92 110.119 174.349 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 327' ' ' THR . . . . . 0.412 ' CB ' ' HB3' ' A' ' 312' ' ' ARG . 4.9 t -161.84 -42.51 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.601 -0.727 . . . . 2.06 111.485 -175.842 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.429 ' O ' ' HG3' ' A' ' 328' ' ' LYS . 25.1 pttm -79.21 95.1 5.54 Favored 'General case' 0 N--CA 1.454 -0.245 0 CA-C-O 121.568 0.699 . . . . 3.15 110.512 -178.344 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.431 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 85.42 -15.36 46.07 Favored Glycine 0 N--CA 1.448 -0.566 0 CA-C-N 115.484 -0.78 . . . . 1.17 112.617 179.505 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -104.36 100.59 22.7 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 120.483 0.182 . . . . 2.56 111.27 -179.096 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 331' ' ' PRO . . . . . 0.431 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 73.8 Cg_endo -88.06 131.55 2.67 Favored 'Trans proline' 0 N--CA 1.453 -0.888 0 C-N-CA 122.686 2.257 . . . . 0.73 112.027 172.385 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 78.7 t80 -110.28 120.83 43.69 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 109.513 -0.551 . . . . 0.76 109.513 177.53 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 53.2 t -114.49 116.04 51.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.417 -0.356 . . . . 1.14 110.432 -177.402 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.503 ' HZ ' HG22 ' A' ' 349' ' ' VAL . 33.5 p90 -129.0 156.85 43.15 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.832 0.349 . . . . 0.48 110.404 178.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 335' ' ' LYS . . . . . 0.564 ' HG3' ' HB3' ' A' ' 308' ' ' ARG . 3.6 mppt? -99.51 135.68 40.56 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.198 -0.456 . . . . 3.11 110.604 -179.576 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 9.6 mp -77.03 134.51 38.78 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.42 -0.585 . . . . 1.2 109.42 174.105 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 100.72 -1.45 55.51 Favored Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.265 -0.969 . . . . 1.02 112.323 -175.544 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 338' ' ' GLN . . . . . 0.45 ' HG2' ' O ' ' A' ' 335' ' ' LYS . 12.1 pt20 -87.94 138.92 31.03 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.673 -0.492 . . . . 3.1 109.673 177.371 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -82.17 46.29 3.49 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.614 -0.803 . . . . 0.98 112.348 -178.307 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 19.6 mt-10 -121.15 -20.73 6.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.825 0.345 . . . . 2.09 110.68 179.209 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 23.0 m -100.49 160.83 3.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 116.416 -0.356 . . . . 1.27 110.556 -176.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 342' ' ' ILE . . . . . 0.64 HD13 ' HA ' ' A' ' 367' ' ' ALA . 5.2 pt -82.84 159.92 3.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.313 -0.625 . . . . 1.08 109.313 175.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 343' ' ' LYS . . . . . 0.524 ' HE2' HD12 ' A' ' 347' ' ' ILE . 17.0 mtpt -60.98 -37.31 82.01 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 121.082 -0.247 . . . . 3.46 111.648 -173.285 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 344' ' ' GLY . . . . . 0.599 ' HA3' HD11 ' A' ' 362' ' ' ILE . . . -53.29 -35.43 50.18 Favored Glycine 0 CA--C 1.519 0.307 0 C-N-CA 121.003 -0.618 . . . . 0.32 112.556 176.575 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 8.0 m95 -73.6 -61.61 1.78 Allowed 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 111.796 0.295 . . . . 0.44 111.796 178.531 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -52.8 -36.77 58.82 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-O 120.918 0.39 . . . . 1.75 111.476 -178.387 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 347' ' ' ILE . . . . . 0.524 HD12 ' HE2' ' A' ' 343' ' ' LYS . 74.9 mt -84.48 -48.16 16.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.236 -0.438 . . . . 1.18 111.387 -177.474 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -64.7 -33.5 87.39 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 121.039 -0.6 . . . . 0.37 113.28 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 349' ' ' VAL . . . . . 0.529 ' O ' ' HB2' ' A' ' 352' ' ' MET . 95.2 t -80.99 -14.24 12.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.016 0.436 . . . . 1.08 110.752 179.313 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -64.79 115.74 5.6 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.992 0.425 . . . . 1.09 109.954 174.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 88.65 21.94 41.72 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.381 -0.914 . . . . 0.45 112.183 -176.088 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 352' ' ' MET . . . . . 0.767 ' HE3' ' HG2' ' A' ' 358' ' ' ARG . 0.0 OUTLIER -81.08 151.36 28.37 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.109 -0.7 . . . . 1.3 109.109 174.407 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 353' ' ' ALA . . . . . . . . . . . . . . . -121.49 130.63 53.67 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.731 0.3 . . . . 1.33 111.35 -176.449 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 98.2 t -57.43 119.43 2.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 116.067 -0.515 . . . . 1.24 110.428 174.326 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 107.65 -10.71 38.56 Favored Glycine 0 N--CA 1.448 -0.533 0 C-N-CA 121.065 -0.588 . . . . 0.44 111.965 -177.466 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -104.24 160.41 15.9 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.802 -0.714 . . . . 0.37 112.868 -178.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 357' ' ' GLU . . . . . 0.566 ' HB2' ' HB3' ' A' ' 387' ' ' LYS . 41.5 tt0 -136.85 134.17 36.63 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 122.773 0.429 . . . . 1.63 109.937 178.731 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 358' ' ' ARG . . . . . 0.767 ' HG2' ' HE3' ' A' ' 352' ' ' MET . 4.3 ptp180 -146.65 146.86 30.53 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 121.317 0.58 . . . . 1.53 111.298 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 359' ' ' ARG . . . . . . . . . . . . . 35.1 ttm180 -87.79 119.08 27.78 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.111 -0.949 . . . . 3.26 109.909 177.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 53.7 mt -98.29 119.67 46.62 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 CA-C-N 115.942 -0.572 . . . . 1.13 109.892 179.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 361' ' ' VAL . . . . . . . . . . . . . 74.6 t -103.23 109.09 25.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 115.244 -0.889 . . . . 1.14 108.856 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 362' ' ' ILE . . . . . 0.599 HD11 ' HA3' ' A' ' 344' ' ' GLY . 28.8 mt -115.57 107.91 48.09 Favored Pre-proline 0 C--N 1.323 -0.564 0 CA-C-N 116.484 -0.325 . . . . 1.13 111.038 -173.313 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 363' ' ' PRO . . . . . 0.481 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 11.6 Cg_endo -56.35 151.48 44.45 Favored 'Trans proline' 0 C--O 1.236 0.425 0 C-N-CA 122.373 2.048 . . . . 1.05 111.152 171.377 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 364' ' ' ALA . . . . . . . . . . . . . . . -46.96 -48.95 51.83 Favored Pre-proline 0 CA--C 1.541 0.624 0 N-CA-C 114.126 1.158 . . . . 1.16 114.126 -174.137 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 365' ' ' PRO . . . . . 0.481 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 75.5 Cg_exo -51.42 -29.05 29.66 Favored 'Trans proline' 0 C--N 1.365 1.399 0 C-N-CA 122.54 2.16 . . . . 1.14 114.05 -176.162 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 366' ' ' TYR . . . . . . . . . . . . . 9.1 m-85 -106.17 4.39 28.94 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 111.917 0.339 . . . . 1.03 111.917 -175.357 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 367' ' ' ALA . . . . . 0.649 ' HB2' HD13 ' A' ' 382' ' ' LEU . . . -117.08 -30.21 5.73 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 112.251 0.464 . . . . 1.07 112.251 -179.174 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 9.5 m-85 -165.46 -32.46 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 120.941 0.401 . . . . 1.44 110.53 -176.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 101.62 -128.79 9.68 Favored Glycine 0 N--CA 1.446 -0.636 0 C-N-CA 120.821 -0.704 . . . . 0.65 111.983 177.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 21.1 ptmt -108.84 11.02 26.43 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.007 0.432 . . . . 3.34 110.538 -179.504 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 51.9 tt0 -85.05 103.15 13.82 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.972 -0.558 . . . . 2.88 110.306 -177.179 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 372' ' ' ALA . . . . . . . . . . . . . . . -77.65 94.93 4.48 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.076 0.465 . . . . 1.39 110.919 -179.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 80.2 mt -73.91 155.88 88.39 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-N 115.706 -0.679 . . . . 1.55 109.599 176.159 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -57.61 114.32 1.9 Allowed 'Trans proline' 0 N--CA 1.46 -0.454 0 C-N-CA 121.664 1.576 . . . . 1.61 110.81 173.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 97.62 -29.55 10.8 Favored Glycine 0 CA--C 1.519 0.305 0 C-N-CA 121.034 -0.603 . . . . 0.96 112.558 -177.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 376' ' ' ILE . . . . . 0.604 HG12 HD22 ' A' ' 317' ' ' LEU . 25.9 mt -124.45 85.47 55.9 Favored Pre-proline 0 C--N 1.328 -0.347 0 O-C-N 122.808 -0.23 . . . . 1.29 110.554 -178.591 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 377' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -75.02 165.73 30.68 Favored 'Trans proline' 0 N--CA 1.46 -0.49 0 C-N-CA 122.666 2.244 . . . . 1.08 112.413 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 378' ' ' ALA . . . . . 0.425 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -64.96 159.84 22.06 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.084 -0.507 . . . . 1.52 111.595 -178.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 379' ' ' ASN . . . . . 0.425 ' HB2' ' O ' ' A' ' 378' ' ' ALA . 12.3 m120 73.66 -8.16 1.43 Allowed 'General case' 0 N--CA 1.473 0.676 0 CA-C-N 115.501 -0.772 . . . . 1.97 111.833 179.376 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 48.6 m -70.13 114.3 8.15 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.056 0.455 . . . . 1.91 110.928 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 381' ' ' GLU . . . . . 0.45 ' HB3' ' HD3' ' A' ' 318' ' ' LYS . 33.0 tt0 -73.5 106.8 5.44 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.549 -0.75 . . . . 1.03 109.862 177.548 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 382' ' ' LEU . . . . . 0.649 HD13 ' HB2' ' A' ' 367' ' ' ALA . 65.9 mt -78.91 141.23 37.78 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.68 0.276 . . . . 1.13 110.394 -178.241 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 24.3 m -123.91 124.85 43.54 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-O 121.002 0.43 . . . . 1.12 110.218 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -120.01 112.19 18.84 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.245 -0.434 . . . . 0.4 110.932 -178.142 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 385' ' ' ASP . . . . . 0.417 ' O ' ' HA ' ' A' ' 313' ' ' TYR . 72.4 m-20 -86.37 105.4 16.68 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 108.728 -0.841 . . . . 1.8 108.728 174.093 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 386' ' ' VAL . . . . . 0.615 HG13 ' HB3' ' A' ' 313' ' ' TYR . 22.2 m -121.72 136.47 58.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.212 0.53 . . . . 1.13 112.072 -173.64 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 387' ' ' LYS . . . . . 0.566 ' HB3' ' HB2' ' A' ' 357' ' ' GLU . 1.3 ptpp? -123.86 137.28 54.68 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.818 -0.628 . . . . 3.1 109.449 170.181 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 388' ' ' LEU . . . . . 0.786 HD12 ' HB ' ' A' ' 309' ' ' VAL . 19.1 tp -95.42 134.28 38.41 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 109.551 -0.537 . . . . 1.05 109.551 -177.377 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 30.9 m -127.91 -5.07 4.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 111.955 0.354 . . . . 1.2 111.955 -174.146 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 12.5 p -165.68 159.77 16.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.653 -0.248 . . . . 1.82 111.093 -178.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 391' ' ' MET . . . . . 0.695 ' HG2' ' HG2' ' A' ' 392' ' ' LYS . 41.8 ttm -164.59 155.94 15.4 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.971 -0.559 . . . . 1.14 109.832 178.282 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 392' ' ' LYS . . . . . 0.695 ' HG2' ' HG2' ' A' ' 391' ' ' MET . 32.1 mmmt . . . . . 0 C--O 1.247 0.923 0 O-C-N 124.259 0.975 . . . . 5.51 111.611 175.154 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.462 HG23 ' HB2' ' A' ' 293' ' ' GLU . 18.2 p . . . . . 0 C--O 1.235 0.302 0 CA-C-O 121.091 0.472 . . . . 1.27 111.679 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 284' ' ' LYS . . . . . 0.458 ' O ' ' HA ' ' A' ' 291' ' ' ILE . 92.8 mttt -118.52 144.17 46.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.41 -0.814 . . . . 2.51 111.026 -173.497 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . 0.493 HD12 ' HA2' ' A' ' 289' ' ' GLY . 56.3 tp -102.8 123.99 47.49 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.466 -0.788 . . . . 1.52 110.373 -177.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.446 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 98.6 mt -113.35 -175.74 2.74 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.9 -0.591 . . . . 1.39 109.703 178.44 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 287' ' ' GLU . . . . . 0.451 ' HG2' ' OH ' ' A' ' 366' ' ' TYR . 27.6 tt0 -56.73 144.07 34.05 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.178 0.513 . . . . 2.64 111.629 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.406 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 72.48 0.32 46.58 Favored Glycine 0 CA--C 1.52 0.352 0 CA-C-N 115.78 -0.646 . . . . 1.84 113.806 179.033 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . 0.493 ' HA2' HD12 ' A' ' 285' ' ' LEU . . . 95.11 12.37 55.07 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.696 -0.764 . . . . 1.16 113.028 179.109 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 290' ' ' ILE . . . . . 0.446 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 71.9 mt -66.62 121.54 15.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 121.253 0.549 . . . . 1.16 110.957 -179.071 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . 0.621 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 18.5 mm -104.38 138.96 26.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 115.737 -0.665 . . . . 1.6 110.232 178.898 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 292' ' ' ILE . . . . . . . . . . . . . 21.5 pt -127.29 129.36 70.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 120.925 0.393 . . . . 1.17 110.685 177.109 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 293' ' ' GLU . . . . . 0.462 ' HB2' HG23 ' A' ' 283' ' ' THR . 24.6 tt0 -118.83 117.96 30.28 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.661 -0.7 . . . . 2.31 109.759 177.906 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -88.33 96.14 10.46 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.654 -0.869 . . . . 2.36 108.654 -178.655 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 295' ' ' ARG . . . . . 0.818 HH22 ' HB3' ' A' ' 385' ' ' ASP . 38.0 ttp180 -76.11 -47.28 25.05 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.598 -0.728 . . . . 3.99 111.587 -171.751 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.7 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 23.3 t -119.03 103.5 14.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 N-CA-C 109.057 -0.719 . . . . 1.31 109.057 172.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 32.1 p -62.09 113.32 2.77 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 114.931 -1.031 . . . . 2.46 112.197 -174.023 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -119.88 152.02 17.2 Favored Glycine 0 N--CA 1.444 -0.769 0 CA-C-N 115.652 -0.703 . . . . 1.04 111.642 178.003 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -127.74 114.12 16.88 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.759 0.314 . . . . 5.01 110.336 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -170.56 -154.6 9.65 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 121.011 -0.614 . . . . 1.59 112.013 -179.414 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . 0.57 ' HD2' ' HB ' ' A' ' 354' ' ' VAL . 28.1 Cg_exo -62.33 137.85 67.97 Favored 'Trans proline' 0 C--O 1.233 0.234 0 C-N-CA 122.833 2.355 . . . . 1.1 112.048 178.656 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 302' ' ' HIS . . . . . 0.5 ' HA ' ' O ' ' A' ' 352' ' ' MET . 39.0 m80 -102.5 134.25 46.14 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 120.938 0.399 . . . . 1.85 110.714 178.157 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -69.54 132.41 46.22 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.986 -0.552 . . . . 1.17 111.685 -178.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 32.6 mmtp -117.19 177.96 4.53 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.042 -0.725 . . . . 3.26 109.042 176.105 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 61.4 mttm -68.77 132.24 46.48 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 109.698 -0.482 . . . . 3.21 109.698 173.27 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 84.74 7.97 83.43 Favored Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.697 -0.764 . . . . 0.7 112.553 -176.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 20.2 m -96.72 147.81 23.53 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 110.286 -0.265 . . . . 1.07 110.286 177.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 47.4 mtt180 -102.56 130.82 49.52 Favored 'General case' 0 CA--C 1.515 -0.395 0 N-CA-C 108.993 -0.743 . . . . 3.98 108.993 178.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.794 ' HB ' HD12 ' A' ' 388' ' ' LEU . 19.7 m -130.39 137.75 55.49 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-O 121.125 0.488 . . . . 1.1 111.815 -177.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -107.7 120.11 5.98 Favored Glycine 0 N--CA 1.444 -0.789 0 N-CA-C 109.826 -1.31 . . . . 0.32 109.826 176.336 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 311' ' ' MET . . . . . 0.61 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 22.9 ptm -140.01 177.04 8.25 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.58 0.705 . . . . 1.55 112.212 -171.321 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 312' ' ' ARG . . . . . 0.471 ' HB3' ' HA ' ' A' ' 327' ' ' THR . 20.9 mtm180 -133.64 145.37 49.92 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 107.228 -1.397 . . . . 3.0 107.228 174.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 313' ' ' TYR . . . . . 0.523 ' CB ' HG13 ' A' ' 386' ' ' VAL . 41.7 p90 -161.57 158.7 26.72 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 113.23 0.826 . . . . 1.24 113.23 -173.362 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 47.8 t -125.99 127.08 70.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 114.695 -1.139 . . . . 1.09 109.688 174.621 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -96.96 106.73 3.39 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 121.116 -0.564 . . . . 0.32 112.139 -179.656 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 316' ' ' LYS . . . . . 0.775 ' HG2' HG23 ' A' ' 322' ' ' VAL . 86.4 mttt -113.07 154.2 26.94 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.282 0.563 . . . . 2.61 111.722 -175.328 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 317' ' ' LEU . . . . . 0.406 HD13 ' HB3' ' A' ' 321' ' ' LYS . 88.8 mt -88.84 164.81 15.04 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.639 -0.71 . . . . 1.32 109.107 169.682 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 318' ' ' LYS . . . . . . . . . . . . . 37.8 ttpt -66.55 -21.94 66.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.991 0.424 . . . . 2.9 110.858 178.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 28.1 p30 -83.74 4.72 27.61 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.011 0.434 . . . . 2.39 111.028 179.101 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 91.21 -9.5 77.4 Favored Glycine 0 C--N 1.33 0.235 0 C-N-CA 121.252 -0.499 . . . . 0.69 113.258 174.673 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 321' ' ' LYS . . . . . 0.406 ' HB3' HD13 ' A' ' 317' ' ' LEU . 22.2 ttmm -77.98 123.55 26.94 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.896 0.379 . . . . 2.86 110.37 -179.003 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.775 HG23 ' HG2' ' A' ' 316' ' ' LYS . 67.7 t -85.44 128.49 39.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 116.171 -0.468 . . . . 1.96 110.368 -179.681 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 35.6 p90 -100.81 -35.26 9.5 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.645 -0.422 . . . . 0.56 111.587 -179.343 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -146.95 168.55 21.21 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 120.789 -0.364 . . . . 1.68 110.108 178.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . 0.573 ' N ' ' HD3' ' A' ' 325' ' ' LYS . 0.0 OUTLIER -176.55 143.48 0.48 Allowed 'General case' 0 C--O 1.233 0.192 0 CA-C-O 121.247 0.546 . . . . 2.55 111.781 -173.612 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 3.1 p30 -150.73 118.06 6.02 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.576 -0.738 . . . . 1.92 109.41 165.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 327' ' ' THR . . . . . 0.471 ' HA ' ' HB3' ' A' ' 312' ' ' ARG . 30.7 m -150.7 -55.39 0.15 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.952 -0.567 . . . . 2.06 111.169 -175.781 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 34.8 mtmm -72.04 94.21 1.47 Allowed 'General case' 0 C--O 1.235 0.299 0 CA-C-O 120.981 0.42 . . . . 3.15 111.272 -177.225 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.485 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 80.24 -10.68 41.0 Favored Glycine 0 N--CA 1.45 -0.422 0 CA-C-N 115.863 -0.608 . . . . 1.17 112.971 175.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 25.6 mtpp -103.9 100.7 21.31 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.789 0.294 . . . . 2.56 110.955 -177.507 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 331' ' ' PRO . . . . . 0.485 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 64.2 Cg_endo -88.26 136.38 3.41 Favored 'Trans proline' 0 N--CA 1.453 -0.907 0 C-N-CA 122.724 2.282 . . . . 0.73 112.115 172.547 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 75.4 t80 -110.78 122.83 48.8 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.461 -0.57 . . . . 0.76 109.461 177.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 333' ' ' VAL . . . . . 0.489 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 51.5 t -118.78 115.07 46.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 N-CA-C 110.176 -0.305 . . . . 1.14 110.176 -176.731 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.61 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 23.4 p90 -133.48 172.19 13.06 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.649 0.262 . . . . 0.48 110.597 -178.743 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 335' ' ' LYS . . . . . 0.674 ' H ' ' HD2' ' A' ' 335' ' ' LYS . 0.0 OUTLIER -117.29 140.38 49.62 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.335 -0.393 . . . . 3.11 110.208 -179.928 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 10.1 mp -79.22 151.03 31.44 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.707 0.289 . . . . 1.2 110.646 178.486 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 92.31 9.14 62.14 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.828 -0.701 . . . . 1.02 112.007 -176.105 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 338' ' ' GLN . . . . . 0.505 HE22 ' HB2' ' A' ' 334' ' ' PHE . 29.3 pt20 -98.17 161.54 13.66 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.796 0.332 . . . . 3.1 110.511 -179.687 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -99.82 4.54 57.79 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.852 -0.689 . . . . 0.98 112.277 -179.588 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 66.9 mm-40 -73.54 -34.13 65.05 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.904 0.383 . . . . 2.09 110.674 178.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 34.4 m -100.41 156.47 4.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.988 -0.551 . . . . 1.27 110.972 -178.165 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 12.8 pt -71.44 161.91 4.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.471 -0.331 . . . . 1.08 110.523 177.734 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.4 -38.45 87.1 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.359 -0.382 . . . . 3.46 111.84 -176.738 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -51.56 -36.53 39.41 Favored Glycine 0 C--N 1.331 0.255 0 C-N-CA 121.135 -0.555 . . . . 0.32 112.544 175.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 9.3 m95 -73.25 -60.3 2.31 Favored 'General case' 0 C--O 1.223 -0.338 0 CA-C-O 120.405 0.145 . . . . 0.44 111.067 177.181 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -49.45 -33.87 15.25 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.242 -0.436 . . . . 1.75 112.109 179.774 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 65.9 mt -85.76 -54.96 7.34 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.358 0 CA-C-N 116.638 -0.255 . . . . 1.18 111.661 178.55 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -60.97 -36.68 92.6 Favored Glycine 0 CA--C 1.521 0.434 0 C-N-CA 121.585 -0.34 . . . . 0.37 113.822 -177.462 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 349' ' ' VAL . . . . . 0.464 ' O ' ' HB2' ' A' ' 352' ' ' MET . 95.1 t -72.0 -24.96 23.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 120.904 0.383 . . . . 1.08 110.691 179.601 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.53 108.71 2.1 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.804 -0.443 . . . . 1.09 109.804 175.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 107.73 4.67 34.16 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 121.11 -0.567 . . . . 0.45 112.216 -175.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 352' ' ' MET . . . . . 0.882 ' HE3' ' HG2' ' A' ' 358' ' ' ARG . 0.0 OUTLIER -73.03 140.8 47.52 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 109.276 -0.639 . . . . 1.3 109.276 176.158 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 353' ' ' ALA . . . . . 0.449 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -108.08 132.07 53.95 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.732 0.301 . . . . 1.33 111.042 -177.353 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 354' ' ' VAL . . . . . 0.57 ' HB ' ' HD2' ' A' ' 301' ' ' PRO . 78.4 t -56.58 116.22 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 120.968 0.414 . . . . 1.24 110.551 175.031 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 110.67 -19.31 26.18 Favored Glycine 0 N--CA 1.445 -0.754 0 N-CA-C 111.59 -0.604 . . . . 0.44 111.59 -177.35 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -83.9 148.26 24.47 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 121.168 -0.539 . . . . 0.37 112.694 -176.307 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 357' ' ' GLU . . . . . 0.7 ' HB3' ' HB ' ' A' ' 296' ' ' VAL . 5.0 tp10 -126.61 117.94 23.82 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 108.973 -0.751 . . . . 1.63 108.973 179.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 358' ' ' ARG . . . . . 0.882 ' HG2' ' HE3' ' A' ' 352' ' ' MET . 6.2 ptp180 -145.16 148.44 33.59 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.362 0.601 . . . . 1.53 112.303 -173.15 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 359' ' ' ARG . . . . . 0.459 ' HD2' ' OE1' ' A' ' 293' ' ' GLU . 60.2 mtt85 -89.24 128.02 35.81 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.75 -0.659 . . . . 3.26 110.233 171.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 57.9 mt -110.97 118.39 57.23 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 N-CA-C 109.201 -0.666 . . . . 1.13 109.201 174.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 361' ' ' VAL . . . . . 0.621 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 51.4 t -96.97 117.51 41.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.19 -0.67 . . . . 1.14 109.19 178.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 362' ' ' ILE . . . . . . . . . . . . . 65.1 mt -115.01 103.98 54.31 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 116.339 -0.392 . . . . 1.13 110.818 -174.241 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 363' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -60.29 160.08 24.52 Favored 'Trans proline' 0 N--CA 1.463 -0.285 0 C-N-CA 122.642 2.228 . . . . 1.05 112.007 174.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 364' ' ' ALA . . . . . 0.479 ' N ' ' HD2' ' A' ' 365' ' ' PRO . . . -47.23 -51.09 44.34 Favored Pre-proline 0 CA--C 1.539 0.535 0 N-CA-C 114.191 1.182 . . . . 1.16 114.191 -176.126 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 365' ' ' PRO . . . . . 0.479 ' HD2' ' N ' ' A' ' 364' ' ' ALA . 16.8 Cg_endo -56.66 -25.87 62.19 Favored 'Trans proline' 0 C--N 1.358 1.078 0 C-N-CA 122.256 1.971 . . . . 1.14 114.168 -171.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 366' ' ' TYR . . . . . 0.451 ' OH ' ' HG2' ' A' ' 287' ' ' GLU . 4.1 m-85 -103.36 12.11 35.78 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-O 121.036 0.446 . . . . 1.03 111.236 -177.085 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -127.56 -116.43 0.26 Allowed 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 115.664 -0.698 . . . . 1.07 110.162 173.515 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 86.2 m-85 -85.51 -14.4 46.07 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.689 0.28 . . . . 1.44 111.712 -177.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 62.94 -109.18 2.53 Favored Glycine 0 N--CA 1.452 -0.265 0 CA-C-N 116.183 -0.462 . . . . 0.65 113.572 174.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 370' ' ' LYS . . . . . 0.456 ' HA ' ' HB2' ' A' ' 378' ' ' ALA . 58.0 mttm -102.72 8.06 39.58 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 111.722 0.267 . . . . 3.34 111.722 -175.763 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 371' ' ' GLN . . . . . 0.785 ' HA ' HE21 ' A' ' 371' ' ' GLN . 0.0 OUTLIER -88.83 99.55 12.47 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.964 0.411 . . . . 2.88 110.382 179.676 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 372' ' ' ALA . . . . . . . . . . . . . . . -74.31 110.8 8.9 Favored 'General case' 0 N--CA 1.45 -0.441 0 CA-C-N 115.931 -0.577 . . . . 1.39 111.005 178.644 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 71.9 mt -101.37 161.0 24.97 Favored Pre-proline 0 C--N 1.321 -0.641 0 N-CA-C 109.076 -0.713 . . . . 1.55 109.076 176.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_exo -60.55 114.64 2.22 Favored 'Trans proline' 0 N--CA 1.46 -0.484 0 C-N-CA 121.546 1.498 . . . . 1.61 110.96 174.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 92.0 -19.87 46.34 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.749 -0.738 . . . . 0.96 112.327 -178.559 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 23.6 mt -132.47 78.4 67.71 Favored Pre-proline 0 N--CA 1.465 0.287 0 CA-C-O 120.836 0.35 . . . . 1.29 110.512 -179.018 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 377' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_exo -70.72 166.89 27.33 Favored 'Trans proline' 0 N--CA 1.463 -0.319 0 C-N-CA 122.764 2.31 . . . . 1.08 113.017 -178.192 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 378' ' ' ALA . . . . . 0.456 ' HB2' ' HA ' ' A' ' 370' ' ' LYS . . . -56.1 151.78 11.65 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.742 -0.663 . . . . 1.52 110.846 178.036 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 379' ' ' ASN . . . . . 0.42 ' HA ' ' CB ' ' A' ' 364' ' ' ALA . 15.0 m120 64.92 32.25 10.83 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.184 0.516 . . . . 1.97 110.306 -178.423 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -77.63 117.02 18.65 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-N 115.643 -0.708 . . . . 1.91 111.158 177.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 381' ' ' GLU . . . . . . . . . . . . . 19.3 tt0 -92.05 100.63 13.23 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.031 -0.729 . . . . 1.03 109.031 177.394 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 78.8 mt -94.3 149.53 21.15 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.776 -0.647 . . . . 1.13 112.155 -170.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 29.5 m -127.99 128.43 45.02 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.746 -0.464 . . . . 1.12 109.746 176.304 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -119.65 113.09 20.15 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.573 -0.285 . . . . 0.4 111.248 -177.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 385' ' ' ASP . . . . . 0.818 ' HB3' HH22 ' A' ' 295' ' ' ARG . 1.6 m-20 -79.58 105.33 10.81 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.22 -1.03 . . . . 1.8 108.22 172.267 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 386' ' ' VAL . . . . . 0.586 ' HB ' ' CE ' ' A' ' 311' ' ' MET . 33.8 m -126.09 131.32 71.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.386 0.613 . . . . 1.13 112.456 -171.833 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 387' ' ' LYS . . . . . 0.486 ' HB2' ' CD ' ' A' ' 357' ' ' GLU . 49.9 tttm -126.63 132.07 51.32 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.933 -0.576 . . . . 3.1 109.835 175.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 388' ' ' LEU . . . . . 0.794 HD12 ' HB ' ' A' ' 309' ' ' VAL . 23.2 tp -94.67 137.53 33.66 Favored 'General case' 0 C--N 1.319 -0.717 0 N-CA-C 108.992 -0.744 . . . . 1.05 108.992 -178.45 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 33.7 m -126.93 -7.09 4.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 111.993 0.368 . . . . 1.2 111.993 -174.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 25.2 p -167.5 164.25 14.85 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.701 0.286 . . . . 1.82 111.273 -177.498 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 391' ' ' MET . . . . . . . . . . . . . 39.6 ttm -158.74 147.55 18.66 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.053 -0.521 . . . . 1.14 110.337 179.392 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 392' ' ' LYS . . . . . 0.797 ' HZ1' ' HB3' ' A' ' 392' ' ' LYS . 8.3 mtpm? . . . . . 0 C--O 1.248 0.993 0 CA-C-O 118.603 -0.713 . . . . 5.51 109.961 177.633 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 22.3 p . . . . . 0 C--O 1.236 0.366 0 CA-C-O 120.871 0.367 . . . . 1.27 111.711 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 60.6 mttp -134.33 141.32 46.87 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.779 -0.646 . . . . 2.51 109.676 175.562 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 39.3 tp -95.48 122.35 38.12 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 116.184 -0.462 . . . . 1.52 111.04 -178.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.643 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 98.2 mt -96.35 -170.92 2.18 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.931 -0.577 . . . . 1.39 110.599 176.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 287' ' ' GLU . . . . . 0.469 ' HG3' ' OH ' ' A' ' 366' ' ' TYR . 6.5 tp10 -52.86 145.21 12.98 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 115.901 -0.59 . . . . 2.64 111.551 178.808 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.494 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 72.22 -101.61 1.07 Allowed Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.947 -0.57 . . . . 1.84 111.736 -177.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . -148.15 25.57 1.42 Allowed Glycine 0 N--CA 1.444 -0.791 0 N-CA-C 110.214 -1.155 . . . . 1.16 110.214 175.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 290' ' ' ILE . . . . . 0.643 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 73.1 mt -72.36 124.72 29.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.235 -0.482 . . . . 1.16 110.446 -175.731 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . 0.564 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 16.2 mt -107.28 139.39 29.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 116.201 -0.454 . . . . 1.6 109.965 -177.217 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 292' ' ' ILE . . . . . . . . . . . . . 14.8 pt -128.06 127.53 67.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 121.176 0.512 . . . . 1.17 110.797 177.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 293' ' ' GLU . . . . . 0.431 ' CD ' HH21 ' A' ' 359' ' ' ARG . 30.2 tt0 -114.65 118.26 33.17 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 114.929 -1.032 . . . . 2.31 109.123 177.518 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -81.23 114.08 19.79 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.222 -0.591 . . . . 2.36 110.06 -174.09 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 295' ' ' ARG . . . . . 0.524 ' HG2' ' HA ' ' A' ' 358' ' ' ARG . 20.3 mmm180 -86.45 -56.08 3.6 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.632 -0.713 . . . . 3.99 110.365 -174.242 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.544 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 96.7 t -124.0 125.01 70.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.908 -0.587 . . . . 1.31 109.905 178.745 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 3.9 t -64.1 141.25 58.84 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.284 0.564 . . . . 2.46 111.688 -177.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -150.78 142.11 9.28 Favored Glycine 0 N--CA 1.443 -0.89 0 N-CA-C 110.992 -0.843 . . . . 1.04 110.992 176.024 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 51.5 pttt -131.55 117.61 18.99 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.379 0.609 . . . . 5.01 110.534 177.188 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -172.01 -154.43 10.03 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.335 -0.848 . . . . 1.59 111.063 -177.688 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . 0.452 ' O ' ' HA ' ' A' ' 353' ' ' ALA . 24.6 Cg_exo -62.66 133.53 42.77 Favored 'Trans proline' 0 N--CA 1.462 -0.34 0 C-N-CA 122.356 2.038 . . . . 1.1 111.404 176.282 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 35.9 m80 -95.12 130.15 41.94 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.308 -0.406 . . . . 1.85 110.45 178.474 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 303' ' ' ALA . . . . . 0.444 ' HB3' HG12 ' A' ' 309' ' ' VAL . . . -67.12 133.58 50.1 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.587 -0.733 . . . . 1.17 111.434 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 64.4 pttt -132.2 179.13 6.29 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 108.762 -0.829 . . . . 3.26 108.762 173.499 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 23.5 ttmm -66.33 135.62 54.63 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 120.587 -0.445 . . . . 3.21 110.333 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 92.48 -7.04 77.97 Favored Glycine 0 CA--C 1.521 0.42 0 C-N-CA 121.078 -0.582 . . . . 0.7 112.427 -174.774 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 30.3 m -88.97 150.03 23.01 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.716 0.293 . . . . 1.07 110.842 -178.484 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 82.2 mtt180 -115.31 102.52 9.93 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 109.468 -0.567 . . . . 3.98 109.468 -178.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.803 ' HB ' HD12 ' A' ' 388' ' ' LEU . 35.7 m -102.52 148.26 8.11 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.807 0 CA-C-N 115.592 -0.731 . . . . 1.1 112.458 -175.384 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -113.37 118.24 4.46 Favored Glycine 0 N--CA 1.446 -0.69 0 N-CA-C 110.672 -0.971 . . . . 0.32 110.672 176.554 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 311' ' ' MET . . . . . 0.5 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 6.8 ptm -139.48 178.49 7.18 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.788 0.804 . . . . 1.55 112.434 -172.531 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 55.0 mtt180 -136.06 152.57 51.02 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 113.896 -1.502 . . . . 3.0 107.68 176.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 313' ' ' TYR . . . . . 0.546 ' CB ' HG13 ' A' ' 386' ' ' VAL . 32.8 p90 -159.57 158.89 32.54 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 119.556 -0.858 . . . . 1.24 113.276 -174.474 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . 0.484 HG11 ' HG3' ' A' ' 316' ' ' LYS . 57.9 t -127.02 102.99 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 CA-C-N 114.811 -1.086 . . . . 1.09 109.355 171.071 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -87.13 110.32 3.54 Favored Glycine 0 C--O 1.237 0.336 0 N-CA-C 112.082 -0.407 . . . . 0.32 112.082 -178.47 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 316' ' ' LYS . . . . . 0.738 ' HG2' ' HB ' ' A' ' 322' ' ' VAL . 33.2 mtmm -126.37 156.03 41.16 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.842 0.353 . . . . 2.61 110.92 -174.794 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 317' ' ' LEU . . . . . 0.508 HD13 ' HB3' ' A' ' 321' ' ' LYS . 82.6 mt -81.73 173.33 12.41 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.821 -0.627 . . . . 1.32 110.963 177.007 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 318' ' ' LYS . . . . . . . . . . . . . 60.3 tttp -65.26 -22.27 66.84 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.606 -0.724 . . . . 2.9 110.674 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 32.6 p-10 -91.67 -1.36 57.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.411 -0.359 . . . . 2.39 111.095 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 97.83 -5.31 61.77 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.927 -0.654 . . . . 0.69 113.211 178.129 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 321' ' ' LYS . . . . . 0.508 ' HB3' HD13 ' A' ' 317' ' ' LEU . 14.4 tppt? -73.09 111.71 8.45 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.834 0.349 . . . . 2.86 110.27 -179.767 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.738 ' HB ' ' HG2' ' A' ' 316' ' ' LYS . 5.4 p -81.4 124.33 38.77 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 116.178 -0.464 . . . . 1.96 110.425 179.034 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 50.4 p90 -102.36 -32.23 10.11 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.908 -0.317 . . . . 0.56 111.323 -177.492 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -148.3 132.46 17.35 Favored 'General case' 0 CA--C 1.515 -0.38 0 N-CA-C 109.954 -0.387 . . . . 1.68 109.954 -179.203 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 59.3 pttt -153.97 134.7 13.67 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.907 0.384 . . . . 2.55 111.449 -174.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 326' ' ' ASN . . . . . 0.601 ' HB2' ' HB2' ' A' ' 330' ' ' LYS . 3.9 p30 -146.66 117.08 7.45 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.697 0.76 . . . . 1.92 110.322 169.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 3.2 p -142.16 -40.83 0.35 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.909 -1.041 . . . . 2.06 110.363 179.205 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 21.1 pttp -80.51 101.93 9.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.331 0.586 . . . . 3.15 111.432 -178.731 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.494 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 76.04 -13.85 6.88 Favored Glycine 0 N--CA 1.452 -0.237 0 CA-C-N 115.616 -0.72 . . . . 1.17 113.633 175.212 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 330' ' ' LYS . . . . . 0.601 ' HB2' ' HB2' ' A' ' 326' ' ' ASN . 27.4 mmmt -103.76 101.52 25.11 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 117.305 0.552 . . . . 2.56 111.068 -178.025 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 331' ' ' PRO . . . . . 0.494 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 72.2 Cg_endo -87.83 126.59 2.14 Favored 'Trans proline' 0 N--CA 1.45 -1.042 0 C-N-CA 122.96 2.44 . . . . 0.73 111.826 172.647 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 65.4 t80 -100.04 118.89 37.37 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 110.092 -0.336 . . . . 0.76 110.092 179.376 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 333' ' ' VAL . . . . . 0.476 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 61.6 t -119.32 114.82 45.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 N-CA-C 110.119 -0.326 . . . . 1.14 110.119 -178.734 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.5 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 14.1 p90 -131.64 159.38 38.48 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.958 0.409 . . . . 0.48 110.201 -179.64 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 335' ' ' LYS . . . . . 0.423 ' HG3' ' HG3' ' A' ' 338' ' ' GLN . 18.2 pttm -99.72 128.92 45.81 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.902 -0.59 . . . . 3.11 110.346 177.336 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 10.0 mp -64.54 117.53 7.5 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.484 -0.561 . . . . 1.2 109.484 174.645 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 129.36 10.09 3.11 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.774 -0.727 . . . . 1.02 111.699 -172.027 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 338' ' ' GLN . . . . . 0.626 ' HB3' ' HG2' ' A' ' 340' ' ' GLU . 91.8 mt-30 -84.35 141.93 30.53 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.962 0.411 . . . . 3.1 110.62 176.111 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -96.11 -4.95 59.73 Favored Glycine 0 N--CA 1.448 -0.512 0 N-CA-C 110.857 -0.897 . . . . 0.98 110.857 175.194 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 340' ' ' GLU . . . . . 0.626 ' HG2' ' HB3' ' A' ' 338' ' ' GLN . 5.5 pt-20 -84.18 -20.15 32.87 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.078 -0.561 . . . . 2.09 110.984 179.21 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 33.4 m -94.06 154.92 3.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 109.524 -0.547 . . . . 1.27 109.524 174.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 13.4 pt -74.86 154.25 6.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 N-CA-C 110.034 -0.358 . . . . 1.08 110.034 179.24 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 343' ' ' LYS . . . . . 0.424 ' HA ' ' HE2' ' A' ' 343' ' ' LYS . 5.7 mmpt? -60.62 -30.69 70.01 Favored 'General case' 0 N--CA 1.464 0.258 0 N-CA-C 111.73 0.27 . . . . 3.46 111.73 -174.72 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -55.55 -28.44 51.33 Favored Glycine 0 CA--C 1.521 0.437 0 C-N-CA 121.14 -0.553 . . . . 0.32 112.884 174.387 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 8.4 m95 -82.26 -60.96 2.03 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 111.648 0.24 . . . . 0.44 111.648 178.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -48.49 -35.73 13.69 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 120.923 0.392 . . . . 1.75 111.73 177.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 62.1 mt -88.51 -51.89 11.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.163 -0.471 . . . . 1.18 111.756 179.139 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 348' ' ' GLY . . . . . 0.414 ' HA2' HD11 ' A' ' 286' ' ' LEU . . . -61.08 -36.34 92.17 Favored Glycine 0 C--N 1.331 0.301 0 C-N-CA 121.36 -0.448 . . . . 0.37 113.73 -176.797 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 88.6 t -73.66 -23.2 19.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 121.182 0.515 . . . . 1.08 110.775 -179.579 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -70.18 105.61 3.0 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.097 0.475 . . . . 1.09 110.512 179.357 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 120.9 -2.78 11.81 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.864 -0.684 . . . . 0.45 112.303 -176.794 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 352' ' ' MET . . . . . 0.438 ' HG2' ' HD2' ' A' ' 358' ' ' ARG . 69.1 mtp -82.13 144.41 30.77 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.905 0.353 . . . . 1.3 110.622 176.356 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 353' ' ' ALA . . . . . 0.452 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -108.57 147.99 30.97 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.879 -0.6 . . . . 1.33 110.682 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 85.7 t -57.7 117.71 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 121.121 0.486 . . . . 1.24 110.835 176.048 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 110.67 -27.15 11.58 Favored Glycine 0 N--CA 1.445 -0.752 0 N-CA-C 111.049 -0.82 . . . . 0.44 111.049 -176.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -73.99 139.21 25.76 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 121.3 -0.476 . . . . 0.37 112.744 -177.162 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 357' ' ' GLU . . . . . 0.713 ' HB2' ' HG3' ' A' ' 387' ' ' LYS . 36.6 tt0 -125.0 133.87 52.82 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 109.063 -0.718 . . . . 1.63 109.063 178.358 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 358' ' ' ARG . . . . . 0.524 ' HA ' ' HG2' ' A' ' 295' ' ' ARG . 8.0 ptp180 -155.44 143.89 20.31 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.66 0.743 . . . . 1.53 112.294 -178.841 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 359' ' ' ARG . . . . . 0.431 HH21 ' CD ' ' A' ' 293' ' ' GLU . 20.9 ttp85 -86.25 117.95 25.39 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 114.773 -1.103 . . . . 3.26 109.485 177.813 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 50.3 mt -99.73 121.81 50.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.729 -0.669 . . . . 1.13 110.235 -178.31 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 361' ' ' VAL . . . . . 0.564 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 47.7 t -102.45 113.35 38.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 N-CA-C 109.15 -0.685 . . . . 1.14 109.15 176.574 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 362' ' ' ILE . . . . . . . . . . . . . 62.1 mt -113.19 101.49 53.53 Favored Pre-proline 0 C--N 1.324 -0.514 0 CA-C-O 120.728 0.299 . . . . 1.13 110.987 -175.096 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 363' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -56.43 159.9 12.36 Favored 'Trans proline' 0 C--O 1.237 0.463 0 C-N-CA 122.571 2.181 . . . . 1.05 112.41 171.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 364' ' ' ALA . . . . . 0.518 ' N ' ' HD2' ' A' ' 365' ' ' PRO . . . -47.72 -49.59 56.09 Favored Pre-proline 0 CA--C 1.539 0.547 0 N-CA-C 114.528 1.307 . . . . 1.16 114.528 -173.348 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 365' ' ' PRO . . . . . 0.518 ' HD2' ' N ' ' A' ' 364' ' ' ALA . 9.6 Cg_endo -51.03 -32.18 37.81 Favored 'Trans proline' 0 C--N 1.361 1.2 0 C-N-CA 122.567 2.178 . . . . 1.14 114.186 -172.832 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 366' ' ' TYR . . . . . 0.494 ' CE2' ' HA3' ' A' ' 288' ' ' GLY . 13.8 m-85 -100.52 12.13 37.97 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.831 -0.348 . . . . 1.03 111.841 -175.466 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -127.06 -109.6 0.3 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.441 -0.345 . . . . 1.07 110.907 174.799 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 78.8 m-85 -93.59 -15.83 25.0 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 111.977 0.362 . . . . 1.44 111.977 -179.723 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 64.82 -113.91 6.3 Favored Glycine 0 CA--C 1.52 0.388 0 C-N-CA 121.047 -0.597 . . . . 0.65 113.691 175.627 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 65.6 mttm -92.1 3.91 54.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.751 0.31 . . . . 3.34 111.525 -174.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -80.63 99.27 8.06 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.863 0.363 . . . . 2.88 111.638 -177.334 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 372' ' ' ALA . . . . . . . . . . . . . . . -78.29 92.48 4.52 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 115.952 -0.567 . . . . 1.39 109.908 171.362 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 30.5 mt -84.0 159.28 60.33 Favored Pre-proline 0 C--N 1.316 -0.885 0 CA-C-N 115.636 -0.711 . . . . 1.55 109.342 -179.686 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.55 113.0 1.43 Allowed 'Trans proline' 0 N--CA 1.461 -0.394 0 C-N-CA 121.507 1.472 . . . . 1.61 110.684 173.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 96.81 -29.92 9.74 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.809 -0.71 . . . . 0.96 112.533 -178.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 40.0 mt -125.95 88.94 53.38 Favored Pre-proline 0 C--N 1.332 -0.192 0 CA-C-N 116.772 0.286 . . . . 1.29 110.279 -179.242 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 377' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_exo -69.58 166.52 27.09 Favored 'Trans proline' 0 N--CA 1.463 -0.3 0 C-N-CA 122.596 2.198 . . . . 1.08 113.191 -178.355 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 378' ' ' ALA . . . . . . . . . . . . . . . -61.06 157.32 15.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.202 -0.908 . . . . 1.52 111.985 -176.771 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 379' ' ' ASN . . . . . 0.482 ' HA ' ' HB1' ' A' ' 364' ' ' ALA . 18.6 m120 65.69 23.16 11.59 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-N 115.377 -0.828 . . . . 1.97 111.113 177.798 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 59.6 p -66.72 116.43 7.62 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.003 -0.544 . . . . 1.91 111.134 179.501 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 381' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -80.37 98.55 7.52 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 108.971 -0.751 . . . . 1.03 108.971 174.541 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 92.6 mt -85.34 136.06 33.63 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.941 0.4 . . . . 1.13 111.248 -176.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 32.6 m -118.97 118.54 31.78 Favored 'General case' 0 N--CA 1.444 -0.734 0 N-CA-C 109.93 -0.396 . . . . 1.12 109.93 177.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -113.16 109.39 18.7 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.867 -0.42 . . . . 0.4 109.867 -177.204 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -87.39 104.88 16.85 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 108.034 -1.098 . . . . 1.8 108.034 176.636 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 386' ' ' VAL . . . . . 0.546 HG13 ' CB ' ' A' ' 313' ' ' TYR . 19.9 m -122.89 148.68 26.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 121.563 0.697 . . . . 1.13 112.382 -170.057 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 387' ' ' LYS . . . . . 0.713 ' HG3' ' HB2' ' A' ' 357' ' ' GLU . 46.5 tttm -137.39 129.91 29.83 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.402 -0.817 . . . . 3.1 109.652 176.128 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 388' ' ' LEU . . . . . 0.803 HD12 ' HB ' ' A' ' 309' ' ' VAL . 24.6 tp -89.58 134.55 34.08 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.776 -0.824 . . . . 1.05 108.776 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 27.5 m -129.36 -3.49 3.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 N-CA-C 112.251 0.463 . . . . 1.2 112.251 -174.064 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 10.2 t -168.5 156.67 8.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.69 0.281 . . . . 1.82 110.806 -177.506 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 391' ' ' MET . . . . . 0.56 ' HE3' HG13 ' A' ' 309' ' ' VAL . 40.5 ttm -156.33 155.26 31.93 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.229 -0.656 . . . . 1.14 109.229 174.401 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 392' ' ' LYS . . . . . 0.438 ' HE2' ' HB2' ' A' ' 392' ' ' LYS . 3.4 ptmm? . . . . . 0 C--O 1.25 1.123 0 CA-C-O 118.654 -0.689 . . . . 5.51 110.7 175.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 15.2 p . . . . . 0 N--CA 1.452 -0.363 0 CA-C-O 120.778 0.323 . . . . 1.27 111.277 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 284' ' ' LYS . . . . . 0.559 ' HB2' HG13 ' A' ' 292' ' ' ILE . 72.4 mmtt -130.12 135.94 48.76 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 109.213 -0.662 . . . . 2.51 109.213 179.723 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 31.1 tp -104.78 124.16 48.93 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 120.896 0.379 . . . . 1.52 110.138 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.776 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 76.7 mt -112.63 -175.21 2.62 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.578 -0.737 . . . . 1.39 109.813 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 2.6 tp10 -60.61 147.37 42.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.148 0.499 . . . . 2.64 111.336 -177.765 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.582 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 69.37 -1.77 12.17 Favored Glycine 0 N--CA 1.452 -0.297 0 CA-C-N 115.84 -0.618 . . . . 1.84 113.648 -179.892 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 97.6 14.8 39.51 Favored Glycine 0 N--CA 1.446 -0.681 0 C-N-CA 120.21 -0.995 . . . . 1.16 113.556 -179.274 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 290' ' ' ILE . . . . . 0.776 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 79.5 mt -64.16 122.57 15.31 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.167 0 CA-C-N 117.488 0.644 . . . . 1.16 110.507 176.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . 0.545 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 80.2 mt -107.36 138.27 34.3 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 N-CA-C 110.355 -0.239 . . . . 1.6 110.355 177.08 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 292' ' ' ILE . . . . . 0.559 HG13 ' HB2' ' A' ' 284' ' ' LYS . 23.6 pt -127.02 130.85 71.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 N-CA-C 109.489 -0.56 . . . . 1.17 109.489 174.34 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 293' ' ' GLU . . . . . 0.407 ' CD ' HH21 ' A' ' 359' ' ' ARG . 34.3 tt0 -123.43 121.42 35.69 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 115.176 -0.92 . . . . 2.31 109.954 -177.139 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 51.9 m-20 -78.3 110.93 13.76 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.712 -0.477 . . . . 2.36 109.712 -176.637 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 295' ' ' ARG . . . . . . . . . . . . . 39.1 ttt180 -88.14 -58.24 2.64 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.832 -0.622 . . . . 3.99 110.499 -175.176 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.585 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 58.1 t -128.24 141.36 46.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 110.203 -0.295 . . . . 1.31 110.203 177.207 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 9.0 t -96.07 149.84 21.16 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.3 -0.409 . . . . 2.46 111.033 -178.197 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -152.93 -164.64 12.65 Favored Glycine 0 C--N 1.331 0.261 0 C-N-CA 121.428 -0.415 . . . . 1.04 112.174 -177.19 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 299' ' ' LYS . . . . . 0.561 ' O ' ' HB2' ' A' ' 353' ' ' ALA . 62.0 tttp -72.78 139.54 47.15 Favored 'General case' 0 CA--C 1.52 -0.211 0 N-CA-C 108.595 -0.891 . . . . 5.01 108.595 173.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -116.34 80.48 0.3 Allowed Glycine 0 N--CA 1.445 -0.756 0 C-N-CA 119.314 -1.422 . . . . 1.59 115.272 -170.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . 0.538 ' HD2' ' H ' ' A' ' 354' ' ' VAL . 8.2 Cg_exo -74.57 131.51 14.92 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.036 1.824 . . . . 1.1 108.145 159.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 302' ' ' HIS . . . . . 0.422 ' O ' ' HE3' ' A' ' 304' ' ' LYS . 27.4 m80 -85.91 107.35 17.67 Favored 'General case' 0 C--N 1.319 -0.731 0 C-N-CA 120.314 -0.554 . . . . 1.85 111.423 -169.093 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -66.33 109.08 2.55 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.703 -0.681 . . . . 1.17 110.375 175.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 304' ' ' LYS . . . . . 0.422 ' HE3' ' O ' ' A' ' 302' ' ' HIS . 11.5 ptpt -127.47 -174.44 3.18 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 116.326 -0.397 . . . . 3.26 110.161 -179.171 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.793 ' HG3' ' HA3' ' A' ' 337' ' ' GLY . 62.3 tttm -65.71 124.51 22.6 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.994 0.426 . . . . 3.21 111.019 -175.251 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 97.14 -11.24 65.71 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 121.075 -0.583 . . . . 0.7 112.81 -178.063 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 307' ' ' THR . . . . . 0.426 ' O ' ' HA ' ' A' ' 335' ' ' LYS . 28.4 m -82.92 142.8 31.16 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 122.881 -0.188 . . . . 1.07 110.524 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 22.6 ptt180 -106.78 116.03 31.22 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 121.306 0.574 . . . . 3.98 109.583 -178.234 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.804 ' HB ' HD12 ' A' ' 388' ' ' LEU . 31.1 m -113.69 147.8 17.0 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 115.644 -0.707 . . . . 1.1 111.918 -177.397 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -116.67 114.19 2.97 Favored Glycine 0 N--CA 1.443 -0.896 0 N-CA-C 110.126 -1.19 . . . . 0.32 110.126 174.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 311' ' ' MET . . . . . 0.471 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 6.9 ptm -131.65 177.68 7.33 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 121.897 0.856 . . . . 1.55 112.488 -172.283 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -138.07 150.31 46.78 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 113.726 -1.579 . . . . 3.0 107.794 177.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 313' ' ' TYR . . . . . 0.455 ' CB ' HG13 ' A' ' 386' ' ' VAL . 44.3 p90 -156.45 155.33 31.88 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 120.741 -0.384 . . . . 1.24 111.375 -169.74 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . 0.582 HG12 ' HE3' ' A' ' 316' ' ' LYS . 38.2 t -120.46 105.71 17.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-N 115.587 -0.733 . . . . 1.09 109.247 169.206 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -84.82 109.38 3.26 Favored Glycine 0 N--CA 1.445 -0.717 0 CA-C-N 116.088 -0.506 . . . . 0.32 112.168 -178.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 316' ' ' LYS . . . . . 0.765 ' HG2' HG23 ' A' ' 322' ' ' VAL . 93.6 mttt -123.32 161.05 25.42 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-N 114.929 -0.636 . . . . 2.61 110.464 -178.308 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 317' ' ' LEU . . . . . 0.488 HD13 ' HD3' ' A' ' 321' ' ' LYS . 83.6 mt -88.18 165.81 14.81 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 109.392 -0.596 . . . . 1.32 109.392 170.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 318' ' ' LYS . . . . . 0.895 ' HD2' ' HB3' ' A' ' 381' ' ' GLU . 0.2 OUTLIER -61.15 -19.37 61.46 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.31 -0.405 . . . . 2.9 111.633 179.844 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 319' ' ' ASN . . . . . 0.407 ' OD1' ' HB2' ' A' ' 317' ' ' LEU . 28.5 p-10 -90.41 -1.61 57.92 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 116.577 -0.283 . . . . 2.39 111.146 -178.575 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 94.5 6.8 60.86 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.505 -0.855 . . . . 0.69 113.11 177.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 321' ' ' LYS . . . . . 0.488 ' HD3' HD13 ' A' ' 317' ' ' LEU . 63.5 tttp -81.99 118.57 23.09 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.947 0.403 . . . . 2.86 110.472 177.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.765 HG23 ' HG2' ' A' ' 316' ' ' LYS . 12.6 t -85.56 129.78 37.39 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 116.115 -0.493 . . . . 1.96 109.948 179.381 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 32.3 p90 -111.48 -43.57 3.66 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 120.528 -0.469 . . . . 0.56 111.586 178.508 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -148.07 128.56 14.03 Favored 'General case' 0 CA--C 1.514 -0.431 0 C-N-CA 120.507 -0.477 . . . . 1.68 110.958 -177.658 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . 0.526 ' HE3' HG12 ' A' ' 322' ' ' VAL . 8.4 pttp -145.75 128.31 16.08 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.092 0.472 . . . . 2.55 110.88 -179.05 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 326' ' ' ASN . . . . . 0.409 ' C ' ' HG1' ' A' ' 327' ' ' THR . 55.6 m-80 -125.25 116.49 22.06 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.544 -0.753 . . . . 1.92 109.055 173.605 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 327' ' ' THR . . . . . 0.409 ' HG1' ' C ' ' A' ' 326' ' ' ASN . 26.3 m -157.0 -38.89 0.07 Allowed 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.675 -0.693 . . . . 2.06 110.155 -177.202 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 29.6 mmmt -75.18 92.74 2.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.788 -0.642 . . . . 3.15 110.372 179.589 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.43 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 75.1 -17.7 2.86 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 121.245 -0.502 . . . . 1.17 113.606 177.491 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 82.4 mttt -103.37 103.26 34.26 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 117.001 0.401 . . . . 2.56 111.571 -175.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 331' ' ' PRO . . . . . 0.43 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 98.3 Cg_endo -87.91 145.83 6.6 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 122.825 2.35 . . . . 0.73 112.167 171.698 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 72.3 t80 -111.15 119.51 39.2 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.364 -0.606 . . . . 0.76 109.364 175.526 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 46.7 t -111.64 126.3 69.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 120.648 0.261 . . . . 1.14 110.842 -177.236 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.597 ' HB2' HE22 ' A' ' 338' ' ' GLN . 28.4 p90 -153.54 169.19 23.81 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.34 -0.391 . . . . 0.48 110.2 178.415 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 335' ' ' LYS . . . . . 0.487 ' HE2' ' HB3' ' A' ' 338' ' ' GLN . 0.0 OUTLIER -112.77 146.22 39.18 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.152 0.501 . . . . 3.11 111.418 177.201 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 10.9 mp -78.35 150.89 33.12 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.853 -0.612 . . . . 1.2 110.262 177.661 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 337' ' ' GLY . . . . . 0.793 ' HA3' ' HG3' ' A' ' 305' ' ' LYS . . . 89.12 27.14 24.19 Favored Glycine 0 N--CA 1.445 -0.706 0 C-N-CA 120.739 -0.743 . . . . 1.02 112.459 -177.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 338' ' ' GLN . . . . . 0.597 HE22 ' HB2' ' A' ' 334' ' ' PHE . 30.2 pt20 -118.97 163.06 17.5 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 110.085 -0.339 . . . . 3.1 110.085 176.406 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -93.6 2.84 70.79 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.952 -0.642 . . . . 0.98 112.329 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -76.43 -24.78 53.96 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.948 0.404 . . . . 2.09 110.876 -178.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 31.0 m -108.74 152.66 10.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.241 -0.436 . . . . 1.27 110.755 -178.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 342' ' ' ILE . . . . . 0.492 ' HB ' ' HA ' ' A' ' 367' ' ' ALA . 14.8 pt -70.52 156.24 7.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.858 -0.423 . . . . 1.08 109.858 178.457 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -64.48 -32.61 74.32 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.626 -0.261 . . . . 3.46 111.396 -175.386 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -53.41 -41.86 63.88 Favored Glycine 0 CA--C 1.523 0.561 0 C-N-CA 120.613 -0.803 . . . . 0.32 112.16 173.462 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 7.8 m95 -70.51 -58.42 3.73 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.75 0.309 . . . . 0.44 110.489 175.474 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -49.49 -32.27 11.78 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 115.877 -0.601 . . . . 1.75 112.355 -179.308 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 69.2 mt -89.17 -53.21 9.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.501 -0.318 . . . . 1.18 111.789 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -64.32 -32.93 85.82 Favored Glycine 0 C--N 1.332 0.307 0 C-N-CA 121.189 -0.529 . . . . 0.37 113.664 -177.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 89.8 t -78.44 -16.33 13.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.988 0.423 . . . . 1.08 111.035 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.01 106.41 1.25 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.235 0.541 . . . . 1.09 110.241 178.592 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 98.31 22.33 15.1 Favored Glycine 0 N--CA 1.444 -0.787 0 CA-C-N 115.6 -0.727 . . . . 0.45 112.577 -178.234 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 352' ' ' MET . . . . . . . . . . . . . 64.1 mmm -69.22 173.38 5.73 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.562 0.22 . . . . 1.3 110.636 173.308 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 353' ' ' ALA . . . . . 0.561 ' HB2' ' O ' ' A' ' 299' ' ' LYS . . . -135.71 136.61 40.99 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.107 -0.497 . . . . 1.33 111.05 -177.605 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 354' ' ' VAL . . . . . 0.538 ' H ' ' HD2' ' A' ' 301' ' ' PRO . 59.4 t -65.76 112.05 1.75 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.202 0 CA-C-O 121.436 0.636 . . . . 1.24 109.923 174.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 104.56 -24.16 29.45 Favored Glycine 0 N--CA 1.439 -1.134 0 N-CA-C 110.134 -1.186 . . . . 0.44 110.134 -172.7 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -73.85 145.66 35.59 Favored Glycine 0 N--CA 1.444 -0.793 0 N-CA-C 112.04 -0.424 . . . . 0.37 112.04 179.874 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 357' ' ' GLU . . . . . 0.732 ' HG3' ' HB2' ' A' ' 387' ' ' LYS . 34.0 tt0 -135.75 131.54 35.68 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 108.238 -1.023 . . . . 1.63 108.238 -173.227 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 358' ' ' ARG . . . . . . . . . . . . . 2.1 ptp180 -154.86 148.22 25.06 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.369 0.604 . . . . 1.53 112.495 -177.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 359' ' ' ARG . . . . . 0.407 HH21 ' CD ' ' A' ' 293' ' ' GLU . 14.8 ttp180 -89.21 114.76 26.11 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.377 -0.829 . . . . 3.26 109.817 176.502 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 65.4 mt -102.67 118.72 49.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 109.955 -0.387 . . . . 1.13 109.955 179.087 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 361' ' ' VAL . . . . . 0.545 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 41.8 t -101.19 111.15 29.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 109.209 -0.663 . . . . 1.14 109.209 179.63 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 362' ' ' ILE . . . . . 0.472 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 60.4 mt -108.09 112.48 61.47 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-O 120.985 0.421 . . . . 1.13 111.531 -171.402 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 363' ' ' PRO . . . . . 0.526 ' HD2' HG12 ' A' ' 290' ' ' ILE . 33.7 Cg_endo -64.19 155.34 65.73 Favored 'Trans proline' 0 C--O 1.235 0.356 0 C-N-CA 122.902 2.401 . . . . 1.05 111.791 175.153 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 364' ' ' ALA . . . . . 0.411 ' CB ' ' HA ' ' A' ' 379' ' ' ASN . . . -51.16 -49.5 81.05 Favored Pre-proline 0 CA--C 1.541 0.598 0 N-CA-C 114.14 1.163 . . . . 1.16 114.14 -174.775 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 365' ' ' PRO . . . . . 0.459 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 32.2 Cg_exo -59.0 -24.41 73.22 Favored 'Trans proline' 0 C--N 1.362 1.274 0 C-N-CA 122.176 1.917 . . . . 1.14 113.671 -173.056 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 366' ' ' TYR . . . . . 0.582 ' CE2' ' HA3' ' A' ' 288' ' ' GLY . 5.4 m-85 -100.27 10.74 40.79 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.048 0.452 . . . . 1.03 111.385 -176.707 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 367' ' ' ALA . . . . . 0.492 ' HA ' ' HB ' ' A' ' 342' ' ' ILE . . . -122.24 -106.04 0.37 Allowed 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.903 -0.59 . . . . 1.07 110.406 174.191 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 368' ' ' TYR . . . . . 0.459 ' HB3' ' HB3' ' A' ' 371' ' ' GLN . 96.4 m-85 -92.42 -16.12 26.31 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.642 0.258 . . . . 1.44 111.52 178.38 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 68.53 -110.73 3.56 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.911 -0.661 . . . . 0.65 112.669 178.525 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 370' ' ' LYS . . . . . 0.474 ' HA ' ' HB3' ' A' ' 378' ' ' ALA . 48.9 mtpt -101.27 10.18 40.96 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.766 0.317 . . . . 3.34 111.174 -177.538 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 371' ' ' GLN . . . . . 0.459 ' HB3' ' HB3' ' A' ' 368' ' ' TYR . 64.5 tt0 -82.58 100.97 10.46 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 120.864 0.364 . . . . 2.88 110.572 178.656 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 372' ' ' ALA . . . . . 0.527 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -78.84 107.9 11.89 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.264 -0.426 . . . . 1.39 111.295 178.602 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 83.6 mt -102.47 161.81 22.14 Favored Pre-proline 0 C--N 1.32 -0.691 0 N-CA-C 109.403 -0.592 . . . . 1.55 109.403 174.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_endo -64.27 114.61 2.74 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 121.592 1.528 . . . . 1.61 110.929 172.452 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 96.2 -28.58 12.41 Favored Glycine 0 CA--C 1.521 0.466 0 C-N-CA 120.89 -0.671 . . . . 0.96 112.225 -176.665 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 376' ' ' ILE . . . . . 0.503 HG21 HD22 ' A' ' 382' ' ' LEU . 23.0 mt -130.74 77.62 75.27 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 120.701 0.286 . . . . 1.29 110.303 179.137 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 377' ' ' PRO . . . . . 0.527 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 73.5 Cg_endo -77.77 167.86 23.26 Favored 'Trans proline' 0 N--CA 1.461 -0.395 0 C-N-CA 122.38 2.054 . . . . 1.08 112.805 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 378' ' ' ALA . . . . . 0.474 ' HB3' ' HA ' ' A' ' 370' ' ' LYS . . . -53.07 143.2 18.11 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 116.055 -0.52 . . . . 1.52 111.979 -179.72 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 379' ' ' ASN . . . . . 0.411 ' HA ' ' CB ' ' A' ' 364' ' ' ALA . 12.3 m120 67.95 19.92 9.31 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 115.556 -0.747 . . . . 1.97 112.286 176.356 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 67.1 m -87.2 131.63 34.13 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.332 0.587 . . . . 1.91 111.232 176.55 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 381' ' ' GLU . . . . . 0.895 ' HB3' ' HD2' ' A' ' 318' ' ' LYS . 34.1 tt0 -84.71 112.86 20.86 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.999 -1.0 . . . . 1.03 109.93 178.33 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 382' ' ' LEU . . . . . 0.503 HD22 HG21 ' A' ' 376' ' ' ILE . 91.5 mt -89.67 139.49 30.51 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.334 -0.394 . . . . 1.13 110.243 179.765 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 37.8 m -119.33 119.12 33.07 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.322 -0.621 . . . . 1.12 109.322 176.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -115.13 109.88 18.68 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 121.124 0.488 . . . . 0.4 110.444 -177.213 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -87.52 106.92 18.32 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 108.149 -1.056 . . . . 1.8 108.149 174.113 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 386' ' ' VAL . . . . . 0.455 HG13 ' CB ' ' A' ' 313' ' ' TYR . 29.6 m -122.9 148.37 26.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.621 0.724 . . . . 1.13 112.123 -168.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 387' ' ' LYS . . . . . 0.732 ' HB2' ' HG3' ' A' ' 357' ' ' GLU . 40.7 tttp -139.05 132.96 30.98 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.74 -1.118 . . . . 3.1 109.317 175.222 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 388' ' ' LEU . . . . . 0.804 HD12 ' HB ' ' A' ' 309' ' ' VAL . 30.6 tp -91.98 131.62 37.14 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 108.666 -0.864 . . . . 1.05 108.666 -179.178 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 28.9 m -120.01 -4.39 9.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 112.232 0.456 . . . . 1.2 112.232 -173.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 11.3 t -170.51 152.06 3.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.968 0.413 . . . . 1.82 111.154 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 391' ' ' MET . . . . . 0.502 ' SD ' ' HB2' ' A' ' 301' ' ' PRO . 31.6 ttm -157.25 147.47 20.94 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.747 -0.661 . . . . 1.14 109.497 174.626 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 20.8 tptm . . . . . 0 C--O 1.248 0.992 0 CA-C-O 117.88 -1.057 . . . . 5.51 111.438 173.471 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.953 HG23 ' HG2' ' A' ' 293' ' ' GLU . 31.6 p . . . . . 0 N--CA 1.455 -0.201 0 N-CA-C 110.21 -0.292 . . . . 1.27 110.21 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 284' ' ' LYS . . . . . 0.443 ' HB2' HG13 ' A' ' 292' ' ' ILE . 23.8 mmtp -122.03 146.99 46.64 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.94 0.4 . . . . 2.51 111.115 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 40.3 tp -103.97 121.17 42.58 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.542 -0.754 . . . . 1.52 110.242 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.549 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 94.9 mt -101.78 -169.5 1.69 Allowed 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.978 -0.555 . . . . 1.39 110.407 178.048 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -68.37 146.58 53.12 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.702 -0.681 . . . . 2.64 110.154 -179.651 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 73.71 10.63 80.23 Favored Glycine 0 CA--C 1.517 0.163 0 C-N-CA 121.102 -0.571 . . . . 1.84 113.687 178.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 81.44 16.84 72.69 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.63 -0.795 . . . . 1.16 112.596 178.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 290' ' ' ILE . . . . . 0.549 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 84.1 mt -69.64 125.76 28.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 N-CA-C 109.94 -0.393 . . . . 1.16 109.94 177.82 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . 0.657 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 20.1 mt -104.14 134.91 44.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 N-CA-C 109.286 -0.635 . . . . 1.6 109.286 179.386 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 292' ' ' ILE . . . . . 0.443 HG13 ' HB2' ' A' ' 284' ' ' LYS . 18.2 pt -124.13 127.14 73.24 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 CA-C-O 121.112 0.482 . . . . 1.17 110.172 177.873 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 293' ' ' GLU . . . . . 0.953 ' HG2' HG23 ' A' ' 283' ' ' THR . 29.4 mt-10 -117.94 114.35 23.07 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.499 -0.773 . . . . 2.31 109.469 -179.812 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . 0.443 ' C ' ' HE ' ' A' ' 295' ' ' ARG . 8.2 t70 -80.15 135.09 36.22 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 109.255 -0.646 . . . . 2.36 109.255 -175.383 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 295' ' ' ARG . . . . . 0.571 ' HG2' ' HA ' ' A' ' 358' ' ' ARG . 1.7 mmp_? -105.76 -60.3 1.65 Allowed 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 110.02 -0.363 . . . . 3.99 110.02 -175.175 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . . . . . . . . . 84.0 t -122.2 109.98 25.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 116.039 -0.528 . . . . 1.31 109.594 174.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 18.1 p -61.93 109.24 1.2 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.522 -0.763 . . . . 2.46 111.405 -177.392 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -101.2 171.38 22.32 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.669 -0.776 . . . . 1.04 112.033 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 8.0 tmtm? -145.69 110.58 5.18 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.297 -0.631 . . . . 5.01 109.297 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -172.24 -154.25 9.96 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.78 -0.724 . . . . 1.59 111.713 -178.596 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . 0.704 ' HD2' ' HB ' ' A' ' 354' ' ' VAL . 24.0 Cg_exo -64.46 134.34 41.16 Favored 'Trans proline' 0 C--O 1.232 0.192 0 C-N-CA 123.129 2.553 . . . . 1.1 112.342 177.28 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 44.4 m-70 -98.32 132.25 43.95 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.317 -0.401 . . . . 1.85 110.048 179.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -81.3 143.26 32.37 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 112.487 0.551 . . . . 1.17 112.487 -176.009 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -127.26 -178.85 4.6 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.657 -0.701 . . . . 3.26 110.041 174.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.796 ' HG3' ' HA3' ' A' ' 337' ' ' GLY . 46.7 tttm -68.47 135.49 51.74 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.864 0.364 . . . . 3.21 110.342 175.218 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 93.13 -17.83 57.46 Favored Glycine 0 N--CA 1.451 -0.318 0 CA-C-N 116.107 -0.497 . . . . 0.7 112.257 -176.517 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 27.0 m -74.83 142.53 44.18 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.729 0.3 . . . . 1.07 110.679 -179.236 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 308' ' ' ARG . . . . . 0.441 HH11 ' HD3' ' A' ' 308' ' ' ARG . 22.0 mtm180 -104.61 103.73 13.44 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 109.04 -0.726 . . . . 3.98 109.04 178.58 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.819 ' HB ' HD12 ' A' ' 388' ' ' LEU . 28.4 m -104.35 145.36 13.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 CA-C-N 116.011 -0.54 . . . . 1.1 111.567 -177.569 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -111.51 120.68 5.5 Favored Glycine 0 N--CA 1.445 -0.739 0 N-CA-C 109.709 -1.356 . . . . 0.32 109.709 176.405 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 311' ' ' MET . . . . . 0.54 ' CE ' ' HB ' ' A' ' 386' ' ' VAL . 22.0 ptm -136.44 176.79 8.38 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.591 0.71 . . . . 1.55 112.309 -169.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 312' ' ' ARG . . . . . 0.537 ' HD2' ' HA ' ' A' ' 327' ' ' THR . 12.5 mmt-85 -127.57 151.09 49.34 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 107.303 -1.369 . . . . 3.0 107.303 172.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 313' ' ' TYR . . . . . 0.465 ' CB ' HG13 ' A' ' 386' ' ' VAL . 51.3 p90 -167.04 158.53 12.39 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.326 0.584 . . . . 1.24 111.953 -176.82 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . 0.43 HG13 ' HG3' ' A' ' 316' ' ' LYS . 42.6 t -123.15 112.32 33.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.124 -0.944 . . . . 1.09 109.559 174.131 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -84.73 105.51 2.86 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 121.073 -0.585 . . . . 0.32 111.942 -177.661 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 316' ' ' LYS . . . . . 0.495 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 45.8 mtmt -119.31 154.35 33.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.143 0.497 . . . . 2.61 111.681 -176.225 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 78.3 mt -91.15 160.56 15.5 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.811 -0.631 . . . . 1.32 109.97 176.152 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 318' ' ' LYS . . . . . 0.637 ' HD2' ' HB3' ' A' ' 381' ' ' GLU . 85.3 tttt -62.4 -18.45 61.64 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-O 121.345 0.593 . . . . 2.9 110.138 175.603 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -79.61 -2.03 40.72 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 115.566 -0.743 . . . . 2.39 110.788 179.623 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 89.96 -2.91 82.44 Favored Glycine 0 C--N 1.329 0.178 0 C-N-CA 120.648 -0.787 . . . . 0.69 112.795 177.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -93.83 128.37 40.06 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.691 0.281 . . . . 2.86 110.587 -179.073 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.495 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 7.1 p -85.41 136.64 22.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 116.249 -0.432 . . . . 1.96 110.277 177.144 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 42.5 p90 -108.24 -35.67 6.49 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 120.791 -0.364 . . . . 0.56 111.36 -179.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -147.05 162.28 39.12 Favored 'General case' 0 N--CA 1.464 0.261 0 C-N-CA 120.976 -0.289 . . . . 1.68 110.569 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 3.7 ptpp? -164.55 138.72 5.29 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.76 0.314 . . . . 2.55 111.323 -177.136 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 55.0 m-80 -140.58 117.12 10.82 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 108.798 -0.815 . . . . 1.92 108.798 173.56 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 327' ' ' THR . . . . . 0.537 ' HA ' ' HD2' ' A' ' 312' ' ' ARG . 5.2 t -160.73 -49.44 0.05 OUTLIER 'General case' 0 C--N 1.324 -0.5 0 C-N-CA 120.859 -0.337 . . . . 2.06 111.726 -177.16 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 19.9 pttp -94.77 104.94 16.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.364 0.602 . . . . 3.15 110.839 -178.218 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.401 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 87.94 -29.61 5.42 Favored Glycine 0 N--CA 1.45 -0.394 0 CA-C-N 115.409 -0.814 . . . . 1.17 112.756 177.49 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 92.3 mttt -102.09 106.49 48.2 Favored Pre-proline 0 C--N 1.326 -0.428 0 CA-C-O 120.735 0.302 . . . . 2.56 111.335 -176.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 331' ' ' PRO . . . . . 0.401 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 80.3 Cg_endo -87.31 125.72 2.21 Favored 'Trans proline' 0 N--CA 1.448 -1.167 0 C-N-CA 122.765 2.31 . . . . 0.73 111.405 173.126 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 64.7 t80 -103.66 114.36 28.56 Favored 'General case' 0 C--N 1.318 -0.777 0 C-N-CA 120.677 -0.409 . . . . 0.76 110.002 179.43 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 333' ' ' VAL . . . . . 0.47 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 58.4 t -115.86 122.61 69.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.767 -0.651 . . . . 1.14 109.868 -178.57 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.465 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 13.2 p90 -138.19 165.87 25.6 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.945 0.403 . . . . 0.48 110.229 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 335' ' ' LYS . . . . . 0.528 ' HG3' ' HG3' ' A' ' 338' ' ' GLN . 21.4 pttm -110.08 129.44 55.69 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.977 -0.556 . . . . 3.11 110.608 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 9.6 mp -72.44 146.52 46.87 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.849 -0.614 . . . . 1.2 111.732 -178.704 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 337' ' ' GLY . . . . . 0.796 ' HA3' ' HG3' ' A' ' 305' ' ' LYS . . . 88.44 25.05 31.75 Favored Glycine 0 N--CA 1.447 -0.614 0 CA-C-N 115.632 -0.713 . . . . 1.02 112.769 170.614 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 338' ' ' GLN . . . . . 0.528 ' HG3' ' HG3' ' A' ' 335' ' ' LYS . 48.3 mm-40 -123.09 149.47 44.41 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.732 -0.47 . . . . 3.1 109.732 -179.458 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -78.49 43.3 2.31 Favored Glycine 0 CA--C 1.518 0.279 0 C-N-CA 120.875 -0.678 . . . . 0.98 112.786 178.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 340' ' ' GLU . . . . . 0.477 ' HG2' ' HB2' ' A' ' 338' ' ' GLN . 10.4 pt-20 -122.29 -3.21 8.97 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.153 0.502 . . . . 2.09 110.087 175.647 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 23.9 m -128.49 166.51 25.63 Favored 'Isoleucine or valine' 0 C--O 1.233 0.229 0 CA-C-N 115.47 -0.787 . . . . 1.27 109.057 174.335 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 342' ' ' ILE . . . . . 0.723 ' HB ' ' HA ' ' A' ' 367' ' ' ALA . 14.0 pt -82.63 154.35 3.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.325 -0.62 . . . . 1.08 109.325 176.397 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 343' ' ' LYS . . . . . 0.411 ' HA ' ' OD2' ' A' ' 346' ' ' ASP . 6.9 mtmm -65.93 -31.39 72.29 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 111.78 0.289 . . . . 3.46 111.78 -172.355 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 344' ' ' GLY . . . . . 0.537 ' HA2' ' CD1' ' A' ' 290' ' ' ILE . . . -54.39 -32.0 51.63 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.69 -0.766 . . . . 0.32 111.851 173.031 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 7.2 m95 -76.03 -55.63 5.42 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 111.847 0.314 . . . . 0.44 111.847 177.367 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 346' ' ' ASP . . . . . 0.411 ' OD2' ' HA ' ' A' ' 343' ' ' LYS . 0.1 OUTLIER -64.75 -24.32 67.53 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 122.186 -0.321 . . . . 1.75 111.603 -174.844 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 56.8 mt -89.8 -49.4 13.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.631 -0.259 . . . . 1.18 111.029 176.546 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -61.49 -36.57 92.76 Favored Glycine 0 CA--C 1.52 0.387 0 C-N-CA 120.982 -0.628 . . . . 0.37 113.171 179.345 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 349' ' ' VAL . . . . . 0.473 ' O ' ' HB2' ' A' ' 352' ' ' MET . 95.4 t -78.79 -14.16 13.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.115 0.484 . . . . 1.08 110.934 178.602 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -69.87 120.56 15.78 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 109.471 -0.566 . . . . 1.09 109.471 176.242 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 85.45 14.05 69.25 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.865 -0.684 . . . . 0.45 112.023 -176.591 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 352' ' ' MET . . . . . 0.821 ' HE3' ' HG2' ' A' ' 358' ' ' ARG . 0.0 OUTLIER -81.01 137.0 36.07 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 108.867 -0.79 . . . . 1.3 108.867 176.442 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 353' ' ' ALA . . . . . 0.442 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -109.28 130.56 55.49 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.982 0.42 . . . . 1.33 111.097 -174.882 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 354' ' ' VAL . . . . . 0.704 ' HB ' ' HD2' ' A' ' 301' ' ' PRO . 95.8 t -54.23 121.03 2.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.906 -0.588 . . . . 1.24 111.306 176.686 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 107.52 -8.73 37.74 Favored Glycine 0 N--CA 1.444 -0.797 0 CA-C-N 115.73 -0.668 . . . . 0.44 112.152 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 356' ' ' GLY . . . . . 0.442 ' O ' ' HE2' ' A' ' 352' ' ' MET . . . -100.97 154.9 19.22 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.836 -0.697 . . . . 0.37 112.571 -178.417 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 357' ' ' GLU . . . . . 0.694 ' HG2' ' HD2' ' A' ' 387' ' ' LYS . 54.0 mt-10 -122.5 130.76 53.39 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.443 -0.577 . . . . 1.63 109.443 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 358' ' ' ARG . . . . . 0.821 ' HG2' ' HE3' ' A' ' 352' ' ' MET . 4.1 ptp180 -156.06 142.24 18.29 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.232 0.539 . . . . 1.53 111.094 176.522 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 359' ' ' ARG . . . . . . . . . . . . . 53.9 ttp180 -93.31 133.63 36.35 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.508 -0.769 . . . . 3.26 109.82 -178.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 38.8 mt -110.16 119.86 60.01 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-N 116.168 -0.469 . . . . 1.13 110.24 -179.418 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 361' ' ' VAL . . . . . 0.657 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 45.6 t -98.87 112.76 31.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 108.616 -0.883 . . . . 1.14 108.616 176.316 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 362' ' ' ILE . . . . . 0.433 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 54.4 mt -112.83 108.0 54.07 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-O 120.7 0.286 . . . . 1.13 111.441 -172.127 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 363' ' ' PRO . . . . . 0.614 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 19.4 Cg_endo -59.36 152.09 63.36 Favored 'Trans proline' 0 C--O 1.235 0.35 0 C-N-CA 122.564 2.176 . . . . 1.05 111.771 170.798 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 364' ' ' ALA . . . . . . . . . . . . . . . -48.43 -46.8 69.47 Favored Pre-proline 0 CA--C 1.544 0.718 0 N-CA-C 114.077 1.14 . . . . 1.16 114.077 -176.544 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 365' ' ' PRO . . . . . 0.614 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 83.7 Cg_exo -49.24 -36.55 37.5 Favored 'Trans proline' 0 C--N 1.361 1.19 0 C-N-CA 122.687 2.258 . . . . 1.14 114.068 -177.134 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 366' ' ' TYR . . . . . 0.446 ' HD1' HD12 ' A' ' 290' ' ' ILE . 2.9 m-85 -101.4 8.5 42.18 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.797 -0.361 . . . . 1.03 111.158 -176.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 367' ' ' ALA . . . . . 0.723 ' HA ' ' HB ' ' A' ' 342' ' ' ILE . . . -110.76 -119.3 0.29 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.162 -0.472 . . . . 1.07 109.973 175.107 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 82.6 m-85 -86.92 5.9 34.69 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 121.081 0.467 . . . . 1.44 111.238 178.245 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 67.05 -109.06 2.7 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.909 -0.587 . . . . 0.65 112.352 176.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 20.3 pttm -120.71 15.58 11.86 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.774 0.321 . . . . 3.34 110.963 -178.823 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 8.7 tp-100 -83.18 106.99 15.43 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.947 0.403 . . . . 2.88 110.149 178.267 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 372' ' ' ALA . . . . . 0.497 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -75.38 102.03 4.98 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 116.034 -0.53 . . . . 1.39 110.918 179.606 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 76.5 mt -88.9 163.83 33.55 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.706 -0.679 . . . . 1.55 109.254 177.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -61.77 113.98 2.07 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 121.594 1.529 . . . . 1.61 110.69 173.283 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 93.39 -26.66 14.53 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.83 -0.7 . . . . 0.96 112.754 -177.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 376' ' ' ILE . . . . . 0.418 HG21 HD22 ' A' ' 382' ' ' LEU . 39.6 mt -126.5 81.92 67.29 Favored Pre-proline 0 CA--C 1.532 0.288 0 CA-C-O 120.86 0.362 . . . . 1.29 110.978 -178.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 377' ' ' PRO . . . . . 0.497 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 56.1 Cg_endo -76.77 167.58 25.09 Favored 'Trans proline' 0 N--CA 1.459 -0.537 0 C-N-CA 122.413 2.075 . . . . 1.08 112.457 178.126 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 378' ' ' ALA . . . . . . . . . . . . . . . -54.51 145.89 17.51 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.804 -0.635 . . . . 1.52 111.488 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 379' ' ' ASN . . . . . . . . . . . . . 52.5 m-80 73.05 14.25 4.73 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 115.747 -0.661 . . . . 1.97 112.147 176.613 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 66.5 m -78.97 115.03 18.4 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.258 0.551 . . . . 1.91 110.45 175.645 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 381' ' ' GLU . . . . . 0.637 ' HB3' ' HD2' ' A' ' 318' ' ' LYS . 33.0 tt0 -74.33 101.47 4.07 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.421 -0.809 . . . . 1.03 108.865 177.38 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 382' ' ' LEU . . . . . 0.418 HD22 HG21 ' A' ' 376' ' ' ILE . 79.4 mt -85.47 142.07 29.48 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 120.714 0.293 . . . . 1.13 110.897 -174.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 18.8 m -121.89 117.22 25.94 Favored 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 109.732 -0.47 . . . . 1.12 109.732 178.706 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 384' ' ' PHE . . . . . 0.404 ' CD2' HD13 ' A' ' 362' ' ' ILE . 82.5 m-85 -112.67 109.94 19.77 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 121.094 0.474 . . . . 0.4 110.067 -176.81 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -88.5 105.13 17.42 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 108.667 -0.864 . . . . 1.8 108.667 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 386' ' ' VAL . . . . . 0.54 ' HB ' ' CE ' ' A' ' 311' ' ' MET . 12.3 m -124.8 152.07 30.77 Favored 'Isoleucine or valine' 0 C--O 1.235 0.341 0 CA-C-O 121.756 0.788 . . . . 1.13 112.832 -167.208 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 387' ' ' LYS . . . . . 0.694 ' HD2' ' HG2' ' A' ' 357' ' ' GLU . 71.6 tttt -143.7 136.38 27.27 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.1 -0.955 . . . . 3.1 109.583 174.541 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 388' ' ' LEU . . . . . 0.819 HD12 ' HB ' ' A' ' 309' ' ' VAL . 30.7 tp -95.94 131.2 42.55 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.729 -0.471 . . . . 1.05 109.729 -177.487 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 32.9 m -122.16 -8.96 8.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 N-CA-C 112.226 0.454 . . . . 1.2 112.226 -174.202 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 13.9 p -166.94 161.18 14.91 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.003 0.43 . . . . 1.82 111.852 -176.013 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 391' ' ' MET . . . . . 0.574 ' HG2' ' HG2' ' A' ' 392' ' ' LYS . 29.9 ttm -151.51 143.37 23.79 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.403 -0.817 . . . . 1.14 109.428 176.678 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 392' ' ' LYS . . . . . 0.574 ' HG2' ' HG2' ' A' ' 391' ' ' MET . 19.4 pttp . . . . . 0 C--O 1.248 0.989 0 CA-C-O 117.888 -1.054 . . . . 5.51 112.369 179.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.429 HG23 ' HB3' ' A' ' 293' ' ' GLU . 17.9 p . . . . . 0 N--CA 1.444 -0.733 0 CA-C-O 120.999 0.428 . . . . 1.27 111.081 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 15.1 ptpt -140.68 146.18 37.51 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.2 -0.455 . . . . 2.51 110.959 176.527 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . 0.509 HD12 ' HA2' ' A' ' 289' ' ' GLY . 22.1 tp -89.5 129.41 35.99 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.294 -0.866 . . . . 1.52 111.292 -175.823 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.521 HD12 HD11 ' A' ' 292' ' ' ILE . 81.7 mt -105.62 -166.71 1.24 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.975 -0.557 . . . . 1.39 110.284 175.854 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 287' ' ' GLU . . . . . 0.494 ' HG3' ' OH ' ' A' ' 366' ' ' TYR . 8.2 tp10 -51.11 142.0 13.23 Favored 'General case' 0 C--O 1.234 0.28 0 O-C-N 123.706 0.629 . . . . 2.64 111.557 -179.832 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 72.67 -99.63 0.93 Allowed Glycine 0 N--CA 1.446 -0.682 0 CA-C-N 115.551 -0.75 . . . . 1.84 111.37 -174.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . 0.509 ' HA2' HD12 ' A' ' 285' ' ' LEU . . . -153.77 32.91 0.75 Allowed Glycine 0 N--CA 1.443 -0.837 0 N-CA-C 110.428 -1.069 . . . . 1.16 110.428 174.138 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 290' ' ' ILE . . . . . 0.497 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 76.9 mt -74.77 124.41 32.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.564 -0.318 . . . . 1.16 110.394 -176.14 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . 0.599 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 7.8 mt -104.24 136.45 37.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 N-CA-C 109.651 -0.5 . . . . 1.6 109.651 -179.591 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 292' ' ' ILE . . . . . 0.521 HD11 HD12 ' A' ' 286' ' ' LEU . 33.5 pt -133.37 137.28 53.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 120.699 -0.4 . . . . 1.17 111.07 179.481 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 293' ' ' GLU . . . . . 0.591 ' CG ' ' HB3' ' A' ' 359' ' ' ARG . 12.1 pt-20 -139.74 143.3 36.92 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.231 -0.895 . . . . 2.31 109.709 178.336 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -94.0 139.86 30.42 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 120.996 0.427 . . . . 2.36 111.035 179.548 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 295' ' ' ARG . . . . . 0.406 HH11 ' HD2' ' A' ' 295' ' ' ARG . 11.3 mmt85 -114.7 -47.11 2.91 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.569 -0.741 . . . . 3.99 111.414 -174.55 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.554 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 97.6 t -120.9 132.55 70.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.392 -0.367 . . . . 1.31 110.414 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 10.3 p -63.5 137.8 58.27 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.845 -0.616 . . . . 2.46 112.05 -176.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -165.35 132.77 2.76 Favored Glycine 0 N--CA 1.446 -0.659 0 CA-C-N 115.781 -0.645 . . . . 1.04 111.815 179.294 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 11.1 ptpp? -133.44 116.49 16.07 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.255 0.55 . . . . 5.01 109.905 176.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -171.55 -154.1 9.6 Favored Glycine 0 N--CA 1.442 -0.918 0 N-CA-C 111.193 -0.763 . . . . 1.59 111.193 -177.232 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . 0.434 ' O ' ' HA ' ' A' ' 353' ' ' ALA . 26.2 Cg_exo -61.66 133.01 43.01 Favored 'Trans proline' 0 C--O 1.237 0.443 0 C-N-CA 122.625 2.217 . . . . 1.1 111.472 178.233 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 25.0 m80 -101.47 133.48 46.06 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.247 -0.433 . . . . 1.85 111.298 -177.524 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -64.76 126.5 28.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.503 -0.772 . . . . 1.17 111.179 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 38.2 ttpt -136.4 169.77 17.13 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.2 -0.667 . . . . 3.26 109.2 -177.225 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.648 ' HZ3' ' HA2' ' A' ' 337' ' ' GLY . 57.0 tttp -63.07 128.2 34.77 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.912 0.386 . . . . 3.21 110.18 177.051 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 97.6 -4.91 62.0 Favored Glycine 0 N--CA 1.451 -0.347 0 CA-C-N 115.935 -0.575 . . . . 0.7 111.84 -176.756 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 27.4 m -93.74 146.32 23.94 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.708 0.29 . . . . 1.07 110.994 -179.363 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 308' ' ' ARG . . . . . 0.487 ' HG2' ' HB3' ' A' ' 335' ' ' LYS . 54.6 mtm180 -110.65 104.12 12.77 Favored 'General case' 0 CA--C 1.516 -0.349 0 N-CA-C 109.346 -0.612 . . . . 3.98 109.346 177.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.797 ' HB ' HD12 ' A' ' 388' ' ' LEU . 31.5 m -102.65 147.01 9.73 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 CA-C-O 121.349 0.595 . . . . 1.1 111.944 -173.457 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -118.02 117.21 3.67 Favored Glycine 0 N--CA 1.446 -0.678 0 N-CA-C 109.669 -1.372 . . . . 0.32 109.669 176.068 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 311' ' ' MET . . . . . 0.47 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 21.4 ptm -135.23 177.02 8.14 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.577 0.703 . . . . 1.55 112.729 -169.133 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 64.4 mtt180 -134.47 147.63 50.42 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 107.332 -1.359 . . . . 3.0 107.332 176.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 313' ' ' TYR . . . . . 0.661 ' HB2' HG13 ' A' ' 386' ' ' VAL . 48.6 p90 -164.29 157.92 18.25 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 112.878 0.696 . . . . 1.24 112.878 -172.54 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 62.0 t -125.45 116.18 45.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 114.818 -1.083 . . . . 1.09 109.44 174.411 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -101.43 116.85 5.67 Favored Glycine 0 C--O 1.24 0.475 0 C-N-CA 120.912 -0.661 . . . . 0.32 112.213 -177.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 316' ' ' LYS . . . . . 0.526 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 98.3 mttt -119.41 162.42 18.85 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.372 0.606 . . . . 2.61 111.058 -178.01 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 63.2 mt -88.04 167.13 13.95 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.02 -0.991 . . . . 1.32 109.301 173.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 318' ' ' LYS . . . . . 0.483 ' HD3' ' H ' ' A' ' 381' ' ' GLU . 19.3 pttp -66.51 -8.84 29.16 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.38 0.609 . . . . 2.9 110.299 175.379 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 319' ' ' ASN . . . . . 0.424 HD21 ' HG2' ' A' ' 321' ' ' LYS . 8.3 t30 -86.22 -6.94 58.88 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.678 -0.692 . . . . 2.39 110.302 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 96.47 -12.92 66.13 Favored Glycine 0 N--CA 1.451 -0.303 0 CA-C-N 115.833 -0.621 . . . . 0.69 112.557 178.553 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 321' ' ' LYS . . . . . 0.424 ' HG2' HD21 ' A' ' 319' ' ' ASN . 14.4 mmmm -82.94 132.04 35.17 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.681 0.277 . . . . 2.86 110.903 -177.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.526 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 5.6 p -84.07 134.06 27.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 116.097 -0.501 . . . . 1.96 109.892 177.182 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 34.4 p90 -105.5 -31.73 8.85 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 120.843 -0.343 . . . . 0.56 111.424 179.556 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -148.67 151.83 35.62 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 110.062 -0.347 . . . . 1.68 110.062 178.274 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . 0.588 ' N ' ' HD3' ' A' ' 325' ' ' LYS . 0.0 OUTLIER -160.19 135.24 7.89 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.96 0.41 . . . . 2.55 110.11 -177.908 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 49.0 m-80 -138.51 118.19 13.1 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.512 -0.551 . . . . 1.92 109.512 179.415 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 6.6 t -162.26 -43.49 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.576 -0.284 . . . . 2.06 110.965 -178.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.409 ' O ' ' HG3' ' A' ' 328' ' ' LYS . 6.9 ptpp? -99.51 120.64 39.96 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.862 -0.421 . . . . 3.15 109.862 177.167 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.4 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 79.13 -37.18 1.96 Allowed Glycine 0 CA--C 1.52 0.367 0 C-N-CA 121.139 -0.553 . . . . 1.17 113.034 178.02 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 32.7 mmtp -103.64 100.58 19.86 Favored Pre-proline 0 C--N 1.33 -0.28 0 N-CA-C 111.801 0.297 . . . . 2.56 111.801 -178.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 331' ' ' PRO . . . . . 0.4 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 92.4 Cg_endo -87.54 127.4 2.36 Favored 'Trans proline' 0 N--CA 1.45 -1.032 0 C-N-CA 122.456 2.104 . . . . 0.73 110.775 168.144 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 82.9 t80 -102.03 117.63 35.2 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.57 -0.452 . . . . 0.76 110.408 -178.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 87.5 t -114.61 122.5 68.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.828 -0.624 . . . . 1.14 110.076 179.343 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.47 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 14.1 p90 -138.49 155.77 48.13 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.713 -0.477 . . . . 0.48 109.713 175.325 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 335' ' ' LYS . . . . . 0.487 ' HB3' ' HG2' ' A' ' 308' ' ' ARG . 0.0 OUTLIER -108.99 135.17 50.6 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.306 -0.407 . . . . 3.11 111.117 179.861 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 9.5 mp -77.83 110.74 12.98 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.662 -0.699 . . . . 1.2 109.471 179.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 337' ' ' GLY . . . . . 0.648 ' HA2' ' HZ3' ' A' ' 305' ' ' LYS . . . 177.92 -62.72 0.09 OUTLIER Glycine 0 N--CA 1.444 -0.777 0 C-N-CA 120.71 -0.757 . . . . 1.02 111.594 -178.271 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 338' ' ' GLN . . . . . . . . . . . . . 20.8 pt20 -96.56 153.13 18.02 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.055 0.455 . . . . 3.1 110.598 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -88.84 59.74 3.94 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 121.022 -0.609 . . . . 0.98 112.372 -174.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 340' ' ' GLU . . . . . 0.458 ' CD ' ' HZ3' ' A' ' 335' ' ' LYS . 21.8 pt-20 -87.83 -20.82 25.54 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.522 0.677 . . . . 2.09 109.62 174.217 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 22.1 m -95.81 167.76 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.084 -0.962 . . . . 1.27 108.999 174.129 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 342' ' ' ILE . . . . . 0.592 ' HB ' ' HA ' ' A' ' 367' ' ' ALA . 22.1 pt -71.74 147.49 10.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 N-CA-C 109.13 -0.693 . . . . 1.08 109.13 174.168 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 1.3 mtmt -49.92 -40.44 43.33 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 112.724 0.639 . . . . 3.46 112.724 -171.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -55.64 -25.31 42.79 Favored Glycine 0 CA--C 1.524 0.623 0 C-N-CA 121.333 -0.46 . . . . 0.32 113.825 179.014 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 8.2 m95 -74.77 -59.31 2.79 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.915 0.358 . . . . 0.44 111.848 -179.501 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -49.68 -36.99 26.95 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-O 121.082 0.468 . . . . 1.75 111.197 177.729 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 60.8 mt -80.55 -52.28 14.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.821 -0.627 . . . . 1.18 111.738 -178.529 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -67.83 -35.57 85.25 Favored Glycine 0 CA--C 1.519 0.287 0 C-N-CA 121.192 -0.528 . . . . 0.37 113.812 -177.406 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 91.7 t -75.8 -23.97 16.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.699 0.285 . . . . 1.08 110.906 -179.077 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.79 96.84 0.3 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.126 0.489 . . . . 1.09 110.372 177.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 121.49 5.76 9.14 Favored Glycine 0 CA--C 1.52 0.367 0 C-N-CA 121.127 -0.559 . . . . 0.45 112.648 -175.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 352' ' ' MET . . . . . . . . . . . . . 85.6 mmm -84.99 138.57 32.38 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.68 0.276 . . . . 1.3 110.995 175.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 353' ' ' ALA . . . . . 0.434 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -106.19 141.82 36.91 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 116.077 -0.51 . . . . 1.33 111.214 -177.865 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 58.9 t -57.49 120.65 3.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.077 -0.511 . . . . 1.24 110.4 173.188 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 104.08 -12.11 52.27 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 121.188 -0.53 . . . . 0.44 112.087 179.745 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -102.44 143.5 15.91 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.845 -0.693 . . . . 0.37 112.407 -177.347 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 357' ' ' GLU . . . . . 0.554 ' HB3' ' HB ' ' A' ' 296' ' ' VAL . 32.5 tt0 -117.08 133.39 56.06 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 110.192 -0.299 . . . . 1.63 110.192 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 358' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -144.81 144.13 30.99 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.213 0.53 . . . . 1.53 111.113 -179.088 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 359' ' ' ARG . . . . . 0.593 ' HD2' HG23 ' A' ' 383' ' ' THR . 22.9 tpp85 -88.82 119.35 29.23 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.451 -0.795 . . . . 3.26 110.113 176.255 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 58.3 mt -105.33 121.23 57.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.962 -0.385 . . . . 1.13 109.962 177.418 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 361' ' ' VAL . . . . . 0.599 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 44.7 t -101.88 116.94 46.42 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 N-CA-C 109.471 -0.566 . . . . 1.14 109.471 176.793 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 362' ' ' ILE . . . . . 0.494 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 59.0 mt -113.25 109.38 51.74 Favored Pre-proline 0 C--N 1.322 -0.595 0 CA-C-N 116.42 -0.354 . . . . 1.13 111.346 -173.495 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 363' ' ' PRO . . . . . 0.527 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 10.2 Cg_endo -53.56 152.35 21.57 Favored 'Trans proline' 0 C--O 1.236 0.401 0 C-N-CA 123.158 2.572 . . . . 1.05 112.23 173.098 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 364' ' ' ALA . . . . . . . . . . . . . . . -52.09 -49.03 86.71 Favored Pre-proline 0 CA--C 1.542 0.639 0 N-CA-C 113.375 0.88 . . . . 1.16 113.375 -175.802 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 365' ' ' PRO . . . . . 0.527 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 53.4 Cg_exo -53.83 -32.19 65.55 Favored 'Trans proline' 0 C--N 1.364 1.371 0 C-N-CA 122.482 2.121 . . . . 1.14 113.754 -177.062 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 366' ' ' TYR . . . . . 0.494 ' OH ' ' HG3' ' A' ' 287' ' ' GLU . 4.9 m-85 -94.66 9.71 37.73 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.217 0.532 . . . . 1.03 110.942 -175.622 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 367' ' ' ALA . . . . . 0.592 ' HA ' ' HB ' ' A' ' 342' ' ' ILE . . . -120.1 -109.22 0.35 Allowed 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.592 -0.731 . . . . 1.07 109.805 171.58 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 92.3 m-85 -81.58 -12.59 58.71 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 121.003 0.43 . . . . 1.44 111.534 179.404 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 369' ' ' GLY . . . . . 0.517 ' HA2' ' HA ' ' A' ' 365' ' ' PRO . . . 86.63 -114.1 4.02 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.846 -0.692 . . . . 0.65 112.789 175.658 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 43.6 mttp -115.05 14.65 17.15 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.012 0.434 . . . . 3.34 110.479 -175.454 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 8.5 tp-100 -87.81 117.13 26.44 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.003 -0.544 . . . . 2.88 110.645 -176.653 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 372' ' ' ALA . . . . . 0.415 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -87.56 98.89 11.66 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.069 -0.514 . . . . 1.39 110.67 177.814 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 76.9 mt -90.05 157.01 46.24 Favored Pre-proline 0 C--N 1.322 -0.619 0 CA-C-N 115.962 -0.563 . . . . 1.55 109.951 178.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -61.21 114.25 2.11 Favored 'Trans proline' 0 N--CA 1.459 -0.527 0 C-N-CA 121.803 1.669 . . . . 1.61 110.603 171.668 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 96.57 -30.39 8.88 Favored Glycine 0 N--CA 1.448 -0.559 0 CA-C-N 115.879 -0.6 . . . . 0.96 112.22 -176.264 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 23.4 mt -129.26 78.26 76.26 Favored Pre-proline 0 C--N 1.329 -0.299 0 N-CA-C 110.145 -0.317 . . . . 1.29 110.145 -179.475 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 377' ' ' PRO . . . . . 0.415 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 4.1 Cg_exo -76.86 166.21 27.29 Favored 'Trans proline' 0 N--CA 1.459 -0.54 0 C-N-CA 122.674 2.249 . . . . 1.08 112.143 -179.375 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 378' ' ' ALA . . . . . 0.473 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -59.14 152.86 19.38 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.293 -0.412 . . . . 1.52 110.695 176.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 379' ' ' ASN . . . . . 0.473 ' HB2' ' O ' ' A' ' 378' ' ' ALA . 16.8 m120 74.95 4.88 4.33 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 123.012 0.525 . . . . 1.97 111.492 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 49.1 m -83.97 94.6 8.31 Favored 'General case' 0 N--CA 1.451 -0.392 0 CA-C-O 121.335 0.588 . . . . 1.91 110.127 176.323 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 381' ' ' GLU . . . . . 0.483 ' H ' ' HD3' ' A' ' 318' ' ' LYS . 19.0 tt0 -67.04 112.34 4.33 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 114.972 -1.013 . . . . 1.03 109.617 179.354 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 82.4 mt -78.02 140.98 39.18 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.092 -0.504 . . . . 1.13 110.952 -173.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 383' ' ' THR . . . . . 0.593 HG23 ' HD2' ' A' ' 359' ' ' ARG . 25.1 m -120.19 119.54 33.54 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 109.29 -0.633 . . . . 1.12 109.29 -179.182 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -115.63 114.62 25.15 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.05 0.452 . . . . 0.4 111.19 -175.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 20.8 t70 -91.82 104.47 16.91 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 107.885 -1.154 . . . . 1.8 107.885 174.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 386' ' ' VAL . . . . . 0.661 HG13 ' HB2' ' A' ' 313' ' ' TYR . 17.3 m -129.71 147.61 33.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 112.46 0.541 . . . . 1.13 112.46 -167.097 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 387' ' ' LYS . . . . . 0.447 ' HB3' ' HA ' ' A' ' 357' ' ' GLU . 23.7 pttt -144.74 149.91 36.35 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.803 -0.635 . . . . 3.1 111.271 170.804 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 388' ' ' LEU . . . . . 0.797 HD12 ' HB ' ' A' ' 309' ' ' VAL . 26.9 tp -99.2 138.4 36.35 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.274 -0.875 . . . . 1.05 109.244 -176.702 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 31.8 m -128.83 -8.34 3.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 112.511 0.56 . . . . 1.2 112.511 -174.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 74.2 m -161.55 157.92 25.57 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.624 0.249 . . . . 1.82 110.837 -179.491 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 391' ' ' MET . . . . . . . . . . . . . 39.7 ttm -155.4 132.03 10.5 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-N 116.333 -0.394 . . . . 1.14 110.881 -178.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 66.6 mttm . . . . . 0 C--O 1.25 1.094 0 CA-C-O 118.432 -0.794 . . . . 5.51 109.603 176.781 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.536 ' HA ' ' O ' ' A' ' 292' ' ' ILE . 24.0 p . . . . . 0 N--CA 1.443 -0.807 0 CA-C-O 120.958 0.408 . . . . 1.27 111.866 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 284' ' ' LYS . . . . . 0.501 ' HB2' ' CG1' ' A' ' 292' ' ' ILE . 13.5 mmmm -110.0 137.94 47.08 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.94 -0.763 . . . . 2.51 108.94 174.762 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . 0.414 HD12 ' HA2' ' A' ' 289' ' ' GLY . 42.8 tp -100.26 121.71 41.91 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.934 0.397 . . . . 1.52 110.59 -178.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.639 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 88.3 mt -108.54 -164.56 0.96 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.818 -0.628 . . . . 1.39 110.477 -178.621 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -64.64 145.38 56.26 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 116.099 -0.5 . . . . 2.64 111.749 -178.533 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.633 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 65.76 8.97 43.49 Favored Glycine 0 C--N 1.329 0.154 0 CA-C-N 115.925 -0.58 . . . . 1.84 113.7 177.605 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . 0.414 ' HA2' HD12 ' A' ' 285' ' ' LEU . . . 90.95 12.29 60.55 Favored Glycine 0 N--CA 1.441 -0.988 0 C-N-CA 120.516 -0.849 . . . . 1.16 113.067 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 290' ' ' ILE . . . . . 0.639 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 94.9 mt -60.67 127.44 20.22 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.139 0 CA-C-N 117.373 0.587 . . . . 1.16 110.204 177.526 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . 0.51 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 18.1 mt -113.29 139.82 36.63 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 116.37 -0.377 . . . . 1.6 110.181 -178.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 292' ' ' ILE . . . . . 0.536 ' O ' ' HA ' ' A' ' 283' ' ' THR . 22.5 pt -128.34 127.06 66.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 120.891 0.377 . . . . 1.17 109.987 175.369 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 293' ' ' GLU . . . . . . . . . . . . . 4.6 tm-20 -105.25 108.44 19.95 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 108.812 -0.81 . . . . 2.31 108.812 -179.443 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -78.11 101.55 7.06 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-O 121.156 0.503 . . . . 2.36 110.576 -171.195 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 295' ' ' ARG . . . . . . . . . . . . . 6.2 tpt180 -88.08 -59.41 2.25 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.184 -0.916 . . . . 3.99 111.879 -170.314 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . . . . . . . . . 91.9 t -120.34 132.85 68.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.592 -0.277 . . . . 1.31 110.77 -178.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 6.8 p -92.18 120.55 32.87 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.106 -0.497 . . . . 2.46 110.915 178.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -126.96 -165.03 11.84 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.691 -0.766 . . . . 1.04 112.788 -175.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 299' ' ' LYS . . . . . 0.586 ' O ' ' HB2' ' A' ' 353' ' ' ALA . 74.1 mmtt -73.38 151.75 41.09 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.135 -0.691 . . . . 5.01 109.135 177.706 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -119.75 79.72 0.32 Allowed Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 119.316 -1.421 . . . . 1.59 115.074 -168.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . 0.597 ' HD2' ' H ' ' A' ' 354' ' ' VAL . 2.4 Cg_endo -85.84 133.69 4.35 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 122.735 2.29 . . . . 1.1 109.062 160.234 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 33.6 m170 -92.16 116.46 28.97 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 120.438 -0.505 . . . . 1.85 112.245 -171.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -66.24 121.2 14.67 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.413 -0.812 . . . . 1.17 110.157 173.14 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 31.9 mtmm -123.12 179.2 4.77 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.468 -0.333 . . . . 3.26 110.377 -176.123 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 61.9 tttp -63.9 113.68 3.6 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.391 -0.368 . . . . 3.21 110.349 179.618 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 98.62 -7.1 61.16 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.888 -0.673 . . . . 0.7 112.547 -179.276 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 38.9 m -77.61 145.55 36.72 Favored 'General case' 0 CA--C 1.534 0.346 0 O-C-N 122.776 -0.25 . . . . 1.07 110.547 -179.499 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 73.4 mtt180 -105.25 113.87 27.71 Favored 'General case' 0 CA--C 1.519 -0.227 0 N-CA-C 109.565 -0.531 . . . . 3.98 109.565 -177.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.703 ' HB ' HD12 ' A' ' 388' ' ' LEU . 30.2 m -107.28 139.02 30.44 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 CA-C-O 121.273 0.559 . . . . 1.1 111.348 178.498 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -109.88 115.39 4.16 Favored Glycine 0 N--CA 1.445 -0.717 0 N-CA-C 110.23 -1.148 . . . . 0.32 110.23 175.278 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 311' ' ' MET . . . . . 0.586 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 22.4 ptm -136.7 177.44 7.85 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.399 0.619 . . . . 1.55 112.153 -169.659 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 312' ' ' ARG . . . . . 0.506 ' HD3' ' O ' ' A' ' 327' ' ' THR . 98.9 mtt180 -137.05 147.01 45.89 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 107.677 -1.231 . . . . 3.0 107.677 175.341 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 313' ' ' TYR . . . . . 0.423 ' HA ' ' O ' ' A' ' 385' ' ' ASP . 25.2 p90 -161.49 159.93 28.55 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 112.941 0.719 . . . . 1.24 112.941 -169.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 48.7 t -126.41 120.74 57.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 114.839 -1.073 . . . . 1.09 109.68 174.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -94.64 106.03 3.36 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.388 -0.434 . . . . 0.32 112.19 -177.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 316' ' ' LYS . . . . . 0.541 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 84.3 mttt -114.09 156.31 24.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.064 0.459 . . . . 2.61 110.932 -177.038 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 96.5 mt -89.31 163.11 15.49 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.045 -0.525 . . . . 1.32 109.585 172.103 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 318' ' ' LYS . . . . . 0.698 ' HD3' ' HB3' ' A' ' 381' ' ' GLU . 61.7 pttt -65.68 -11.55 46.07 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 121.01 0.433 . . . . 2.9 111.338 178.405 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 9.0 t30 -87.98 -7.88 56.45 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.083 0.468 . . . . 2.39 110.216 178.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 101.17 -15.61 57.69 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 121.09 -0.576 . . . . 0.69 112.197 -178.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 59.0 tptt -70.89 117.28 12.19 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.644 0.259 . . . . 2.86 110.73 -179.272 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.541 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 6.1 p -85.58 131.77 33.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 N-CA-C 110.028 -0.36 . . . . 1.96 110.028 176.819 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 31.6 p90 -106.35 -50.09 3.22 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 120.862 -0.335 . . . . 0.56 110.991 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 324' ' ' ASP . . . . . 0.486 ' C ' ' HD3' ' A' ' 325' ' ' LYS . 12.0 t70 -123.86 154.32 39.81 Favored 'General case' 0 CA--C 1.513 -0.446 0 N-CA-C 109.492 -0.559 . . . . 1.68 109.492 -179.302 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . 0.492 ' N ' ' HD3' ' A' ' 325' ' ' LYS . 0.0 OUTLIER -167.9 131.1 1.61 Allowed 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.959 0.409 . . . . 2.55 111.143 -174.147 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 1.9 p30 -146.52 115.78 7.03 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.684 0.754 . . . . 1.92 109.719 170.336 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 327' ' ' THR . . . . . 0.506 ' O ' ' HD3' ' A' ' 312' ' ' ARG . 1.7 p -148.96 -47.17 0.14 Allowed 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 114.935 -1.029 . . . . 2.06 110.922 -172.717 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.587 ' HZ3' ' HB2' ' A' ' 328' ' ' LYS . 0.1 OUTLIER -73.66 93.34 2.06 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.492 0.663 . . . . 3.15 111.534 -178.111 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.463 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 75.37 -11.5 8.96 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 115.508 -0.769 . . . . 1.17 113.629 175.288 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 45.9 mtpt -103.25 100.63 18.49 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-N 117.32 0.56 . . . . 2.56 111.41 -177.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 331' ' ' PRO . . . . . 0.463 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 86.0 Cg_endo -87.76 139.7 4.83 Favored 'Trans proline' 0 N--CA 1.452 -0.953 0 C-N-CA 122.749 2.299 . . . . 0.73 111.854 170.664 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 79.2 t80 -109.84 128.14 55.14 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.253 -0.647 . . . . 0.76 109.253 176.359 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 61.9 t -115.22 119.6 62.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 N-CA-C 109.839 -0.43 . . . . 1.14 109.839 -176.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.586 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 21.2 p90 -138.92 166.59 24.07 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.853 -0.425 . . . . 0.48 109.853 179.66 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 335' ' ' LYS . . . . . . . . . . . . . 58.6 pttt -111.12 140.49 45.62 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.16 -0.473 . . . . 3.11 110.403 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 11.2 mp -71.53 139.0 49.32 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.729 -0.471 . . . . 1.2 109.729 175.246 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 94.76 5.95 60.99 Favored Glycine 0 N--CA 1.442 -0.93 0 C-N-CA 120.791 -0.719 . . . . 1.02 113.002 -174.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 338' ' ' GLN . . . . . 0.564 HE21 HG11 ' A' ' 341' ' ' VAL . 13.7 pt20 -85.16 148.86 25.9 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 117.381 0.591 . . . . 3.1 109.558 176.165 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -90.37 15.23 60.49 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.75 -0.738 . . . . 0.98 114.407 -166.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -109.92 -9.07 14.79 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 117.646 0.723 . . . . 2.09 111.481 178.397 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 341' ' ' VAL . . . . . 0.564 HG11 HE21 ' A' ' 338' ' ' GLN . 26.3 m -95.71 146.29 7.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 C-N-CA 120.769 -0.372 . . . . 1.27 110.144 178.697 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 17.4 pt -73.58 157.1 6.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 109.965 -0.383 . . . . 1.08 109.965 178.678 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 343' ' ' LYS . . . . . 0.448 ' HA ' ' HE3' ' A' ' 343' ' ' LYS . 0.0 OUTLIER -62.74 -35.26 79.19 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 111.626 0.232 . . . . 3.46 111.626 -175.895 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -52.28 -42.15 55.62 Favored Glycine 0 C--O 1.228 -0.251 0 C-N-CA 120.774 -0.726 . . . . 0.32 112.363 174.243 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 4.2 m95 -68.8 -60.34 2.46 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.819 0.342 . . . . 0.44 111.043 176.441 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -51.66 -33.97 35.99 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.594 -0.73 . . . . 1.75 112.121 -177.477 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 60.0 mt -85.19 -52.53 12.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 116.4 -0.363 . . . . 1.18 111.283 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -60.47 -35.05 87.94 Favored Glycine 0 CA--C 1.524 0.628 0 C-N-CA 121.261 -0.495 . . . . 0.37 113.794 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 349' ' ' VAL . . . . . 0.409 ' O ' ' HB2' ' A' ' 352' ' ' MET . 93.1 t -77.68 -18.27 14.05 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 CA-C-O 120.994 0.426 . . . . 1.08 111.382 -179.311 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -64.22 100.34 0.33 Allowed 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.157 0.503 . . . . 1.09 110.634 177.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 105.52 12.05 27.57 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.914 -0.66 . . . . 0.45 112.205 -177.014 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 352' ' ' MET . . . . . 0.523 ' HE3' ' HG2' ' A' ' 358' ' ' ARG . 0.0 OUTLIER -66.58 143.89 56.76 Favored 'General case' 0 C--N 1.331 -0.216 0 N-CA-C 109.79 -0.448 . . . . 1.3 109.79 177.675 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 353' ' ' ALA . . . . . 0.586 ' HB2' ' O ' ' A' ' 299' ' ' LYS . . . -104.06 127.06 51.61 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.321 -0.399 . . . . 1.33 111.715 -173.082 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 354' ' ' VAL . . . . . 0.597 ' H ' ' HD2' ' A' ' 301' ' ' PRO . 98.3 t -64.84 112.97 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.239 0.542 . . . . 1.24 110.743 174.504 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 109.96 -10.88 31.97 Favored Glycine 0 N--CA 1.442 -0.9 0 N-CA-C 111.313 -0.715 . . . . 0.44 111.313 -176.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -101.54 159.77 18.38 Favored Glycine 0 N--CA 1.442 -0.952 0 C-N-CA 121.048 -0.596 . . . . 0.37 112.302 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 357' ' ' GLU . . . . . 0.854 ' HB2' ' HD3' ' A' ' 387' ' ' LYS . 43.3 tt0 -135.35 140.97 45.47 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.491 -0.559 . . . . 1.63 109.491 -179.505 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 358' ' ' ARG . . . . . 0.523 ' HG2' ' HE3' ' A' ' 352' ' ' MET . 5.9 ptp180 -156.2 144.91 20.2 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.026 0.441 . . . . 1.53 110.861 177.182 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 359' ' ' ARG . . . . . . . . . . . . . 82.8 mtm180 -91.44 120.02 31.91 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 115.968 -0.56 . . . . 3.26 110.444 179.174 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 360' ' ' ILE . . . . . 0.534 HG12 HG23 ' A' ' 292' ' ' ILE . 62.3 mt -101.68 119.32 49.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-N 115.734 -0.666 . . . . 1.13 110.638 -176.476 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 361' ' ' VAL . . . . . 0.51 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 46.3 t -103.48 112.74 38.09 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 108.972 -0.751 . . . . 1.14 108.972 177.025 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 362' ' ' ILE . . . . . . . . . . . . . 57.6 mt -109.74 102.24 49.47 Favored Pre-proline 0 C--N 1.319 -0.723 0 CA-C-N 116.037 -0.528 . . . . 1.13 110.999 -174.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 363' ' ' PRO . . . . . 0.496 ' HA ' ' HG3' ' A' ' 381' ' ' GLU . 71.2 Cg_exo -54.39 155.48 16.29 Favored 'Trans proline' 0 N--CA 1.459 -0.559 0 C-N-CA 122.532 2.155 . . . . 1.05 112.206 171.231 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 364' ' ' ALA . . . . . 0.532 ' N ' ' HD2' ' A' ' 365' ' ' PRO . . . -46.03 -50.1 37.5 Favored Pre-proline 0 C--N 1.327 -0.41 0 N-CA-C 114.364 1.246 . . . . 1.16 114.364 -174.743 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 365' ' ' PRO . . . . . 0.532 ' HD2' ' N ' ' A' ' 364' ' ' ALA . 9.8 Cg_endo -52.53 -31.58 49.58 Favored 'Trans proline' 0 C--N 1.36 1.168 0 C-N-CA 122.685 2.256 . . . . 1.14 114.387 -172.144 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 366' ' ' TYR . . . . . 0.633 ' CE2' ' HA3' ' A' ' 288' ' ' GLY . 9.6 m-85 -101.62 13.46 34.86 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-O 121.017 0.437 . . . . 1.03 112.035 -176.708 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -126.59 -108.05 0.31 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.963 -0.562 . . . . 1.07 110.563 173.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 40.6 m-85 -84.08 -21.83 31.37 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.821 0.343 . . . . 1.44 111.211 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 70.68 -118.1 7.47 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.841 -0.695 . . . . 0.65 112.15 -178.14 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 370' ' ' LYS . . . . . 0.581 ' HA ' ' HB2' ' A' ' 378' ' ' ALA . 19.4 ptmt -101.77 17.39 23.11 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.975 0.416 . . . . 3.34 110.735 178.863 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 59.4 tt0 -84.86 102.58 13.2 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.941 -0.572 . . . . 2.88 110.154 176.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 372' ' ' ALA . . . . . . . . . . . . . . . -81.68 108.25 15.09 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.873 0.368 . . . . 1.39 111.202 177.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 86.6 mt -90.02 159.33 42.87 Favored Pre-proline 0 C--N 1.322 -0.626 0 N-CA-C 109.088 -0.708 . . . . 1.55 109.088 175.193 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -62.26 114.24 2.25 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 121.656 1.57 . . . . 1.61 110.555 172.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 96.26 -29.28 10.4 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.67 -0.776 . . . . 0.96 112.439 -178.155 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 43.3 mt -128.36 86.66 57.27 Favored Pre-proline 0 C--N 1.332 -0.152 0 N-CA-C 110.011 -0.366 . . . . 1.29 110.011 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 377' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -80.03 168.0 19.37 Favored 'Trans proline' 0 N--CA 1.462 -0.354 0 C-N-CA 122.724 2.283 . . . . 1.08 113.017 -176.579 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 378' ' ' ALA . . . . . 0.581 ' HB2' ' HA ' ' A' ' 370' ' ' LYS . . . -52.95 150.16 5.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.5 -0.773 . . . . 1.52 111.703 178.73 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 379' ' ' ASN . . . . . 0.441 ' HA ' ' HB1' ' A' ' 364' ' ' ALA . 49.9 m-80 70.91 15.14 6.82 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 115.473 -0.785 . . . . 1.97 111.265 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 21.5 t -76.67 125.98 30.19 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 109.587 -0.523 . . . . 1.91 109.587 175.156 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 381' ' ' GLU . . . . . 0.698 ' HB3' ' HD3' ' A' ' 318' ' ' LYS . 27.2 tt0 -102.24 112.57 25.32 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 108.67 -0.863 . . . . 1.03 108.67 -179.01 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 75.8 mt -86.26 146.53 26.48 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 116.179 -0.464 . . . . 1.13 111.12 -172.709 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 63.0 m -123.52 122.84 39.24 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.386 -0.598 . . . . 1.12 109.386 173.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 76.8 m-85 -119.84 111.71 18.32 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 116.483 -0.326 . . . . 0.4 111.079 -177.01 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 385' ' ' ASP . . . . . 0.423 ' O ' ' HA ' ' A' ' 313' ' ' TYR . 3.6 m-20 -72.54 104.18 3.77 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 107.924 -1.139 . . . . 1.8 107.924 167.834 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 386' ' ' VAL . . . . . 0.503 ' HB ' ' CE ' ' A' ' 311' ' ' MET . 32.2 m -119.11 135.61 58.97 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.426 0.631 . . . . 1.13 111.012 -176.227 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 387' ' ' LYS . . . . . 0.854 ' HD3' ' HB2' ' A' ' 357' ' ' GLU . 21.6 ttpt -141.32 128.65 21.11 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.296 -0.865 . . . . 3.1 109.449 178.44 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 388' ' ' LEU . . . . . 0.703 HD12 ' HB ' ' A' ' 309' ' ' VAL . 22.6 tp -95.04 136.76 34.97 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.932 -0.576 . . . . 1.05 109.575 -172.65 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 35.8 m -126.0 -5.0 5.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 N-CA-C 112.392 0.516 . . . . 1.2 112.392 -174.654 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 11.3 p -169.15 157.41 7.7 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.816 -0.354 . . . . 1.82 111.473 -177.444 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 391' ' ' MET . . . . . 0.487 ' HE3' HG13 ' A' ' 309' ' ' VAL . 34.1 ttm -160.89 139.11 9.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.16 -0.473 . . . . 1.14 110.485 177.448 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 18.2 tptm . . . . . 0 C--O 1.246 0.892 0 CA-C-O 117.961 -1.019 . . . . 5.51 111.402 175.167 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.451 ' HA ' ' O ' ' A' ' 292' ' ' ILE . 16.9 p . . . . . 0 N--CA 1.444 -0.729 0 CA-C-O 121.083 0.468 . . . . 1.27 111.412 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 28.2 mmtp -127.46 139.74 52.61 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.729 -0.669 . . . . 2.51 109.629 175.821 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . 0.445 HD12 ' HA2' ' A' ' 289' ' ' GLY . 37.6 tp -96.28 121.1 37.71 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.909 -0.587 . . . . 1.52 110.217 179.539 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.645 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 95.2 mt -105.83 -171.73 1.96 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.912 -0.586 . . . . 1.39 110.378 -179.413 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 287' ' ' GLU . . . . . 0.458 ' HG3' ' OH ' ' A' ' 366' ' ' TYR . 4.9 tp10 -64.51 145.37 56.22 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.889 -0.596 . . . . 2.64 111.105 -176.381 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.405 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 70.93 7.19 61.65 Favored Glycine 0 C--N 1.332 0.31 0 C-N-CA 121.055 -0.593 . . . . 1.84 113.126 -178.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . 0.445 ' HA2' HD12 ' A' ' 285' ' ' LEU . . . 84.81 19.93 58.83 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.858 -0.687 . . . . 1.16 113.216 -179.613 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 290' ' ' ILE . . . . . 0.645 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 96.1 mt -66.39 126.46 25.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 109.985 -0.376 . . . . 1.16 109.985 177.557 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 14.8 mt -110.53 137.14 44.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 N-CA-C 109.726 -0.472 . . . . 1.6 109.726 -178.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 292' ' ' ILE . . . . . 0.451 ' O ' ' HA ' ' A' ' 283' ' ' THR . 21.7 pt -127.02 128.24 70.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-O 121.054 0.454 . . . . 1.17 111.069 179.626 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 293' ' ' GLU . . . . . 0.722 ' HB3' ' HB3' ' A' ' 359' ' ' ARG . 6.6 tp10 -104.62 105.54 15.67 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.177 -1.046 . . . . 2.31 108.177 174.223 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -78.02 110.16 12.71 Favored 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 120.562 -0.455 . . . . 2.36 109.816 -172.221 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 295' ' ' ARG . . . . . 0.68 ' HB2' ' HG3' ' A' ' 357' ' ' GLU . 14.6 mmm180 -78.05 -59.66 2.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.889 -0.596 . . . . 3.99 110.855 -171.304 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.52 ' HB ' ' HG2' ' A' ' 357' ' ' GLU . 97.8 t -137.16 119.06 18.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 C-N-CA 121.141 -0.223 . . . . 1.31 110.626 177.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 14.9 p -68.27 108.04 3.04 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 116.079 -0.51 . . . . 2.46 110.494 176.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -94.91 157.39 22.17 Favored Glycine 0 N--CA 1.442 -0.926 0 C-N-CA 120.764 -0.731 . . . . 1.04 111.56 178.677 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 299' ' ' LYS . . . . . 0.402 ' HE3' ' HB3' ' A' ' 299' ' ' LYS . 18.3 ttpp -115.75 111.03 19.94 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 109.764 -0.458 . . . . 5.01 109.764 178.535 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -171.72 -162.39 23.91 Favored Glycine 0 N--CA 1.44 -1.096 0 N-CA-C 111.105 -0.798 . . . . 1.59 111.105 179.742 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . 0.405 ' HD2' ' HB ' ' A' ' 354' ' ' VAL . 21.6 Cg_exo -65.76 133.33 33.59 Favored 'Trans proline' 0 N--CA 1.461 -0.394 0 C-N-CA 122.496 2.131 . . . . 1.1 111.661 175.703 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 302' ' ' HIS . . . . . 0.514 ' HA ' ' O ' ' A' ' 352' ' ' MET . 64.4 m80 -89.01 133.69 34.25 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.116 0.484 . . . . 1.85 110.579 -179.706 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -87.17 129.25 35.02 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.773 -0.649 . . . . 1.17 111.621 -177.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 59.7 pttt -124.34 -176.3 3.48 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.5 -0.555 . . . . 3.26 109.5 174.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.702 ' HG3' ' HA3' ' A' ' 337' ' ' GLY . 50.7 tttm -66.98 133.66 50.4 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.028 0.442 . . . . 3.21 110.229 -178.527 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 91.96 -8.91 77.63 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 121.064 -0.589 . . . . 0.7 112.669 -176.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 25.6 m -82.06 145.51 30.15 Favored 'General case' 0 CA--C 1.535 0.365 0 CA-C-O 120.688 0.28 . . . . 1.07 110.766 -178.689 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 89.6 mtt180 -108.33 103.23 12.35 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-O 121.098 0.475 . . . . 3.98 109.771 -178.221 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.861 ' HB ' HD12 ' A' ' 388' ' ' LEU . 32.4 m -112.13 159.83 11.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-N 115.549 -0.751 . . . . 1.1 112.244 -175.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -123.26 123.55 5.33 Favored Glycine 0 N--CA 1.447 -0.573 0 N-CA-C 110.524 -1.03 . . . . 0.32 110.524 176.333 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 10.4 ptp -134.48 178.15 7.21 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.399 0.619 . . . . 1.55 111.815 -173.377 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 88.1 mtt180 -137.53 143.4 41.61 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 107.217 -1.401 . . . . 3.0 107.217 176.02 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 313' ' ' TYR . . . . . 0.579 ' CB ' HG13 ' A' ' 386' ' ' VAL . 49.4 p90 -162.55 152.16 15.84 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 112.646 0.61 . . . . 1.24 112.646 -167.238 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 51.1 t -116.92 119.0 60.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.091 -0.959 . . . . 1.09 109.627 173.111 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -97.93 109.15 3.75 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 121.343 -0.456 . . . . 0.32 112.261 -178.022 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 316' ' ' LYS . . . . . 0.544 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 56.3 mttm -120.42 162.97 18.62 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.173 0.511 . . . . 2.61 111.025 -177.157 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 81.9 mt -86.54 164.54 16.84 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 108.033 -1.099 . . . . 1.32 108.033 166.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 318' ' ' LYS . . . . . . . . . . . . . 47.7 pttt -64.44 -8.46 13.57 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.483 0.659 . . . . 2.9 110.303 173.505 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -79.51 -12.59 59.86 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 115.289 -0.869 . . . . 2.39 109.799 176.52 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 95.59 -24.93 27.14 Favored Glycine 0 N--CA 1.453 -0.187 0 N-CA-C 111.572 -0.611 . . . . 0.69 111.572 -176.445 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 23.7 ttmm -60.08 120.04 8.96 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.015 -0.593 . . . . 2.86 110.831 177.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.544 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 5.3 p -88.86 127.22 41.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.133 -0.485 . . . . 1.96 110.201 179.491 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 49.4 p90 -98.88 -27.19 14.02 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.828 -0.349 . . . . 0.56 111.16 -178.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -155.18 145.79 22.22 Favored 'General case' 0 CA--C 1.514 -0.408 0 N-CA-C 109.981 -0.377 . . . . 1.68 109.981 175.599 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . 0.486 ' N ' ' HD3' ' A' ' 325' ' ' LYS . 0.0 OUTLIER -149.74 128.7 12.61 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.379 0.609 . . . . 2.55 111.335 -179.257 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 23.6 m-80 -125.21 114.51 19.07 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 107.055 -1.461 . . . . 1.92 107.055 174.452 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 10.4 m -155.29 -58.79 0.1 Allowed 'General case' 0 C--N 1.318 -0.803 0 C-N-CA 120.367 -0.533 . . . . 2.06 111.784 -168.49 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 9.4 ptmm? -68.05 92.01 0.37 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.288 0.566 . . . . 3.15 111.625 -172.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.437 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 63.51 2.77 6.19 Favored Glycine 0 C--N 1.335 0.513 0 CA-C-N 115.582 -0.736 . . . . 1.17 113.048 -178.402 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 83.9 tttt -105.63 101.9 35.0 Favored Pre-proline 0 C--N 1.325 -0.47 0 N-CA-C 111.772 0.286 . . . . 2.56 111.772 -172.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 331' ' ' PRO . . . . . 0.437 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 95.8 Cg_endo -87.76 161.74 7.7 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 123.067 2.511 . . . . 0.73 112.567 174.289 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 66.4 t80 -134.72 126.45 29.06 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.224 -0.444 . . . . 0.76 109.844 174.038 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 333' ' ' VAL . . . . . 0.497 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 59.6 t -109.48 120.91 61.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.556 -0.293 . . . . 1.14 110.363 -177.002 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 22.3 p90 -142.93 160.13 40.93 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.193 0.52 . . . . 0.48 111.711 -178.608 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 335' ' ' LYS . . . . . . . . . . . . . 11.2 ttmt -89.34 128.15 35.86 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.309 -0.859 . . . . 3.11 110.345 176.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 6.8 mp -69.32 136.85 52.38 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.673 0.273 . . . . 1.2 110.598 173.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 337' ' ' GLY . . . . . 0.702 ' HA3' ' HG3' ' A' ' 305' ' ' LYS . . . 79.08 58.02 3.07 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 121.112 -0.566 . . . . 1.02 112.708 178.62 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 338' ' ' GLN . . . . . . . . . . . . . 29.0 pt20 -142.55 161.21 38.64 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.776 -0.453 . . . . 3.1 109.776 176.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -81.74 1.39 86.33 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.18 -0.533 . . . . 0.98 112.617 -173.797 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 21.0 mm-40 -76.25 -21.66 56.08 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.153 0.501 . . . . 2.09 110.307 178.461 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 18.7 m -114.51 166.64 8.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.898 -0.592 . . . . 1.27 110.046 -177.317 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 10.4 pt -85.11 154.46 3.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 N-CA-C 109.518 -0.549 . . . . 1.08 109.518 175.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 343' ' ' LYS . . . . . 0.612 ' HA ' ' OD1' ' A' ' 346' ' ' ASP . 13.7 mmmm -60.18 -28.54 68.03 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.391 0.515 . . . . 3.46 112.391 -172.62 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 344' ' ' GLY . . . . . 0.483 ' HA2' ' CD1' ' A' ' 290' ' ' ILE . . . -56.27 -31.13 59.15 Favored Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.467 -0.873 . . . . 0.32 112.656 174.204 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 9.2 m95 -74.62 -60.65 2.18 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 112.303 0.483 . . . . 0.44 112.303 -179.189 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 346' ' ' ASP . . . . . 0.612 ' OD1' ' HA ' ' A' ' 343' ' ' LYS . 8.1 p-10 -64.55 -24.73 67.7 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.634 0.254 . . . . 1.75 111.468 -173.63 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 48.7 mt -84.44 -51.31 14.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 116.318 -0.401 . . . . 1.18 111.126 177.347 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -64.28 -36.46 93.25 Favored Glycine 0 CA--C 1.524 0.624 0 C-N-CA 121.032 -0.604 . . . . 0.37 113.355 179.599 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 349' ' ' VAL . . . . . 0.506 ' O ' ' HB2' ' A' ' 352' ' ' MET . 77.1 t -80.55 -14.4 12.88 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.88 0.371 . . . . 1.08 111.349 -179.218 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -63.2 113.25 3.06 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.957 0.408 . . . . 1.09 110.682 177.86 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 96.32 19.57 27.66 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.969 -0.634 . . . . 0.45 111.924 -177.048 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 352' ' ' MET . . . . . 0.757 ' HE3' ' HG2' ' A' ' 358' ' ' ARG . 0.0 OUTLIER -76.66 155.87 33.06 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.722 -0.473 . . . . 1.3 109.722 174.907 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 353' ' ' ALA . . . . . . . . . . . . . . . -131.04 133.79 46.06 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.671 0.272 . . . . 1.33 110.921 -179.435 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 354' ' ' VAL . . . . . 0.405 ' HB ' ' HD2' ' A' ' 301' ' ' PRO . 95.1 t -55.39 114.79 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.976 -0.556 . . . . 1.24 110.909 175.733 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 113.83 -8.06 23.72 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.975 -0.631 . . . . 0.44 112.097 -179.019 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -109.79 162.42 12.69 Favored Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.73 -0.747 . . . . 0.37 112.785 -179.713 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 357' ' ' GLU . . . . . 0.752 ' HB3' ' HB3' ' A' ' 387' ' ' LYS . 9.6 pt-20 -140.64 145.54 36.74 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 110.172 -0.307 . . . . 1.63 110.172 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 358' ' ' ARG . . . . . 0.757 ' HG2' ' HE3' ' A' ' 352' ' ' MET . 2.8 ptp180 -154.44 145.53 22.75 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.378 0.608 . . . . 1.53 111.67 178.393 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 359' ' ' ARG . . . . . 0.722 ' HB3' ' HB3' ' A' ' 293' ' ' GLU . 34.5 ttt180 -86.82 114.46 23.5 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 114.948 -1.024 . . . . 3.26 109.938 -179.707 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 56.1 mt -101.6 117.52 47.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 120.896 0.379 . . . . 1.13 110.46 -178.196 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 361' ' ' VAL . . . . . . . . . . . . . 46.5 t -104.01 112.2 36.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 109.346 -0.612 . . . . 1.14 109.346 178.078 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 362' ' ' ILE . . . . . 0.446 HD11 ' HA3' ' A' ' 344' ' ' GLY . 54.5 mt -109.23 106.51 58.78 Favored Pre-proline 0 C--N 1.32 -0.694 0 CA-C-N 116.259 -0.428 . . . . 1.13 110.784 -174.181 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 363' ' ' PRO . . . . . 0.501 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 18.4 Cg_endo -58.35 159.53 19.14 Favored 'Trans proline' 0 C--O 1.235 0.372 0 C-N-CA 122.487 2.125 . . . . 1.05 111.848 173.327 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 364' ' ' ALA . . . . . 0.433 ' HB1' ' HA ' ' A' ' 379' ' ' ASN . . . -49.37 -50.16 66.69 Favored Pre-proline 0 CA--C 1.538 0.504 0 N-CA-C 114.002 1.112 . . . . 1.16 114.002 -174.448 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 365' ' ' PRO . . . . . 0.501 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 77.5 Cg_exo -51.38 -30.9 36.04 Favored 'Trans proline' 0 C--N 1.364 1.368 0 C-N-CA 122.294 1.996 . . . . 1.14 114.047 -174.935 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 366' ' ' TYR . . . . . 0.458 ' OH ' ' HG3' ' A' ' 287' ' ' GLU . 3.7 m-85 -102.26 14.13 32.79 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 112.158 0.429 . . . . 1.03 112.158 -177.503 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -129.23 -107.57 0.29 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.147 -0.479 . . . . 1.07 110.386 173.249 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 32.8 m-85 -87.96 -14.2 39.8 Favored 'General case' 0 N--CA 1.466 0.34 0 N-CA-C 112.09 0.404 . . . . 1.44 112.09 -179.113 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 70.01 -122.96 12.07 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.918 -0.658 . . . . 0.65 112.773 178.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 4.7 ptpp? -97.2 4.07 51.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.685 0.279 . . . . 3.34 111.12 -178.247 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 15.8 mm100 -75.36 98.92 3.97 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.085 0.469 . . . . 2.88 110.787 -179.261 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 372' ' ' ALA . . . . . . . . . . . . . . . -72.21 90.98 1.26 Allowed 'General case' 0 N--CA 1.447 -0.586 0 CA-C-N 115.695 -0.684 . . . . 1.39 110.454 175.593 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 36.7 mt -74.51 159.24 83.92 Favored Pre-proline 0 C--N 1.323 -0.568 0 CA-C-N 115.516 -0.765 . . . . 1.55 109.144 178.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -58.63 113.97 1.79 Allowed 'Trans proline' 0 N--CA 1.459 -0.529 0 C-N-CA 121.749 1.633 . . . . 1.61 110.721 173.73 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 93.84 -27.76 11.97 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.767 -0.73 . . . . 0.96 112.796 -177.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 56.6 mt -125.18 89.41 52.65 Favored Pre-proline 0 C--N 1.327 -0.37 0 CA-C-O 120.71 0.29 . . . . 1.29 110.84 -177.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 377' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -72.52 168.09 25.31 Favored 'Trans proline' 0 C--O 1.234 0.276 0 C-N-CA 123.143 2.562 . . . . 1.08 113.009 -178.112 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 378' ' ' ALA . . . . . 0.477 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -53.2 155.09 2.81 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.512 -0.767 . . . . 1.52 111.212 178.148 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 379' ' ' ASN . . . . . 0.477 ' HB2' ' O ' ' A' ' 378' ' ' ALA . 33.1 m-80 71.97 32.16 1.89 Allowed 'General case' 0 N--CA 1.467 0.419 0 O-C-N 123.805 0.69 . . . . 1.97 109.43 -172.228 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 1.8 p -70.7 87.88 0.7 Allowed 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 114.896 -1.047 . . . . 1.91 111.283 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 381' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -80.27 98.91 7.6 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 108.68 -0.859 . . . . 1.03 108.68 174.565 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 67.8 mt -85.96 146.98 26.44 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.0 -0.545 . . . . 1.13 110.292 -176.561 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 28.9 m -124.08 122.68 38.51 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 109.566 -0.531 . . . . 1.12 109.566 175.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -117.83 110.62 18.0 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.424 -0.353 . . . . 0.4 110.429 -178.575 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -84.0 103.81 13.55 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 107.813 -1.18 . . . . 1.8 107.813 172.478 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 386' ' ' VAL . . . . . 0.579 HG13 ' CB ' ' A' ' 313' ' ' TYR . 18.5 m -122.02 149.93 25.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 121.235 0.54 . . . . 1.13 112.185 -170.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 387' ' ' LYS . . . . . 0.752 ' HB3' ' HB3' ' A' ' 357' ' ' GLU . 11.1 ptpt -141.6 139.58 33.13 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.686 -0.688 . . . . 3.1 110.313 172.35 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 388' ' ' LEU . . . . . 0.861 HD12 ' HB ' ' A' ' 309' ' ' VAL . 31.0 tp -91.53 127.18 36.88 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.766 -0.827 . . . . 1.05 108.766 179.566 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 33.3 m -124.77 -10.84 6.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 C-N-CA 120.585 -0.446 . . . . 1.2 111.872 -172.676 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 50.0 m -157.96 159.83 36.9 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.844 0.354 . . . . 1.82 111.268 -179.33 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 391' ' ' MET . . . . . . . . . . . . . 38.7 ttm -160.32 150.82 18.47 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.339 -0.615 . . . . 1.14 109.339 175.354 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 18.5 ptpt . . . . . 0 C--O 1.249 1.067 0 C-N-CA 124.251 1.02 . . . . 5.51 112.805 176.866 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 2.9 p . . . . . 0 N--CA 1.444 -0.768 0 CA-C-O 121.351 0.596 . . . . 1.27 110.232 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 32.2 mmtp -108.16 130.54 55.12 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 115.652 -0.704 . . . . 2.51 110.041 -178.222 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 32.3 tp -95.47 125.44 40.08 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.949 -0.569 . . . . 1.52 109.959 179.836 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.742 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 90.4 mt -102.75 -178.12 3.58 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.688 -0.687 . . . . 1.39 109.433 179.302 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 14.3 tt0 -66.37 152.04 45.87 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.704 -0.48 . . . . 2.64 109.704 179.791 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 72.71 -4.41 21.83 Favored Glycine 0 C--O 1.229 -0.177 0 C-N-CA 120.823 -0.703 . . . . 1.84 113.08 -174.265 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 90.33 21.34 38.37 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.504 -0.855 . . . . 1.16 113.53 179.547 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 290' ' ' ILE . . . . . 0.742 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 61.9 mt -69.81 133.43 31.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 117.39 0.595 . . . . 1.16 110.344 177.828 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . 0.515 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 17.8 mt -113.08 139.49 37.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 C-N-CA 121.106 -0.237 . . . . 1.6 110.836 -178.576 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 292' ' ' ILE . . . . . 0.489 ' HB ' ' HD3' ' A' ' 358' ' ' ARG . 17.7 pt -132.08 129.3 60.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 121.151 0.501 . . . . 1.17 110.956 177.185 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 293' ' ' GLU . . . . . 0.426 ' C ' ' HG3' ' A' ' 358' ' ' ARG . 4.5 tp10 -125.15 119.21 27.93 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.516 -0.766 . . . . 2.31 109.664 178.699 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . 0.675 ' OD2' ' HA ' ' A' ' 297' ' ' THR . 6.2 t70 -80.3 96.18 6.56 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.475 -0.565 . . . . 2.36 109.475 -175.727 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 295' ' ' ARG . . . . . . . . . . . . . 66.6 ttt180 -69.37 -45.73 68.65 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.784 -0.644 . . . . 3.99 110.146 -175.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.573 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 88.8 t -123.4 123.71 68.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 N-CA-C 108.523 -0.917 . . . . 1.31 108.523 172.313 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 297' ' ' THR . . . . . 0.675 ' HA ' ' OD2' ' A' ' 294' ' ' ASP . 5.1 t -60.76 109.75 1.13 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.718 0.771 . . . . 2.46 110.994 -174.156 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 298' ' ' GLY . . . . . 0.512 ' HA3' ' HA3' ' A' ' 356' ' ' GLY . . . -99.33 111.22 4.16 Favored Glycine 0 N--CA 1.445 -0.708 0 CA-C-N 115.313 -0.858 . . . . 1.04 112.948 -178.036 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 36.9 mmtm -125.39 110.14 13.6 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 108.982 -0.747 . . . . 5.01 108.982 173.829 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -173.3 -152.68 8.97 Favored Glycine 0 N--CA 1.447 -0.573 0 N-CA-C 111.218 -0.753 . . . . 1.59 111.218 -174.404 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . 0.606 ' O ' ' HA ' ' A' ' 353' ' ' ALA . 32.8 Cg_exo -58.32 132.92 51.66 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.413 2.075 . . . . 1.1 111.312 174.103 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 26.6 m80 -96.63 127.92 43.08 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.941 0.401 . . . . 1.85 111.132 -173.61 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -73.51 117.62 15.49 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.066 -0.516 . . . . 1.17 111.056 179.202 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 63.2 mttm -118.9 -179.4 3.8 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.194 -0.457 . . . . 3.26 110.583 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 49.7 mtmt -72.68 127.15 31.69 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 109.9 -0.408 . . . . 3.21 109.9 179.223 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 94.8 -0.51 64.89 Favored Glycine 0 CA--C 1.518 0.223 0 C-N-CA 120.747 -0.739 . . . . 0.7 112.047 -176.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 19.8 m -91.29 145.31 24.75 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 110.239 -0.282 . . . . 1.07 110.239 177.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 51.4 mtp180 -108.12 106.47 16.69 Favored 'General case' 0 CA--C 1.519 -0.225 0 N-CA-C 109.648 -0.501 . . . . 3.98 109.648 178.693 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.863 ' HB ' HD12 ' A' ' 388' ' ' LEU . 32.7 m -106.25 154.11 7.45 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.959 0 CA-C-O 121.086 0.469 . . . . 1.1 111.747 -174.09 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -122.74 127.73 6.82 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 110.823 -0.911 . . . . 0.32 110.823 177.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 11.9 ptp -135.22 177.01 8.15 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.754 0.788 . . . . 1.55 112.789 -173.82 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 44.3 mtm180 -135.96 146.21 47.01 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 107.068 -1.456 . . . . 3.0 107.068 173.005 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 313' ' ' TYR . . . . . 0.567 ' CB ' HG11 ' A' ' 386' ' ' VAL . 41.9 p90 -159.13 155.52 27.39 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 113.214 0.82 . . . . 1.24 113.214 -168.118 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 58.1 t -122.56 113.24 37.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 114.94 -1.027 . . . . 1.09 109.361 170.185 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -97.56 115.64 5.31 Favored Glycine 0 C--O 1.238 0.374 0 C-N-CA 120.85 -0.69 . . . . 0.32 112.556 -176.331 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 316' ' ' LYS . . . . . 0.613 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 91.9 mttt -117.86 162.45 18.09 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-O 121.275 0.559 . . . . 2.61 110.758 -179.066 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 93.6 mt -90.01 165.89 13.77 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.423 -0.808 . . . . 1.32 109.558 173.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 318' ' ' LYS . . . . . 0.564 ' HB2' ' HB3' ' A' ' 381' ' ' GLU . 56.9 tttp -59.88 -23.09 63.16 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.22 0.533 . . . . 2.9 110.306 176.448 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -70.14 -15.63 62.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.38 -0.827 . . . . 2.39 110.894 -179.559 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 98.84 -5.43 59.79 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.51 -0.852 . . . . 0.69 112.195 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -91.48 133.28 35.64 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 120.682 0.277 . . . . 2.86 110.3 179.004 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.613 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 8.0 p -77.3 140.21 17.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.467 -0.333 . . . . 1.96 110.322 178.575 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 34.9 p90 -103.62 -33.43 8.99 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.54 -0.464 . . . . 0.56 110.994 177.636 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -162.7 162.99 27.1 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 121.063 -0.255 . . . . 1.68 110.343 175.132 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -159.61 129.63 5.55 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.891 0.377 . . . . 2.55 110.623 -178.33 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 35.1 m-80 -120.56 116.62 25.74 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.606 -0.887 . . . . 1.92 108.606 172.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.76 -69.25 0.2 Allowed 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.096 -0.502 . . . . 2.06 111.76 -174.324 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 24.7 pttm -68.41 97.28 0.74 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.698 0.761 . . . . 3.15 111.836 -174.121 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.477 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 86.71 -16.61 45.01 Favored Glycine 0 N--CA 1.446 -0.638 0 CA-C-N 115.269 -0.878 . . . . 1.17 113.591 175.375 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 27.6 mmmt -104.83 100.02 21.73 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 117.228 0.514 . . . . 2.56 111.471 -175.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 331' ' ' PRO . . . . . 0.477 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 72.1 Cg_endo -87.56 127.86 2.42 Favored 'Trans proline' 0 N--CA 1.455 -0.744 0 C-N-CA 122.883 2.389 . . . . 0.73 111.854 172.809 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 70.6 t80 -102.56 120.55 40.74 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 110.135 -0.321 . . . . 0.76 110.135 179.458 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 60.4 t -112.51 122.42 66.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.915 0.388 . . . . 1.14 110.413 -178.154 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 31.1 p90 -139.8 158.76 43.57 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.089 -0.505 . . . . 0.48 109.73 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 335' ' ' LYS . . . . . . . . . . . . . 16.9 ptmt -100.15 141.02 33.55 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.214 0.53 . . . . 3.11 111.217 179.128 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 11.2 mp -77.34 123.49 26.58 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.769 -0.651 . . . . 1.2 109.695 173.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 111.79 12.33 14.73 Favored Glycine 0 N--CA 1.446 -0.68 0 C-N-CA 120.683 -0.77 . . . . 1.02 111.931 -177.47 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 338' ' ' GLN . . . . . 0.698 HE21 HG11 ' A' ' 341' ' ' VAL . 13.2 pt20 -97.91 151.09 20.62 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.963 -0.384 . . . . 3.1 109.963 176.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -89.28 15.21 58.92 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 121.029 -0.605 . . . . 0.98 111.815 -179.047 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -87.32 -15.15 38.83 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.077 0.465 . . . . 2.09 110.261 178.298 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 341' ' ' VAL . . . . . 0.698 HG11 HE21 ' A' ' 338' ' ' GLN . 32.6 m -107.24 164.28 4.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.838 -0.619 . . . . 1.27 110.575 -177.644 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 342' ' ' ILE . . . . . 0.467 ' HB ' ' HA ' ' A' ' 367' ' ' ALA . 10.0 pt -88.67 165.36 2.06 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 109.718 -0.475 . . . . 1.08 109.718 176.546 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 343' ' ' LYS . . . . . 0.415 ' HA ' ' CE ' ' A' ' 343' ' ' LYS . 0.0 OUTLIER -56.11 -37.3 69.22 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 111.908 0.336 . . . . 3.46 111.908 -174.644 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 344' ' ' GLY . . . . . 0.572 ' HA2' HD11 ' A' ' 290' ' ' ILE . . . -55.72 -30.84 57.19 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.938 -0.649 . . . . 0.32 113.126 177.506 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 345' ' ' TRP . . . . . 0.416 ' CD1' HG12 ' A' ' 342' ' ' ILE . 18.4 m95 -77.83 -61.23 2.06 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 112.506 0.558 . . . . 0.44 112.506 -176.886 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -64.23 -20.55 66.11 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.669 0.271 . . . . 1.75 111.41 -175.69 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 71.5 mt -89.41 -55.73 5.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 116.471 -0.332 . . . . 1.18 111.685 174.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -65.71 -38.55 94.61 Favored Glycine 0 CA--C 1.523 0.59 0 C-N-CA 121.297 -0.478 . . . . 0.37 114.135 -177.372 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 83.9 t -75.22 -21.25 16.4 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 CA-C-O 120.953 0.406 . . . . 1.08 110.905 -178.612 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.2 104.53 0.93 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.164 0.506 . . . . 1.09 110.953 -179.291 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 113.84 0.58 24.31 Favored Glycine 0 N--CA 1.445 -0.712 0 C-N-CA 120.823 -0.704 . . . . 0.45 112.851 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 352' ' ' MET . . . . . . . . . . . . . 60.0 mtp -75.37 157.69 33.85 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 117.313 0.557 . . . . 1.3 110.307 174.69 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 353' ' ' ALA . . . . . 0.606 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -123.09 144.58 49.22 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.221 -0.445 . . . . 1.33 111.543 -174.861 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 73.4 t -58.2 123.15 9.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.962 -0.563 . . . . 1.24 110.357 175.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 104.23 -16.44 49.43 Favored Glycine 0 N--CA 1.446 -0.663 0 C-N-CA 120.831 -0.7 . . . . 0.44 111.528 -177.109 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 356' ' ' GLY . . . . . 0.512 ' HA3' ' HA3' ' A' ' 298' ' ' GLY . . . -87.35 154.29 26.06 Favored Glycine 0 N--CA 1.443 -0.851 0 C-N-CA 120.875 -0.678 . . . . 0.37 112.646 179.484 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 357' ' ' GLU . . . . . 0.64 ' HG3' ' HB3' ' A' ' 387' ' ' LYS . 41.2 tt0 -137.87 121.65 17.56 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.951 -0.759 . . . . 1.63 108.951 -177.833 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 358' ' ' ARG . . . . . 0.489 ' HD3' ' HB ' ' A' ' 292' ' ' ILE . 35.0 ttm180 -148.41 133.99 18.75 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.071 0.463 . . . . 1.53 110.933 -170.883 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 359' ' ' ARG . . . . . . . . . . . . . 31.8 ttp85 -86.02 122.78 30.54 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.717 -0.674 . . . . 3.26 110.459 -179.186 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 360' ' ' ILE . . . . . 0.483 HG12 HG23 ' A' ' 292' ' ' ILE . 56.8 mt -109.52 121.44 62.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.866 -0.606 . . . . 1.13 110.272 -179.646 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 361' ' ' VAL . . . . . 0.515 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 48.6 t -104.19 119.84 53.57 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 N-CA-C 109.256 -0.646 . . . . 1.14 109.256 177.699 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 362' ' ' ILE . . . . . 0.473 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 55.9 mt -118.23 100.95 51.7 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-N 116.322 -0.399 . . . . 1.13 111.535 -174.092 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 363' ' ' PRO . . . . . 0.516 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 12.3 Cg_endo -56.9 158.12 18.04 Favored 'Trans proline' 0 C--O 1.238 0.498 0 C-N-CA 122.99 2.46 . . . . 1.05 112.547 172.127 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 364' ' ' ALA . . . . . 0.486 ' CB ' ' HA ' ' A' ' 379' ' ' ASN . . . -50.18 -47.41 82.07 Favored Pre-proline 0 CA--C 1.539 0.52 0 N-CA-C 114.516 1.302 . . . . 1.16 114.516 -173.723 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 365' ' ' PRO . . . . . 0.516 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 82.6 Cg_exo -49.22 -36.55 37.25 Favored 'Trans proline' 0 C--N 1.361 1.231 0 C-N-CA 122.218 1.945 . . . . 1.14 113.632 -176.704 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 366' ' ' TYR . . . . . 0.416 ' CD1' HD12 ' A' ' 290' ' ' ILE . 3.6 m-85 -101.31 12.55 37.25 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.761 0.315 . . . . 1.03 111.643 -177.097 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 367' ' ' ALA . . . . . 0.467 ' HA ' ' HB ' ' A' ' 342' ' ' ILE . . . -119.31 -112.52 0.33 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.168 -0.469 . . . . 1.07 110.505 175.207 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -91.39 -1.88 57.47 Favored 'General case' 0 N--CA 1.464 0.228 0 N-CA-C 112.194 0.442 . . . . 1.44 112.194 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 66.43 -114.97 6.93 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 121.103 -0.57 . . . . 0.65 113.65 175.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 370' ' ' LYS . . . . . 0.426 ' HB3' ' HE2' ' A' ' 370' ' ' LYS . 14.8 ptpt -112.81 20.31 16.58 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.856 0.36 . . . . 3.34 111.502 -174.497 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 27.9 mm-40 -90.14 113.45 25.21 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.29 -0.414 . . . . 2.88 110.088 176.596 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 372' ' ' ALA . . . . . . . . . . . . . . . -83.51 96.18 8.52 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.175 0.512 . . . . 1.39 111.17 178.827 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 373' ' ' LEU . . . . . 0.5 ' HB3' ' HD2' ' A' ' 374' ' ' PRO . 59.1 mt -80.37 166.67 38.38 Favored Pre-proline 0 C--N 1.32 -0.698 0 CA-C-N 115.562 -0.744 . . . . 1.55 109.487 178.728 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 374' ' ' PRO . . . . . 0.5 ' HD2' ' HB3' ' A' ' 373' ' ' LEU . 22.9 Cg_endo -64.33 113.36 2.22 Favored 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 121.514 1.476 . . . . 1.61 110.818 172.438 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 90.65 -24.53 16.96 Favored Glycine 0 CA--C 1.519 0.312 0 C-N-CA 120.739 -0.743 . . . . 0.96 112.757 -179.003 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 39.8 mt -125.56 83.04 62.47 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.683 0.278 . . . . 1.29 110.304 -178.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 377' ' ' PRO . . . . . 0.4 ' O ' ' HB2' ' A' ' 380' ' ' SER . 9.2 Cg_exo -72.59 166.5 29.7 Favored 'Trans proline' 0 N--CA 1.464 -0.253 0 C-N-CA 123.17 2.58 . . . . 1.08 113.247 -178.124 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 378' ' ' ALA . . . . . 0.426 ' HB2' ' HA ' ' A' ' 370' ' ' LYS . . . -55.02 147.55 15.47 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-N 115.557 -0.747 . . . . 1.52 111.43 178.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 379' ' ' ASN . . . . . 0.486 ' HA ' ' CB ' ' A' ' 364' ' ' ALA . 44.4 m-80 65.54 30.65 10.54 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 115.676 -0.693 . . . . 1.97 111.3 -179.144 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 380' ' ' SER . . . . . 0.4 ' HB2' ' O ' ' A' ' 377' ' ' PRO . 22.2 t -85.41 134.54 34.07 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 116.08 -0.509 . . . . 1.91 109.78 175.769 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 381' ' ' GLU . . . . . 0.564 ' HB3' ' HB2' ' A' ' 318' ' ' LYS . 30.7 tt0 -99.43 105.16 17.07 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.305 -0.628 . . . . 1.03 109.305 179.066 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 74.2 mt -84.72 142.09 30.1 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.397 -0.365 . . . . 1.13 110.796 -177.65 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 383' ' ' THR . . . . . 0.453 HG21 HG23 ' A' ' 361' ' ' VAL . 25.7 m -122.39 122.77 39.79 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 109.726 -0.472 . . . . 1.12 109.726 177.794 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -117.44 109.59 16.96 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.928 0.394 . . . . 0.4 110.32 -178.181 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -88.81 104.4 16.88 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.154 -1.054 . . . . 1.8 108.154 174.254 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 386' ' ' VAL . . . . . 0.567 HG11 ' CB ' ' A' ' 313' ' ' TYR . 20.0 m -125.25 151.37 30.99 Favored 'Isoleucine or valine' 0 C--O 1.232 0.141 0 CA-C-O 121.358 0.599 . . . . 1.13 112.287 -169.131 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 387' ' ' LYS . . . . . 0.64 ' HB3' ' HG3' ' A' ' 357' ' ' GLU . 14.6 ptmm? -139.54 142.21 37.21 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.774 -0.648 . . . . 3.1 109.814 172.534 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 388' ' ' LEU . . . . . 0.863 HD12 ' HB ' ' A' ' 309' ' ' VAL . 19.3 tp -93.14 135.43 34.33 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.691 -0.485 . . . . 1.05 109.691 -176.471 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 34.7 m -127.53 -6.51 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 N-CA-C 112.268 0.47 . . . . 1.2 112.268 -176.442 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 44.1 t -160.57 160.35 31.71 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.528 0.204 . . . . 1.82 110.942 -177.784 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 391' ' ' MET . . . . . 0.407 ' HA ' ' HA ' ' A' ' 309' ' ' VAL . 30.9 ttm -165.61 134.1 3.16 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.998 -0.546 . . . . 1.14 110.18 179.684 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 63.7 mttp . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.513 -0.756 . . . . 5.51 109.716 175.758 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 1.45 0 N-CA-C 111.946 -0.462 . . . . 11.6 111.946 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -135.91 129.22 31.91 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 110.026 -0.361 . . . . 9.39 110.026 179.391 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 278' ' ' MET . . . . . . . . . . . . . 23.1 ttt -90.1 96.06 10.49 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.109 0.481 . . . . 8.15 110.818 -177.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -99.67 4.41 45.59 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.743 -0.662 . . . . 6.73 110.301 174.567 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 35.4 ttmt 56.51 84.14 0.21 Allowed Pre-proline 0 C--O 1.236 0.366 0 CA-C-N 114.898 -1.046 . . . . 7.18 110.999 -179.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -74.94 62.41 5.8 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 123.34 2.693 . . . . 5.4 112.148 -179.013 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 282' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -139.55 -165.27 1.84 Allowed 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.501 -0.772 . . . . 3.88 109.619 178.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 18.2 p -91.04 131.5 36.59 Favored 'General case' 0 C--N 1.31 -1.123 0 CA-C-N 115.437 -0.801 . . . . 1.27 110.896 178.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 284' ' ' LYS . . . . . 0.403 ' O ' ' HA ' ' A' ' 291' ' ' ILE . 41.8 mtmt -131.55 159.21 38.85 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.519 -0.764 . . . . 2.51 110.414 -174.407 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . 0.502 HD12 ' HA2' ' A' ' 289' ' ' GLY . 42.3 tp -111.93 127.07 55.75 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.217 -0.447 . . . . 1.52 111.987 -170.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.423 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 99.2 mt -108.32 -161.83 0.79 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.839 -0.618 . . . . 1.39 110.309 173.653 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -51.99 140.48 20.15 Favored 'General case' 0 N--CA 1.447 -0.591 0 C-N-CA 123.263 0.625 . . . . 2.64 112.301 179.293 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.472 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 70.4 -102.94 1.08 Allowed Glycine 0 N--CA 1.446 -0.69 0 CA-C-N 115.482 -0.781 . . . . 1.84 111.595 -177.63 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . 0.502 ' HA2' HD12 ' A' ' 285' ' ' LEU . . . -145.92 28.2 1.73 Allowed Glycine 0 N--CA 1.442 -0.948 0 N-CA-C 110.603 -0.999 . . . . 1.16 110.603 176.08 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 290' ' ' ILE . . . . . 0.423 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 75.4 mt -71.14 120.9 19.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.803 0.335 . . . . 1.16 110.733 -177.73 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . 0.403 ' HA ' ' O ' ' A' ' 284' ' ' LYS . 92.1 mt -103.72 138.53 27.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.274 -0.421 . . . . 1.6 110.171 178.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 292' ' ' ILE . . . . . 0.416 HG23 HG12 ' A' ' 360' ' ' ILE . 24.9 pt -124.46 128.21 73.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-O 121.3 0.571 . . . . 1.17 109.864 178.038 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 293' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -114.59 110.78 20.31 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.282 -0.872 . . . . 2.31 109.117 179.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 20.7 m-20 -83.83 103.75 13.37 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.386 0.612 . . . . 2.36 109.851 -173.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 295' ' ' ARG . . . . . . . . . . . . . 10.5 mmm180 -76.8 -49.4 15.95 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 114.809 -1.087 . . . . 3.99 110.663 -173.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . . . . . . . . . 97.9 t -118.66 130.09 73.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 115.662 -0.699 . . . . 1.31 110.358 -176.025 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 1.6 m -63.03 107.25 0.97 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.156 -0.475 . . . . 2.46 110.554 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -118.01 116.25 3.39 Favored Glycine 0 N--CA 1.445 -0.759 0 C-N-CA 120.802 -0.713 . . . . 1.04 112.402 -177.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 13.1 tptm -121.9 113.13 19.19 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.575 -0.528 . . . . 5.01 109.575 175.296 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -170.79 -153.71 9.04 Favored Glycine 0 N--CA 1.436 -1.304 0 N-CA-C 111.042 -0.823 . . . . 1.59 111.042 -178.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . 0.403 ' HB2' ' SD ' ' A' ' 391' ' ' MET . 36.8 Cg_exo -60.75 132.7 44.0 Favored 'Trans proline' 0 N--CA 1.461 -0.397 0 C-N-CA 122.6 2.2 . . . . 1.1 111.756 177.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 302' ' ' HIS . . . . . 0.417 ' HA ' ' O ' ' A' ' 352' ' ' MET . 37.3 m80 -88.82 138.44 31.41 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.207 -0.451 . . . . 1.85 110.786 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -85.68 117.37 24.53 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.897 -0.592 . . . . 1.17 111.25 -179.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 21.9 pttp -116.87 -178.54 3.46 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.045 -0.724 . . . . 3.26 109.045 173.15 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 51.4 mttm -68.13 142.4 55.77 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 110.119 -0.326 . . . . 3.21 110.119 176.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 85.29 -7.86 73.79 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 121.085 -0.578 . . . . 0.7 112.225 -175.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 307' ' ' THR . . . . . 0.451 ' O ' ' HA ' ' A' ' 335' ' ' LYS . 87.0 m -89.25 135.47 33.56 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.758 0.314 . . . . 1.07 111.119 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . 0.416 HH21 ' C ' ' A' ' 392' ' ' LYS . 73.1 mtm180 -94.24 102.34 14.35 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.687 -0.688 . . . . 3.98 109.903 -177.643 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.795 ' HB ' HD12 ' A' ' 388' ' ' LEU . 34.1 m -103.43 141.54 19.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 CA-C-O 121.426 0.631 . . . . 1.1 111.75 -177.679 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -115.51 121.66 5.34 Favored Glycine 0 N--CA 1.445 -0.759 0 N-CA-C 110.325 -1.11 . . . . 0.32 110.325 177.462 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 13.9 ptp -135.77 177.67 7.65 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.513 0.673 . . . . 1.55 112.304 -173.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -136.65 143.47 43.49 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 106.938 -1.504 . . . . 3.0 106.938 174.157 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 313' ' ' TYR . . . . . 0.499 ' CB ' HG13 ' A' ' 386' ' ' VAL . 18.2 p90 -157.52 157.49 33.92 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 113.39 0.885 . . . . 1.24 113.39 -170.245 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 58.0 t -124.34 120.94 60.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 114.795 -1.093 . . . . 1.09 109.219 173.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -97.86 110.29 3.99 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 120.959 -0.639 . . . . 0.32 112.573 -176.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 316' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -116.15 154.63 29.67 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.177 0.513 . . . . 2.61 110.929 -178.49 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 317' ' ' LEU . . . . . 0.537 HD13 ' HD3' ' A' ' 321' ' ' LYS . 80.1 mt -86.92 170.39 11.66 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.795 -0.639 . . . . 1.32 110.134 171.13 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 318' ' ' LYS . . . . . 0.432 ' HB2' ' HB3' ' A' ' 381' ' ' GLU . 57.7 tttp -59.07 -25.44 63.77 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.14 -0.482 . . . . 2.9 111.298 179.493 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 28.1 p-10 -87.7 -3.04 58.98 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 120.555 0.216 . . . . 2.39 111.267 -178.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 95.52 3.75 61.07 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.775 -0.726 . . . . 0.69 112.7 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 321' ' ' LYS . . . . . 0.537 ' HD3' HD13 ' A' ' 317' ' ' LEU . 53.4 tttp -75.18 113.55 12.65 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.751 0.31 . . . . 2.86 110.259 179.431 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . . . . . . . . . 4.7 p -85.52 119.52 34.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-O 121.287 0.565 . . . . 1.96 110.431 179.222 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 52.2 p90 -110.14 -27.13 9.3 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.072 -0.513 . . . . 0.56 111.284 -177.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -130.88 156.61 44.76 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 108.952 -0.758 . . . . 1.68 108.952 178.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 59.6 pttt -174.44 135.81 0.44 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.099 0.476 . . . . 2.55 111.525 -176.012 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 6.0 p30 -150.35 118.56 6.36 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.68 -0.691 . . . . 1.92 109.316 166.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 29.7 m -140.63 -46.8 0.41 Allowed 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.642 -0.708 . . . . 2.06 110.94 -175.451 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 83.9 mttt -79.66 92.55 5.38 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.79 -0.641 . . . . 3.15 111.259 -173.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.455 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 65.78 7.92 38.05 Favored Glycine 0 CA--C 1.52 0.391 0 CA-C-N 115.853 -0.612 . . . . 1.17 113.742 174.418 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 68.9 mmtt -103.93 100.4 20.26 Favored Pre-proline 0 C--N 1.324 -0.52 0 CA-C-N 116.688 0.244 . . . . 2.56 111.39 -177.29 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 331' ' ' PRO . . . . . 0.455 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 94.1 Cg_endo -88.38 129.54 2.3 Favored 'Trans proline' 0 N--CA 1.453 -0.895 0 C-N-CA 122.839 2.359 . . . . 0.73 112.298 173.199 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -103.74 118.89 37.77 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.956 -0.757 . . . . 0.76 108.956 174.208 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 56.7 t -112.15 125.87 69.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.904 0.383 . . . . 1.14 110.172 -177.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.732 ' HB2' HE22 ' A' ' 338' ' ' GLN . 29.8 p90 -147.31 156.38 42.86 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.835 -0.62 . . . . 0.48 109.511 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 335' ' ' LYS . . . . . 0.451 ' HA ' ' O ' ' A' ' 307' ' ' THR . 0.2 OUTLIER -111.08 142.12 43.65 Favored 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 120.034 -0.667 . . . . 3.11 110.508 177.709 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 9.3 mp -69.84 148.17 49.41 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.851 -0.613 . . . . 1.2 109.91 178.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 103.38 -8.3 52.24 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.7 -0.762 . . . . 1.02 112.942 -178.162 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 338' ' ' GLN . . . . . 0.732 HE22 ' HB2' ' A' ' 334' ' ' PHE . 30.1 pt20 -83.91 160.82 21.02 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.832 0.316 . . . . 3.1 110.215 179.367 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -107.32 21.63 30.59 Favored Glycine 0 CA--C 1.52 0.354 0 C-N-CA 120.485 -0.864 . . . . 0.98 114.307 -172.481 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -114.93 9.56 16.16 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 117.574 0.687 . . . . 2.09 111.093 178.47 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 27.3 m -116.11 146.55 20.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 108.341 -0.985 . . . . 1.27 108.341 172.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 11.4 pt -68.88 151.98 9.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 N-CA-C 109.743 -0.466 . . . . 1.08 109.743 -178.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . 0.49 ' HA ' ' HE2' ' A' ' 343' ' ' LYS . 6.2 mmpt? -61.85 -30.38 70.81 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 111.894 0.331 . . . . 3.46 111.894 -172.778 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -54.86 -31.4 54.68 Favored Glycine 0 CA--C 1.521 0.457 0 C-N-CA 120.878 -0.677 . . . . 0.32 112.343 173.647 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 9.3 m95 -77.48 -60.8 2.22 Favored 'General case' 0 C--O 1.22 -0.452 0 CA-C-O 120.531 0.205 . . . . 0.44 111.055 176.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -51.14 -28.87 11.93 Favored 'General case' 0 N--CA 1.47 0.544 0 N-CA-C 112.327 0.491 . . . . 1.75 112.327 -179.336 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 63.6 mt -91.19 -51.17 12.08 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.533 0 N-CA-C 111.946 0.35 . . . . 1.18 111.946 177.523 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -63.95 -31.1 79.68 Favored Glycine 0 CA--C 1.524 0.606 0 C-N-CA 121.282 -0.485 . . . . 0.37 113.758 -178.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 349' ' ' VAL . . . . . 0.536 ' O ' ' HB2' ' A' ' 352' ' ' MET . 90.8 t -79.7 -19.87 12.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 121.024 0.44 . . . . 1.08 110.645 179.704 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -64.6 113.64 3.86 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.373 -0.376 . . . . 1.09 110.132 178.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 97.07 15.17 39.79 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 121.035 -0.603 . . . . 0.45 112.11 -176.634 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 352' ' ' MET . . . . . 0.828 ' HE3' ' HG2' ' A' ' 358' ' ' ARG . 0.0 OUTLIER -77.12 154.9 32.78 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 109.296 -0.631 . . . . 1.3 109.296 175.264 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 353' ' ' ALA . . . . . . . . . . . . . . . -129.95 134.92 47.77 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.729 0.299 . . . . 1.33 111.166 -177.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 61.4 t -59.85 123.39 12.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.017 -0.538 . . . . 1.24 110.681 177.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 109.47 -12.36 33.2 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 121.136 -0.554 . . . . 0.44 112.022 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -104.89 150.9 17.2 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.761 -0.733 . . . . 0.37 112.737 -179.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 357' ' ' GLU . . . . . 0.426 ' CB ' ' HB3' ' A' ' 387' ' ' LYS . 40.0 tt0 -122.44 140.37 52.8 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.247 -0.649 . . . . 1.63 109.247 176.461 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 358' ' ' ARG . . . . . 0.828 ' HG2' ' HE3' ' A' ' 352' ' ' MET . 3.1 ptp180 -146.15 137.55 24.71 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.157 0.503 . . . . 1.53 111.178 175.425 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 359' ' ' ARG . . . . . . . . . . . . . 11.9 ttp180 -87.27 117.63 26.16 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.047 -0.723 . . . . 3.26 109.047 174.734 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 360' ' ' ILE . . . . . 0.416 HG12 HG23 ' A' ' 292' ' ' ILE . 65.1 mt -103.17 126.26 57.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-N 115.979 -0.555 . . . . 1.13 110.535 -175.125 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 361' ' ' VAL . . . . . . . . . . . . . 47.7 t -100.73 115.12 41.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 109.175 -0.676 . . . . 1.14 109.175 175.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 362' ' ' ILE . . . . . 0.401 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 60.5 mt -110.21 108.97 58.86 Favored Pre-proline 0 C--N 1.322 -0.603 0 CA-C-N 116.447 -0.342 . . . . 1.13 110.689 -175.456 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 363' ' ' PRO . . . . . 0.468 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 35.6 Cg_endo -65.51 162.03 35.75 Favored 'Trans proline' 0 C--O 1.239 0.541 0 C-N-CA 122.42 2.08 . . . . 1.05 111.613 175.432 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 364' ' ' ALA . . . . . . . . . . . . . . . -52.61 -48.89 88.87 Favored Pre-proline 0 CA--C 1.537 0.47 0 N-CA-C 113.85 1.055 . . . . 1.16 113.85 -173.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 365' ' ' PRO . . . . . 0.468 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 74.1 Cg_exo -52.14 -29.74 38.35 Favored 'Trans proline' 0 C--N 1.359 1.09 0 C-N-CA 122.501 2.134 . . . . 1.14 114.212 -175.505 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 366' ' ' TYR . . . . . 0.472 ' CE2' ' HA3' ' A' ' 288' ' ' GLY . 43.1 m-85 -101.05 10.16 41.35 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 112.196 0.443 . . . . 1.03 112.196 -175.75 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -125.39 -110.81 0.3 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.806 -0.179 . . . . 1.07 110.572 175.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -90.02 -22.17 22.01 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.991 0.424 . . . . 1.44 111.317 178.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 70.7 -95.87 0.56 Allowed Glycine 0 N--CA 1.448 -0.51 0 CA-C-N 115.996 -0.547 . . . . 0.65 113.761 175.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 23.4 pttm -109.17 8.12 25.76 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.622 0.248 . . . . 3.34 111.645 -171.625 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 6.3 tp-100 -89.48 120.25 30.63 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.864 0.364 . . . . 2.88 110.56 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 372' ' ' ALA . . . . . 0.714 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -92.47 93.71 8.71 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-O 121.436 0.636 . . . . 1.39 110.592 178.025 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 43.3 mt -81.97 162.99 55.4 Favored Pre-proline 0 C--N 1.318 -0.784 0 CA-C-N 115.373 -0.83 . . . . 1.55 109.079 176.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_exo -61.14 114.97 2.42 Favored 'Trans proline' 0 N--CA 1.462 -0.378 0 C-N-CA 121.478 1.452 . . . . 1.61 110.645 172.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 91.23 -26.63 11.01 Favored Glycine 0 CA--C 1.521 0.413 0 C-N-CA 121.086 -0.578 . . . . 0.96 112.525 -178.457 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 23.5 mt -126.62 81.94 67.66 Favored Pre-proline 0 CA--C 1.533 0.32 0 CA-C-O 120.638 0.256 . . . . 1.29 110.518 -177.118 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 377' ' ' PRO . . . . . 0.714 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 73.5 Cg_endo -80.17 167.85 19.28 Favored 'Trans proline' 0 N--CA 1.463 -0.322 0 C-N-CA 122.693 2.262 . . . . 1.08 113.156 -177.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 378' ' ' ALA . . . . . 0.401 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -49.12 147.25 3.04 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 115.572 -0.74 . . . . 1.52 111.862 178.834 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 379' ' ' ASN . . . . . 0.401 ' HB2' ' O ' ' A' ' 378' ' ' ALA . 42.2 m-80 67.75 33.31 4.94 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 115.712 -0.676 . . . . 1.97 110.688 -175.752 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 2.4 p -82.29 133.16 35.23 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.922 -0.581 . . . . 1.91 111.42 179.506 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 381' ' ' GLU . . . . . 0.432 ' HB3' ' HB2' ' A' ' 318' ' ' LYS . 32.1 tt0 -104.03 106.64 17.21 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.73 -0.668 . . . . 1.03 109.398 177.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 89.9 mt -86.83 139.97 30.15 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.832 0.349 . . . . 1.13 111.093 -177.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 33.4 m -117.89 117.51 29.49 Favored 'General case' 0 N--CA 1.446 -0.629 0 N-CA-C 109.153 -0.684 . . . . 1.12 109.153 175.645 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 33.9 m-85 -113.69 117.29 31.14 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.214 0.53 . . . . 0.4 111.784 -175.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 385' ' ' ASP . . . . . 0.414 ' O ' ' HA ' ' A' ' 313' ' ' TYR . 10.4 t70 -85.49 103.82 14.71 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 107.946 -1.131 . . . . 1.8 107.946 172.311 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 386' ' ' VAL . . . . . 0.499 HG13 ' CB ' ' A' ' 313' ' ' TYR . 35.3 m -130.29 141.17 47.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.65 0.738 . . . . 1.13 111.89 -173.159 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 387' ' ' LYS . . . . . 0.426 ' HB3' ' CB ' ' A' ' 357' ' ' GLU . 10.7 pttm -141.07 141.54 34.25 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.148 -0.933 . . . . 3.1 109.747 174.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 388' ' ' LEU . . . . . 0.795 HD12 ' HB ' ' A' ' 309' ' ' VAL . 16.9 tp -94.24 127.35 40.04 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.962 -0.755 . . . . 1.05 108.962 -176.656 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 34.2 m -125.92 -0.6 4.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 C-N-CA 120.897 -0.321 . . . . 1.2 111.056 -172.094 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 22.9 t -165.15 157.52 15.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.254 -0.43 . . . . 1.82 111.164 179.65 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 391' ' ' MET . . . . . 0.42 ' HE3' HG13 ' A' ' 309' ' ' VAL . 39.1 ttm -162.29 132.86 4.85 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.412 -0.813 . . . . 1.14 109.407 175.902 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 392' ' ' LYS . . . . . 0.416 ' C ' HH21 ' A' ' 308' ' ' ARG . 31.9 mmtp . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.496 -0.764 . . . . 5.51 110.408 -177.64 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.581 0 N-CA-C 111.992 -0.443 . . . . 11.6 111.992 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -129.56 166.75 19.08 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.788 0.328 . . . . 9.39 110.626 -178.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 278' ' ' MET . . . . . . . . . . . . . 28.2 ttt -78.36 92.31 4.55 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.15 -0.477 . . . . 8.15 110.268 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -126.41 83.74 2.2 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.045 -0.525 . . . . 6.73 110.612 178.645 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 45.6 mttp -142.78 151.39 56.6 Favored Pre-proline 0 C--N 1.322 -0.63 0 CA-C-N 115.567 -0.742 . . . . 7.18 110.156 -178.691 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_exo -57.29 136.3 75.44 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 122.792 2.328 . . . . 5.4 112.309 179.597 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 282' ' ' LYS . . . . . . . . . . . . . 30.1 mtmm -79.19 98.11 6.47 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.005 -0.543 . . . . 3.88 110.639 -177.277 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.526 HG23 ' HG2' ' A' ' 293' ' ' GLU . 28.3 p -101.4 153.9 19.28 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.682 -0.69 . . . . 1.27 111.377 -178.745 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 43.4 mtpt -127.58 156.98 41.39 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.528 -0.545 . . . . 2.51 109.528 175.037 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 37.7 tp -112.47 119.24 37.53 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.373 -0.376 . . . . 1.52 110.087 -178.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.619 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 92.3 mt -99.37 -170.16 1.87 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.927 -0.579 . . . . 1.39 110.411 178.574 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -50.86 142.93 10.79 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.11 0.481 . . . . 2.64 111.554 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 73.08 -102.74 1.28 Allowed Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 121.069 -0.586 . . . . 1.84 111.9 -178.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . -146.44 28.04 1.65 Allowed Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 110.691 -0.964 . . . . 1.16 110.691 177.184 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 290' ' ' ILE . . . . . 0.619 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 66.2 mt -74.48 125.57 34.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 115.335 -0.432 . . . . 1.16 110.53 -175.702 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 8.1 mt -111.12 142.69 22.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 N-CA-C 109.384 -0.599 . . . . 1.6 109.384 -179.024 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 292' ' ' ILE . . . . . . . . . . . . . 18.5 pt -132.8 128.47 57.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 120.859 0.361 . . . . 1.17 111.222 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 293' ' ' GLU . . . . . 0.58 ' HB2' ' HB3' ' A' ' 359' ' ' ARG . 40.0 mt-10 -103.99 131.79 50.88 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.334 -0.848 . . . . 2.31 110.204 175.618 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -79.98 126.48 31.08 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.234 0.54 . . . . 2.36 109.966 175.492 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 295' ' ' ARG . . . . . 0.573 ' HA ' ' HE ' ' A' ' 295' ' ' ARG . 2.6 mmp_? -105.28 -59.23 1.79 Allowed 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.46 -0.57 . . . . 3.99 109.46 175.36 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.616 ' HB ' ' HG2' ' A' ' 357' ' ' GLU . 90.0 t -131.77 105.18 9.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.822 -0.626 . . . . 1.31 109.334 174.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 10.2 t -68.9 138.72 54.89 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.068 0.461 . . . . 2.46 109.827 178.013 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -128.47 161.82 22.17 Favored Glycine 0 N--CA 1.442 -0.959 0 C-N-CA 120.316 -0.945 . . . . 1.04 112.067 -175.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 23.3 tptm -127.26 110.96 13.39 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 109.799 -0.445 . . . . 5.01 109.799 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -171.43 -154.58 9.95 Favored Glycine 0 N--CA 1.441 -0.98 0 N-CA-C 111.381 -0.688 . . . . 1.59 111.381 -178.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . 0.542 ' O ' ' HA ' ' A' ' 353' ' ' ALA . 21.9 Cg_exo -65.12 133.73 36.64 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.988 2.459 . . . . 1.1 111.744 177.546 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 52.7 m80 -93.32 139.55 30.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.731 0.301 . . . . 1.85 110.35 -179.376 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -74.03 151.73 40.16 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.053 -0.522 . . . . 1.17 111.832 -179.153 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . 0.449 ' HG2' ' N ' ' A' ' 305' ' ' LYS . 25.6 ttpp -152.98 169.25 23.35 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 115.855 -0.611 . . . . 3.26 109.387 -178.602 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.449 ' N ' ' HG2' ' A' ' 304' ' ' LYS . 99.4 mttt -64.91 130.94 45.29 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 110.136 -0.32 . . . . 3.21 110.136 176.252 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 92.44 -11.8 71.23 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 121.094 -0.575 . . . . 0.7 111.852 -178.682 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 52.5 m -83.5 140.08 32.52 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 122.457 0.303 . . . . 1.07 110.57 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 50.7 mtt180 -100.68 104.74 16.05 Favored 'General case' 0 CA--C 1.516 -0.36 0 N-CA-C 109.002 -0.74 . . . . 3.98 109.002 -179.514 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.85 ' HB ' HD12 ' A' ' 388' ' ' LEU . 33.7 m -102.12 140.01 21.72 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.915 0 CA-C-O 121.276 0.56 . . . . 1.1 111.14 -176.719 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 310' ' ' GLY . . . . . 0.443 ' HA2' ' HA ' ' A' ' 333' ' ' VAL . . . -115.01 125.85 6.94 Favored Glycine 0 N--CA 1.441 -1.029 0 N-CA-C 110.136 -1.186 . . . . 0.32 110.136 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 13.4 ptp -134.07 177.04 8.05 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-O 121.459 0.647 . . . . 1.55 112.123 -173.75 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 312' ' ' ARG . . . . . 0.733 ' HE ' HG12 ' A' ' 389' ' ' VAL . 72.5 mtm180 -138.25 140.85 39.85 Favored 'General case' 0 C--N 1.317 -0.813 0 N-CA-C 106.995 -1.483 . . . . 3.0 106.995 172.351 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 313' ' ' TYR . . . . . 0.423 ' CE2' ' HH2' ' A' ' 345' ' ' TRP . 9.8 p90 -158.55 169.53 24.23 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 119.593 -0.843 . . . . 1.24 113.056 -167.404 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 26.2 t -129.42 108.07 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 CA-C-N 114.33 -1.305 . . . . 1.09 109.086 171.234 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -88.28 110.38 3.63 Favored Glycine 0 N--CA 1.447 -0.576 0 N-CA-C 111.761 -0.535 . . . . 0.32 111.761 -177.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 316' ' ' LYS . . . . . 0.834 ' HG2' HG23 ' A' ' 322' ' ' VAL . 51.0 mttp -115.81 164.38 14.46 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.175 0.512 . . . . 2.61 110.831 -176.331 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 94.1 mt -87.95 158.67 18.6 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 107.561 -1.274 . . . . 1.32 107.561 164.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 318' ' ' LYS . . . . . 0.78 ' HG2' ' HB3' ' A' ' 381' ' ' GLU . 0.1 OUTLIER -63.29 -8.76 9.25 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.011 0.434 . . . . 2.9 111.232 178.978 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 85.8 m-20 -81.16 -14.55 57.51 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.123 -0.489 . . . . 2.39 110.769 177.059 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 109.55 -18.53 29.79 Favored Glycine 0 CA--C 1.518 0.25 0 C-N-CA 120.806 -0.711 . . . . 0.69 112.853 179.148 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 55.2 mtpt -78.08 138.57 38.83 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.662 0.268 . . . . 2.86 111.249 -176.572 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.834 HG23 ' HG2' ' A' ' 316' ' ' LYS . 47.7 t -97.8 136.84 27.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.123 -0.489 . . . . 1.96 110.466 -176.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -118.21 -24.8 6.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.85 0.357 . . . . 0.56 111.164 179.416 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -140.27 146.83 39.1 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.469 -0.567 . . . . 1.68 109.469 177.173 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 21.0 ptmt -163.25 137.66 6.17 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.041 0.448 . . . . 2.55 111.48 -175.631 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 326' ' ' ASN . . . . . 0.412 ' HB2' ' HB2' ' A' ' 330' ' ' LYS . 5.8 p30 -154.58 128.9 9.05 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.796 -0.638 . . . . 1.92 110.279 170.145 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 327' ' ' THR . . . . . 0.447 ' HA ' ' HD2' ' A' ' 312' ' ' ARG . 7.6 t -163.07 -33.92 0.04 OUTLIER 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.676 -0.693 . . . . 2.06 110.573 -177.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 58.8 mttp -89.29 95.46 10.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.657 -0.247 . . . . 3.15 110.441 177.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.487 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 73.65 -10.33 7.01 Favored Glycine 0 CA--C 1.518 0.275 0 C-N-CA 121.137 -0.554 . . . . 1.17 113.439 177.234 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 330' ' ' LYS . . . . . 0.412 ' HB2' ' HB2' ' A' ' 326' ' ' ASN . 58.7 mttm -103.03 100.74 17.97 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 116.945 0.372 . . . . 2.56 111.291 -177.305 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 331' ' ' PRO . . . . . 0.487 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 87.5 Cg_endo -88.84 143.51 5.05 Favored 'Trans proline' 0 N--CA 1.452 -0.917 0 C-N-CA 122.7 2.267 . . . . 0.73 112.034 170.925 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 73.8 t80 -116.01 115.65 26.51 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.594 -0.521 . . . . 0.76 109.594 174.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 333' ' ' VAL . . . . . 0.443 ' HA ' ' HA2' ' A' ' 310' ' ' GLY . 42.7 t -114.73 117.08 54.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 120.559 0.218 . . . . 1.14 110.517 -175.375 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.503 ' HZ ' HG22 ' A' ' 349' ' ' VAL . 27.8 p90 -136.18 160.78 37.63 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 110.173 -0.306 . . . . 0.48 110.173 -178.749 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 335' ' ' LYS . . . . . 0.639 ' O ' ' HG2' ' A' ' 338' ' ' GLN . 6.0 ptmt -106.04 134.62 48.88 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.016 0.436 . . . . 3.11 111.513 -179.187 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 10.8 mp -68.82 117.8 10.98 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.332 -0.395 . . . . 1.2 110.174 177.452 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 128.86 -19.27 5.55 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.832 -0.699 . . . . 1.02 112.207 -179.279 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 338' ' ' GLN . . . . . 0.741 HE21 ' HB2' ' A' ' 340' ' ' GLU . 18.8 pt20 -72.53 138.55 47.0 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.836 0.35 . . . . 3.1 110.742 179.883 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -86.65 20.31 24.21 Favored Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 120.931 -0.652 . . . . 0.98 111.56 176.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 340' ' ' GLU . . . . . 0.741 ' HB2' HE21 ' A' ' 338' ' ' GLN . 11.5 mt-10 -89.22 -11.05 44.77 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.287 -0.635 . . . . 2.09 109.287 178.007 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 35.5 m -112.98 173.53 2.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.353 -0.84 . . . . 1.27 109.587 177.386 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 342' ' ' ILE . . . . . 0.552 HD13 ' HA ' ' A' ' 367' ' ' ALA . 8.7 pt -92.81 159.96 2.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 N-CA-C 109.736 -0.468 . . . . 1.08 109.736 178.322 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . 0.489 ' HA ' ' HE2' ' A' ' 343' ' ' LYS . 3.4 mmpt? -55.97 -35.73 67.06 Favored 'General case' 0 N--CA 1.467 0.377 0 N-CA-C 112.219 0.451 . . . . 3.46 112.219 -174.78 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 344' ' ' GLY . . . . . 0.428 ' HA3' HD11 ' A' ' 362' ' ' ILE . . . -56.18 -28.74 54.94 Favored Glycine 0 CA--C 1.521 0.446 0 C-N-CA 120.805 -0.712 . . . . 0.32 113.061 177.628 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 345' ' ' TRP . . . . . 0.423 ' HH2' ' CE2' ' A' ' 313' ' ' TYR . 11.2 m95 -79.01 -59.99 2.56 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 112.715 0.635 . . . . 0.44 112.715 -177.063 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 9.0 p-10 -63.92 -22.85 67.11 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 118.046 0.384 . . . . 1.75 111.268 -175.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 73.5 mt -86.52 -53.63 9.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.05 -0.523 . . . . 1.18 111.249 176.477 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -64.52 -32.61 84.78 Favored Glycine 0 CA--C 1.523 0.549 0 C-N-CA 121.184 -0.531 . . . . 0.37 113.894 -178.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 349' ' ' VAL . . . . . 0.503 HG22 ' HZ ' ' A' ' 334' ' ' PHE . 93.7 t -80.48 -14.4 12.91 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 CA-C-O 121.047 0.451 . . . . 1.08 111.242 -179.798 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.08 131.67 47.17 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.237 0.541 . . . . 1.09 110.632 178.531 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 79.89 16.15 77.68 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.821 -0.704 . . . . 0.45 112.387 -179.145 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 352' ' ' MET . . . . . 0.41 ' SD ' ' HG2' ' A' ' 358' ' ' ARG . 42.7 mmm -82.6 149.46 27.42 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.643 0.259 . . . . 1.3 110.53 174.238 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 353' ' ' ALA . . . . . 0.542 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -122.84 137.83 54.82 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.031 -0.531 . . . . 1.33 110.491 -179.56 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 354' ' ' VAL . . . . . 0.51 ' HB ' ' HD2' ' A' ' 301' ' ' PRO . 87.6 t -55.33 122.85 5.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.147 -0.479 . . . . 1.24 110.679 176.499 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 111.27 -16.1 27.37 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.927 -0.654 . . . . 0.44 112.175 -178.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -108.37 160.81 13.58 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.692 -0.766 . . . . 0.37 112.439 -178.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 357' ' ' GLU . . . . . 0.845 ' HB3' ' HB2' ' A' ' 387' ' ' LYS . 9.9 pt-20 -139.03 135.91 34.74 Favored 'General case' 0 C--O 1.238 0.462 0 CA-C-O 121.08 0.467 . . . . 1.63 111.171 178.573 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 358' ' ' ARG . . . . . 0.41 ' HG2' ' SD ' ' A' ' 352' ' ' MET . 4.9 ptp180 -132.17 140.46 48.75 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.83 -0.623 . . . . 1.53 109.931 177.445 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 359' ' ' ARG . . . . . 0.58 ' HB3' ' HB2' ' A' ' 293' ' ' GLU . 39.6 ttm180 -86.42 116.15 24.39 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.909 -0.587 . . . . 3.26 109.671 177.086 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 42.2 mt -99.42 117.77 45.05 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 CA-C-N 116.007 -0.542 . . . . 1.13 110.485 -177.536 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 361' ' ' VAL . . . . . . . . . . . . . 47.2 t -100.52 112.4 33.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 N-CA-C 108.714 -0.847 . . . . 1.14 108.714 175.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 362' ' ' ILE . . . . . 0.444 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 47.9 mt -110.59 109.37 58.04 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 116.073 -0.512 . . . . 1.13 111.67 -171.001 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 363' ' ' PRO . . . . . 0.457 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 13.8 Cg_endo -57.0 157.22 21.13 Favored 'Trans proline' 0 C--O 1.235 0.357 0 C-N-CA 123.098 2.532 . . . . 1.05 112.185 172.045 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 364' ' ' ALA . . . . . 0.566 ' CB ' ' HA ' ' A' ' 379' ' ' ASN . . . -47.0 -53.8 24.6 Favored Pre-proline 0 CA--C 1.538 0.482 0 N-CA-C 114.051 1.13 . . . . 1.16 114.051 -176.138 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 365' ' ' PRO . . . . . 0.457 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 27.3 Cg_endo -61.6 -15.32 40.98 Favored 'Trans proline' 0 C--N 1.358 1.049 0 C-N-CA 122.2 1.933 . . . . 1.14 114.207 -172.376 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 366' ' ' TYR . . . . . . . . . . . . . 12.2 m-85 -109.25 5.08 23.42 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.794 0.331 . . . . 1.03 111.387 -178.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 367' ' ' ALA . . . . . 0.552 ' HA ' HD13 ' A' ' 342' ' ' ILE . . . -119.52 -125.09 0.28 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.435 -0.348 . . . . 1.07 110.41 176.454 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 42.0 m-85 -68.9 -19.02 64.2 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-O 120.562 0.22 . . . . 1.44 111.297 179.232 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 74.96 -117.63 5.41 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.957 -0.639 . . . . 0.65 113.177 177.587 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 370' ' ' LYS . . . . . 0.454 ' HA ' ' HB2' ' A' ' 378' ' ' ALA . 0.0 OUTLIER -111.54 13.57 21.35 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.652 -0.274 . . . . 3.34 111.467 -173.931 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 51.0 tp60 -103.98 108.28 19.55 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.137 0.494 . . . . 2.88 110.875 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 372' ' ' ALA . . . . . 0.447 ' HB2' ' HA ' ' A' ' 377' ' ' PRO . . . -75.42 119.18 19.16 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-N 115.77 -0.65 . . . . 1.39 111.664 178.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 75.3 mt -90.68 160.07 39.48 Favored Pre-proline 0 C--N 1.32 -0.716 0 N-CA-C 108.975 -0.75 . . . . 1.55 108.975 174.309 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -59.6 114.18 1.94 Allowed 'Trans proline' 0 N--CA 1.461 -0.384 0 C-N-CA 121.326 1.351 . . . . 1.61 110.831 173.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 97.2 -29.5 10.65 Favored Glycine 0 CA--C 1.52 0.38 0 C-N-CA 121.129 -0.558 . . . . 0.96 112.768 -177.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 37.7 mt -126.7 94.23 40.56 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.66 0.23 . . . . 1.29 110.461 -178.237 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 377' ' ' PRO . . . . . 0.447 ' HA ' ' HB2' ' A' ' 372' ' ' ALA . 72.1 Cg_endo -75.47 167.36 26.76 Favored 'Trans proline' 0 N--CA 1.461 -0.418 0 C-N-CA 122.51 2.14 . . . . 1.08 112.839 -176.523 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 378' ' ' ALA . . . . . 0.454 ' HB2' ' HA ' ' A' ' 370' ' ' LYS . . . -57.82 152.13 16.45 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.842 -0.617 . . . . 1.52 111.42 178.656 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 379' ' ' ASN . . . . . 0.566 ' HA ' ' CB ' ' A' ' 364' ' ' ALA . 13.6 m120 72.12 14.25 5.68 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 115.714 -0.676 . . . . 1.97 111.962 179.072 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 33.7 m -70.45 112.43 6.74 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.187 0.517 . . . . 1.91 110.861 176.327 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 381' ' ' GLU . . . . . 0.78 ' HB3' ' HG2' ' A' ' 318' ' ' LYS . 40.9 tt0 -72.95 105.11 4.3 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.259 -0.882 . . . . 1.03 109.444 175.236 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 86.6 mt -82.67 148.99 27.61 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.025 -0.534 . . . . 1.13 111.569 -175.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 29.4 m -130.57 120.09 23.51 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.589 -0.522 . . . . 1.12 109.589 176.08 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 -121.39 110.45 16.1 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.757 0.313 . . . . 0.4 111.484 -174.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 23.2 m-20 -82.42 103.92 12.34 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 108.375 -0.972 . . . . 1.8 108.375 168.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 386' ' ' VAL . . . . . . . . . . . . . 28.2 m -118.28 128.33 75.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.256 0.551 . . . . 1.13 111.56 -175.533 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 387' ' ' LYS . . . . . 0.845 ' HB2' ' HB3' ' A' ' 357' ' ' GLU . 28.9 ttpt -120.58 131.11 54.49 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.621 -0.718 . . . . 3.1 109.756 175.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 388' ' ' LEU . . . . . 0.85 HD12 ' HB ' ' A' ' 309' ' ' VAL . 17.7 tp -87.43 130.29 34.73 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.33 -0.619 . . . . 1.05 109.33 -174.851 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 389' ' ' VAL . . . . . 0.733 HG12 ' HE ' ' A' ' 312' ' ' ARG . 17.6 m -121.08 -12.75 8.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 111.997 0.369 . . . . 1.2 111.997 -172.625 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 55.4 p -162.28 170.6 18.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.704 0.288 . . . . 1.82 110.8 -178.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 391' ' ' MET . . . . . 0.532 ' HE3' HG13 ' A' ' 309' ' ' VAL . 36.8 ttm -169.74 137.94 1.78 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.112 -0.495 . . . . 1.14 110.652 -179.053 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 99.2 mttt . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.35 -0.833 . . . . 5.51 110.265 177.587 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.622 0 N-CA-C 112.36 -0.296 . . . . 11.6 112.36 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -88.12 -40.67 13.58 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 111.669 0.248 . . . . 9.39 111.669 -177.241 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 278' ' ' MET . . . . . . . . . . . . . 16.6 tpt 66.54 96.29 0.06 Allowed 'General case' 0 N--CA 1.465 0.275 0 CA-C-O 121.518 0.675 . . . . 8.15 111.101 -178.36 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -120.35 23.29 10.97 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.773 -0.649 . . . . 6.73 110.613 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -100.37 133.78 21.16 Favored Pre-proline 0 C--N 1.321 -0.637 0 CA-C-N 115.809 -0.632 . . . . 7.18 110.251 -177.208 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 69.0 Cg_endo -74.5 153.51 44.48 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 122.762 2.308 . . . . 5.4 113.166 -176.209 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 282' ' ' LYS . . . . . 0.463 ' HD3' ' HA ' ' A' ' 282' ' ' LYS . 64.8 mmtt -156.97 23.47 0.32 Allowed 'General case' 0 CA--C 1.503 -0.844 0 CA-C-N 115.389 -0.823 . . . . 3.88 110.189 177.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 20.8 p -157.01 126.29 6.02 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 114.532 -1.213 . . . . 1.27 110.991 -175.373 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 25.5 mtpp -129.98 135.38 48.24 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.879 -0.415 . . . . 2.51 109.879 170.651 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 47.7 tp -94.01 120.77 34.71 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.884 -0.598 . . . . 1.52 109.989 -177.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.59 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 88.3 mt -104.54 -171.95 2.02 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.554 -0.748 . . . . 1.39 110.308 178.433 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 287' ' ' GLU . . . . . 0.626 ' HG3' ' OH ' ' A' ' 366' ' ' TYR . 7.3 tp10 -61.31 145.32 51.83 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.634 -0.712 . . . . 2.64 111.377 -177.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 67.24 17.29 68.03 Favored Glycine 0 CA--C 1.521 0.439 0 C-N-CA 121.171 -0.537 . . . . 1.84 113.967 176.008 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 82.06 17.4 69.76 Favored Glycine 0 C--N 1.33 0.197 0 C-N-CA 120.512 -0.851 . . . . 1.16 113.179 178.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 290' ' ' ILE . . . . . 0.59 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 87.8 mt -69.62 126.47 29.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 109.813 -0.439 . . . . 1.16 109.813 176.759 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 10.5 mt -114.81 135.21 55.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 109.448 -0.575 . . . . 1.6 109.448 -179.771 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 292' ' ' ILE . . . . . . . . . . . . . 24.5 pt -124.19 129.64 74.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-O 121.019 0.438 . . . . 1.17 110.563 -177.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 293' ' ' GLU . . . . . . . . . . . . . 25.9 tt0 -107.7 121.18 44.18 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.403 -0.817 . . . . 2.31 109.367 178.033 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -83.19 120.85 26.32 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.352 0.596 . . . . 2.36 109.95 -179.624 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 295' ' ' ARG . . . . . 0.541 ' HD2' ' HB2' ' A' ' 359' ' ' ARG . 68.6 mtp180 -102.06 -50.77 3.56 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.37 -0.377 . . . . 3.99 110.312 -176.768 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.489 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 60.3 t -118.71 115.09 46.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 109.78 -0.452 . . . . 1.31 109.78 174.676 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 20.7 p -81.06 121.52 26.18 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.036 -0.529 . . . . 2.46 111.682 -177.507 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -134.99 173.71 21.46 Favored Glycine 0 N--CA 1.446 -0.654 0 N-CA-C 111.632 -0.587 . . . . 1.04 111.632 179.049 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -151.27 128.17 11.0 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.261 0.553 . . . . 5.01 109.892 174.572 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -172.92 -153.5 9.54 Favored Glycine 0 N--CA 1.443 -0.874 0 N-CA-C 110.869 -0.892 . . . . 1.59 110.869 -177.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_exo -56.64 133.36 57.53 Favored 'Trans proline' 0 N--CA 1.462 -0.372 0 C-N-CA 122.369 2.046 . . . . 1.1 111.017 173.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 302' ' ' HIS . . . . . 0.413 ' HA ' ' O ' ' A' ' 352' ' ' MET . 53.6 m80 -100.48 144.24 29.71 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.42 -0.355 . . . . 1.85 111.033 -176.604 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 303' ' ' ALA . . . . . 0.421 ' HB3' HG12 ' A' ' 309' ' ' VAL . . . -77.39 125.84 29.96 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.832 -0.622 . . . . 1.17 111.382 -179.239 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -133.21 179.47 6.18 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.717 -0.674 . . . . 3.26 109.922 176.472 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.917 ' HG3' ' HA3' ' A' ' 337' ' ' GLY . 87.0 tttt -67.39 130.99 44.82 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.839 0.352 . . . . 3.21 110.268 177.03 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 95.99 -26.02 22.7 Favored Glycine 0 N--CA 1.448 -0.542 0 N-CA-C 111.42 -0.672 . . . . 0.7 111.42 -177.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 307' ' ' THR . . . . . 0.62 ' O ' ' HA ' ' A' ' 335' ' ' LYS . 9.7 m -72.51 131.36 42.43 Favored 'General case' 0 N--CA 1.449 -0.52 0 CA-C-N 115.619 -0.291 . . . . 1.07 110.224 178.239 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . 0.63 ' HG2' ' HB3' ' A' ' 335' ' ' LYS . 49.6 mtp180 -102.18 104.37 14.95 Favored 'General case' 0 N--CA 1.452 -0.356 0 N-CA-C 108.651 -0.87 . . . . 3.98 108.651 -179.676 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.781 ' HB ' HD12 ' A' ' 388' ' ' LEU . 32.0 m -99.58 140.02 19.88 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-O 121.243 0.544 . . . . 1.1 111.267 -171.034 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -103.79 113.3 4.43 Favored Glycine 0 N--CA 1.442 -0.933 0 CA-C-N 114.956 -1.02 . . . . 0.32 110.646 179.508 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 13.3 ptp -133.62 176.89 8.15 Favored 'General case' 0 N--CA 1.441 -0.92 0 CA-C-O 121.92 0.867 . . . . 1.55 112.273 -173.516 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 49.4 mtp180 -135.46 145.16 46.91 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 113.81 -1.541 . . . . 3.0 106.976 177.174 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 313' ' ' TYR . . . . . 0.515 ' HA ' ' O ' ' A' ' 385' ' ' ASP . 44.9 p90 -161.42 155.63 22.57 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.461 0.648 . . . . 1.24 112.708 -170.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 57.7 t -122.48 120.01 59.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 114.756 -1.111 . . . . 1.09 109.45 175.263 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -101.37 115.23 5.21 Favored Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.83 -0.7 . . . . 0.32 112.461 -177.046 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 316' ' ' LYS . . . . . 0.493 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 62.7 mttm -112.29 151.09 30.08 Favored 'General case' 0 C--N 1.331 -0.221 0 O-C-N 123.946 0.439 . . . . 2.61 111.193 -179.278 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 317' ' ' LEU . . . . . 0.558 HD22 HG12 ' A' ' 376' ' ' ILE . 80.1 mt -84.95 -178.5 6.85 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.505 -0.771 . . . . 1.32 112.114 178.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 318' ' ' LYS . . . . . 0.506 ' HD3' ' H ' ' A' ' 381' ' ' GLU . 49.7 tptt -57.43 -32.59 67.03 Favored 'General case' 0 N--CA 1.461 0.111 0 CA-C-N 115.198 -0.91 . . . . 2.9 110.854 176.82 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 27.0 p-10 -92.7 6.9 45.78 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.078 -0.51 . . . . 2.39 111.368 -177.244 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 88.13 -8.22 79.02 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.638 -0.791 . . . . 0.69 112.641 178.155 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 28.7 tptp -66.25 114.19 5.14 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.028 0.442 . . . . 2.86 110.634 179.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.493 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 4.0 p -68.15 122.44 19.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-N 115.788 -0.642 . . . . 1.96 109.856 175.571 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 323' ' ' PHE . . . . . 0.455 ' HD1' ' HG ' ' A' ' 317' ' ' LEU . 43.1 p90 -100.83 -30.48 11.66 Favored 'General case' 0 C--N 1.322 -0.596 0 C-N-CA 120.738 -0.385 . . . . 0.56 110.794 -178.776 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -149.48 160.08 43.76 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.835 -0.346 . . . . 1.68 110.622 178.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 14.8 pttp -166.66 128.42 1.75 Allowed 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.129 -0.487 . . . . 2.55 110.505 -178.38 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -124.82 117.9 25.18 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.947 -0.76 . . . . 1.92 108.947 178.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 2.0 t -164.05 -45.04 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.47 -0.332 . . . . 2.06 111.278 -175.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 12.6 ptmm? -89.44 100.41 13.21 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.317 0.579 . . . . 3.15 110.84 -177.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.445 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 86.28 -26.76 6.03 Favored Glycine 0 N--CA 1.452 -0.292 0 CA-C-N 115.532 -0.758 . . . . 1.17 113.074 178.023 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -103.36 100.78 19.44 Favored Pre-proline 0 C--N 1.329 -0.309 0 N-CA-C 111.729 0.27 . . . . 2.56 111.729 -177.001 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 331' ' ' PRO . . . . . 0.445 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 84.2 Cg_endo -87.79 125.93 2.07 Favored 'Trans proline' 0 N--CA 1.45 -1.078 0 C-N-CA 122.35 2.034 . . . . 0.73 110.342 165.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 43.1 t80 -99.92 115.6 30.02 Favored 'General case' 0 C--N 1.321 -0.639 0 C-N-CA 120.486 -0.485 . . . . 0.76 110.107 -177.323 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 333' ' ' VAL . . . . . 0.636 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 47.5 t -111.94 113.17 43.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 116.032 -0.531 . . . . 1.14 109.939 -177.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 30.7 p90 -135.99 149.44 48.86 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.313 -0.403 . . . . 0.48 110.41 -178.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 335' ' ' LYS . . . . . 0.63 ' HB3' ' HG2' ' A' ' 308' ' ' ARG . 12.0 ptmt -92.84 139.22 30.77 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 116.181 -0.463 . . . . 3.11 111.133 177.577 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 9.8 mp -77.64 151.76 34.17 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 109.517 -0.549 . . . . 1.2 109.517 172.267 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 337' ' ' GLY . . . . . 0.917 ' HA3' ' HG3' ' A' ' 305' ' ' LYS . . . 90.78 40.36 5.62 Favored Glycine 0 N--CA 1.446 -0.687 0 C-N-CA 120.698 -0.763 . . . . 1.02 112.577 -177.662 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 338' ' ' GLN . . . . . 0.483 ' HB3' ' HE2' ' A' ' 335' ' ' LYS . 29.7 pt20 -148.26 157.63 43.61 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.454 -0.573 . . . . 3.1 109.454 176.179 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -89.73 20.1 37.3 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.756 -0.735 . . . . 0.98 112.352 -176.223 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -85.18 -15.07 44.92 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.301 0.572 . . . . 2.09 110.012 178.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 25.4 m -123.58 156.78 30.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.843 -0.617 . . . . 1.27 109.855 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 342' ' ' ILE . . . . . 0.433 HD13 ' HA ' ' A' ' 367' ' ' ALA . 11.3 pt -76.79 159.93 5.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 N-CA-C 110.203 -0.295 . . . . 1.08 110.203 -179.826 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . 0.459 ' HA ' ' CE ' ' A' ' 343' ' ' LYS . 4.7 mmpt? -63.14 -34.38 77.48 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.19 0.441 . . . . 3.46 112.19 -173.88 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 344' ' ' GLY . . . . . 0.424 ' HA3' HD11 ' A' ' 362' ' ' ILE . . . -54.19 -33.54 52.08 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.72 -0.753 . . . . 0.32 112.383 174.564 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 11.8 m95 -81.23 -59.83 2.5 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 120.584 0.231 . . . . 0.44 110.781 177.568 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 31.5 t70 -48.76 -31.11 6.44 Favored 'General case' 0 CA--C 1.537 0.463 0 CA-C-N 116.193 -0.458 . . . . 1.75 112.107 179.049 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 71.6 mt -93.2 -52.39 9.91 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.404 0 CA-C-N 116.626 -0.261 . . . . 1.18 111.69 178.323 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -63.8 -31.84 82.16 Favored Glycine 0 C--N 1.335 0.505 0 C-N-CA 121.318 -0.468 . . . . 0.37 113.767 -176.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 98.7 t -78.28 -20.52 13.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-O 120.984 0.421 . . . . 1.08 110.812 179.442 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -63.8 118.35 8.21 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.96 0.409 . . . . 1.09 110.163 178.185 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 100.2 0.61 55.89 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.69 -0.766 . . . . 0.45 112.397 -178.017 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 352' ' ' MET . . . . . 0.413 ' O ' ' HA ' ' A' ' 302' ' ' HIS . 58.0 mmm -68.69 139.97 55.42 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.673 0.273 . . . . 1.3 110.668 175.893 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 353' ' ' ALA . . . . . . . . . . . . . . . -109.69 137.19 47.86 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.877 -0.601 . . . . 1.33 110.819 -178.734 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 68.4 t -56.85 117.19 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.279 -0.419 . . . . 1.24 110.125 173.449 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 111.07 -6.08 28.91 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 121.229 -0.51 . . . . 0.44 112.477 -178.555 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -105.36 154.93 17.11 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.748 -0.739 . . . . 0.37 113.126 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 357' ' ' GLU . . . . . 0.489 ' HB3' ' HB ' ' A' ' 296' ' ' VAL . 25.8 tt0 -132.61 133.53 43.76 Favored 'General case' 0 C--N 1.329 -0.293 0 C-N-CA 122.944 0.498 . . . . 1.63 109.868 -179.486 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 358' ' ' ARG . . . . . . . . . . . . . 5.0 ptp180 -144.48 143.23 30.77 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.094 0.473 . . . . 1.53 111.063 177.598 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 359' ' ' ARG . . . . . 0.541 ' HB2' ' HD2' ' A' ' 295' ' ' ARG . 11.8 ttp180 -93.35 121.47 34.77 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.696 -0.684 . . . . 3.26 109.422 174.551 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 44.9 mt -106.07 127.64 61.06 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-N 116.134 -0.485 . . . . 1.13 110.577 -175.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 361' ' ' VAL . . . . . . . . . . . . . 58.8 t -107.16 109.24 27.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 N-CA-C 108.868 -0.79 . . . . 1.14 108.868 175.312 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 362' ' ' ILE . . . . . 0.431 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 51.5 mt -107.11 110.04 63.25 Favored Pre-proline 0 C--N 1.322 -0.598 0 CA-C-N 116.43 -0.35 . . . . 1.13 111.495 -174.255 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 363' ' ' PRO . . . . . 0.49 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 13.2 Cg_endo -57.45 152.83 44.7 Favored 'Trans proline' 0 N--CA 1.46 -0.487 0 C-N-CA 122.641 2.228 . . . . 1.05 111.18 170.4 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 364' ' ' ALA . . . . . 0.501 ' HB1' ' HA ' ' A' ' 379' ' ' ASN . . . -47.93 -49.86 56.59 Favored Pre-proline 0 CA--C 1.537 0.479 0 N-CA-C 113.913 1.079 . . . . 1.16 113.913 -173.87 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 365' ' ' PRO . . . . . 0.49 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 77.6 Cg_exo -49.5 -35.4 36.6 Favored 'Trans proline' 0 C--N 1.36 1.18 0 C-N-CA 122.564 2.176 . . . . 1.14 114.555 -173.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 366' ' ' TYR . . . . . 0.626 ' OH ' ' HG3' ' A' ' 287' ' ' GLU . 3.1 m-85 -101.23 13.82 33.91 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.481 -0.488 . . . . 1.03 112.234 -174.857 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 367' ' ' ALA . . . . . 0.433 ' HA ' HD13 ' A' ' 342' ' ' ILE . . . -116.58 -105.3 0.4 Allowed 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.306 -0.406 . . . . 1.07 109.926 172.539 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 76.4 m-85 -95.87 4.82 52.48 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.988 0.423 . . . . 1.44 111.158 175.232 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 61.35 -117.4 11.48 Favored Glycine 0 N--CA 1.45 -0.371 0 CA-C-N 115.829 -0.623 . . . . 0.65 113.34 174.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 95.4 mttt -103.14 14.32 32.04 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.686 -0.257 . . . . 3.34 110.778 -176.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 27.8 tp60 -87.27 103.92 15.9 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.355 -0.384 . . . . 2.88 110.773 -177.769 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 372' ' ' ALA . . . . . 0.553 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -74.84 104.15 5.35 Favored 'General case' 0 N--CA 1.45 -0.448 0 CA-C-O 121.077 0.465 . . . . 1.39 110.542 174.517 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 90.2 mt -94.34 162.75 25.22 Favored Pre-proline 0 C--N 1.321 -0.668 0 CA-C-N 115.796 -0.638 . . . . 1.55 109.44 176.589 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_endo -63.15 114.86 2.65 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 121.724 1.616 . . . . 1.61 110.606 170.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 93.83 -30.03 7.93 Favored Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 120.941 -0.647 . . . . 0.96 112.279 -176.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 376' ' ' ILE . . . . . 0.558 HG12 HD22 ' A' ' 317' ' ' LEU . 24.3 mt -128.36 79.92 73.28 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.668 0.27 . . . . 1.29 110.615 -178.524 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 377' ' ' PRO . . . . . 0.553 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 72.5 Cg_endo -75.44 167.96 25.52 Favored 'Trans proline' 0 N--CA 1.463 -0.276 0 C-N-CA 122.379 2.053 . . . . 1.08 112.313 -179.675 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 378' ' ' ALA . . . . . 0.447 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -55.96 146.14 23.15 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.362 -0.381 . . . . 1.52 111.01 178.588 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 379' ' ' ASN . . . . . 0.501 ' HA ' ' HB1' ' A' ' 364' ' ' ALA . 49.1 m-80 75.56 9.29 3.64 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 123.435 0.694 . . . . 1.97 112.138 179.723 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 62.2 m -72.02 107.03 4.52 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.32 0.581 . . . . 1.91 110.774 174.591 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 381' ' ' GLU . . . . . 0.506 ' H ' ' HD3' ' A' ' 318' ' ' LYS . 4.5 tt0 -77.01 99.62 5.35 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.02 -0.991 . . . . 1.03 109.153 177.628 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 83.2 mt -82.46 140.44 33.38 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.167 -0.47 . . . . 1.13 110.878 -173.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 25.5 m -117.66 120.57 38.42 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 109.622 -0.51 . . . . 1.12 109.622 178.779 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 92.3 m-85 -118.92 113.68 21.4 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.611 -0.268 . . . . 0.4 111.168 -176.66 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 385' ' ' ASP . . . . . 0.515 ' O ' ' HA ' ' A' ' 313' ' ' TYR . 23.3 t70 -83.19 104.98 13.79 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 108.428 -0.952 . . . . 1.8 108.428 171.495 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 386' ' ' VAL . . . . . . . . . . . . . 36.0 m -115.27 133.21 62.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-O 121.665 0.745 . . . . 1.13 111.469 -174.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 387' ' ' LYS . . . . . . . . . . . . . 3.3 ptpp? -129.6 126.39 38.35 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.085 -0.961 . . . . 3.1 109.841 176.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 388' ' ' LEU . . . . . 0.781 HD12 ' HB ' ' A' ' 309' ' ' VAL . 22.3 tp -91.64 127.99 37.3 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 108.279 -1.008 . . . . 1.05 108.279 -179.738 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 28.2 m -127.76 -6.18 4.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 C-N-CA 120.77 -0.372 . . . . 1.2 111.591 -171.248 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 13.4 p -167.98 171.08 10.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.381 -0.372 . . . . 1.82 110.534 179.167 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 391' ' ' MET . . . . . 0.517 ' HE3' HG13 ' A' ' 309' ' ' VAL . 31.7 ttm -164.45 143.72 7.37 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.9 0.381 . . . . 1.14 111.348 -178.232 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 3.2 tppp? . . . . . 0 C--O 1.251 1.133 0 CA-C-O 118.678 -0.677 . . . . 5.51 109.257 173.038 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.704 0 N-CA-C 111.816 -0.513 . . . . 11.6 111.816 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -119.42 -17.82 8.68 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.768 0.284 . . . . 9.39 111.566 -177.715 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 278' ' ' MET . . . . . . . . . . . . . 15.7 tpt -113.22 118.8 35.67 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.982 0.42 . . . . 8.15 111.244 -176.736 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -116.72 165.77 12.9 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.683 -0.689 . . . . 6.73 109.337 174.191 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 53.8 mtpt -120.7 81.29 32.84 Favored Pre-proline 0 C--N 1.326 -0.441 0 C-N-CA 120.707 -0.397 . . . . 7.18 110.948 -178.41 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -84.66 4.65 6.73 Favored 'Trans proline' 0 C--N 1.347 0.477 0 C-N-CA 123.245 2.63 . . . . 5.4 111.455 177.658 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 282' ' ' LYS . . . . . . . . . . . . . 48.8 mtpt -75.3 -166.71 0.54 Allowed 'General case' 0 N--CA 1.445 -0.725 0 CA-C-N 114.791 -1.095 . . . . 3.88 111.449 179.308 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.5 HG23 ' HB3' ' A' ' 293' ' ' GLU . 1.9 p -91.49 136.55 33.04 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-N 114.776 -1.102 . . . . 1.27 110.016 179.575 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 92.7 mttt -101.45 154.73 18.56 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 110.418 -0.215 . . . . 2.51 110.418 179.371 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 59.9 tp -110.43 112.73 24.86 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 109.722 -0.473 . . . . 1.52 109.722 176.129 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.72 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 89.4 mt -100.41 -170.97 1.94 Allowed 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.057 -0.52 . . . . 1.39 110.924 -178.132 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 287' ' ' GLU . . . . . 0.429 ' HB3' HD11 ' A' ' 347' ' ' ILE . 28.1 tt0 -50.32 136.74 19.64 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 116.011 -0.54 . . . . 2.64 111.788 -179.043 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 76.22 -99.42 1.3 Allowed Glycine 0 N--CA 1.445 -0.761 0 C-N-CA 120.755 -0.736 . . . . 1.84 111.561 -177.114 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . -151.17 31.91 0.96 Allowed Glycine 0 N--CA 1.447 -0.575 0 N-CA-C 110.736 -0.945 . . . . 1.16 110.736 175.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 290' ' ' ILE . . . . . 0.72 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 72.6 mt -74.38 121.94 26.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 110.127 -0.324 . . . . 1.16 110.127 -176.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 17.9 mt -115.1 139.86 39.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 109.307 -0.627 . . . . 1.6 109.307 -178.736 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 292' ' ' ILE . . . . . . . . . . . . . 22.0 pt -136.91 127.02 39.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 C-N-CA 120.816 -0.354 . . . . 1.17 110.637 -179.098 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 293' ' ' GLU . . . . . 0.5 ' HB3' HG23 ' A' ' 283' ' ' THR . 16.9 pt-20 -110.87 131.83 54.71 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.09 -0.505 . . . . 2.31 109.933 173.271 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -89.64 109.03 20.03 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.186 0.517 . . . . 2.36 109.69 -173.106 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 295' ' ' ARG . . . . . 0.767 ' HG3' HG21 ' A' ' 296' ' ' VAL . 21.6 tpt180 -77.89 -54.35 6.42 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.278 -0.874 . . . . 3.99 111.232 -173.807 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.767 HG21 ' HG3' ' A' ' 295' ' ' ARG . 65.0 t -128.63 106.68 14.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 N-CA-C 109.199 -0.667 . . . . 1.31 109.199 178.614 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 25.3 m -73.34 114.0 11.05 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.11 0.481 . . . . 2.46 111.739 -175.519 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -113.76 171.15 13.65 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.565 -0.743 . . . . 1.04 111.46 178.125 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 26.4 tptp -137.73 127.4 25.25 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.419 0.628 . . . . 5.01 111.111 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -170.98 -155.02 10.12 Favored Glycine 0 N--CA 1.44 -1.034 0 N-CA-C 109.966 -1.254 . . . . 1.59 109.966 176.202 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . 0.547 ' HB2' ' SD ' ' A' ' 391' ' ' MET . 11.5 Cg_endo -59.48 146.87 93.76 Favored 'Trans proline' 0 CA--C 1.53 0.297 0 C-N-CA 122.305 2.003 . . . . 1.1 110.974 170.342 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 29.1 m80 -106.75 139.09 41.72 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.067 0.46 . . . . 1.85 111.445 -178.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -73.68 142.28 46.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.408 -0.814 . . . . 1.17 112.438 -175.497 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 57.6 tttp -150.24 165.52 32.7 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 108.149 -1.056 . . . . 3.26 108.149 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 65.8 mttm -62.92 134.94 56.99 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-N 118.203 0.456 . . . . 3.21 109.929 174.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 92.23 -6.54 78.49 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 121.087 -0.578 . . . . 0.7 111.859 -174.174 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 24.7 m -102.65 145.95 28.91 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.975 -0.379 . . . . 1.07 109.975 179.414 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . 0.564 ' HB3' ' HG3' ' A' ' 335' ' ' LYS . 11.5 ptp85 -108.86 123.82 49.67 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 109.499 -0.556 . . . . 3.98 109.499 179.723 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.786 ' HB ' HD12 ' A' ' 388' ' ' LEU . 34.4 m -110.86 139.17 35.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-O 121.387 0.613 . . . . 1.1 111.649 179.477 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -111.05 115.84 4.08 Favored Glycine 0 N--CA 1.444 -0.772 0 N-CA-C 110.189 -1.165 . . . . 0.32 110.189 176.858 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 14.2 ptp -133.38 177.75 7.44 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-O 121.498 0.666 . . . . 1.55 111.879 -170.498 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 312' ' ' ARG . . . . . 0.412 ' HB3' ' CB ' ' A' ' 327' ' ' THR . 94.1 mtt180 -131.89 144.84 51.15 Favored 'General case' 0 C--N 1.319 -0.717 0 N-CA-C 107.182 -1.414 . . . . 3.0 107.182 175.431 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 313' ' ' TYR . . . . . 0.615 ' HB3' HG13 ' A' ' 386' ' ' VAL . 33.6 p90 -159.53 159.27 33.18 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 113.162 0.801 . . . . 1.24 113.162 -172.519 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 60.5 t -128.27 113.26 29.5 Favored 'Isoleucine or valine' 0 C--O 1.237 0.423 0 CA-C-N 114.782 -1.099 . . . . 1.09 109.024 171.652 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -93.36 116.28 5.14 Favored Glycine 0 C--O 1.239 0.454 0 C-N-CA 121.241 -0.504 . . . . 0.32 112.602 -176.44 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 316' ' ' LYS . . . . . 0.729 ' HG2' HG23 ' A' ' 322' ' ' VAL . 26.7 mttp -122.19 154.76 37.03 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-O 121.181 0.515 . . . . 2.61 110.885 -177.521 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 317' ' ' LEU . . . . . 0.604 HD22 HG12 ' A' ' 376' ' ' ILE . 69.5 mt -81.04 164.16 22.69 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.202 -0.908 . . . . 1.32 109.471 172.481 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 318' ' ' LYS . . . . . 0.45 ' HD3' ' HB3' ' A' ' 381' ' ' GLU . 53.2 tptt -60.8 -25.31 66.48 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.074 0.464 . . . . 2.9 110.072 175.333 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 74.7 m-20 -75.18 -0.85 20.73 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.82 -0.627 . . . . 2.39 111.196 -179.283 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 84.97 10.73 78.11 Favored Glycine 0 C--N 1.334 0.423 0 C-N-CA 120.902 -0.666 . . . . 0.69 112.592 178.307 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 321' ' ' LYS . . . . . 0.527 ' HB2' HD13 ' A' ' 317' ' ' LEU . 30.6 mmtp -95.71 125.04 40.01 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.276 -0.268 . . . . 2.86 110.276 -179.489 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.729 HG23 ' HG2' ' A' ' 316' ' ' LYS . 50.3 t -83.31 115.36 25.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 110.214 -0.291 . . . . 1.96 110.214 179.221 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 47.7 p90 -91.72 -30.82 16.07 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.919 -0.312 . . . . 0.56 111.131 -178.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -150.5 153.1 35.23 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 110.025 -0.361 . . . . 1.68 110.025 177.531 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 21.0 pttm -163.41 133.32 4.27 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.965 0.412 . . . . 2.55 110.438 -177.08 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 4.1 p30 -155.13 121.44 5.25 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.443 0.639 . . . . 1.92 110.119 174.349 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 327' ' ' THR . . . . . 0.412 ' CB ' ' HB3' ' A' ' 312' ' ' ARG . 4.9 t -161.84 -42.51 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.601 -0.727 . . . . 2.06 111.485 -175.842 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.429 ' O ' ' HG3' ' A' ' 328' ' ' LYS . 25.1 pttm -79.21 95.1 5.54 Favored 'General case' 0 N--CA 1.454 -0.245 0 CA-C-O 121.568 0.699 . . . . 3.15 110.512 -178.344 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.431 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 85.42 -15.36 46.07 Favored Glycine 0 N--CA 1.448 -0.566 0 CA-C-N 115.484 -0.78 . . . . 1.17 112.617 179.505 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -104.36 100.59 22.7 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 120.483 0.182 . . . . 2.56 111.27 -179.096 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 331' ' ' PRO . . . . . 0.431 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 73.8 Cg_endo -88.06 131.55 2.67 Favored 'Trans proline' 0 N--CA 1.453 -0.888 0 C-N-CA 122.686 2.257 . . . . 0.73 112.027 172.385 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 78.7 t80 -110.28 120.83 43.69 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 109.513 -0.551 . . . . 0.76 109.513 177.53 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 53.2 t -114.49 116.04 51.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.417 -0.356 . . . . 1.14 110.432 -177.402 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.503 ' HZ ' HG22 ' A' ' 349' ' ' VAL . 33.5 p90 -129.0 156.85 43.15 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.832 0.349 . . . . 0.48 110.404 178.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 335' ' ' LYS . . . . . 0.564 ' HG3' ' HB3' ' A' ' 308' ' ' ARG . 3.6 mppt? -99.51 135.68 40.56 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.198 -0.456 . . . . 3.11 110.604 -179.576 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 9.6 mp -77.03 134.51 38.78 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.42 -0.585 . . . . 1.2 109.42 174.105 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 100.72 -1.45 55.51 Favored Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.265 -0.969 . . . . 1.02 112.323 -175.544 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 338' ' ' GLN . . . . . 0.45 ' HG2' ' O ' ' A' ' 335' ' ' LYS . 12.1 pt20 -87.94 138.92 31.03 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.673 -0.492 . . . . 3.1 109.673 177.371 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -82.17 46.29 3.49 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.614 -0.803 . . . . 0.98 112.348 -178.307 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 19.6 mt-10 -121.15 -20.73 6.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.825 0.345 . . . . 2.09 110.68 179.209 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 23.0 m -100.49 160.83 3.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 116.416 -0.356 . . . . 1.27 110.556 -176.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 342' ' ' ILE . . . . . 0.64 HD13 ' HA ' ' A' ' 367' ' ' ALA . 5.2 pt -82.84 159.92 3.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.313 -0.625 . . . . 1.08 109.313 175.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . 0.524 ' HE2' HD12 ' A' ' 347' ' ' ILE . 17.0 mtpt -60.98 -37.31 82.01 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 121.082 -0.247 . . . . 3.46 111.648 -173.285 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 344' ' ' GLY . . . . . 0.599 ' HA3' HD11 ' A' ' 362' ' ' ILE . . . -53.29 -35.43 50.18 Favored Glycine 0 CA--C 1.519 0.307 0 C-N-CA 121.003 -0.618 . . . . 0.32 112.556 176.575 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 8.0 m95 -73.6 -61.61 1.78 Allowed 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 111.796 0.295 . . . . 0.44 111.796 178.531 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -52.8 -36.77 58.82 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-O 120.918 0.39 . . . . 1.75 111.476 -178.387 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 347' ' ' ILE . . . . . 0.524 HD12 ' HE2' ' A' ' 343' ' ' LYS . 74.9 mt -84.48 -48.16 16.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.236 -0.438 . . . . 1.18 111.387 -177.474 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -64.7 -33.5 87.39 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 121.039 -0.6 . . . . 0.37 113.28 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 349' ' ' VAL . . . . . 0.529 ' O ' ' HB2' ' A' ' 352' ' ' MET . 95.2 t -80.99 -14.24 12.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.016 0.436 . . . . 1.08 110.752 179.313 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -64.79 115.74 5.6 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.992 0.425 . . . . 1.09 109.954 174.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 88.65 21.94 41.72 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.381 -0.914 . . . . 0.45 112.183 -176.088 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 352' ' ' MET . . . . . 0.767 ' HE3' ' HG2' ' A' ' 358' ' ' ARG . 0.0 OUTLIER -81.08 151.36 28.37 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.109 -0.7 . . . . 1.3 109.109 174.407 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 353' ' ' ALA . . . . . . . . . . . . . . . -121.49 130.63 53.67 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.731 0.3 . . . . 1.33 111.35 -176.449 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 98.2 t -57.43 119.43 2.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 116.067 -0.515 . . . . 1.24 110.428 174.326 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 107.65 -10.71 38.56 Favored Glycine 0 N--CA 1.448 -0.533 0 C-N-CA 121.065 -0.588 . . . . 0.44 111.965 -177.466 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -104.24 160.41 15.9 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.802 -0.714 . . . . 0.37 112.868 -178.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 357' ' ' GLU . . . . . 0.566 ' HB2' ' HB3' ' A' ' 387' ' ' LYS . 41.5 tt0 -136.85 134.17 36.63 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 122.773 0.429 . . . . 1.63 109.937 178.731 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 358' ' ' ARG . . . . . 0.767 ' HG2' ' HE3' ' A' ' 352' ' ' MET . 4.3 ptp180 -146.65 146.86 30.53 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 121.317 0.58 . . . . 1.53 111.298 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 359' ' ' ARG . . . . . . . . . . . . . 35.1 ttm180 -87.79 119.08 27.78 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.111 -0.949 . . . . 3.26 109.909 177.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 53.7 mt -98.29 119.67 46.62 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 CA-C-N 115.942 -0.572 . . . . 1.13 109.892 179.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 361' ' ' VAL . . . . . . . . . . . . . 74.6 t -103.23 109.09 25.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 115.244 -0.889 . . . . 1.14 108.856 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 362' ' ' ILE . . . . . 0.599 HD11 ' HA3' ' A' ' 344' ' ' GLY . 28.8 mt -115.57 107.91 48.09 Favored Pre-proline 0 C--N 1.323 -0.564 0 CA-C-N 116.484 -0.325 . . . . 1.13 111.038 -173.313 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 363' ' ' PRO . . . . . 0.481 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 11.6 Cg_endo -56.35 151.48 44.45 Favored 'Trans proline' 0 C--O 1.236 0.425 0 C-N-CA 122.373 2.048 . . . . 1.05 111.152 171.377 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 364' ' ' ALA . . . . . . . . . . . . . . . -46.96 -48.95 51.83 Favored Pre-proline 0 CA--C 1.541 0.624 0 N-CA-C 114.126 1.158 . . . . 1.16 114.126 -174.137 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 365' ' ' PRO . . . . . 0.481 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 75.5 Cg_exo -51.42 -29.05 29.66 Favored 'Trans proline' 0 C--N 1.365 1.399 0 C-N-CA 122.54 2.16 . . . . 1.14 114.05 -176.162 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 366' ' ' TYR . . . . . . . . . . . . . 9.1 m-85 -106.17 4.39 28.94 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 111.917 0.339 . . . . 1.03 111.917 -175.357 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 367' ' ' ALA . . . . . 0.649 ' HB2' HD13 ' A' ' 382' ' ' LEU . . . -117.08 -30.21 5.73 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 112.251 0.464 . . . . 1.07 112.251 -179.174 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 9.5 m-85 -165.46 -32.46 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 120.941 0.401 . . . . 1.44 110.53 -176.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 101.62 -128.79 9.68 Favored Glycine 0 N--CA 1.446 -0.636 0 C-N-CA 120.821 -0.704 . . . . 0.65 111.983 177.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 21.1 ptmt -108.84 11.02 26.43 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.007 0.432 . . . . 3.34 110.538 -179.504 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 51.9 tt0 -85.05 103.15 13.82 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.972 -0.558 . . . . 2.88 110.306 -177.179 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 372' ' ' ALA . . . . . . . . . . . . . . . -77.65 94.93 4.48 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.076 0.465 . . . . 1.39 110.919 -179.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 80.2 mt -73.91 155.88 88.39 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-N 115.706 -0.679 . . . . 1.55 109.599 176.159 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -57.61 114.32 1.9 Allowed 'Trans proline' 0 N--CA 1.46 -0.454 0 C-N-CA 121.664 1.576 . . . . 1.61 110.81 173.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 97.62 -29.55 10.8 Favored Glycine 0 CA--C 1.519 0.305 0 C-N-CA 121.034 -0.603 . . . . 0.96 112.558 -177.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 376' ' ' ILE . . . . . 0.604 HG12 HD22 ' A' ' 317' ' ' LEU . 25.9 mt -124.45 85.47 55.9 Favored Pre-proline 0 C--N 1.328 -0.347 0 O-C-N 122.808 -0.23 . . . . 1.29 110.554 -178.591 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 377' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -75.02 165.73 30.68 Favored 'Trans proline' 0 N--CA 1.46 -0.49 0 C-N-CA 122.666 2.244 . . . . 1.08 112.413 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 378' ' ' ALA . . . . . 0.425 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -64.96 159.84 22.06 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.084 -0.507 . . . . 1.52 111.595 -178.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 379' ' ' ASN . . . . . 0.425 ' HB2' ' O ' ' A' ' 378' ' ' ALA . 12.3 m120 73.66 -8.16 1.43 Allowed 'General case' 0 N--CA 1.473 0.676 0 CA-C-N 115.501 -0.772 . . . . 1.97 111.833 179.376 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 48.6 m -70.13 114.3 8.15 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.056 0.455 . . . . 1.91 110.928 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 381' ' ' GLU . . . . . 0.45 ' HB3' ' HD3' ' A' ' 318' ' ' LYS . 33.0 tt0 -73.5 106.8 5.44 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.549 -0.75 . . . . 1.03 109.862 177.548 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 382' ' ' LEU . . . . . 0.649 HD13 ' HB2' ' A' ' 367' ' ' ALA . 65.9 mt -78.91 141.23 37.78 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.68 0.276 . . . . 1.13 110.394 -178.241 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 24.3 m -123.91 124.85 43.54 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-O 121.002 0.43 . . . . 1.12 110.218 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -120.01 112.19 18.84 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.245 -0.434 . . . . 0.4 110.932 -178.142 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 385' ' ' ASP . . . . . 0.417 ' O ' ' HA ' ' A' ' 313' ' ' TYR . 72.4 m-20 -86.37 105.4 16.68 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 108.728 -0.841 . . . . 1.8 108.728 174.093 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 386' ' ' VAL . . . . . 0.615 HG13 ' HB3' ' A' ' 313' ' ' TYR . 22.2 m -121.72 136.47 58.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.212 0.53 . . . . 1.13 112.072 -173.64 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 387' ' ' LYS . . . . . 0.566 ' HB3' ' HB2' ' A' ' 357' ' ' GLU . 1.3 ptpp? -123.86 137.28 54.68 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.818 -0.628 . . . . 3.1 109.449 170.181 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 388' ' ' LEU . . . . . 0.786 HD12 ' HB ' ' A' ' 309' ' ' VAL . 19.1 tp -95.42 134.28 38.41 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 109.551 -0.537 . . . . 1.05 109.551 -177.377 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 30.9 m -127.91 -5.07 4.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 111.955 0.354 . . . . 1.2 111.955 -174.146 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 12.5 p -165.68 159.77 16.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.653 -0.248 . . . . 1.82 111.093 -178.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 391' ' ' MET . . . . . 0.695 ' HG2' ' HG2' ' A' ' 392' ' ' LYS . 41.8 ttm -164.59 155.94 15.4 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.971 -0.559 . . . . 1.14 109.832 178.282 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 392' ' ' LYS . . . . . 0.695 ' HG2' ' HG2' ' A' ' 391' ' ' MET . 32.1 mmmt . . . . . 0 C--O 1.247 0.923 0 O-C-N 124.259 0.975 . . . . 5.51 111.611 175.154 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.665 0 N-CA-C 111.663 -0.575 . . . . 11.6 111.663 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -109.71 170.28 8.17 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.816 0.341 . . . . 9.39 110.673 -179.452 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 278' ' ' MET . . . . . 0.419 ' O ' ' HD2' ' A' ' 282' ' ' LYS . 95.4 mmm -97.79 -39.85 8.83 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.203 -0.453 . . . . 8.15 110.001 179.587 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . 62.22 78.0 0.31 Allowed 'General case' 0 C--O 1.236 0.355 0 CA-C-N 115.35 -0.841 . . . . 6.73 111.381 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 71.9 mttt 70.67 161.23 0.15 Allowed Pre-proline 0 N--CA 1.468 0.453 0 CA-C-N 115.311 -0.859 . . . . 7.18 111.259 177.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -62.39 109.95 0.96 Allowed 'Trans proline' 0 C--O 1.235 0.351 0 C-N-CA 122.417 2.078 . . . . 5.4 111.638 175.091 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 282' ' ' LYS . . . . . 0.419 ' HD2' ' O ' ' A' ' 278' ' ' MET . 24.8 mtpp -91.18 68.54 6.02 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.446 0.641 . . . . 3.88 110.161 -178.714 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.462 HG23 ' HB2' ' A' ' 293' ' ' GLU . 18.2 p -88.68 150.77 22.84 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.239 -0.892 . . . . 1.27 111.679 -178.702 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 284' ' ' LYS . . . . . 0.458 ' O ' ' HA ' ' A' ' 291' ' ' ILE . 92.8 mttt -118.52 144.17 46.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.41 -0.814 . . . . 2.51 111.026 -173.497 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . 0.493 HD12 ' HA2' ' A' ' 289' ' ' GLY . 56.3 tp -102.8 123.99 47.49 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.466 -0.788 . . . . 1.52 110.373 -177.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.446 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 98.6 mt -113.35 -175.74 2.74 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.9 -0.591 . . . . 1.39 109.703 178.44 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 287' ' ' GLU . . . . . 0.451 ' HG2' ' OH ' ' A' ' 366' ' ' TYR . 27.6 tt0 -56.73 144.07 34.05 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.178 0.513 . . . . 2.64 111.629 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.406 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 72.48 0.32 46.58 Favored Glycine 0 CA--C 1.52 0.352 0 CA-C-N 115.78 -0.646 . . . . 1.84 113.806 179.033 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . 0.493 ' HA2' HD12 ' A' ' 285' ' ' LEU . . . 95.11 12.37 55.07 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.696 -0.764 . . . . 1.16 113.028 179.109 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 290' ' ' ILE . . . . . 0.446 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 71.9 mt -66.62 121.54 15.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 121.253 0.549 . . . . 1.16 110.957 -179.071 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . 0.621 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 18.5 mm -104.38 138.96 26.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 115.737 -0.665 . . . . 1.6 110.232 178.898 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 292' ' ' ILE . . . . . . . . . . . . . 21.5 pt -127.29 129.36 70.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 120.925 0.393 . . . . 1.17 110.685 177.109 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 293' ' ' GLU . . . . . 0.462 ' HB2' HG23 ' A' ' 283' ' ' THR . 24.6 tt0 -118.83 117.96 30.28 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.661 -0.7 . . . . 2.31 109.759 177.906 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -88.33 96.14 10.46 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.654 -0.869 . . . . 2.36 108.654 -178.655 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 295' ' ' ARG . . . . . 0.818 HH22 ' HB3' ' A' ' 385' ' ' ASP . 38.0 ttp180 -76.11 -47.28 25.05 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.598 -0.728 . . . . 3.99 111.587 -171.751 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.7 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 23.3 t -119.03 103.5 14.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 N-CA-C 109.057 -0.719 . . . . 1.31 109.057 172.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 32.1 p -62.09 113.32 2.77 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 114.931 -1.031 . . . . 2.46 112.197 -174.023 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -119.88 152.02 17.2 Favored Glycine 0 N--CA 1.444 -0.769 0 CA-C-N 115.652 -0.703 . . . . 1.04 111.642 178.003 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -127.74 114.12 16.88 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.759 0.314 . . . . 5.01 110.336 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -170.56 -154.6 9.65 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 121.011 -0.614 . . . . 1.59 112.013 -179.414 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . 0.57 ' HD2' ' HB ' ' A' ' 354' ' ' VAL . 28.1 Cg_exo -62.33 137.85 67.97 Favored 'Trans proline' 0 C--O 1.233 0.234 0 C-N-CA 122.833 2.355 . . . . 1.1 112.048 178.656 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 302' ' ' HIS . . . . . 0.5 ' HA ' ' O ' ' A' ' 352' ' ' MET . 39.0 m80 -102.5 134.25 46.14 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 120.938 0.399 . . . . 1.85 110.714 178.157 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -69.54 132.41 46.22 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.986 -0.552 . . . . 1.17 111.685 -178.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 32.6 mmtp -117.19 177.96 4.53 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.042 -0.725 . . . . 3.26 109.042 176.105 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 61.4 mttm -68.77 132.24 46.48 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 109.698 -0.482 . . . . 3.21 109.698 173.27 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 84.74 7.97 83.43 Favored Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.697 -0.764 . . . . 0.7 112.553 -176.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 20.2 m -96.72 147.81 23.53 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 110.286 -0.265 . . . . 1.07 110.286 177.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 47.4 mtt180 -102.56 130.82 49.52 Favored 'General case' 0 CA--C 1.515 -0.395 0 N-CA-C 108.993 -0.743 . . . . 3.98 108.993 178.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.794 ' HB ' HD12 ' A' ' 388' ' ' LEU . 19.7 m -130.39 137.75 55.49 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-O 121.125 0.488 . . . . 1.1 111.815 -177.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -107.7 120.11 5.98 Favored Glycine 0 N--CA 1.444 -0.789 0 N-CA-C 109.826 -1.31 . . . . 0.32 109.826 176.336 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 311' ' ' MET . . . . . 0.61 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 22.9 ptm -140.01 177.04 8.25 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.58 0.705 . . . . 1.55 112.212 -171.321 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 312' ' ' ARG . . . . . 0.471 ' HB3' ' HA ' ' A' ' 327' ' ' THR . 20.9 mtm180 -133.64 145.37 49.92 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 107.228 -1.397 . . . . 3.0 107.228 174.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 313' ' ' TYR . . . . . 0.523 ' CB ' HG13 ' A' ' 386' ' ' VAL . 41.7 p90 -161.57 158.7 26.72 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 113.23 0.826 . . . . 1.24 113.23 -173.362 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 47.8 t -125.99 127.08 70.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 114.695 -1.139 . . . . 1.09 109.688 174.621 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -96.96 106.73 3.39 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 121.116 -0.564 . . . . 0.32 112.139 -179.656 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 316' ' ' LYS . . . . . 0.775 ' HG2' HG23 ' A' ' 322' ' ' VAL . 86.4 mttt -113.07 154.2 26.94 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.282 0.563 . . . . 2.61 111.722 -175.328 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 317' ' ' LEU . . . . . 0.406 HD13 ' HB3' ' A' ' 321' ' ' LYS . 88.8 mt -88.84 164.81 15.04 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.639 -0.71 . . . . 1.32 109.107 169.682 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 318' ' ' LYS . . . . . . . . . . . . . 37.8 ttpt -66.55 -21.94 66.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.991 0.424 . . . . 2.9 110.858 178.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 28.1 p30 -83.74 4.72 27.61 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.011 0.434 . . . . 2.39 111.028 179.101 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 91.21 -9.5 77.4 Favored Glycine 0 C--N 1.33 0.235 0 C-N-CA 121.252 -0.499 . . . . 0.69 113.258 174.673 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 321' ' ' LYS . . . . . 0.406 ' HB3' HD13 ' A' ' 317' ' ' LEU . 22.2 ttmm -77.98 123.55 26.94 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.896 0.379 . . . . 2.86 110.37 -179.003 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.775 HG23 ' HG2' ' A' ' 316' ' ' LYS . 67.7 t -85.44 128.49 39.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 116.171 -0.468 . . . . 1.96 110.368 -179.681 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 35.6 p90 -100.81 -35.26 9.5 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.645 -0.422 . . . . 0.56 111.587 -179.343 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -146.95 168.55 21.21 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 120.789 -0.364 . . . . 1.68 110.108 178.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . 0.573 ' N ' ' HD3' ' A' ' 325' ' ' LYS . 0.0 OUTLIER -176.55 143.48 0.48 Allowed 'General case' 0 C--O 1.233 0.192 0 CA-C-O 121.247 0.546 . . . . 2.55 111.781 -173.612 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 3.1 p30 -150.73 118.06 6.02 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.576 -0.738 . . . . 1.92 109.41 165.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 327' ' ' THR . . . . . 0.471 ' HA ' ' HB3' ' A' ' 312' ' ' ARG . 30.7 m -150.7 -55.39 0.15 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.952 -0.567 . . . . 2.06 111.169 -175.781 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 34.8 mtmm -72.04 94.21 1.47 Allowed 'General case' 0 C--O 1.235 0.299 0 CA-C-O 120.981 0.42 . . . . 3.15 111.272 -177.225 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.485 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 80.24 -10.68 41.0 Favored Glycine 0 N--CA 1.45 -0.422 0 CA-C-N 115.863 -0.608 . . . . 1.17 112.971 175.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 25.6 mtpp -103.9 100.7 21.31 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.789 0.294 . . . . 2.56 110.955 -177.507 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 331' ' ' PRO . . . . . 0.485 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 64.2 Cg_endo -88.26 136.38 3.41 Favored 'Trans proline' 0 N--CA 1.453 -0.907 0 C-N-CA 122.724 2.282 . . . . 0.73 112.115 172.547 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 75.4 t80 -110.78 122.83 48.8 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.461 -0.57 . . . . 0.76 109.461 177.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 333' ' ' VAL . . . . . 0.489 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 51.5 t -118.78 115.07 46.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 N-CA-C 110.176 -0.305 . . . . 1.14 110.176 -176.731 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.61 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 23.4 p90 -133.48 172.19 13.06 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.649 0.262 . . . . 0.48 110.597 -178.743 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 335' ' ' LYS . . . . . 0.674 ' H ' ' HD2' ' A' ' 335' ' ' LYS . 0.0 OUTLIER -117.29 140.38 49.62 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.335 -0.393 . . . . 3.11 110.208 -179.928 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 10.1 mp -79.22 151.03 31.44 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.707 0.289 . . . . 1.2 110.646 178.486 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 92.31 9.14 62.14 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.828 -0.701 . . . . 1.02 112.007 -176.105 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 338' ' ' GLN . . . . . 0.505 HE22 ' HB2' ' A' ' 334' ' ' PHE . 29.3 pt20 -98.17 161.54 13.66 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.796 0.332 . . . . 3.1 110.511 -179.687 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -99.82 4.54 57.79 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.852 -0.689 . . . . 0.98 112.277 -179.588 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 66.9 mm-40 -73.54 -34.13 65.05 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.904 0.383 . . . . 2.09 110.674 178.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 34.4 m -100.41 156.47 4.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.988 -0.551 . . . . 1.27 110.972 -178.165 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 12.8 pt -71.44 161.91 4.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.471 -0.331 . . . . 1.08 110.523 177.734 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.4 -38.45 87.1 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.359 -0.382 . . . . 3.46 111.84 -176.738 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -51.56 -36.53 39.41 Favored Glycine 0 C--N 1.331 0.255 0 C-N-CA 121.135 -0.555 . . . . 0.32 112.544 175.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 9.3 m95 -73.25 -60.3 2.31 Favored 'General case' 0 C--O 1.223 -0.338 0 CA-C-O 120.405 0.145 . . . . 0.44 111.067 177.181 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -49.45 -33.87 15.25 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.242 -0.436 . . . . 1.75 112.109 179.774 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 65.9 mt -85.76 -54.96 7.34 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.358 0 CA-C-N 116.638 -0.255 . . . . 1.18 111.661 178.55 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -60.97 -36.68 92.6 Favored Glycine 0 CA--C 1.521 0.434 0 C-N-CA 121.585 -0.34 . . . . 0.37 113.822 -177.462 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 349' ' ' VAL . . . . . 0.464 ' O ' ' HB2' ' A' ' 352' ' ' MET . 95.1 t -72.0 -24.96 23.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 120.904 0.383 . . . . 1.08 110.691 179.601 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.53 108.71 2.1 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.804 -0.443 . . . . 1.09 109.804 175.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 107.73 4.67 34.16 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 121.11 -0.567 . . . . 0.45 112.216 -175.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 352' ' ' MET . . . . . 0.882 ' HE3' ' HG2' ' A' ' 358' ' ' ARG . 0.0 OUTLIER -73.03 140.8 47.52 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 109.276 -0.639 . . . . 1.3 109.276 176.158 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 353' ' ' ALA . . . . . 0.449 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -108.08 132.07 53.95 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.732 0.301 . . . . 1.33 111.042 -177.353 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 354' ' ' VAL . . . . . 0.57 ' HB ' ' HD2' ' A' ' 301' ' ' PRO . 78.4 t -56.58 116.22 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 120.968 0.414 . . . . 1.24 110.551 175.031 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 110.67 -19.31 26.18 Favored Glycine 0 N--CA 1.445 -0.754 0 N-CA-C 111.59 -0.604 . . . . 0.44 111.59 -177.35 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -83.9 148.26 24.47 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 121.168 -0.539 . . . . 0.37 112.694 -176.307 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 357' ' ' GLU . . . . . 0.7 ' HB3' ' HB ' ' A' ' 296' ' ' VAL . 5.0 tp10 -126.61 117.94 23.82 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 108.973 -0.751 . . . . 1.63 108.973 179.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 358' ' ' ARG . . . . . 0.882 ' HG2' ' HE3' ' A' ' 352' ' ' MET . 6.2 ptp180 -145.16 148.44 33.59 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.362 0.601 . . . . 1.53 112.303 -173.15 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 359' ' ' ARG . . . . . 0.459 ' HD2' ' OE1' ' A' ' 293' ' ' GLU . 60.2 mtt85 -89.24 128.02 35.81 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.75 -0.659 . . . . 3.26 110.233 171.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 57.9 mt -110.97 118.39 57.23 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 N-CA-C 109.201 -0.666 . . . . 1.13 109.201 174.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 361' ' ' VAL . . . . . 0.621 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 51.4 t -96.97 117.51 41.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.19 -0.67 . . . . 1.14 109.19 178.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 362' ' ' ILE . . . . . . . . . . . . . 65.1 mt -115.01 103.98 54.31 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 116.339 -0.392 . . . . 1.13 110.818 -174.241 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 363' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -60.29 160.08 24.52 Favored 'Trans proline' 0 N--CA 1.463 -0.285 0 C-N-CA 122.642 2.228 . . . . 1.05 112.007 174.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 364' ' ' ALA . . . . . 0.479 ' N ' ' HD2' ' A' ' 365' ' ' PRO . . . -47.23 -51.09 44.34 Favored Pre-proline 0 CA--C 1.539 0.535 0 N-CA-C 114.191 1.182 . . . . 1.16 114.191 -176.126 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 365' ' ' PRO . . . . . 0.479 ' HD2' ' N ' ' A' ' 364' ' ' ALA . 16.8 Cg_endo -56.66 -25.87 62.19 Favored 'Trans proline' 0 C--N 1.358 1.078 0 C-N-CA 122.256 1.971 . . . . 1.14 114.168 -171.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 366' ' ' TYR . . . . . 0.451 ' OH ' ' HG2' ' A' ' 287' ' ' GLU . 4.1 m-85 -103.36 12.11 35.78 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-O 121.036 0.446 . . . . 1.03 111.236 -177.085 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -127.56 -116.43 0.26 Allowed 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 115.664 -0.698 . . . . 1.07 110.162 173.515 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 86.2 m-85 -85.51 -14.4 46.07 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.689 0.28 . . . . 1.44 111.712 -177.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 62.94 -109.18 2.53 Favored Glycine 0 N--CA 1.452 -0.265 0 CA-C-N 116.183 -0.462 . . . . 0.65 113.572 174.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 370' ' ' LYS . . . . . 0.456 ' HA ' ' HB2' ' A' ' 378' ' ' ALA . 58.0 mttm -102.72 8.06 39.58 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 111.722 0.267 . . . . 3.34 111.722 -175.763 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 371' ' ' GLN . . . . . 0.785 ' HA ' HE21 ' A' ' 371' ' ' GLN . 0.0 OUTLIER -88.83 99.55 12.47 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.964 0.411 . . . . 2.88 110.382 179.676 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 372' ' ' ALA . . . . . . . . . . . . . . . -74.31 110.8 8.9 Favored 'General case' 0 N--CA 1.45 -0.441 0 CA-C-N 115.931 -0.577 . . . . 1.39 111.005 178.644 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 71.9 mt -101.37 161.0 24.97 Favored Pre-proline 0 C--N 1.321 -0.641 0 N-CA-C 109.076 -0.713 . . . . 1.55 109.076 176.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_exo -60.55 114.64 2.22 Favored 'Trans proline' 0 N--CA 1.46 -0.484 0 C-N-CA 121.546 1.498 . . . . 1.61 110.96 174.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 92.0 -19.87 46.34 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.749 -0.738 . . . . 0.96 112.327 -178.559 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 23.6 mt -132.47 78.4 67.71 Favored Pre-proline 0 N--CA 1.465 0.287 0 CA-C-O 120.836 0.35 . . . . 1.29 110.512 -179.018 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 377' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_exo -70.72 166.89 27.33 Favored 'Trans proline' 0 N--CA 1.463 -0.319 0 C-N-CA 122.764 2.31 . . . . 1.08 113.017 -178.192 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 378' ' ' ALA . . . . . 0.456 ' HB2' ' HA ' ' A' ' 370' ' ' LYS . . . -56.1 151.78 11.65 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.742 -0.663 . . . . 1.52 110.846 178.036 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 379' ' ' ASN . . . . . 0.42 ' HA ' ' CB ' ' A' ' 364' ' ' ALA . 15.0 m120 64.92 32.25 10.83 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.184 0.516 . . . . 1.97 110.306 -178.423 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -77.63 117.02 18.65 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-N 115.643 -0.708 . . . . 1.91 111.158 177.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 381' ' ' GLU . . . . . . . . . . . . . 19.3 tt0 -92.05 100.63 13.23 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.031 -0.729 . . . . 1.03 109.031 177.394 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 78.8 mt -94.3 149.53 21.15 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.776 -0.647 . . . . 1.13 112.155 -170.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 29.5 m -127.99 128.43 45.02 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.746 -0.464 . . . . 1.12 109.746 176.304 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -119.65 113.09 20.15 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.573 -0.285 . . . . 0.4 111.248 -177.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 385' ' ' ASP . . . . . 0.818 ' HB3' HH22 ' A' ' 295' ' ' ARG . 1.6 m-20 -79.58 105.33 10.81 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.22 -1.03 . . . . 1.8 108.22 172.267 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 386' ' ' VAL . . . . . 0.586 ' HB ' ' CE ' ' A' ' 311' ' ' MET . 33.8 m -126.09 131.32 71.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.386 0.613 . . . . 1.13 112.456 -171.833 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 387' ' ' LYS . . . . . 0.486 ' HB2' ' CD ' ' A' ' 357' ' ' GLU . 49.9 tttm -126.63 132.07 51.32 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.933 -0.576 . . . . 3.1 109.835 175.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 388' ' ' LEU . . . . . 0.794 HD12 ' HB ' ' A' ' 309' ' ' VAL . 23.2 tp -94.67 137.53 33.66 Favored 'General case' 0 C--N 1.319 -0.717 0 N-CA-C 108.992 -0.744 . . . . 1.05 108.992 -178.45 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 33.7 m -126.93 -7.09 4.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 111.993 0.368 . . . . 1.2 111.993 -174.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 25.2 p -167.5 164.25 14.85 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.701 0.286 . . . . 1.82 111.273 -177.498 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 391' ' ' MET . . . . . . . . . . . . . 39.6 ttm -158.74 147.55 18.66 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.053 -0.521 . . . . 1.14 110.337 179.392 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 392' ' ' LYS . . . . . 0.797 ' HZ1' ' HB3' ' A' ' 392' ' ' LYS . 8.3 mtpm? . . . . . 0 C--O 1.248 0.993 0 CA-C-O 118.603 -0.713 . . . . 5.51 109.961 177.633 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.765 0 N-CA-C 111.841 -0.504 . . . . 11.6 111.841 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -92.91 164.53 13.28 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 110.27 -0.27 . . . . 9.39 110.27 177.667 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 278' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -103.38 156.03 18.04 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 110.054 -0.35 . . . . 8.15 110.054 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -130.55 52.88 2.0 Allowed 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.017 0.437 . . . . 6.73 110.99 -179.441 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.72 122.18 2.45 Favored Pre-proline 0 C--N 1.325 -0.46 0 CA-C-N 116.142 -0.481 . . . . 7.18 110.618 177.62 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -64.79 113.84 2.51 Favored 'Trans proline' 0 C--O 1.233 0.248 0 C-N-CA 122.421 2.081 . . . . 5.4 111.569 177.728 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 282' ' ' LYS . . . . . . . . . . . . . 4.4 mtpm? -87.07 97.18 10.59 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.762 -0.458 . . . . 3.88 109.762 -178.533 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 22.3 p -107.67 173.17 6.44 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.133 -0.485 . . . . 1.27 111.711 -174.461 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 60.6 mttp -134.33 141.32 46.87 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.779 -0.646 . . . . 2.51 109.676 175.562 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 39.3 tp -95.48 122.35 38.12 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 116.184 -0.462 . . . . 1.52 111.04 -178.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.643 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 98.2 mt -96.35 -170.92 2.18 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.931 -0.577 . . . . 1.39 110.599 176.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 287' ' ' GLU . . . . . 0.469 ' HG3' ' OH ' ' A' ' 366' ' ' TYR . 6.5 tp10 -52.86 145.21 12.98 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 115.901 -0.59 . . . . 2.64 111.551 178.808 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.494 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 72.22 -101.61 1.07 Allowed Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.947 -0.57 . . . . 1.84 111.736 -177.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . -148.15 25.57 1.42 Allowed Glycine 0 N--CA 1.444 -0.791 0 N-CA-C 110.214 -1.155 . . . . 1.16 110.214 175.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 290' ' ' ILE . . . . . 0.643 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 73.1 mt -72.36 124.72 29.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.235 -0.482 . . . . 1.16 110.446 -175.731 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . 0.564 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 16.2 mt -107.28 139.39 29.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 116.201 -0.454 . . . . 1.6 109.965 -177.217 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 292' ' ' ILE . . . . . . . . . . . . . 14.8 pt -128.06 127.53 67.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 121.176 0.512 . . . . 1.17 110.797 177.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 293' ' ' GLU . . . . . 0.431 ' CD ' HH21 ' A' ' 359' ' ' ARG . 30.2 tt0 -114.65 118.26 33.17 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 114.929 -1.032 . . . . 2.31 109.123 177.518 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -81.23 114.08 19.79 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.222 -0.591 . . . . 2.36 110.06 -174.09 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 295' ' ' ARG . . . . . 0.524 ' HG2' ' HA ' ' A' ' 358' ' ' ARG . 20.3 mmm180 -86.45 -56.08 3.6 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.632 -0.713 . . . . 3.99 110.365 -174.242 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.544 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 96.7 t -124.0 125.01 70.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.908 -0.587 . . . . 1.31 109.905 178.745 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 3.9 t -64.1 141.25 58.84 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.284 0.564 . . . . 2.46 111.688 -177.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -150.78 142.11 9.28 Favored Glycine 0 N--CA 1.443 -0.89 0 N-CA-C 110.992 -0.843 . . . . 1.04 110.992 176.024 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 51.5 pttt -131.55 117.61 18.99 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.379 0.609 . . . . 5.01 110.534 177.188 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -172.01 -154.43 10.03 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.335 -0.848 . . . . 1.59 111.063 -177.688 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . 0.452 ' O ' ' HA ' ' A' ' 353' ' ' ALA . 24.6 Cg_exo -62.66 133.53 42.77 Favored 'Trans proline' 0 N--CA 1.462 -0.34 0 C-N-CA 122.356 2.038 . . . . 1.1 111.404 176.282 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 35.9 m80 -95.12 130.15 41.94 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.308 -0.406 . . . . 1.85 110.45 178.474 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 303' ' ' ALA . . . . . 0.444 ' HB3' HG12 ' A' ' 309' ' ' VAL . . . -67.12 133.58 50.1 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.587 -0.733 . . . . 1.17 111.434 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 64.4 pttt -132.2 179.13 6.29 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 108.762 -0.829 . . . . 3.26 108.762 173.499 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 23.5 ttmm -66.33 135.62 54.63 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 120.587 -0.445 . . . . 3.21 110.333 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 92.48 -7.04 77.97 Favored Glycine 0 CA--C 1.521 0.42 0 C-N-CA 121.078 -0.582 . . . . 0.7 112.427 -174.774 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 30.3 m -88.97 150.03 23.01 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.716 0.293 . . . . 1.07 110.842 -178.484 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 82.2 mtt180 -115.31 102.52 9.93 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 109.468 -0.567 . . . . 3.98 109.468 -178.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.803 ' HB ' HD12 ' A' ' 388' ' ' LEU . 35.7 m -102.52 148.26 8.11 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.807 0 CA-C-N 115.592 -0.731 . . . . 1.1 112.458 -175.384 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -113.37 118.24 4.46 Favored Glycine 0 N--CA 1.446 -0.69 0 N-CA-C 110.672 -0.971 . . . . 0.32 110.672 176.554 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 311' ' ' MET . . . . . 0.5 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 6.8 ptm -139.48 178.49 7.18 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.788 0.804 . . . . 1.55 112.434 -172.531 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 55.0 mtt180 -136.06 152.57 51.02 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 113.896 -1.502 . . . . 3.0 107.68 176.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 313' ' ' TYR . . . . . 0.546 ' CB ' HG13 ' A' ' 386' ' ' VAL . 32.8 p90 -159.57 158.89 32.54 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 119.556 -0.858 . . . . 1.24 113.276 -174.474 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . 0.484 HG11 ' HG3' ' A' ' 316' ' ' LYS . 57.9 t -127.02 102.99 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 CA-C-N 114.811 -1.086 . . . . 1.09 109.355 171.071 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -87.13 110.32 3.54 Favored Glycine 0 C--O 1.237 0.336 0 N-CA-C 112.082 -0.407 . . . . 0.32 112.082 -178.47 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 316' ' ' LYS . . . . . 0.738 ' HG2' ' HB ' ' A' ' 322' ' ' VAL . 33.2 mtmm -126.37 156.03 41.16 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.842 0.353 . . . . 2.61 110.92 -174.794 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 317' ' ' LEU . . . . . 0.508 HD13 ' HB3' ' A' ' 321' ' ' LYS . 82.6 mt -81.73 173.33 12.41 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.821 -0.627 . . . . 1.32 110.963 177.007 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 318' ' ' LYS . . . . . . . . . . . . . 60.3 tttp -65.26 -22.27 66.84 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.606 -0.724 . . . . 2.9 110.674 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 32.6 p-10 -91.67 -1.36 57.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.411 -0.359 . . . . 2.39 111.095 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 97.83 -5.31 61.77 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.927 -0.654 . . . . 0.69 113.211 178.129 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 321' ' ' LYS . . . . . 0.508 ' HB3' HD13 ' A' ' 317' ' ' LEU . 14.4 tppt? -73.09 111.71 8.45 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.834 0.349 . . . . 2.86 110.27 -179.767 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.738 ' HB ' ' HG2' ' A' ' 316' ' ' LYS . 5.4 p -81.4 124.33 38.77 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 116.178 -0.464 . . . . 1.96 110.425 179.034 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 50.4 p90 -102.36 -32.23 10.11 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.908 -0.317 . . . . 0.56 111.323 -177.492 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -148.3 132.46 17.35 Favored 'General case' 0 CA--C 1.515 -0.38 0 N-CA-C 109.954 -0.387 . . . . 1.68 109.954 -179.203 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 59.3 pttt -153.97 134.7 13.67 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.907 0.384 . . . . 2.55 111.449 -174.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 326' ' ' ASN . . . . . 0.601 ' HB2' ' HB2' ' A' ' 330' ' ' LYS . 3.9 p30 -146.66 117.08 7.45 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.697 0.76 . . . . 1.92 110.322 169.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 3.2 p -142.16 -40.83 0.35 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.909 -1.041 . . . . 2.06 110.363 179.205 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 21.1 pttp -80.51 101.93 9.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.331 0.586 . . . . 3.15 111.432 -178.731 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.494 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 76.04 -13.85 6.88 Favored Glycine 0 N--CA 1.452 -0.237 0 CA-C-N 115.616 -0.72 . . . . 1.17 113.633 175.212 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 330' ' ' LYS . . . . . 0.601 ' HB2' ' HB2' ' A' ' 326' ' ' ASN . 27.4 mmmt -103.76 101.52 25.11 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 117.305 0.552 . . . . 2.56 111.068 -178.025 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 331' ' ' PRO . . . . . 0.494 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 72.2 Cg_endo -87.83 126.59 2.14 Favored 'Trans proline' 0 N--CA 1.45 -1.042 0 C-N-CA 122.96 2.44 . . . . 0.73 111.826 172.647 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 65.4 t80 -100.04 118.89 37.37 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 110.092 -0.336 . . . . 0.76 110.092 179.376 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 333' ' ' VAL . . . . . 0.476 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 61.6 t -119.32 114.82 45.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 N-CA-C 110.119 -0.326 . . . . 1.14 110.119 -178.734 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.5 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 14.1 p90 -131.64 159.38 38.48 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.958 0.409 . . . . 0.48 110.201 -179.64 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 335' ' ' LYS . . . . . 0.423 ' HG3' ' HG3' ' A' ' 338' ' ' GLN . 18.2 pttm -99.72 128.92 45.81 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.902 -0.59 . . . . 3.11 110.346 177.336 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 10.0 mp -64.54 117.53 7.5 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.484 -0.561 . . . . 1.2 109.484 174.645 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 129.36 10.09 3.11 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.774 -0.727 . . . . 1.02 111.699 -172.027 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 338' ' ' GLN . . . . . 0.626 ' HB3' ' HG2' ' A' ' 340' ' ' GLU . 91.8 mt-30 -84.35 141.93 30.53 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.962 0.411 . . . . 3.1 110.62 176.111 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -96.11 -4.95 59.73 Favored Glycine 0 N--CA 1.448 -0.512 0 N-CA-C 110.857 -0.897 . . . . 0.98 110.857 175.194 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 340' ' ' GLU . . . . . 0.626 ' HG2' ' HB3' ' A' ' 338' ' ' GLN . 5.5 pt-20 -84.18 -20.15 32.87 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.078 -0.561 . . . . 2.09 110.984 179.21 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 33.4 m -94.06 154.92 3.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 109.524 -0.547 . . . . 1.27 109.524 174.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 13.4 pt -74.86 154.25 6.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 N-CA-C 110.034 -0.358 . . . . 1.08 110.034 179.24 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . 0.424 ' HA ' ' HE2' ' A' ' 343' ' ' LYS . 5.7 mmpt? -60.62 -30.69 70.01 Favored 'General case' 0 N--CA 1.464 0.258 0 N-CA-C 111.73 0.27 . . . . 3.46 111.73 -174.72 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -55.55 -28.44 51.33 Favored Glycine 0 CA--C 1.521 0.437 0 C-N-CA 121.14 -0.553 . . . . 0.32 112.884 174.387 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 8.4 m95 -82.26 -60.96 2.03 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 111.648 0.24 . . . . 0.44 111.648 178.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -48.49 -35.73 13.69 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 120.923 0.392 . . . . 1.75 111.73 177.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 62.1 mt -88.51 -51.89 11.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.163 -0.471 . . . . 1.18 111.756 179.139 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 348' ' ' GLY . . . . . 0.414 ' HA2' HD11 ' A' ' 286' ' ' LEU . . . -61.08 -36.34 92.17 Favored Glycine 0 C--N 1.331 0.301 0 C-N-CA 121.36 -0.448 . . . . 0.37 113.73 -176.797 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 88.6 t -73.66 -23.2 19.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 121.182 0.515 . . . . 1.08 110.775 -179.579 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -70.18 105.61 3.0 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.097 0.475 . . . . 1.09 110.512 179.357 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 120.9 -2.78 11.81 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.864 -0.684 . . . . 0.45 112.303 -176.794 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 352' ' ' MET . . . . . 0.438 ' HG2' ' HD2' ' A' ' 358' ' ' ARG . 69.1 mtp -82.13 144.41 30.77 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.905 0.353 . . . . 1.3 110.622 176.356 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 353' ' ' ALA . . . . . 0.452 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -108.57 147.99 30.97 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.879 -0.6 . . . . 1.33 110.682 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 85.7 t -57.7 117.71 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 121.121 0.486 . . . . 1.24 110.835 176.048 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 110.67 -27.15 11.58 Favored Glycine 0 N--CA 1.445 -0.752 0 N-CA-C 111.049 -0.82 . . . . 0.44 111.049 -176.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -73.99 139.21 25.76 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 121.3 -0.476 . . . . 0.37 112.744 -177.162 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 357' ' ' GLU . . . . . 0.713 ' HB2' ' HG3' ' A' ' 387' ' ' LYS . 36.6 tt0 -125.0 133.87 52.82 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 109.063 -0.718 . . . . 1.63 109.063 178.358 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 358' ' ' ARG . . . . . 0.524 ' HA ' ' HG2' ' A' ' 295' ' ' ARG . 8.0 ptp180 -155.44 143.89 20.31 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.66 0.743 . . . . 1.53 112.294 -178.841 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 359' ' ' ARG . . . . . 0.431 HH21 ' CD ' ' A' ' 293' ' ' GLU . 20.9 ttp85 -86.25 117.95 25.39 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 114.773 -1.103 . . . . 3.26 109.485 177.813 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 50.3 mt -99.73 121.81 50.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.729 -0.669 . . . . 1.13 110.235 -178.31 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 361' ' ' VAL . . . . . 0.564 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 47.7 t -102.45 113.35 38.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 N-CA-C 109.15 -0.685 . . . . 1.14 109.15 176.574 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 362' ' ' ILE . . . . . . . . . . . . . 62.1 mt -113.19 101.49 53.53 Favored Pre-proline 0 C--N 1.324 -0.514 0 CA-C-O 120.728 0.299 . . . . 1.13 110.987 -175.096 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 363' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -56.43 159.9 12.36 Favored 'Trans proline' 0 C--O 1.237 0.463 0 C-N-CA 122.571 2.181 . . . . 1.05 112.41 171.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 364' ' ' ALA . . . . . 0.518 ' N ' ' HD2' ' A' ' 365' ' ' PRO . . . -47.72 -49.59 56.09 Favored Pre-proline 0 CA--C 1.539 0.547 0 N-CA-C 114.528 1.307 . . . . 1.16 114.528 -173.348 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 365' ' ' PRO . . . . . 0.518 ' HD2' ' N ' ' A' ' 364' ' ' ALA . 9.6 Cg_endo -51.03 -32.18 37.81 Favored 'Trans proline' 0 C--N 1.361 1.2 0 C-N-CA 122.567 2.178 . . . . 1.14 114.186 -172.832 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 366' ' ' TYR . . . . . 0.494 ' CE2' ' HA3' ' A' ' 288' ' ' GLY . 13.8 m-85 -100.52 12.13 37.97 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.831 -0.348 . . . . 1.03 111.841 -175.466 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -127.06 -109.6 0.3 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.441 -0.345 . . . . 1.07 110.907 174.799 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 78.8 m-85 -93.59 -15.83 25.0 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 111.977 0.362 . . . . 1.44 111.977 -179.723 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 64.82 -113.91 6.3 Favored Glycine 0 CA--C 1.52 0.388 0 C-N-CA 121.047 -0.597 . . . . 0.65 113.691 175.627 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 65.6 mttm -92.1 3.91 54.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.751 0.31 . . . . 3.34 111.525 -174.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -80.63 99.27 8.06 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.863 0.363 . . . . 2.88 111.638 -177.334 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 372' ' ' ALA . . . . . . . . . . . . . . . -78.29 92.48 4.52 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 115.952 -0.567 . . . . 1.39 109.908 171.362 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 30.5 mt -84.0 159.28 60.33 Favored Pre-proline 0 C--N 1.316 -0.885 0 CA-C-N 115.636 -0.711 . . . . 1.55 109.342 -179.686 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.55 113.0 1.43 Allowed 'Trans proline' 0 N--CA 1.461 -0.394 0 C-N-CA 121.507 1.472 . . . . 1.61 110.684 173.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 96.81 -29.92 9.74 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.809 -0.71 . . . . 0.96 112.533 -178.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 40.0 mt -125.95 88.94 53.38 Favored Pre-proline 0 C--N 1.332 -0.192 0 CA-C-N 116.772 0.286 . . . . 1.29 110.279 -179.242 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 377' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_exo -69.58 166.52 27.09 Favored 'Trans proline' 0 N--CA 1.463 -0.3 0 C-N-CA 122.596 2.198 . . . . 1.08 113.191 -178.355 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 378' ' ' ALA . . . . . . . . . . . . . . . -61.06 157.32 15.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.202 -0.908 . . . . 1.52 111.985 -176.771 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 379' ' ' ASN . . . . . 0.482 ' HA ' ' HB1' ' A' ' 364' ' ' ALA . 18.6 m120 65.69 23.16 11.59 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-N 115.377 -0.828 . . . . 1.97 111.113 177.798 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 59.6 p -66.72 116.43 7.62 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.003 -0.544 . . . . 1.91 111.134 179.501 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 381' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -80.37 98.55 7.52 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 108.971 -0.751 . . . . 1.03 108.971 174.541 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 92.6 mt -85.34 136.06 33.63 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.941 0.4 . . . . 1.13 111.248 -176.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 32.6 m -118.97 118.54 31.78 Favored 'General case' 0 N--CA 1.444 -0.734 0 N-CA-C 109.93 -0.396 . . . . 1.12 109.93 177.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -113.16 109.39 18.7 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.867 -0.42 . . . . 0.4 109.867 -177.204 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -87.39 104.88 16.85 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 108.034 -1.098 . . . . 1.8 108.034 176.636 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 386' ' ' VAL . . . . . 0.546 HG13 ' CB ' ' A' ' 313' ' ' TYR . 19.9 m -122.89 148.68 26.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 121.563 0.697 . . . . 1.13 112.382 -170.057 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 387' ' ' LYS . . . . . 0.713 ' HG3' ' HB2' ' A' ' 357' ' ' GLU . 46.5 tttm -137.39 129.91 29.83 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.402 -0.817 . . . . 3.1 109.652 176.128 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 388' ' ' LEU . . . . . 0.803 HD12 ' HB ' ' A' ' 309' ' ' VAL . 24.6 tp -89.58 134.55 34.08 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.776 -0.824 . . . . 1.05 108.776 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 27.5 m -129.36 -3.49 3.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 N-CA-C 112.251 0.463 . . . . 1.2 112.251 -174.064 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 10.2 t -168.5 156.67 8.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.69 0.281 . . . . 1.82 110.806 -177.506 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 391' ' ' MET . . . . . 0.56 ' HE3' HG13 ' A' ' 309' ' ' VAL . 40.5 ttm -156.33 155.26 31.93 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.229 -0.656 . . . . 1.14 109.229 174.401 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 392' ' ' LYS . . . . . 0.438 ' HE2' ' HB2' ' A' ' 392' ' ' LYS . 3.4 ptmm? . . . . . 0 C--O 1.25 1.123 0 CA-C-O 118.654 -0.689 . . . . 5.51 110.7 175.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.706 0 N-CA-C 112.105 -0.398 . . . . 11.6 112.105 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -145.91 104.63 3.87 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.979 0.419 . . . . 9.39 110.879 -179.112 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 278' ' ' MET . . . . . 0.774 ' HE1' ' HA ' ' A' ' 278' ' ' MET . 3.2 tpt -155.2 98.33 1.99 Allowed 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.07 -0.514 . . . . 8.15 109.993 176.501 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -142.39 100.63 3.74 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.095 -0.502 . . . . 6.73 110.977 179.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 54.0 mttp 70.83 140.82 0.08 OUTLIER Pre-proline 0 CA--C 1.535 0.375 0 O-C-N 123.862 0.726 . . . . 7.18 112.06 176.117 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -59.41 140.09 92.68 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 123.19 2.593 . . . . 5.4 112.693 -178.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 282' ' ' LYS . . . . . . . . . . . . . 63.3 mttm -131.94 109.09 9.81 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.703 -0.68 . . . . 3.88 110.537 -179.388 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 15.2 p -106.72 165.6 11.19 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.908 -0.587 . . . . 1.27 111.277 -178.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 284' ' ' LYS . . . . . 0.559 ' HB2' HG13 ' A' ' 292' ' ' ILE . 72.4 mmtt -130.12 135.94 48.76 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 109.213 -0.662 . . . . 2.51 109.213 179.723 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 31.1 tp -104.78 124.16 48.93 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 120.896 0.379 . . . . 1.52 110.138 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.776 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 76.7 mt -112.63 -175.21 2.62 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.578 -0.737 . . . . 1.39 109.813 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 2.6 tp10 -60.61 147.37 42.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.148 0.499 . . . . 2.64 111.336 -177.765 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.582 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 69.37 -1.77 12.17 Favored Glycine 0 N--CA 1.452 -0.297 0 CA-C-N 115.84 -0.618 . . . . 1.84 113.648 -179.892 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 97.6 14.8 39.51 Favored Glycine 0 N--CA 1.446 -0.681 0 C-N-CA 120.21 -0.995 . . . . 1.16 113.556 -179.274 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 290' ' ' ILE . . . . . 0.776 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 79.5 mt -64.16 122.57 15.31 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.167 0 CA-C-N 117.488 0.644 . . . . 1.16 110.507 176.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . 0.545 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 80.2 mt -107.36 138.27 34.3 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 N-CA-C 110.355 -0.239 . . . . 1.6 110.355 177.08 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 292' ' ' ILE . . . . . 0.559 HG13 ' HB2' ' A' ' 284' ' ' LYS . 23.6 pt -127.02 130.85 71.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 N-CA-C 109.489 -0.56 . . . . 1.17 109.489 174.34 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 293' ' ' GLU . . . . . 0.407 ' CD ' HH21 ' A' ' 359' ' ' ARG . 34.3 tt0 -123.43 121.42 35.69 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 115.176 -0.92 . . . . 2.31 109.954 -177.139 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 51.9 m-20 -78.3 110.93 13.76 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.712 -0.477 . . . . 2.36 109.712 -176.637 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 295' ' ' ARG . . . . . . . . . . . . . 39.1 ttt180 -88.14 -58.24 2.64 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.832 -0.622 . . . . 3.99 110.499 -175.176 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.585 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 58.1 t -128.24 141.36 46.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 110.203 -0.295 . . . . 1.31 110.203 177.207 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 9.0 t -96.07 149.84 21.16 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.3 -0.409 . . . . 2.46 111.033 -178.197 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -152.93 -164.64 12.65 Favored Glycine 0 C--N 1.331 0.261 0 C-N-CA 121.428 -0.415 . . . . 1.04 112.174 -177.19 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . 0.561 ' O ' ' HB2' ' A' ' 353' ' ' ALA . 62.0 tttp -72.78 139.54 47.15 Favored 'General case' 0 CA--C 1.52 -0.211 0 N-CA-C 108.595 -0.891 . . . . 5.01 108.595 173.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -116.34 80.48 0.3 Allowed Glycine 0 N--CA 1.445 -0.756 0 C-N-CA 119.314 -1.422 . . . . 1.59 115.272 -170.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . 0.538 ' HD2' ' H ' ' A' ' 354' ' ' VAL . 8.2 Cg_exo -74.57 131.51 14.92 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.036 1.824 . . . . 1.1 108.145 159.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 302' ' ' HIS . . . . . 0.422 ' O ' ' HE3' ' A' ' 304' ' ' LYS . 27.4 m80 -85.91 107.35 17.67 Favored 'General case' 0 C--N 1.319 -0.731 0 C-N-CA 120.314 -0.554 . . . . 1.85 111.423 -169.093 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -66.33 109.08 2.55 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.703 -0.681 . . . . 1.17 110.375 175.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . 0.422 ' HE3' ' O ' ' A' ' 302' ' ' HIS . 11.5 ptpt -127.47 -174.44 3.18 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 116.326 -0.397 . . . . 3.26 110.161 -179.171 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.793 ' HG3' ' HA3' ' A' ' 337' ' ' GLY . 62.3 tttm -65.71 124.51 22.6 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.994 0.426 . . . . 3.21 111.019 -175.251 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 97.14 -11.24 65.71 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 121.075 -0.583 . . . . 0.7 112.81 -178.063 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 307' ' ' THR . . . . . 0.426 ' O ' ' HA ' ' A' ' 335' ' ' LYS . 28.4 m -82.92 142.8 31.16 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 122.881 -0.188 . . . . 1.07 110.524 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 22.6 ptt180 -106.78 116.03 31.22 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 121.306 0.574 . . . . 3.98 109.583 -178.234 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.804 ' HB ' HD12 ' A' ' 388' ' ' LEU . 31.1 m -113.69 147.8 17.0 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 115.644 -0.707 . . . . 1.1 111.918 -177.397 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -116.67 114.19 2.97 Favored Glycine 0 N--CA 1.443 -0.896 0 N-CA-C 110.126 -1.19 . . . . 0.32 110.126 174.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 311' ' ' MET . . . . . 0.471 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 6.9 ptm -131.65 177.68 7.33 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 121.897 0.856 . . . . 1.55 112.488 -172.283 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -138.07 150.31 46.78 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 113.726 -1.579 . . . . 3.0 107.794 177.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 313' ' ' TYR . . . . . 0.455 ' CB ' HG13 ' A' ' 386' ' ' VAL . 44.3 p90 -156.45 155.33 31.88 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 120.741 -0.384 . . . . 1.24 111.375 -169.74 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . 0.582 HG12 ' HE3' ' A' ' 316' ' ' LYS . 38.2 t -120.46 105.71 17.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-N 115.587 -0.733 . . . . 1.09 109.247 169.206 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -84.82 109.38 3.26 Favored Glycine 0 N--CA 1.445 -0.717 0 CA-C-N 116.088 -0.506 . . . . 0.32 112.168 -178.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 316' ' ' LYS . . . . . 0.765 ' HG2' HG23 ' A' ' 322' ' ' VAL . 93.6 mttt -123.32 161.05 25.42 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-N 114.929 -0.636 . . . . 2.61 110.464 -178.308 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 317' ' ' LEU . . . . . 0.488 HD13 ' HD3' ' A' ' 321' ' ' LYS . 83.6 mt -88.18 165.81 14.81 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 109.392 -0.596 . . . . 1.32 109.392 170.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 318' ' ' LYS . . . . . 0.895 ' HD2' ' HB3' ' A' ' 381' ' ' GLU . 0.2 OUTLIER -61.15 -19.37 61.46 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.31 -0.405 . . . . 2.9 111.633 179.844 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 319' ' ' ASN . . . . . 0.407 ' OD1' ' HB2' ' A' ' 317' ' ' LEU . 28.5 p-10 -90.41 -1.61 57.92 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 116.577 -0.283 . . . . 2.39 111.146 -178.575 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 94.5 6.8 60.86 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.505 -0.855 . . . . 0.69 113.11 177.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 321' ' ' LYS . . . . . 0.488 ' HD3' HD13 ' A' ' 317' ' ' LEU . 63.5 tttp -81.99 118.57 23.09 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.947 0.403 . . . . 2.86 110.472 177.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.765 HG23 ' HG2' ' A' ' 316' ' ' LYS . 12.6 t -85.56 129.78 37.39 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 116.115 -0.493 . . . . 1.96 109.948 179.381 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 32.3 p90 -111.48 -43.57 3.66 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 120.528 -0.469 . . . . 0.56 111.586 178.508 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -148.07 128.56 14.03 Favored 'General case' 0 CA--C 1.514 -0.431 0 C-N-CA 120.507 -0.477 . . . . 1.68 110.958 -177.658 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . 0.526 ' HE3' HG12 ' A' ' 322' ' ' VAL . 8.4 pttp -145.75 128.31 16.08 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.092 0.472 . . . . 2.55 110.88 -179.05 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 326' ' ' ASN . . . . . 0.409 ' C ' ' HG1' ' A' ' 327' ' ' THR . 55.6 m-80 -125.25 116.49 22.06 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.544 -0.753 . . . . 1.92 109.055 173.605 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 327' ' ' THR . . . . . 0.409 ' HG1' ' C ' ' A' ' 326' ' ' ASN . 26.3 m -157.0 -38.89 0.07 Allowed 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.675 -0.693 . . . . 2.06 110.155 -177.202 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 29.6 mmmt -75.18 92.74 2.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.788 -0.642 . . . . 3.15 110.372 179.589 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.43 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 75.1 -17.7 2.86 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 121.245 -0.502 . . . . 1.17 113.606 177.491 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 82.4 mttt -103.37 103.26 34.26 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 117.001 0.401 . . . . 2.56 111.571 -175.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 331' ' ' PRO . . . . . 0.43 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 98.3 Cg_endo -87.91 145.83 6.6 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 122.825 2.35 . . . . 0.73 112.167 171.698 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 72.3 t80 -111.15 119.51 39.2 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.364 -0.606 . . . . 0.76 109.364 175.526 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 46.7 t -111.64 126.3 69.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 120.648 0.261 . . . . 1.14 110.842 -177.236 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.597 ' HB2' HE22 ' A' ' 338' ' ' GLN . 28.4 p90 -153.54 169.19 23.81 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.34 -0.391 . . . . 0.48 110.2 178.415 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 335' ' ' LYS . . . . . 0.487 ' HE2' ' HB3' ' A' ' 338' ' ' GLN . 0.0 OUTLIER -112.77 146.22 39.18 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.152 0.501 . . . . 3.11 111.418 177.201 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 10.9 mp -78.35 150.89 33.12 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.853 -0.612 . . . . 1.2 110.262 177.661 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 337' ' ' GLY . . . . . 0.793 ' HA3' ' HG3' ' A' ' 305' ' ' LYS . . . 89.12 27.14 24.19 Favored Glycine 0 N--CA 1.445 -0.706 0 C-N-CA 120.739 -0.743 . . . . 1.02 112.459 -177.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 338' ' ' GLN . . . . . 0.597 HE22 ' HB2' ' A' ' 334' ' ' PHE . 30.2 pt20 -118.97 163.06 17.5 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 110.085 -0.339 . . . . 3.1 110.085 176.406 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -93.6 2.84 70.79 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.952 -0.642 . . . . 0.98 112.329 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -76.43 -24.78 53.96 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.948 0.404 . . . . 2.09 110.876 -178.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 31.0 m -108.74 152.66 10.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.241 -0.436 . . . . 1.27 110.755 -178.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 342' ' ' ILE . . . . . 0.492 ' HB ' ' HA ' ' A' ' 367' ' ' ALA . 14.8 pt -70.52 156.24 7.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.858 -0.423 . . . . 1.08 109.858 178.457 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -64.48 -32.61 74.32 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.626 -0.261 . . . . 3.46 111.396 -175.386 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -53.41 -41.86 63.88 Favored Glycine 0 CA--C 1.523 0.561 0 C-N-CA 120.613 -0.803 . . . . 0.32 112.16 173.462 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 7.8 m95 -70.51 -58.42 3.73 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.75 0.309 . . . . 0.44 110.489 175.474 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -49.49 -32.27 11.78 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 115.877 -0.601 . . . . 1.75 112.355 -179.308 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 69.2 mt -89.17 -53.21 9.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.501 -0.318 . . . . 1.18 111.789 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -64.32 -32.93 85.82 Favored Glycine 0 C--N 1.332 0.307 0 C-N-CA 121.189 -0.529 . . . . 0.37 113.664 -177.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 89.8 t -78.44 -16.33 13.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.988 0.423 . . . . 1.08 111.035 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.01 106.41 1.25 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.235 0.541 . . . . 1.09 110.241 178.592 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 98.31 22.33 15.1 Favored Glycine 0 N--CA 1.444 -0.787 0 CA-C-N 115.6 -0.727 . . . . 0.45 112.577 -178.234 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 352' ' ' MET . . . . . . . . . . . . . 64.1 mmm -69.22 173.38 5.73 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.562 0.22 . . . . 1.3 110.636 173.308 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 353' ' ' ALA . . . . . 0.561 ' HB2' ' O ' ' A' ' 299' ' ' LYS . . . -135.71 136.61 40.99 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.107 -0.497 . . . . 1.33 111.05 -177.605 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 354' ' ' VAL . . . . . 0.538 ' H ' ' HD2' ' A' ' 301' ' ' PRO . 59.4 t -65.76 112.05 1.75 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.202 0 CA-C-O 121.436 0.636 . . . . 1.24 109.923 174.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 104.56 -24.16 29.45 Favored Glycine 0 N--CA 1.439 -1.134 0 N-CA-C 110.134 -1.186 . . . . 0.44 110.134 -172.7 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -73.85 145.66 35.59 Favored Glycine 0 N--CA 1.444 -0.793 0 N-CA-C 112.04 -0.424 . . . . 0.37 112.04 179.874 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 357' ' ' GLU . . . . . 0.732 ' HG3' ' HB2' ' A' ' 387' ' ' LYS . 34.0 tt0 -135.75 131.54 35.68 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 108.238 -1.023 . . . . 1.63 108.238 -173.227 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 358' ' ' ARG . . . . . . . . . . . . . 2.1 ptp180 -154.86 148.22 25.06 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.369 0.604 . . . . 1.53 112.495 -177.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 359' ' ' ARG . . . . . 0.407 HH21 ' CD ' ' A' ' 293' ' ' GLU . 14.8 ttp180 -89.21 114.76 26.11 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.377 -0.829 . . . . 3.26 109.817 176.502 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 65.4 mt -102.67 118.72 49.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 109.955 -0.387 . . . . 1.13 109.955 179.087 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 361' ' ' VAL . . . . . 0.545 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 41.8 t -101.19 111.15 29.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 109.209 -0.663 . . . . 1.14 109.209 179.63 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 362' ' ' ILE . . . . . 0.472 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 60.4 mt -108.09 112.48 61.47 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-O 120.985 0.421 . . . . 1.13 111.531 -171.402 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 363' ' ' PRO . . . . . 0.526 ' HD2' HG12 ' A' ' 290' ' ' ILE . 33.7 Cg_endo -64.19 155.34 65.73 Favored 'Trans proline' 0 C--O 1.235 0.356 0 C-N-CA 122.902 2.401 . . . . 1.05 111.791 175.153 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 364' ' ' ALA . . . . . 0.411 ' CB ' ' HA ' ' A' ' 379' ' ' ASN . . . -51.16 -49.5 81.05 Favored Pre-proline 0 CA--C 1.541 0.598 0 N-CA-C 114.14 1.163 . . . . 1.16 114.14 -174.775 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 365' ' ' PRO . . . . . 0.459 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 32.2 Cg_exo -59.0 -24.41 73.22 Favored 'Trans proline' 0 C--N 1.362 1.274 0 C-N-CA 122.176 1.917 . . . . 1.14 113.671 -173.056 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 366' ' ' TYR . . . . . 0.582 ' CE2' ' HA3' ' A' ' 288' ' ' GLY . 5.4 m-85 -100.27 10.74 40.79 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.048 0.452 . . . . 1.03 111.385 -176.707 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 367' ' ' ALA . . . . . 0.492 ' HA ' ' HB ' ' A' ' 342' ' ' ILE . . . -122.24 -106.04 0.37 Allowed 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.903 -0.59 . . . . 1.07 110.406 174.191 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 368' ' ' TYR . . . . . 0.459 ' HB3' ' HB3' ' A' ' 371' ' ' GLN . 96.4 m-85 -92.42 -16.12 26.31 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.642 0.258 . . . . 1.44 111.52 178.38 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 68.53 -110.73 3.56 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.911 -0.661 . . . . 0.65 112.669 178.525 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 370' ' ' LYS . . . . . 0.474 ' HA ' ' HB3' ' A' ' 378' ' ' ALA . 48.9 mtpt -101.27 10.18 40.96 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.766 0.317 . . . . 3.34 111.174 -177.538 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 371' ' ' GLN . . . . . 0.459 ' HB3' ' HB3' ' A' ' 368' ' ' TYR . 64.5 tt0 -82.58 100.97 10.46 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 120.864 0.364 . . . . 2.88 110.572 178.656 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 372' ' ' ALA . . . . . 0.527 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -78.84 107.9 11.89 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.264 -0.426 . . . . 1.39 111.295 178.602 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 83.6 mt -102.47 161.81 22.14 Favored Pre-proline 0 C--N 1.32 -0.691 0 N-CA-C 109.403 -0.592 . . . . 1.55 109.403 174.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_endo -64.27 114.61 2.74 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 121.592 1.528 . . . . 1.61 110.929 172.452 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 96.2 -28.58 12.41 Favored Glycine 0 CA--C 1.521 0.466 0 C-N-CA 120.89 -0.671 . . . . 0.96 112.225 -176.665 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 376' ' ' ILE . . . . . 0.503 HG21 HD22 ' A' ' 382' ' ' LEU . 23.0 mt -130.74 77.62 75.27 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 120.701 0.286 . . . . 1.29 110.303 179.137 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 377' ' ' PRO . . . . . 0.527 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 73.5 Cg_endo -77.77 167.86 23.26 Favored 'Trans proline' 0 N--CA 1.461 -0.395 0 C-N-CA 122.38 2.054 . . . . 1.08 112.805 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 378' ' ' ALA . . . . . 0.474 ' HB3' ' HA ' ' A' ' 370' ' ' LYS . . . -53.07 143.2 18.11 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 116.055 -0.52 . . . . 1.52 111.979 -179.72 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 379' ' ' ASN . . . . . 0.411 ' HA ' ' CB ' ' A' ' 364' ' ' ALA . 12.3 m120 67.95 19.92 9.31 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 115.556 -0.747 . . . . 1.97 112.286 176.356 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 67.1 m -87.2 131.63 34.13 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.332 0.587 . . . . 1.91 111.232 176.55 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 381' ' ' GLU . . . . . 0.895 ' HB3' ' HD2' ' A' ' 318' ' ' LYS . 34.1 tt0 -84.71 112.86 20.86 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.999 -1.0 . . . . 1.03 109.93 178.33 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 382' ' ' LEU . . . . . 0.503 HD22 HG21 ' A' ' 376' ' ' ILE . 91.5 mt -89.67 139.49 30.51 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.334 -0.394 . . . . 1.13 110.243 179.765 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 37.8 m -119.33 119.12 33.07 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.322 -0.621 . . . . 1.12 109.322 176.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -115.13 109.88 18.68 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 121.124 0.488 . . . . 0.4 110.444 -177.213 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -87.52 106.92 18.32 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 108.149 -1.056 . . . . 1.8 108.149 174.113 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 386' ' ' VAL . . . . . 0.455 HG13 ' CB ' ' A' ' 313' ' ' TYR . 29.6 m -122.9 148.37 26.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.621 0.724 . . . . 1.13 112.123 -168.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 387' ' ' LYS . . . . . 0.732 ' HB2' ' HG3' ' A' ' 357' ' ' GLU . 40.7 tttp -139.05 132.96 30.98 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.74 -1.118 . . . . 3.1 109.317 175.222 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 388' ' ' LEU . . . . . 0.804 HD12 ' HB ' ' A' ' 309' ' ' VAL . 30.6 tp -91.98 131.62 37.14 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 108.666 -0.864 . . . . 1.05 108.666 -179.178 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 28.9 m -120.01 -4.39 9.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 112.232 0.456 . . . . 1.2 112.232 -173.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 11.3 t -170.51 152.06 3.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.968 0.413 . . . . 1.82 111.154 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 391' ' ' MET . . . . . 0.502 ' SD ' ' HB2' ' A' ' 301' ' ' PRO . 31.6 ttm -157.25 147.47 20.94 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.747 -0.661 . . . . 1.14 109.497 174.626 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 20.8 tptm . . . . . 0 C--O 1.248 0.992 0 CA-C-O 117.88 -1.057 . . . . 5.51 111.438 173.471 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.764 0 N-CA-C 111.847 -0.501 . . . . 11.6 111.847 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -87.77 -10.16 51.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.48 0.181 . . . . 9.39 111.371 -177.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 278' ' ' MET . . . . . 0.455 ' O ' ' HG3' ' A' ' 280' ' ' LYS . 45.2 mtm 69.06 -1.93 1.95 Allowed 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 123.14 0.576 . . . . 8.15 111.357 178.173 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . 63.23 18.55 11.06 Favored 'General case' 0 N--CA 1.463 0.204 0 C-N-CA 123.097 0.559 . . . . 6.73 111.302 -176.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . 0.455 ' HG3' ' O ' ' A' ' 278' ' ' MET . 28.1 mtpp -120.17 144.08 37.06 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 120.613 0.244 . . . . 7.18 110.637 -177.036 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 281' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' A' ' 280' ' ' LYS . 25.8 Cg_exo -63.38 155.42 62.23 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.978 2.452 . . . . 5.4 113.286 -177.862 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 282' ' ' LYS . . . . . . . . . . . . . 58.6 mttm -96.11 107.31 19.6 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.807 -0.633 . . . . 3.88 111.001 -178.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.953 HG23 ' HG2' ' A' ' 293' ' ' GLU . 31.6 p -109.74 126.36 53.65 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 110.21 -0.292 . . . . 1.27 110.21 173.226 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 284' ' ' LYS . . . . . 0.443 ' HB2' HG13 ' A' ' 292' ' ' ILE . 23.8 mmtp -122.03 146.99 46.64 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.94 0.4 . . . . 2.51 111.115 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 40.3 tp -103.97 121.17 42.58 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.542 -0.754 . . . . 1.52 110.242 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.549 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 94.9 mt -101.78 -169.5 1.69 Allowed 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.978 -0.555 . . . . 1.39 110.407 178.048 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -68.37 146.58 53.12 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.702 -0.681 . . . . 2.64 110.154 -179.651 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 73.71 10.63 80.23 Favored Glycine 0 CA--C 1.517 0.163 0 C-N-CA 121.102 -0.571 . . . . 1.84 113.687 178.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 81.44 16.84 72.69 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.63 -0.795 . . . . 1.16 112.596 178.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 290' ' ' ILE . . . . . 0.549 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 84.1 mt -69.64 125.76 28.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 N-CA-C 109.94 -0.393 . . . . 1.16 109.94 177.82 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . 0.657 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 20.1 mt -104.14 134.91 44.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 N-CA-C 109.286 -0.635 . . . . 1.6 109.286 179.386 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 292' ' ' ILE . . . . . 0.443 HG13 ' HB2' ' A' ' 284' ' ' LYS . 18.2 pt -124.13 127.14 73.24 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 CA-C-O 121.112 0.482 . . . . 1.17 110.172 177.873 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 293' ' ' GLU . . . . . 0.953 ' HG2' HG23 ' A' ' 283' ' ' THR . 29.4 mt-10 -117.94 114.35 23.07 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.499 -0.773 . . . . 2.31 109.469 -179.812 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . 0.443 ' C ' ' HE ' ' A' ' 295' ' ' ARG . 8.2 t70 -80.15 135.09 36.22 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 109.255 -0.646 . . . . 2.36 109.255 -175.383 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 295' ' ' ARG . . . . . 0.571 ' HG2' ' HA ' ' A' ' 358' ' ' ARG . 1.7 mmp_? -105.76 -60.3 1.65 Allowed 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 110.02 -0.363 . . . . 3.99 110.02 -175.175 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . . . . . . . . . 84.0 t -122.2 109.98 25.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 116.039 -0.528 . . . . 1.31 109.594 174.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 18.1 p -61.93 109.24 1.2 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.522 -0.763 . . . . 2.46 111.405 -177.392 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -101.2 171.38 22.32 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.669 -0.776 . . . . 1.04 112.033 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 8.0 tmtm? -145.69 110.58 5.18 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.297 -0.631 . . . . 5.01 109.297 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -172.24 -154.25 9.96 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.78 -0.724 . . . . 1.59 111.713 -178.596 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . 0.704 ' HD2' ' HB ' ' A' ' 354' ' ' VAL . 24.0 Cg_exo -64.46 134.34 41.16 Favored 'Trans proline' 0 C--O 1.232 0.192 0 C-N-CA 123.129 2.553 . . . . 1.1 112.342 177.28 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 44.4 m-70 -98.32 132.25 43.95 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.317 -0.401 . . . . 1.85 110.048 179.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -81.3 143.26 32.37 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 112.487 0.551 . . . . 1.17 112.487 -176.009 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -127.26 -178.85 4.6 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.657 -0.701 . . . . 3.26 110.041 174.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.796 ' HG3' ' HA3' ' A' ' 337' ' ' GLY . 46.7 tttm -68.47 135.49 51.74 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.864 0.364 . . . . 3.21 110.342 175.218 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 93.13 -17.83 57.46 Favored Glycine 0 N--CA 1.451 -0.318 0 CA-C-N 116.107 -0.497 . . . . 0.7 112.257 -176.517 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 27.0 m -74.83 142.53 44.18 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.729 0.3 . . . . 1.07 110.679 -179.236 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . 0.441 HH11 ' HD3' ' A' ' 308' ' ' ARG . 22.0 mtm180 -104.61 103.73 13.44 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 109.04 -0.726 . . . . 3.98 109.04 178.58 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.819 ' HB ' HD12 ' A' ' 388' ' ' LEU . 28.4 m -104.35 145.36 13.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 CA-C-N 116.011 -0.54 . . . . 1.1 111.567 -177.569 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -111.51 120.68 5.5 Favored Glycine 0 N--CA 1.445 -0.739 0 N-CA-C 109.709 -1.356 . . . . 0.32 109.709 176.405 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 311' ' ' MET . . . . . 0.54 ' CE ' ' HB ' ' A' ' 386' ' ' VAL . 22.0 ptm -136.44 176.79 8.38 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.591 0.71 . . . . 1.55 112.309 -169.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 312' ' ' ARG . . . . . 0.537 ' HD2' ' HA ' ' A' ' 327' ' ' THR . 12.5 mmt-85 -127.57 151.09 49.34 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 107.303 -1.369 . . . . 3.0 107.303 172.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 313' ' ' TYR . . . . . 0.465 ' CB ' HG13 ' A' ' 386' ' ' VAL . 51.3 p90 -167.04 158.53 12.39 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.326 0.584 . . . . 1.24 111.953 -176.82 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . 0.43 HG13 ' HG3' ' A' ' 316' ' ' LYS . 42.6 t -123.15 112.32 33.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.124 -0.944 . . . . 1.09 109.559 174.131 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -84.73 105.51 2.86 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 121.073 -0.585 . . . . 0.32 111.942 -177.661 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 316' ' ' LYS . . . . . 0.495 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 45.8 mtmt -119.31 154.35 33.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.143 0.497 . . . . 2.61 111.681 -176.225 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 78.3 mt -91.15 160.56 15.5 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.811 -0.631 . . . . 1.32 109.97 176.152 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 318' ' ' LYS . . . . . 0.637 ' HD2' ' HB3' ' A' ' 381' ' ' GLU . 85.3 tttt -62.4 -18.45 61.64 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-O 121.345 0.593 . . . . 2.9 110.138 175.603 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -79.61 -2.03 40.72 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 115.566 -0.743 . . . . 2.39 110.788 179.623 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 89.96 -2.91 82.44 Favored Glycine 0 C--N 1.329 0.178 0 C-N-CA 120.648 -0.787 . . . . 0.69 112.795 177.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -93.83 128.37 40.06 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.691 0.281 . . . . 2.86 110.587 -179.073 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.495 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 7.1 p -85.41 136.64 22.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 116.249 -0.432 . . . . 1.96 110.277 177.144 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 42.5 p90 -108.24 -35.67 6.49 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 120.791 -0.364 . . . . 0.56 111.36 -179.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -147.05 162.28 39.12 Favored 'General case' 0 N--CA 1.464 0.261 0 C-N-CA 120.976 -0.289 . . . . 1.68 110.569 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 3.7 ptpp? -164.55 138.72 5.29 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.76 0.314 . . . . 2.55 111.323 -177.136 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 55.0 m-80 -140.58 117.12 10.82 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 108.798 -0.815 . . . . 1.92 108.798 173.56 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 327' ' ' THR . . . . . 0.537 ' HA ' ' HD2' ' A' ' 312' ' ' ARG . 5.2 t -160.73 -49.44 0.05 OUTLIER 'General case' 0 C--N 1.324 -0.5 0 C-N-CA 120.859 -0.337 . . . . 2.06 111.726 -177.16 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 19.9 pttp -94.77 104.94 16.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.364 0.602 . . . . 3.15 110.839 -178.218 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.401 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 87.94 -29.61 5.42 Favored Glycine 0 N--CA 1.45 -0.394 0 CA-C-N 115.409 -0.814 . . . . 1.17 112.756 177.49 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 92.3 mttt -102.09 106.49 48.2 Favored Pre-proline 0 C--N 1.326 -0.428 0 CA-C-O 120.735 0.302 . . . . 2.56 111.335 -176.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 331' ' ' PRO . . . . . 0.401 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 80.3 Cg_endo -87.31 125.72 2.21 Favored 'Trans proline' 0 N--CA 1.448 -1.167 0 C-N-CA 122.765 2.31 . . . . 0.73 111.405 173.126 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 64.7 t80 -103.66 114.36 28.56 Favored 'General case' 0 C--N 1.318 -0.777 0 C-N-CA 120.677 -0.409 . . . . 0.76 110.002 179.43 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 333' ' ' VAL . . . . . 0.47 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 58.4 t -115.86 122.61 69.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.767 -0.651 . . . . 1.14 109.868 -178.57 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.465 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 13.2 p90 -138.19 165.87 25.6 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.945 0.403 . . . . 0.48 110.229 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 335' ' ' LYS . . . . . 0.528 ' HG3' ' HG3' ' A' ' 338' ' ' GLN . 21.4 pttm -110.08 129.44 55.69 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.977 -0.556 . . . . 3.11 110.608 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 9.6 mp -72.44 146.52 46.87 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.849 -0.614 . . . . 1.2 111.732 -178.704 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 337' ' ' GLY . . . . . 0.796 ' HA3' ' HG3' ' A' ' 305' ' ' LYS . . . 88.44 25.05 31.75 Favored Glycine 0 N--CA 1.447 -0.614 0 CA-C-N 115.632 -0.713 . . . . 1.02 112.769 170.614 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 338' ' ' GLN . . . . . 0.528 ' HG3' ' HG3' ' A' ' 335' ' ' LYS . 48.3 mm-40 -123.09 149.47 44.41 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.732 -0.47 . . . . 3.1 109.732 -179.458 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -78.49 43.3 2.31 Favored Glycine 0 CA--C 1.518 0.279 0 C-N-CA 120.875 -0.678 . . . . 0.98 112.786 178.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 340' ' ' GLU . . . . . 0.477 ' HG2' ' HB2' ' A' ' 338' ' ' GLN . 10.4 pt-20 -122.29 -3.21 8.97 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.153 0.502 . . . . 2.09 110.087 175.647 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 23.9 m -128.49 166.51 25.63 Favored 'Isoleucine or valine' 0 C--O 1.233 0.229 0 CA-C-N 115.47 -0.787 . . . . 1.27 109.057 174.335 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 342' ' ' ILE . . . . . 0.723 ' HB ' ' HA ' ' A' ' 367' ' ' ALA . 14.0 pt -82.63 154.35 3.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.325 -0.62 . . . . 1.08 109.325 176.397 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . 0.411 ' HA ' ' OD2' ' A' ' 346' ' ' ASP . 6.9 mtmm -65.93 -31.39 72.29 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 111.78 0.289 . . . . 3.46 111.78 -172.355 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 344' ' ' GLY . . . . . 0.537 ' HA2' ' CD1' ' A' ' 290' ' ' ILE . . . -54.39 -32.0 51.63 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.69 -0.766 . . . . 0.32 111.851 173.031 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 7.2 m95 -76.03 -55.63 5.42 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 111.847 0.314 . . . . 0.44 111.847 177.367 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 346' ' ' ASP . . . . . 0.411 ' OD2' ' HA ' ' A' ' 343' ' ' LYS . 0.1 OUTLIER -64.75 -24.32 67.53 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 122.186 -0.321 . . . . 1.75 111.603 -174.844 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 56.8 mt -89.8 -49.4 13.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.631 -0.259 . . . . 1.18 111.029 176.546 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -61.49 -36.57 92.76 Favored Glycine 0 CA--C 1.52 0.387 0 C-N-CA 120.982 -0.628 . . . . 0.37 113.171 179.345 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 349' ' ' VAL . . . . . 0.473 ' O ' ' HB2' ' A' ' 352' ' ' MET . 95.4 t -78.79 -14.16 13.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.115 0.484 . . . . 1.08 110.934 178.602 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -69.87 120.56 15.78 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 109.471 -0.566 . . . . 1.09 109.471 176.242 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 85.45 14.05 69.25 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.865 -0.684 . . . . 0.45 112.023 -176.591 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 352' ' ' MET . . . . . 0.821 ' HE3' ' HG2' ' A' ' 358' ' ' ARG . 0.0 OUTLIER -81.01 137.0 36.07 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 108.867 -0.79 . . . . 1.3 108.867 176.442 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 353' ' ' ALA . . . . . 0.442 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -109.28 130.56 55.49 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.982 0.42 . . . . 1.33 111.097 -174.882 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 354' ' ' VAL . . . . . 0.704 ' HB ' ' HD2' ' A' ' 301' ' ' PRO . 95.8 t -54.23 121.03 2.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.906 -0.588 . . . . 1.24 111.306 176.686 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 107.52 -8.73 37.74 Favored Glycine 0 N--CA 1.444 -0.797 0 CA-C-N 115.73 -0.668 . . . . 0.44 112.152 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 356' ' ' GLY . . . . . 0.442 ' O ' ' HE2' ' A' ' 352' ' ' MET . . . -100.97 154.9 19.22 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.836 -0.697 . . . . 0.37 112.571 -178.417 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 357' ' ' GLU . . . . . 0.694 ' HG2' ' HD2' ' A' ' 387' ' ' LYS . 54.0 mt-10 -122.5 130.76 53.39 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.443 -0.577 . . . . 1.63 109.443 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 358' ' ' ARG . . . . . 0.821 ' HG2' ' HE3' ' A' ' 352' ' ' MET . 4.1 ptp180 -156.06 142.24 18.29 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.232 0.539 . . . . 1.53 111.094 176.522 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 359' ' ' ARG . . . . . . . . . . . . . 53.9 ttp180 -93.31 133.63 36.35 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.508 -0.769 . . . . 3.26 109.82 -178.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 38.8 mt -110.16 119.86 60.01 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-N 116.168 -0.469 . . . . 1.13 110.24 -179.418 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 361' ' ' VAL . . . . . 0.657 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 45.6 t -98.87 112.76 31.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 108.616 -0.883 . . . . 1.14 108.616 176.316 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 362' ' ' ILE . . . . . 0.433 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 54.4 mt -112.83 108.0 54.07 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-O 120.7 0.286 . . . . 1.13 111.441 -172.127 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 363' ' ' PRO . . . . . 0.614 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 19.4 Cg_endo -59.36 152.09 63.36 Favored 'Trans proline' 0 C--O 1.235 0.35 0 C-N-CA 122.564 2.176 . . . . 1.05 111.771 170.798 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 364' ' ' ALA . . . . . . . . . . . . . . . -48.43 -46.8 69.47 Favored Pre-proline 0 CA--C 1.544 0.718 0 N-CA-C 114.077 1.14 . . . . 1.16 114.077 -176.544 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 365' ' ' PRO . . . . . 0.614 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 83.7 Cg_exo -49.24 -36.55 37.5 Favored 'Trans proline' 0 C--N 1.361 1.19 0 C-N-CA 122.687 2.258 . . . . 1.14 114.068 -177.134 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 366' ' ' TYR . . . . . 0.446 ' HD1' HD12 ' A' ' 290' ' ' ILE . 2.9 m-85 -101.4 8.5 42.18 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.797 -0.361 . . . . 1.03 111.158 -176.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 367' ' ' ALA . . . . . 0.723 ' HA ' ' HB ' ' A' ' 342' ' ' ILE . . . -110.76 -119.3 0.29 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.162 -0.472 . . . . 1.07 109.973 175.107 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 82.6 m-85 -86.92 5.9 34.69 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 121.081 0.467 . . . . 1.44 111.238 178.245 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 67.05 -109.06 2.7 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.909 -0.587 . . . . 0.65 112.352 176.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 20.3 pttm -120.71 15.58 11.86 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.774 0.321 . . . . 3.34 110.963 -178.823 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 8.7 tp-100 -83.18 106.99 15.43 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.947 0.403 . . . . 2.88 110.149 178.267 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 372' ' ' ALA . . . . . 0.497 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -75.38 102.03 4.98 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 116.034 -0.53 . . . . 1.39 110.918 179.606 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 76.5 mt -88.9 163.83 33.55 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.706 -0.679 . . . . 1.55 109.254 177.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -61.77 113.98 2.07 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 121.594 1.529 . . . . 1.61 110.69 173.283 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 93.39 -26.66 14.53 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.83 -0.7 . . . . 0.96 112.754 -177.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 376' ' ' ILE . . . . . 0.418 HG21 HD22 ' A' ' 382' ' ' LEU . 39.6 mt -126.5 81.92 67.29 Favored Pre-proline 0 CA--C 1.532 0.288 0 CA-C-O 120.86 0.362 . . . . 1.29 110.978 -178.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 377' ' ' PRO . . . . . 0.497 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 56.1 Cg_endo -76.77 167.58 25.09 Favored 'Trans proline' 0 N--CA 1.459 -0.537 0 C-N-CA 122.413 2.075 . . . . 1.08 112.457 178.126 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 378' ' ' ALA . . . . . . . . . . . . . . . -54.51 145.89 17.51 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.804 -0.635 . . . . 1.52 111.488 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 379' ' ' ASN . . . . . . . . . . . . . 52.5 m-80 73.05 14.25 4.73 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 115.747 -0.661 . . . . 1.97 112.147 176.613 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 66.5 m -78.97 115.03 18.4 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.258 0.551 . . . . 1.91 110.45 175.645 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 381' ' ' GLU . . . . . 0.637 ' HB3' ' HD2' ' A' ' 318' ' ' LYS . 33.0 tt0 -74.33 101.47 4.07 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.421 -0.809 . . . . 1.03 108.865 177.38 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 382' ' ' LEU . . . . . 0.418 HD22 HG21 ' A' ' 376' ' ' ILE . 79.4 mt -85.47 142.07 29.48 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 120.714 0.293 . . . . 1.13 110.897 -174.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 18.8 m -121.89 117.22 25.94 Favored 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 109.732 -0.47 . . . . 1.12 109.732 178.706 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 384' ' ' PHE . . . . . 0.404 ' CD2' HD13 ' A' ' 362' ' ' ILE . 82.5 m-85 -112.67 109.94 19.77 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 121.094 0.474 . . . . 0.4 110.067 -176.81 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -88.5 105.13 17.42 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 108.667 -0.864 . . . . 1.8 108.667 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 386' ' ' VAL . . . . . 0.54 ' HB ' ' CE ' ' A' ' 311' ' ' MET . 12.3 m -124.8 152.07 30.77 Favored 'Isoleucine or valine' 0 C--O 1.235 0.341 0 CA-C-O 121.756 0.788 . . . . 1.13 112.832 -167.208 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 387' ' ' LYS . . . . . 0.694 ' HD2' ' HG2' ' A' ' 357' ' ' GLU . 71.6 tttt -143.7 136.38 27.27 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.1 -0.955 . . . . 3.1 109.583 174.541 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 388' ' ' LEU . . . . . 0.819 HD12 ' HB ' ' A' ' 309' ' ' VAL . 30.7 tp -95.94 131.2 42.55 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.729 -0.471 . . . . 1.05 109.729 -177.487 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 32.9 m -122.16 -8.96 8.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 N-CA-C 112.226 0.454 . . . . 1.2 112.226 -174.202 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 13.9 p -166.94 161.18 14.91 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.003 0.43 . . . . 1.82 111.852 -176.013 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 391' ' ' MET . . . . . 0.574 ' HG2' ' HG2' ' A' ' 392' ' ' LYS . 29.9 ttm -151.51 143.37 23.79 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.403 -0.817 . . . . 1.14 109.428 176.678 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 392' ' ' LYS . . . . . 0.574 ' HG2' ' HG2' ' A' ' 391' ' ' MET . 19.4 pttp . . . . . 0 C--O 1.248 0.989 0 CA-C-O 117.888 -1.054 . . . . 5.51 112.369 179.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.873 0 N-CA-C 112.08 -0.408 . . . . 11.6 112.08 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . 57.46 87.14 0.07 Allowed 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 122.996 0.518 . . . . 9.39 111.62 -178.624 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 278' ' ' MET . . . . . . . . . . . . . 23.4 ptm -78.8 131.54 36.54 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.203 -0.453 . . . . 8.15 110.795 -176.233 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -110.46 118.29 35.88 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.184 -0.462 . . . . 6.73 110.232 176.251 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 40.8 ttmt 69.65 90.94 0.08 OUTLIER Pre-proline 0 C--O 1.237 0.435 0 O-C-N 123.728 0.642 . . . . 7.18 110.579 -179.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -64.61 136.05 48.21 Favored 'Trans proline' 0 C--N 1.349 0.557 0 C-N-CA 123.124 2.549 . . . . 5.4 112.274 -178.452 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 282' ' ' LYS . . . . . . . . . . . . . 39.8 mmtm -93.89 80.38 4.16 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.054 0.454 . . . . 3.88 110.465 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.429 HG23 ' HB3' ' A' ' 293' ' ' GLU . 17.9 p -93.71 132.53 37.97 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 115.703 -0.68 . . . . 1.27 111.081 -179.765 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 15.1 ptpt -140.68 146.18 37.51 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.2 -0.455 . . . . 2.51 110.959 176.527 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . 0.509 HD12 ' HA2' ' A' ' 289' ' ' GLY . 22.1 tp -89.5 129.41 35.99 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.294 -0.866 . . . . 1.52 111.292 -175.823 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.521 HD12 HD11 ' A' ' 292' ' ' ILE . 81.7 mt -105.62 -166.71 1.24 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.975 -0.557 . . . . 1.39 110.284 175.854 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 287' ' ' GLU . . . . . 0.494 ' HG3' ' OH ' ' A' ' 366' ' ' TYR . 8.2 tp10 -51.11 142.0 13.23 Favored 'General case' 0 C--O 1.234 0.28 0 O-C-N 123.706 0.629 . . . . 2.64 111.557 -179.832 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 72.67 -99.63 0.93 Allowed Glycine 0 N--CA 1.446 -0.682 0 CA-C-N 115.551 -0.75 . . . . 1.84 111.37 -174.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . 0.509 ' HA2' HD12 ' A' ' 285' ' ' LEU . . . -153.77 32.91 0.75 Allowed Glycine 0 N--CA 1.443 -0.837 0 N-CA-C 110.428 -1.069 . . . . 1.16 110.428 174.138 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 290' ' ' ILE . . . . . 0.497 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 76.9 mt -74.77 124.41 32.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.564 -0.318 . . . . 1.16 110.394 -176.14 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . 0.599 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 7.8 mt -104.24 136.45 37.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 N-CA-C 109.651 -0.5 . . . . 1.6 109.651 -179.591 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 292' ' ' ILE . . . . . 0.521 HD11 HD12 ' A' ' 286' ' ' LEU . 33.5 pt -133.37 137.28 53.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 120.699 -0.4 . . . . 1.17 111.07 179.481 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 293' ' ' GLU . . . . . 0.591 ' CG ' ' HB3' ' A' ' 359' ' ' ARG . 12.1 pt-20 -139.74 143.3 36.92 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.231 -0.895 . . . . 2.31 109.709 178.336 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -94.0 139.86 30.42 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 120.996 0.427 . . . . 2.36 111.035 179.548 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 295' ' ' ARG . . . . . 0.406 HH11 ' HD2' ' A' ' 295' ' ' ARG . 11.3 mmt85 -114.7 -47.11 2.91 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.569 -0.741 . . . . 3.99 111.414 -174.55 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.554 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 97.6 t -120.9 132.55 70.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.392 -0.367 . . . . 1.31 110.414 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 10.3 p -63.5 137.8 58.27 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.845 -0.616 . . . . 2.46 112.05 -176.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -165.35 132.77 2.76 Favored Glycine 0 N--CA 1.446 -0.659 0 CA-C-N 115.781 -0.645 . . . . 1.04 111.815 179.294 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 11.1 ptpp? -133.44 116.49 16.07 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.255 0.55 . . . . 5.01 109.905 176.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -171.55 -154.1 9.6 Favored Glycine 0 N--CA 1.442 -0.918 0 N-CA-C 111.193 -0.763 . . . . 1.59 111.193 -177.232 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . 0.434 ' O ' ' HA ' ' A' ' 353' ' ' ALA . 26.2 Cg_exo -61.66 133.01 43.01 Favored 'Trans proline' 0 C--O 1.237 0.443 0 C-N-CA 122.625 2.217 . . . . 1.1 111.472 178.233 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 25.0 m80 -101.47 133.48 46.06 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.247 -0.433 . . . . 1.85 111.298 -177.524 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -64.76 126.5 28.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.503 -0.772 . . . . 1.17 111.179 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 38.2 ttpt -136.4 169.77 17.13 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.2 -0.667 . . . . 3.26 109.2 -177.225 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.648 ' HZ3' ' HA2' ' A' ' 337' ' ' GLY . 57.0 tttp -63.07 128.2 34.77 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.912 0.386 . . . . 3.21 110.18 177.051 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 97.6 -4.91 62.0 Favored Glycine 0 N--CA 1.451 -0.347 0 CA-C-N 115.935 -0.575 . . . . 0.7 111.84 -176.756 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 27.4 m -93.74 146.32 23.94 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.708 0.29 . . . . 1.07 110.994 -179.363 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . 0.487 ' HG2' ' HB3' ' A' ' 335' ' ' LYS . 54.6 mtm180 -110.65 104.12 12.77 Favored 'General case' 0 CA--C 1.516 -0.349 0 N-CA-C 109.346 -0.612 . . . . 3.98 109.346 177.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.797 ' HB ' HD12 ' A' ' 388' ' ' LEU . 31.5 m -102.65 147.01 9.73 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 CA-C-O 121.349 0.595 . . . . 1.1 111.944 -173.457 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -118.02 117.21 3.67 Favored Glycine 0 N--CA 1.446 -0.678 0 N-CA-C 109.669 -1.372 . . . . 0.32 109.669 176.068 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 311' ' ' MET . . . . . 0.47 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 21.4 ptm -135.23 177.02 8.14 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.577 0.703 . . . . 1.55 112.729 -169.133 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 64.4 mtt180 -134.47 147.63 50.42 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 107.332 -1.359 . . . . 3.0 107.332 176.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 313' ' ' TYR . . . . . 0.661 ' HB2' HG13 ' A' ' 386' ' ' VAL . 48.6 p90 -164.29 157.92 18.25 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 112.878 0.696 . . . . 1.24 112.878 -172.54 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 62.0 t -125.45 116.18 45.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 114.818 -1.083 . . . . 1.09 109.44 174.411 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -101.43 116.85 5.67 Favored Glycine 0 C--O 1.24 0.475 0 C-N-CA 120.912 -0.661 . . . . 0.32 112.213 -177.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 316' ' ' LYS . . . . . 0.526 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 98.3 mttt -119.41 162.42 18.85 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.372 0.606 . . . . 2.61 111.058 -178.01 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 63.2 mt -88.04 167.13 13.95 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.02 -0.991 . . . . 1.32 109.301 173.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 318' ' ' LYS . . . . . 0.483 ' HD3' ' H ' ' A' ' 381' ' ' GLU . 19.3 pttp -66.51 -8.84 29.16 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.38 0.609 . . . . 2.9 110.299 175.379 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 319' ' ' ASN . . . . . 0.424 HD21 ' HG2' ' A' ' 321' ' ' LYS . 8.3 t30 -86.22 -6.94 58.88 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.678 -0.692 . . . . 2.39 110.302 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 96.47 -12.92 66.13 Favored Glycine 0 N--CA 1.451 -0.303 0 CA-C-N 115.833 -0.621 . . . . 0.69 112.557 178.553 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 321' ' ' LYS . . . . . 0.424 ' HG2' HD21 ' A' ' 319' ' ' ASN . 14.4 mmmm -82.94 132.04 35.17 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.681 0.277 . . . . 2.86 110.903 -177.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.526 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 5.6 p -84.07 134.06 27.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 116.097 -0.501 . . . . 1.96 109.892 177.182 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 34.4 p90 -105.5 -31.73 8.85 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 120.843 -0.343 . . . . 0.56 111.424 179.556 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -148.67 151.83 35.62 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 110.062 -0.347 . . . . 1.68 110.062 178.274 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . 0.588 ' N ' ' HD3' ' A' ' 325' ' ' LYS . 0.0 OUTLIER -160.19 135.24 7.89 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.96 0.41 . . . . 2.55 110.11 -177.908 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 49.0 m-80 -138.51 118.19 13.1 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.512 -0.551 . . . . 1.92 109.512 179.415 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 6.6 t -162.26 -43.49 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.576 -0.284 . . . . 2.06 110.965 -178.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.409 ' O ' ' HG3' ' A' ' 328' ' ' LYS . 6.9 ptpp? -99.51 120.64 39.96 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.862 -0.421 . . . . 3.15 109.862 177.167 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.4 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 79.13 -37.18 1.96 Allowed Glycine 0 CA--C 1.52 0.367 0 C-N-CA 121.139 -0.553 . . . . 1.17 113.034 178.02 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 32.7 mmtp -103.64 100.58 19.86 Favored Pre-proline 0 C--N 1.33 -0.28 0 N-CA-C 111.801 0.297 . . . . 2.56 111.801 -178.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 331' ' ' PRO . . . . . 0.4 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 92.4 Cg_endo -87.54 127.4 2.36 Favored 'Trans proline' 0 N--CA 1.45 -1.032 0 C-N-CA 122.456 2.104 . . . . 0.73 110.775 168.144 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 82.9 t80 -102.03 117.63 35.2 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.57 -0.452 . . . . 0.76 110.408 -178.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 87.5 t -114.61 122.5 68.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.828 -0.624 . . . . 1.14 110.076 179.343 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.47 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 14.1 p90 -138.49 155.77 48.13 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.713 -0.477 . . . . 0.48 109.713 175.325 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 335' ' ' LYS . . . . . 0.487 ' HB3' ' HG2' ' A' ' 308' ' ' ARG . 0.0 OUTLIER -108.99 135.17 50.6 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.306 -0.407 . . . . 3.11 111.117 179.861 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 9.5 mp -77.83 110.74 12.98 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.662 -0.699 . . . . 1.2 109.471 179.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 337' ' ' GLY . . . . . 0.648 ' HA2' ' HZ3' ' A' ' 305' ' ' LYS . . . 177.92 -62.72 0.09 OUTLIER Glycine 0 N--CA 1.444 -0.777 0 C-N-CA 120.71 -0.757 . . . . 1.02 111.594 -178.271 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 338' ' ' GLN . . . . . . . . . . . . . 20.8 pt20 -96.56 153.13 18.02 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.055 0.455 . . . . 3.1 110.598 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -88.84 59.74 3.94 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 121.022 -0.609 . . . . 0.98 112.372 -174.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 340' ' ' GLU . . . . . 0.458 ' CD ' ' HZ3' ' A' ' 335' ' ' LYS . 21.8 pt-20 -87.83 -20.82 25.54 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.522 0.677 . . . . 2.09 109.62 174.217 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 22.1 m -95.81 167.76 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.084 -0.962 . . . . 1.27 108.999 174.129 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 342' ' ' ILE . . . . . 0.592 ' HB ' ' HA ' ' A' ' 367' ' ' ALA . 22.1 pt -71.74 147.49 10.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 N-CA-C 109.13 -0.693 . . . . 1.08 109.13 174.168 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 1.3 mtmt -49.92 -40.44 43.33 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 112.724 0.639 . . . . 3.46 112.724 -171.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -55.64 -25.31 42.79 Favored Glycine 0 CA--C 1.524 0.623 0 C-N-CA 121.333 -0.46 . . . . 0.32 113.825 179.014 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 8.2 m95 -74.77 -59.31 2.79 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.915 0.358 . . . . 0.44 111.848 -179.501 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -49.68 -36.99 26.95 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-O 121.082 0.468 . . . . 1.75 111.197 177.729 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 60.8 mt -80.55 -52.28 14.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.821 -0.627 . . . . 1.18 111.738 -178.529 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -67.83 -35.57 85.25 Favored Glycine 0 CA--C 1.519 0.287 0 C-N-CA 121.192 -0.528 . . . . 0.37 113.812 -177.406 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 91.7 t -75.8 -23.97 16.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.699 0.285 . . . . 1.08 110.906 -179.077 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.79 96.84 0.3 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.126 0.489 . . . . 1.09 110.372 177.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 121.49 5.76 9.14 Favored Glycine 0 CA--C 1.52 0.367 0 C-N-CA 121.127 -0.559 . . . . 0.45 112.648 -175.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 352' ' ' MET . . . . . . . . . . . . . 85.6 mmm -84.99 138.57 32.38 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.68 0.276 . . . . 1.3 110.995 175.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 353' ' ' ALA . . . . . 0.434 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -106.19 141.82 36.91 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 116.077 -0.51 . . . . 1.33 111.214 -177.865 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 58.9 t -57.49 120.65 3.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.077 -0.511 . . . . 1.24 110.4 173.188 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 104.08 -12.11 52.27 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 121.188 -0.53 . . . . 0.44 112.087 179.745 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -102.44 143.5 15.91 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.845 -0.693 . . . . 0.37 112.407 -177.347 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 357' ' ' GLU . . . . . 0.554 ' HB3' ' HB ' ' A' ' 296' ' ' VAL . 32.5 tt0 -117.08 133.39 56.06 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 110.192 -0.299 . . . . 1.63 110.192 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 358' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -144.81 144.13 30.99 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.213 0.53 . . . . 1.53 111.113 -179.088 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 359' ' ' ARG . . . . . 0.593 ' HD2' HG23 ' A' ' 383' ' ' THR . 22.9 tpp85 -88.82 119.35 29.23 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.451 -0.795 . . . . 3.26 110.113 176.255 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 58.3 mt -105.33 121.23 57.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.962 -0.385 . . . . 1.13 109.962 177.418 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 361' ' ' VAL . . . . . 0.599 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 44.7 t -101.88 116.94 46.42 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 N-CA-C 109.471 -0.566 . . . . 1.14 109.471 176.793 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 362' ' ' ILE . . . . . 0.494 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 59.0 mt -113.25 109.38 51.74 Favored Pre-proline 0 C--N 1.322 -0.595 0 CA-C-N 116.42 -0.354 . . . . 1.13 111.346 -173.495 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 363' ' ' PRO . . . . . 0.527 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 10.2 Cg_endo -53.56 152.35 21.57 Favored 'Trans proline' 0 C--O 1.236 0.401 0 C-N-CA 123.158 2.572 . . . . 1.05 112.23 173.098 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 364' ' ' ALA . . . . . . . . . . . . . . . -52.09 -49.03 86.71 Favored Pre-proline 0 CA--C 1.542 0.639 0 N-CA-C 113.375 0.88 . . . . 1.16 113.375 -175.802 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 365' ' ' PRO . . . . . 0.527 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 53.4 Cg_exo -53.83 -32.19 65.55 Favored 'Trans proline' 0 C--N 1.364 1.371 0 C-N-CA 122.482 2.121 . . . . 1.14 113.754 -177.062 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 366' ' ' TYR . . . . . 0.494 ' OH ' ' HG3' ' A' ' 287' ' ' GLU . 4.9 m-85 -94.66 9.71 37.73 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.217 0.532 . . . . 1.03 110.942 -175.622 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 367' ' ' ALA . . . . . 0.592 ' HA ' ' HB ' ' A' ' 342' ' ' ILE . . . -120.1 -109.22 0.35 Allowed 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.592 -0.731 . . . . 1.07 109.805 171.58 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 92.3 m-85 -81.58 -12.59 58.71 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 121.003 0.43 . . . . 1.44 111.534 179.404 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 369' ' ' GLY . . . . . 0.517 ' HA2' ' HA ' ' A' ' 365' ' ' PRO . . . 86.63 -114.1 4.02 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.846 -0.692 . . . . 0.65 112.789 175.658 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 43.6 mttp -115.05 14.65 17.15 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.012 0.434 . . . . 3.34 110.479 -175.454 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 8.5 tp-100 -87.81 117.13 26.44 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.003 -0.544 . . . . 2.88 110.645 -176.653 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 372' ' ' ALA . . . . . 0.415 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -87.56 98.89 11.66 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.069 -0.514 . . . . 1.39 110.67 177.814 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 76.9 mt -90.05 157.01 46.24 Favored Pre-proline 0 C--N 1.322 -0.619 0 CA-C-N 115.962 -0.563 . . . . 1.55 109.951 178.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -61.21 114.25 2.11 Favored 'Trans proline' 0 N--CA 1.459 -0.527 0 C-N-CA 121.803 1.669 . . . . 1.61 110.603 171.668 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 96.57 -30.39 8.88 Favored Glycine 0 N--CA 1.448 -0.559 0 CA-C-N 115.879 -0.6 . . . . 0.96 112.22 -176.264 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 23.4 mt -129.26 78.26 76.26 Favored Pre-proline 0 C--N 1.329 -0.299 0 N-CA-C 110.145 -0.317 . . . . 1.29 110.145 -179.475 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 377' ' ' PRO . . . . . 0.415 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 4.1 Cg_exo -76.86 166.21 27.29 Favored 'Trans proline' 0 N--CA 1.459 -0.54 0 C-N-CA 122.674 2.249 . . . . 1.08 112.143 -179.375 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 378' ' ' ALA . . . . . 0.473 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -59.14 152.86 19.38 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.293 -0.412 . . . . 1.52 110.695 176.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 379' ' ' ASN . . . . . 0.473 ' HB2' ' O ' ' A' ' 378' ' ' ALA . 16.8 m120 74.95 4.88 4.33 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 123.012 0.525 . . . . 1.97 111.492 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 49.1 m -83.97 94.6 8.31 Favored 'General case' 0 N--CA 1.451 -0.392 0 CA-C-O 121.335 0.588 . . . . 1.91 110.127 176.323 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 381' ' ' GLU . . . . . 0.483 ' H ' ' HD3' ' A' ' 318' ' ' LYS . 19.0 tt0 -67.04 112.34 4.33 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 114.972 -1.013 . . . . 1.03 109.617 179.354 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 82.4 mt -78.02 140.98 39.18 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.092 -0.504 . . . . 1.13 110.952 -173.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 383' ' ' THR . . . . . 0.593 HG23 ' HD2' ' A' ' 359' ' ' ARG . 25.1 m -120.19 119.54 33.54 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 109.29 -0.633 . . . . 1.12 109.29 -179.182 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -115.63 114.62 25.15 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.05 0.452 . . . . 0.4 111.19 -175.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 20.8 t70 -91.82 104.47 16.91 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 107.885 -1.154 . . . . 1.8 107.885 174.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 386' ' ' VAL . . . . . 0.661 HG13 ' HB2' ' A' ' 313' ' ' TYR . 17.3 m -129.71 147.61 33.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 112.46 0.541 . . . . 1.13 112.46 -167.097 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 387' ' ' LYS . . . . . 0.447 ' HB3' ' HA ' ' A' ' 357' ' ' GLU . 23.7 pttt -144.74 149.91 36.35 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.803 -0.635 . . . . 3.1 111.271 170.804 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 388' ' ' LEU . . . . . 0.797 HD12 ' HB ' ' A' ' 309' ' ' VAL . 26.9 tp -99.2 138.4 36.35 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.274 -0.875 . . . . 1.05 109.244 -176.702 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 31.8 m -128.83 -8.34 3.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 112.511 0.56 . . . . 1.2 112.511 -174.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 74.2 m -161.55 157.92 25.57 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.624 0.249 . . . . 1.82 110.837 -179.491 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 391' ' ' MET . . . . . . . . . . . . . 39.7 ttm -155.4 132.03 10.5 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-N 116.333 -0.394 . . . . 1.14 110.881 -178.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 66.6 mttm . . . . . 0 C--O 1.25 1.094 0 CA-C-O 118.432 -0.794 . . . . 5.51 109.603 176.781 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.55 0 N-CA-C 111.482 -0.647 . . . . 11.6 111.482 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -143.05 155.8 44.7 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.754 0.311 . . . . 9.39 110.521 -178.086 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 278' ' ' MET . . . . . . . . . . . . . 12.2 tpt -96.94 104.41 16.42 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.127 -0.488 . . . . 8.15 110.158 179.565 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -90.77 96.79 10.82 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.244 -0.434 . . . . 6.73 110.501 -178.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . 0.45 ' HA ' ' HD3' ' A' ' 281' ' ' PRO . 35.2 mtmm 70.98 133.32 0.04 OUTLIER Pre-proline 0 N--CA 1.467 0.384 0 O-C-N 124.036 0.835 . . . . 7.18 111.375 -177.105 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 281' ' ' PRO . . . . . 0.45 ' HD3' ' HA ' ' A' ' 280' ' ' LYS . 27.3 Cg_exo -62.38 126.76 19.2 Favored 'Trans proline' 0 C--O 1.237 0.427 0 C-N-CA 122.397 2.065 . . . . 5.4 111.355 177.37 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 282' ' ' LYS . . . . . . . . . . . . . 27.4 mmtp -90.22 103.76 16.41 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.264 0.554 . . . . 3.88 110.299 -176.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.536 ' HA ' ' O ' ' A' ' 292' ' ' ILE . 24.0 p -111.67 137.02 50.11 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-N 115.451 -0.795 . . . . 1.27 111.866 -175.677 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 284' ' ' LYS . . . . . 0.501 ' HB2' ' CG1' ' A' ' 292' ' ' ILE . 13.5 mmmm -110.0 137.94 47.08 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.94 -0.763 . . . . 2.51 108.94 174.762 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . 0.414 HD12 ' HA2' ' A' ' 289' ' ' GLY . 42.8 tp -100.26 121.71 41.91 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.934 0.397 . . . . 1.52 110.59 -178.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.639 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 88.3 mt -108.54 -164.56 0.96 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.818 -0.628 . . . . 1.39 110.477 -178.621 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -64.64 145.38 56.26 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 116.099 -0.5 . . . . 2.64 111.749 -178.533 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.633 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 65.76 8.97 43.49 Favored Glycine 0 C--N 1.329 0.154 0 CA-C-N 115.925 -0.58 . . . . 1.84 113.7 177.605 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . 0.414 ' HA2' HD12 ' A' ' 285' ' ' LEU . . . 90.95 12.29 60.55 Favored Glycine 0 N--CA 1.441 -0.988 0 C-N-CA 120.516 -0.849 . . . . 1.16 113.067 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 290' ' ' ILE . . . . . 0.639 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 94.9 mt -60.67 127.44 20.22 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.139 0 CA-C-N 117.373 0.587 . . . . 1.16 110.204 177.526 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . 0.51 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 18.1 mt -113.29 139.82 36.63 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 116.37 -0.377 . . . . 1.6 110.181 -178.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 292' ' ' ILE . . . . . 0.536 ' O ' ' HA ' ' A' ' 283' ' ' THR . 22.5 pt -128.34 127.06 66.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 120.891 0.377 . . . . 1.17 109.987 175.369 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 293' ' ' GLU . . . . . . . . . . . . . 4.6 tm-20 -105.25 108.44 19.95 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 108.812 -0.81 . . . . 2.31 108.812 -179.443 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -78.11 101.55 7.06 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-O 121.156 0.503 . . . . 2.36 110.576 -171.195 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 295' ' ' ARG . . . . . . . . . . . . . 6.2 tpt180 -88.08 -59.41 2.25 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.184 -0.916 . . . . 3.99 111.879 -170.314 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . . . . . . . . . 91.9 t -120.34 132.85 68.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.592 -0.277 . . . . 1.31 110.77 -178.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 6.8 p -92.18 120.55 32.87 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.106 -0.497 . . . . 2.46 110.915 178.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -126.96 -165.03 11.84 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.691 -0.766 . . . . 1.04 112.788 -175.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . 0.586 ' O ' ' HB2' ' A' ' 353' ' ' ALA . 74.1 mmtt -73.38 151.75 41.09 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.135 -0.691 . . . . 5.01 109.135 177.706 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -119.75 79.72 0.32 Allowed Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 119.316 -1.421 . . . . 1.59 115.074 -168.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . 0.597 ' HD2' ' H ' ' A' ' 354' ' ' VAL . 2.4 Cg_endo -85.84 133.69 4.35 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 122.735 2.29 . . . . 1.1 109.062 160.234 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 33.6 m170 -92.16 116.46 28.97 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 120.438 -0.505 . . . . 1.85 112.245 -171.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -66.24 121.2 14.67 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.413 -0.812 . . . . 1.17 110.157 173.14 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 31.9 mtmm -123.12 179.2 4.77 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.468 -0.333 . . . . 3.26 110.377 -176.123 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 61.9 tttp -63.9 113.68 3.6 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.391 -0.368 . . . . 3.21 110.349 179.618 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 98.62 -7.1 61.16 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.888 -0.673 . . . . 0.7 112.547 -179.276 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 38.9 m -77.61 145.55 36.72 Favored 'General case' 0 CA--C 1.534 0.346 0 O-C-N 122.776 -0.25 . . . . 1.07 110.547 -179.499 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 73.4 mtt180 -105.25 113.87 27.71 Favored 'General case' 0 CA--C 1.519 -0.227 0 N-CA-C 109.565 -0.531 . . . . 3.98 109.565 -177.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.703 ' HB ' HD12 ' A' ' 388' ' ' LEU . 30.2 m -107.28 139.02 30.44 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 CA-C-O 121.273 0.559 . . . . 1.1 111.348 178.498 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -109.88 115.39 4.16 Favored Glycine 0 N--CA 1.445 -0.717 0 N-CA-C 110.23 -1.148 . . . . 0.32 110.23 175.278 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 311' ' ' MET . . . . . 0.586 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 22.4 ptm -136.7 177.44 7.85 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.399 0.619 . . . . 1.55 112.153 -169.659 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 312' ' ' ARG . . . . . 0.506 ' HD3' ' O ' ' A' ' 327' ' ' THR . 98.9 mtt180 -137.05 147.01 45.89 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 107.677 -1.231 . . . . 3.0 107.677 175.341 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 313' ' ' TYR . . . . . 0.423 ' HA ' ' O ' ' A' ' 385' ' ' ASP . 25.2 p90 -161.49 159.93 28.55 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 112.941 0.719 . . . . 1.24 112.941 -169.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 48.7 t -126.41 120.74 57.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 114.839 -1.073 . . . . 1.09 109.68 174.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -94.64 106.03 3.36 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.388 -0.434 . . . . 0.32 112.19 -177.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 316' ' ' LYS . . . . . 0.541 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 84.3 mttt -114.09 156.31 24.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.064 0.459 . . . . 2.61 110.932 -177.038 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 96.5 mt -89.31 163.11 15.49 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.045 -0.525 . . . . 1.32 109.585 172.103 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 318' ' ' LYS . . . . . 0.698 ' HD3' ' HB3' ' A' ' 381' ' ' GLU . 61.7 pttt -65.68 -11.55 46.07 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 121.01 0.433 . . . . 2.9 111.338 178.405 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 9.0 t30 -87.98 -7.88 56.45 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.083 0.468 . . . . 2.39 110.216 178.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 101.17 -15.61 57.69 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 121.09 -0.576 . . . . 0.69 112.197 -178.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 59.0 tptt -70.89 117.28 12.19 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.644 0.259 . . . . 2.86 110.73 -179.272 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.541 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 6.1 p -85.58 131.77 33.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 N-CA-C 110.028 -0.36 . . . . 1.96 110.028 176.819 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 31.6 p90 -106.35 -50.09 3.22 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 120.862 -0.335 . . . . 0.56 110.991 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 324' ' ' ASP . . . . . 0.486 ' C ' ' HD3' ' A' ' 325' ' ' LYS . 12.0 t70 -123.86 154.32 39.81 Favored 'General case' 0 CA--C 1.513 -0.446 0 N-CA-C 109.492 -0.559 . . . . 1.68 109.492 -179.302 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . 0.492 ' N ' ' HD3' ' A' ' 325' ' ' LYS . 0.0 OUTLIER -167.9 131.1 1.61 Allowed 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.959 0.409 . . . . 2.55 111.143 -174.147 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 1.9 p30 -146.52 115.78 7.03 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.684 0.754 . . . . 1.92 109.719 170.336 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 327' ' ' THR . . . . . 0.506 ' O ' ' HD3' ' A' ' 312' ' ' ARG . 1.7 p -148.96 -47.17 0.14 Allowed 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 114.935 -1.029 . . . . 2.06 110.922 -172.717 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.587 ' HZ3' ' HB2' ' A' ' 328' ' ' LYS . 0.1 OUTLIER -73.66 93.34 2.06 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.492 0.663 . . . . 3.15 111.534 -178.111 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.463 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 75.37 -11.5 8.96 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 115.508 -0.769 . . . . 1.17 113.629 175.288 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 45.9 mtpt -103.25 100.63 18.49 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-N 117.32 0.56 . . . . 2.56 111.41 -177.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 331' ' ' PRO . . . . . 0.463 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 86.0 Cg_endo -87.76 139.7 4.83 Favored 'Trans proline' 0 N--CA 1.452 -0.953 0 C-N-CA 122.749 2.299 . . . . 0.73 111.854 170.664 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 79.2 t80 -109.84 128.14 55.14 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.253 -0.647 . . . . 0.76 109.253 176.359 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 61.9 t -115.22 119.6 62.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 N-CA-C 109.839 -0.43 . . . . 1.14 109.839 -176.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.586 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 21.2 p90 -138.92 166.59 24.07 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.853 -0.425 . . . . 0.48 109.853 179.66 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 335' ' ' LYS . . . . . . . . . . . . . 58.6 pttt -111.12 140.49 45.62 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.16 -0.473 . . . . 3.11 110.403 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 11.2 mp -71.53 139.0 49.32 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.729 -0.471 . . . . 1.2 109.729 175.246 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 94.76 5.95 60.99 Favored Glycine 0 N--CA 1.442 -0.93 0 C-N-CA 120.791 -0.719 . . . . 1.02 113.002 -174.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 338' ' ' GLN . . . . . 0.564 HE21 HG11 ' A' ' 341' ' ' VAL . 13.7 pt20 -85.16 148.86 25.9 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 117.381 0.591 . . . . 3.1 109.558 176.165 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -90.37 15.23 60.49 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.75 -0.738 . . . . 0.98 114.407 -166.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -109.92 -9.07 14.79 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 117.646 0.723 . . . . 2.09 111.481 178.397 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 341' ' ' VAL . . . . . 0.564 HG11 HE21 ' A' ' 338' ' ' GLN . 26.3 m -95.71 146.29 7.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 C-N-CA 120.769 -0.372 . . . . 1.27 110.144 178.697 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 17.4 pt -73.58 157.1 6.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 109.965 -0.383 . . . . 1.08 109.965 178.678 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . 0.448 ' HA ' ' HE3' ' A' ' 343' ' ' LYS . 0.0 OUTLIER -62.74 -35.26 79.19 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 111.626 0.232 . . . . 3.46 111.626 -175.895 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -52.28 -42.15 55.62 Favored Glycine 0 C--O 1.228 -0.251 0 C-N-CA 120.774 -0.726 . . . . 0.32 112.363 174.243 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 4.2 m95 -68.8 -60.34 2.46 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.819 0.342 . . . . 0.44 111.043 176.441 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -51.66 -33.97 35.99 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.594 -0.73 . . . . 1.75 112.121 -177.477 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 60.0 mt -85.19 -52.53 12.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 116.4 -0.363 . . . . 1.18 111.283 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -60.47 -35.05 87.94 Favored Glycine 0 CA--C 1.524 0.628 0 C-N-CA 121.261 -0.495 . . . . 0.37 113.794 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 349' ' ' VAL . . . . . 0.409 ' O ' ' HB2' ' A' ' 352' ' ' MET . 93.1 t -77.68 -18.27 14.05 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 CA-C-O 120.994 0.426 . . . . 1.08 111.382 -179.311 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -64.22 100.34 0.33 Allowed 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.157 0.503 . . . . 1.09 110.634 177.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 105.52 12.05 27.57 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.914 -0.66 . . . . 0.45 112.205 -177.014 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 352' ' ' MET . . . . . 0.523 ' HE3' ' HG2' ' A' ' 358' ' ' ARG . 0.0 OUTLIER -66.58 143.89 56.76 Favored 'General case' 0 C--N 1.331 -0.216 0 N-CA-C 109.79 -0.448 . . . . 1.3 109.79 177.675 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 353' ' ' ALA . . . . . 0.586 ' HB2' ' O ' ' A' ' 299' ' ' LYS . . . -104.06 127.06 51.61 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.321 -0.399 . . . . 1.33 111.715 -173.082 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 354' ' ' VAL . . . . . 0.597 ' H ' ' HD2' ' A' ' 301' ' ' PRO . 98.3 t -64.84 112.97 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.239 0.542 . . . . 1.24 110.743 174.504 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 109.96 -10.88 31.97 Favored Glycine 0 N--CA 1.442 -0.9 0 N-CA-C 111.313 -0.715 . . . . 0.44 111.313 -176.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -101.54 159.77 18.38 Favored Glycine 0 N--CA 1.442 -0.952 0 C-N-CA 121.048 -0.596 . . . . 0.37 112.302 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 357' ' ' GLU . . . . . 0.854 ' HB2' ' HD3' ' A' ' 387' ' ' LYS . 43.3 tt0 -135.35 140.97 45.47 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.491 -0.559 . . . . 1.63 109.491 -179.505 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 358' ' ' ARG . . . . . 0.523 ' HG2' ' HE3' ' A' ' 352' ' ' MET . 5.9 ptp180 -156.2 144.91 20.2 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.026 0.441 . . . . 1.53 110.861 177.182 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 359' ' ' ARG . . . . . . . . . . . . . 82.8 mtm180 -91.44 120.02 31.91 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 115.968 -0.56 . . . . 3.26 110.444 179.174 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 360' ' ' ILE . . . . . 0.534 HG12 HG23 ' A' ' 292' ' ' ILE . 62.3 mt -101.68 119.32 49.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-N 115.734 -0.666 . . . . 1.13 110.638 -176.476 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 361' ' ' VAL . . . . . 0.51 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 46.3 t -103.48 112.74 38.09 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 108.972 -0.751 . . . . 1.14 108.972 177.025 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 362' ' ' ILE . . . . . . . . . . . . . 57.6 mt -109.74 102.24 49.47 Favored Pre-proline 0 C--N 1.319 -0.723 0 CA-C-N 116.037 -0.528 . . . . 1.13 110.999 -174.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 363' ' ' PRO . . . . . 0.496 ' HA ' ' HG3' ' A' ' 381' ' ' GLU . 71.2 Cg_exo -54.39 155.48 16.29 Favored 'Trans proline' 0 N--CA 1.459 -0.559 0 C-N-CA 122.532 2.155 . . . . 1.05 112.206 171.231 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 364' ' ' ALA . . . . . 0.532 ' N ' ' HD2' ' A' ' 365' ' ' PRO . . . -46.03 -50.1 37.5 Favored Pre-proline 0 C--N 1.327 -0.41 0 N-CA-C 114.364 1.246 . . . . 1.16 114.364 -174.743 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 365' ' ' PRO . . . . . 0.532 ' HD2' ' N ' ' A' ' 364' ' ' ALA . 9.8 Cg_endo -52.53 -31.58 49.58 Favored 'Trans proline' 0 C--N 1.36 1.168 0 C-N-CA 122.685 2.256 . . . . 1.14 114.387 -172.144 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 366' ' ' TYR . . . . . 0.633 ' CE2' ' HA3' ' A' ' 288' ' ' GLY . 9.6 m-85 -101.62 13.46 34.86 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-O 121.017 0.437 . . . . 1.03 112.035 -176.708 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -126.59 -108.05 0.31 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.963 -0.562 . . . . 1.07 110.563 173.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 40.6 m-85 -84.08 -21.83 31.37 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.821 0.343 . . . . 1.44 111.211 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 70.68 -118.1 7.47 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.841 -0.695 . . . . 0.65 112.15 -178.14 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 370' ' ' LYS . . . . . 0.581 ' HA ' ' HB2' ' A' ' 378' ' ' ALA . 19.4 ptmt -101.77 17.39 23.11 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.975 0.416 . . . . 3.34 110.735 178.863 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 59.4 tt0 -84.86 102.58 13.2 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.941 -0.572 . . . . 2.88 110.154 176.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 372' ' ' ALA . . . . . . . . . . . . . . . -81.68 108.25 15.09 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.873 0.368 . . . . 1.39 111.202 177.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 86.6 mt -90.02 159.33 42.87 Favored Pre-proline 0 C--N 1.322 -0.626 0 N-CA-C 109.088 -0.708 . . . . 1.55 109.088 175.193 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -62.26 114.24 2.25 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 121.656 1.57 . . . . 1.61 110.555 172.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 96.26 -29.28 10.4 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.67 -0.776 . . . . 0.96 112.439 -178.155 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 43.3 mt -128.36 86.66 57.27 Favored Pre-proline 0 C--N 1.332 -0.152 0 N-CA-C 110.011 -0.366 . . . . 1.29 110.011 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 377' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -80.03 168.0 19.37 Favored 'Trans proline' 0 N--CA 1.462 -0.354 0 C-N-CA 122.724 2.283 . . . . 1.08 113.017 -176.579 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 378' ' ' ALA . . . . . 0.581 ' HB2' ' HA ' ' A' ' 370' ' ' LYS . . . -52.95 150.16 5.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.5 -0.773 . . . . 1.52 111.703 178.73 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 379' ' ' ASN . . . . . 0.441 ' HA ' ' HB1' ' A' ' 364' ' ' ALA . 49.9 m-80 70.91 15.14 6.82 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 115.473 -0.785 . . . . 1.97 111.265 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 21.5 t -76.67 125.98 30.19 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 109.587 -0.523 . . . . 1.91 109.587 175.156 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 381' ' ' GLU . . . . . 0.698 ' HB3' ' HD3' ' A' ' 318' ' ' LYS . 27.2 tt0 -102.24 112.57 25.32 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 108.67 -0.863 . . . . 1.03 108.67 -179.01 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 75.8 mt -86.26 146.53 26.48 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 116.179 -0.464 . . . . 1.13 111.12 -172.709 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 63.0 m -123.52 122.84 39.24 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.386 -0.598 . . . . 1.12 109.386 173.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 76.8 m-85 -119.84 111.71 18.32 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 116.483 -0.326 . . . . 0.4 111.079 -177.01 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 385' ' ' ASP . . . . . 0.423 ' O ' ' HA ' ' A' ' 313' ' ' TYR . 3.6 m-20 -72.54 104.18 3.77 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 107.924 -1.139 . . . . 1.8 107.924 167.834 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 386' ' ' VAL . . . . . 0.503 ' HB ' ' CE ' ' A' ' 311' ' ' MET . 32.2 m -119.11 135.61 58.97 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.426 0.631 . . . . 1.13 111.012 -176.227 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 387' ' ' LYS . . . . . 0.854 ' HD3' ' HB2' ' A' ' 357' ' ' GLU . 21.6 ttpt -141.32 128.65 21.11 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.296 -0.865 . . . . 3.1 109.449 178.44 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 388' ' ' LEU . . . . . 0.703 HD12 ' HB ' ' A' ' 309' ' ' VAL . 22.6 tp -95.04 136.76 34.97 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.932 -0.576 . . . . 1.05 109.575 -172.65 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 35.8 m -126.0 -5.0 5.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 N-CA-C 112.392 0.516 . . . . 1.2 112.392 -174.654 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 11.3 p -169.15 157.41 7.7 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.816 -0.354 . . . . 1.82 111.473 -177.444 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 391' ' ' MET . . . . . 0.487 ' HE3' HG13 ' A' ' 309' ' ' VAL . 34.1 ttm -160.89 139.11 9.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.16 -0.473 . . . . 1.14 110.485 177.448 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 18.2 tptm . . . . . 0 C--O 1.246 0.892 0 CA-C-O 117.961 -1.019 . . . . 5.51 111.402 175.167 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.616 0 N-CA-C 111.609 -0.597 . . . . 11.6 111.609 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -90.04 -54.98 3.8 Favored 'General case' 0 C--N 1.324 -0.542 0 O-C-N 122.888 -0.184 . . . . 9.39 111.203 -176.336 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 278' ' ' MET . . . . . . . . . . . . . 13.7 tpt 61.53 101.23 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.212 0 O-C-N 123.926 0.766 . . . . 8.15 109.982 -172.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -60.19 -27.86 67.48 Favored 'General case' 0 CA--C 1.515 -0.38 0 CA-C-N 115.977 -0.556 . . . . 6.73 112.061 -173.617 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 14.6 tppt? -167.37 108.53 0.61 Allowed Pre-proline 0 C--N 1.31 -1.134 0 CA-C-N 115.451 -0.795 . . . . 7.18 109.888 179.259 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_exo -61.93 124.84 15.23 Favored 'Trans proline' 0 C--O 1.235 0.364 0 C-N-CA 122.69 2.26 . . . . 5.4 111.726 179.286 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 282' ' ' LYS . . . . . . . . . . . . . 32.4 mmmt -124.78 88.97 2.98 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.85 -0.614 . . . . 3.88 109.588 -176.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.451 ' HA ' ' O ' ' A' ' 292' ' ' ILE . 16.9 p -105.91 145.85 30.74 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.651 -0.704 . . . . 1.27 111.412 -175.594 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 28.2 mmtp -127.46 139.74 52.61 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.729 -0.669 . . . . 2.51 109.629 175.821 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . 0.445 HD12 ' HA2' ' A' ' 289' ' ' GLY . 37.6 tp -96.28 121.1 37.71 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.909 -0.587 . . . . 1.52 110.217 179.539 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.645 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 95.2 mt -105.83 -171.73 1.96 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.912 -0.586 . . . . 1.39 110.378 -179.413 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 287' ' ' GLU . . . . . 0.458 ' HG3' ' OH ' ' A' ' 366' ' ' TYR . 4.9 tp10 -64.51 145.37 56.22 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.889 -0.596 . . . . 2.64 111.105 -176.381 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.405 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 70.93 7.19 61.65 Favored Glycine 0 C--N 1.332 0.31 0 C-N-CA 121.055 -0.593 . . . . 1.84 113.126 -178.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . 0.445 ' HA2' HD12 ' A' ' 285' ' ' LEU . . . 84.81 19.93 58.83 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.858 -0.687 . . . . 1.16 113.216 -179.613 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 290' ' ' ILE . . . . . 0.645 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 96.1 mt -66.39 126.46 25.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 109.985 -0.376 . . . . 1.16 109.985 177.557 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 14.8 mt -110.53 137.14 44.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 N-CA-C 109.726 -0.472 . . . . 1.6 109.726 -178.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 292' ' ' ILE . . . . . 0.451 ' O ' ' HA ' ' A' ' 283' ' ' THR . 21.7 pt -127.02 128.24 70.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-O 121.054 0.454 . . . . 1.17 111.069 179.626 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 293' ' ' GLU . . . . . 0.722 ' HB3' ' HB3' ' A' ' 359' ' ' ARG . 6.6 tp10 -104.62 105.54 15.67 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.177 -1.046 . . . . 2.31 108.177 174.223 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -78.02 110.16 12.71 Favored 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 120.562 -0.455 . . . . 2.36 109.816 -172.221 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 295' ' ' ARG . . . . . 0.68 ' HB2' ' HG3' ' A' ' 357' ' ' GLU . 14.6 mmm180 -78.05 -59.66 2.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.889 -0.596 . . . . 3.99 110.855 -171.304 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.52 ' HB ' ' HG2' ' A' ' 357' ' ' GLU . 97.8 t -137.16 119.06 18.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 C-N-CA 121.141 -0.223 . . . . 1.31 110.626 177.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 14.9 p -68.27 108.04 3.04 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 116.079 -0.51 . . . . 2.46 110.494 176.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -94.91 157.39 22.17 Favored Glycine 0 N--CA 1.442 -0.926 0 C-N-CA 120.764 -0.731 . . . . 1.04 111.56 178.677 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . 0.402 ' HE3' ' HB3' ' A' ' 299' ' ' LYS . 18.3 ttpp -115.75 111.03 19.94 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 109.764 -0.458 . . . . 5.01 109.764 178.535 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -171.72 -162.39 23.91 Favored Glycine 0 N--CA 1.44 -1.096 0 N-CA-C 111.105 -0.798 . . . . 1.59 111.105 179.742 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . 0.405 ' HD2' ' HB ' ' A' ' 354' ' ' VAL . 21.6 Cg_exo -65.76 133.33 33.59 Favored 'Trans proline' 0 N--CA 1.461 -0.394 0 C-N-CA 122.496 2.131 . . . . 1.1 111.661 175.703 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 302' ' ' HIS . . . . . 0.514 ' HA ' ' O ' ' A' ' 352' ' ' MET . 64.4 m80 -89.01 133.69 34.25 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.116 0.484 . . . . 1.85 110.579 -179.706 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -87.17 129.25 35.02 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.773 -0.649 . . . . 1.17 111.621 -177.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 59.7 pttt -124.34 -176.3 3.48 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.5 -0.555 . . . . 3.26 109.5 174.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.702 ' HG3' ' HA3' ' A' ' 337' ' ' GLY . 50.7 tttm -66.98 133.66 50.4 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.028 0.442 . . . . 3.21 110.229 -178.527 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 91.96 -8.91 77.63 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 121.064 -0.589 . . . . 0.7 112.669 -176.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 25.6 m -82.06 145.51 30.15 Favored 'General case' 0 CA--C 1.535 0.365 0 CA-C-O 120.688 0.28 . . . . 1.07 110.766 -178.689 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 89.6 mtt180 -108.33 103.23 12.35 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-O 121.098 0.475 . . . . 3.98 109.771 -178.221 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.861 ' HB ' HD12 ' A' ' 388' ' ' LEU . 32.4 m -112.13 159.83 11.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-N 115.549 -0.751 . . . . 1.1 112.244 -175.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -123.26 123.55 5.33 Favored Glycine 0 N--CA 1.447 -0.573 0 N-CA-C 110.524 -1.03 . . . . 0.32 110.524 176.333 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 10.4 ptp -134.48 178.15 7.21 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.399 0.619 . . . . 1.55 111.815 -173.377 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 88.1 mtt180 -137.53 143.4 41.61 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 107.217 -1.401 . . . . 3.0 107.217 176.02 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 313' ' ' TYR . . . . . 0.579 ' CB ' HG13 ' A' ' 386' ' ' VAL . 49.4 p90 -162.55 152.16 15.84 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 112.646 0.61 . . . . 1.24 112.646 -167.238 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 51.1 t -116.92 119.0 60.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.091 -0.959 . . . . 1.09 109.627 173.111 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -97.93 109.15 3.75 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 121.343 -0.456 . . . . 0.32 112.261 -178.022 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 316' ' ' LYS . . . . . 0.544 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 56.3 mttm -120.42 162.97 18.62 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.173 0.511 . . . . 2.61 111.025 -177.157 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 81.9 mt -86.54 164.54 16.84 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 108.033 -1.099 . . . . 1.32 108.033 166.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 318' ' ' LYS . . . . . . . . . . . . . 47.7 pttt -64.44 -8.46 13.57 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.483 0.659 . . . . 2.9 110.303 173.505 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -79.51 -12.59 59.86 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 115.289 -0.869 . . . . 2.39 109.799 176.52 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 95.59 -24.93 27.14 Favored Glycine 0 N--CA 1.453 -0.187 0 N-CA-C 111.572 -0.611 . . . . 0.69 111.572 -176.445 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 23.7 ttmm -60.08 120.04 8.96 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.015 -0.593 . . . . 2.86 110.831 177.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.544 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 5.3 p -88.86 127.22 41.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.133 -0.485 . . . . 1.96 110.201 179.491 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 49.4 p90 -98.88 -27.19 14.02 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.828 -0.349 . . . . 0.56 111.16 -178.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -155.18 145.79 22.22 Favored 'General case' 0 CA--C 1.514 -0.408 0 N-CA-C 109.981 -0.377 . . . . 1.68 109.981 175.599 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . 0.486 ' N ' ' HD3' ' A' ' 325' ' ' LYS . 0.0 OUTLIER -149.74 128.7 12.61 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.379 0.609 . . . . 2.55 111.335 -179.257 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 23.6 m-80 -125.21 114.51 19.07 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 107.055 -1.461 . . . . 1.92 107.055 174.452 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 10.4 m -155.29 -58.79 0.1 Allowed 'General case' 0 C--N 1.318 -0.803 0 C-N-CA 120.367 -0.533 . . . . 2.06 111.784 -168.49 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 9.4 ptmm? -68.05 92.01 0.37 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.288 0.566 . . . . 3.15 111.625 -172.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.437 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 63.51 2.77 6.19 Favored Glycine 0 C--N 1.335 0.513 0 CA-C-N 115.582 -0.736 . . . . 1.17 113.048 -178.402 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 83.9 tttt -105.63 101.9 35.0 Favored Pre-proline 0 C--N 1.325 -0.47 0 N-CA-C 111.772 0.286 . . . . 2.56 111.772 -172.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 331' ' ' PRO . . . . . 0.437 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 95.8 Cg_endo -87.76 161.74 7.7 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 123.067 2.511 . . . . 0.73 112.567 174.289 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 66.4 t80 -134.72 126.45 29.06 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.224 -0.444 . . . . 0.76 109.844 174.038 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 333' ' ' VAL . . . . . 0.497 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 59.6 t -109.48 120.91 61.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.556 -0.293 . . . . 1.14 110.363 -177.002 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 22.3 p90 -142.93 160.13 40.93 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.193 0.52 . . . . 0.48 111.711 -178.608 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 335' ' ' LYS . . . . . . . . . . . . . 11.2 ttmt -89.34 128.15 35.86 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.309 -0.859 . . . . 3.11 110.345 176.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 6.8 mp -69.32 136.85 52.38 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.673 0.273 . . . . 1.2 110.598 173.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 337' ' ' GLY . . . . . 0.702 ' HA3' ' HG3' ' A' ' 305' ' ' LYS . . . 79.08 58.02 3.07 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 121.112 -0.566 . . . . 1.02 112.708 178.62 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 338' ' ' GLN . . . . . . . . . . . . . 29.0 pt20 -142.55 161.21 38.64 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.776 -0.453 . . . . 3.1 109.776 176.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -81.74 1.39 86.33 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.18 -0.533 . . . . 0.98 112.617 -173.797 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 21.0 mm-40 -76.25 -21.66 56.08 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.153 0.501 . . . . 2.09 110.307 178.461 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 18.7 m -114.51 166.64 8.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.898 -0.592 . . . . 1.27 110.046 -177.317 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 10.4 pt -85.11 154.46 3.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 N-CA-C 109.518 -0.549 . . . . 1.08 109.518 175.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . 0.612 ' HA ' ' OD1' ' A' ' 346' ' ' ASP . 13.7 mmmm -60.18 -28.54 68.03 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.391 0.515 . . . . 3.46 112.391 -172.62 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 344' ' ' GLY . . . . . 0.483 ' HA2' ' CD1' ' A' ' 290' ' ' ILE . . . -56.27 -31.13 59.15 Favored Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.467 -0.873 . . . . 0.32 112.656 174.204 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 9.2 m95 -74.62 -60.65 2.18 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 112.303 0.483 . . . . 0.44 112.303 -179.189 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 346' ' ' ASP . . . . . 0.612 ' OD1' ' HA ' ' A' ' 343' ' ' LYS . 8.1 p-10 -64.55 -24.73 67.7 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.634 0.254 . . . . 1.75 111.468 -173.63 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 48.7 mt -84.44 -51.31 14.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 116.318 -0.401 . . . . 1.18 111.126 177.347 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -64.28 -36.46 93.25 Favored Glycine 0 CA--C 1.524 0.624 0 C-N-CA 121.032 -0.604 . . . . 0.37 113.355 179.599 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 349' ' ' VAL . . . . . 0.506 ' O ' ' HB2' ' A' ' 352' ' ' MET . 77.1 t -80.55 -14.4 12.88 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.88 0.371 . . . . 1.08 111.349 -179.218 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -63.2 113.25 3.06 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.957 0.408 . . . . 1.09 110.682 177.86 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 96.32 19.57 27.66 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.969 -0.634 . . . . 0.45 111.924 -177.048 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 352' ' ' MET . . . . . 0.757 ' HE3' ' HG2' ' A' ' 358' ' ' ARG . 0.0 OUTLIER -76.66 155.87 33.06 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.722 -0.473 . . . . 1.3 109.722 174.907 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 353' ' ' ALA . . . . . . . . . . . . . . . -131.04 133.79 46.06 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.671 0.272 . . . . 1.33 110.921 -179.435 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 354' ' ' VAL . . . . . 0.405 ' HB ' ' HD2' ' A' ' 301' ' ' PRO . 95.1 t -55.39 114.79 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.976 -0.556 . . . . 1.24 110.909 175.733 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 113.83 -8.06 23.72 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.975 -0.631 . . . . 0.44 112.097 -179.019 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -109.79 162.42 12.69 Favored Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.73 -0.747 . . . . 0.37 112.785 -179.713 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 357' ' ' GLU . . . . . 0.752 ' HB3' ' HB3' ' A' ' 387' ' ' LYS . 9.6 pt-20 -140.64 145.54 36.74 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 110.172 -0.307 . . . . 1.63 110.172 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 358' ' ' ARG . . . . . 0.757 ' HG2' ' HE3' ' A' ' 352' ' ' MET . 2.8 ptp180 -154.44 145.53 22.75 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.378 0.608 . . . . 1.53 111.67 178.393 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 359' ' ' ARG . . . . . 0.722 ' HB3' ' HB3' ' A' ' 293' ' ' GLU . 34.5 ttt180 -86.82 114.46 23.5 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 114.948 -1.024 . . . . 3.26 109.938 -179.707 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 56.1 mt -101.6 117.52 47.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 120.896 0.379 . . . . 1.13 110.46 -178.196 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 361' ' ' VAL . . . . . . . . . . . . . 46.5 t -104.01 112.2 36.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 109.346 -0.612 . . . . 1.14 109.346 178.078 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 362' ' ' ILE . . . . . 0.446 HD11 ' HA3' ' A' ' 344' ' ' GLY . 54.5 mt -109.23 106.51 58.78 Favored Pre-proline 0 C--N 1.32 -0.694 0 CA-C-N 116.259 -0.428 . . . . 1.13 110.784 -174.181 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 363' ' ' PRO . . . . . 0.501 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 18.4 Cg_endo -58.35 159.53 19.14 Favored 'Trans proline' 0 C--O 1.235 0.372 0 C-N-CA 122.487 2.125 . . . . 1.05 111.848 173.327 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 364' ' ' ALA . . . . . 0.433 ' HB1' ' HA ' ' A' ' 379' ' ' ASN . . . -49.37 -50.16 66.69 Favored Pre-proline 0 CA--C 1.538 0.504 0 N-CA-C 114.002 1.112 . . . . 1.16 114.002 -174.448 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 365' ' ' PRO . . . . . 0.501 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 77.5 Cg_exo -51.38 -30.9 36.04 Favored 'Trans proline' 0 C--N 1.364 1.368 0 C-N-CA 122.294 1.996 . . . . 1.14 114.047 -174.935 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 366' ' ' TYR . . . . . 0.458 ' OH ' ' HG3' ' A' ' 287' ' ' GLU . 3.7 m-85 -102.26 14.13 32.79 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 112.158 0.429 . . . . 1.03 112.158 -177.503 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -129.23 -107.57 0.29 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.147 -0.479 . . . . 1.07 110.386 173.249 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 32.8 m-85 -87.96 -14.2 39.8 Favored 'General case' 0 N--CA 1.466 0.34 0 N-CA-C 112.09 0.404 . . . . 1.44 112.09 -179.113 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 70.01 -122.96 12.07 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.918 -0.658 . . . . 0.65 112.773 178.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 4.7 ptpp? -97.2 4.07 51.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.685 0.279 . . . . 3.34 111.12 -178.247 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 15.8 mm100 -75.36 98.92 3.97 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.085 0.469 . . . . 2.88 110.787 -179.261 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 372' ' ' ALA . . . . . . . . . . . . . . . -72.21 90.98 1.26 Allowed 'General case' 0 N--CA 1.447 -0.586 0 CA-C-N 115.695 -0.684 . . . . 1.39 110.454 175.593 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 36.7 mt -74.51 159.24 83.92 Favored Pre-proline 0 C--N 1.323 -0.568 0 CA-C-N 115.516 -0.765 . . . . 1.55 109.144 178.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -58.63 113.97 1.79 Allowed 'Trans proline' 0 N--CA 1.459 -0.529 0 C-N-CA 121.749 1.633 . . . . 1.61 110.721 173.73 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 93.84 -27.76 11.97 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.767 -0.73 . . . . 0.96 112.796 -177.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 56.6 mt -125.18 89.41 52.65 Favored Pre-proline 0 C--N 1.327 -0.37 0 CA-C-O 120.71 0.29 . . . . 1.29 110.84 -177.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 377' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -72.52 168.09 25.31 Favored 'Trans proline' 0 C--O 1.234 0.276 0 C-N-CA 123.143 2.562 . . . . 1.08 113.009 -178.112 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 378' ' ' ALA . . . . . 0.477 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -53.2 155.09 2.81 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.512 -0.767 . . . . 1.52 111.212 178.148 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 379' ' ' ASN . . . . . 0.477 ' HB2' ' O ' ' A' ' 378' ' ' ALA . 33.1 m-80 71.97 32.16 1.89 Allowed 'General case' 0 N--CA 1.467 0.419 0 O-C-N 123.805 0.69 . . . . 1.97 109.43 -172.228 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 1.8 p -70.7 87.88 0.7 Allowed 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 114.896 -1.047 . . . . 1.91 111.283 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 381' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -80.27 98.91 7.6 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 108.68 -0.859 . . . . 1.03 108.68 174.565 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 67.8 mt -85.96 146.98 26.44 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.0 -0.545 . . . . 1.13 110.292 -176.561 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 28.9 m -124.08 122.68 38.51 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 109.566 -0.531 . . . . 1.12 109.566 175.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -117.83 110.62 18.0 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.424 -0.353 . . . . 0.4 110.429 -178.575 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -84.0 103.81 13.55 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 107.813 -1.18 . . . . 1.8 107.813 172.478 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 386' ' ' VAL . . . . . 0.579 HG13 ' CB ' ' A' ' 313' ' ' TYR . 18.5 m -122.02 149.93 25.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 121.235 0.54 . . . . 1.13 112.185 -170.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 387' ' ' LYS . . . . . 0.752 ' HB3' ' HB3' ' A' ' 357' ' ' GLU . 11.1 ptpt -141.6 139.58 33.13 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.686 -0.688 . . . . 3.1 110.313 172.35 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 388' ' ' LEU . . . . . 0.861 HD12 ' HB ' ' A' ' 309' ' ' VAL . 31.0 tp -91.53 127.18 36.88 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.766 -0.827 . . . . 1.05 108.766 179.566 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 33.3 m -124.77 -10.84 6.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 C-N-CA 120.585 -0.446 . . . . 1.2 111.872 -172.676 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 50.0 m -157.96 159.83 36.9 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.844 0.354 . . . . 1.82 111.268 -179.33 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 391' ' ' MET . . . . . . . . . . . . . 38.7 ttm -160.32 150.82 18.47 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.339 -0.615 . . . . 1.14 109.339 175.354 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 18.5 ptpt . . . . . 0 C--O 1.249 1.067 0 C-N-CA 124.251 1.02 . . . . 5.51 112.805 176.866 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.85 0 N-CA-C 111.405 -0.678 . . . . 11.6 111.405 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -97.95 -175.13 3.06 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.579 -0.526 . . . . 9.39 109.579 175.142 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 278' ' ' MET . . . . . . . . . . . . . 88.7 mtp -72.62 -64.59 0.93 Allowed 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 109.365 -0.606 . . . . 8.15 109.365 176.164 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . 65.78 153.18 0.07 Allowed 'General case' 0 N--CA 1.467 0.38 0 O-C-N 124.088 0.867 . . . . 6.73 112.678 176.379 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 84.9 tttt 67.7 127.32 0.03 OUTLIER Pre-proline 0 N--CA 1.466 0.366 0 CA-C-N 115.542 -0.754 . . . . 7.18 112.118 176.31 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -67.02 142.62 62.5 Favored 'Trans proline' 0 N--CA 1.461 -0.389 0 C-N-CA 122.335 2.023 . . . . 5.4 111.459 176.167 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 282' ' ' LYS . . . . . . . . . . . . . 60.5 mttm -112.87 -175.74 2.74 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.928 -0.397 . . . . 3.88 109.928 179.192 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 2.9 p -90.03 126.6 35.82 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-O 121.351 0.596 . . . . 1.27 110.232 178.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 32.2 mmtp -108.16 130.54 55.12 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 115.652 -0.704 . . . . 2.51 110.041 -178.222 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 32.3 tp -95.47 125.44 40.08 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.949 -0.569 . . . . 1.52 109.959 179.836 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.742 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 90.4 mt -102.75 -178.12 3.58 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.688 -0.687 . . . . 1.39 109.433 179.302 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 14.3 tt0 -66.37 152.04 45.87 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.704 -0.48 . . . . 2.64 109.704 179.791 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 72.71 -4.41 21.83 Favored Glycine 0 C--O 1.229 -0.177 0 C-N-CA 120.823 -0.703 . . . . 1.84 113.08 -174.265 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 90.33 21.34 38.37 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.504 -0.855 . . . . 1.16 113.53 179.547 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 290' ' ' ILE . . . . . 0.742 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 61.9 mt -69.81 133.43 31.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 117.39 0.595 . . . . 1.16 110.344 177.828 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . 0.515 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 17.8 mt -113.08 139.49 37.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 C-N-CA 121.106 -0.237 . . . . 1.6 110.836 -178.576 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 292' ' ' ILE . . . . . 0.489 ' HB ' ' HD3' ' A' ' 358' ' ' ARG . 17.7 pt -132.08 129.3 60.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 121.151 0.501 . . . . 1.17 110.956 177.185 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 293' ' ' GLU . . . . . 0.426 ' C ' ' HG3' ' A' ' 358' ' ' ARG . 4.5 tp10 -125.15 119.21 27.93 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.516 -0.766 . . . . 2.31 109.664 178.699 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . 0.675 ' OD2' ' HA ' ' A' ' 297' ' ' THR . 6.2 t70 -80.3 96.18 6.56 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.475 -0.565 . . . . 2.36 109.475 -175.727 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 295' ' ' ARG . . . . . . . . . . . . . 66.6 ttt180 -69.37 -45.73 68.65 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.784 -0.644 . . . . 3.99 110.146 -175.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.573 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 88.8 t -123.4 123.71 68.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 N-CA-C 108.523 -0.917 . . . . 1.31 108.523 172.313 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 297' ' ' THR . . . . . 0.675 ' HA ' ' OD2' ' A' ' 294' ' ' ASP . 5.1 t -60.76 109.75 1.13 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.718 0.771 . . . . 2.46 110.994 -174.156 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 298' ' ' GLY . . . . . 0.512 ' HA3' ' HA3' ' A' ' 356' ' ' GLY . . . -99.33 111.22 4.16 Favored Glycine 0 N--CA 1.445 -0.708 0 CA-C-N 115.313 -0.858 . . . . 1.04 112.948 -178.036 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 36.9 mmtm -125.39 110.14 13.6 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 108.982 -0.747 . . . . 5.01 108.982 173.829 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -173.3 -152.68 8.97 Favored Glycine 0 N--CA 1.447 -0.573 0 N-CA-C 111.218 -0.753 . . . . 1.59 111.218 -174.404 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . 0.606 ' O ' ' HA ' ' A' ' 353' ' ' ALA . 32.8 Cg_exo -58.32 132.92 51.66 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.413 2.075 . . . . 1.1 111.312 174.103 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 26.6 m80 -96.63 127.92 43.08 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.941 0.401 . . . . 1.85 111.132 -173.61 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -73.51 117.62 15.49 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.066 -0.516 . . . . 1.17 111.056 179.202 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 63.2 mttm -118.9 -179.4 3.8 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.194 -0.457 . . . . 3.26 110.583 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 49.7 mtmt -72.68 127.15 31.69 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 109.9 -0.408 . . . . 3.21 109.9 179.223 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 94.8 -0.51 64.89 Favored Glycine 0 CA--C 1.518 0.223 0 C-N-CA 120.747 -0.739 . . . . 0.7 112.047 -176.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 19.8 m -91.29 145.31 24.75 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 110.239 -0.282 . . . . 1.07 110.239 177.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 51.4 mtp180 -108.12 106.47 16.69 Favored 'General case' 0 CA--C 1.519 -0.225 0 N-CA-C 109.648 -0.501 . . . . 3.98 109.648 178.693 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.863 ' HB ' HD12 ' A' ' 388' ' ' LEU . 32.7 m -106.25 154.11 7.45 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.959 0 CA-C-O 121.086 0.469 . . . . 1.1 111.747 -174.09 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -122.74 127.73 6.82 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 110.823 -0.911 . . . . 0.32 110.823 177.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 11.9 ptp -135.22 177.01 8.15 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.754 0.788 . . . . 1.55 112.789 -173.82 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 44.3 mtm180 -135.96 146.21 47.01 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 107.068 -1.456 . . . . 3.0 107.068 173.005 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 313' ' ' TYR . . . . . 0.567 ' CB ' HG11 ' A' ' 386' ' ' VAL . 41.9 p90 -159.13 155.52 27.39 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 113.214 0.82 . . . . 1.24 113.214 -168.118 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 58.1 t -122.56 113.24 37.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 114.94 -1.027 . . . . 1.09 109.361 170.185 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -97.56 115.64 5.31 Favored Glycine 0 C--O 1.238 0.374 0 C-N-CA 120.85 -0.69 . . . . 0.32 112.556 -176.331 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 316' ' ' LYS . . . . . 0.613 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 91.9 mttt -117.86 162.45 18.09 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-O 121.275 0.559 . . . . 2.61 110.758 -179.066 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 93.6 mt -90.01 165.89 13.77 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.423 -0.808 . . . . 1.32 109.558 173.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 318' ' ' LYS . . . . . 0.564 ' HB2' ' HB3' ' A' ' 381' ' ' GLU . 56.9 tttp -59.88 -23.09 63.16 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.22 0.533 . . . . 2.9 110.306 176.448 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -70.14 -15.63 62.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.38 -0.827 . . . . 2.39 110.894 -179.559 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 98.84 -5.43 59.79 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.51 -0.852 . . . . 0.69 112.195 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -91.48 133.28 35.64 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 120.682 0.277 . . . . 2.86 110.3 179.004 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.613 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 8.0 p -77.3 140.21 17.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.467 -0.333 . . . . 1.96 110.322 178.575 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 34.9 p90 -103.62 -33.43 8.99 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.54 -0.464 . . . . 0.56 110.994 177.636 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -162.7 162.99 27.1 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 121.063 -0.255 . . . . 1.68 110.343 175.132 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -159.61 129.63 5.55 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.891 0.377 . . . . 2.55 110.623 -178.33 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 35.1 m-80 -120.56 116.62 25.74 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.606 -0.887 . . . . 1.92 108.606 172.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.76 -69.25 0.2 Allowed 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.096 -0.502 . . . . 2.06 111.76 -174.324 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 24.7 pttm -68.41 97.28 0.74 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.698 0.761 . . . . 3.15 111.836 -174.121 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.477 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 86.71 -16.61 45.01 Favored Glycine 0 N--CA 1.446 -0.638 0 CA-C-N 115.269 -0.878 . . . . 1.17 113.591 175.375 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 27.6 mmmt -104.83 100.02 21.73 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 117.228 0.514 . . . . 2.56 111.471 -175.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 331' ' ' PRO . . . . . 0.477 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 72.1 Cg_endo -87.56 127.86 2.42 Favored 'Trans proline' 0 N--CA 1.455 -0.744 0 C-N-CA 122.883 2.389 . . . . 0.73 111.854 172.809 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 70.6 t80 -102.56 120.55 40.74 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 110.135 -0.321 . . . . 0.76 110.135 179.458 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 60.4 t -112.51 122.42 66.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.915 0.388 . . . . 1.14 110.413 -178.154 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 31.1 p90 -139.8 158.76 43.57 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.089 -0.505 . . . . 0.48 109.73 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 335' ' ' LYS . . . . . . . . . . . . . 16.9 ptmt -100.15 141.02 33.55 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.214 0.53 . . . . 3.11 111.217 179.128 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 11.2 mp -77.34 123.49 26.58 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.769 -0.651 . . . . 1.2 109.695 173.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 111.79 12.33 14.73 Favored Glycine 0 N--CA 1.446 -0.68 0 C-N-CA 120.683 -0.77 . . . . 1.02 111.931 -177.47 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 338' ' ' GLN . . . . . 0.698 HE21 HG11 ' A' ' 341' ' ' VAL . 13.2 pt20 -97.91 151.09 20.62 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.963 -0.384 . . . . 3.1 109.963 176.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -89.28 15.21 58.92 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 121.029 -0.605 . . . . 0.98 111.815 -179.047 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -87.32 -15.15 38.83 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.077 0.465 . . . . 2.09 110.261 178.298 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 341' ' ' VAL . . . . . 0.698 HG11 HE21 ' A' ' 338' ' ' GLN . 32.6 m -107.24 164.28 4.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.838 -0.619 . . . . 1.27 110.575 -177.644 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 342' ' ' ILE . . . . . 0.467 ' HB ' ' HA ' ' A' ' 367' ' ' ALA . 10.0 pt -88.67 165.36 2.06 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 109.718 -0.475 . . . . 1.08 109.718 176.546 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . 0.415 ' HA ' ' CE ' ' A' ' 343' ' ' LYS . 0.0 OUTLIER -56.11 -37.3 69.22 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 111.908 0.336 . . . . 3.46 111.908 -174.644 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 344' ' ' GLY . . . . . 0.572 ' HA2' HD11 ' A' ' 290' ' ' ILE . . . -55.72 -30.84 57.19 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.938 -0.649 . . . . 0.32 113.126 177.506 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 345' ' ' TRP . . . . . 0.416 ' CD1' HG12 ' A' ' 342' ' ' ILE . 18.4 m95 -77.83 -61.23 2.06 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 112.506 0.558 . . . . 0.44 112.506 -176.886 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -64.23 -20.55 66.11 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.669 0.271 . . . . 1.75 111.41 -175.69 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 71.5 mt -89.41 -55.73 5.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 116.471 -0.332 . . . . 1.18 111.685 174.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -65.71 -38.55 94.61 Favored Glycine 0 CA--C 1.523 0.59 0 C-N-CA 121.297 -0.478 . . . . 0.37 114.135 -177.372 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 83.9 t -75.22 -21.25 16.4 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 CA-C-O 120.953 0.406 . . . . 1.08 110.905 -178.612 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.2 104.53 0.93 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.164 0.506 . . . . 1.09 110.953 -179.291 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 113.84 0.58 24.31 Favored Glycine 0 N--CA 1.445 -0.712 0 C-N-CA 120.823 -0.704 . . . . 0.45 112.851 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 352' ' ' MET . . . . . . . . . . . . . 60.0 mtp -75.37 157.69 33.85 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 117.313 0.557 . . . . 1.3 110.307 174.69 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 353' ' ' ALA . . . . . 0.606 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -123.09 144.58 49.22 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.221 -0.445 . . . . 1.33 111.543 -174.861 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 73.4 t -58.2 123.15 9.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.962 -0.563 . . . . 1.24 110.357 175.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 104.23 -16.44 49.43 Favored Glycine 0 N--CA 1.446 -0.663 0 C-N-CA 120.831 -0.7 . . . . 0.44 111.528 -177.109 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 356' ' ' GLY . . . . . 0.512 ' HA3' ' HA3' ' A' ' 298' ' ' GLY . . . -87.35 154.29 26.06 Favored Glycine 0 N--CA 1.443 -0.851 0 C-N-CA 120.875 -0.678 . . . . 0.37 112.646 179.484 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 357' ' ' GLU . . . . . 0.64 ' HG3' ' HB3' ' A' ' 387' ' ' LYS . 41.2 tt0 -137.87 121.65 17.56 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.951 -0.759 . . . . 1.63 108.951 -177.833 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 358' ' ' ARG . . . . . 0.489 ' HD3' ' HB ' ' A' ' 292' ' ' ILE . 35.0 ttm180 -148.41 133.99 18.75 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.071 0.463 . . . . 1.53 110.933 -170.883 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 359' ' ' ARG . . . . . . . . . . . . . 31.8 ttp85 -86.02 122.78 30.54 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.717 -0.674 . . . . 3.26 110.459 -179.186 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 360' ' ' ILE . . . . . 0.483 HG12 HG23 ' A' ' 292' ' ' ILE . 56.8 mt -109.52 121.44 62.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.866 -0.606 . . . . 1.13 110.272 -179.646 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 361' ' ' VAL . . . . . 0.515 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 48.6 t -104.19 119.84 53.57 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 N-CA-C 109.256 -0.646 . . . . 1.14 109.256 177.699 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 362' ' ' ILE . . . . . 0.473 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 55.9 mt -118.23 100.95 51.7 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-N 116.322 -0.399 . . . . 1.13 111.535 -174.092 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 363' ' ' PRO . . . . . 0.516 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 12.3 Cg_endo -56.9 158.12 18.04 Favored 'Trans proline' 0 C--O 1.238 0.498 0 C-N-CA 122.99 2.46 . . . . 1.05 112.547 172.127 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 364' ' ' ALA . . . . . 0.486 ' CB ' ' HA ' ' A' ' 379' ' ' ASN . . . -50.18 -47.41 82.07 Favored Pre-proline 0 CA--C 1.539 0.52 0 N-CA-C 114.516 1.302 . . . . 1.16 114.516 -173.723 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 365' ' ' PRO . . . . . 0.516 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 82.6 Cg_exo -49.22 -36.55 37.25 Favored 'Trans proline' 0 C--N 1.361 1.231 0 C-N-CA 122.218 1.945 . . . . 1.14 113.632 -176.704 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 366' ' ' TYR . . . . . 0.416 ' CD1' HD12 ' A' ' 290' ' ' ILE . 3.6 m-85 -101.31 12.55 37.25 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.761 0.315 . . . . 1.03 111.643 -177.097 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 367' ' ' ALA . . . . . 0.467 ' HA ' ' HB ' ' A' ' 342' ' ' ILE . . . -119.31 -112.52 0.33 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.168 -0.469 . . . . 1.07 110.505 175.207 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -91.39 -1.88 57.47 Favored 'General case' 0 N--CA 1.464 0.228 0 N-CA-C 112.194 0.442 . . . . 1.44 112.194 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 66.43 -114.97 6.93 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 121.103 -0.57 . . . . 0.65 113.65 175.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 370' ' ' LYS . . . . . 0.426 ' HB3' ' HE2' ' A' ' 370' ' ' LYS . 14.8 ptpt -112.81 20.31 16.58 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.856 0.36 . . . . 3.34 111.502 -174.497 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 27.9 mm-40 -90.14 113.45 25.21 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.29 -0.414 . . . . 2.88 110.088 176.596 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 372' ' ' ALA . . . . . . . . . . . . . . . -83.51 96.18 8.52 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.175 0.512 . . . . 1.39 111.17 178.827 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 373' ' ' LEU . . . . . 0.5 ' HB3' ' HD2' ' A' ' 374' ' ' PRO . 59.1 mt -80.37 166.67 38.38 Favored Pre-proline 0 C--N 1.32 -0.698 0 CA-C-N 115.562 -0.744 . . . . 1.55 109.487 178.728 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 374' ' ' PRO . . . . . 0.5 ' HD2' ' HB3' ' A' ' 373' ' ' LEU . 22.9 Cg_endo -64.33 113.36 2.22 Favored 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 121.514 1.476 . . . . 1.61 110.818 172.438 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 90.65 -24.53 16.96 Favored Glycine 0 CA--C 1.519 0.312 0 C-N-CA 120.739 -0.743 . . . . 0.96 112.757 -179.003 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 39.8 mt -125.56 83.04 62.47 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.683 0.278 . . . . 1.29 110.304 -178.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 377' ' ' PRO . . . . . 0.4 ' O ' ' HB2' ' A' ' 380' ' ' SER . 9.2 Cg_exo -72.59 166.5 29.7 Favored 'Trans proline' 0 N--CA 1.464 -0.253 0 C-N-CA 123.17 2.58 . . . . 1.08 113.247 -178.124 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 378' ' ' ALA . . . . . 0.426 ' HB2' ' HA ' ' A' ' 370' ' ' LYS . . . -55.02 147.55 15.47 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-N 115.557 -0.747 . . . . 1.52 111.43 178.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 379' ' ' ASN . . . . . 0.486 ' HA ' ' CB ' ' A' ' 364' ' ' ALA . 44.4 m-80 65.54 30.65 10.54 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 115.676 -0.693 . . . . 1.97 111.3 -179.144 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 380' ' ' SER . . . . . 0.4 ' HB2' ' O ' ' A' ' 377' ' ' PRO . 22.2 t -85.41 134.54 34.07 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 116.08 -0.509 . . . . 1.91 109.78 175.769 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 381' ' ' GLU . . . . . 0.564 ' HB3' ' HB2' ' A' ' 318' ' ' LYS . 30.7 tt0 -99.43 105.16 17.07 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.305 -0.628 . . . . 1.03 109.305 179.066 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 74.2 mt -84.72 142.09 30.1 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.397 -0.365 . . . . 1.13 110.796 -177.65 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 383' ' ' THR . . . . . 0.453 HG21 HG23 ' A' ' 361' ' ' VAL . 25.7 m -122.39 122.77 39.79 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 109.726 -0.472 . . . . 1.12 109.726 177.794 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -117.44 109.59 16.96 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.928 0.394 . . . . 0.4 110.32 -178.181 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -88.81 104.4 16.88 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.154 -1.054 . . . . 1.8 108.154 174.254 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 386' ' ' VAL . . . . . 0.567 HG11 ' CB ' ' A' ' 313' ' ' TYR . 20.0 m -125.25 151.37 30.99 Favored 'Isoleucine or valine' 0 C--O 1.232 0.141 0 CA-C-O 121.358 0.599 . . . . 1.13 112.287 -169.131 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 387' ' ' LYS . . . . . 0.64 ' HB3' ' HG3' ' A' ' 357' ' ' GLU . 14.6 ptmm? -139.54 142.21 37.21 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.774 -0.648 . . . . 3.1 109.814 172.534 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 388' ' ' LEU . . . . . 0.863 HD12 ' HB ' ' A' ' 309' ' ' VAL . 19.3 tp -93.14 135.43 34.33 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.691 -0.485 . . . . 1.05 109.691 -176.471 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 34.7 m -127.53 -6.51 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 N-CA-C 112.268 0.47 . . . . 1.2 112.268 -176.442 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 44.1 t -160.57 160.35 31.71 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.528 0.204 . . . . 1.82 110.942 -177.784 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 391' ' ' MET . . . . . 0.407 ' HA ' ' HA ' ' A' ' 309' ' ' VAL . 30.9 ttm -165.61 134.1 3.16 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.998 -0.546 . . . . 1.14 110.18 179.684 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 63.7 mttp . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.513 -0.756 . . . . 5.51 109.716 175.758 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 18.2 p . . . . . 0 N--CA 1.443 -0.79 0 CA-C-O 121.543 0.687 . . . . 0.76000000000000001 110.896 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 284' ' ' LYS . . . . . 0.408 ' O ' ' HA ' ' A' ' 291' ' ' ILE . 41.8 mtmt -131.55 159.21 38.85 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.519 -0.764 . . . . 2.0600000000000001 110.414 -174.407 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 285' ' ' LEU . . . . . 0.513 HD11 ' HA2' ' A' ' 289' ' ' GLY . 42.3 tp -111.93 127.07 55.75 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.217 -0.447 . . . . 0.97999999999999998 111.987 -170.888 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.44 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 99.2 mt -108.32 -161.83 0.79 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.839 -0.618 . . . . 0.80000000000000004 110.309 173.653 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -51.99 140.48 20.15 Favored 'General case' 0 N--CA 1.447 -0.591 0 C-N-CA 123.263 0.625 . . . . 2.6400000000000001 112.301 179.293 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.487 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 70.4 -102.94 1.08 Allowed Glycine 0 N--CA 1.446 -0.69 0 CA-C-N 115.482 -0.781 . . . . 1.8400000000000001 111.595 -177.63 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 289' ' ' GLY . . . . . 0.513 ' HA2' HD11 ' A' ' 285' ' ' LEU . . . -145.92 28.2 1.73 Allowed Glycine 0 N--CA 1.442 -0.948 0 N-CA-C 110.603 -0.999 . . . . 0.64000000000000001 110.603 176.08 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 290' ' ' ILE . . . . . 0.44 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 75.4 mt -71.14 120.9 19.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.803 0.335 . . . . 0.41999999999999998 110.733 -177.73 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.408 ' HA ' ' O ' ' A' ' 284' ' ' LYS . 92.1 mt -103.72 138.53 27.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.274 -0.421 . . . . 0.93000000000000005 110.171 178.839 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 292' ' ' ILE . . . . . 0.43 HG22 HG12 ' A' ' 360' ' ' ILE . 24.9 pt -124.46 128.21 73.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-O 121.3 0.571 . . . . 0.47999999999999998 109.864 178.038 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 293' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -114.59 110.78 20.31 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.282 -0.872 . . . . 2.3100000000000001 109.117 179.538 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 20.7 m-20 -83.83 103.75 13.37 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.386 0.612 . . . . 2.3599999999999999 109.851 -173.853 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 295' ' ' ARG . . . . . . . . . . . . . 10.5 mmm180 -76.8 -49.4 15.95 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 114.809 -1.087 . . . . 3.5 110.663 -173.949 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 296' ' ' VAL . . . . . . . . . . . . . 97.9 t -118.66 130.09 73.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 115.662 -0.699 . . . . 0.69999999999999996 110.358 -176.025 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 1.6 m -63.03 107.25 0.97 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.156 -0.475 . . . . 1.9299999999999999 110.554 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -118.01 116.25 3.39 Favored Glycine 0 N--CA 1.445 -0.759 0 C-N-CA 120.802 -0.713 . . . . 1.04 112.402 -177.976 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 13.1 tptm -121.9 113.13 19.19 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.575 -0.528 . . . . 4.4900000000000002 109.575 175.296 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -170.79 -153.71 9.04 Favored Glycine 0 N--CA 1.436 -1.304 0 N-CA-C 111.042 -0.823 . . . . 1.04 111.042 -178.856 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 301' ' ' PRO . . . . . 0.428 ' HB2' ' SD ' ' A' ' 391' ' ' MET . 36.8 Cg_exo -60.75 132.7 44.0 Favored 'Trans proline' 0 N--CA 1.461 -0.397 0 C-N-CA 122.6 2.2 . . . . 0.88 111.756 177.79 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 302' ' ' HIS . . . . . 0.417 ' HA ' ' O ' ' A' ' 352' ' ' MET . 37.3 m80 -88.82 138.44 31.41 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.207 -0.451 . . . . 1.49 110.786 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -85.68 117.37 24.53 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.897 -0.592 . . . . 0.54000000000000004 111.25 -179.579 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 21.9 pttp -116.87 -178.54 3.46 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.045 -0.724 . . . . 2.8399999999999999 109.045 173.15 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 51.4 mttm -68.13 142.4 55.77 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 110.119 -0.326 . . . . 2.8399999999999999 110.119 176.754 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 85.29 -7.86 73.79 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 121.085 -0.578 . . . . 0.69999999999999996 112.225 -175.874 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 307' ' ' THR . . . . . 0.472 ' O ' ' HA ' ' A' ' 335' ' ' LYS . 87.0 m -89.25 135.47 33.56 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.758 0.314 . . . . 0.40000000000000002 111.119 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 308' ' ' ARG . . . . . 0.424 HH21 ' C ' ' A' ' 392' ' ' LYS . 73.1 mtm180 -94.24 102.34 14.35 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.687 -0.688 . . . . 3.4500000000000002 109.903 -177.643 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.869 ' HB ' HD11 ' A' ' 388' ' ' LEU . 34.1 m -103.43 141.54 19.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 CA-C-O 121.426 0.631 . . . . 0.34000000000000002 111.75 -177.679 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -115.51 121.66 5.34 Favored Glycine 0 N--CA 1.445 -0.759 0 N-CA-C 110.325 -1.11 . . . . 0.27000000000000002 110.325 177.462 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 13.9 ptp -135.77 177.67 7.65 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.513 0.673 . . . . 0.76000000000000001 112.304 -173.798 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -136.65 143.47 43.49 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 106.938 -1.504 . . . . 2.5099999999999998 106.938 174.157 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 313' ' ' TYR . . . . . 0.509 ' CB ' HG12 ' A' ' 386' ' ' VAL . 18.2 p90 -157.52 157.49 33.92 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 113.39 0.885 . . . . 0.68000000000000005 113.39 -170.245 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 58.0 t -124.34 120.94 60.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 114.795 -1.093 . . . . 0.34999999999999998 109.219 173.815 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -97.86 110.29 3.99 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 120.959 -0.639 . . . . 0.28000000000000003 112.573 -176.828 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 316' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -116.15 154.63 29.67 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.177 0.513 . . . . 1.9399999999999999 110.929 -178.49 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 317' ' ' LEU . . . . . 0.542 HD12 ' HD3' ' A' ' 321' ' ' LYS . 80.1 mt -86.92 170.39 11.66 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.795 -0.639 . . . . 0.65000000000000002 110.134 171.13 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 318' ' ' LYS . . . . . 0.441 ' HB2' ' HB3' ' A' ' 381' ' ' GLU . 57.7 tttp -59.07 -25.44 63.77 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.14 -0.482 . . . . 2.4199999999999999 111.298 179.493 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 28.1 p-10 -87.7 -3.04 58.98 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 120.555 0.216 . . . . 2.2000000000000002 111.267 -178.802 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 95.52 3.75 61.07 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.775 -0.726 . . . . 0.68999999999999995 112.7 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 321' ' ' LYS . . . . . 0.542 ' HD3' HD12 ' A' ' 317' ' ' LEU . 53.4 tttp -75.18 113.55 12.65 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.751 0.31 . . . . 2.4199999999999999 110.259 179.431 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 322' ' ' VAL . . . . . . . . . . . . . 4.7 p -85.52 119.52 34.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-O 121.287 0.565 . . . . 1.26 110.431 179.222 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 52.2 p90 -110.14 -27.13 9.3 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.072 -0.513 . . . . 0.55000000000000004 111.284 -177.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -130.88 156.61 44.76 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 108.952 -0.758 . . . . 1.6799999999999999 108.952 178.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 59.6 pttt -174.44 135.81 0.44 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.099 0.476 . . . . 1.99 111.525 -176.012 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 6.0 p30 -150.35 118.56 6.36 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.68 -0.691 . . . . 1.9199999999999999 109.316 166.843 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 29.7 m -140.63 -46.8 0.41 Allowed 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.642 -0.708 . . . . 1.6899999999999999 110.94 -175.451 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 83.9 mttt -79.66 92.55 5.38 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.79 -0.641 . . . . 2.5499999999999998 111.259 -173.372 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.48 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 65.78 7.92 38.05 Favored Glycine 0 CA--C 1.52 0.391 0 CA-C-N 115.853 -0.612 . . . . 0.96999999999999997 113.742 174.418 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 68.9 mmtt -103.93 100.4 20.26 Favored Pre-proline 0 C--N 1.324 -0.52 0 CA-C-N 116.688 0.244 . . . . 2.0800000000000001 111.39 -177.29 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 331' ' ' PRO . . . . . 0.48 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 94.1 Cg_endo -88.38 129.54 2.3 Favored 'Trans proline' 0 N--CA 1.453 -0.895 0 C-N-CA 122.839 2.359 . . . . 0.62 112.298 173.199 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -103.74 118.89 37.77 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.956 -0.757 . . . . 0.64000000000000001 108.956 174.208 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 56.7 t -112.15 125.87 69.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.904 0.383 . . . . 0.38 110.172 -177.606 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.459 ' HB2' ' OE1' ' A' ' 338' ' ' GLN . 29.8 p90 -147.31 156.38 42.86 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.835 -0.62 . . . . 0.40999999999999998 109.511 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 335' ' ' LYS . . . . . 0.472 ' HA ' ' O ' ' A' ' 307' ' ' THR . 0.2 OUTLIER -111.08 142.12 43.65 Favored 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 120.034 -0.667 . . . . 2.5800000000000001 110.508 177.709 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 9.3 mp -69.84 148.17 49.41 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.851 -0.613 . . . . 0.57999999999999996 109.91 178.906 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 103.38 -8.3 52.24 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.7 -0.762 . . . . 0.93999999999999995 112.942 -178.162 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 338' ' ' GLN . . . . . 0.459 ' OE1' ' HB2' ' A' ' 334' ' ' PHE . 4.1 pt20 -83.91 160.82 21.02 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.832 0.316 . . . . 2.6200000000000001 110.215 179.367 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -107.32 21.63 30.59 Favored Glycine 0 CA--C 1.52 0.354 0 C-N-CA 120.485 -0.864 . . . . 0.73999999999999999 114.307 -172.481 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -114.93 9.56 16.16 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 117.574 0.687 . . . . 2.0899999999999999 111.093 178.47 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 27.3 m -116.11 146.55 20.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 108.341 -0.985 . . . . 0.42999999999999999 108.341 172.852 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 11.4 pt -68.88 151.98 9.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 N-CA-C 109.743 -0.466 . . . . 0.32000000000000001 109.743 -178.875 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 343' ' ' LYS . . . . . 0.524 ' HE2' ' HA ' ' A' ' 343' ' ' LYS . 6.2 mmpt? -61.85 -30.38 70.81 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 111.894 0.331 . . . . 2.9300000000000002 111.894 -172.778 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -54.86 -31.4 54.68 Favored Glycine 0 CA--C 1.521 0.457 0 C-N-CA 120.878 -0.677 . . . . 0.29999999999999999 112.343 173.647 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 9.3 m95 -77.48 -60.8 2.22 Favored 'General case' 0 C--O 1.22 -0.452 0 CA-C-O 120.531 0.205 . . . . 0.39000000000000001 111.055 176.778 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -51.14 -28.87 11.93 Favored 'General case' 0 N--CA 1.47 0.544 0 N-CA-C 112.327 0.491 . . . . 1.75 112.327 -179.336 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 63.6 mt -91.19 -51.17 12.08 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.533 0 N-CA-C 111.946 0.35 . . . . 0.39000000000000001 111.946 177.523 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -63.95 -31.1 79.68 Favored Glycine 0 CA--C 1.524 0.606 0 C-N-CA 121.282 -0.485 . . . . 0.34000000000000002 113.758 -178.709 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 349' ' ' VAL . . . . . 0.546 ' O ' ' HB2' ' A' ' 352' ' ' MET . 90.8 t -79.7 -19.87 12.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 121.024 0.44 . . . . 0.32000000000000001 110.645 179.704 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -64.6 113.64 3.86 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.373 -0.376 . . . . 0.46999999999999997 110.132 178.316 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 97.07 15.17 39.79 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 121.035 -0.603 . . . . 0.39000000000000001 112.11 -176.634 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 352' ' ' MET . . . . . 0.546 ' HB2' ' O ' ' A' ' 349' ' ' VAL . 0.0 OUTLIER -77.12 154.9 32.78 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 109.296 -0.631 . . . . 1.28 109.296 175.264 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 353' ' ' ALA . . . . . 0.405 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -129.95 134.92 47.77 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.729 0.299 . . . . 0.55000000000000004 111.166 -177.393 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 61.4 t -59.85 123.39 12.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.017 -0.538 . . . . 0.35999999999999999 110.681 177.302 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 109.47 -12.36 33.2 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 121.136 -0.554 . . . . 0.44 112.022 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -104.89 150.9 17.2 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.761 -0.733 . . . . 0.29999999999999999 112.737 -179.538 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 357' ' ' GLU . . . . . 0.442 ' CB ' ' HB3' ' A' ' 387' ' ' LYS . 40.0 tt0 -122.44 140.37 52.8 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.247 -0.649 . . . . 1.4099999999999999 109.247 176.461 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 358' ' ' ARG . . . . . . . . . . . . . 3.1 ptp180 -146.15 137.55 24.71 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.157 0.503 . . . . 1.3700000000000001 111.178 175.425 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 359' ' ' ARG . . . . . . . . . . . . . 11.9 ttp180 -87.27 117.63 26.16 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.047 -0.723 . . . . 2.79 109.047 174.734 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 360' ' ' ILE . . . . . 0.43 HG12 HG22 ' A' ' 292' ' ' ILE . 65.1 mt -103.17 126.26 57.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-N 115.979 -0.555 . . . . 0.38 110.535 -175.125 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 361' ' ' VAL . . . . . . . . . . . . . 47.7 t -100.73 115.12 41.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 109.175 -0.676 . . . . 0.39000000000000001 109.175 175.427 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 362' ' ' ILE . . . . . 0.411 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 60.5 mt -110.21 108.97 58.86 Favored Pre-proline 0 C--N 1.322 -0.603 0 CA-C-N 116.447 -0.342 . . . . 0.28999999999999998 110.689 -175.456 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 363' ' ' PRO . . . . . 0.485 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 35.6 Cg_endo -65.51 162.03 35.75 Favored 'Trans proline' 0 C--O 1.239 0.541 0 C-N-CA 122.42 2.08 . . . . 0.66000000000000003 111.613 175.432 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 364' ' ' ALA . . . . . . . . . . . . . . . -52.61 -48.89 88.87 Favored Pre-proline 0 CA--C 1.537 0.47 0 N-CA-C 113.85 1.055 . . . . 0.41999999999999998 113.85 -173.69 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 365' ' ' PRO . . . . . 0.485 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 74.1 Cg_exo -52.14 -29.74 38.35 Favored 'Trans proline' 0 C--N 1.359 1.09 0 C-N-CA 122.501 2.134 . . . . 0.69999999999999996 114.212 -175.505 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 366' ' ' TYR . . . . . 0.487 ' CE2' ' HA3' ' A' ' 288' ' ' GLY . 43.1 m-85 -101.05 10.16 41.35 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 112.196 0.443 . . . . 0.68999999999999995 112.196 -175.75 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -125.39 -110.81 0.3 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.806 -0.179 . . . . 0.85999999999999999 110.572 175.484 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -90.02 -22.17 22.01 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.991 0.424 . . . . 1.0 111.317 178.849 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 70.7 -95.87 0.56 Allowed Glycine 0 N--CA 1.448 -0.51 0 CA-C-N 115.996 -0.547 . . . . 0.56000000000000005 113.761 175.584 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 23.4 pttm -109.17 8.12 25.76 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.622 0.248 . . . . 2.7599999999999998 111.645 -171.625 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 6.3 tp-100 -89.48 120.25 30.63 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.864 0.364 . . . . 2.6499999999999999 110.56 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 372' ' ' ALA . . . . . 0.794 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -92.47 93.71 8.71 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-O 121.436 0.636 . . . . 1.01 110.592 178.025 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 43.3 mt -81.97 162.99 55.4 Favored Pre-proline 0 C--N 1.318 -0.784 0 CA-C-N 115.373 -0.83 . . . . 0.93000000000000005 109.079 176.849 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_exo -61.14 114.97 2.42 Favored 'Trans proline' 0 N--CA 1.462 -0.378 0 C-N-CA 121.478 1.452 . . . . 1.3100000000000001 110.645 172.814 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 91.23 -26.63 11.01 Favored Glycine 0 CA--C 1.521 0.413 0 C-N-CA 121.086 -0.578 . . . . 0.90000000000000002 112.525 -178.457 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 23.5 mt -126.62 81.94 67.66 Favored Pre-proline 0 CA--C 1.533 0.32 0 CA-C-O 120.638 0.256 . . . . 0.73999999999999999 110.518 -177.118 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 377' ' ' PRO . . . . . 0.794 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 73.5 Cg_endo -80.17 167.85 19.28 Favored 'Trans proline' 0 N--CA 1.463 -0.322 0 C-N-CA 122.693 2.262 . . . . 0.70999999999999996 113.156 -177.79 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 378' ' ' ALA . . . . . 0.408 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -49.12 147.25 3.04 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 115.572 -0.74 . . . . 0.73999999999999999 111.862 178.834 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 379' ' ' ASN . . . . . 0.408 ' HB2' ' O ' ' A' ' 378' ' ' ALA . 42.2 m-80 67.75 33.31 4.94 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 115.712 -0.676 . . . . 1.49 110.688 -175.752 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 2.4 p -82.29 133.16 35.23 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.922 -0.581 . . . . 1.8400000000000001 111.42 179.506 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 381' ' ' GLU . . . . . 0.441 ' HB3' ' HB2' ' A' ' 318' ' ' LYS . 32.1 tt0 -104.03 106.64 17.21 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.73 -0.668 . . . . 1.03 109.398 177.98 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 382' ' ' LEU . . . . . 0.4 HD23 HD23 ' A' ' 317' ' ' LEU . 89.9 mt -86.83 139.97 30.15 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.832 0.349 . . . . 0.37 111.093 -177.916 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 33.4 m -117.89 117.51 29.49 Favored 'General case' 0 N--CA 1.446 -0.629 0 N-CA-C 109.153 -0.684 . . . . 0.27000000000000002 109.153 175.645 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 33.9 m-85 -113.69 117.29 31.14 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.214 0.53 . . . . 0.32000000000000001 111.784 -175.712 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -85.49 103.82 14.71 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 107.946 -1.131 . . . . 1.8 107.946 172.311 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 386' ' ' VAL . . . . . 0.509 HG12 ' CB ' ' A' ' 313' ' ' TYR . 35.3 m -130.29 141.17 47.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.65 0.738 . . . . 0.31 111.89 -173.159 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 387' ' ' LYS . . . . . 0.442 ' HB3' ' CB ' ' A' ' 357' ' ' GLU . 10.7 pttm -141.07 141.54 34.25 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.148 -0.933 . . . . 2.5299999999999998 109.747 174.851 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 388' ' ' LEU . . . . . 0.869 HD11 ' HB ' ' A' ' 309' ' ' VAL . 16.9 tp -94.24 127.35 40.04 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.962 -0.755 . . . . 0.28000000000000003 108.962 -176.656 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 34.2 m -125.92 -0.6 4.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 C-N-CA 120.897 -0.321 . . . . 0.45000000000000001 111.056 -172.094 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 22.9 t -165.15 157.52 15.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.254 -0.43 . . . . 1.3200000000000001 111.164 179.65 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 391' ' ' MET . . . . . 0.428 ' SD ' ' HB2' ' A' ' 301' ' ' PRO . 39.1 ttm -162.29 132.86 4.85 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.412 -0.813 . . . . 0.56000000000000005 109.407 175.902 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 392' ' ' LYS . . . . . 0.424 ' C ' HH21 ' A' ' 308' ' ' ARG . 31.9 mmtp . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.496 -0.764 . . . . 4.9100000000000001 110.408 -177.64 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.543 HG22 ' HG2' ' A' ' 293' ' ' GLU . 28.3 p . . . . . 0 N--CA 1.449 -0.497 0 CA-C-O 120.894 0.378 . . . . 0.76000000000000001 111.377 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 43.4 mtpt -127.58 156.98 41.39 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.528 -0.545 . . . . 2.0600000000000001 109.528 175.037 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 37.7 tp -112.47 119.24 37.53 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.373 -0.376 . . . . 0.97999999999999998 110.087 -178.872 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.638 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 92.3 mt -99.37 -170.16 1.87 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.927 -0.579 . . . . 0.80000000000000004 110.411 178.574 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -50.86 142.93 10.79 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.11 0.481 . . . . 2.6400000000000001 111.554 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 73.08 -102.74 1.28 Allowed Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 121.069 -0.586 . . . . 1.8400000000000001 111.9 -178.654 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . -146.44 28.04 1.65 Allowed Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 110.691 -0.964 . . . . 0.64000000000000001 110.691 177.184 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 290' ' ' ILE . . . . . 0.638 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 66.2 mt -74.48 125.57 34.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 115.335 -0.432 . . . . 0.41999999999999998 110.53 -175.702 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.401 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 8.1 mt -111.12 142.69 22.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 N-CA-C 109.384 -0.599 . . . . 0.93000000000000005 109.384 -179.024 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 292' ' ' ILE . . . . . . . . . . . . . 18.5 pt -132.8 128.47 57.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 120.859 0.361 . . . . 0.47999999999999998 111.222 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 293' ' ' GLU . . . . . 0.601 ' HB2' ' HB3' ' A' ' 359' ' ' ARG . 40.0 mt-10 -103.99 131.79 50.88 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.334 -0.848 . . . . 2.3100000000000001 110.204 175.618 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -79.98 126.48 31.08 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.234 0.54 . . . . 2.3599999999999999 109.966 175.492 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 295' ' ' ARG . . . . . 0.602 ' HA ' ' HE ' ' A' ' 295' ' ' ARG . 2.6 mmp_? -105.28 -59.23 1.79 Allowed 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.46 -0.57 . . . . 3.5 109.46 175.36 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.644 ' HB ' ' HG2' ' A' ' 357' ' ' GLU . 90.0 t -131.77 105.18 9.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.822 -0.626 . . . . 0.69999999999999996 109.334 174.915 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 10.2 t -68.9 138.72 54.89 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.068 0.461 . . . . 1.9299999999999999 109.827 178.013 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -128.47 161.82 22.17 Favored Glycine 0 N--CA 1.442 -0.959 0 C-N-CA 120.316 -0.945 . . . . 1.04 112.067 -175.95 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 23.3 tptm -127.26 110.96 13.39 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 109.799 -0.445 . . . . 4.4900000000000002 109.799 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -171.43 -154.58 9.95 Favored Glycine 0 N--CA 1.441 -0.98 0 N-CA-C 111.381 -0.688 . . . . 1.04 111.381 -178.895 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 301' ' ' PRO . . . . . 0.554 ' O ' ' HA ' ' A' ' 353' ' ' ALA . 21.9 Cg_exo -65.12 133.73 36.64 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.988 2.459 . . . . 0.88 111.744 177.546 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 52.7 m80 -93.32 139.55 30.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.731 0.301 . . . . 1.49 110.35 -179.376 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -74.03 151.73 40.16 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.053 -0.522 . . . . 0.54000000000000004 111.832 -179.153 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 304' ' ' LYS . . . . . 0.46 ' HG2' ' N ' ' A' ' 305' ' ' LYS . 25.6 ttpp -152.98 169.25 23.35 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 115.855 -0.611 . . . . 2.8399999999999999 109.387 -178.602 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.46 ' N ' ' HG2' ' A' ' 304' ' ' LYS . 99.4 mttt -64.91 130.94 45.29 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 110.136 -0.32 . . . . 2.8399999999999999 110.136 176.252 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 92.44 -11.8 71.23 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 121.094 -0.575 . . . . 0.69999999999999996 111.852 -178.682 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 52.5 m -83.5 140.08 32.52 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 122.457 0.303 . . . . 0.40000000000000002 110.57 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 50.7 mtt180 -100.68 104.74 16.05 Favored 'General case' 0 CA--C 1.516 -0.36 0 N-CA-C 109.002 -0.74 . . . . 3.4500000000000002 109.002 -179.514 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.848 ' HB ' HD11 ' A' ' 388' ' ' LEU . 33.7 m -102.12 140.01 21.72 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.915 0 CA-C-O 121.276 0.56 . . . . 0.34000000000000002 111.14 -176.719 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 310' ' ' GLY . . . . . 0.467 ' HA2' ' HA ' ' A' ' 333' ' ' VAL . . . -115.01 125.85 6.94 Favored Glycine 0 N--CA 1.441 -1.029 0 N-CA-C 110.136 -1.186 . . . . 0.27000000000000002 110.136 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 13.4 ptp -134.07 177.04 8.05 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-O 121.459 0.647 . . . . 0.76000000000000001 112.123 -173.75 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 312' ' ' ARG . . . . . 0.776 ' HE ' HG11 ' A' ' 389' ' ' VAL . 72.5 mtm180 -138.25 140.85 39.85 Favored 'General case' 0 C--N 1.317 -0.813 0 N-CA-C 106.995 -1.483 . . . . 2.5099999999999998 106.995 172.351 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 313' ' ' TYR . . . . . 0.42 ' CE2' ' HH2' ' A' ' 345' ' ' TRP . 9.8 p90 -158.55 169.53 24.23 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 119.593 -0.843 . . . . 0.68000000000000005 113.056 -167.404 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 26.2 t -129.42 108.07 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 CA-C-N 114.33 -1.305 . . . . 0.34999999999999998 109.086 171.234 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -88.28 110.38 3.63 Favored Glycine 0 N--CA 1.447 -0.576 0 N-CA-C 111.761 -0.535 . . . . 0.28000000000000003 111.761 -177.803 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 316' ' ' LYS . . . . . 0.86 ' HG2' HG22 ' A' ' 322' ' ' VAL . 51.0 mttp -115.81 164.38 14.46 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.175 0.512 . . . . 1.9399999999999999 110.831 -176.331 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 94.1 mt -87.95 158.67 18.6 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 107.561 -1.274 . . . . 0.65000000000000002 107.561 164.702 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 318' ' ' LYS . . . . . 0.801 ' HG2' ' HB3' ' A' ' 381' ' ' GLU . 0.1 OUTLIER -63.29 -8.76 9.25 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.011 0.434 . . . . 2.4199999999999999 111.232 178.978 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 85.8 m-20 -81.16 -14.55 57.51 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.123 -0.489 . . . . 2.2000000000000002 110.769 177.059 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 109.55 -18.53 29.79 Favored Glycine 0 CA--C 1.518 0.25 0 C-N-CA 120.806 -0.711 . . . . 0.68999999999999995 112.853 179.148 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 55.2 mtpt -78.08 138.57 38.83 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.662 0.268 . . . . 2.4199999999999999 111.249 -176.572 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.86 HG22 ' HG2' ' A' ' 316' ' ' LYS . 47.7 t -97.8 136.84 27.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.123 -0.489 . . . . 1.26 110.466 -176.95 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -118.21 -24.8 6.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.85 0.357 . . . . 0.55000000000000004 111.164 179.416 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -140.27 146.83 39.1 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.469 -0.567 . . . . 1.6799999999999999 109.469 177.173 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 21.0 ptmt -163.25 137.66 6.17 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.041 0.448 . . . . 1.99 111.48 -175.631 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 326' ' ' ASN . . . . . 0.451 ' HB2' ' HB2' ' A' ' 330' ' ' LYS . 5.8 p30 -154.58 128.9 9.05 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.796 -0.638 . . . . 1.9199999999999999 110.279 170.145 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 327' ' ' THR . . . . . 0.459 ' HA ' ' HD2' ' A' ' 312' ' ' ARG . 7.6 t -163.07 -33.92 0.04 OUTLIER 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.676 -0.693 . . . . 1.6899999999999999 110.573 -177.92 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 58.8 mttp -89.29 95.46 10.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.657 -0.247 . . . . 2.5499999999999998 110.441 177.887 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.511 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 73.65 -10.33 7.01 Favored Glycine 0 CA--C 1.518 0.275 0 C-N-CA 121.137 -0.554 . . . . 0.96999999999999997 113.439 177.234 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 330' ' ' LYS . . . . . 0.451 ' HB2' ' HB2' ' A' ' 326' ' ' ASN . 58.7 mttm -103.03 100.74 17.97 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 116.945 0.372 . . . . 2.0800000000000001 111.291 -177.305 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 331' ' ' PRO . . . . . 0.511 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 87.5 Cg_endo -88.84 143.51 5.05 Favored 'Trans proline' 0 N--CA 1.452 -0.917 0 C-N-CA 122.7 2.267 . . . . 0.62 112.034 170.925 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 73.8 t80 -116.01 115.65 26.51 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.594 -0.521 . . . . 0.64000000000000001 109.594 174.777 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 333' ' ' VAL . . . . . 0.467 ' HA ' ' HA2' ' A' ' 310' ' ' GLY . 42.7 t -114.73 117.08 54.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 120.559 0.218 . . . . 0.38 110.517 -175.375 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.523 ' HZ ' HG21 ' A' ' 349' ' ' VAL . 27.8 p90 -136.18 160.78 37.63 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 110.173 -0.306 . . . . 0.40999999999999998 110.173 -178.749 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 335' ' ' LYS . . . . . 0.641 ' O ' ' HG2' ' A' ' 338' ' ' GLN . 6.0 ptmt -106.04 134.62 48.88 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.016 0.436 . . . . 2.5800000000000001 111.513 -179.187 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 10.8 mp -68.82 117.8 10.98 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.332 -0.395 . . . . 0.57999999999999996 110.174 177.452 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 128.86 -19.27 5.55 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.832 -0.699 . . . . 0.93999999999999995 112.207 -179.279 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 338' ' ' GLN . . . . . 0.798 HE21 ' HB2' ' A' ' 340' ' ' GLU . 18.8 pt20 -72.53 138.55 47.0 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.836 0.35 . . . . 2.6200000000000001 110.742 179.883 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -86.65 20.31 24.21 Favored Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 120.931 -0.652 . . . . 0.73999999999999999 111.56 176.669 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 340' ' ' GLU . . . . . 0.798 ' HB2' HE21 ' A' ' 338' ' ' GLN . 11.5 mt-10 -89.22 -11.05 44.77 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.287 -0.635 . . . . 2.0899999999999999 109.287 178.007 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 35.5 m -112.98 173.53 2.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.353 -0.84 . . . . 0.42999999999999999 109.587 177.386 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 342' ' ' ILE . . . . . 0.57 HD12 ' HA ' ' A' ' 367' ' ' ALA . 8.7 pt -92.81 159.96 2.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 N-CA-C 109.736 -0.468 . . . . 0.32000000000000001 109.736 178.322 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 343' ' ' LYS . . . . . 0.509 ' HE2' ' HA ' ' A' ' 343' ' ' LYS . 3.4 mmpt? -55.97 -35.73 67.06 Favored 'General case' 0 N--CA 1.467 0.377 0 N-CA-C 112.219 0.451 . . . . 2.9300000000000002 112.219 -174.78 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 344' ' ' GLY . . . . . 0.428 ' HA3' HD13 ' A' ' 362' ' ' ILE . . . -56.18 -28.74 54.94 Favored Glycine 0 CA--C 1.521 0.446 0 C-N-CA 120.805 -0.712 . . . . 0.29999999999999999 113.061 177.628 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 345' ' ' TRP . . . . . 0.42 ' HH2' ' CE2' ' A' ' 313' ' ' TYR . 11.2 m95 -79.01 -59.99 2.56 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 112.715 0.635 . . . . 0.39000000000000001 112.715 -177.063 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 9.0 p-10 -63.92 -22.85 67.11 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 118.046 0.384 . . . . 1.75 111.268 -175.815 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 73.5 mt -86.52 -53.63 9.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.05 -0.523 . . . . 0.39000000000000001 111.249 176.477 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -64.52 -32.61 84.78 Favored Glycine 0 CA--C 1.523 0.549 0 C-N-CA 121.184 -0.531 . . . . 0.34000000000000002 113.894 -178.973 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 349' ' ' VAL . . . . . 0.523 HG21 ' HZ ' ' A' ' 334' ' ' PHE . 93.7 t -80.48 -14.4 12.91 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 CA-C-O 121.047 0.451 . . . . 0.32000000000000001 111.242 -179.798 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.08 131.67 47.17 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.237 0.541 . . . . 0.46999999999999997 110.632 178.531 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 79.89 16.15 77.68 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.821 -0.704 . . . . 0.39000000000000001 112.387 -179.145 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 352' ' ' MET . . . . . 0.408 ' SD ' ' HG2' ' A' ' 358' ' ' ARG . 42.7 mmm -82.6 149.46 27.42 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.643 0.259 . . . . 1.28 110.53 174.238 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 353' ' ' ALA . . . . . 0.554 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -122.84 137.83 54.82 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.031 -0.531 . . . . 0.55000000000000004 110.491 -179.56 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 354' ' ' VAL . . . . . 0.531 ' HB ' ' HD2' ' A' ' 301' ' ' PRO . 87.6 t -55.33 122.85 5.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.147 -0.479 . . . . 0.35999999999999999 110.679 176.499 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 111.27 -16.1 27.37 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.927 -0.654 . . . . 0.44 112.175 -178.95 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -108.37 160.81 13.58 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.692 -0.766 . . . . 0.29999999999999999 112.439 -178.994 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 357' ' ' GLU . . . . . 0.845 ' HB3' ' HB2' ' A' ' 387' ' ' LYS . 9.9 pt-20 -139.03 135.91 34.74 Favored 'General case' 0 C--O 1.238 0.462 0 CA-C-O 121.08 0.467 . . . . 1.4099999999999999 111.171 178.573 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 358' ' ' ARG . . . . . 0.408 ' HG2' ' SD ' ' A' ' 352' ' ' MET . 4.9 ptp180 -132.17 140.46 48.75 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.83 -0.623 . . . . 1.3700000000000001 109.931 177.445 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 359' ' ' ARG . . . . . 0.601 ' HB3' ' HB2' ' A' ' 293' ' ' GLU . 39.6 ttm180 -86.42 116.15 24.39 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.909 -0.587 . . . . 2.79 109.671 177.086 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 42.2 mt -99.42 117.77 45.05 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 CA-C-N 116.007 -0.542 . . . . 0.38 110.485 -177.536 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 361' ' ' VAL . . . . . 0.401 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 47.2 t -100.52 112.4 33.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 N-CA-C 108.714 -0.847 . . . . 0.39000000000000001 108.714 175.952 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 362' ' ' ILE . . . . . 0.462 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 47.9 mt -110.59 109.37 58.04 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 116.073 -0.512 . . . . 0.28999999999999998 111.67 -171.001 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 363' ' ' PRO . . . . . 0.462 ' HD2' ' HA ' ' A' ' 362' ' ' ILE . 13.8 Cg_endo -57.0 157.22 21.13 Favored 'Trans proline' 0 C--O 1.235 0.357 0 C-N-CA 123.098 2.532 . . . . 0.66000000000000003 112.185 172.045 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 364' ' ' ALA . . . . . 0.584 ' HB2' ' HA ' ' A' ' 379' ' ' ASN . . . -47.0 -53.8 24.6 Favored Pre-proline 0 CA--C 1.538 0.482 0 N-CA-C 114.051 1.13 . . . . 0.41999999999999998 114.051 -176.138 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 365' ' ' PRO . . . . . 0.442 ' HD2' ' N ' ' A' ' 364' ' ' ALA . 27.3 Cg_endo -61.6 -15.32 40.98 Favored 'Trans proline' 0 C--N 1.358 1.049 0 C-N-CA 122.2 1.933 . . . . 0.69999999999999996 114.207 -172.376 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 366' ' ' TYR . . . . . . . . . . . . . 12.2 m-85 -109.25 5.08 23.42 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.794 0.331 . . . . 0.68999999999999995 111.387 -178.727 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 367' ' ' ALA . . . . . 0.57 ' HA ' HD12 ' A' ' 342' ' ' ILE . . . -119.52 -125.09 0.28 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.435 -0.348 . . . . 0.85999999999999999 110.41 176.454 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 42.0 m-85 -68.9 -19.02 64.2 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-O 120.562 0.22 . . . . 1.0 111.297 179.232 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 74.96 -117.63 5.41 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.957 -0.639 . . . . 0.56000000000000005 113.177 177.587 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 370' ' ' LYS . . . . . 0.446 ' HA ' ' HB1' ' A' ' 378' ' ' ALA . 0.0 OUTLIER -111.54 13.57 21.35 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.652 -0.274 . . . . 2.7599999999999998 111.467 -173.931 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 51.0 tp60 -103.98 108.28 19.55 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.137 0.494 . . . . 2.6499999999999999 110.875 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 372' ' ' ALA . . . . . 0.41 ' HB1' ' HA ' ' A' ' 377' ' ' PRO . . . -75.42 119.18 19.16 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-N 115.77 -0.65 . . . . 1.01 111.664 178.99 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 75.3 mt -90.68 160.07 39.48 Favored Pre-proline 0 C--N 1.32 -0.716 0 N-CA-C 108.975 -0.75 . . . . 0.93000000000000005 108.975 174.309 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -59.6 114.18 1.94 Allowed 'Trans proline' 0 N--CA 1.461 -0.384 0 C-N-CA 121.326 1.351 . . . . 1.3100000000000001 110.831 173.641 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 97.2 -29.5 10.65 Favored Glycine 0 CA--C 1.52 0.38 0 C-N-CA 121.129 -0.558 . . . . 0.90000000000000002 112.768 -177.94 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 37.7 mt -126.7 94.23 40.56 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.66 0.23 . . . . 0.73999999999999999 110.461 -178.237 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 377' ' ' PRO . . . . . 0.41 ' HA ' ' HB1' ' A' ' 372' ' ' ALA . 72.1 Cg_endo -75.47 167.36 26.76 Favored 'Trans proline' 0 N--CA 1.461 -0.418 0 C-N-CA 122.51 2.14 . . . . 0.70999999999999996 112.839 -176.523 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 378' ' ' ALA . . . . . 0.446 ' HB1' ' HA ' ' A' ' 370' ' ' LYS . . . -57.82 152.13 16.45 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.842 -0.617 . . . . 0.73999999999999999 111.42 178.656 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 379' ' ' ASN . . . . . 0.584 ' HA ' ' HB2' ' A' ' 364' ' ' ALA . 82.6 m-20 72.12 14.25 5.68 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 115.714 -0.676 . . . . 1.49 111.962 179.072 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 33.7 m -70.45 112.43 6.74 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.187 0.517 . . . . 1.8400000000000001 110.861 176.327 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 381' ' ' GLU . . . . . 0.801 ' HB3' ' HG2' ' A' ' 318' ' ' LYS . 40.9 tt0 -72.95 105.11 4.3 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.259 -0.882 . . . . 1.03 109.444 175.236 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 86.6 mt -82.67 148.99 27.61 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.025 -0.534 . . . . 0.37 111.569 -175.687 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 29.4 m -130.57 120.09 23.51 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.589 -0.522 . . . . 0.27000000000000002 109.589 176.08 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 -121.39 110.45 16.1 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.757 0.313 . . . . 0.32000000000000001 111.484 -174.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 23.2 m-20 -82.42 103.92 12.34 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 108.375 -0.972 . . . . 1.8 108.375 168.955 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 386' ' ' VAL . . . . . . . . . . . . . 28.2 m -118.28 128.33 75.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.256 0.551 . . . . 0.31 111.56 -175.533 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 387' ' ' LYS . . . . . 0.845 ' HB2' ' HB3' ' A' ' 357' ' ' GLU . 28.9 ttpt -120.58 131.11 54.49 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.621 -0.718 . . . . 2.5299999999999998 109.756 175.9 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 388' ' ' LEU . . . . . 0.848 HD11 ' HB ' ' A' ' 309' ' ' VAL . 17.7 tp -87.43 130.29 34.73 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.33 -0.619 . . . . 0.28000000000000003 109.33 -174.851 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 389' ' ' VAL . . . . . 0.776 HG11 ' HE ' ' A' ' 312' ' ' ARG . 17.6 m -121.08 -12.75 8.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 111.997 0.369 . . . . 0.45000000000000001 111.997 -172.625 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 55.4 p -162.28 170.6 18.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.704 0.288 . . . . 1.3200000000000001 110.8 -178.837 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 391' ' ' MET . . . . . 0.432 ' HE3' ' HB2' ' A' ' 391' ' ' MET . 36.8 ttm -169.74 137.94 1.78 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.112 -0.495 . . . . 0.56000000000000005 110.652 -179.053 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 99.2 mttt . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.35 -0.833 . . . . 4.9100000000000001 110.265 177.587 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 20.8 p . . . . . 0 N--CA 1.446 -0.626 0 CA-C-O 120.741 0.305 . . . . 0.76000000000000001 110.991 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 25.5 mtpp -129.98 135.38 48.24 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.879 -0.415 . . . . 2.0600000000000001 109.879 170.651 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 285' ' ' LEU . . . . . 0.414 HD11 ' HA2' ' A' ' 289' ' ' GLY . 47.7 tp -94.01 120.77 34.71 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.884 -0.598 . . . . 0.97999999999999998 109.989 -177.94 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.609 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 88.3 mt -104.54 -171.95 2.02 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.554 -0.748 . . . . 0.80000000000000004 110.308 178.433 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 287' ' ' GLU . . . . . 0.65 ' HG3' ' OH ' ' A' ' 366' ' ' TYR . 7.3 tp10 -61.31 145.32 51.83 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.634 -0.712 . . . . 2.6400000000000001 111.377 -177.817 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 67.24 17.29 68.03 Favored Glycine 0 CA--C 1.521 0.439 0 C-N-CA 121.171 -0.537 . . . . 1.8400000000000001 113.967 176.008 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 289' ' ' GLY . . . . . 0.414 ' HA2' HD11 ' A' ' 285' ' ' LEU . . . 82.06 17.4 69.76 Favored Glycine 0 C--N 1.33 0.197 0 C-N-CA 120.512 -0.851 . . . . 0.64000000000000001 113.179 178.086 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 290' ' ' ILE . . . . . 0.609 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 87.8 mt -69.62 126.47 29.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 109.813 -0.439 . . . . 0.41999999999999998 109.813 176.759 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 10.5 mt -114.81 135.21 55.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 109.448 -0.575 . . . . 0.93000000000000005 109.448 -179.771 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 292' ' ' ILE . . . . . . . . . . . . . 24.5 pt -124.19 129.64 74.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-O 121.019 0.438 . . . . 0.47999999999999998 110.563 -177.8 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 293' ' ' GLU . . . . . . . . . . . . . 25.9 tt0 -107.7 121.18 44.18 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.403 -0.817 . . . . 2.3100000000000001 109.367 178.033 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -83.19 120.85 26.32 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.352 0.596 . . . . 2.3599999999999999 109.95 -179.624 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 295' ' ' ARG . . . . . 0.569 ' HD2' ' HB2' ' A' ' 359' ' ' ARG . 68.6 mtp180 -102.06 -50.77 3.56 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.37 -0.377 . . . . 3.5 110.312 -176.768 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.51 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 60.3 t -118.71 115.09 46.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 109.78 -0.452 . . . . 0.69999999999999996 109.78 174.676 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 20.7 p -81.06 121.52 26.18 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.036 -0.529 . . . . 1.9299999999999999 111.682 -177.507 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -134.99 173.71 21.46 Favored Glycine 0 N--CA 1.446 -0.654 0 N-CA-C 111.632 -0.587 . . . . 1.04 111.632 179.049 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -151.27 128.17 11.0 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.261 0.553 . . . . 4.4900000000000002 109.892 174.572 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -172.92 -153.5 9.54 Favored Glycine 0 N--CA 1.443 -0.874 0 N-CA-C 110.869 -0.892 . . . . 1.04 110.869 -177.721 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_exo -56.64 133.36 57.53 Favored 'Trans proline' 0 N--CA 1.462 -0.372 0 C-N-CA 122.369 2.046 . . . . 0.88 111.017 173.706 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 302' ' ' HIS . . . . . 0.418 ' HA ' ' O ' ' A' ' 352' ' ' MET . 53.6 m80 -100.48 144.24 29.71 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.42 -0.355 . . . . 1.49 111.033 -176.604 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 303' ' ' ALA . . . . . 0.442 ' HB2' HG11 ' A' ' 309' ' ' VAL . . . -77.39 125.84 29.96 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.832 -0.622 . . . . 0.54000000000000004 111.382 -179.239 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 304' ' ' LYS . . . . . 0.404 ' O ' ' HB2' ' A' ' 336' ' ' LEU . 98.4 mttt -133.21 179.47 6.18 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.717 -0.674 . . . . 2.8399999999999999 109.922 176.472 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.942 ' HG3' ' HA3' ' A' ' 337' ' ' GLY . 87.0 tttt -67.39 130.99 44.82 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.839 0.352 . . . . 2.8399999999999999 110.268 177.03 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 95.99 -26.02 22.7 Favored Glycine 0 N--CA 1.448 -0.542 0 N-CA-C 111.42 -0.672 . . . . 0.69999999999999996 111.42 -177.903 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 307' ' ' THR . . . . . 0.628 ' O ' ' HA ' ' A' ' 335' ' ' LYS . 9.7 m -72.51 131.36 42.43 Favored 'General case' 0 N--CA 1.449 -0.52 0 CA-C-N 115.619 -0.291 . . . . 0.40000000000000002 110.224 178.239 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 308' ' ' ARG . . . . . 0.645 ' HG2' ' HB3' ' A' ' 335' ' ' LYS . 49.6 mtp180 -102.18 104.37 14.95 Favored 'General case' 0 N--CA 1.452 -0.356 0 N-CA-C 108.651 -0.87 . . . . 3.4500000000000002 108.651 -179.676 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.787 ' HB ' HD11 ' A' ' 388' ' ' LEU . 32.0 m -99.58 140.02 19.88 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-O 121.243 0.544 . . . . 0.34000000000000002 111.267 -171.034 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -103.79 113.3 4.43 Favored Glycine 0 N--CA 1.442 -0.933 0 CA-C-N 114.956 -1.02 . . . . 0.27000000000000002 110.646 179.508 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 13.3 ptp -133.62 176.89 8.15 Favored 'General case' 0 N--CA 1.441 -0.92 0 CA-C-O 121.92 0.867 . . . . 0.76000000000000001 112.273 -173.516 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 49.4 mtp180 -135.46 145.16 46.91 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 113.81 -1.541 . . . . 2.5099999999999998 106.976 177.174 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 313' ' ' TYR . . . . . 0.511 ' HA ' ' O ' ' A' ' 385' ' ' ASP . 44.9 p90 -161.42 155.63 22.57 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.461 0.648 . . . . 0.68000000000000005 112.708 -170.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 57.7 t -122.48 120.01 59.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 114.756 -1.111 . . . . 0.34999999999999998 109.45 175.263 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -101.37 115.23 5.21 Favored Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.83 -0.7 . . . . 0.28000000000000003 112.461 -177.046 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 316' ' ' LYS . . . . . 0.502 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 62.7 mttm -112.29 151.09 30.08 Favored 'General case' 0 C--N 1.331 -0.221 0 O-C-N 123.946 0.439 . . . . 1.9399999999999999 111.193 -179.278 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 317' ' ' LEU . . . . . 0.579 HD21 HG12 ' A' ' 376' ' ' ILE . 80.1 mt -84.95 -178.5 6.85 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.505 -0.771 . . . . 0.65000000000000002 112.114 178.883 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 318' ' ' LYS . . . . . 0.591 ' HD3' ' H ' ' A' ' 381' ' ' GLU . 49.7 tptt -57.43 -32.59 67.03 Favored 'General case' 0 N--CA 1.461 0.111 0 CA-C-N 115.198 -0.91 . . . . 2.4199999999999999 110.854 176.82 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 27.0 p-10 -92.7 6.9 45.78 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.078 -0.51 . . . . 2.2000000000000002 111.368 -177.244 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 88.13 -8.22 79.02 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.638 -0.791 . . . . 0.68999999999999995 112.641 178.155 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 28.7 tptp -66.25 114.19 5.14 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.028 0.442 . . . . 2.4199999999999999 110.634 179.526 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.502 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 4.0 p -68.15 122.44 19.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-N 115.788 -0.642 . . . . 1.26 109.856 175.571 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 323' ' ' PHE . . . . . 0.46 ' HD1' ' HG ' ' A' ' 317' ' ' LEU . 43.1 p90 -100.83 -30.48 11.66 Favored 'General case' 0 C--N 1.322 -0.596 0 C-N-CA 120.738 -0.385 . . . . 0.55000000000000004 110.794 -178.776 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -149.48 160.08 43.76 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.835 -0.346 . . . . 1.6799999999999999 110.622 178.719 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 14.8 pttp -166.66 128.42 1.75 Allowed 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.129 -0.487 . . . . 1.99 110.505 -178.38 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -124.82 117.9 25.18 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.947 -0.76 . . . . 1.9199999999999999 108.947 178.82 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 2.0 t -164.05 -45.04 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.47 -0.332 . . . . 1.6899999999999999 111.278 -175.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 12.6 ptmm? -89.44 100.41 13.21 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.317 0.579 . . . . 2.5499999999999998 110.84 -177.842 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.473 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 86.28 -26.76 6.03 Favored Glycine 0 N--CA 1.452 -0.292 0 CA-C-N 115.532 -0.758 . . . . 0.96999999999999997 113.074 178.023 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -103.36 100.78 19.44 Favored Pre-proline 0 C--N 1.329 -0.309 0 N-CA-C 111.729 0.27 . . . . 2.0800000000000001 111.729 -177.001 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 331' ' ' PRO . . . . . 0.473 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 84.2 Cg_endo -87.79 125.93 2.07 Favored 'Trans proline' 0 N--CA 1.45 -1.078 0 C-N-CA 122.35 2.034 . . . . 0.62 110.342 165.869 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 43.1 t80 -99.92 115.6 30.02 Favored 'General case' 0 C--N 1.321 -0.639 0 C-N-CA 120.486 -0.485 . . . . 0.64000000000000001 110.107 -177.323 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 333' ' ' VAL . . . . . 0.638 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 47.5 t -111.94 113.17 43.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 116.032 -0.531 . . . . 0.38 109.939 -177.951 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 30.7 p90 -135.99 149.44 48.86 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.313 -0.403 . . . . 0.40999999999999998 110.41 -178.566 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 335' ' ' LYS . . . . . 0.645 ' HB3' ' HG2' ' A' ' 308' ' ' ARG . 12.0 ptmt -92.84 139.22 30.77 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 116.181 -0.463 . . . . 2.5800000000000001 111.133 177.577 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 336' ' ' LEU . . . . . 0.404 ' HB2' ' O ' ' A' ' 304' ' ' LYS . 9.8 mp -77.64 151.76 34.17 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 109.517 -0.549 . . . . 0.57999999999999996 109.517 172.267 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 337' ' ' GLY . . . . . 0.942 ' HA3' ' HG3' ' A' ' 305' ' ' LYS . . . 90.78 40.36 5.62 Favored Glycine 0 N--CA 1.446 -0.687 0 C-N-CA 120.698 -0.763 . . . . 0.93999999999999995 112.577 -177.662 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 338' ' ' GLN . . . . . 0.494 ' HB3' ' HE2' ' A' ' 335' ' ' LYS . 29.7 pt20 -148.26 157.63 43.61 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.454 -0.573 . . . . 2.6200000000000001 109.454 176.179 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -89.73 20.1 37.3 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.756 -0.735 . . . . 0.73999999999999999 112.352 -176.223 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -85.18 -15.07 44.92 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.301 0.572 . . . . 2.0899999999999999 110.012 178.873 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 25.4 m -123.58 156.78 30.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.843 -0.617 . . . . 0.42999999999999999 109.855 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 342' ' ' ILE . . . . . 0.456 HD12 ' HA ' ' A' ' 367' ' ' ALA . 11.3 pt -76.79 159.93 5.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 N-CA-C 110.203 -0.295 . . . . 0.32000000000000001 110.203 -179.826 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 343' ' ' LYS . . . . . 0.478 ' HE2' ' HA ' ' A' ' 343' ' ' LYS . 4.7 mmpt? -63.14 -34.38 77.48 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.19 0.441 . . . . 2.9300000000000002 112.19 -173.88 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 344' ' ' GLY . . . . . 0.43 ' HA3' HD13 ' A' ' 362' ' ' ILE . . . -54.19 -33.54 52.08 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.72 -0.753 . . . . 0.29999999999999999 112.383 174.564 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 11.8 m95 -81.23 -59.83 2.5 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 120.584 0.231 . . . . 0.39000000000000001 110.781 177.568 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 31.5 t70 -48.76 -31.11 6.44 Favored 'General case' 0 CA--C 1.537 0.463 0 CA-C-N 116.193 -0.458 . . . . 1.75 112.107 179.049 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 71.6 mt -93.2 -52.39 9.91 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.404 0 CA-C-N 116.626 -0.261 . . . . 0.39000000000000001 111.69 178.323 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -63.8 -31.84 82.16 Favored Glycine 0 C--N 1.335 0.505 0 C-N-CA 121.318 -0.468 . . . . 0.34000000000000002 113.767 -176.775 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 98.7 t -78.28 -20.52 13.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-O 120.984 0.421 . . . . 0.32000000000000001 110.812 179.442 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -63.8 118.35 8.21 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.96 0.409 . . . . 0.46999999999999997 110.163 178.185 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 100.2 0.61 55.89 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.69 -0.766 . . . . 0.39000000000000001 112.397 -178.017 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 352' ' ' MET . . . . . 0.418 ' O ' ' HA ' ' A' ' 302' ' ' HIS . 58.0 mmm -68.69 139.97 55.42 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.673 0.273 . . . . 1.28 110.668 175.893 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 353' ' ' ALA . . . . . . . . . . . . . . . -109.69 137.19 47.86 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.877 -0.601 . . . . 0.55000000000000004 110.819 -178.734 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 68.4 t -56.85 117.19 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.279 -0.419 . . . . 0.35999999999999999 110.125 173.449 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 111.07 -6.08 28.91 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 121.229 -0.51 . . . . 0.44 112.477 -178.555 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -105.36 154.93 17.11 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.748 -0.739 . . . . 0.29999999999999999 113.126 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 357' ' ' GLU . . . . . 0.51 ' HB3' ' HB ' ' A' ' 296' ' ' VAL . 25.8 tt0 -132.61 133.53 43.76 Favored 'General case' 0 C--N 1.329 -0.293 0 C-N-CA 122.944 0.498 . . . . 1.4099999999999999 109.868 -179.486 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 358' ' ' ARG . . . . . . . . . . . . . 5.0 ptp180 -144.48 143.23 30.77 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.094 0.473 . . . . 1.3700000000000001 111.063 177.598 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 359' ' ' ARG . . . . . 0.569 ' HB2' ' HD2' ' A' ' 295' ' ' ARG . 11.8 ttp180 -93.35 121.47 34.77 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.696 -0.684 . . . . 2.79 109.422 174.551 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 44.9 mt -106.07 127.64 61.06 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-N 116.134 -0.485 . . . . 0.38 110.577 -175.821 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 361' ' ' VAL . . . . . . . . . . . . . 58.8 t -107.16 109.24 27.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 N-CA-C 108.868 -0.79 . . . . 0.39000000000000001 108.868 175.312 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 362' ' ' ILE . . . . . 0.449 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 51.5 mt -107.11 110.04 63.25 Favored Pre-proline 0 C--N 1.322 -0.598 0 CA-C-N 116.43 -0.35 . . . . 0.28999999999999998 111.495 -174.255 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 363' ' ' PRO . . . . . 0.498 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 13.2 Cg_endo -57.45 152.83 44.7 Favored 'Trans proline' 0 N--CA 1.46 -0.487 0 C-N-CA 122.641 2.228 . . . . 0.66000000000000003 111.18 170.4 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 364' ' ' ALA . . . . . 0.502 ' HB2' ' HA ' ' A' ' 379' ' ' ASN . . . -47.93 -49.86 56.59 Favored Pre-proline 0 CA--C 1.537 0.479 0 N-CA-C 113.913 1.079 . . . . 0.41999999999999998 113.913 -173.87 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 365' ' ' PRO . . . . . 0.498 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 77.6 Cg_exo -49.5 -35.4 36.6 Favored 'Trans proline' 0 C--N 1.36 1.18 0 C-N-CA 122.564 2.176 . . . . 0.69999999999999996 114.555 -173.748 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 366' ' ' TYR . . . . . 0.65 ' OH ' ' HG3' ' A' ' 287' ' ' GLU . 3.1 m-85 -101.23 13.82 33.91 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.481 -0.488 . . . . 0.68999999999999995 112.234 -174.857 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 367' ' ' ALA . . . . . 0.456 ' HA ' HD12 ' A' ' 342' ' ' ILE . . . -116.58 -105.3 0.4 Allowed 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.306 -0.406 . . . . 0.85999999999999999 109.926 172.539 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 76.4 m-85 -95.87 4.82 52.48 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.988 0.423 . . . . 1.0 111.158 175.232 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 61.35 -117.4 11.48 Favored Glycine 0 N--CA 1.45 -0.371 0 CA-C-N 115.829 -0.623 . . . . 0.56000000000000005 113.34 174.811 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 95.4 mttt -103.14 14.32 32.04 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.686 -0.257 . . . . 2.7599999999999998 110.778 -176.748 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 27.8 tp60 -87.27 103.92 15.9 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.355 -0.384 . . . . 2.6499999999999999 110.773 -177.769 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 372' ' ' ALA . . . . . 0.633 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -74.84 104.15 5.35 Favored 'General case' 0 N--CA 1.45 -0.448 0 CA-C-O 121.077 0.465 . . . . 1.01 110.542 174.517 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 90.2 mt -94.34 162.75 25.22 Favored Pre-proline 0 C--N 1.321 -0.668 0 CA-C-N 115.796 -0.638 . . . . 0.93000000000000005 109.44 176.589 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_endo -63.15 114.86 2.65 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 121.724 1.616 . . . . 1.3100000000000001 110.606 170.65 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 93.83 -30.03 7.93 Favored Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 120.941 -0.647 . . . . 0.90000000000000002 112.279 -176.84 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 376' ' ' ILE . . . . . 0.579 HG12 HD21 ' A' ' 317' ' ' LEU . 24.3 mt -128.36 79.92 73.28 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.668 0.27 . . . . 0.73999999999999999 110.615 -178.524 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 377' ' ' PRO . . . . . 0.633 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 72.5 Cg_endo -75.44 167.96 25.52 Favored 'Trans proline' 0 N--CA 1.463 -0.276 0 C-N-CA 122.379 2.053 . . . . 0.70999999999999996 112.313 -179.675 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 378' ' ' ALA . . . . . 0.448 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -55.96 146.14 23.15 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.362 -0.381 . . . . 0.73999999999999999 111.01 178.588 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 379' ' ' ASN . . . . . 0.502 ' HA ' ' HB2' ' A' ' 364' ' ' ALA . 49.1 m-80 75.56 9.29 3.64 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 123.435 0.694 . . . . 1.49 112.138 179.723 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 62.2 m -72.02 107.03 4.52 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.32 0.581 . . . . 1.8400000000000001 110.774 174.591 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 381' ' ' GLU . . . . . 0.591 ' H ' ' HD3' ' A' ' 318' ' ' LYS . 4.5 tt0 -77.01 99.62 5.35 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.02 -0.991 . . . . 1.03 109.153 177.628 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 83.2 mt -82.46 140.44 33.38 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.167 -0.47 . . . . 0.37 110.878 -173.83 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 25.5 m -117.66 120.57 38.42 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 109.622 -0.51 . . . . 0.27000000000000002 109.622 178.779 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 92.3 m-85 -118.92 113.68 21.4 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.611 -0.268 . . . . 0.32000000000000001 111.168 -176.66 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 385' ' ' ASP . . . . . 0.511 ' O ' ' HA ' ' A' ' 313' ' ' TYR . 23.3 t70 -83.19 104.98 13.79 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 108.428 -0.952 . . . . 1.8 108.428 171.495 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 386' ' ' VAL . . . . . . . . . . . . . 36.0 m -115.27 133.21 62.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-O 121.665 0.745 . . . . 0.31 111.469 -174.949 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 387' ' ' LYS . . . . . . . . . . . . . 3.3 ptpp? -129.6 126.39 38.35 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.085 -0.961 . . . . 2.5299999999999998 109.841 176.764 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 388' ' ' LEU . . . . . 0.787 HD11 ' HB ' ' A' ' 309' ' ' VAL . 22.3 tp -91.64 127.99 37.3 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 108.279 -1.008 . . . . 0.28000000000000003 108.279 -179.738 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 28.2 m -127.76 -6.18 4.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 C-N-CA 120.77 -0.372 . . . . 0.45000000000000001 111.591 -171.248 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 13.4 p -167.98 171.08 10.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.381 -0.372 . . . . 1.3200000000000001 110.534 179.167 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 391' ' ' MET . . . . . 0.439 ' HE3' ' HB2' ' A' ' 391' ' ' MET . 31.7 ttm -164.45 143.72 7.37 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.9 0.381 . . . . 0.56000000000000005 111.348 -178.232 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 3.2 tppp? . . . . . 0 C--O 1.251 1.133 0 CA-C-O 118.678 -0.677 . . . . 4.9100000000000001 109.257 173.038 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.542 HG22 ' HB3' ' A' ' 293' ' ' GLU . 1.9 p . . . . . 0 N--CA 1.445 -0.7 0 N-CA-C 110.016 -0.365 . . . . 0.76000000000000001 110.016 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 92.7 mttt -101.45 154.73 18.56 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 110.418 -0.215 . . . . 2.0600000000000001 110.418 179.371 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 59.9 tp -110.43 112.73 24.86 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 109.722 -0.473 . . . . 0.97999999999999998 109.722 176.129 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.738 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 89.4 mt -100.41 -170.97 1.94 Allowed 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.057 -0.52 . . . . 0.80000000000000004 110.924 -178.132 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 287' ' ' GLU . . . . . 0.461 ' HB3' HD13 ' A' ' 347' ' ' ILE . 28.1 tt0 -50.32 136.74 19.64 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 116.011 -0.54 . . . . 2.6400000000000001 111.788 -179.043 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 76.22 -99.42 1.3 Allowed Glycine 0 N--CA 1.445 -0.761 0 C-N-CA 120.755 -0.736 . . . . 1.8400000000000001 111.561 -177.114 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . -151.17 31.91 0.96 Allowed Glycine 0 N--CA 1.447 -0.575 0 N-CA-C 110.736 -0.945 . . . . 0.64000000000000001 110.736 175.873 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 290' ' ' ILE . . . . . 0.738 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 72.6 mt -74.38 121.94 26.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 110.127 -0.324 . . . . 0.41999999999999998 110.127 -176.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 17.9 mt -115.1 139.86 39.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 109.307 -0.627 . . . . 0.93000000000000005 109.307 -178.736 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 292' ' ' ILE . . . . . 0.406 ' O ' ' HA ' ' A' ' 283' ' ' THR . 22.0 pt -136.91 127.02 39.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 C-N-CA 120.816 -0.354 . . . . 0.47999999999999998 110.637 -179.098 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 293' ' ' GLU . . . . . 0.542 ' HB3' HG22 ' A' ' 283' ' ' THR . 16.9 pt-20 -110.87 131.83 54.71 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.09 -0.505 . . . . 2.3100000000000001 109.933 173.271 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -89.64 109.03 20.03 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.186 0.517 . . . . 2.3599999999999999 109.69 -173.106 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 295' ' ' ARG . . . . . 0.799 ' HG3' HG23 ' A' ' 296' ' ' VAL . 21.6 tpt180 -77.89 -54.35 6.42 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.278 -0.874 . . . . 3.5 111.232 -173.807 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.799 HG23 ' HG3' ' A' ' 295' ' ' ARG . 65.0 t -128.63 106.68 14.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 N-CA-C 109.199 -0.667 . . . . 0.69999999999999996 109.199 178.614 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 25.3 m -73.34 114.0 11.05 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.11 0.481 . . . . 1.9299999999999999 111.739 -175.519 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -113.76 171.15 13.65 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.565 -0.743 . . . . 1.04 111.46 178.125 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 26.4 tptp -137.73 127.4 25.25 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.419 0.628 . . . . 4.4900000000000002 111.111 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -170.98 -155.02 10.12 Favored Glycine 0 N--CA 1.44 -1.034 0 N-CA-C 109.966 -1.254 . . . . 1.04 109.966 176.202 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 301' ' ' PRO . . . . . 0.553 ' HB2' ' SD ' ' A' ' 391' ' ' MET . 11.5 Cg_endo -59.48 146.87 93.76 Favored 'Trans proline' 0 CA--C 1.53 0.297 0 C-N-CA 122.305 2.003 . . . . 0.88 110.974 170.342 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 29.1 m80 -106.75 139.09 41.72 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.067 0.46 . . . . 1.49 111.445 -178.448 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 303' ' ' ALA . . . . . 0.438 ' HB2' HG11 ' A' ' 309' ' ' VAL . . . -73.68 142.28 46.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.408 -0.814 . . . . 0.54000000000000004 112.438 -175.497 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 57.6 tttp -150.24 165.52 32.7 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 108.149 -1.056 . . . . 2.8399999999999999 108.149 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 65.8 mttm -62.92 134.94 56.99 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-N 118.203 0.456 . . . . 2.8399999999999999 109.929 174.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 92.23 -6.54 78.49 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 121.087 -0.578 . . . . 0.69999999999999996 111.859 -174.174 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 24.7 m -102.65 145.95 28.91 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.975 -0.379 . . . . 0.40000000000000002 109.975 179.414 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 308' ' ' ARG . . . . . 0.589 ' HB3' ' HG3' ' A' ' 335' ' ' LYS . 11.5 ptp85 -108.86 123.82 49.67 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 109.499 -0.556 . . . . 3.4500000000000002 109.499 179.723 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.832 ' HB ' HD11 ' A' ' 388' ' ' LEU . 34.4 m -110.86 139.17 35.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-O 121.387 0.613 . . . . 0.34000000000000002 111.649 179.477 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 310' ' ' GLY . . . . . 0.412 ' HA2' ' HA ' ' A' ' 333' ' ' VAL . . . -111.05 115.84 4.08 Favored Glycine 0 N--CA 1.444 -0.772 0 N-CA-C 110.189 -1.165 . . . . 0.27000000000000002 110.189 176.858 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 14.2 ptp -133.38 177.75 7.44 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-O 121.498 0.666 . . . . 0.76000000000000001 111.879 -170.498 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 312' ' ' ARG . . . . . 0.424 ' HB3' ' CB ' ' A' ' 327' ' ' THR . 94.1 mtt180 -131.89 144.84 51.15 Favored 'General case' 0 C--N 1.319 -0.717 0 N-CA-C 107.182 -1.414 . . . . 2.5099999999999998 107.182 175.431 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 313' ' ' TYR . . . . . 0.632 ' HB3' HG12 ' A' ' 386' ' ' VAL . 33.6 p90 -159.53 159.27 33.18 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 113.162 0.801 . . . . 0.68000000000000005 113.162 -172.519 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 60.5 t -128.27 113.26 29.5 Favored 'Isoleucine or valine' 0 C--O 1.237 0.423 0 CA-C-N 114.782 -1.099 . . . . 0.34999999999999998 109.024 171.652 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -93.36 116.28 5.14 Favored Glycine 0 C--O 1.239 0.454 0 C-N-CA 121.241 -0.504 . . . . 0.28000000000000003 112.602 -176.44 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 316' ' ' LYS . . . . . 0.726 ' HG2' HG22 ' A' ' 322' ' ' VAL . 26.7 mttp -122.19 154.76 37.03 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-O 121.181 0.515 . . . . 1.9399999999999999 110.885 -177.521 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 317' ' ' LEU . . . . . 0.61 HD21 HG12 ' A' ' 376' ' ' ILE . 69.5 mt -81.04 164.16 22.69 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.202 -0.908 . . . . 0.65000000000000002 109.471 172.481 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 318' ' ' LYS . . . . . 0.452 ' HB2' ' O ' ' A' ' 381' ' ' GLU . 53.2 tptt -60.8 -25.31 66.48 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.074 0.464 . . . . 2.4199999999999999 110.072 175.333 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 74.7 m-20 -75.18 -0.85 20.73 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.82 -0.627 . . . . 2.2000000000000002 111.196 -179.283 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 84.97 10.73 78.11 Favored Glycine 0 C--N 1.334 0.423 0 C-N-CA 120.902 -0.666 . . . . 0.68999999999999995 112.592 178.307 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 321' ' ' LYS . . . . . 0.547 ' HB2' HD12 ' A' ' 317' ' ' LEU . 30.6 mmtp -95.71 125.04 40.01 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.276 -0.268 . . . . 2.4199999999999999 110.276 -179.489 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.726 HG22 ' HG2' ' A' ' 316' ' ' LYS . 50.3 t -83.31 115.36 25.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 110.214 -0.291 . . . . 1.26 110.214 179.221 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 47.7 p90 -91.72 -30.82 16.07 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.919 -0.312 . . . . 0.55000000000000004 111.131 -178.732 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -150.5 153.1 35.23 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 110.025 -0.361 . . . . 1.6799999999999999 110.025 177.531 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 21.0 pttm -163.41 133.32 4.27 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.965 0.412 . . . . 1.99 110.438 -177.08 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 4.1 p30 -155.13 121.44 5.25 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.443 0.639 . . . . 1.9199999999999999 110.119 174.349 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 327' ' ' THR . . . . . 0.424 ' CB ' ' HB3' ' A' ' 312' ' ' ARG . 4.9 t -161.84 -42.51 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.601 -0.727 . . . . 1.6899999999999999 111.485 -175.842 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.44 ' O ' ' HG3' ' A' ' 328' ' ' LYS . 25.1 pttm -79.21 95.1 5.54 Favored 'General case' 0 N--CA 1.454 -0.245 0 CA-C-O 121.568 0.699 . . . . 2.5499999999999998 110.512 -178.344 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.454 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 85.42 -15.36 46.07 Favored Glycine 0 N--CA 1.448 -0.566 0 CA-C-N 115.484 -0.78 . . . . 0.96999999999999997 112.617 179.505 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -104.36 100.59 22.7 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 120.483 0.182 . . . . 2.0800000000000001 111.27 -179.096 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 331' ' ' PRO . . . . . 0.454 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 73.8 Cg_endo -88.06 131.55 2.67 Favored 'Trans proline' 0 N--CA 1.453 -0.888 0 C-N-CA 122.686 2.257 . . . . 0.62 112.027 172.385 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 78.7 t80 -110.28 120.83 43.69 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 109.513 -0.551 . . . . 0.64000000000000001 109.513 177.53 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 333' ' ' VAL . . . . . 0.412 ' HA ' ' HA2' ' A' ' 310' ' ' GLY . 53.2 t -114.49 116.04 51.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.417 -0.356 . . . . 0.38 110.432 -177.402 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.513 ' HZ ' HG21 ' A' ' 349' ' ' VAL . 33.5 p90 -129.0 156.85 43.15 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.832 0.349 . . . . 0.40999999999999998 110.404 178.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 335' ' ' LYS . . . . . 0.589 ' HG3' ' HB3' ' A' ' 308' ' ' ARG . 3.6 mppt? -99.51 135.68 40.56 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.198 -0.456 . . . . 2.5800000000000001 110.604 -179.576 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 9.6 mp -77.03 134.51 38.78 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.42 -0.585 . . . . 0.57999999999999996 109.42 174.105 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 100.72 -1.45 55.51 Favored Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.265 -0.969 . . . . 0.93999999999999995 112.323 -175.544 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 338' ' ' GLN . . . . . 0.439 ' HG2' ' O ' ' A' ' 335' ' ' LYS . 12.1 pt20 -87.94 138.92 31.03 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.673 -0.492 . . . . 2.6200000000000001 109.673 177.371 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -82.17 46.29 3.49 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.614 -0.803 . . . . 0.73999999999999999 112.348 -178.307 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 19.6 mt-10 -121.15 -20.73 6.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.825 0.345 . . . . 2.0899999999999999 110.68 179.209 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 23.0 m -100.49 160.83 3.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 116.416 -0.356 . . . . 0.42999999999999999 110.556 -176.584 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 342' ' ' ILE . . . . . 0.64 HD12 ' HA ' ' A' ' 367' ' ' ALA . 5.2 pt -82.84 159.92 3.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.313 -0.625 . . . . 0.32000000000000001 109.313 175.97 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 343' ' ' LYS . . . . . 0.51 ' HE2' HD11 ' A' ' 347' ' ' ILE . 17.0 mtpt -60.98 -37.31 82.01 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 121.082 -0.247 . . . . 2.9300000000000002 111.648 -173.285 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 344' ' ' GLY . . . . . 0.589 ' HA3' HD13 ' A' ' 362' ' ' ILE . . . -53.29 -35.43 50.18 Favored Glycine 0 CA--C 1.519 0.307 0 C-N-CA 121.003 -0.618 . . . . 0.29999999999999999 112.556 176.575 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 8.0 m95 -73.6 -61.61 1.78 Allowed 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 111.796 0.295 . . . . 0.39000000000000001 111.796 178.531 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -52.8 -36.77 58.82 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-O 120.918 0.39 . . . . 1.75 111.476 -178.387 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 347' ' ' ILE . . . . . 0.51 HD11 ' HE2' ' A' ' 343' ' ' LYS . 74.9 mt -84.48 -48.16 16.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.236 -0.438 . . . . 0.39000000000000001 111.387 -177.474 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -64.7 -33.5 87.39 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 121.039 -0.6 . . . . 0.34000000000000002 113.28 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 349' ' ' VAL . . . . . 0.543 ' O ' ' HB2' ' A' ' 352' ' ' MET . 95.2 t -80.99 -14.24 12.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.016 0.436 . . . . 0.32000000000000001 110.752 179.313 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -64.79 115.74 5.6 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.992 0.425 . . . . 0.46999999999999997 109.954 174.861 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 88.65 21.94 41.72 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.381 -0.914 . . . . 0.39000000000000001 112.183 -176.088 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 352' ' ' MET . . . . . 0.543 ' HB2' ' O ' ' A' ' 349' ' ' VAL . 0.0 OUTLIER -81.08 151.36 28.37 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.109 -0.7 . . . . 1.28 109.109 174.407 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 353' ' ' ALA . . . . . . . . . . . . . . . -121.49 130.63 53.67 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.731 0.3 . . . . 0.55000000000000004 111.35 -176.449 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 98.2 t -57.43 119.43 2.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 116.067 -0.515 . . . . 0.35999999999999999 110.428 174.326 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 107.65 -10.71 38.56 Favored Glycine 0 N--CA 1.448 -0.533 0 C-N-CA 121.065 -0.588 . . . . 0.44 111.965 -177.466 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -104.24 160.41 15.9 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.802 -0.714 . . . . 0.29999999999999999 112.868 -178.812 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 357' ' ' GLU . . . . . 0.567 ' HB2' ' HB3' ' A' ' 387' ' ' LYS . 41.5 tt0 -136.85 134.17 36.63 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 122.773 0.429 . . . . 1.4099999999999999 109.937 178.731 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 358' ' ' ARG . . . . . 0.459 ' HA ' ' H ' ' A' ' 295' ' ' ARG . 4.3 ptp180 -146.65 146.86 30.53 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 121.317 0.58 . . . . 1.3700000000000001 111.298 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 359' ' ' ARG . . . . . . . . . . . . . 35.1 ttm180 -87.79 119.08 27.78 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.111 -0.949 . . . . 2.79 109.909 177.66 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 53.7 mt -98.29 119.67 46.62 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 CA-C-N 115.942 -0.572 . . . . 0.38 109.892 179.65 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 361' ' ' VAL . . . . . . . . . . . . . 74.6 t -103.23 109.09 25.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 115.244 -0.889 . . . . 0.39000000000000001 108.856 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 362' ' ' ILE . . . . . 0.589 HD13 ' HA3' ' A' ' 344' ' ' GLY . 28.8 mt -115.57 107.91 48.09 Favored Pre-proline 0 C--N 1.323 -0.564 0 CA-C-N 116.484 -0.325 . . . . 0.28999999999999998 111.038 -173.313 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 363' ' ' PRO . . . . . 0.488 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 11.6 Cg_endo -56.35 151.48 44.45 Favored 'Trans proline' 0 C--O 1.236 0.425 0 C-N-CA 122.373 2.048 . . . . 0.66000000000000003 111.152 171.377 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 364' ' ' ALA . . . . . . . . . . . . . . . -46.96 -48.95 51.83 Favored Pre-proline 0 CA--C 1.541 0.624 0 N-CA-C 114.126 1.158 . . . . 0.41999999999999998 114.126 -174.137 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 365' ' ' PRO . . . . . 0.488 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 75.5 Cg_exo -51.42 -29.05 29.66 Favored 'Trans proline' 0 C--N 1.365 1.399 0 C-N-CA 122.54 2.16 . . . . 0.69999999999999996 114.05 -176.162 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 366' ' ' TYR . . . . . . . . . . . . . 9.1 m-85 -106.17 4.39 28.94 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 111.917 0.339 . . . . 0.68999999999999995 111.917 -175.357 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 367' ' ' ALA . . . . . 0.688 ' HB1' HD12 ' A' ' 382' ' ' LEU . . . -117.08 -30.21 5.73 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 112.251 0.464 . . . . 0.85999999999999999 112.251 -179.174 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 9.5 m-85 -165.46 -32.46 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 120.941 0.401 . . . . 1.0 110.53 -176.762 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 101.62 -128.79 9.68 Favored Glycine 0 N--CA 1.446 -0.636 0 C-N-CA 120.821 -0.704 . . . . 0.56000000000000005 111.983 177.863 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 21.1 ptmt -108.84 11.02 26.43 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.007 0.432 . . . . 2.7599999999999998 110.538 -179.504 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 51.9 tt0 -85.05 103.15 13.82 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.972 -0.558 . . . . 2.6499999999999999 110.306 -177.179 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 372' ' ' ALA . . . . . . . . . . . . . . . -77.65 94.93 4.48 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.076 0.465 . . . . 1.01 110.919 -179.687 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 80.2 mt -73.91 155.88 88.39 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-N 115.706 -0.679 . . . . 0.93000000000000005 109.599 176.159 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -57.61 114.32 1.9 Allowed 'Trans proline' 0 N--CA 1.46 -0.454 0 C-N-CA 121.664 1.576 . . . . 1.3100000000000001 110.81 173.886 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 97.62 -29.55 10.8 Favored Glycine 0 CA--C 1.519 0.305 0 C-N-CA 121.034 -0.603 . . . . 0.90000000000000002 112.558 -177.948 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 376' ' ' ILE . . . . . 0.61 HG12 HD21 ' A' ' 317' ' ' LEU . 25.9 mt -124.45 85.47 55.9 Favored Pre-proline 0 C--N 1.328 -0.347 0 O-C-N 122.808 -0.23 . . . . 0.73999999999999999 110.554 -178.591 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 377' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -75.02 165.73 30.68 Favored 'Trans proline' 0 N--CA 1.46 -0.49 0 C-N-CA 122.666 2.244 . . . . 0.70999999999999996 112.413 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 378' ' ' ALA . . . . . 0.426 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -64.96 159.84 22.06 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.084 -0.507 . . . . 0.73999999999999999 111.595 -178.967 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 379' ' ' ASN . . . . . 0.426 ' HB2' ' O ' ' A' ' 378' ' ' ALA . 83.3 m-20 73.66 -8.16 1.43 Allowed 'General case' 0 N--CA 1.473 0.676 0 CA-C-N 115.501 -0.772 . . . . 1.49 111.833 179.376 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 48.6 m -70.13 114.3 8.15 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.056 0.455 . . . . 1.8400000000000001 110.928 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 381' ' ' GLU . . . . . 0.452 ' O ' ' HB2' ' A' ' 318' ' ' LYS . 33.0 tt0 -73.5 106.8 5.44 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.549 -0.75 . . . . 1.03 109.862 177.548 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 382' ' ' LEU . . . . . 0.688 HD12 ' HB1' ' A' ' 367' ' ' ALA . 65.9 mt -78.91 141.23 37.78 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.68 0.276 . . . . 0.37 110.394 -178.241 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 24.3 m -123.91 124.85 43.54 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-O 121.002 0.43 . . . . 0.27000000000000002 110.218 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -120.01 112.19 18.84 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.245 -0.434 . . . . 0.32000000000000001 110.932 -178.142 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 385' ' ' ASP . . . . . 0.406 ' O ' ' HA ' ' A' ' 313' ' ' TYR . 72.4 m-20 -86.37 105.4 16.68 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 108.728 -0.841 . . . . 1.8 108.728 174.093 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 386' ' ' VAL . . . . . 0.632 HG12 ' HB3' ' A' ' 313' ' ' TYR . 22.2 m -121.72 136.47 58.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.212 0.53 . . . . 0.31 112.072 -173.64 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 387' ' ' LYS . . . . . 0.567 ' HB3' ' HB2' ' A' ' 357' ' ' GLU . 1.3 ptpp? -123.86 137.28 54.68 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.818 -0.628 . . . . 2.5299999999999998 109.449 170.181 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 388' ' ' LEU . . . . . 0.832 HD11 ' HB ' ' A' ' 309' ' ' VAL . 19.1 tp -95.42 134.28 38.41 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 109.551 -0.537 . . . . 0.28000000000000003 109.551 -177.377 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 30.9 m -127.91 -5.07 4.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 111.955 0.354 . . . . 0.45000000000000001 111.955 -174.146 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 12.5 p -165.68 159.77 16.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.653 -0.248 . . . . 1.3200000000000001 111.093 -178.484 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 391' ' ' MET . . . . . 0.708 ' HG2' ' HG2' ' A' ' 392' ' ' LYS . 41.8 ttm -164.59 155.94 15.4 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.971 -0.559 . . . . 0.56000000000000005 109.832 178.282 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 392' ' ' LYS . . . . . 0.708 ' HG2' ' HG2' ' A' ' 391' ' ' MET . 32.1 mmmt . . . . . 0 C--O 1.247 0.923 0 O-C-N 124.259 0.975 . . . . 4.9100000000000001 111.611 175.154 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.456 HG22 ' HB2' ' A' ' 293' ' ' GLU . 18.2 p . . . . . 0 C--O 1.235 0.302 0 CA-C-O 121.091 0.472 . . . . 0.76000000000000001 111.679 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 284' ' ' LYS . . . . . 0.466 ' O ' ' HA ' ' A' ' 291' ' ' ILE . 92.8 mttt -118.52 144.17 46.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.41 -0.814 . . . . 2.0600000000000001 111.026 -173.497 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 285' ' ' LEU . . . . . 0.547 HD11 ' HA2' ' A' ' 289' ' ' GLY . 56.3 tp -102.8 123.99 47.49 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.466 -0.788 . . . . 0.97999999999999998 110.373 -177.964 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.461 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 98.6 mt -113.35 -175.74 2.74 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.9 -0.591 . . . . 0.80000000000000004 109.703 178.44 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 287' ' ' GLU . . . . . 0.447 ' HG2' ' OH ' ' A' ' 366' ' ' TYR . 27.6 tt0 -56.73 144.07 34.05 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.178 0.513 . . . . 2.6400000000000001 111.629 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.423 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 72.48 0.32 46.58 Favored Glycine 0 CA--C 1.52 0.352 0 CA-C-N 115.78 -0.646 . . . . 1.8400000000000001 113.806 179.033 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 289' ' ' GLY . . . . . 0.547 ' HA2' HD11 ' A' ' 285' ' ' LEU . . . 95.11 12.37 55.07 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.696 -0.764 . . . . 0.64000000000000001 113.028 179.109 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 290' ' ' ILE . . . . . 0.461 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 71.9 mt -66.62 121.54 15.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 121.253 0.549 . . . . 0.41999999999999998 110.957 -179.071 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.628 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 18.5 mm -104.38 138.96 26.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 115.737 -0.665 . . . . 0.93000000000000005 110.232 178.898 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 292' ' ' ILE . . . . . . . . . . . . . 21.5 pt -127.29 129.36 70.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 120.925 0.393 . . . . 0.47999999999999998 110.685 177.109 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 293' ' ' GLU . . . . . 0.459 ' OE1' ' HD2' ' A' ' 359' ' ' ARG . 24.6 tt0 -118.83 117.96 30.28 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.661 -0.7 . . . . 2.3100000000000001 109.759 177.906 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 294' ' ' ASP . . . . . 0.403 ' OD1' ' HA ' ' A' ' 297' ' ' THR . 0.5 OUTLIER -88.33 96.14 10.46 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.654 -0.869 . . . . 2.3599999999999999 108.654 -178.655 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 295' ' ' ARG . . . . . 0.828 HH22 ' HB3' ' A' ' 385' ' ' ASP . 38.0 ttp180 -76.11 -47.28 25.05 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.598 -0.728 . . . . 3.5 111.587 -171.751 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.736 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 23.3 t -119.03 103.5 14.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 N-CA-C 109.057 -0.719 . . . . 0.69999999999999996 109.057 172.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 297' ' ' THR . . . . . 0.403 ' HA ' ' OD1' ' A' ' 294' ' ' ASP . 32.1 p -62.09 113.32 2.77 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 114.931 -1.031 . . . . 1.9299999999999999 112.197 -174.023 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -119.88 152.02 17.2 Favored Glycine 0 N--CA 1.444 -0.769 0 CA-C-N 115.652 -0.703 . . . . 1.04 111.642 178.003 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -127.74 114.12 16.88 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.759 0.314 . . . . 4.4900000000000002 110.336 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -170.56 -154.6 9.65 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 121.011 -0.614 . . . . 1.04 112.013 -179.414 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 301' ' ' PRO . . . . . 0.592 ' HD2' ' HB ' ' A' ' 354' ' ' VAL . 28.1 Cg_exo -62.33 137.85 67.97 Favored 'Trans proline' 0 C--O 1.233 0.234 0 C-N-CA 122.833 2.355 . . . . 0.88 112.048 178.656 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 302' ' ' HIS . . . . . 0.505 ' HA ' ' O ' ' A' ' 352' ' ' MET . 39.0 m80 -102.5 134.25 46.14 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 120.938 0.399 . . . . 1.49 110.714 178.157 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -69.54 132.41 46.22 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.986 -0.552 . . . . 0.54000000000000004 111.685 -178.558 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 32.6 mmtp -117.19 177.96 4.53 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.042 -0.725 . . . . 2.8399999999999999 109.042 176.105 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 61.4 mttm -68.77 132.24 46.48 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 109.698 -0.482 . . . . 2.8399999999999999 109.698 173.27 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 84.74 7.97 83.43 Favored Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.697 -0.764 . . . . 0.69999999999999996 112.553 -176.97 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 20.2 m -96.72 147.81 23.53 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 110.286 -0.265 . . . . 0.40000000000000002 110.286 177.381 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 47.4 mtt180 -102.56 130.82 49.52 Favored 'General case' 0 CA--C 1.515 -0.395 0 N-CA-C 108.993 -0.743 . . . . 3.4500000000000002 108.993 178.743 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.836 ' HB ' HD11 ' A' ' 388' ' ' LEU . 19.7 m -130.39 137.75 55.49 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-O 121.125 0.488 . . . . 0.34000000000000002 111.815 -177.961 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -107.7 120.11 5.98 Favored Glycine 0 N--CA 1.444 -0.789 0 N-CA-C 109.826 -1.31 . . . . 0.27000000000000002 109.826 176.336 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 311' ' ' MET . . . . . 0.599 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 22.9 ptm -140.01 177.04 8.25 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.58 0.705 . . . . 0.76000000000000001 112.212 -171.321 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 312' ' ' ARG . . . . . 0.493 ' HB3' ' HA ' ' A' ' 327' ' ' THR . 20.9 mtm180 -133.64 145.37 49.92 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 107.228 -1.397 . . . . 2.5099999999999998 107.228 174.937 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 313' ' ' TYR . . . . . 0.535 ' CB ' HG12 ' A' ' 386' ' ' VAL . 41.7 p90 -161.57 158.7 26.72 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 113.23 0.826 . . . . 0.68000000000000005 113.23 -173.362 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 47.8 t -125.99 127.08 70.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 114.695 -1.139 . . . . 0.34999999999999998 109.688 174.621 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -96.96 106.73 3.39 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 121.116 -0.564 . . . . 0.28000000000000003 112.139 -179.656 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 316' ' ' LYS . . . . . 0.796 ' HG2' HG22 ' A' ' 322' ' ' VAL . 86.4 mttt -113.07 154.2 26.94 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.282 0.563 . . . . 1.9399999999999999 111.722 -175.328 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 317' ' ' LEU . . . . . 0.431 HD12 ' HB3' ' A' ' 321' ' ' LYS . 88.8 mt -88.84 164.81 15.04 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.639 -0.71 . . . . 0.65000000000000002 109.107 169.682 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 318' ' ' LYS . . . . . . . . . . . . . 37.8 ttpt -66.55 -21.94 66.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.991 0.424 . . . . 2.4199999999999999 110.858 178.928 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 28.1 p30 -83.74 4.72 27.61 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.011 0.434 . . . . 2.2000000000000002 111.028 179.101 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 91.21 -9.5 77.4 Favored Glycine 0 C--N 1.33 0.235 0 C-N-CA 121.252 -0.499 . . . . 0.68999999999999995 113.258 174.673 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 321' ' ' LYS . . . . . 0.431 ' HB3' HD12 ' A' ' 317' ' ' LEU . 22.2 ttmm -77.98 123.55 26.94 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.896 0.379 . . . . 2.4199999999999999 110.37 -179.003 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.796 HG22 ' HG2' ' A' ' 316' ' ' LYS . 67.7 t -85.44 128.49 39.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 116.171 -0.468 . . . . 1.26 110.368 -179.681 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 35.6 p90 -100.81 -35.26 9.5 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.645 -0.422 . . . . 0.55000000000000004 111.587 -179.343 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -146.95 168.55 21.21 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 120.789 -0.364 . . . . 1.6799999999999999 110.108 178.21 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 325' ' ' LYS . . . . . 0.581 ' HD3' ' N ' ' A' ' 325' ' ' LYS . 0.0 OUTLIER -176.55 143.48 0.48 Allowed 'General case' 0 C--O 1.233 0.192 0 CA-C-O 121.247 0.546 . . . . 1.99 111.781 -173.612 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 3.1 p30 -150.73 118.06 6.02 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.576 -0.738 . . . . 1.9199999999999999 109.41 165.601 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 327' ' ' THR . . . . . 0.493 ' HA ' ' HB3' ' A' ' 312' ' ' ARG . 30.7 m -150.7 -55.39 0.15 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.952 -0.567 . . . . 1.6899999999999999 111.169 -175.781 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 34.8 mtmm -72.04 94.21 1.47 Allowed 'General case' 0 C--O 1.235 0.299 0 CA-C-O 120.981 0.42 . . . . 2.5499999999999998 111.272 -177.225 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.506 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 80.24 -10.68 41.0 Favored Glycine 0 N--CA 1.45 -0.422 0 CA-C-N 115.863 -0.608 . . . . 0.96999999999999997 112.971 175.99 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 25.6 mtpp -103.9 100.7 21.31 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.789 0.294 . . . . 2.0800000000000001 110.955 -177.507 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 331' ' ' PRO . . . . . 0.506 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 64.2 Cg_endo -88.26 136.38 3.41 Favored 'Trans proline' 0 N--CA 1.453 -0.907 0 C-N-CA 122.724 2.282 . . . . 0.62 112.115 172.547 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 75.4 t80 -110.78 122.83 48.8 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.461 -0.57 . . . . 0.64000000000000001 109.461 177.772 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 333' ' ' VAL . . . . . 0.489 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 51.5 t -118.78 115.07 46.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 N-CA-C 110.176 -0.305 . . . . 0.38 110.176 -176.731 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.599 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 23.4 p90 -133.48 172.19 13.06 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.649 0.262 . . . . 0.40999999999999998 110.597 -178.743 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 335' ' ' LYS . . . . . 0.747 ' HD2' ' H ' ' A' ' 335' ' ' LYS . 0.0 OUTLIER -117.29 140.38 49.62 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.335 -0.393 . . . . 2.5800000000000001 110.208 -179.928 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 10.1 mp -79.22 151.03 31.44 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.707 0.289 . . . . 0.57999999999999996 110.646 178.486 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 92.31 9.14 62.14 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.828 -0.701 . . . . 0.93999999999999995 112.007 -176.105 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 338' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -98.17 161.54 13.66 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.796 0.332 . . . . 2.6200000000000001 110.511 -179.687 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -99.82 4.54 57.79 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.852 -0.689 . . . . 0.73999999999999999 112.277 -179.588 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 66.9 mm-40 -73.54 -34.13 65.05 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.904 0.383 . . . . 2.0899999999999999 110.674 178.347 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 34.4 m -100.41 156.47 4.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.988 -0.551 . . . . 0.42999999999999999 110.972 -178.165 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 12.8 pt -71.44 161.91 4.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.471 -0.331 . . . . 0.32000000000000001 110.523 177.734 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.4 -38.45 87.1 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.359 -0.382 . . . . 2.9300000000000002 111.84 -176.738 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -51.56 -36.53 39.41 Favored Glycine 0 C--N 1.331 0.255 0 C-N-CA 121.135 -0.555 . . . . 0.29999999999999999 112.544 175.924 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 9.3 m95 -73.25 -60.3 2.31 Favored 'General case' 0 C--O 1.223 -0.338 0 CA-C-O 120.405 0.145 . . . . 0.39000000000000001 111.067 177.181 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -49.45 -33.87 15.25 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.242 -0.436 . . . . 1.75 112.109 179.774 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 65.9 mt -85.76 -54.96 7.34 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.358 0 CA-C-N 116.638 -0.255 . . . . 0.39000000000000001 111.661 178.55 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -60.97 -36.68 92.6 Favored Glycine 0 CA--C 1.521 0.434 0 C-N-CA 121.585 -0.34 . . . . 0.34000000000000002 113.822 -177.462 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 349' ' ' VAL . . . . . 0.485 HG21 ' HZ ' ' A' ' 334' ' ' PHE . 95.1 t -72.0 -24.96 23.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 120.904 0.383 . . . . 0.32000000000000001 110.691 179.601 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.53 108.71 2.1 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.804 -0.443 . . . . 0.46999999999999997 109.804 175.849 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 107.73 4.67 34.16 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 121.11 -0.567 . . . . 0.39000000000000001 112.216 -175.494 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 352' ' ' MET . . . . . 0.505 ' O ' ' HA ' ' A' ' 302' ' ' HIS . 0.0 OUTLIER -73.03 140.8 47.52 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 109.276 -0.639 . . . . 1.28 109.276 176.158 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 353' ' ' ALA . . . . . 0.46 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -108.08 132.07 53.95 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.732 0.301 . . . . 0.55000000000000004 111.042 -177.353 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 354' ' ' VAL . . . . . 0.592 ' HB ' ' HD2' ' A' ' 301' ' ' PRO . 78.4 t -56.58 116.22 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 120.968 0.414 . . . . 0.35999999999999999 110.551 175.031 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 110.67 -19.31 26.18 Favored Glycine 0 N--CA 1.445 -0.754 0 N-CA-C 111.59 -0.604 . . . . 0.44 111.59 -177.35 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -83.9 148.26 24.47 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 121.168 -0.539 . . . . 0.29999999999999999 112.694 -176.307 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 357' ' ' GLU . . . . . 0.736 ' HB3' ' HB ' ' A' ' 296' ' ' VAL . 5.0 tp10 -126.61 117.94 23.82 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 108.973 -0.751 . . . . 1.4099999999999999 108.973 179.876 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 358' ' ' ARG . . . . . 0.481 ' HG2' ' CE ' ' A' ' 352' ' ' MET . 6.2 ptp180 -145.16 148.44 33.59 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.362 0.601 . . . . 1.3700000000000001 112.303 -173.15 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 359' ' ' ARG . . . . . 0.459 ' HD2' ' OE1' ' A' ' 293' ' ' GLU . 60.2 mtt85 -89.24 128.02 35.81 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.75 -0.659 . . . . 2.79 110.233 171.975 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 57.9 mt -110.97 118.39 57.23 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 N-CA-C 109.201 -0.666 . . . . 0.38 109.201 174.396 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 361' ' ' VAL . . . . . 0.628 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 51.4 t -96.97 117.51 41.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.19 -0.67 . . . . 0.39000000000000001 109.19 178.997 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 362' ' ' ILE . . . . . . . . . . . . . 65.1 mt -115.01 103.98 54.31 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 116.339 -0.392 . . . . 0.28999999999999998 110.818 -174.241 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 363' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -60.29 160.08 24.52 Favored 'Trans proline' 0 N--CA 1.463 -0.285 0 C-N-CA 122.642 2.228 . . . . 0.66000000000000003 112.007 174.771 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 364' ' ' ALA . . . . . 0.497 ' N ' ' HD2' ' A' ' 365' ' ' PRO . . . -47.23 -51.09 44.34 Favored Pre-proline 0 CA--C 1.539 0.535 0 N-CA-C 114.191 1.182 . . . . 0.41999999999999998 114.191 -176.126 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 365' ' ' PRO . . . . . 0.497 ' HD2' ' N ' ' A' ' 364' ' ' ALA . 16.8 Cg_endo -56.66 -25.87 62.19 Favored 'Trans proline' 0 C--N 1.358 1.078 0 C-N-CA 122.256 1.971 . . . . 0.69999999999999996 114.168 -171.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 366' ' ' TYR . . . . . 0.447 ' OH ' ' HG2' ' A' ' 287' ' ' GLU . 4.1 m-85 -103.36 12.11 35.78 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-O 121.036 0.446 . . . . 0.68999999999999995 111.236 -177.085 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -127.56 -116.43 0.26 Allowed 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 115.664 -0.698 . . . . 0.85999999999999999 110.162 173.515 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 86.2 m-85 -85.51 -14.4 46.07 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.689 0.28 . . . . 1.0 111.712 -177.804 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 62.94 -109.18 2.53 Favored Glycine 0 N--CA 1.452 -0.265 0 CA-C-N 116.183 -0.462 . . . . 0.56000000000000005 113.572 174.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 370' ' ' LYS . . . . . 0.482 ' HA ' ' HB1' ' A' ' 378' ' ' ALA . 58.0 mttm -102.72 8.06 39.58 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 111.722 0.267 . . . . 2.7599999999999998 111.722 -175.763 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 7.4 tp60 -88.83 99.55 12.47 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.964 0.411 . . . . 2.6499999999999999 110.382 179.676 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 372' ' ' ALA . . . . . . . . . . . . . . . -74.31 110.8 8.9 Favored 'General case' 0 N--CA 1.45 -0.441 0 CA-C-N 115.931 -0.577 . . . . 1.01 111.005 178.644 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 71.9 mt -101.37 161.0 24.97 Favored Pre-proline 0 C--N 1.321 -0.641 0 N-CA-C 109.076 -0.713 . . . . 0.93000000000000005 109.076 176.601 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_exo -60.55 114.64 2.22 Favored 'Trans proline' 0 N--CA 1.46 -0.484 0 C-N-CA 121.546 1.498 . . . . 1.3100000000000001 110.96 174.791 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 92.0 -19.87 46.34 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.749 -0.738 . . . . 0.90000000000000002 112.327 -178.559 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 23.6 mt -132.47 78.4 67.71 Favored Pre-proline 0 N--CA 1.465 0.287 0 CA-C-O 120.836 0.35 . . . . 0.73999999999999999 110.512 -179.018 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 377' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_exo -70.72 166.89 27.33 Favored 'Trans proline' 0 N--CA 1.463 -0.319 0 C-N-CA 122.764 2.31 . . . . 0.70999999999999996 113.017 -178.192 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 378' ' ' ALA . . . . . 0.482 ' HB1' ' HA ' ' A' ' 370' ' ' LYS . . . -56.1 151.78 11.65 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.742 -0.663 . . . . 0.73999999999999999 110.846 178.036 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 379' ' ' ASN . . . . . 0.414 ' HA ' ' CB ' ' A' ' 364' ' ' ALA . 84.1 m-20 64.92 32.25 10.83 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.184 0.516 . . . . 1.49 110.306 -178.423 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -77.63 117.02 18.65 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-N 115.643 -0.708 . . . . 1.8400000000000001 111.158 177.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 381' ' ' GLU . . . . . . . . . . . . . 19.3 tt0 -92.05 100.63 13.23 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.031 -0.729 . . . . 1.03 109.031 177.394 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 78.8 mt -94.3 149.53 21.15 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.776 -0.647 . . . . 0.37 112.155 -170.952 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 29.5 m -127.99 128.43 45.02 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.746 -0.464 . . . . 0.27000000000000002 109.746 176.304 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -119.65 113.09 20.15 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.573 -0.285 . . . . 0.32000000000000001 111.248 -177.885 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 385' ' ' ASP . . . . . 0.828 ' HB3' HH22 ' A' ' 295' ' ' ARG . 1.6 m-20 -79.58 105.33 10.81 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.22 -1.03 . . . . 1.8 108.22 172.267 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 386' ' ' VAL . . . . . 0.591 ' HB ' ' CE ' ' A' ' 311' ' ' MET . 33.8 m -126.09 131.32 71.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.386 0.613 . . . . 0.31 112.456 -171.833 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 387' ' ' LYS . . . . . 0.489 ' HB2' ' CD ' ' A' ' 357' ' ' GLU . 49.9 tttm -126.63 132.07 51.32 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.933 -0.576 . . . . 2.5299999999999998 109.835 175.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 388' ' ' LEU . . . . . 0.836 HD11 ' HB ' ' A' ' 309' ' ' VAL . 23.2 tp -94.67 137.53 33.66 Favored 'General case' 0 C--N 1.319 -0.717 0 N-CA-C 108.992 -0.744 . . . . 0.28000000000000003 108.992 -178.45 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 33.7 m -126.93 -7.09 4.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 111.993 0.368 . . . . 0.45000000000000001 111.993 -174.953 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 25.2 p -167.5 164.25 14.85 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.701 0.286 . . . . 1.3200000000000001 111.273 -177.498 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 391' ' ' MET . . . . . 0.401 ' HE3' ' HB2' ' A' ' 391' ' ' MET . 39.6 ttm -158.74 147.55 18.66 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.053 -0.521 . . . . 0.56000000000000005 110.337 179.392 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 392' ' ' LYS . . . . . 0.479 ' NZ ' ' HB3' ' A' ' 392' ' ' LYS . 8.3 mtpm? . . . . . 0 C--O 1.248 0.993 0 CA-C-O 118.603 -0.713 . . . . 4.9100000000000001 109.961 177.633 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 22.3 p . . . . . 0 C--O 1.236 0.366 0 CA-C-O 120.871 0.367 . . . . 0.76000000000000001 111.711 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 60.6 mttp -134.33 141.32 46.87 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.779 -0.646 . . . . 2.0600000000000001 109.676 175.562 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 39.3 tp -95.48 122.35 38.12 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 116.184 -0.462 . . . . 0.97999999999999998 111.04 -178.872 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.662 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 98.2 mt -96.35 -170.92 2.18 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.931 -0.577 . . . . 0.80000000000000004 110.599 176.945 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 287' ' ' GLU . . . . . 0.478 ' HG3' ' OH ' ' A' ' 366' ' ' TYR . 6.5 tp10 -52.86 145.21 12.98 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 115.901 -0.59 . . . . 2.6400000000000001 111.551 178.808 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.514 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 72.22 -101.61 1.07 Allowed Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.947 -0.57 . . . . 1.8400000000000001 111.736 -177.962 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . -148.15 25.57 1.42 Allowed Glycine 0 N--CA 1.444 -0.791 0 N-CA-C 110.214 -1.155 . . . . 0.64000000000000001 110.214 175.808 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 290' ' ' ILE . . . . . 0.662 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 73.1 mt -72.36 124.72 29.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.235 -0.482 . . . . 0.41999999999999998 110.446 -175.731 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.582 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 16.2 mt -107.28 139.39 29.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 116.201 -0.454 . . . . 0.93000000000000005 109.965 -177.217 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 292' ' ' ILE . . . . . . . . . . . . . 14.8 pt -128.06 127.53 67.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 121.176 0.512 . . . . 0.47999999999999998 110.797 177.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 293' ' ' GLU . . . . . 0.435 ' CD ' HH21 ' A' ' 359' ' ' ARG . 30.2 tt0 -114.65 118.26 33.17 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 114.929 -1.032 . . . . 2.3100000000000001 109.123 177.518 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -81.23 114.08 19.79 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.222 -0.591 . . . . 2.3599999999999999 110.06 -174.09 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 295' ' ' ARG . . . . . 0.561 ' HG2' ' HA ' ' A' ' 358' ' ' ARG . 20.3 mmm180 -86.45 -56.08 3.6 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.632 -0.713 . . . . 3.5 110.365 -174.242 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.569 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 96.7 t -124.0 125.01 70.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.908 -0.587 . . . . 0.69999999999999996 109.905 178.745 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 3.9 t -64.1 141.25 58.84 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.284 0.564 . . . . 1.9299999999999999 111.688 -177.956 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -150.78 142.11 9.28 Favored Glycine 0 N--CA 1.443 -0.89 0 N-CA-C 110.992 -0.843 . . . . 1.04 110.992 176.024 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 51.5 pttt -131.55 117.61 18.99 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.379 0.609 . . . . 4.4900000000000002 110.534 177.188 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -172.01 -154.43 10.03 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.335 -0.848 . . . . 1.04 111.063 -177.688 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 301' ' ' PRO . . . . . 0.463 ' O ' ' HA ' ' A' ' 353' ' ' ALA . 24.6 Cg_exo -62.66 133.53 42.77 Favored 'Trans proline' 0 N--CA 1.462 -0.34 0 C-N-CA 122.356 2.038 . . . . 0.88 111.404 176.282 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 35.9 m80 -95.12 130.15 41.94 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.308 -0.406 . . . . 1.49 110.45 178.474 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 303' ' ' ALA . . . . . 0.496 ' HB2' HG11 ' A' ' 309' ' ' VAL . . . -67.12 133.58 50.1 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.587 -0.733 . . . . 0.54000000000000004 111.434 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 64.4 pttt -132.2 179.13 6.29 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 108.762 -0.829 . . . . 2.8399999999999999 108.762 173.499 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 23.5 ttmm -66.33 135.62 54.63 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 120.587 -0.445 . . . . 2.8399999999999999 110.333 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 92.48 -7.04 77.97 Favored Glycine 0 CA--C 1.521 0.42 0 C-N-CA 121.078 -0.582 . . . . 0.69999999999999996 112.427 -174.774 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 30.3 m -88.97 150.03 23.01 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.716 0.293 . . . . 0.40000000000000002 110.842 -178.484 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 82.2 mtt180 -115.31 102.52 9.93 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 109.468 -0.567 . . . . 3.4500000000000002 109.468 -178.993 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.802 ' HB ' HD11 ' A' ' 388' ' ' LEU . 35.7 m -102.52 148.26 8.11 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.807 0 CA-C-N 115.592 -0.731 . . . . 0.34000000000000002 112.458 -175.384 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -113.37 118.24 4.46 Favored Glycine 0 N--CA 1.446 -0.69 0 N-CA-C 110.672 -0.971 . . . . 0.27000000000000002 110.672 176.554 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 311' ' ' MET . . . . . 0.5 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 6.8 ptm -139.48 178.49 7.18 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.788 0.804 . . . . 0.76000000000000001 112.434 -172.531 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 55.0 mtt180 -136.06 152.57 51.02 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 113.896 -1.502 . . . . 2.5099999999999998 107.68 176.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 313' ' ' TYR . . . . . 0.559 ' CB ' HG12 ' A' ' 386' ' ' VAL . 32.8 p90 -159.57 158.89 32.54 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 119.556 -0.858 . . . . 0.68000000000000005 113.276 -174.474 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 314' ' ' VAL . . . . . 0.572 HG12 ' HG3' ' A' ' 316' ' ' LYS . 57.9 t -127.02 102.99 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 CA-C-N 114.811 -1.086 . . . . 0.34999999999999998 109.355 171.071 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -87.13 110.32 3.54 Favored Glycine 0 C--O 1.237 0.336 0 N-CA-C 112.082 -0.407 . . . . 0.28000000000000003 112.082 -178.47 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 316' ' ' LYS . . . . . 0.757 ' HG2' ' HB ' ' A' ' 322' ' ' VAL . 33.2 mtmm -126.37 156.03 41.16 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.842 0.353 . . . . 1.9399999999999999 110.92 -174.794 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 317' ' ' LEU . . . . . 0.536 HD12 ' HB3' ' A' ' 321' ' ' LYS . 82.6 mt -81.73 173.33 12.41 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.821 -0.627 . . . . 0.65000000000000002 110.963 177.007 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 318' ' ' LYS . . . . . . . . . . . . . 60.3 tttp -65.26 -22.27 66.84 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.606 -0.724 . . . . 2.4199999999999999 110.674 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 32.6 p-10 -91.67 -1.36 57.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.411 -0.359 . . . . 2.2000000000000002 111.095 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 97.83 -5.31 61.77 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.927 -0.654 . . . . 0.68999999999999995 113.211 178.129 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 321' ' ' LYS . . . . . 0.536 ' HB3' HD12 ' A' ' 317' ' ' LEU . 14.4 tppt? -73.09 111.71 8.45 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.834 0.349 . . . . 2.4199999999999999 110.27 -179.767 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.757 ' HB ' ' HG2' ' A' ' 316' ' ' LYS . 5.4 p -81.4 124.33 38.77 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 116.178 -0.464 . . . . 1.26 110.425 179.034 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 50.4 p90 -102.36 -32.23 10.11 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.908 -0.317 . . . . 0.55000000000000004 111.323 -177.492 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -148.3 132.46 17.35 Favored 'General case' 0 CA--C 1.515 -0.38 0 N-CA-C 109.954 -0.387 . . . . 1.6799999999999999 109.954 -179.203 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 325' ' ' LYS . . . . . 0.414 ' HD3' HG21 ' A' ' 322' ' ' VAL . 59.3 pttt -153.97 134.7 13.67 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.907 0.384 . . . . 1.99 111.449 -174.824 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 326' ' ' ASN . . . . . 0.635 ' HB2' ' HB2' ' A' ' 330' ' ' LYS . 3.9 p30 -146.66 117.08 7.45 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.697 0.76 . . . . 1.9199999999999999 110.322 169.88 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 3.2 p -142.16 -40.83 0.35 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.909 -1.041 . . . . 1.6899999999999999 110.363 179.205 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 21.1 pttp -80.51 101.93 9.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.331 0.586 . . . . 2.5499999999999998 111.432 -178.731 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.514 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 76.04 -13.85 6.88 Favored Glycine 0 N--CA 1.452 -0.237 0 CA-C-N 115.616 -0.72 . . . . 0.96999999999999997 113.633 175.212 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 330' ' ' LYS . . . . . 0.635 ' HB2' ' HB2' ' A' ' 326' ' ' ASN . 27.4 mmmt -103.76 101.52 25.11 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 117.305 0.552 . . . . 2.0800000000000001 111.068 -178.025 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 331' ' ' PRO . . . . . 0.514 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 72.2 Cg_endo -87.83 126.59 2.14 Favored 'Trans proline' 0 N--CA 1.45 -1.042 0 C-N-CA 122.96 2.44 . . . . 0.62 111.826 172.647 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 65.4 t80 -100.04 118.89 37.37 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 110.092 -0.336 . . . . 0.64000000000000001 110.092 179.376 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 333' ' ' VAL . . . . . 0.472 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 61.6 t -119.32 114.82 45.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 N-CA-C 110.119 -0.326 . . . . 0.38 110.119 -178.734 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.5 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 14.1 p90 -131.64 159.38 38.48 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.958 0.409 . . . . 0.40999999999999998 110.201 -179.64 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 335' ' ' LYS . . . . . 0.462 ' HG3' ' HG3' ' A' ' 338' ' ' GLN . 18.2 pttm -99.72 128.92 45.81 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.902 -0.59 . . . . 2.5800000000000001 110.346 177.336 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 10.0 mp -64.54 117.53 7.5 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.484 -0.561 . . . . 0.57999999999999996 109.484 174.645 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 129.36 10.09 3.11 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.774 -0.727 . . . . 0.93999999999999995 111.699 -172.027 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 338' ' ' GLN . . . . . 0.652 ' HB3' ' HG2' ' A' ' 340' ' ' GLU . 91.8 mt-30 -84.35 141.93 30.53 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.962 0.411 . . . . 2.6200000000000001 110.62 176.111 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -96.11 -4.95 59.73 Favored Glycine 0 N--CA 1.448 -0.512 0 N-CA-C 110.857 -0.897 . . . . 0.73999999999999999 110.857 175.194 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 340' ' ' GLU . . . . . 0.652 ' HG2' ' HB3' ' A' ' 338' ' ' GLN . 5.5 pt-20 -84.18 -20.15 32.87 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.078 -0.561 . . . . 2.0899999999999999 110.984 179.21 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 33.4 m -94.06 154.92 3.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 109.524 -0.547 . . . . 0.42999999999999999 109.524 174.797 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 13.4 pt -74.86 154.25 6.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 N-CA-C 110.034 -0.358 . . . . 0.32000000000000001 110.034 179.24 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 343' ' ' LYS . . . . . 0.45 ' HE2' ' HA ' ' A' ' 343' ' ' LYS . 5.7 mmpt? -60.62 -30.69 70.01 Favored 'General case' 0 N--CA 1.464 0.258 0 N-CA-C 111.73 0.27 . . . . 2.9300000000000002 111.73 -174.72 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -55.55 -28.44 51.33 Favored Glycine 0 CA--C 1.521 0.437 0 C-N-CA 121.14 -0.553 . . . . 0.29999999999999999 112.884 174.387 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 8.4 m95 -82.26 -60.96 2.03 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 111.648 0.24 . . . . 0.39000000000000001 111.648 178.917 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -48.49 -35.73 13.69 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 120.923 0.392 . . . . 1.75 111.73 177.921 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 62.1 mt -88.51 -51.89 11.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.163 -0.471 . . . . 0.39000000000000001 111.756 179.139 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 348' ' ' GLY . . . . . 0.423 ' HA2' HD13 ' A' ' 286' ' ' LEU . . . -61.08 -36.34 92.17 Favored Glycine 0 C--N 1.331 0.301 0 C-N-CA 121.36 -0.448 . . . . 0.34000000000000002 113.73 -176.797 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 88.6 t -73.66 -23.2 19.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 121.182 0.515 . . . . 0.32000000000000001 110.775 -179.579 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -70.18 105.61 3.0 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.097 0.475 . . . . 0.46999999999999997 110.512 179.357 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 120.9 -2.78 11.81 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.864 -0.684 . . . . 0.39000000000000001 112.303 -176.794 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 352' ' ' MET . . . . . 0.451 ' HG2' ' HD2' ' A' ' 358' ' ' ARG . 69.1 mtp -82.13 144.41 30.77 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.905 0.353 . . . . 1.28 110.622 176.356 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 353' ' ' ALA . . . . . 0.463 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -108.57 147.99 30.97 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.879 -0.6 . . . . 0.55000000000000004 110.682 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 85.7 t -57.7 117.71 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 121.121 0.486 . . . . 0.35999999999999999 110.835 176.048 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 110.67 -27.15 11.58 Favored Glycine 0 N--CA 1.445 -0.752 0 N-CA-C 111.049 -0.82 . . . . 0.44 111.049 -176.761 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -73.99 139.21 25.76 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 121.3 -0.476 . . . . 0.29999999999999999 112.744 -177.162 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 357' ' ' GLU . . . . . 0.709 ' HB2' ' HG3' ' A' ' 387' ' ' LYS . 36.6 tt0 -125.0 133.87 52.82 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 109.063 -0.718 . . . . 1.4099999999999999 109.063 178.358 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 358' ' ' ARG . . . . . 0.561 ' HA ' ' HG2' ' A' ' 295' ' ' ARG . 8.0 ptp180 -155.44 143.89 20.31 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.66 0.743 . . . . 1.3700000000000001 112.294 -178.841 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 359' ' ' ARG . . . . . 0.435 HH21 ' CD ' ' A' ' 293' ' ' GLU . 20.9 ttp85 -86.25 117.95 25.39 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 114.773 -1.103 . . . . 2.79 109.485 177.813 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 50.3 mt -99.73 121.81 50.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.729 -0.669 . . . . 0.38 110.235 -178.31 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 361' ' ' VAL . . . . . 0.582 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 47.7 t -102.45 113.35 38.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 N-CA-C 109.15 -0.685 . . . . 0.39000000000000001 109.15 176.574 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 362' ' ' ILE . . . . . . . . . . . . . 62.1 mt -113.19 101.49 53.53 Favored Pre-proline 0 C--N 1.324 -0.514 0 CA-C-O 120.728 0.299 . . . . 0.28999999999999998 110.987 -175.096 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 363' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -56.43 159.9 12.36 Favored 'Trans proline' 0 C--O 1.237 0.463 0 C-N-CA 122.571 2.181 . . . . 0.66000000000000003 112.41 171.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 364' ' ' ALA . . . . . 0.546 ' HB2' ' HA ' ' A' ' 379' ' ' ASN . . . -47.72 -49.59 56.09 Favored Pre-proline 0 CA--C 1.539 0.547 0 N-CA-C 114.528 1.307 . . . . 0.41999999999999998 114.528 -173.348 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 365' ' ' PRO . . . . . 0.531 ' HD2' ' N ' ' A' ' 364' ' ' ALA . 9.6 Cg_endo -51.03 -32.18 37.81 Favored 'Trans proline' 0 C--N 1.361 1.2 0 C-N-CA 122.567 2.178 . . . . 0.69999999999999996 114.186 -172.832 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 366' ' ' TYR . . . . . 0.514 ' CE2' ' HA3' ' A' ' 288' ' ' GLY . 13.8 m-85 -100.52 12.13 37.97 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.831 -0.348 . . . . 0.68999999999999995 111.841 -175.466 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -127.06 -109.6 0.3 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.441 -0.345 . . . . 0.85999999999999999 110.907 174.799 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 78.8 m-85 -93.59 -15.83 25.0 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 111.977 0.362 . . . . 1.0 111.977 -179.723 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 64.82 -113.91 6.3 Favored Glycine 0 CA--C 1.52 0.388 0 C-N-CA 121.047 -0.597 . . . . 0.56000000000000005 113.691 175.627 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 65.6 mttm -92.1 3.91 54.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.751 0.31 . . . . 2.7599999999999998 111.525 -174.84 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -80.63 99.27 8.06 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.863 0.363 . . . . 2.6499999999999999 111.638 -177.334 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 372' ' ' ALA . . . . . . . . . . . . . . . -78.29 92.48 4.52 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 115.952 -0.567 . . . . 1.01 109.908 171.362 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 30.5 mt -84.0 159.28 60.33 Favored Pre-proline 0 C--N 1.316 -0.885 0 CA-C-N 115.636 -0.711 . . . . 0.93000000000000005 109.342 -179.686 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.55 113.0 1.43 Allowed 'Trans proline' 0 N--CA 1.461 -0.394 0 C-N-CA 121.507 1.472 . . . . 1.3100000000000001 110.684 173.742 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 96.81 -29.92 9.74 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.809 -0.71 . . . . 0.90000000000000002 112.533 -178.496 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 40.0 mt -125.95 88.94 53.38 Favored Pre-proline 0 C--N 1.332 -0.192 0 CA-C-N 116.772 0.286 . . . . 0.73999999999999999 110.279 -179.242 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 377' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_exo -69.58 166.52 27.09 Favored 'Trans proline' 0 N--CA 1.463 -0.3 0 C-N-CA 122.596 2.198 . . . . 0.70999999999999996 113.191 -178.355 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 378' ' ' ALA . . . . . . . . . . . . . . . -61.06 157.32 15.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.202 -0.908 . . . . 0.73999999999999999 111.985 -176.771 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 379' ' ' ASN . . . . . 0.546 ' HA ' ' HB2' ' A' ' 364' ' ' ALA . 18.6 m120 65.69 23.16 11.59 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-N 115.377 -0.828 . . . . 1.49 111.113 177.798 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 59.6 p -66.72 116.43 7.62 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.003 -0.544 . . . . 1.8400000000000001 111.134 179.501 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 381' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -80.37 98.55 7.52 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 108.971 -0.751 . . . . 1.03 108.971 174.541 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 92.6 mt -85.34 136.06 33.63 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.941 0.4 . . . . 0.37 111.248 -176.812 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 32.6 m -118.97 118.54 31.78 Favored 'General case' 0 N--CA 1.444 -0.734 0 N-CA-C 109.93 -0.396 . . . . 0.27000000000000002 109.93 177.824 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -113.16 109.39 18.7 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.867 -0.42 . . . . 0.32000000000000001 109.867 -177.204 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -87.39 104.88 16.85 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 108.034 -1.098 . . . . 1.8 108.034 176.636 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 386' ' ' VAL . . . . . 0.559 HG12 ' CB ' ' A' ' 313' ' ' TYR . 19.9 m -122.89 148.68 26.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 121.563 0.697 . . . . 0.31 112.382 -170.057 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 387' ' ' LYS . . . . . 0.709 ' HG3' ' HB2' ' A' ' 357' ' ' GLU . 46.5 tttm -137.39 129.91 29.83 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.402 -0.817 . . . . 2.5299999999999998 109.652 176.128 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 388' ' ' LEU . . . . . 0.802 HD11 ' HB ' ' A' ' 309' ' ' VAL . 24.6 tp -89.58 134.55 34.08 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.776 -0.824 . . . . 0.28000000000000003 108.776 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 27.5 m -129.36 -3.49 3.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 N-CA-C 112.251 0.463 . . . . 0.45000000000000001 112.251 -174.064 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 10.2 t -168.5 156.67 8.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.69 0.281 . . . . 1.3200000000000001 110.806 -177.506 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 391' ' ' MET . . . . . 0.499 ' HE2' HG12 ' A' ' 309' ' ' VAL . 40.5 ttm -156.33 155.26 31.93 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.229 -0.656 . . . . 0.56000000000000005 109.229 174.401 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 392' ' ' LYS . . . . . 0.42 ' HE2' ' HB2' ' A' ' 392' ' ' LYS . 3.4 ptmm? . . . . . 0 C--O 1.25 1.123 0 CA-C-O 118.654 -0.689 . . . . 4.9100000000000001 110.7 175.486 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 15.2 p . . . . . 0 N--CA 1.452 -0.363 0 CA-C-O 120.778 0.323 . . . . 0.76000000000000001 111.277 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 284' ' ' LYS . . . . . 0.573 ' HB2' HG13 ' A' ' 292' ' ' ILE . 72.4 mmtt -130.12 135.94 48.76 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 109.213 -0.662 . . . . 2.0600000000000001 109.213 179.723 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 31.1 tp -104.78 124.16 48.93 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 120.896 0.379 . . . . 0.97999999999999998 110.138 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.786 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 76.7 mt -112.63 -175.21 2.62 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.578 -0.737 . . . . 0.80000000000000004 109.813 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 2.6 tp10 -60.61 147.37 42.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.148 0.499 . . . . 2.6400000000000001 111.336 -177.765 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.595 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 69.37 -1.77 12.17 Favored Glycine 0 N--CA 1.452 -0.297 0 CA-C-N 115.84 -0.618 . . . . 1.8400000000000001 113.648 -179.892 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 97.6 14.8 39.51 Favored Glycine 0 N--CA 1.446 -0.681 0 C-N-CA 120.21 -0.995 . . . . 0.64000000000000001 113.556 -179.274 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 290' ' ' ILE . . . . . 0.786 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 79.5 mt -64.16 122.57 15.31 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.167 0 CA-C-N 117.488 0.644 . . . . 0.41999999999999998 110.507 176.908 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.557 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 80.2 mt -107.36 138.27 34.3 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 N-CA-C 110.355 -0.239 . . . . 0.93000000000000005 110.355 177.08 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 292' ' ' ILE . . . . . 0.573 HG13 ' HB2' ' A' ' 284' ' ' LYS . 23.6 pt -127.02 130.85 71.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 N-CA-C 109.489 -0.56 . . . . 0.47999999999999998 109.489 174.34 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 293' ' ' GLU . . . . . 0.415 ' CD ' HH21 ' A' ' 359' ' ' ARG . 34.3 tt0 -123.43 121.42 35.69 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 115.176 -0.92 . . . . 2.3100000000000001 109.954 -177.139 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 51.9 m-20 -78.3 110.93 13.76 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.712 -0.477 . . . . 2.3599999999999999 109.712 -176.637 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 295' ' ' ARG . . . . . . . . . . . . . 39.1 ttt180 -88.14 -58.24 2.64 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.832 -0.622 . . . . 3.5 110.499 -175.176 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.601 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 58.1 t -128.24 141.36 46.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 110.203 -0.295 . . . . 0.69999999999999996 110.203 177.207 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 9.0 t -96.07 149.84 21.16 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.3 -0.409 . . . . 1.9299999999999999 111.033 -178.197 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -152.93 -164.64 12.65 Favored Glycine 0 C--N 1.331 0.261 0 C-N-CA 121.428 -0.415 . . . . 1.04 112.174 -177.19 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 299' ' ' LYS . . . . . 0.572 ' O ' ' HB1' ' A' ' 353' ' ' ALA . 62.0 tttp -72.78 139.54 47.15 Favored 'General case' 0 CA--C 1.52 -0.211 0 N-CA-C 108.595 -0.891 . . . . 4.4900000000000002 108.595 173.793 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -116.34 80.48 0.3 Allowed Glycine 0 N--CA 1.445 -0.756 0 C-N-CA 119.314 -1.422 . . . . 1.04 115.272 -170.838 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 301' ' ' PRO . . . . . 0.596 ' HD2' ' H ' ' A' ' 354' ' ' VAL . 8.2 Cg_exo -74.57 131.51 14.92 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.036 1.824 . . . . 0.88 108.145 159.9 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 302' ' ' HIS . . . . . 0.439 ' O ' ' HE3' ' A' ' 304' ' ' LYS . 27.4 m80 -85.91 107.35 17.67 Favored 'General case' 0 C--N 1.319 -0.731 0 C-N-CA 120.314 -0.554 . . . . 1.49 111.423 -169.093 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -66.33 109.08 2.55 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.703 -0.681 . . . . 0.54000000000000004 110.375 175.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 304' ' ' LYS . . . . . 0.439 ' HE3' ' O ' ' A' ' 302' ' ' HIS . 11.5 ptpt -127.47 -174.44 3.18 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 116.326 -0.397 . . . . 2.8399999999999999 110.161 -179.171 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.819 ' HG3' ' HA3' ' A' ' 337' ' ' GLY . 62.3 tttm -65.71 124.51 22.6 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.994 0.426 . . . . 2.8399999999999999 111.019 -175.251 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 97.14 -11.24 65.71 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 121.075 -0.583 . . . . 0.69999999999999996 112.81 -178.063 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 307' ' ' THR . . . . . 0.447 ' O ' ' HA ' ' A' ' 335' ' ' LYS . 28.4 m -82.92 142.8 31.16 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 122.881 -0.188 . . . . 0.40000000000000002 110.524 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 22.6 ptt180 -106.78 116.03 31.22 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 121.306 0.574 . . . . 3.4500000000000002 109.583 -178.234 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.783 ' HB ' HD11 ' A' ' 388' ' ' LEU . 31.1 m -113.69 147.8 17.0 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 115.644 -0.707 . . . . 0.34000000000000002 111.918 -177.397 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -116.67 114.19 2.97 Favored Glycine 0 N--CA 1.443 -0.896 0 N-CA-C 110.126 -1.19 . . . . 0.27000000000000002 110.126 174.897 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 311' ' ' MET . . . . . 0.478 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 6.9 ptm -131.65 177.68 7.33 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 121.897 0.856 . . . . 0.76000000000000001 112.488 -172.283 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -138.07 150.31 46.78 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 113.726 -1.579 . . . . 2.5099999999999998 107.794 177.924 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 313' ' ' TYR . . . . . 0.466 ' CB ' HG12 ' A' ' 386' ' ' VAL . 44.3 p90 -156.45 155.33 31.88 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 120.741 -0.384 . . . . 0.68000000000000005 111.375 -169.74 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 314' ' ' VAL . . . . . 0.565 HG11 ' HE3' ' A' ' 316' ' ' LYS . 38.2 t -120.46 105.71 17.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-N 115.587 -0.733 . . . . 0.34999999999999998 109.247 169.206 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -84.82 109.38 3.26 Favored Glycine 0 N--CA 1.445 -0.717 0 CA-C-N 116.088 -0.506 . . . . 0.28000000000000003 112.168 -178.653 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 316' ' ' LYS . . . . . 0.765 ' HG2' HG22 ' A' ' 322' ' ' VAL . 93.6 mttt -123.32 161.05 25.42 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-N 114.929 -0.636 . . . . 1.9399999999999999 110.464 -178.308 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 317' ' ' LEU . . . . . 0.493 HD12 ' HD3' ' A' ' 321' ' ' LYS . 83.6 mt -88.18 165.81 14.81 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 109.392 -0.596 . . . . 0.65000000000000002 109.392 170.899 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 318' ' ' LYS . . . . . 0.907 ' HD2' ' HB3' ' A' ' 381' ' ' GLU . 0.2 OUTLIER -61.15 -19.37 61.46 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.31 -0.405 . . . . 2.4199999999999999 111.633 179.844 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 319' ' ' ASN . . . . . 0.421 ' OD1' ' HB2' ' A' ' 317' ' ' LEU . 28.5 p-10 -90.41 -1.61 57.92 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 116.577 -0.283 . . . . 2.2000000000000002 111.146 -178.575 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 94.5 6.8 60.86 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.505 -0.855 . . . . 0.68999999999999995 113.11 177.836 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 321' ' ' LYS . . . . . 0.493 ' HD3' HD12 ' A' ' 317' ' ' LEU . 63.5 tttp -81.99 118.57 23.09 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.947 0.403 . . . . 2.4199999999999999 110.472 177.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.765 HG22 ' HG2' ' A' ' 316' ' ' LYS . 12.6 t -85.56 129.78 37.39 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 116.115 -0.493 . . . . 1.26 109.948 179.381 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 32.3 p90 -111.48 -43.57 3.66 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 120.528 -0.469 . . . . 0.55000000000000004 111.586 178.508 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -148.07 128.56 14.03 Favored 'General case' 0 CA--C 1.514 -0.431 0 C-N-CA 120.507 -0.477 . . . . 1.6799999999999999 110.958 -177.658 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 325' ' ' LYS . . . . . 0.553 ' HE3' HG11 ' A' ' 322' ' ' VAL . 8.4 pttp -145.75 128.31 16.08 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.092 0.472 . . . . 1.99 110.88 -179.05 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 55.6 m-80 -125.25 116.49 22.06 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.544 -0.753 . . . . 1.9199999999999999 109.055 173.605 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 26.3 m -157.0 -38.89 0.07 Allowed 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.675 -0.693 . . . . 1.6899999999999999 110.155 -177.202 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 29.6 mmmt -75.18 92.74 2.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.788 -0.642 . . . . 2.5499999999999998 110.372 179.589 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.454 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 75.1 -17.7 2.86 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 121.245 -0.502 . . . . 0.96999999999999997 113.606 177.491 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 82.4 mttt -103.37 103.26 34.26 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 117.001 0.401 . . . . 2.0800000000000001 111.571 -175.433 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 331' ' ' PRO . . . . . 0.454 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 98.3 Cg_endo -87.91 145.83 6.6 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 122.825 2.35 . . . . 0.62 112.167 171.698 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 72.3 t80 -111.15 119.51 39.2 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.364 -0.606 . . . . 0.64000000000000001 109.364 175.526 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 46.7 t -111.64 126.3 69.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 120.648 0.261 . . . . 0.38 110.842 -177.236 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.478 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 28.4 p90 -153.54 169.19 23.81 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.34 -0.391 . . . . 0.40999999999999998 110.2 178.415 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 335' ' ' LYS . . . . . 0.49 ' HE2' ' HB3' ' A' ' 338' ' ' GLN . 0.0 OUTLIER -112.77 146.22 39.18 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.152 0.501 . . . . 2.5800000000000001 111.418 177.201 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 10.9 mp -78.35 150.89 33.12 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.853 -0.612 . . . . 0.57999999999999996 110.262 177.661 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 337' ' ' GLY . . . . . 0.819 ' HA3' ' HG3' ' A' ' 305' ' ' LYS . . . 89.12 27.14 24.19 Favored Glycine 0 N--CA 1.445 -0.706 0 C-N-CA 120.739 -0.743 . . . . 0.93999999999999995 112.459 -177.409 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 338' ' ' GLN . . . . . 0.49 ' HB3' ' HE2' ' A' ' 335' ' ' LYS . 3.8 pt20 -118.97 163.06 17.5 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 110.085 -0.339 . . . . 2.6200000000000001 110.085 176.406 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -93.6 2.84 70.79 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.952 -0.642 . . . . 0.73999999999999999 112.329 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -76.43 -24.78 53.96 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.948 0.404 . . . . 2.0899999999999999 110.876 -178.914 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 31.0 m -108.74 152.66 10.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.241 -0.436 . . . . 0.42999999999999999 110.755 -178.734 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 342' ' ' ILE . . . . . 0.502 ' HB ' ' HA ' ' A' ' 367' ' ' ALA . 14.8 pt -70.52 156.24 7.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.858 -0.423 . . . . 0.32000000000000001 109.858 178.457 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -64.48 -32.61 74.32 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.626 -0.261 . . . . 2.9300000000000002 111.396 -175.386 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -53.41 -41.86 63.88 Favored Glycine 0 CA--C 1.523 0.561 0 C-N-CA 120.613 -0.803 . . . . 0.29999999999999999 112.16 173.462 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 7.8 m95 -70.51 -58.42 3.73 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.75 0.309 . . . . 0.39000000000000001 110.489 175.474 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -49.49 -32.27 11.78 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 115.877 -0.601 . . . . 1.75 112.355 -179.308 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 69.2 mt -89.17 -53.21 9.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.501 -0.318 . . . . 0.39000000000000001 111.789 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -64.32 -32.93 85.82 Favored Glycine 0 C--N 1.332 0.307 0 C-N-CA 121.189 -0.529 . . . . 0.34000000000000002 113.664 -177.709 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 89.8 t -78.44 -16.33 13.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.988 0.423 . . . . 0.32000000000000001 111.035 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.01 106.41 1.25 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.235 0.541 . . . . 0.46999999999999997 110.241 178.592 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 98.31 22.33 15.1 Favored Glycine 0 N--CA 1.444 -0.787 0 CA-C-N 115.6 -0.727 . . . . 0.39000000000000001 112.577 -178.234 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 352' ' ' MET . . . . . . . . . . . . . 64.1 mmm -69.22 173.38 5.73 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.562 0.22 . . . . 1.28 110.636 173.308 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 353' ' ' ALA . . . . . 0.572 ' HB1' ' O ' ' A' ' 299' ' ' LYS . . . -135.71 136.61 40.99 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.107 -0.497 . . . . 0.55000000000000004 111.05 -177.605 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 354' ' ' VAL . . . . . 0.596 ' H ' ' HD2' ' A' ' 301' ' ' PRO . 59.4 t -65.76 112.05 1.75 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.202 0 CA-C-O 121.436 0.636 . . . . 0.35999999999999999 109.923 174.856 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 104.56 -24.16 29.45 Favored Glycine 0 N--CA 1.439 -1.134 0 N-CA-C 110.134 -1.186 . . . . 0.44 110.134 -172.7 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -73.85 145.66 35.59 Favored Glycine 0 N--CA 1.444 -0.793 0 N-CA-C 112.04 -0.424 . . . . 0.29999999999999999 112.04 179.874 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 357' ' ' GLU . . . . . 0.724 ' HG3' ' HB2' ' A' ' 387' ' ' LYS . 34.0 tt0 -135.75 131.54 35.68 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 108.238 -1.023 . . . . 1.4099999999999999 108.238 -173.227 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 358' ' ' ARG . . . . . . . . . . . . . 2.1 ptp180 -154.86 148.22 25.06 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.369 0.604 . . . . 1.3700000000000001 112.495 -177.745 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 359' ' ' ARG . . . . . 0.415 HH21 ' CD ' ' A' ' 293' ' ' GLU . 14.8 ttp180 -89.21 114.76 26.11 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.377 -0.829 . . . . 2.79 109.817 176.502 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 65.4 mt -102.67 118.72 49.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 109.955 -0.387 . . . . 0.38 109.955 179.087 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 361' ' ' VAL . . . . . 0.557 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 41.8 t -101.19 111.15 29.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 109.209 -0.663 . . . . 0.39000000000000001 109.209 179.63 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 362' ' ' ILE . . . . . 0.482 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 60.4 mt -108.09 112.48 61.47 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-O 120.985 0.421 . . . . 0.28999999999999998 111.531 -171.402 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 363' ' ' PRO . . . . . 0.557 ' HD2' HG12 ' A' ' 290' ' ' ILE . 33.7 Cg_endo -64.19 155.34 65.73 Favored 'Trans proline' 0 C--O 1.235 0.356 0 C-N-CA 122.902 2.401 . . . . 0.66000000000000003 111.791 175.153 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 364' ' ' ALA . . . . . 0.424 ' CB ' ' HA ' ' A' ' 379' ' ' ASN . . . -51.16 -49.5 81.05 Favored Pre-proline 0 CA--C 1.541 0.598 0 N-CA-C 114.14 1.163 . . . . 0.41999999999999998 114.14 -174.775 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 365' ' ' PRO . . . . . 0.474 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 32.2 Cg_exo -59.0 -24.41 73.22 Favored 'Trans proline' 0 C--N 1.362 1.274 0 C-N-CA 122.176 1.917 . . . . 0.69999999999999996 113.671 -173.056 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 366' ' ' TYR . . . . . 0.595 ' CE2' ' HA3' ' A' ' 288' ' ' GLY . 5.4 m-85 -100.27 10.74 40.79 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.048 0.452 . . . . 0.68999999999999995 111.385 -176.707 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 367' ' ' ALA . . . . . 0.502 ' HA ' ' HB ' ' A' ' 342' ' ' ILE . . . -122.24 -106.04 0.37 Allowed 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.903 -0.59 . . . . 0.85999999999999999 110.406 174.191 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 368' ' ' TYR . . . . . 0.473 ' HB3' ' HB3' ' A' ' 371' ' ' GLN . 96.4 m-85 -92.42 -16.12 26.31 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.642 0.258 . . . . 1.0 111.52 178.38 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 68.53 -110.73 3.56 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.911 -0.661 . . . . 0.56000000000000005 112.669 178.525 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 370' ' ' LYS . . . . . 0.419 ' HA ' ' HB1' ' A' ' 378' ' ' ALA . 48.9 mtpt -101.27 10.18 40.96 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.766 0.317 . . . . 2.7599999999999998 111.174 -177.538 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 371' ' ' GLN . . . . . 0.473 ' HB3' ' HB3' ' A' ' 368' ' ' TYR . 64.5 tt0 -82.58 100.97 10.46 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 120.864 0.364 . . . . 2.6499999999999999 110.572 178.656 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 372' ' ' ALA . . . . . 0.605 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -78.84 107.9 11.89 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.264 -0.426 . . . . 1.01 111.295 178.602 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 83.6 mt -102.47 161.81 22.14 Favored Pre-proline 0 C--N 1.32 -0.691 0 N-CA-C 109.403 -0.592 . . . . 0.93000000000000005 109.403 174.764 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_endo -64.27 114.61 2.74 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 121.592 1.528 . . . . 1.3100000000000001 110.929 172.452 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 96.2 -28.58 12.41 Favored Glycine 0 CA--C 1.521 0.466 0 C-N-CA 120.89 -0.671 . . . . 0.90000000000000002 112.225 -176.665 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 376' ' ' ILE . . . . . 0.547 HG23 HD21 ' A' ' 382' ' ' LEU . 23.0 mt -130.74 77.62 75.27 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 120.701 0.286 . . . . 0.73999999999999999 110.303 179.137 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 377' ' ' PRO . . . . . 0.605 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 73.5 Cg_endo -77.77 167.86 23.26 Favored 'Trans proline' 0 N--CA 1.461 -0.395 0 C-N-CA 122.38 2.054 . . . . 0.70999999999999996 112.805 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 378' ' ' ALA . . . . . 0.419 ' HB1' ' HA ' ' A' ' 370' ' ' LYS . . . -53.07 143.2 18.11 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 116.055 -0.52 . . . . 0.73999999999999999 111.979 -179.72 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 379' ' ' ASN . . . . . 0.424 ' HA ' ' CB ' ' A' ' 364' ' ' ALA . 93.8 m-20 67.95 19.92 9.31 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 115.556 -0.747 . . . . 1.49 112.286 176.356 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 67.1 m -87.2 131.63 34.13 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.332 0.587 . . . . 1.8400000000000001 111.232 176.55 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 381' ' ' GLU . . . . . 0.907 ' HB3' ' HD2' ' A' ' 318' ' ' LYS . 34.1 tt0 -84.71 112.86 20.86 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.999 -1.0 . . . . 1.03 109.93 178.33 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 382' ' ' LEU . . . . . 0.547 HD21 HG23 ' A' ' 376' ' ' ILE . 91.5 mt -89.67 139.49 30.51 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.334 -0.394 . . . . 0.37 110.243 179.765 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 37.8 m -119.33 119.12 33.07 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.322 -0.621 . . . . 0.27000000000000002 109.322 176.553 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -115.13 109.88 18.68 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 121.124 0.488 . . . . 0.32000000000000001 110.444 -177.213 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -87.52 106.92 18.32 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 108.149 -1.056 . . . . 1.8 108.149 174.113 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 386' ' ' VAL . . . . . 0.466 HG12 ' CB ' ' A' ' 313' ' ' TYR . 29.6 m -122.9 148.37 26.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.621 0.724 . . . . 0.31 112.123 -168.873 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 387' ' ' LYS . . . . . 0.724 ' HB2' ' HG3' ' A' ' 357' ' ' GLU . 40.7 tttp -139.05 132.96 30.98 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.74 -1.118 . . . . 2.5299999999999998 109.317 175.222 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 388' ' ' LEU . . . . . 0.783 HD11 ' HB ' ' A' ' 309' ' ' VAL . 30.6 tp -91.98 131.62 37.14 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 108.666 -0.864 . . . . 0.28000000000000003 108.666 -179.178 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 28.9 m -120.01 -4.39 9.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 112.232 0.456 . . . . 0.45000000000000001 112.232 -173.893 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 11.3 t -170.51 152.06 3.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.968 0.413 . . . . 1.3200000000000001 111.154 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 391' ' ' MET . . . . . 0.62 ' HE2' HG12 ' A' ' 309' ' ' VAL . 31.6 ttm -157.25 147.47 20.94 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.747 -0.661 . . . . 0.56000000000000005 109.497 174.626 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 20.8 tptm . . . . . 0 C--O 1.248 0.992 0 CA-C-O 117.88 -1.057 . . . . 4.9100000000000001 111.438 173.471 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.963 HG22 ' HG2' ' A' ' 293' ' ' GLU . 31.6 p . . . . . 0 N--CA 1.455 -0.201 0 N-CA-C 110.21 -0.292 . . . . 0.76000000000000001 110.21 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 284' ' ' LYS . . . . . 0.457 ' HB2' HG13 ' A' ' 292' ' ' ILE . 23.8 mmtp -122.03 146.99 46.64 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.94 0.4 . . . . 2.0600000000000001 111.115 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 40.3 tp -103.97 121.17 42.58 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.542 -0.754 . . . . 0.97999999999999998 110.242 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.565 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 94.9 mt -101.78 -169.5 1.69 Allowed 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.978 -0.555 . . . . 0.80000000000000004 110.407 178.048 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -68.37 146.58 53.12 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.702 -0.681 . . . . 2.6400000000000001 110.154 -179.651 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 73.71 10.63 80.23 Favored Glycine 0 CA--C 1.517 0.163 0 C-N-CA 121.102 -0.571 . . . . 1.8400000000000001 113.687 178.869 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 81.44 16.84 72.69 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.63 -0.795 . . . . 0.64000000000000001 112.596 178.929 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 290' ' ' ILE . . . . . 0.565 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 84.1 mt -69.64 125.76 28.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 N-CA-C 109.94 -0.393 . . . . 0.41999999999999998 109.94 177.82 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.68 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 20.1 mt -104.14 134.91 44.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 N-CA-C 109.286 -0.635 . . . . 0.93000000000000005 109.286 179.386 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 292' ' ' ILE . . . . . 0.457 HG13 ' HB2' ' A' ' 284' ' ' LYS . 18.2 pt -124.13 127.14 73.24 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 CA-C-O 121.112 0.482 . . . . 0.47999999999999998 110.172 177.873 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 293' ' ' GLU . . . . . 0.963 ' HG2' HG22 ' A' ' 283' ' ' THR . 29.4 mt-10 -117.94 114.35 23.07 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.499 -0.773 . . . . 2.3100000000000001 109.469 -179.812 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 294' ' ' ASP . . . . . 0.477 ' C ' ' HE ' ' A' ' 295' ' ' ARG . 8.2 t70 -80.15 135.09 36.22 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 109.255 -0.646 . . . . 2.3599999999999999 109.255 -175.383 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 295' ' ' ARG . . . . . 0.584 ' HG2' ' HA ' ' A' ' 358' ' ' ARG . 1.7 mmp_? -105.76 -60.3 1.65 Allowed 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 110.02 -0.363 . . . . 3.5 110.02 -175.175 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 296' ' ' VAL . . . . . . . . . . . . . 84.0 t -122.2 109.98 25.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 116.039 -0.528 . . . . 0.69999999999999996 109.594 174.486 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 18.1 p -61.93 109.24 1.2 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.522 -0.763 . . . . 1.9299999999999999 111.405 -177.392 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -101.2 171.38 22.32 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.669 -0.776 . . . . 1.04 112.033 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 8.0 tmtm? -145.69 110.58 5.18 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.297 -0.631 . . . . 4.4900000000000002 109.297 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -172.24 -154.25 9.96 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.78 -0.724 . . . . 1.04 111.713 -178.596 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 301' ' ' PRO . . . . . 0.731 ' HD2' ' HB ' ' A' ' 354' ' ' VAL . 24.0 Cg_exo -64.46 134.34 41.16 Favored 'Trans proline' 0 C--O 1.232 0.192 0 C-N-CA 123.129 2.553 . . . . 0.88 112.342 177.28 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 44.4 m-70 -98.32 132.25 43.95 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.317 -0.401 . . . . 1.49 110.048 179.632 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -81.3 143.26 32.37 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 112.487 0.551 . . . . 0.54000000000000004 112.487 -176.009 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -127.26 -178.85 4.6 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.657 -0.701 . . . . 2.8399999999999999 110.041 174.877 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.81 ' HG3' ' HA3' ' A' ' 337' ' ' GLY . 46.7 tttm -68.47 135.49 51.74 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.864 0.364 . . . . 2.8399999999999999 110.342 175.218 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 93.13 -17.83 57.46 Favored Glycine 0 N--CA 1.451 -0.318 0 CA-C-N 116.107 -0.497 . . . . 0.69999999999999996 112.257 -176.517 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 27.0 m -74.83 142.53 44.18 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.729 0.3 . . . . 0.40000000000000002 110.679 -179.236 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 22.0 mtm180 -104.61 103.73 13.44 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 109.04 -0.726 . . . . 3.4500000000000002 109.04 178.58 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.831 ' HB ' HD11 ' A' ' 388' ' ' LEU . 28.4 m -104.35 145.36 13.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 CA-C-N 116.011 -0.54 . . . . 0.34000000000000002 111.567 -177.569 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -111.51 120.68 5.5 Favored Glycine 0 N--CA 1.445 -0.739 0 N-CA-C 109.709 -1.356 . . . . 0.27000000000000002 109.709 176.405 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 311' ' ' MET . . . . . 0.543 ' CE ' ' HB ' ' A' ' 386' ' ' VAL . 22.0 ptm -136.44 176.79 8.38 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.591 0.71 . . . . 0.76000000000000001 112.309 -169.937 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 312' ' ' ARG . . . . . 0.539 ' HD2' ' HA ' ' A' ' 327' ' ' THR . 12.5 mmt-85 -127.57 151.09 49.34 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 107.303 -1.369 . . . . 2.5099999999999998 107.303 172.887 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 313' ' ' TYR . . . . . 0.474 ' CB ' HG12 ' A' ' 386' ' ' VAL . 51.3 p90 -167.04 158.53 12.39 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.326 0.584 . . . . 0.68000000000000005 111.953 -176.82 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 314' ' ' VAL . . . . . 0.445 HG12 ' HG3' ' A' ' 316' ' ' LYS . 42.6 t -123.15 112.32 33.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.124 -0.944 . . . . 0.34999999999999998 109.559 174.131 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -84.73 105.51 2.86 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 121.073 -0.585 . . . . 0.28000000000000003 111.942 -177.661 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 316' ' ' LYS . . . . . 0.504 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 45.8 mtmt -119.31 154.35 33.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.143 0.497 . . . . 1.9399999999999999 111.681 -176.225 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 78.3 mt -91.15 160.56 15.5 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.811 -0.631 . . . . 0.65000000000000002 109.97 176.152 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 318' ' ' LYS . . . . . 0.665 ' HD2' ' HB3' ' A' ' 381' ' ' GLU . 85.3 tttt -62.4 -18.45 61.64 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-O 121.345 0.593 . . . . 2.4199999999999999 110.138 175.603 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -79.61 -2.03 40.72 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 115.566 -0.743 . . . . 2.2000000000000002 110.788 179.623 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 89.96 -2.91 82.44 Favored Glycine 0 C--N 1.329 0.178 0 C-N-CA 120.648 -0.787 . . . . 0.68999999999999995 112.795 177.364 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -93.83 128.37 40.06 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.691 0.281 . . . . 2.4199999999999999 110.587 -179.073 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.504 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 7.1 p -85.41 136.64 22.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 116.249 -0.432 . . . . 1.26 110.277 177.144 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 42.5 p90 -108.24 -35.67 6.49 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 120.791 -0.364 . . . . 0.55000000000000004 111.36 -179.558 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -147.05 162.28 39.12 Favored 'General case' 0 N--CA 1.464 0.261 0 C-N-CA 120.976 -0.289 . . . . 1.6799999999999999 110.569 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 3.7 ptpp? -164.55 138.72 5.29 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.76 0.314 . . . . 1.99 111.323 -177.136 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 55.0 m-80 -140.58 117.12 10.82 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 108.798 -0.815 . . . . 1.9199999999999999 108.798 173.56 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 327' ' ' THR . . . . . 0.539 ' HA ' ' HD2' ' A' ' 312' ' ' ARG . 5.2 t -160.73 -49.44 0.05 OUTLIER 'General case' 0 C--N 1.324 -0.5 0 C-N-CA 120.859 -0.337 . . . . 1.6899999999999999 111.726 -177.16 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 19.9 pttp -94.77 104.94 16.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.364 0.602 . . . . 2.5499999999999998 110.839 -178.218 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.421 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 87.94 -29.61 5.42 Favored Glycine 0 N--CA 1.45 -0.394 0 CA-C-N 115.409 -0.814 . . . . 0.96999999999999997 112.756 177.49 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 92.3 mttt -102.09 106.49 48.2 Favored Pre-proline 0 C--N 1.326 -0.428 0 CA-C-O 120.735 0.302 . . . . 2.0800000000000001 111.335 -176.791 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 331' ' ' PRO . . . . . 0.421 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 80.3 Cg_endo -87.31 125.72 2.21 Favored 'Trans proline' 0 N--CA 1.448 -1.167 0 C-N-CA 122.765 2.31 . . . . 0.62 111.405 173.126 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 64.7 t80 -103.66 114.36 28.56 Favored 'General case' 0 C--N 1.318 -0.777 0 C-N-CA 120.677 -0.409 . . . . 0.64000000000000001 110.002 179.43 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 333' ' ' VAL . . . . . 0.468 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 58.4 t -115.86 122.61 69.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.767 -0.651 . . . . 0.38 109.868 -178.57 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.466 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 13.2 p90 -138.19 165.87 25.6 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.945 0.403 . . . . 0.40999999999999998 110.229 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 335' ' ' LYS . . . . . 0.548 ' HG3' ' HG3' ' A' ' 338' ' ' GLN . 21.4 pttm -110.08 129.44 55.69 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.977 -0.556 . . . . 2.5800000000000001 110.608 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 9.6 mp -72.44 146.52 46.87 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.849 -0.614 . . . . 0.57999999999999996 111.732 -178.704 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 337' ' ' GLY . . . . . 0.81 ' HA3' ' HG3' ' A' ' 305' ' ' LYS . . . 88.44 25.05 31.75 Favored Glycine 0 N--CA 1.447 -0.614 0 CA-C-N 115.632 -0.713 . . . . 0.93999999999999995 112.769 170.614 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 338' ' ' GLN . . . . . 0.548 ' HG3' ' HG3' ' A' ' 335' ' ' LYS . 48.3 mm-40 -123.09 149.47 44.41 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.732 -0.47 . . . . 2.6200000000000001 109.732 -179.458 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -78.49 43.3 2.31 Favored Glycine 0 CA--C 1.518 0.279 0 C-N-CA 120.875 -0.678 . . . . 0.73999999999999999 112.786 178.919 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 340' ' ' GLU . . . . . 0.516 ' HG2' ' HB2' ' A' ' 338' ' ' GLN . 10.4 pt-20 -122.29 -3.21 8.97 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.153 0.502 . . . . 2.0899999999999999 110.087 175.647 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 23.9 m -128.49 166.51 25.63 Favored 'Isoleucine or valine' 0 C--O 1.233 0.229 0 CA-C-N 115.47 -0.787 . . . . 0.42999999999999999 109.057 174.335 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 342' ' ' ILE . . . . . 0.739 ' HB ' ' HA ' ' A' ' 367' ' ' ALA . 14.0 pt -82.63 154.35 3.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.325 -0.62 . . . . 0.32000000000000001 109.325 176.397 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 343' ' ' LYS . . . . . 0.424 ' HA ' ' OD2' ' A' ' 346' ' ' ASP . 6.9 mtmm -65.93 -31.39 72.29 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 111.78 0.289 . . . . 2.9300000000000002 111.78 -172.355 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 344' ' ' GLY . . . . . 0.548 ' HA2' HD13 ' A' ' 290' ' ' ILE . . . -54.39 -32.0 51.63 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.69 -0.766 . . . . 0.29999999999999999 111.851 173.031 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 7.2 m95 -76.03 -55.63 5.42 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 111.847 0.314 . . . . 0.39000000000000001 111.847 177.367 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 346' ' ' ASP . . . . . 0.424 ' OD2' ' HA ' ' A' ' 343' ' ' LYS . 0.1 OUTLIER -64.75 -24.32 67.53 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 122.186 -0.321 . . . . 1.75 111.603 -174.844 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 56.8 mt -89.8 -49.4 13.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.631 -0.259 . . . . 0.39000000000000001 111.029 176.546 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -61.49 -36.57 92.76 Favored Glycine 0 CA--C 1.52 0.387 0 C-N-CA 120.982 -0.628 . . . . 0.34000000000000002 113.171 179.345 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 349' ' ' VAL . . . . . 0.489 ' O ' ' HB2' ' A' ' 352' ' ' MET . 95.4 t -78.79 -14.16 13.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.115 0.484 . . . . 0.32000000000000001 110.934 178.602 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -69.87 120.56 15.78 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 109.471 -0.566 . . . . 0.46999999999999997 109.471 176.242 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 85.45 14.05 69.25 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.865 -0.684 . . . . 0.39000000000000001 112.023 -176.591 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 352' ' ' MET . . . . . 0.489 ' HB2' ' O ' ' A' ' 349' ' ' VAL . 0.0 OUTLIER -81.01 137.0 36.07 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 108.867 -0.79 . . . . 1.28 108.867 176.442 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 353' ' ' ALA . . . . . 0.453 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -109.28 130.56 55.49 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.982 0.42 . . . . 0.55000000000000004 111.097 -174.882 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 354' ' ' VAL . . . . . 0.731 ' HB ' ' HD2' ' A' ' 301' ' ' PRO . 95.8 t -54.23 121.03 2.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.906 -0.588 . . . . 0.35999999999999999 111.306 176.686 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 107.52 -8.73 37.74 Favored Glycine 0 N--CA 1.444 -0.797 0 CA-C-N 115.73 -0.668 . . . . 0.44 112.152 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -100.97 154.9 19.22 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.836 -0.697 . . . . 0.29999999999999999 112.571 -178.417 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 357' ' ' GLU . . . . . 0.667 ' HG2' ' HD2' ' A' ' 387' ' ' LYS . 54.0 mt-10 -122.5 130.76 53.39 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.443 -0.577 . . . . 1.4099999999999999 109.443 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 358' ' ' ARG . . . . . 0.584 ' HA ' ' HG2' ' A' ' 295' ' ' ARG . 4.1 ptp180 -156.06 142.24 18.29 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.232 0.539 . . . . 1.3700000000000001 111.094 176.522 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 359' ' ' ARG . . . . . . . . . . . . . 53.9 ttp180 -93.31 133.63 36.35 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.508 -0.769 . . . . 2.79 109.82 -178.86 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 38.8 mt -110.16 119.86 60.01 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-N 116.168 -0.469 . . . . 0.38 110.24 -179.418 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 361' ' ' VAL . . . . . 0.68 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 45.6 t -98.87 112.76 31.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 108.616 -0.883 . . . . 0.39000000000000001 108.616 176.316 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 362' ' ' ILE . . . . . 0.449 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 54.4 mt -112.83 108.0 54.07 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-O 120.7 0.286 . . . . 0.28999999999999998 111.441 -172.127 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 363' ' ' PRO . . . . . 0.631 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 19.4 Cg_endo -59.36 152.09 63.36 Favored 'Trans proline' 0 C--O 1.235 0.35 0 C-N-CA 122.564 2.176 . . . . 0.66000000000000003 111.771 170.798 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 364' ' ' ALA . . . . . . . . . . . . . . . -48.43 -46.8 69.47 Favored Pre-proline 0 CA--C 1.544 0.718 0 N-CA-C 114.077 1.14 . . . . 0.41999999999999998 114.077 -176.544 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 365' ' ' PRO . . . . . 0.631 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 83.7 Cg_exo -49.24 -36.55 37.5 Favored 'Trans proline' 0 C--N 1.361 1.19 0 C-N-CA 122.687 2.258 . . . . 0.69999999999999996 114.068 -177.134 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 366' ' ' TYR . . . . . 0.471 ' HD1' HD11 ' A' ' 290' ' ' ILE . 2.9 m-85 -101.4 8.5 42.18 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.797 -0.361 . . . . 0.68999999999999995 111.158 -176.913 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 367' ' ' ALA . . . . . 0.739 ' HA ' ' HB ' ' A' ' 342' ' ' ILE . . . -110.76 -119.3 0.29 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.162 -0.472 . . . . 0.85999999999999999 109.973 175.107 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 82.6 m-85 -86.92 5.9 34.69 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 121.081 0.467 . . . . 1.0 111.238 178.245 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 67.05 -109.06 2.7 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.909 -0.587 . . . . 0.56000000000000005 112.352 176.876 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 20.3 pttm -120.71 15.58 11.86 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.774 0.321 . . . . 2.7599999999999998 110.963 -178.823 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 56.3 tp60 -83.18 106.99 15.43 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.947 0.403 . . . . 2.6499999999999999 110.149 178.267 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 372' ' ' ALA . . . . . 0.555 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -75.38 102.03 4.98 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 116.034 -0.53 . . . . 1.01 110.918 179.606 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 76.5 mt -88.9 163.83 33.55 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.706 -0.679 . . . . 0.93000000000000005 109.254 177.35 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -61.77 113.98 2.07 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 121.594 1.529 . . . . 1.3100000000000001 110.69 173.283 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 93.39 -26.66 14.53 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.83 -0.7 . . . . 0.90000000000000002 112.754 -177.881 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 376' ' ' ILE . . . . . 0.448 HG23 HD21 ' A' ' 382' ' ' LEU . 39.6 mt -126.5 81.92 67.29 Favored Pre-proline 0 CA--C 1.532 0.288 0 CA-C-O 120.86 0.362 . . . . 0.73999999999999999 110.978 -178.887 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 377' ' ' PRO . . . . . 0.555 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 56.1 Cg_endo -76.77 167.58 25.09 Favored 'Trans proline' 0 N--CA 1.459 -0.537 0 C-N-CA 122.413 2.075 . . . . 0.70999999999999996 112.457 178.126 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 378' ' ' ALA . . . . . . . . . . . . . . . -54.51 145.89 17.51 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.804 -0.635 . . . . 0.73999999999999999 111.488 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 379' ' ' ASN . . . . . . . . . . . . . 52.5 m-80 73.05 14.25 4.73 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 115.747 -0.661 . . . . 1.49 112.147 176.613 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 66.5 m -78.97 115.03 18.4 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.258 0.551 . . . . 1.8400000000000001 110.45 175.645 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 381' ' ' GLU . . . . . 0.665 ' HB3' ' HD2' ' A' ' 318' ' ' LYS . 33.0 tt0 -74.33 101.47 4.07 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.421 -0.809 . . . . 1.03 108.865 177.38 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 382' ' ' LEU . . . . . 0.448 HD21 HG23 ' A' ' 376' ' ' ILE . 79.4 mt -85.47 142.07 29.48 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 120.714 0.293 . . . . 0.37 110.897 -174.966 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 18.8 m -121.89 117.22 25.94 Favored 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 109.732 -0.47 . . . . 0.27000000000000002 109.732 178.706 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 384' ' ' PHE . . . . . 0.415 ' CD2' HD12 ' A' ' 362' ' ' ILE . 82.5 m-85 -112.67 109.94 19.77 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 121.094 0.474 . . . . 0.32000000000000001 110.067 -176.81 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -88.5 105.13 17.42 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 108.667 -0.864 . . . . 1.8 108.667 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 386' ' ' VAL . . . . . 0.543 ' HB ' ' CE ' ' A' ' 311' ' ' MET . 12.3 m -124.8 152.07 30.77 Favored 'Isoleucine or valine' 0 C--O 1.235 0.341 0 CA-C-O 121.756 0.788 . . . . 0.31 112.832 -167.208 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 387' ' ' LYS . . . . . 0.667 ' HD2' ' HG2' ' A' ' 357' ' ' GLU . 71.6 tttt -143.7 136.38 27.27 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.1 -0.955 . . . . 2.5299999999999998 109.583 174.541 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 388' ' ' LEU . . . . . 0.831 HD11 ' HB ' ' A' ' 309' ' ' VAL . 30.7 tp -95.94 131.2 42.55 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.729 -0.471 . . . . 0.28000000000000003 109.729 -177.487 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 32.9 m -122.16 -8.96 8.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 N-CA-C 112.226 0.454 . . . . 0.45000000000000001 112.226 -174.202 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 13.9 p -166.94 161.18 14.91 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.003 0.43 . . . . 1.3200000000000001 111.852 -176.013 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 391' ' ' MET . . . . . 0.587 ' HG2' ' HG2' ' A' ' 392' ' ' LYS . 29.9 ttm -151.51 143.37 23.79 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.403 -0.817 . . . . 0.56000000000000005 109.428 176.678 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 392' ' ' LYS . . . . . 0.587 ' HG2' ' HG2' ' A' ' 391' ' ' MET . 19.4 pttp . . . . . 0 C--O 1.248 0.989 0 CA-C-O 117.888 -1.054 . . . . 4.9100000000000001 112.369 179.19 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.432 HG22 ' HB3' ' A' ' 293' ' ' GLU . 17.9 p . . . . . 0 N--CA 1.444 -0.733 0 CA-C-O 120.999 0.428 . . . . 0.76000000000000001 111.081 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 15.1 ptpt -140.68 146.18 37.51 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.2 -0.455 . . . . 2.0600000000000001 110.959 176.527 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 285' ' ' LEU . . . . . 0.54 HD11 ' HA2' ' A' ' 289' ' ' GLY . 22.1 tp -89.5 129.41 35.99 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.294 -0.866 . . . . 0.97999999999999998 111.292 -175.823 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.545 HD11 HD13 ' A' ' 292' ' ' ILE . 81.7 mt -105.62 -166.71 1.24 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.975 -0.557 . . . . 0.80000000000000004 110.284 175.854 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 287' ' ' GLU . . . . . 0.526 ' HG3' ' OH ' ' A' ' 366' ' ' TYR . 8.2 tp10 -51.11 142.0 13.23 Favored 'General case' 0 C--O 1.234 0.28 0 O-C-N 123.706 0.629 . . . . 2.6400000000000001 111.557 -179.832 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 72.67 -99.63 0.93 Allowed Glycine 0 N--CA 1.446 -0.682 0 CA-C-N 115.551 -0.75 . . . . 1.8400000000000001 111.37 -174.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 289' ' ' GLY . . . . . 0.54 ' HA2' HD11 ' A' ' 285' ' ' LEU . . . -153.77 32.91 0.75 Allowed Glycine 0 N--CA 1.443 -0.837 0 N-CA-C 110.428 -1.069 . . . . 0.64000000000000001 110.428 174.138 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 290' ' ' ILE . . . . . 0.511 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 76.9 mt -74.77 124.41 32.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.564 -0.318 . . . . 0.41999999999999998 110.394 -176.14 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.619 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 7.8 mt -104.24 136.45 37.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 N-CA-C 109.651 -0.5 . . . . 0.93000000000000005 109.651 -179.591 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 292' ' ' ILE . . . . . 0.545 HD13 HD11 ' A' ' 286' ' ' LEU . 33.5 pt -133.37 137.28 53.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 120.699 -0.4 . . . . 0.47999999999999998 111.07 179.481 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 293' ' ' GLU . . . . . 0.601 ' CG ' ' HB3' ' A' ' 359' ' ' ARG . 12.1 pt-20 -139.74 143.3 36.92 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.231 -0.895 . . . . 2.3100000000000001 109.709 178.336 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -94.0 139.86 30.42 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 120.996 0.427 . . . . 2.3599999999999999 111.035 179.548 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 295' ' ' ARG . . . . . 0.404 HH11 ' HD2' ' A' ' 295' ' ' ARG . 11.3 mmt85 -114.7 -47.11 2.91 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.569 -0.741 . . . . 3.5 111.414 -174.55 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.57 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 97.6 t -120.9 132.55 70.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.392 -0.367 . . . . 0.69999999999999996 110.414 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 10.3 p -63.5 137.8 58.27 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.845 -0.616 . . . . 1.9299999999999999 112.05 -176.911 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -165.35 132.77 2.76 Favored Glycine 0 N--CA 1.446 -0.659 0 CA-C-N 115.781 -0.645 . . . . 1.04 111.815 179.294 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 11.1 ptpp? -133.44 116.49 16.07 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.255 0.55 . . . . 4.4900000000000002 109.905 176.909 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -171.55 -154.1 9.6 Favored Glycine 0 N--CA 1.442 -0.918 0 N-CA-C 111.193 -0.763 . . . . 1.04 111.193 -177.232 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 301' ' ' PRO . . . . . 0.441 ' O ' ' HA ' ' A' ' 353' ' ' ALA . 26.2 Cg_exo -61.66 133.01 43.01 Favored 'Trans proline' 0 C--O 1.237 0.443 0 C-N-CA 122.625 2.217 . . . . 0.88 111.472 178.233 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 25.0 m80 -101.47 133.48 46.06 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.247 -0.433 . . . . 1.49 111.298 -177.524 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -64.76 126.5 28.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.503 -0.772 . . . . 0.54000000000000004 111.179 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 38.2 ttpt -136.4 169.77 17.13 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.2 -0.667 . . . . 2.8399999999999999 109.2 -177.225 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 57.0 tttp -63.07 128.2 34.77 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.912 0.386 . . . . 2.8399999999999999 110.18 177.051 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 97.6 -4.91 62.0 Favored Glycine 0 N--CA 1.451 -0.347 0 CA-C-N 115.935 -0.575 . . . . 0.69999999999999996 111.84 -176.756 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 27.4 m -93.74 146.32 23.94 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.708 0.29 . . . . 0.40000000000000002 110.994 -179.363 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 308' ' ' ARG . . . . . 0.504 ' HG2' ' HB3' ' A' ' 335' ' ' LYS . 54.6 mtm180 -110.65 104.12 12.77 Favored 'General case' 0 CA--C 1.516 -0.349 0 N-CA-C 109.346 -0.612 . . . . 3.4500000000000002 109.346 177.822 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.792 ' HB ' HD11 ' A' ' 388' ' ' LEU . 31.5 m -102.65 147.01 9.73 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 CA-C-O 121.349 0.595 . . . . 0.34000000000000002 111.944 -173.457 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -118.02 117.21 3.67 Favored Glycine 0 N--CA 1.446 -0.678 0 N-CA-C 109.669 -1.372 . . . . 0.27000000000000002 109.669 176.068 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 311' ' ' MET . . . . . 0.457 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 21.4 ptm -135.23 177.02 8.14 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.577 0.703 . . . . 0.76000000000000001 112.729 -169.133 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 64.4 mtt180 -134.47 147.63 50.42 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 107.332 -1.359 . . . . 2.5099999999999998 107.332 176.496 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 313' ' ' TYR . . . . . 0.697 ' HB2' HG12 ' A' ' 386' ' ' VAL . 48.6 p90 -164.29 157.92 18.25 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 112.878 0.696 . . . . 0.68000000000000005 112.878 -172.54 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 62.0 t -125.45 116.18 45.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 114.818 -1.083 . . . . 0.34999999999999998 109.44 174.411 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -101.43 116.85 5.67 Favored Glycine 0 C--O 1.24 0.475 0 C-N-CA 120.912 -0.661 . . . . 0.28000000000000003 112.213 -177.587 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 316' ' ' LYS . . . . . 0.536 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 98.3 mttt -119.41 162.42 18.85 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.372 0.606 . . . . 1.9399999999999999 111.058 -178.01 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 63.2 mt -88.04 167.13 13.95 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.02 -0.991 . . . . 0.65000000000000002 109.301 173.389 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 318' ' ' LYS . . . . . 0.52 ' HD3' ' H ' ' A' ' 381' ' ' GLU . 19.3 pttp -66.51 -8.84 29.16 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.38 0.609 . . . . 2.4199999999999999 110.299 175.379 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 13.2 t-20 -86.22 -6.94 58.88 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.678 -0.692 . . . . 2.2000000000000002 110.302 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 96.47 -12.92 66.13 Favored Glycine 0 N--CA 1.451 -0.303 0 CA-C-N 115.833 -0.621 . . . . 0.68999999999999995 112.557 178.553 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 14.4 mmmm -82.94 132.04 35.17 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.681 0.277 . . . . 2.4199999999999999 110.903 -177.825 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.536 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 5.6 p -84.07 134.06 27.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 116.097 -0.501 . . . . 1.26 109.892 177.182 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 34.4 p90 -105.5 -31.73 8.85 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 120.843 -0.343 . . . . 0.55000000000000004 111.424 179.556 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -148.67 151.83 35.62 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 110.062 -0.347 . . . . 1.6799999999999999 110.062 178.274 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 325' ' ' LYS . . . . . 0.599 ' HD3' ' N ' ' A' ' 325' ' ' LYS . 0.0 OUTLIER -160.19 135.24 7.89 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.96 0.41 . . . . 1.99 110.11 -177.908 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 49.0 m-80 -138.51 118.19 13.1 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.512 -0.551 . . . . 1.9199999999999999 109.512 179.415 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 6.6 t -162.26 -43.49 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.576 -0.284 . . . . 1.6899999999999999 110.965 -178.601 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.406 ' O ' ' HG3' ' A' ' 328' ' ' LYS . 6.9 ptpp? -99.51 120.64 39.96 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.862 -0.421 . . . . 2.5499999999999998 109.862 177.167 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.424 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 79.13 -37.18 1.96 Allowed Glycine 0 CA--C 1.52 0.367 0 C-N-CA 121.139 -0.553 . . . . 0.96999999999999997 113.034 178.02 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 32.7 mmtp -103.64 100.58 19.86 Favored Pre-proline 0 C--N 1.33 -0.28 0 N-CA-C 111.801 0.297 . . . . 2.0800000000000001 111.801 -178.906 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 331' ' ' PRO . . . . . 0.424 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 92.4 Cg_endo -87.54 127.4 2.36 Favored 'Trans proline' 0 N--CA 1.45 -1.032 0 C-N-CA 122.456 2.104 . . . . 0.62 110.775 168.144 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 82.9 t80 -102.03 117.63 35.2 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.57 -0.452 . . . . 0.64000000000000001 110.408 -178.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 87.5 t -114.61 122.5 68.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.828 -0.624 . . . . 0.38 110.076 179.343 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.457 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 14.1 p90 -138.49 155.77 48.13 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.713 -0.477 . . . . 0.40999999999999998 109.713 175.325 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 335' ' ' LYS . . . . . 0.504 ' HB3' ' HG2' ' A' ' 308' ' ' ARG . 0.0 OUTLIER -108.99 135.17 50.6 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.306 -0.407 . . . . 2.5800000000000001 111.117 179.861 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 9.5 mp -77.83 110.74 12.98 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.662 -0.699 . . . . 0.57999999999999996 109.471 179.643 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 177.92 -62.72 0.09 OUTLIER Glycine 0 N--CA 1.444 -0.777 0 C-N-CA 120.71 -0.757 . . . . 0.93999999999999995 111.594 -178.271 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 338' ' ' GLN . . . . . . . . . . . . . 20.8 pt20 -96.56 153.13 18.02 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.055 0.455 . . . . 2.6200000000000001 110.598 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -88.84 59.74 3.94 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 121.022 -0.609 . . . . 0.73999999999999999 112.372 -174.785 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 21.8 pt-20 -87.83 -20.82 25.54 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.522 0.677 . . . . 2.0899999999999999 109.62 174.217 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 22.1 m -95.81 167.76 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.084 -0.962 . . . . 0.42999999999999999 108.999 174.129 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 342' ' ' ILE . . . . . 0.598 ' HB ' ' HA ' ' A' ' 367' ' ' ALA . 22.1 pt -71.74 147.49 10.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 N-CA-C 109.13 -0.693 . . . . 0.32000000000000001 109.13 174.168 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 1.3 mtmt -49.92 -40.44 43.33 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 112.724 0.639 . . . . 2.9300000000000002 112.724 -171.718 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -55.64 -25.31 42.79 Favored Glycine 0 CA--C 1.524 0.623 0 C-N-CA 121.333 -0.46 . . . . 0.29999999999999999 113.825 179.014 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 8.2 m95 -74.77 -59.31 2.79 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.915 0.358 . . . . 0.39000000000000001 111.848 -179.501 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -49.68 -36.99 26.95 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-O 121.082 0.468 . . . . 1.75 111.197 177.729 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 60.8 mt -80.55 -52.28 14.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.821 -0.627 . . . . 0.39000000000000001 111.738 -178.529 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -67.83 -35.57 85.25 Favored Glycine 0 CA--C 1.519 0.287 0 C-N-CA 121.192 -0.528 . . . . 0.34000000000000002 113.812 -177.406 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 91.7 t -75.8 -23.97 16.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.699 0.285 . . . . 0.32000000000000001 110.906 -179.077 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.79 96.84 0.3 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.126 0.489 . . . . 0.46999999999999997 110.372 177.724 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 121.49 5.76 9.14 Favored Glycine 0 CA--C 1.52 0.367 0 C-N-CA 121.127 -0.559 . . . . 0.39000000000000001 112.648 -175.696 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 352' ' ' MET . . . . . . . . . . . . . 85.6 mmm -84.99 138.57 32.38 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.68 0.276 . . . . 1.28 110.995 175.882 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 353' ' ' ALA . . . . . 0.441 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -106.19 141.82 36.91 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 116.077 -0.51 . . . . 0.55000000000000004 111.214 -177.865 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 58.9 t -57.49 120.65 3.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.077 -0.511 . . . . 0.35999999999999999 110.4 173.188 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 104.08 -12.11 52.27 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 121.188 -0.53 . . . . 0.44 112.087 179.745 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -102.44 143.5 15.91 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.845 -0.693 . . . . 0.29999999999999999 112.407 -177.347 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 357' ' ' GLU . . . . . 0.57 ' HB3' ' HB ' ' A' ' 296' ' ' VAL . 32.5 tt0 -117.08 133.39 56.06 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 110.192 -0.299 . . . . 1.4099999999999999 110.192 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 358' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -144.81 144.13 30.99 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.213 0.53 . . . . 1.3700000000000001 111.113 -179.088 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 359' ' ' ARG . . . . . 0.624 ' HD2' HG22 ' A' ' 383' ' ' THR . 22.9 tpp85 -88.82 119.35 29.23 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.451 -0.795 . . . . 2.79 110.113 176.255 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 58.3 mt -105.33 121.23 57.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.962 -0.385 . . . . 0.38 109.962 177.418 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 361' ' ' VAL . . . . . 0.619 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 44.7 t -101.88 116.94 46.42 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 N-CA-C 109.471 -0.566 . . . . 0.39000000000000001 109.471 176.793 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 362' ' ' ILE . . . . . 0.51 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 59.0 mt -113.25 109.38 51.74 Favored Pre-proline 0 C--N 1.322 -0.595 0 CA-C-N 116.42 -0.354 . . . . 0.28999999999999998 111.346 -173.495 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 363' ' ' PRO . . . . . 0.529 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 10.2 Cg_endo -53.56 152.35 21.57 Favored 'Trans proline' 0 C--O 1.236 0.401 0 C-N-CA 123.158 2.572 . . . . 0.66000000000000003 112.23 173.098 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 364' ' ' ALA . . . . . 0.405 ' HB3' ' HD3' ' A' ' 365' ' ' PRO . . . -52.09 -49.03 86.71 Favored Pre-proline 0 CA--C 1.542 0.639 0 N-CA-C 113.375 0.88 . . . . 0.41999999999999998 113.375 -175.802 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 365' ' ' PRO . . . . . 0.595 ' HA ' ' HA2' ' A' ' 369' ' ' GLY . 53.4 Cg_exo -53.83 -32.19 65.55 Favored 'Trans proline' 0 C--N 1.364 1.371 0 C-N-CA 122.482 2.121 . . . . 0.69999999999999996 113.754 -177.062 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 366' ' ' TYR . . . . . 0.526 ' OH ' ' HG3' ' A' ' 287' ' ' GLU . 4.9 m-85 -94.66 9.71 37.73 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.217 0.532 . . . . 0.68999999999999995 110.942 -175.622 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 367' ' ' ALA . . . . . 0.598 ' HA ' ' HB ' ' A' ' 342' ' ' ILE . . . -120.1 -109.22 0.35 Allowed 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.592 -0.731 . . . . 0.85999999999999999 109.805 171.58 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 92.3 m-85 -81.58 -12.59 58.71 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 121.003 0.43 . . . . 1.0 111.534 179.404 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 369' ' ' GLY . . . . . 0.595 ' HA2' ' HA ' ' A' ' 365' ' ' PRO . . . 86.63 -114.1 4.02 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.846 -0.692 . . . . 0.56000000000000005 112.789 175.658 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 43.6 mttp -115.05 14.65 17.15 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.012 0.434 . . . . 2.7599999999999998 110.479 -175.454 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 55.3 tp60 -87.81 117.13 26.44 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.003 -0.544 . . . . 2.6499999999999999 110.645 -176.653 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 372' ' ' ALA . . . . . 0.49 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -87.56 98.89 11.66 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.069 -0.514 . . . . 1.01 110.67 177.814 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 76.9 mt -90.05 157.01 46.24 Favored Pre-proline 0 C--N 1.322 -0.619 0 CA-C-N 115.962 -0.563 . . . . 0.93000000000000005 109.951 178.994 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -61.21 114.25 2.11 Favored 'Trans proline' 0 N--CA 1.459 -0.527 0 C-N-CA 121.803 1.669 . . . . 1.3100000000000001 110.603 171.668 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 96.57 -30.39 8.88 Favored Glycine 0 N--CA 1.448 -0.559 0 CA-C-N 115.879 -0.6 . . . . 0.90000000000000002 112.22 -176.264 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 23.4 mt -129.26 78.26 76.26 Favored Pre-proline 0 C--N 1.329 -0.299 0 N-CA-C 110.145 -0.317 . . . . 0.73999999999999999 110.145 -179.475 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 377' ' ' PRO . . . . . 0.49 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 4.1 Cg_exo -76.86 166.21 27.29 Favored 'Trans proline' 0 N--CA 1.459 -0.54 0 C-N-CA 122.674 2.249 . . . . 0.70999999999999996 112.143 -179.375 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 378' ' ' ALA . . . . . 0.465 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -59.14 152.86 19.38 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.293 -0.412 . . . . 0.73999999999999999 110.695 176.921 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 379' ' ' ASN . . . . . 0.465 ' HB2' ' O ' ' A' ' 378' ' ' ALA . 91.2 m-20 74.95 4.88 4.33 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 123.012 0.525 . . . . 1.49 111.492 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 49.1 m -83.97 94.6 8.31 Favored 'General case' 0 N--CA 1.451 -0.392 0 CA-C-O 121.335 0.588 . . . . 1.8400000000000001 110.127 176.323 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 381' ' ' GLU . . . . . 0.52 ' H ' ' HD3' ' A' ' 318' ' ' LYS . 19.0 tt0 -67.04 112.34 4.33 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 114.972 -1.013 . . . . 1.03 109.617 179.354 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 82.4 mt -78.02 140.98 39.18 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.092 -0.504 . . . . 0.37 110.952 -173.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 383' ' ' THR . . . . . 0.624 HG22 ' HD2' ' A' ' 359' ' ' ARG . 25.1 m -120.19 119.54 33.54 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 109.29 -0.633 . . . . 0.27000000000000002 109.29 -179.182 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -115.63 114.62 25.15 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.05 0.452 . . . . 0.32000000000000001 111.19 -175.888 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 20.8 t70 -91.82 104.47 16.91 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 107.885 -1.154 . . . . 1.8 107.885 174.894 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 386' ' ' VAL . . . . . 0.697 HG12 ' HB2' ' A' ' 313' ' ' TYR . 17.3 m -129.71 147.61 33.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 112.46 0.541 . . . . 0.31 112.46 -167.097 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 387' ' ' LYS . . . . . 0.476 ' HB3' ' HA ' ' A' ' 357' ' ' GLU . 23.7 pttt -144.74 149.91 36.35 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.803 -0.635 . . . . 2.5299999999999998 111.271 170.804 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 388' ' ' LEU . . . . . 0.792 HD11 ' HB ' ' A' ' 309' ' ' VAL . 26.9 tp -99.2 138.4 36.35 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.274 -0.875 . . . . 0.28000000000000003 109.244 -176.702 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 31.8 m -128.83 -8.34 3.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 112.511 0.56 . . . . 0.45000000000000001 112.511 -174.852 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 74.2 m -161.55 157.92 25.57 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.624 0.249 . . . . 1.3200000000000001 110.837 -179.491 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 391' ' ' MET . . . . . . . . . . . . . 39.7 ttm -155.4 132.03 10.5 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-N 116.333 -0.394 . . . . 0.56000000000000005 110.881 -178.888 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 66.6 mttm . . . . . 0 C--O 1.25 1.094 0 CA-C-O 118.432 -0.794 . . . . 4.9100000000000001 109.603 176.781 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.546 ' HA ' ' O ' ' A' ' 292' ' ' ILE . 24.0 p . . . . . 0 N--CA 1.443 -0.807 0 CA-C-O 120.958 0.408 . . . . 0.76000000000000001 111.866 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 284' ' ' LYS . . . . . 0.511 ' HB2' ' CG1' ' A' ' 292' ' ' ILE . 13.5 mmmm -110.0 137.94 47.08 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.94 -0.763 . . . . 2.0600000000000001 108.94 174.762 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 285' ' ' LEU . . . . . 0.409 HD11 ' HA2' ' A' ' 289' ' ' GLY . 42.8 tp -100.26 121.71 41.91 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.934 0.397 . . . . 0.97999999999999998 110.59 -178.869 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.66 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 88.3 mt -108.54 -164.56 0.96 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.818 -0.628 . . . . 0.80000000000000004 110.477 -178.621 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -64.64 145.38 56.26 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 116.099 -0.5 . . . . 2.6400000000000001 111.749 -178.533 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.643 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 65.76 8.97 43.49 Favored Glycine 0 C--N 1.329 0.154 0 CA-C-N 115.925 -0.58 . . . . 1.8400000000000001 113.7 177.605 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 289' ' ' GLY . . . . . 0.409 ' HA2' HD11 ' A' ' 285' ' ' LEU . . . 90.95 12.29 60.55 Favored Glycine 0 N--CA 1.441 -0.988 0 C-N-CA 120.516 -0.849 . . . . 0.64000000000000001 113.067 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 290' ' ' ILE . . . . . 0.66 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 94.9 mt -60.67 127.44 20.22 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.139 0 CA-C-N 117.373 0.587 . . . . 0.41999999999999998 110.204 177.526 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.534 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 18.1 mt -113.29 139.82 36.63 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 116.37 -0.377 . . . . 0.93000000000000005 110.181 -178.948 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 292' ' ' ILE . . . . . 0.549 HG22 HG12 ' A' ' 360' ' ' ILE . 22.5 pt -128.34 127.06 66.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 120.891 0.377 . . . . 0.47999999999999998 109.987 175.369 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 293' ' ' GLU . . . . . . . . . . . . . 4.6 tm-20 -105.25 108.44 19.95 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 108.812 -0.81 . . . . 2.3100000000000001 108.812 -179.443 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -78.11 101.55 7.06 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-O 121.156 0.503 . . . . 2.3599999999999999 110.576 -171.195 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 295' ' ' ARG . . . . . 0.434 ' HG3' HG23 ' A' ' 296' ' ' VAL . 6.2 tpt180 -88.08 -59.41 2.25 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.184 -0.916 . . . . 3.5 111.879 -170.314 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.434 HG23 ' HG3' ' A' ' 295' ' ' ARG . 91.9 t -120.34 132.85 68.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.592 -0.277 . . . . 0.69999999999999996 110.77 -178.339 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 6.8 p -92.18 120.55 32.87 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.106 -0.497 . . . . 1.9299999999999999 110.915 178.932 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -126.96 -165.03 11.84 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.691 -0.766 . . . . 1.04 112.788 -175.809 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 299' ' ' LYS . . . . . 0.594 ' O ' ' HB1' ' A' ' 353' ' ' ALA . 74.1 mmtt -73.38 151.75 41.09 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.135 -0.691 . . . . 4.4900000000000002 109.135 177.706 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -119.75 79.72 0.32 Allowed Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 119.316 -1.421 . . . . 1.04 115.074 -168.945 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 301' ' ' PRO . . . . . 0.657 ' HD2' ' H ' ' A' ' 354' ' ' VAL . 2.4 Cg_endo -85.84 133.69 4.35 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 122.735 2.29 . . . . 0.88 109.062 160.234 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 33.6 m170 -92.16 116.46 28.97 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 120.438 -0.505 . . . . 1.49 112.245 -171.628 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -66.24 121.2 14.67 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.413 -0.812 . . . . 0.54000000000000004 110.157 173.14 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 31.9 mtmm -123.12 179.2 4.77 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.468 -0.333 . . . . 2.8399999999999999 110.377 -176.123 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 61.9 tttp -63.9 113.68 3.6 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.391 -0.368 . . . . 2.8399999999999999 110.349 179.618 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 98.62 -7.1 61.16 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.888 -0.673 . . . . 0.69999999999999996 112.547 -179.276 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 307' ' ' THR . . . . . 0.406 ' O ' ' HA ' ' A' ' 335' ' ' LYS . 38.9 m -77.61 145.55 36.72 Favored 'General case' 0 CA--C 1.534 0.346 0 O-C-N 122.776 -0.25 . . . . 0.40000000000000002 110.547 -179.499 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 73.4 mtt180 -105.25 113.87 27.71 Favored 'General case' 0 CA--C 1.519 -0.227 0 N-CA-C 109.565 -0.531 . . . . 3.4500000000000002 109.565 -177.697 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.691 ' HB ' HD11 ' A' ' 388' ' ' LEU . 30.2 m -107.28 139.02 30.44 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 CA-C-O 121.273 0.559 . . . . 0.34000000000000002 111.348 178.498 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -109.88 115.39 4.16 Favored Glycine 0 N--CA 1.445 -0.717 0 N-CA-C 110.23 -1.148 . . . . 0.27000000000000002 110.23 175.278 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 311' ' ' MET . . . . . 0.583 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 22.4 ptm -136.7 177.44 7.85 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.399 0.619 . . . . 0.76000000000000001 112.153 -169.659 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 312' ' ' ARG . . . . . 0.517 ' HD3' ' O ' ' A' ' 327' ' ' THR . 98.9 mtt180 -137.05 147.01 45.89 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 107.677 -1.231 . . . . 2.5099999999999998 107.677 175.341 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 313' ' ' TYR . . . . . 0.42 ' HA ' ' O ' ' A' ' 385' ' ' ASP . 25.2 p90 -161.49 159.93 28.55 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 112.941 0.719 . . . . 0.68000000000000005 112.941 -169.869 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 48.7 t -126.41 120.74 57.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 114.839 -1.073 . . . . 0.34999999999999998 109.68 174.932 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -94.64 106.03 3.36 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.388 -0.434 . . . . 0.28000000000000003 112.19 -177.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 316' ' ' LYS . . . . . 0.556 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 84.3 mttt -114.09 156.31 24.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.064 0.459 . . . . 1.9399999999999999 110.932 -177.038 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 96.5 mt -89.31 163.11 15.49 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.045 -0.525 . . . . 0.65000000000000002 109.585 172.103 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 318' ' ' LYS . . . . . 0.728 ' HD3' ' HB3' ' A' ' 381' ' ' GLU . 61.7 pttt -65.68 -11.55 46.07 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 121.01 0.433 . . . . 2.4199999999999999 111.338 178.405 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 9.0 t30 -87.98 -7.88 56.45 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.083 0.468 . . . . 2.2000000000000002 110.216 178.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 101.17 -15.61 57.69 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 121.09 -0.576 . . . . 0.68999999999999995 112.197 -178.906 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 59.0 tptt -70.89 117.28 12.19 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.644 0.259 . . . . 2.4199999999999999 110.73 -179.272 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.556 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 6.1 p -85.58 131.77 33.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 N-CA-C 110.028 -0.36 . . . . 1.26 110.028 176.819 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 31.6 p90 -106.35 -50.09 3.22 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 120.862 -0.335 . . . . 0.55000000000000004 110.991 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 324' ' ' ASP . . . . . 0.494 ' C ' ' HD3' ' A' ' 325' ' ' LYS . 12.0 t70 -123.86 154.32 39.81 Favored 'General case' 0 CA--C 1.513 -0.446 0 N-CA-C 109.492 -0.559 . . . . 1.6799999999999999 109.492 -179.302 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 325' ' ' LYS . . . . . 0.494 ' HD3' ' C ' ' A' ' 324' ' ' ASP . 0.0 OUTLIER -167.9 131.1 1.61 Allowed 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.959 0.409 . . . . 1.99 111.143 -174.147 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 1.9 p30 -146.52 115.78 7.03 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.684 0.754 . . . . 1.9199999999999999 109.719 170.336 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 327' ' ' THR . . . . . 0.517 ' O ' ' HD3' ' A' ' 312' ' ' ARG . 1.7 p -148.96 -47.17 0.14 Allowed 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 114.935 -1.029 . . . . 1.6899999999999999 110.922 -172.717 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.66 93.34 2.06 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.492 0.663 . . . . 2.5499999999999998 111.534 -178.111 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.487 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 75.37 -11.5 8.96 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 115.508 -0.769 . . . . 0.96999999999999997 113.629 175.288 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 45.9 mtpt -103.25 100.63 18.49 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-N 117.32 0.56 . . . . 2.0800000000000001 111.41 -177.635 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 331' ' ' PRO . . . . . 0.487 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 86.0 Cg_endo -87.76 139.7 4.83 Favored 'Trans proline' 0 N--CA 1.452 -0.953 0 C-N-CA 122.749 2.299 . . . . 0.62 111.854 170.664 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 79.2 t80 -109.84 128.14 55.14 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.253 -0.647 . . . . 0.64000000000000001 109.253 176.359 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 61.9 t -115.22 119.6 62.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 N-CA-C 109.839 -0.43 . . . . 0.38 109.839 -176.98 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.583 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 21.2 p90 -138.92 166.59 24.07 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.853 -0.425 . . . . 0.40999999999999998 109.853 179.66 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 335' ' ' LYS . . . . . 0.407 ' HG3' ' HB3' ' A' ' 338' ' ' GLN . 58.6 pttt -111.12 140.49 45.62 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.16 -0.473 . . . . 2.5800000000000001 110.403 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 11.2 mp -71.53 139.0 49.32 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.729 -0.471 . . . . 0.57999999999999996 109.729 175.246 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 94.76 5.95 60.99 Favored Glycine 0 N--CA 1.442 -0.93 0 C-N-CA 120.791 -0.719 . . . . 0.93999999999999995 113.002 -174.858 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 338' ' ' GLN . . . . . 0.6 HE21 HG13 ' A' ' 341' ' ' VAL . 13.7 pt20 -85.16 148.86 25.9 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 117.381 0.591 . . . . 2.6200000000000001 109.558 176.165 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -90.37 15.23 60.49 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.75 -0.738 . . . . 0.73999999999999999 114.407 -166.843 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -109.92 -9.07 14.79 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 117.646 0.723 . . . . 2.0899999999999999 111.481 178.397 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 341' ' ' VAL . . . . . 0.6 HG13 HE21 ' A' ' 338' ' ' GLN . 26.3 m -95.71 146.29 7.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 C-N-CA 120.769 -0.372 . . . . 0.42999999999999999 110.144 178.697 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 17.4 pt -73.58 157.1 6.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 109.965 -0.383 . . . . 0.32000000000000001 109.965 178.678 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 343' ' ' LYS . . . . . 0.453 ' HA ' ' HE3' ' A' ' 343' ' ' LYS . 0.0 OUTLIER -62.74 -35.26 79.19 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 111.626 0.232 . . . . 2.9300000000000002 111.626 -175.895 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -52.28 -42.15 55.62 Favored Glycine 0 C--O 1.228 -0.251 0 C-N-CA 120.774 -0.726 . . . . 0.29999999999999999 112.363 174.243 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 4.2 m95 -68.8 -60.34 2.46 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.819 0.342 . . . . 0.39000000000000001 111.043 176.441 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -51.66 -33.97 35.99 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.594 -0.73 . . . . 1.75 112.121 -177.477 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 60.0 mt -85.19 -52.53 12.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 116.4 -0.363 . . . . 0.39000000000000001 111.283 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -60.47 -35.05 87.94 Favored Glycine 0 CA--C 1.524 0.628 0 C-N-CA 121.261 -0.495 . . . . 0.34000000000000002 113.794 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 349' ' ' VAL . . . . . 0.422 ' O ' ' HB2' ' A' ' 352' ' ' MET . 93.1 t -77.68 -18.27 14.05 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 CA-C-O 120.994 0.426 . . . . 0.32000000000000001 111.382 -179.311 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -64.22 100.34 0.33 Allowed 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.157 0.503 . . . . 0.46999999999999997 110.634 177.934 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 105.52 12.05 27.57 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.914 -0.66 . . . . 0.39000000000000001 112.205 -177.014 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 352' ' ' MET . . . . . 0.422 ' HB2' ' O ' ' A' ' 349' ' ' VAL . 0.0 OUTLIER -66.58 143.89 56.76 Favored 'General case' 0 C--N 1.331 -0.216 0 N-CA-C 109.79 -0.448 . . . . 1.28 109.79 177.675 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 353' ' ' ALA . . . . . 0.594 ' HB1' ' O ' ' A' ' 299' ' ' LYS . . . -104.06 127.06 51.61 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.321 -0.399 . . . . 0.55000000000000004 111.715 -173.082 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 354' ' ' VAL . . . . . 0.657 ' H ' ' HD2' ' A' ' 301' ' ' PRO . 98.3 t -64.84 112.97 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.239 0.542 . . . . 0.35999999999999999 110.743 174.504 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 109.96 -10.88 31.97 Favored Glycine 0 N--CA 1.442 -0.9 0 N-CA-C 111.313 -0.715 . . . . 0.44 111.313 -176.761 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -101.54 159.77 18.38 Favored Glycine 0 N--CA 1.442 -0.952 0 C-N-CA 121.048 -0.596 . . . . 0.29999999999999999 112.302 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 357' ' ' GLU . . . . . 0.862 ' HB2' ' HD3' ' A' ' 387' ' ' LYS . 43.3 tt0 -135.35 140.97 45.47 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.491 -0.559 . . . . 1.4099999999999999 109.491 -179.505 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 358' ' ' ARG . . . . . . . . . . . . . 5.9 ptp180 -156.2 144.91 20.2 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.026 0.441 . . . . 1.3700000000000001 110.861 177.182 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 359' ' ' ARG . . . . . . . . . . . . . 82.8 mtm180 -91.44 120.02 31.91 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 115.968 -0.56 . . . . 2.79 110.444 179.174 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 360' ' ' ILE . . . . . 0.549 HG12 HG22 ' A' ' 292' ' ' ILE . 62.3 mt -101.68 119.32 49.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-N 115.734 -0.666 . . . . 0.38 110.638 -176.476 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 361' ' ' VAL . . . . . 0.534 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 46.3 t -103.48 112.74 38.09 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 108.972 -0.751 . . . . 0.39000000000000001 108.972 177.025 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 362' ' ' ILE . . . . . . . . . . . . . 57.6 mt -109.74 102.24 49.47 Favored Pre-proline 0 C--N 1.319 -0.723 0 CA-C-N 116.037 -0.528 . . . . 0.28999999999999998 110.999 -174.761 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 363' ' ' PRO . . . . . 0.472 ' HA ' ' HG3' ' A' ' 381' ' ' GLU . 71.2 Cg_exo -54.39 155.48 16.29 Favored 'Trans proline' 0 N--CA 1.459 -0.559 0 C-N-CA 122.532 2.155 . . . . 0.66000000000000003 112.206 171.231 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 364' ' ' ALA . . . . . 0.547 ' N ' ' HD2' ' A' ' 365' ' ' PRO . . . -46.03 -50.1 37.5 Favored Pre-proline 0 C--N 1.327 -0.41 0 N-CA-C 114.364 1.246 . . . . 0.41999999999999998 114.364 -174.743 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 365' ' ' PRO . . . . . 0.547 ' HD2' ' N ' ' A' ' 364' ' ' ALA . 9.8 Cg_endo -52.53 -31.58 49.58 Favored 'Trans proline' 0 C--N 1.36 1.168 0 C-N-CA 122.685 2.256 . . . . 0.69999999999999996 114.387 -172.144 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 366' ' ' TYR . . . . . 0.643 ' CE2' ' HA3' ' A' ' 288' ' ' GLY . 9.6 m-85 -101.62 13.46 34.86 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-O 121.017 0.437 . . . . 0.68999999999999995 112.035 -176.708 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -126.59 -108.05 0.31 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.963 -0.562 . . . . 0.85999999999999999 110.563 173.744 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 368' ' ' TYR . . . . . 0.406 ' CE2' HD11 ' A' ' 382' ' ' LEU . 40.6 m-85 -84.08 -21.83 31.37 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.821 0.343 . . . . 1.0 111.211 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 70.68 -118.1 7.47 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.841 -0.695 . . . . 0.56000000000000005 112.15 -178.14 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 370' ' ' LYS . . . . . 0.555 ' HA ' ' HB1' ' A' ' 378' ' ' ALA . 19.4 ptmt -101.77 17.39 23.11 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.975 0.416 . . . . 2.7599999999999998 110.735 178.863 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 59.4 tt0 -84.86 102.58 13.2 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.941 -0.572 . . . . 2.6499999999999999 110.154 176.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 372' ' ' ALA . . . . . 0.433 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -81.68 108.25 15.09 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.873 0.368 . . . . 1.01 111.202 177.834 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 86.6 mt -90.02 159.33 42.87 Favored Pre-proline 0 C--N 1.322 -0.626 0 N-CA-C 109.088 -0.708 . . . . 0.93000000000000005 109.088 175.193 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -62.26 114.24 2.25 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 121.656 1.57 . . . . 1.3100000000000001 110.555 172.797 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 96.26 -29.28 10.4 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.67 -0.776 . . . . 0.90000000000000002 112.439 -178.155 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 43.3 mt -128.36 86.66 57.27 Favored Pre-proline 0 C--N 1.332 -0.152 0 N-CA-C 110.011 -0.366 . . . . 0.73999999999999999 110.011 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 377' ' ' PRO . . . . . 0.433 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 83.8 Cg_endo -80.03 168.0 19.37 Favored 'Trans proline' 0 N--CA 1.462 -0.354 0 C-N-CA 122.724 2.283 . . . . 0.70999999999999996 113.017 -176.579 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 378' ' ' ALA . . . . . 0.555 ' HB1' ' HA ' ' A' ' 370' ' ' LYS . . . -52.95 150.16 5.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.5 -0.773 . . . . 0.73999999999999999 111.703 178.73 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 379' ' ' ASN . . . . . 0.434 ' HA ' ' HB2' ' A' ' 364' ' ' ALA . 49.9 m-80 70.91 15.14 6.82 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 115.473 -0.785 . . . . 1.49 111.265 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 21.5 t -76.67 125.98 30.19 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 109.587 -0.523 . . . . 1.8400000000000001 109.587 175.156 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 381' ' ' GLU . . . . . 0.728 ' HB3' ' HD3' ' A' ' 318' ' ' LYS . 27.2 tt0 -102.24 112.57 25.32 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 108.67 -0.863 . . . . 1.03 108.67 -179.01 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 382' ' ' LEU . . . . . 0.406 HD11 ' CE2' ' A' ' 368' ' ' TYR . 75.8 mt -86.26 146.53 26.48 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 116.179 -0.464 . . . . 0.37 111.12 -172.709 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 63.0 m -123.52 122.84 39.24 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.386 -0.598 . . . . 0.27000000000000002 109.386 173.785 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 76.8 m-85 -119.84 111.71 18.32 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 116.483 -0.326 . . . . 0.32000000000000001 111.079 -177.01 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 385' ' ' ASP . . . . . 0.42 ' O ' ' HA ' ' A' ' 313' ' ' TYR . 3.6 m-20 -72.54 104.18 3.77 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 107.924 -1.139 . . . . 1.8 107.924 167.834 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 386' ' ' VAL . . . . . 0.505 ' HB ' ' CE ' ' A' ' 311' ' ' MET . 32.2 m -119.11 135.61 58.97 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.426 0.631 . . . . 0.31 111.012 -176.227 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 387' ' ' LYS . . . . . 0.862 ' HD3' ' HB2' ' A' ' 357' ' ' GLU . 21.6 ttpt -141.32 128.65 21.11 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.296 -0.865 . . . . 2.5299999999999998 109.449 178.44 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 388' ' ' LEU . . . . . 0.691 HD11 ' HB ' ' A' ' 309' ' ' VAL . 22.6 tp -95.04 136.76 34.97 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.932 -0.576 . . . . 0.28000000000000003 109.575 -172.65 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 35.8 m -126.0 -5.0 5.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 N-CA-C 112.392 0.516 . . . . 0.45000000000000001 112.392 -174.654 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 11.3 p -169.15 157.41 7.7 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.816 -0.354 . . . . 1.3200000000000001 111.473 -177.444 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 391' ' ' MET . . . . . 0.55 ' HE2' HG12 ' A' ' 309' ' ' VAL . 34.1 ttm -160.89 139.11 9.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.16 -0.473 . . . . 0.56000000000000005 110.485 177.448 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 18.2 tptm . . . . . 0 C--O 1.246 0.892 0 CA-C-O 117.961 -1.019 . . . . 4.9100000000000001 111.402 175.167 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.456 ' HA ' ' O ' ' A' ' 292' ' ' ILE . 16.9 p . . . . . 0 N--CA 1.444 -0.729 0 CA-C-O 121.083 0.468 . . . . 0.76000000000000001 111.412 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 28.2 mmtp -127.46 139.74 52.61 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.729 -0.669 . . . . 2.0600000000000001 109.629 175.821 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 285' ' ' LEU . . . . . 0.461 HD11 ' HA2' ' A' ' 289' ' ' GLY . 37.6 tp -96.28 121.1 37.71 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.909 -0.587 . . . . 0.97999999999999998 110.217 179.539 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.669 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 95.2 mt -105.83 -171.73 1.96 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.912 -0.586 . . . . 0.80000000000000004 110.378 -179.413 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 287' ' ' GLU . . . . . 0.476 ' HG3' ' OH ' ' A' ' 366' ' ' TYR . 4.9 tp10 -64.51 145.37 56.22 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.889 -0.596 . . . . 2.6400000000000001 111.105 -176.381 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.423 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 70.93 7.19 61.65 Favored Glycine 0 C--N 1.332 0.31 0 C-N-CA 121.055 -0.593 . . . . 1.8400000000000001 113.126 -178.999 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 289' ' ' GLY . . . . . 0.461 ' HA2' HD11 ' A' ' 285' ' ' LEU . . . 84.81 19.93 58.83 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.858 -0.687 . . . . 0.64000000000000001 113.216 -179.613 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 290' ' ' ILE . . . . . 0.669 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 96.1 mt -66.39 126.46 25.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 109.985 -0.376 . . . . 0.41999999999999998 109.985 177.557 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 14.8 mt -110.53 137.14 44.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 N-CA-C 109.726 -0.472 . . . . 0.93000000000000005 109.726 -178.748 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 292' ' ' ILE . . . . . 0.456 ' O ' ' HA ' ' A' ' 283' ' ' THR . 21.7 pt -127.02 128.24 70.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-O 121.054 0.454 . . . . 0.47999999999999998 111.069 179.626 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 293' ' ' GLU . . . . . 0.746 ' HB3' ' HB3' ' A' ' 359' ' ' ARG . 6.6 tp10 -104.62 105.54 15.67 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.177 -1.046 . . . . 2.3100000000000001 108.177 174.223 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -78.02 110.16 12.71 Favored 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 120.562 -0.455 . . . . 2.3599999999999999 109.816 -172.221 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 295' ' ' ARG . . . . . 0.705 ' HB2' ' HG3' ' A' ' 357' ' ' GLU . 14.6 mmm180 -78.05 -59.66 2.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.889 -0.596 . . . . 3.5 110.855 -171.304 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.552 ' HB ' ' HG2' ' A' ' 357' ' ' GLU . 97.8 t -137.16 119.06 18.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 C-N-CA 121.141 -0.223 . . . . 0.69999999999999996 110.626 177.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 14.9 p -68.27 108.04 3.04 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 116.079 -0.51 . . . . 1.9299999999999999 110.494 176.129 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -94.91 157.39 22.17 Favored Glycine 0 N--CA 1.442 -0.926 0 C-N-CA 120.764 -0.731 . . . . 1.04 111.56 178.677 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 18.3 ttpp -115.75 111.03 19.94 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 109.764 -0.458 . . . . 4.4900000000000002 109.764 178.535 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -171.72 -162.39 23.91 Favored Glycine 0 N--CA 1.44 -1.096 0 N-CA-C 111.105 -0.798 . . . . 1.04 111.105 179.742 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 301' ' ' PRO . . . . . 0.435 ' HD2' ' HB ' ' A' ' 354' ' ' VAL . 21.6 Cg_exo -65.76 133.33 33.59 Favored 'Trans proline' 0 N--CA 1.461 -0.394 0 C-N-CA 122.496 2.131 . . . . 0.88 111.661 175.703 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 302' ' ' HIS . . . . . 0.52 ' HA ' ' O ' ' A' ' 352' ' ' MET . 64.4 m80 -89.01 133.69 34.25 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.116 0.484 . . . . 1.49 110.579 -179.706 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 303' ' ' ALA . . . . . 0.44 ' HB2' HG11 ' A' ' 309' ' ' VAL . . . -87.17 129.25 35.02 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.773 -0.649 . . . . 0.54000000000000004 111.621 -177.988 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 59.7 pttt -124.34 -176.3 3.48 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.5 -0.555 . . . . 2.8399999999999999 109.5 174.94 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.72 ' HG3' ' HA3' ' A' ' 337' ' ' GLY . 50.7 tttm -66.98 133.66 50.4 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.028 0.442 . . . . 2.8399999999999999 110.229 -178.527 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 91.96 -8.91 77.63 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 121.064 -0.589 . . . . 0.69999999999999996 112.669 -176.96 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 25.6 m -82.06 145.51 30.15 Favored 'General case' 0 CA--C 1.535 0.365 0 CA-C-O 120.688 0.28 . . . . 0.40000000000000002 110.766 -178.689 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 89.6 mtt180 -108.33 103.23 12.35 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-O 121.098 0.475 . . . . 3.4500000000000002 109.771 -178.221 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.901 ' HB ' HD11 ' A' ' 388' ' ' LEU . 32.4 m -112.13 159.83 11.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-N 115.549 -0.751 . . . . 0.34000000000000002 112.244 -175.965 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -123.26 123.55 5.33 Favored Glycine 0 N--CA 1.447 -0.573 0 N-CA-C 110.524 -1.03 . . . . 0.27000000000000002 110.524 176.333 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 10.4 ptp -134.48 178.15 7.21 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.399 0.619 . . . . 0.76000000000000001 111.815 -173.377 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 88.1 mtt180 -137.53 143.4 41.61 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 107.217 -1.401 . . . . 2.5099999999999998 107.217 176.02 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 313' ' ' TYR . . . . . 0.593 ' CB ' HG12 ' A' ' 386' ' ' VAL . 49.4 p90 -162.55 152.16 15.84 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 112.646 0.61 . . . . 0.68000000000000005 112.646 -167.238 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 51.1 t -116.92 119.0 60.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.091 -0.959 . . . . 0.34999999999999998 109.627 173.111 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -97.93 109.15 3.75 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 121.343 -0.456 . . . . 0.28000000000000003 112.261 -178.022 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 316' ' ' LYS . . . . . 0.561 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 56.3 mttm -120.42 162.97 18.62 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.173 0.511 . . . . 1.9399999999999999 111.025 -177.157 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 81.9 mt -86.54 164.54 16.84 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 108.033 -1.099 . . . . 0.65000000000000002 108.033 166.858 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 318' ' ' LYS . . . . . . . . . . . . . 47.7 pttt -64.44 -8.46 13.57 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.483 0.659 . . . . 2.4199999999999999 110.303 173.505 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -79.51 -12.59 59.86 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 115.289 -0.869 . . . . 2.2000000000000002 109.799 176.52 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 95.59 -24.93 27.14 Favored Glycine 0 N--CA 1.453 -0.187 0 N-CA-C 111.572 -0.611 . . . . 0.68999999999999995 111.572 -176.445 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 23.7 ttmm -60.08 120.04 8.96 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.015 -0.593 . . . . 2.4199999999999999 110.831 177.92 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.561 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 5.3 p -88.86 127.22 41.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.133 -0.485 . . . . 1.26 110.201 179.491 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 49.4 p90 -98.88 -27.19 14.02 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.828 -0.349 . . . . 0.55000000000000004 111.16 -178.949 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -155.18 145.79 22.22 Favored 'General case' 0 CA--C 1.514 -0.408 0 N-CA-C 109.981 -0.377 . . . . 1.6799999999999999 109.981 175.599 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 325' ' ' LYS . . . . . 0.487 ' HD3' ' N ' ' A' ' 325' ' ' LYS . 0.0 OUTLIER -149.74 128.7 12.61 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.379 0.609 . . . . 1.99 111.335 -179.257 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 23.6 m-80 -125.21 114.51 19.07 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 107.055 -1.461 . . . . 1.9199999999999999 107.055 174.452 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 10.4 m -155.29 -58.79 0.1 Allowed 'General case' 0 C--N 1.318 -0.803 0 C-N-CA 120.367 -0.533 . . . . 1.6899999999999999 111.784 -168.49 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 9.4 ptmm? -68.05 92.01 0.37 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.288 0.566 . . . . 2.5499999999999998 111.625 -172.982 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.452 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 63.51 2.77 6.19 Favored Glycine 0 C--N 1.335 0.513 0 CA-C-N 115.582 -0.736 . . . . 0.96999999999999997 113.048 -178.402 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 83.9 tttt -105.63 101.9 35.0 Favored Pre-proline 0 C--N 1.325 -0.47 0 N-CA-C 111.772 0.286 . . . . 2.0800000000000001 111.772 -172.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 331' ' ' PRO . . . . . 0.452 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 95.8 Cg_endo -87.76 161.74 7.7 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 123.067 2.511 . . . . 0.62 112.567 174.289 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 66.4 t80 -134.72 126.45 29.06 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.224 -0.444 . . . . 0.64000000000000001 109.844 174.038 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 333' ' ' VAL . . . . . 0.5 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 59.6 t -109.48 120.91 61.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.556 -0.293 . . . . 0.38 110.363 -177.002 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 22.3 p90 -142.93 160.13 40.93 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.193 0.52 . . . . 0.40999999999999998 111.711 -178.608 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 335' ' ' LYS . . . . . . . . . . . . . 11.2 ttmt -89.34 128.15 35.86 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.309 -0.859 . . . . 2.5800000000000001 110.345 176.881 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 6.8 mp -69.32 136.85 52.38 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.673 0.273 . . . . 0.57999999999999996 110.598 173.813 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 337' ' ' GLY . . . . . 0.72 ' HA3' ' HG3' ' A' ' 305' ' ' LYS . . . 79.08 58.02 3.07 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 121.112 -0.566 . . . . 0.93999999999999995 112.708 178.62 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 338' ' ' GLN . . . . . . . . . . . . . 29.0 pt20 -142.55 161.21 38.64 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.776 -0.453 . . . . 2.6200000000000001 109.776 176.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -81.74 1.39 86.33 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.18 -0.533 . . . . 0.73999999999999999 112.617 -173.797 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 21.0 mm-40 -76.25 -21.66 56.08 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.153 0.501 . . . . 2.0899999999999999 110.307 178.461 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 18.7 m -114.51 166.64 8.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.898 -0.592 . . . . 0.42999999999999999 110.046 -177.317 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 10.4 pt -85.11 154.46 3.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 N-CA-C 109.518 -0.549 . . . . 0.32000000000000001 109.518 175.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 343' ' ' LYS . . . . . 0.622 ' HA ' ' OD1' ' A' ' 346' ' ' ASP . 13.7 mmmm -60.18 -28.54 68.03 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.391 0.515 . . . . 2.9300000000000002 112.391 -172.62 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 344' ' ' GLY . . . . . 0.498 ' HA2' HD13 ' A' ' 290' ' ' ILE . . . -56.27 -31.13 59.15 Favored Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.467 -0.873 . . . . 0.29999999999999999 112.656 174.204 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 9.2 m95 -74.62 -60.65 2.18 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 112.303 0.483 . . . . 0.39000000000000001 112.303 -179.189 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 346' ' ' ASP . . . . . 0.622 ' OD1' ' HA ' ' A' ' 343' ' ' LYS . 8.1 p-10 -64.55 -24.73 67.7 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.634 0.254 . . . . 1.75 111.468 -173.63 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 48.7 mt -84.44 -51.31 14.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 116.318 -0.401 . . . . 0.39000000000000001 111.126 177.347 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -64.28 -36.46 93.25 Favored Glycine 0 CA--C 1.524 0.624 0 C-N-CA 121.032 -0.604 . . . . 0.34000000000000002 113.355 179.599 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 349' ' ' VAL . . . . . 0.511 ' O ' ' HB2' ' A' ' 352' ' ' MET . 77.1 t -80.55 -14.4 12.88 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.88 0.371 . . . . 0.32000000000000001 111.349 -179.218 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -63.2 113.25 3.06 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.957 0.408 . . . . 0.46999999999999997 110.682 177.86 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 96.32 19.57 27.66 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.969 -0.634 . . . . 0.39000000000000001 111.924 -177.048 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 352' ' ' MET . . . . . 0.52 ' O ' ' HA ' ' A' ' 302' ' ' HIS . 0.0 OUTLIER -76.66 155.87 33.06 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.722 -0.473 . . . . 1.28 109.722 174.907 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 353' ' ' ALA . . . . . . . . . . . . . . . -131.04 133.79 46.06 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.671 0.272 . . . . 0.55000000000000004 110.921 -179.435 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 354' ' ' VAL . . . . . 0.435 ' HB ' ' HD2' ' A' ' 301' ' ' PRO . 95.1 t -55.39 114.79 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.976 -0.556 . . . . 0.35999999999999999 110.909 175.733 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 113.83 -8.06 23.72 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.975 -0.631 . . . . 0.44 112.097 -179.019 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -109.79 162.42 12.69 Favored Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.73 -0.747 . . . . 0.29999999999999999 112.785 -179.713 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 357' ' ' GLU . . . . . 0.785 ' HB3' ' HB3' ' A' ' 387' ' ' LYS . 9.6 pt-20 -140.64 145.54 36.74 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 110.172 -0.307 . . . . 1.4099999999999999 110.172 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 358' ' ' ARG . . . . . 0.503 ' HA ' ' HG2' ' A' ' 295' ' ' ARG . 2.8 ptp180 -154.44 145.53 22.75 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.378 0.608 . . . . 1.3700000000000001 111.67 178.393 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 359' ' ' ARG . . . . . 0.746 ' HB3' ' HB3' ' A' ' 293' ' ' GLU . 34.5 ttt180 -86.82 114.46 23.5 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 114.948 -1.024 . . . . 2.79 109.938 -179.707 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 56.1 mt -101.6 117.52 47.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 120.896 0.379 . . . . 0.38 110.46 -178.196 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 361' ' ' VAL . . . . . . . . . . . . . 46.5 t -104.01 112.2 36.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 109.346 -0.612 . . . . 0.39000000000000001 109.346 178.078 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 362' ' ' ILE . . . . . 0.446 HD13 ' HA3' ' A' ' 344' ' ' GLY . 54.5 mt -109.23 106.51 58.78 Favored Pre-proline 0 C--N 1.32 -0.694 0 CA-C-N 116.259 -0.428 . . . . 0.28999999999999998 110.784 -174.181 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 363' ' ' PRO . . . . . 0.515 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 18.4 Cg_endo -58.35 159.53 19.14 Favored 'Trans proline' 0 C--O 1.235 0.372 0 C-N-CA 122.487 2.125 . . . . 0.66000000000000003 111.848 173.327 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 364' ' ' ALA . . . . . 0.405 ' HB3' ' HD3' ' A' ' 365' ' ' PRO . . . -49.37 -50.16 66.69 Favored Pre-proline 0 CA--C 1.538 0.504 0 N-CA-C 114.002 1.112 . . . . 0.41999999999999998 114.002 -174.448 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 365' ' ' PRO . . . . . 0.515 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 77.5 Cg_exo -51.38 -30.9 36.04 Favored 'Trans proline' 0 C--N 1.364 1.368 0 C-N-CA 122.294 1.996 . . . . 0.69999999999999996 114.047 -174.935 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 366' ' ' TYR . . . . . 0.476 ' OH ' ' HG3' ' A' ' 287' ' ' GLU . 3.7 m-85 -102.26 14.13 32.79 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 112.158 0.429 . . . . 0.68999999999999995 112.158 -177.503 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -129.23 -107.57 0.29 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.147 -0.479 . . . . 0.85999999999999999 110.386 173.249 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 32.8 m-85 -87.96 -14.2 39.8 Favored 'General case' 0 N--CA 1.466 0.34 0 N-CA-C 112.09 0.404 . . . . 1.0 112.09 -179.113 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 70.01 -122.96 12.07 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.918 -0.658 . . . . 0.56000000000000005 112.773 178.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 4.7 ptpp? -97.2 4.07 51.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.685 0.279 . . . . 2.7599999999999998 111.12 -178.247 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 88.4 mm-40 -75.36 98.92 3.97 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.085 0.469 . . . . 2.6499999999999999 110.787 -179.261 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 372' ' ' ALA . . . . . . . . . . . . . . . -72.21 90.98 1.26 Allowed 'General case' 0 N--CA 1.447 -0.586 0 CA-C-N 115.695 -0.684 . . . . 1.01 110.454 175.593 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 36.7 mt -74.51 159.24 83.92 Favored Pre-proline 0 C--N 1.323 -0.568 0 CA-C-N 115.516 -0.765 . . . . 0.93000000000000005 109.144 178.844 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -58.63 113.97 1.79 Allowed 'Trans proline' 0 N--CA 1.459 -0.529 0 C-N-CA 121.749 1.633 . . . . 1.3100000000000001 110.721 173.73 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 93.84 -27.76 11.97 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.767 -0.73 . . . . 0.90000000000000002 112.796 -177.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 56.6 mt -125.18 89.41 52.65 Favored Pre-proline 0 C--N 1.327 -0.37 0 CA-C-O 120.71 0.29 . . . . 0.73999999999999999 110.84 -177.962 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 377' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -72.52 168.09 25.31 Favored 'Trans proline' 0 C--O 1.234 0.276 0 C-N-CA 123.143 2.562 . . . . 0.70999999999999996 113.009 -178.112 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 378' ' ' ALA . . . . . 0.477 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -53.2 155.09 2.81 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.512 -0.767 . . . . 0.73999999999999999 111.212 178.148 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 379' ' ' ASN . . . . . 0.477 ' HB2' ' O ' ' A' ' 378' ' ' ALA . 33.1 m-80 71.97 32.16 1.89 Allowed 'General case' 0 N--CA 1.467 0.419 0 O-C-N 123.805 0.69 . . . . 1.49 109.43 -172.228 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 1.8 p -70.7 87.88 0.7 Allowed 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 114.896 -1.047 . . . . 1.8400000000000001 111.283 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 381' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -80.27 98.91 7.6 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 108.68 -0.859 . . . . 1.03 108.68 174.565 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 67.8 mt -85.96 146.98 26.44 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.0 -0.545 . . . . 0.37 110.292 -176.561 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 28.9 m -124.08 122.68 38.51 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 109.566 -0.531 . . . . 0.27000000000000002 109.566 175.81 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -117.83 110.62 18.0 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.424 -0.353 . . . . 0.32000000000000001 110.429 -178.575 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -84.0 103.81 13.55 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 107.813 -1.18 . . . . 1.8 107.813 172.478 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 386' ' ' VAL . . . . . 0.593 HG12 ' CB ' ' A' ' 313' ' ' TYR . 18.5 m -122.02 149.93 25.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 121.235 0.54 . . . . 0.31 112.185 -170.983 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 387' ' ' LYS . . . . . 0.785 ' HB3' ' HB3' ' A' ' 357' ' ' GLU . 11.1 ptpt -141.6 139.58 33.13 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.686 -0.688 . . . . 2.5299999999999998 110.313 172.35 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 388' ' ' LEU . . . . . 0.901 HD11 ' HB ' ' A' ' 309' ' ' VAL . 31.0 tp -91.53 127.18 36.88 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.766 -0.827 . . . . 0.28000000000000003 108.766 179.566 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 33.3 m -124.77 -10.84 6.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 C-N-CA 120.585 -0.446 . . . . 0.45000000000000001 111.872 -172.676 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 50.0 m -157.96 159.83 36.9 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.844 0.354 . . . . 1.3200000000000001 111.268 -179.33 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 391' ' ' MET . . . . . . . . . . . . . 38.7 ttm -160.32 150.82 18.47 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.339 -0.615 . . . . 0.56000000000000005 109.339 175.354 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 18.5 ptpt . . . . . 0 C--O 1.249 1.067 0 C-N-CA 124.251 1.02 . . . . 4.9100000000000001 112.805 176.866 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 2.9 p . . . . . 0 N--CA 1.444 -0.768 0 CA-C-O 121.351 0.596 . . . . 0.76000000000000001 110.232 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 284' ' ' LYS . . . . . 0.406 ' HB2' HG13 ' A' ' 292' ' ' ILE . 32.2 mmtp -108.16 130.54 55.12 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 115.652 -0.704 . . . . 2.0600000000000001 110.041 -178.222 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 32.3 tp -95.47 125.44 40.08 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.949 -0.569 . . . . 0.97999999999999998 109.959 179.836 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.759 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 90.4 mt -102.75 -178.12 3.58 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.688 -0.687 . . . . 0.80000000000000004 109.433 179.302 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 14.3 tt0 -66.37 152.04 45.87 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.704 -0.48 . . . . 2.6400000000000001 109.704 179.791 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 72.71 -4.41 21.83 Favored Glycine 0 C--O 1.229 -0.177 0 C-N-CA 120.823 -0.703 . . . . 1.8400000000000001 113.08 -174.265 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 90.33 21.34 38.37 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.504 -0.855 . . . . 0.64000000000000001 113.53 179.547 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 290' ' ' ILE . . . . . 0.759 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 61.9 mt -69.81 133.43 31.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 117.39 0.595 . . . . 0.41999999999999998 110.344 177.828 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.528 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 17.8 mt -113.08 139.49 37.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 C-N-CA 121.106 -0.237 . . . . 0.93000000000000005 110.836 -178.576 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 292' ' ' ILE . . . . . 0.511 ' HB ' ' HD3' ' A' ' 358' ' ' ARG . 17.7 pt -132.08 129.3 60.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 121.151 0.501 . . . . 0.47999999999999998 110.956 177.185 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 293' ' ' GLU . . . . . 0.446 ' C ' ' HG3' ' A' ' 358' ' ' ARG . 4.5 tp10 -125.15 119.21 27.93 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.516 -0.766 . . . . 2.3100000000000001 109.664 178.699 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 294' ' ' ASP . . . . . 0.688 ' OD2' ' HA ' ' A' ' 297' ' ' THR . 6.2 t70 -80.3 96.18 6.56 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.475 -0.565 . . . . 2.3599999999999999 109.475 -175.727 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 295' ' ' ARG . . . . . . . . . . . . . 66.6 ttt180 -69.37 -45.73 68.65 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.784 -0.644 . . . . 3.5 110.146 -175.89 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.598 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 88.8 t -123.4 123.71 68.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 N-CA-C 108.523 -0.917 . . . . 0.69999999999999996 108.523 172.313 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 297' ' ' THR . . . . . 0.688 ' HA ' ' OD2' ' A' ' 294' ' ' ASP . 5.1 t -60.76 109.75 1.13 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.718 0.771 . . . . 1.9299999999999999 110.994 -174.156 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 298' ' ' GLY . . . . . 0.538 ' HA3' ' HA3' ' A' ' 356' ' ' GLY . . . -99.33 111.22 4.16 Favored Glycine 0 N--CA 1.445 -0.708 0 CA-C-N 115.313 -0.858 . . . . 1.04 112.948 -178.036 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 36.9 mmtm -125.39 110.14 13.6 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 108.982 -0.747 . . . . 4.4900000000000002 108.982 173.829 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -173.3 -152.68 8.97 Favored Glycine 0 N--CA 1.447 -0.573 0 N-CA-C 111.218 -0.753 . . . . 1.04 111.218 -174.404 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 301' ' ' PRO . . . . . 0.607 ' O ' ' HA ' ' A' ' 353' ' ' ALA . 32.8 Cg_exo -58.32 132.92 51.66 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.413 2.075 . . . . 0.88 111.312 174.103 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 26.6 m80 -96.63 127.92 43.08 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.941 0.401 . . . . 1.49 111.132 -173.61 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -73.51 117.62 15.49 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.066 -0.516 . . . . 0.54000000000000004 111.056 179.202 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 63.2 mttm -118.9 -179.4 3.8 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.194 -0.457 . . . . 2.8399999999999999 110.583 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 49.7 mtmt -72.68 127.15 31.69 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 109.9 -0.408 . . . . 2.8399999999999999 109.9 179.223 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 94.8 -0.51 64.89 Favored Glycine 0 CA--C 1.518 0.223 0 C-N-CA 120.747 -0.739 . . . . 0.69999999999999996 112.047 -176.906 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 19.8 m -91.29 145.31 24.75 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 110.239 -0.282 . . . . 0.40000000000000002 110.239 177.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 51.4 mtp180 -108.12 106.47 16.69 Favored 'General case' 0 CA--C 1.519 -0.225 0 N-CA-C 109.648 -0.501 . . . . 3.4500000000000002 109.648 178.693 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.914 ' HB ' HD11 ' A' ' 388' ' ' LEU . 32.7 m -106.25 154.11 7.45 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.959 0 CA-C-O 121.086 0.469 . . . . 0.34000000000000002 111.747 -174.09 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -122.74 127.73 6.82 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 110.823 -0.911 . . . . 0.27000000000000002 110.823 177.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 11.9 ptp -135.22 177.01 8.15 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.754 0.788 . . . . 0.76000000000000001 112.789 -173.82 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 44.3 mtm180 -135.96 146.21 47.01 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 107.068 -1.456 . . . . 2.5099999999999998 107.068 173.005 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 313' ' ' TYR . . . . . 0.601 ' HB3' HG12 ' A' ' 386' ' ' VAL . 41.9 p90 -159.13 155.52 27.39 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 113.214 0.82 . . . . 0.68000000000000005 113.214 -168.118 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 58.1 t -122.56 113.24 37.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 114.94 -1.027 . . . . 0.34999999999999998 109.361 170.185 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -97.56 115.64 5.31 Favored Glycine 0 C--O 1.238 0.374 0 C-N-CA 120.85 -0.69 . . . . 0.28000000000000003 112.556 -176.331 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 316' ' ' LYS . . . . . 0.637 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 91.9 mttt -117.86 162.45 18.09 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-O 121.275 0.559 . . . . 1.9399999999999999 110.758 -179.066 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 93.6 mt -90.01 165.89 13.77 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.423 -0.808 . . . . 0.65000000000000002 109.558 173.841 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 318' ' ' LYS . . . . . 0.566 ' HB2' ' HB3' ' A' ' 381' ' ' GLU . 56.9 tttp -59.88 -23.09 63.16 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.22 0.533 . . . . 2.4199999999999999 110.306 176.448 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -70.14 -15.63 62.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.38 -0.827 . . . . 2.2000000000000002 110.894 -179.559 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 98.84 -5.43 59.79 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.51 -0.852 . . . . 0.68999999999999995 112.195 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -91.48 133.28 35.64 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 120.682 0.277 . . . . 2.4199999999999999 110.3 179.004 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.637 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 8.0 p -77.3 140.21 17.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.467 -0.333 . . . . 1.26 110.322 178.575 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 34.9 p90 -103.62 -33.43 8.99 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.54 -0.464 . . . . 0.55000000000000004 110.994 177.636 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -162.7 162.99 27.1 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 121.063 -0.255 . . . . 1.6799999999999999 110.343 175.132 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -159.61 129.63 5.55 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.891 0.377 . . . . 1.99 110.623 -178.33 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 35.1 m-80 -120.56 116.62 25.74 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.606 -0.887 . . . . 1.9199999999999999 108.606 172.874 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.76 -69.25 0.2 Allowed 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.096 -0.502 . . . . 1.6899999999999999 111.76 -174.324 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 24.7 pttm -68.41 97.28 0.74 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.698 0.761 . . . . 2.5499999999999998 111.836 -174.121 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.501 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 86.71 -16.61 45.01 Favored Glycine 0 N--CA 1.446 -0.638 0 CA-C-N 115.269 -0.878 . . . . 0.96999999999999997 113.591 175.375 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 27.6 mmmt -104.83 100.02 21.73 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 117.228 0.514 . . . . 2.0800000000000001 111.471 -175.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 331' ' ' PRO . . . . . 0.501 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 72.1 Cg_endo -87.56 127.86 2.42 Favored 'Trans proline' 0 N--CA 1.455 -0.744 0 C-N-CA 122.883 2.389 . . . . 0.62 111.854 172.809 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 70.6 t80 -102.56 120.55 40.74 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 110.135 -0.321 . . . . 0.64000000000000001 110.135 179.458 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 60.4 t -112.51 122.42 66.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.915 0.388 . . . . 0.38 110.413 -178.154 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 31.1 p90 -139.8 158.76 43.57 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.089 -0.505 . . . . 0.40999999999999998 109.73 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 335' ' ' LYS . . . . . . . . . . . . . 16.9 ptmt -100.15 141.02 33.55 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.214 0.53 . . . . 2.5800000000000001 111.217 179.128 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 11.2 mp -77.34 123.49 26.58 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.769 -0.651 . . . . 0.57999999999999996 109.695 173.864 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 111.79 12.33 14.73 Favored Glycine 0 N--CA 1.446 -0.68 0 C-N-CA 120.683 -0.77 . . . . 0.93999999999999995 111.931 -177.47 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 338' ' ' GLN . . . . . . . . . . . . . 4.0 pt20 -97.91 151.09 20.62 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.963 -0.384 . . . . 2.6200000000000001 109.963 176.912 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -89.28 15.21 58.92 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 121.029 -0.605 . . . . 0.73999999999999999 111.815 -179.047 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -87.32 -15.15 38.83 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.077 0.465 . . . . 2.0899999999999999 110.261 178.298 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 32.6 m -107.24 164.28 4.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.838 -0.619 . . . . 0.42999999999999999 110.575 -177.644 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 342' ' ' ILE . . . . . 0.491 ' HB ' ' HA ' ' A' ' 367' ' ' ALA . 10.0 pt -88.67 165.36 2.06 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 109.718 -0.475 . . . . 0.32000000000000001 109.718 176.546 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 343' ' ' LYS . . . . . 0.413 ' CE ' ' HA ' ' A' ' 343' ' ' LYS . 0.0 OUTLIER -56.11 -37.3 69.22 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 111.908 0.336 . . . . 2.9300000000000002 111.908 -174.644 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 344' ' ' GLY . . . . . 0.587 ' HA2' HD13 ' A' ' 290' ' ' ILE . . . -55.72 -30.84 57.19 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.938 -0.649 . . . . 0.29999999999999999 113.126 177.506 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 345' ' ' TRP . . . . . 0.42 ' CD1' HG12 ' A' ' 342' ' ' ILE . 18.4 m95 -77.83 -61.23 2.06 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 112.506 0.558 . . . . 0.39000000000000001 112.506 -176.886 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -64.23 -20.55 66.11 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.669 0.271 . . . . 1.75 111.41 -175.69 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 71.5 mt -89.41 -55.73 5.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 116.471 -0.332 . . . . 0.39000000000000001 111.685 174.792 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -65.71 -38.55 94.61 Favored Glycine 0 CA--C 1.523 0.59 0 C-N-CA 121.297 -0.478 . . . . 0.34000000000000002 114.135 -177.372 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 83.9 t -75.22 -21.25 16.4 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 CA-C-O 120.953 0.406 . . . . 0.32000000000000001 110.905 -178.612 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.2 104.53 0.93 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.164 0.506 . . . . 0.46999999999999997 110.953 -179.291 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 113.84 0.58 24.31 Favored Glycine 0 N--CA 1.445 -0.712 0 C-N-CA 120.823 -0.704 . . . . 0.39000000000000001 112.851 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 352' ' ' MET . . . . . . . . . . . . . 60.0 mtp -75.37 157.69 33.85 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 117.313 0.557 . . . . 1.28 110.307 174.69 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 353' ' ' ALA . . . . . 0.607 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -123.09 144.58 49.22 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.221 -0.445 . . . . 0.55000000000000004 111.543 -174.861 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 73.4 t -58.2 123.15 9.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.962 -0.563 . . . . 0.35999999999999999 110.357 175.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 104.23 -16.44 49.43 Favored Glycine 0 N--CA 1.446 -0.663 0 C-N-CA 120.831 -0.7 . . . . 0.44 111.528 -177.109 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 356' ' ' GLY . . . . . 0.538 ' HA3' ' HA3' ' A' ' 298' ' ' GLY . . . -87.35 154.29 26.06 Favored Glycine 0 N--CA 1.443 -0.851 0 C-N-CA 120.875 -0.678 . . . . 0.29999999999999999 112.646 179.484 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 357' ' ' GLU . . . . . 0.642 ' HG3' ' HB3' ' A' ' 387' ' ' LYS . 41.2 tt0 -137.87 121.65 17.56 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.951 -0.759 . . . . 1.4099999999999999 108.951 -177.833 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 358' ' ' ARG . . . . . 0.511 ' HD3' ' HB ' ' A' ' 292' ' ' ILE . 35.0 ttm180 -148.41 133.99 18.75 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.071 0.463 . . . . 1.3700000000000001 110.933 -170.883 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 359' ' ' ARG . . . . . 0.408 HH11 ' HD2' ' A' ' 359' ' ' ARG . 31.8 ttp85 -86.02 122.78 30.54 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.717 -0.674 . . . . 2.79 110.459 -179.186 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 360' ' ' ILE . . . . . 0.493 HG12 HG22 ' A' ' 292' ' ' ILE . 56.8 mt -109.52 121.44 62.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.866 -0.606 . . . . 0.38 110.272 -179.646 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 361' ' ' VAL . . . . . 0.528 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 48.6 t -104.19 119.84 53.57 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 N-CA-C 109.256 -0.646 . . . . 0.39000000000000001 109.256 177.699 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 362' ' ' ILE . . . . . 0.491 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 55.9 mt -118.23 100.95 51.7 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-N 116.322 -0.399 . . . . 0.28999999999999998 111.535 -174.092 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 363' ' ' PRO . . . . . 0.526 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 12.3 Cg_endo -56.9 158.12 18.04 Favored 'Trans proline' 0 C--O 1.238 0.498 0 C-N-CA 122.99 2.46 . . . . 0.66000000000000003 112.547 172.127 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 364' ' ' ALA . . . . . 0.489 ' CB ' ' HA ' ' A' ' 379' ' ' ASN . . . -50.18 -47.41 82.07 Favored Pre-proline 0 CA--C 1.539 0.52 0 N-CA-C 114.516 1.302 . . . . 0.41999999999999998 114.516 -173.723 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 365' ' ' PRO . . . . . 0.526 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 82.6 Cg_exo -49.22 -36.55 37.25 Favored 'Trans proline' 0 C--N 1.361 1.231 0 C-N-CA 122.218 1.945 . . . . 0.69999999999999996 113.632 -176.704 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 366' ' ' TYR . . . . . 0.422 ' CD1' HD11 ' A' ' 290' ' ' ILE . 3.6 m-85 -101.31 12.55 37.25 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.761 0.315 . . . . 0.68999999999999995 111.643 -177.097 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 367' ' ' ALA . . . . . 0.491 ' HA ' ' HB ' ' A' ' 342' ' ' ILE . . . -119.31 -112.52 0.33 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.168 -0.469 . . . . 0.85999999999999999 110.505 175.207 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -91.39 -1.88 57.47 Favored 'General case' 0 N--CA 1.464 0.228 0 N-CA-C 112.194 0.442 . . . . 1.0 112.194 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 66.43 -114.97 6.93 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 121.103 -0.57 . . . . 0.56000000000000005 113.65 175.854 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 370' ' ' LYS . . . . . 0.428 ' HE2' ' HB3' ' A' ' 370' ' ' LYS . 14.8 ptpt -112.81 20.31 16.58 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.856 0.36 . . . . 2.7599999999999998 111.502 -174.497 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 27.9 mm-40 -90.14 113.45 25.21 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.29 -0.414 . . . . 2.6499999999999999 110.088 176.596 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 372' ' ' ALA . . . . . 0.447 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -83.51 96.18 8.52 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.175 0.512 . . . . 1.01 111.17 178.827 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 373' ' ' LEU . . . . . 0.5 ' HB3' ' HD2' ' A' ' 374' ' ' PRO . 59.1 mt -80.37 166.67 38.38 Favored Pre-proline 0 C--N 1.32 -0.698 0 CA-C-N 115.562 -0.744 . . . . 0.93000000000000005 109.487 178.728 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 374' ' ' PRO . . . . . 0.5 ' HD2' ' HB3' ' A' ' 373' ' ' LEU . 22.9 Cg_endo -64.33 113.36 2.22 Favored 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 121.514 1.476 . . . . 1.3100000000000001 110.818 172.438 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 90.65 -24.53 16.96 Favored Glycine 0 CA--C 1.519 0.312 0 C-N-CA 120.739 -0.743 . . . . 0.90000000000000002 112.757 -179.003 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 39.8 mt -125.56 83.04 62.47 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.683 0.278 . . . . 0.73999999999999999 110.304 -178.936 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 377' ' ' PRO . . . . . 0.447 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 9.2 Cg_exo -72.59 166.5 29.7 Favored 'Trans proline' 0 N--CA 1.464 -0.253 0 C-N-CA 123.17 2.58 . . . . 0.70999999999999996 113.247 -178.124 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 378' ' ' ALA . . . . . . . . . . . . . . . -55.02 147.55 15.47 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-N 115.557 -0.747 . . . . 0.73999999999999999 111.43 178.898 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 379' ' ' ASN . . . . . 0.489 ' HA ' ' CB ' ' A' ' 364' ' ' ALA . 44.4 m-80 65.54 30.65 10.54 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 115.676 -0.693 . . . . 1.49 111.3 -179.144 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 380' ' ' SER . . . . . 0.424 ' HB2' ' O ' ' A' ' 377' ' ' PRO . 22.2 t -85.41 134.54 34.07 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 116.08 -0.509 . . . . 1.8400000000000001 109.78 175.769 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 381' ' ' GLU . . . . . 0.566 ' HB3' ' HB2' ' A' ' 318' ' ' LYS . 30.7 tt0 -99.43 105.16 17.07 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.305 -0.628 . . . . 1.03 109.305 179.066 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 74.2 mt -84.72 142.09 30.1 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.397 -0.365 . . . . 0.37 110.796 -177.65 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 383' ' ' THR . . . . . 0.471 HG23 HG22 ' A' ' 361' ' ' VAL . 25.7 m -122.39 122.77 39.79 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 109.726 -0.472 . . . . 0.27000000000000002 109.726 177.794 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -117.44 109.59 16.96 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.928 0.394 . . . . 0.32000000000000001 110.32 -178.181 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -88.81 104.4 16.88 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.154 -1.054 . . . . 1.8 108.154 174.254 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 386' ' ' VAL . . . . . 0.601 HG12 ' HB3' ' A' ' 313' ' ' TYR . 20.0 m -125.25 151.37 30.99 Favored 'Isoleucine or valine' 0 C--O 1.232 0.141 0 CA-C-O 121.358 0.599 . . . . 0.31 112.287 -169.131 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 387' ' ' LYS . . . . . 0.642 ' HB3' ' HG3' ' A' ' 357' ' ' GLU . 14.6 ptmm? -139.54 142.21 37.21 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.774 -0.648 . . . . 2.5299999999999998 109.814 172.534 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 388' ' ' LEU . . . . . 0.914 HD11 ' HB ' ' A' ' 309' ' ' VAL . 19.3 tp -93.14 135.43 34.33 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.691 -0.485 . . . . 0.28000000000000003 109.691 -176.471 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 34.7 m -127.53 -6.51 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 N-CA-C 112.268 0.47 . . . . 0.45000000000000001 112.268 -176.442 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 44.1 t -160.57 160.35 31.71 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.528 0.204 . . . . 1.3200000000000001 110.942 -177.784 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 391' ' ' MET . . . . . 0.427 ' HA ' ' HA ' ' A' ' 309' ' ' VAL . 30.9 ttm -165.61 134.1 3.16 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.998 -0.546 . . . . 0.56000000000000005 110.18 179.684 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 63.7 mttp . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.513 -0.756 . . . . 4.9100000000000001 109.716 175.758 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 1.45 0 N-CA-C 111.946 -0.462 . . . . 11.17 111.946 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -135.91 129.22 31.91 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 110.026 -0.361 . . . . 9.3699999999999992 110.026 179.391 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 278' ' ' MET . . . . . . . . . . . . . 23.1 ttt -90.1 96.06 10.49 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.109 0.481 . . . . 7.6699999999999999 110.818 -177.91 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -99.67 4.41 45.59 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.743 -0.662 . . . . 6.3700000000000001 110.301 174.567 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 35.4 ttmt 56.51 84.14 0.21 Allowed Pre-proline 0 C--O 1.236 0.366 0 CA-C-N 114.898 -1.046 . . . . 6.7599999999999998 110.999 -179.429 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -74.94 62.41 5.8 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 123.34 2.693 . . . . 4.7999999999999998 112.148 -179.013 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 282' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -139.55 -165.27 1.84 Allowed 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.501 -0.772 . . . . 3.46 109.619 178.934 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 18.2 p -91.04 131.5 36.59 Favored 'General case' 0 C--N 1.31 -1.123 0 CA-C-N 115.437 -0.801 . . . . 0.76000000000000001 110.896 178.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 284' ' ' LYS . . . . . 0.408 ' O ' ' HA ' ' A' ' 291' ' ' ILE . 41.8 mtmt -131.55 159.21 38.85 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.519 -0.764 . . . . 2.0600000000000001 110.414 -174.407 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 285' ' ' LEU . . . . . 0.513 HD11 ' HA2' ' A' ' 289' ' ' GLY . 42.3 tp -111.93 127.07 55.75 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.217 -0.447 . . . . 0.97999999999999998 111.987 -170.888 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.44 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 99.2 mt -108.32 -161.83 0.79 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.839 -0.618 . . . . 0.80000000000000004 110.309 173.653 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -51.99 140.48 20.15 Favored 'General case' 0 N--CA 1.447 -0.591 0 C-N-CA 123.263 0.625 . . . . 2.6400000000000001 112.301 179.293 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.487 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 70.4 -102.94 1.08 Allowed Glycine 0 N--CA 1.446 -0.69 0 CA-C-N 115.482 -0.781 . . . . 1.8400000000000001 111.595 -177.63 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 289' ' ' GLY . . . . . 0.513 ' HA2' HD11 ' A' ' 285' ' ' LEU . . . -145.92 28.2 1.73 Allowed Glycine 0 N--CA 1.442 -0.948 0 N-CA-C 110.603 -0.999 . . . . 0.64000000000000001 110.603 176.08 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 290' ' ' ILE . . . . . 0.44 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 75.4 mt -71.14 120.9 19.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.803 0.335 . . . . 0.41999999999999998 110.733 -177.73 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.408 ' HA ' ' O ' ' A' ' 284' ' ' LYS . 92.1 mt -103.72 138.53 27.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.274 -0.421 . . . . 0.93000000000000005 110.171 178.839 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 292' ' ' ILE . . . . . 0.43 HG22 HG12 ' A' ' 360' ' ' ILE . 24.9 pt -124.46 128.21 73.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-O 121.3 0.571 . . . . 0.47999999999999998 109.864 178.038 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 293' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -114.59 110.78 20.31 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.282 -0.872 . . . . 2.3100000000000001 109.117 179.538 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 20.7 m-20 -83.83 103.75 13.37 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.386 0.612 . . . . 2.3599999999999999 109.851 -173.853 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 295' ' ' ARG . . . . . . . . . . . . . 10.5 mmm180 -76.8 -49.4 15.95 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 114.809 -1.087 . . . . 3.5 110.663 -173.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 296' ' ' VAL . . . . . . . . . . . . . 97.9 t -118.66 130.09 73.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 115.662 -0.699 . . . . 0.69999999999999996 110.358 -176.025 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 1.6 m -63.03 107.25 0.97 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.156 -0.475 . . . . 1.9299999999999999 110.554 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -118.01 116.25 3.39 Favored Glycine 0 N--CA 1.445 -0.759 0 C-N-CA 120.802 -0.713 . . . . 1.04 112.402 -177.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 13.1 tptm -121.9 113.13 19.19 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.575 -0.528 . . . . 4.4900000000000002 109.575 175.296 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -170.79 -153.71 9.04 Favored Glycine 0 N--CA 1.436 -1.304 0 N-CA-C 111.042 -0.823 . . . . 1.04 111.042 -178.856 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 301' ' ' PRO . . . . . 0.428 ' HB2' ' SD ' ' A' ' 391' ' ' MET . 36.8 Cg_exo -60.75 132.7 44.0 Favored 'Trans proline' 0 N--CA 1.461 -0.397 0 C-N-CA 122.6 2.2 . . . . 0.88 111.756 177.79 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 302' ' ' HIS . . . . . 0.417 ' HA ' ' O ' ' A' ' 352' ' ' MET . 37.3 m80 -88.82 138.44 31.41 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.207 -0.451 . . . . 1.49 110.786 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -85.68 117.37 24.53 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.897 -0.592 . . . . 0.54000000000000004 111.25 -179.579 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 21.9 pttp -116.87 -178.54 3.46 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.045 -0.724 . . . . 2.8399999999999999 109.045 173.15 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 51.4 mttm -68.13 142.4 55.77 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 110.119 -0.326 . . . . 2.8399999999999999 110.119 176.754 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 85.29 -7.86 73.79 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 121.085 -0.578 . . . . 0.69999999999999996 112.225 -175.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 307' ' ' THR . . . . . 0.472 ' O ' ' HA ' ' A' ' 335' ' ' LYS . 87.0 m -89.25 135.47 33.56 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.758 0.314 . . . . 0.40000000000000002 111.119 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 308' ' ' ARG . . . . . 0.424 HH21 ' C ' ' A' ' 392' ' ' LYS . 73.1 mtm180 -94.24 102.34 14.35 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.687 -0.688 . . . . 3.4500000000000002 109.903 -177.643 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.869 ' HB ' HD11 ' A' ' 388' ' ' LEU . 34.1 m -103.43 141.54 19.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 CA-C-O 121.426 0.631 . . . . 0.34000000000000002 111.75 -177.679 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -115.51 121.66 5.34 Favored Glycine 0 N--CA 1.445 -0.759 0 N-CA-C 110.325 -1.11 . . . . 0.27000000000000002 110.325 177.462 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 13.9 ptp -135.77 177.67 7.65 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.513 0.673 . . . . 0.76000000000000001 112.304 -173.798 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -136.65 143.47 43.49 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 106.938 -1.504 . . . . 2.5099999999999998 106.938 174.157 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 313' ' ' TYR . . . . . 0.509 ' CB ' HG12 ' A' ' 386' ' ' VAL . 18.2 p90 -157.52 157.49 33.92 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 113.39 0.885 . . . . 0.68000000000000005 113.39 -170.245 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 58.0 t -124.34 120.94 60.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 114.795 -1.093 . . . . 0.34999999999999998 109.219 173.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -97.86 110.29 3.99 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 120.959 -0.639 . . . . 0.28000000000000003 112.573 -176.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 316' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -116.15 154.63 29.67 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.177 0.513 . . . . 1.9399999999999999 110.929 -178.49 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 317' ' ' LEU . . . . . 0.542 HD12 ' HD3' ' A' ' 321' ' ' LYS . 80.1 mt -86.92 170.39 11.66 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.795 -0.639 . . . . 0.65000000000000002 110.134 171.13 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 318' ' ' LYS . . . . . 0.441 ' HB2' ' HB3' ' A' ' 381' ' ' GLU . 57.7 tttp -59.07 -25.44 63.77 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.14 -0.482 . . . . 2.4199999999999999 111.298 179.493 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 28.1 p-10 -87.7 -3.04 58.98 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 120.555 0.216 . . . . 2.2000000000000002 111.267 -178.802 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 95.52 3.75 61.07 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.775 -0.726 . . . . 0.68999999999999995 112.7 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 321' ' ' LYS . . . . . 0.542 ' HD3' HD12 ' A' ' 317' ' ' LEU . 53.4 tttp -75.18 113.55 12.65 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.751 0.31 . . . . 2.4199999999999999 110.259 179.431 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 322' ' ' VAL . . . . . . . . . . . . . 4.7 p -85.52 119.52 34.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-O 121.287 0.565 . . . . 1.26 110.431 179.222 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 52.2 p90 -110.14 -27.13 9.3 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.072 -0.513 . . . . 0.55000000000000004 111.284 -177.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -130.88 156.61 44.76 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 108.952 -0.758 . . . . 1.6799999999999999 108.952 178.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 59.6 pttt -174.44 135.81 0.44 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.099 0.476 . . . . 1.99 111.525 -176.012 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 6.0 p30 -150.35 118.56 6.36 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.68 -0.691 . . . . 1.9199999999999999 109.316 166.843 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 29.7 m -140.63 -46.8 0.41 Allowed 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.642 -0.708 . . . . 1.6899999999999999 110.94 -175.451 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 83.9 mttt -79.66 92.55 5.38 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.79 -0.641 . . . . 2.5499999999999998 111.259 -173.372 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.48 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 65.78 7.92 38.05 Favored Glycine 0 CA--C 1.52 0.391 0 CA-C-N 115.853 -0.612 . . . . 0.96999999999999997 113.742 174.418 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 68.9 mmtt -103.93 100.4 20.26 Favored Pre-proline 0 C--N 1.324 -0.52 0 CA-C-N 116.688 0.244 . . . . 2.0800000000000001 111.39 -177.29 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 331' ' ' PRO . . . . . 0.48 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 94.1 Cg_endo -88.38 129.54 2.3 Favored 'Trans proline' 0 N--CA 1.453 -0.895 0 C-N-CA 122.839 2.359 . . . . 0.62 112.298 173.199 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -103.74 118.89 37.77 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.956 -0.757 . . . . 0.64000000000000001 108.956 174.208 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 56.7 t -112.15 125.87 69.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.904 0.383 . . . . 0.38 110.172 -177.606 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.459 ' HB2' ' OE1' ' A' ' 338' ' ' GLN . 29.8 p90 -147.31 156.38 42.86 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.835 -0.62 . . . . 0.40999999999999998 109.511 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 335' ' ' LYS . . . . . 0.472 ' HA ' ' O ' ' A' ' 307' ' ' THR . 0.2 OUTLIER -111.08 142.12 43.65 Favored 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 120.034 -0.667 . . . . 2.5800000000000001 110.508 177.709 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 9.3 mp -69.84 148.17 49.41 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.851 -0.613 . . . . 0.57999999999999996 109.91 178.906 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 103.38 -8.3 52.24 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.7 -0.762 . . . . 0.93999999999999995 112.942 -178.162 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 338' ' ' GLN . . . . . 0.459 ' OE1' ' HB2' ' A' ' 334' ' ' PHE . 4.1 pt20 -83.91 160.82 21.02 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.832 0.316 . . . . 2.6200000000000001 110.215 179.367 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -107.32 21.63 30.59 Favored Glycine 0 CA--C 1.52 0.354 0 C-N-CA 120.485 -0.864 . . . . 0.73999999999999999 114.307 -172.481 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -114.93 9.56 16.16 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 117.574 0.687 . . . . 2.0899999999999999 111.093 178.47 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 27.3 m -116.11 146.55 20.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 108.341 -0.985 . . . . 0.42999999999999999 108.341 172.852 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 11.4 pt -68.88 151.98 9.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 N-CA-C 109.743 -0.466 . . . . 0.32000000000000001 109.743 -178.875 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 343' ' ' LYS . . . . . 0.524 ' HE2' ' HA ' ' A' ' 343' ' ' LYS . 6.2 mmpt? -61.85 -30.38 70.81 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 111.894 0.331 . . . . 2.9300000000000002 111.894 -172.778 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -54.86 -31.4 54.68 Favored Glycine 0 CA--C 1.521 0.457 0 C-N-CA 120.878 -0.677 . . . . 0.29999999999999999 112.343 173.647 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 9.3 m95 -77.48 -60.8 2.22 Favored 'General case' 0 C--O 1.22 -0.452 0 CA-C-O 120.531 0.205 . . . . 0.39000000000000001 111.055 176.778 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -51.14 -28.87 11.93 Favored 'General case' 0 N--CA 1.47 0.544 0 N-CA-C 112.327 0.491 . . . . 1.75 112.327 -179.336 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 63.6 mt -91.19 -51.17 12.08 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.533 0 N-CA-C 111.946 0.35 . . . . 0.39000000000000001 111.946 177.523 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -63.95 -31.1 79.68 Favored Glycine 0 CA--C 1.524 0.606 0 C-N-CA 121.282 -0.485 . . . . 0.34000000000000002 113.758 -178.709 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 349' ' ' VAL . . . . . 0.546 ' O ' ' HB2' ' A' ' 352' ' ' MET . 90.8 t -79.7 -19.87 12.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 121.024 0.44 . . . . 0.32000000000000001 110.645 179.704 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -64.6 113.64 3.86 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.373 -0.376 . . . . 0.46999999999999997 110.132 178.316 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 97.07 15.17 39.79 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 121.035 -0.603 . . . . 0.39000000000000001 112.11 -176.634 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 352' ' ' MET . . . . . 0.546 ' HB2' ' O ' ' A' ' 349' ' ' VAL . 0.0 OUTLIER -77.12 154.9 32.78 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 109.296 -0.631 . . . . 1.28 109.296 175.264 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 353' ' ' ALA . . . . . 0.405 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -129.95 134.92 47.77 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.729 0.299 . . . . 0.55000000000000004 111.166 -177.393 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 61.4 t -59.85 123.39 12.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.017 -0.538 . . . . 0.35999999999999999 110.681 177.302 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 109.47 -12.36 33.2 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 121.136 -0.554 . . . . 0.44 112.022 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -104.89 150.9 17.2 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.761 -0.733 . . . . 0.29999999999999999 112.737 -179.538 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 357' ' ' GLU . . . . . 0.442 ' CB ' ' HB3' ' A' ' 387' ' ' LYS . 40.0 tt0 -122.44 140.37 52.8 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.247 -0.649 . . . . 1.4099999999999999 109.247 176.461 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 358' ' ' ARG . . . . . . . . . . . . . 3.1 ptp180 -146.15 137.55 24.71 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.157 0.503 . . . . 1.3700000000000001 111.178 175.425 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 359' ' ' ARG . . . . . . . . . . . . . 11.9 ttp180 -87.27 117.63 26.16 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.047 -0.723 . . . . 2.79 109.047 174.734 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 360' ' ' ILE . . . . . 0.43 HG12 HG22 ' A' ' 292' ' ' ILE . 65.1 mt -103.17 126.26 57.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-N 115.979 -0.555 . . . . 0.38 110.535 -175.125 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 361' ' ' VAL . . . . . . . . . . . . . 47.7 t -100.73 115.12 41.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 109.175 -0.676 . . . . 0.39000000000000001 109.175 175.427 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 362' ' ' ILE . . . . . 0.411 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 60.5 mt -110.21 108.97 58.86 Favored Pre-proline 0 C--N 1.322 -0.603 0 CA-C-N 116.447 -0.342 . . . . 0.28999999999999998 110.689 -175.456 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 363' ' ' PRO . . . . . 0.485 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 35.6 Cg_endo -65.51 162.03 35.75 Favored 'Trans proline' 0 C--O 1.239 0.541 0 C-N-CA 122.42 2.08 . . . . 0.66000000000000003 111.613 175.432 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 364' ' ' ALA . . . . . . . . . . . . . . . -52.61 -48.89 88.87 Favored Pre-proline 0 CA--C 1.537 0.47 0 N-CA-C 113.85 1.055 . . . . 0.41999999999999998 113.85 -173.69 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 365' ' ' PRO . . . . . 0.485 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 74.1 Cg_exo -52.14 -29.74 38.35 Favored 'Trans proline' 0 C--N 1.359 1.09 0 C-N-CA 122.501 2.134 . . . . 0.69999999999999996 114.212 -175.505 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 366' ' ' TYR . . . . . 0.487 ' CE2' ' HA3' ' A' ' 288' ' ' GLY . 43.1 m-85 -101.05 10.16 41.35 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 112.196 0.443 . . . . 0.68999999999999995 112.196 -175.75 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -125.39 -110.81 0.3 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.806 -0.179 . . . . 0.85999999999999999 110.572 175.484 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -90.02 -22.17 22.01 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.991 0.424 . . . . 1.0 111.317 178.849 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 70.7 -95.87 0.56 Allowed Glycine 0 N--CA 1.448 -0.51 0 CA-C-N 115.996 -0.547 . . . . 0.56000000000000005 113.761 175.584 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 23.4 pttm -109.17 8.12 25.76 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.622 0.248 . . . . 2.7599999999999998 111.645 -171.625 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 6.3 tp-100 -89.48 120.25 30.63 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.864 0.364 . . . . 2.6499999999999999 110.56 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 372' ' ' ALA . . . . . 0.794 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -92.47 93.71 8.71 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-O 121.436 0.636 . . . . 1.01 110.592 178.025 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 43.3 mt -81.97 162.99 55.4 Favored Pre-proline 0 C--N 1.318 -0.784 0 CA-C-N 115.373 -0.83 . . . . 0.93000000000000005 109.079 176.849 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_exo -61.14 114.97 2.42 Favored 'Trans proline' 0 N--CA 1.462 -0.378 0 C-N-CA 121.478 1.452 . . . . 1.3100000000000001 110.645 172.814 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 91.23 -26.63 11.01 Favored Glycine 0 CA--C 1.521 0.413 0 C-N-CA 121.086 -0.578 . . . . 0.90000000000000002 112.525 -178.457 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 23.5 mt -126.62 81.94 67.66 Favored Pre-proline 0 CA--C 1.533 0.32 0 CA-C-O 120.638 0.256 . . . . 0.73999999999999999 110.518 -177.118 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 377' ' ' PRO . . . . . 0.794 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 73.5 Cg_endo -80.17 167.85 19.28 Favored 'Trans proline' 0 N--CA 1.463 -0.322 0 C-N-CA 122.693 2.262 . . . . 0.70999999999999996 113.156 -177.79 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 378' ' ' ALA . . . . . 0.408 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -49.12 147.25 3.04 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 115.572 -0.74 . . . . 0.73999999999999999 111.862 178.834 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 379' ' ' ASN . . . . . 0.408 ' HB2' ' O ' ' A' ' 378' ' ' ALA . 42.2 m-80 67.75 33.31 4.94 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 115.712 -0.676 . . . . 1.49 110.688 -175.752 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 2.4 p -82.29 133.16 35.23 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.922 -0.581 . . . . 1.8400000000000001 111.42 179.506 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 381' ' ' GLU . . . . . 0.441 ' HB3' ' HB2' ' A' ' 318' ' ' LYS . 32.1 tt0 -104.03 106.64 17.21 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.73 -0.668 . . . . 1.03 109.398 177.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 382' ' ' LEU . . . . . 0.4 HD23 HD23 ' A' ' 317' ' ' LEU . 89.9 mt -86.83 139.97 30.15 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.832 0.349 . . . . 0.37 111.093 -177.916 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 33.4 m -117.89 117.51 29.49 Favored 'General case' 0 N--CA 1.446 -0.629 0 N-CA-C 109.153 -0.684 . . . . 0.27000000000000002 109.153 175.645 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 33.9 m-85 -113.69 117.29 31.14 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.214 0.53 . . . . 0.32000000000000001 111.784 -175.712 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -85.49 103.82 14.71 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 107.946 -1.131 . . . . 1.8 107.946 172.311 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 386' ' ' VAL . . . . . 0.509 HG12 ' CB ' ' A' ' 313' ' ' TYR . 35.3 m -130.29 141.17 47.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.65 0.738 . . . . 0.31 111.89 -173.159 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 387' ' ' LYS . . . . . 0.442 ' HB3' ' CB ' ' A' ' 357' ' ' GLU . 10.7 pttm -141.07 141.54 34.25 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.148 -0.933 . . . . 2.5299999999999998 109.747 174.851 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 388' ' ' LEU . . . . . 0.869 HD11 ' HB ' ' A' ' 309' ' ' VAL . 16.9 tp -94.24 127.35 40.04 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.962 -0.755 . . . . 0.28000000000000003 108.962 -176.656 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 34.2 m -125.92 -0.6 4.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 C-N-CA 120.897 -0.321 . . . . 0.45000000000000001 111.056 -172.094 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 22.9 t -165.15 157.52 15.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.254 -0.43 . . . . 1.3200000000000001 111.164 179.65 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 391' ' ' MET . . . . . 0.428 ' SD ' ' HB2' ' A' ' 301' ' ' PRO . 39.1 ttm -162.29 132.86 4.85 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.412 -0.813 . . . . 0.56000000000000005 109.407 175.902 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 392' ' ' LYS . . . . . 0.424 ' C ' HH21 ' A' ' 308' ' ' ARG . 31.9 mmtp . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.496 -0.764 . . . . 4.9100000000000001 110.408 -177.64 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.581 0 N-CA-C 111.992 -0.443 . . . . 11.17 111.992 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -129.56 166.75 19.08 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.788 0.328 . . . . 9.3699999999999992 110.626 -178.888 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 278' ' ' MET . . . . . . . . . . . . . 28.2 ttt -78.36 92.31 4.55 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.15 -0.477 . . . . 7.6699999999999999 110.268 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -126.41 83.74 2.2 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.045 -0.525 . . . . 6.3700000000000001 110.612 178.645 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 45.6 mttp -142.78 151.39 56.6 Favored Pre-proline 0 C--N 1.322 -0.63 0 CA-C-N 115.567 -0.742 . . . . 6.7599999999999998 110.156 -178.691 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_exo -57.29 136.3 75.44 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 122.792 2.328 . . . . 4.7999999999999998 112.309 179.597 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 282' ' ' LYS . . . . . . . . . . . . . 30.1 mtmm -79.19 98.11 6.47 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.005 -0.543 . . . . 3.46 110.639 -177.277 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.543 HG22 ' HG2' ' A' ' 293' ' ' GLU . 28.3 p -101.4 153.9 19.28 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.682 -0.69 . . . . 0.76000000000000001 111.377 -178.745 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 43.4 mtpt -127.58 156.98 41.39 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.528 -0.545 . . . . 2.0600000000000001 109.528 175.037 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 37.7 tp -112.47 119.24 37.53 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.373 -0.376 . . . . 0.97999999999999998 110.087 -178.872 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.638 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 92.3 mt -99.37 -170.16 1.87 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.927 -0.579 . . . . 0.80000000000000004 110.411 178.574 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -50.86 142.93 10.79 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.11 0.481 . . . . 2.6400000000000001 111.554 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 73.08 -102.74 1.28 Allowed Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 121.069 -0.586 . . . . 1.8400000000000001 111.9 -178.654 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . -146.44 28.04 1.65 Allowed Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 110.691 -0.964 . . . . 0.64000000000000001 110.691 177.184 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 290' ' ' ILE . . . . . 0.638 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 66.2 mt -74.48 125.57 34.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 115.335 -0.432 . . . . 0.41999999999999998 110.53 -175.702 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.401 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 8.1 mt -111.12 142.69 22.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 N-CA-C 109.384 -0.599 . . . . 0.93000000000000005 109.384 -179.024 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 292' ' ' ILE . . . . . . . . . . . . . 18.5 pt -132.8 128.47 57.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 120.859 0.361 . . . . 0.47999999999999998 111.222 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 293' ' ' GLU . . . . . 0.601 ' HB2' ' HB3' ' A' ' 359' ' ' ARG . 40.0 mt-10 -103.99 131.79 50.88 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.334 -0.848 . . . . 2.3100000000000001 110.204 175.618 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -79.98 126.48 31.08 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.234 0.54 . . . . 2.3599999999999999 109.966 175.492 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 295' ' ' ARG . . . . . 0.602 ' HA ' ' HE ' ' A' ' 295' ' ' ARG . 2.6 mmp_? -105.28 -59.23 1.79 Allowed 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.46 -0.57 . . . . 3.5 109.46 175.36 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.644 ' HB ' ' HG2' ' A' ' 357' ' ' GLU . 90.0 t -131.77 105.18 9.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.822 -0.626 . . . . 0.69999999999999996 109.334 174.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 10.2 t -68.9 138.72 54.89 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.068 0.461 . . . . 1.9299999999999999 109.827 178.013 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -128.47 161.82 22.17 Favored Glycine 0 N--CA 1.442 -0.959 0 C-N-CA 120.316 -0.945 . . . . 1.04 112.067 -175.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 23.3 tptm -127.26 110.96 13.39 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 109.799 -0.445 . . . . 4.4900000000000002 109.799 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -171.43 -154.58 9.95 Favored Glycine 0 N--CA 1.441 -0.98 0 N-CA-C 111.381 -0.688 . . . . 1.04 111.381 -178.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 301' ' ' PRO . . . . . 0.554 ' O ' ' HA ' ' A' ' 353' ' ' ALA . 21.9 Cg_exo -65.12 133.73 36.64 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.988 2.459 . . . . 0.88 111.744 177.546 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 52.7 m80 -93.32 139.55 30.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.731 0.301 . . . . 1.49 110.35 -179.376 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -74.03 151.73 40.16 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.053 -0.522 . . . . 0.54000000000000004 111.832 -179.153 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 304' ' ' LYS . . . . . 0.46 ' HG2' ' N ' ' A' ' 305' ' ' LYS . 25.6 ttpp -152.98 169.25 23.35 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 115.855 -0.611 . . . . 2.8399999999999999 109.387 -178.602 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.46 ' N ' ' HG2' ' A' ' 304' ' ' LYS . 99.4 mttt -64.91 130.94 45.29 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 110.136 -0.32 . . . . 2.8399999999999999 110.136 176.252 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 92.44 -11.8 71.23 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 121.094 -0.575 . . . . 0.69999999999999996 111.852 -178.682 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 52.5 m -83.5 140.08 32.52 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 122.457 0.303 . . . . 0.40000000000000002 110.57 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 50.7 mtt180 -100.68 104.74 16.05 Favored 'General case' 0 CA--C 1.516 -0.36 0 N-CA-C 109.002 -0.74 . . . . 3.4500000000000002 109.002 -179.514 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.848 ' HB ' HD11 ' A' ' 388' ' ' LEU . 33.7 m -102.12 140.01 21.72 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.915 0 CA-C-O 121.276 0.56 . . . . 0.34000000000000002 111.14 -176.719 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 310' ' ' GLY . . . . . 0.467 ' HA2' ' HA ' ' A' ' 333' ' ' VAL . . . -115.01 125.85 6.94 Favored Glycine 0 N--CA 1.441 -1.029 0 N-CA-C 110.136 -1.186 . . . . 0.27000000000000002 110.136 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 13.4 ptp -134.07 177.04 8.05 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-O 121.459 0.647 . . . . 0.76000000000000001 112.123 -173.75 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 312' ' ' ARG . . . . . 0.776 ' HE ' HG11 ' A' ' 389' ' ' VAL . 72.5 mtm180 -138.25 140.85 39.85 Favored 'General case' 0 C--N 1.317 -0.813 0 N-CA-C 106.995 -1.483 . . . . 2.5099999999999998 106.995 172.351 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 313' ' ' TYR . . . . . 0.42 ' CE2' ' HH2' ' A' ' 345' ' ' TRP . 9.8 p90 -158.55 169.53 24.23 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 119.593 -0.843 . . . . 0.68000000000000005 113.056 -167.404 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 26.2 t -129.42 108.07 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 CA-C-N 114.33 -1.305 . . . . 0.34999999999999998 109.086 171.234 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -88.28 110.38 3.63 Favored Glycine 0 N--CA 1.447 -0.576 0 N-CA-C 111.761 -0.535 . . . . 0.28000000000000003 111.761 -177.803 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 316' ' ' LYS . . . . . 0.86 ' HG2' HG22 ' A' ' 322' ' ' VAL . 51.0 mttp -115.81 164.38 14.46 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.175 0.512 . . . . 1.9399999999999999 110.831 -176.331 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 94.1 mt -87.95 158.67 18.6 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 107.561 -1.274 . . . . 0.65000000000000002 107.561 164.702 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 318' ' ' LYS . . . . . 0.801 ' HG2' ' HB3' ' A' ' 381' ' ' GLU . 0.1 OUTLIER -63.29 -8.76 9.25 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.011 0.434 . . . . 2.4199999999999999 111.232 178.978 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 85.8 m-20 -81.16 -14.55 57.51 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.123 -0.489 . . . . 2.2000000000000002 110.769 177.059 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 109.55 -18.53 29.79 Favored Glycine 0 CA--C 1.518 0.25 0 C-N-CA 120.806 -0.711 . . . . 0.68999999999999995 112.853 179.148 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 55.2 mtpt -78.08 138.57 38.83 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.662 0.268 . . . . 2.4199999999999999 111.249 -176.572 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.86 HG22 ' HG2' ' A' ' 316' ' ' LYS . 47.7 t -97.8 136.84 27.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.123 -0.489 . . . . 1.26 110.466 -176.95 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -118.21 -24.8 6.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.85 0.357 . . . . 0.55000000000000004 111.164 179.416 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -140.27 146.83 39.1 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.469 -0.567 . . . . 1.6799999999999999 109.469 177.173 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 21.0 ptmt -163.25 137.66 6.17 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.041 0.448 . . . . 1.99 111.48 -175.631 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 326' ' ' ASN . . . . . 0.451 ' HB2' ' HB2' ' A' ' 330' ' ' LYS . 5.8 p30 -154.58 128.9 9.05 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.796 -0.638 . . . . 1.9199999999999999 110.279 170.145 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 327' ' ' THR . . . . . 0.459 ' HA ' ' HD2' ' A' ' 312' ' ' ARG . 7.6 t -163.07 -33.92 0.04 OUTLIER 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.676 -0.693 . . . . 1.6899999999999999 110.573 -177.92 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 58.8 mttp -89.29 95.46 10.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.657 -0.247 . . . . 2.5499999999999998 110.441 177.887 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.511 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 73.65 -10.33 7.01 Favored Glycine 0 CA--C 1.518 0.275 0 C-N-CA 121.137 -0.554 . . . . 0.96999999999999997 113.439 177.234 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 330' ' ' LYS . . . . . 0.451 ' HB2' ' HB2' ' A' ' 326' ' ' ASN . 58.7 mttm -103.03 100.74 17.97 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 116.945 0.372 . . . . 2.0800000000000001 111.291 -177.305 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 331' ' ' PRO . . . . . 0.511 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 87.5 Cg_endo -88.84 143.51 5.05 Favored 'Trans proline' 0 N--CA 1.452 -0.917 0 C-N-CA 122.7 2.267 . . . . 0.62 112.034 170.925 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 73.8 t80 -116.01 115.65 26.51 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.594 -0.521 . . . . 0.64000000000000001 109.594 174.777 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 333' ' ' VAL . . . . . 0.467 ' HA ' ' HA2' ' A' ' 310' ' ' GLY . 42.7 t -114.73 117.08 54.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 120.559 0.218 . . . . 0.38 110.517 -175.375 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.523 ' HZ ' HG21 ' A' ' 349' ' ' VAL . 27.8 p90 -136.18 160.78 37.63 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 110.173 -0.306 . . . . 0.40999999999999998 110.173 -178.749 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 335' ' ' LYS . . . . . 0.641 ' O ' ' HG2' ' A' ' 338' ' ' GLN . 6.0 ptmt -106.04 134.62 48.88 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.016 0.436 . . . . 2.5800000000000001 111.513 -179.187 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 10.8 mp -68.82 117.8 10.98 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.332 -0.395 . . . . 0.57999999999999996 110.174 177.452 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 128.86 -19.27 5.55 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.832 -0.699 . . . . 0.93999999999999995 112.207 -179.279 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 338' ' ' GLN . . . . . 0.798 HE21 ' HB2' ' A' ' 340' ' ' GLU . 18.8 pt20 -72.53 138.55 47.0 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.836 0.35 . . . . 2.6200000000000001 110.742 179.883 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -86.65 20.31 24.21 Favored Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 120.931 -0.652 . . . . 0.73999999999999999 111.56 176.669 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 340' ' ' GLU . . . . . 0.798 ' HB2' HE21 ' A' ' 338' ' ' GLN . 11.5 mt-10 -89.22 -11.05 44.77 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.287 -0.635 . . . . 2.0899999999999999 109.287 178.007 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 35.5 m -112.98 173.53 2.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.353 -0.84 . . . . 0.42999999999999999 109.587 177.386 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 342' ' ' ILE . . . . . 0.57 HD12 ' HA ' ' A' ' 367' ' ' ALA . 8.7 pt -92.81 159.96 2.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 N-CA-C 109.736 -0.468 . . . . 0.32000000000000001 109.736 178.322 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 343' ' ' LYS . . . . . 0.509 ' HE2' ' HA ' ' A' ' 343' ' ' LYS . 3.4 mmpt? -55.97 -35.73 67.06 Favored 'General case' 0 N--CA 1.467 0.377 0 N-CA-C 112.219 0.451 . . . . 2.9300000000000002 112.219 -174.78 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 344' ' ' GLY . . . . . 0.428 ' HA3' HD13 ' A' ' 362' ' ' ILE . . . -56.18 -28.74 54.94 Favored Glycine 0 CA--C 1.521 0.446 0 C-N-CA 120.805 -0.712 . . . . 0.29999999999999999 113.061 177.628 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 345' ' ' TRP . . . . . 0.42 ' HH2' ' CE2' ' A' ' 313' ' ' TYR . 11.2 m95 -79.01 -59.99 2.56 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 112.715 0.635 . . . . 0.39000000000000001 112.715 -177.063 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 9.0 p-10 -63.92 -22.85 67.11 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 118.046 0.384 . . . . 1.75 111.268 -175.815 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 73.5 mt -86.52 -53.63 9.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.05 -0.523 . . . . 0.39000000000000001 111.249 176.477 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -64.52 -32.61 84.78 Favored Glycine 0 CA--C 1.523 0.549 0 C-N-CA 121.184 -0.531 . . . . 0.34000000000000002 113.894 -178.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 349' ' ' VAL . . . . . 0.523 HG21 ' HZ ' ' A' ' 334' ' ' PHE . 93.7 t -80.48 -14.4 12.91 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 CA-C-O 121.047 0.451 . . . . 0.32000000000000001 111.242 -179.798 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.08 131.67 47.17 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.237 0.541 . . . . 0.46999999999999997 110.632 178.531 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 79.89 16.15 77.68 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.821 -0.704 . . . . 0.39000000000000001 112.387 -179.145 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 352' ' ' MET . . . . . 0.408 ' SD ' ' HG2' ' A' ' 358' ' ' ARG . 42.7 mmm -82.6 149.46 27.42 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.643 0.259 . . . . 1.28 110.53 174.238 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 353' ' ' ALA . . . . . 0.554 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -122.84 137.83 54.82 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.031 -0.531 . . . . 0.55000000000000004 110.491 -179.56 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 354' ' ' VAL . . . . . 0.531 ' HB ' ' HD2' ' A' ' 301' ' ' PRO . 87.6 t -55.33 122.85 5.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.147 -0.479 . . . . 0.35999999999999999 110.679 176.499 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 111.27 -16.1 27.37 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.927 -0.654 . . . . 0.44 112.175 -178.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -108.37 160.81 13.58 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.692 -0.766 . . . . 0.29999999999999999 112.439 -178.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 357' ' ' GLU . . . . . 0.845 ' HB3' ' HB2' ' A' ' 387' ' ' LYS . 9.9 pt-20 -139.03 135.91 34.74 Favored 'General case' 0 C--O 1.238 0.462 0 CA-C-O 121.08 0.467 . . . . 1.4099999999999999 111.171 178.573 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 358' ' ' ARG . . . . . 0.408 ' HG2' ' SD ' ' A' ' 352' ' ' MET . 4.9 ptp180 -132.17 140.46 48.75 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.83 -0.623 . . . . 1.3700000000000001 109.931 177.445 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 359' ' ' ARG . . . . . 0.601 ' HB3' ' HB2' ' A' ' 293' ' ' GLU . 39.6 ttm180 -86.42 116.15 24.39 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.909 -0.587 . . . . 2.79 109.671 177.086 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 42.2 mt -99.42 117.77 45.05 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 CA-C-N 116.007 -0.542 . . . . 0.38 110.485 -177.536 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 361' ' ' VAL . . . . . 0.401 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 47.2 t -100.52 112.4 33.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 N-CA-C 108.714 -0.847 . . . . 0.39000000000000001 108.714 175.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 362' ' ' ILE . . . . . 0.462 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 47.9 mt -110.59 109.37 58.04 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 116.073 -0.512 . . . . 0.28999999999999998 111.67 -171.001 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 363' ' ' PRO . . . . . 0.462 ' HD2' ' HA ' ' A' ' 362' ' ' ILE . 13.8 Cg_endo -57.0 157.22 21.13 Favored 'Trans proline' 0 C--O 1.235 0.357 0 C-N-CA 123.098 2.532 . . . . 0.66000000000000003 112.185 172.045 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 364' ' ' ALA . . . . . 0.584 ' HB2' ' HA ' ' A' ' 379' ' ' ASN . . . -47.0 -53.8 24.6 Favored Pre-proline 0 CA--C 1.538 0.482 0 N-CA-C 114.051 1.13 . . . . 0.41999999999999998 114.051 -176.138 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 365' ' ' PRO . . . . . 0.442 ' HD2' ' N ' ' A' ' 364' ' ' ALA . 27.3 Cg_endo -61.6 -15.32 40.98 Favored 'Trans proline' 0 C--N 1.358 1.049 0 C-N-CA 122.2 1.933 . . . . 0.69999999999999996 114.207 -172.376 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 366' ' ' TYR . . . . . . . . . . . . . 12.2 m-85 -109.25 5.08 23.42 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.794 0.331 . . . . 0.68999999999999995 111.387 -178.727 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 367' ' ' ALA . . . . . 0.57 ' HA ' HD12 ' A' ' 342' ' ' ILE . . . -119.52 -125.09 0.28 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.435 -0.348 . . . . 0.85999999999999999 110.41 176.454 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 42.0 m-85 -68.9 -19.02 64.2 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-O 120.562 0.22 . . . . 1.0 111.297 179.232 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 74.96 -117.63 5.41 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.957 -0.639 . . . . 0.56000000000000005 113.177 177.587 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 370' ' ' LYS . . . . . 0.446 ' HA ' ' HB1' ' A' ' 378' ' ' ALA . 0.0 OUTLIER -111.54 13.57 21.35 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.652 -0.274 . . . . 2.7599999999999998 111.467 -173.931 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 51.0 tp60 -103.98 108.28 19.55 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.137 0.494 . . . . 2.6499999999999999 110.875 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 372' ' ' ALA . . . . . 0.41 ' HB1' ' HA ' ' A' ' 377' ' ' PRO . . . -75.42 119.18 19.16 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-N 115.77 -0.65 . . . . 1.01 111.664 178.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 75.3 mt -90.68 160.07 39.48 Favored Pre-proline 0 C--N 1.32 -0.716 0 N-CA-C 108.975 -0.75 . . . . 0.93000000000000005 108.975 174.309 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -59.6 114.18 1.94 Allowed 'Trans proline' 0 N--CA 1.461 -0.384 0 C-N-CA 121.326 1.351 . . . . 1.3100000000000001 110.831 173.641 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 97.2 -29.5 10.65 Favored Glycine 0 CA--C 1.52 0.38 0 C-N-CA 121.129 -0.558 . . . . 0.90000000000000002 112.768 -177.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 37.7 mt -126.7 94.23 40.56 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.66 0.23 . . . . 0.73999999999999999 110.461 -178.237 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 377' ' ' PRO . . . . . 0.41 ' HA ' ' HB1' ' A' ' 372' ' ' ALA . 72.1 Cg_endo -75.47 167.36 26.76 Favored 'Trans proline' 0 N--CA 1.461 -0.418 0 C-N-CA 122.51 2.14 . . . . 0.70999999999999996 112.839 -176.523 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 378' ' ' ALA . . . . . 0.446 ' HB1' ' HA ' ' A' ' 370' ' ' LYS . . . -57.82 152.13 16.45 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.842 -0.617 . . . . 0.73999999999999999 111.42 178.656 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 379' ' ' ASN . . . . . 0.584 ' HA ' ' HB2' ' A' ' 364' ' ' ALA . 82.6 m-20 72.12 14.25 5.68 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 115.714 -0.676 . . . . 1.49 111.962 179.072 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 33.7 m -70.45 112.43 6.74 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.187 0.517 . . . . 1.8400000000000001 110.861 176.327 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 381' ' ' GLU . . . . . 0.801 ' HB3' ' HG2' ' A' ' 318' ' ' LYS . 40.9 tt0 -72.95 105.11 4.3 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.259 -0.882 . . . . 1.03 109.444 175.236 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 86.6 mt -82.67 148.99 27.61 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.025 -0.534 . . . . 0.37 111.569 -175.687 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 29.4 m -130.57 120.09 23.51 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.589 -0.522 . . . . 0.27000000000000002 109.589 176.08 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 -121.39 110.45 16.1 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.757 0.313 . . . . 0.32000000000000001 111.484 -174.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 23.2 m-20 -82.42 103.92 12.34 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 108.375 -0.972 . . . . 1.8 108.375 168.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 386' ' ' VAL . . . . . . . . . . . . . 28.2 m -118.28 128.33 75.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.256 0.551 . . . . 0.31 111.56 -175.533 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 387' ' ' LYS . . . . . 0.845 ' HB2' ' HB3' ' A' ' 357' ' ' GLU . 28.9 ttpt -120.58 131.11 54.49 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.621 -0.718 . . . . 2.5299999999999998 109.756 175.9 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 388' ' ' LEU . . . . . 0.848 HD11 ' HB ' ' A' ' 309' ' ' VAL . 17.7 tp -87.43 130.29 34.73 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.33 -0.619 . . . . 0.28000000000000003 109.33 -174.851 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 389' ' ' VAL . . . . . 0.776 HG11 ' HE ' ' A' ' 312' ' ' ARG . 17.6 m -121.08 -12.75 8.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 111.997 0.369 . . . . 0.45000000000000001 111.997 -172.625 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 55.4 p -162.28 170.6 18.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.704 0.288 . . . . 1.3200000000000001 110.8 -178.837 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 391' ' ' MET . . . . . 0.432 ' HE3' ' HB2' ' A' ' 391' ' ' MET . 36.8 ttm -169.74 137.94 1.78 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.112 -0.495 . . . . 0.56000000000000005 110.652 -179.053 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 99.2 mttt . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.35 -0.833 . . . . 4.9100000000000001 110.265 177.587 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.622 0 N-CA-C 112.36 -0.296 . . . . 11.17 112.36 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -88.12 -40.67 13.58 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 111.669 0.248 . . . . 9.3699999999999992 111.669 -177.241 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 278' ' ' MET . . . . . . . . . . . . . 16.6 tpt 66.54 96.29 0.06 Allowed 'General case' 0 N--CA 1.465 0.275 0 CA-C-O 121.518 0.675 . . . . 7.6699999999999999 111.101 -178.36 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -120.35 23.29 10.97 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.773 -0.649 . . . . 6.3700000000000001 110.613 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -100.37 133.78 21.16 Favored Pre-proline 0 C--N 1.321 -0.637 0 CA-C-N 115.809 -0.632 . . . . 6.7599999999999998 110.251 -177.208 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 69.0 Cg_endo -74.5 153.51 44.48 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 122.762 2.308 . . . . 4.7999999999999998 113.166 -176.209 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 282' ' ' LYS . . . . . 0.501 ' HD3' ' HA ' ' A' ' 282' ' ' LYS . 64.8 mmtt -156.97 23.47 0.32 Allowed 'General case' 0 CA--C 1.503 -0.844 0 CA-C-N 115.389 -0.823 . . . . 3.46 110.189 177.935 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 20.8 p -157.01 126.29 6.02 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 114.532 -1.213 . . . . 0.76000000000000001 110.991 -175.373 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 25.5 mtpp -129.98 135.38 48.24 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.879 -0.415 . . . . 2.0600000000000001 109.879 170.651 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 285' ' ' LEU . . . . . 0.414 HD11 ' HA2' ' A' ' 289' ' ' GLY . 47.7 tp -94.01 120.77 34.71 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.884 -0.598 . . . . 0.97999999999999998 109.989 -177.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.609 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 88.3 mt -104.54 -171.95 2.02 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.554 -0.748 . . . . 0.80000000000000004 110.308 178.433 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 287' ' ' GLU . . . . . 0.65 ' HG3' ' OH ' ' A' ' 366' ' ' TYR . 7.3 tp10 -61.31 145.32 51.83 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.634 -0.712 . . . . 2.6400000000000001 111.377 -177.817 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 67.24 17.29 68.03 Favored Glycine 0 CA--C 1.521 0.439 0 C-N-CA 121.171 -0.537 . . . . 1.8400000000000001 113.967 176.008 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 289' ' ' GLY . . . . . 0.414 ' HA2' HD11 ' A' ' 285' ' ' LEU . . . 82.06 17.4 69.76 Favored Glycine 0 C--N 1.33 0.197 0 C-N-CA 120.512 -0.851 . . . . 0.64000000000000001 113.179 178.086 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 290' ' ' ILE . . . . . 0.609 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 87.8 mt -69.62 126.47 29.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 109.813 -0.439 . . . . 0.41999999999999998 109.813 176.759 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 10.5 mt -114.81 135.21 55.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 109.448 -0.575 . . . . 0.93000000000000005 109.448 -179.771 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 292' ' ' ILE . . . . . . . . . . . . . 24.5 pt -124.19 129.64 74.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-O 121.019 0.438 . . . . 0.47999999999999998 110.563 -177.8 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 293' ' ' GLU . . . . . . . . . . . . . 25.9 tt0 -107.7 121.18 44.18 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.403 -0.817 . . . . 2.3100000000000001 109.367 178.033 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -83.19 120.85 26.32 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.352 0.596 . . . . 2.3599999999999999 109.95 -179.624 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 295' ' ' ARG . . . . . 0.569 ' HD2' ' HB2' ' A' ' 359' ' ' ARG . 68.6 mtp180 -102.06 -50.77 3.56 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.37 -0.377 . . . . 3.5 110.312 -176.768 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.51 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 60.3 t -118.71 115.09 46.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 109.78 -0.452 . . . . 0.69999999999999996 109.78 174.676 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 20.7 p -81.06 121.52 26.18 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.036 -0.529 . . . . 1.9299999999999999 111.682 -177.507 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -134.99 173.71 21.46 Favored Glycine 0 N--CA 1.446 -0.654 0 N-CA-C 111.632 -0.587 . . . . 1.04 111.632 179.049 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -151.27 128.17 11.0 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.261 0.553 . . . . 4.4900000000000002 109.892 174.572 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -172.92 -153.5 9.54 Favored Glycine 0 N--CA 1.443 -0.874 0 N-CA-C 110.869 -0.892 . . . . 1.04 110.869 -177.721 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_exo -56.64 133.36 57.53 Favored 'Trans proline' 0 N--CA 1.462 -0.372 0 C-N-CA 122.369 2.046 . . . . 0.88 111.017 173.706 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 302' ' ' HIS . . . . . 0.418 ' HA ' ' O ' ' A' ' 352' ' ' MET . 53.6 m80 -100.48 144.24 29.71 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.42 -0.355 . . . . 1.49 111.033 -176.604 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 303' ' ' ALA . . . . . 0.442 ' HB2' HG11 ' A' ' 309' ' ' VAL . . . -77.39 125.84 29.96 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.832 -0.622 . . . . 0.54000000000000004 111.382 -179.239 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 304' ' ' LYS . . . . . 0.404 ' O ' ' HB2' ' A' ' 336' ' ' LEU . 98.4 mttt -133.21 179.47 6.18 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.717 -0.674 . . . . 2.8399999999999999 109.922 176.472 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.942 ' HG3' ' HA3' ' A' ' 337' ' ' GLY . 87.0 tttt -67.39 130.99 44.82 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.839 0.352 . . . . 2.8399999999999999 110.268 177.03 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 95.99 -26.02 22.7 Favored Glycine 0 N--CA 1.448 -0.542 0 N-CA-C 111.42 -0.672 . . . . 0.69999999999999996 111.42 -177.903 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 307' ' ' THR . . . . . 0.628 ' O ' ' HA ' ' A' ' 335' ' ' LYS . 9.7 m -72.51 131.36 42.43 Favored 'General case' 0 N--CA 1.449 -0.52 0 CA-C-N 115.619 -0.291 . . . . 0.40000000000000002 110.224 178.239 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 308' ' ' ARG . . . . . 0.645 ' HG2' ' HB3' ' A' ' 335' ' ' LYS . 49.6 mtp180 -102.18 104.37 14.95 Favored 'General case' 0 N--CA 1.452 -0.356 0 N-CA-C 108.651 -0.87 . . . . 3.4500000000000002 108.651 -179.676 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.787 ' HB ' HD11 ' A' ' 388' ' ' LEU . 32.0 m -99.58 140.02 19.88 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-O 121.243 0.544 . . . . 0.34000000000000002 111.267 -171.034 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -103.79 113.3 4.43 Favored Glycine 0 N--CA 1.442 -0.933 0 CA-C-N 114.956 -1.02 . . . . 0.27000000000000002 110.646 179.508 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 13.3 ptp -133.62 176.89 8.15 Favored 'General case' 0 N--CA 1.441 -0.92 0 CA-C-O 121.92 0.867 . . . . 0.76000000000000001 112.273 -173.516 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 49.4 mtp180 -135.46 145.16 46.91 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 113.81 -1.541 . . . . 2.5099999999999998 106.976 177.174 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 313' ' ' TYR . . . . . 0.511 ' HA ' ' O ' ' A' ' 385' ' ' ASP . 44.9 p90 -161.42 155.63 22.57 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.461 0.648 . . . . 0.68000000000000005 112.708 -170.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 57.7 t -122.48 120.01 59.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 114.756 -1.111 . . . . 0.34999999999999998 109.45 175.263 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -101.37 115.23 5.21 Favored Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.83 -0.7 . . . . 0.28000000000000003 112.461 -177.046 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 316' ' ' LYS . . . . . 0.502 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 62.7 mttm -112.29 151.09 30.08 Favored 'General case' 0 C--N 1.331 -0.221 0 O-C-N 123.946 0.439 . . . . 1.9399999999999999 111.193 -179.278 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 317' ' ' LEU . . . . . 0.579 HD21 HG12 ' A' ' 376' ' ' ILE . 80.1 mt -84.95 -178.5 6.85 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.505 -0.771 . . . . 0.65000000000000002 112.114 178.883 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 318' ' ' LYS . . . . . 0.591 ' HD3' ' H ' ' A' ' 381' ' ' GLU . 49.7 tptt -57.43 -32.59 67.03 Favored 'General case' 0 N--CA 1.461 0.111 0 CA-C-N 115.198 -0.91 . . . . 2.4199999999999999 110.854 176.82 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 27.0 p-10 -92.7 6.9 45.78 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.078 -0.51 . . . . 2.2000000000000002 111.368 -177.244 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 88.13 -8.22 79.02 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.638 -0.791 . . . . 0.68999999999999995 112.641 178.155 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 28.7 tptp -66.25 114.19 5.14 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.028 0.442 . . . . 2.4199999999999999 110.634 179.526 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.502 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 4.0 p -68.15 122.44 19.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-N 115.788 -0.642 . . . . 1.26 109.856 175.571 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 323' ' ' PHE . . . . . 0.46 ' HD1' ' HG ' ' A' ' 317' ' ' LEU . 43.1 p90 -100.83 -30.48 11.66 Favored 'General case' 0 C--N 1.322 -0.596 0 C-N-CA 120.738 -0.385 . . . . 0.55000000000000004 110.794 -178.776 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -149.48 160.08 43.76 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.835 -0.346 . . . . 1.6799999999999999 110.622 178.719 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 14.8 pttp -166.66 128.42 1.75 Allowed 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.129 -0.487 . . . . 1.99 110.505 -178.38 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -124.82 117.9 25.18 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.947 -0.76 . . . . 1.9199999999999999 108.947 178.82 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 2.0 t -164.05 -45.04 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.47 -0.332 . . . . 1.6899999999999999 111.278 -175.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 12.6 ptmm? -89.44 100.41 13.21 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.317 0.579 . . . . 2.5499999999999998 110.84 -177.842 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.473 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 86.28 -26.76 6.03 Favored Glycine 0 N--CA 1.452 -0.292 0 CA-C-N 115.532 -0.758 . . . . 0.96999999999999997 113.074 178.023 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -103.36 100.78 19.44 Favored Pre-proline 0 C--N 1.329 -0.309 0 N-CA-C 111.729 0.27 . . . . 2.0800000000000001 111.729 -177.001 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 331' ' ' PRO . . . . . 0.473 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 84.2 Cg_endo -87.79 125.93 2.07 Favored 'Trans proline' 0 N--CA 1.45 -1.078 0 C-N-CA 122.35 2.034 . . . . 0.62 110.342 165.869 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 43.1 t80 -99.92 115.6 30.02 Favored 'General case' 0 C--N 1.321 -0.639 0 C-N-CA 120.486 -0.485 . . . . 0.64000000000000001 110.107 -177.323 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 333' ' ' VAL . . . . . 0.638 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 47.5 t -111.94 113.17 43.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 116.032 -0.531 . . . . 0.38 109.939 -177.951 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 30.7 p90 -135.99 149.44 48.86 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.313 -0.403 . . . . 0.40999999999999998 110.41 -178.566 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 335' ' ' LYS . . . . . 0.645 ' HB3' ' HG2' ' A' ' 308' ' ' ARG . 12.0 ptmt -92.84 139.22 30.77 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 116.181 -0.463 . . . . 2.5800000000000001 111.133 177.577 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 336' ' ' LEU . . . . . 0.404 ' HB2' ' O ' ' A' ' 304' ' ' LYS . 9.8 mp -77.64 151.76 34.17 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 109.517 -0.549 . . . . 0.57999999999999996 109.517 172.267 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 337' ' ' GLY . . . . . 0.942 ' HA3' ' HG3' ' A' ' 305' ' ' LYS . . . 90.78 40.36 5.62 Favored Glycine 0 N--CA 1.446 -0.687 0 C-N-CA 120.698 -0.763 . . . . 0.93999999999999995 112.577 -177.662 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 338' ' ' GLN . . . . . 0.494 ' HB3' ' HE2' ' A' ' 335' ' ' LYS . 29.7 pt20 -148.26 157.63 43.61 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.454 -0.573 . . . . 2.6200000000000001 109.454 176.179 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -89.73 20.1 37.3 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.756 -0.735 . . . . 0.73999999999999999 112.352 -176.223 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -85.18 -15.07 44.92 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.301 0.572 . . . . 2.0899999999999999 110.012 178.873 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 25.4 m -123.58 156.78 30.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.843 -0.617 . . . . 0.42999999999999999 109.855 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 342' ' ' ILE . . . . . 0.456 HD12 ' HA ' ' A' ' 367' ' ' ALA . 11.3 pt -76.79 159.93 5.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 N-CA-C 110.203 -0.295 . . . . 0.32000000000000001 110.203 -179.826 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 343' ' ' LYS . . . . . 0.478 ' HE2' ' HA ' ' A' ' 343' ' ' LYS . 4.7 mmpt? -63.14 -34.38 77.48 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.19 0.441 . . . . 2.9300000000000002 112.19 -173.88 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 344' ' ' GLY . . . . . 0.43 ' HA3' HD13 ' A' ' 362' ' ' ILE . . . -54.19 -33.54 52.08 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.72 -0.753 . . . . 0.29999999999999999 112.383 174.564 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 11.8 m95 -81.23 -59.83 2.5 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 120.584 0.231 . . . . 0.39000000000000001 110.781 177.568 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 31.5 t70 -48.76 -31.11 6.44 Favored 'General case' 0 CA--C 1.537 0.463 0 CA-C-N 116.193 -0.458 . . . . 1.75 112.107 179.049 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 71.6 mt -93.2 -52.39 9.91 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.404 0 CA-C-N 116.626 -0.261 . . . . 0.39000000000000001 111.69 178.323 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -63.8 -31.84 82.16 Favored Glycine 0 C--N 1.335 0.505 0 C-N-CA 121.318 -0.468 . . . . 0.34000000000000002 113.767 -176.775 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 98.7 t -78.28 -20.52 13.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-O 120.984 0.421 . . . . 0.32000000000000001 110.812 179.442 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -63.8 118.35 8.21 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.96 0.409 . . . . 0.46999999999999997 110.163 178.185 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 100.2 0.61 55.89 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.69 -0.766 . . . . 0.39000000000000001 112.397 -178.017 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 352' ' ' MET . . . . . 0.418 ' O ' ' HA ' ' A' ' 302' ' ' HIS . 58.0 mmm -68.69 139.97 55.42 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.673 0.273 . . . . 1.28 110.668 175.893 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 353' ' ' ALA . . . . . . . . . . . . . . . -109.69 137.19 47.86 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.877 -0.601 . . . . 0.55000000000000004 110.819 -178.734 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 68.4 t -56.85 117.19 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.279 -0.419 . . . . 0.35999999999999999 110.125 173.449 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 111.07 -6.08 28.91 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 121.229 -0.51 . . . . 0.44 112.477 -178.555 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -105.36 154.93 17.11 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.748 -0.739 . . . . 0.29999999999999999 113.126 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 357' ' ' GLU . . . . . 0.51 ' HB3' ' HB ' ' A' ' 296' ' ' VAL . 25.8 tt0 -132.61 133.53 43.76 Favored 'General case' 0 C--N 1.329 -0.293 0 C-N-CA 122.944 0.498 . . . . 1.4099999999999999 109.868 -179.486 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 358' ' ' ARG . . . . . . . . . . . . . 5.0 ptp180 -144.48 143.23 30.77 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.094 0.473 . . . . 1.3700000000000001 111.063 177.598 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 359' ' ' ARG . . . . . 0.569 ' HB2' ' HD2' ' A' ' 295' ' ' ARG . 11.8 ttp180 -93.35 121.47 34.77 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.696 -0.684 . . . . 2.79 109.422 174.551 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 44.9 mt -106.07 127.64 61.06 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-N 116.134 -0.485 . . . . 0.38 110.577 -175.821 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 361' ' ' VAL . . . . . . . . . . . . . 58.8 t -107.16 109.24 27.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 N-CA-C 108.868 -0.79 . . . . 0.39000000000000001 108.868 175.312 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 362' ' ' ILE . . . . . 0.449 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 51.5 mt -107.11 110.04 63.25 Favored Pre-proline 0 C--N 1.322 -0.598 0 CA-C-N 116.43 -0.35 . . . . 0.28999999999999998 111.495 -174.255 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 363' ' ' PRO . . . . . 0.498 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 13.2 Cg_endo -57.45 152.83 44.7 Favored 'Trans proline' 0 N--CA 1.46 -0.487 0 C-N-CA 122.641 2.228 . . . . 0.66000000000000003 111.18 170.4 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 364' ' ' ALA . . . . . 0.502 ' HB2' ' HA ' ' A' ' 379' ' ' ASN . . . -47.93 -49.86 56.59 Favored Pre-proline 0 CA--C 1.537 0.479 0 N-CA-C 113.913 1.079 . . . . 0.41999999999999998 113.913 -173.87 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 365' ' ' PRO . . . . . 0.498 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 77.6 Cg_exo -49.5 -35.4 36.6 Favored 'Trans proline' 0 C--N 1.36 1.18 0 C-N-CA 122.564 2.176 . . . . 0.69999999999999996 114.555 -173.748 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 366' ' ' TYR . . . . . 0.65 ' OH ' ' HG3' ' A' ' 287' ' ' GLU . 3.1 m-85 -101.23 13.82 33.91 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.481 -0.488 . . . . 0.68999999999999995 112.234 -174.857 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 367' ' ' ALA . . . . . 0.456 ' HA ' HD12 ' A' ' 342' ' ' ILE . . . -116.58 -105.3 0.4 Allowed 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.306 -0.406 . . . . 0.85999999999999999 109.926 172.539 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 76.4 m-85 -95.87 4.82 52.48 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.988 0.423 . . . . 1.0 111.158 175.232 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 61.35 -117.4 11.48 Favored Glycine 0 N--CA 1.45 -0.371 0 CA-C-N 115.829 -0.623 . . . . 0.56000000000000005 113.34 174.811 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 95.4 mttt -103.14 14.32 32.04 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.686 -0.257 . . . . 2.7599999999999998 110.778 -176.748 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 27.8 tp60 -87.27 103.92 15.9 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.355 -0.384 . . . . 2.6499999999999999 110.773 -177.769 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 372' ' ' ALA . . . . . 0.633 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -74.84 104.15 5.35 Favored 'General case' 0 N--CA 1.45 -0.448 0 CA-C-O 121.077 0.465 . . . . 1.01 110.542 174.517 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 90.2 mt -94.34 162.75 25.22 Favored Pre-proline 0 C--N 1.321 -0.668 0 CA-C-N 115.796 -0.638 . . . . 0.93000000000000005 109.44 176.589 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_endo -63.15 114.86 2.65 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 121.724 1.616 . . . . 1.3100000000000001 110.606 170.65 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 93.83 -30.03 7.93 Favored Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 120.941 -0.647 . . . . 0.90000000000000002 112.279 -176.84 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 376' ' ' ILE . . . . . 0.579 HG12 HD21 ' A' ' 317' ' ' LEU . 24.3 mt -128.36 79.92 73.28 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.668 0.27 . . . . 0.73999999999999999 110.615 -178.524 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 377' ' ' PRO . . . . . 0.633 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 72.5 Cg_endo -75.44 167.96 25.52 Favored 'Trans proline' 0 N--CA 1.463 -0.276 0 C-N-CA 122.379 2.053 . . . . 0.70999999999999996 112.313 -179.675 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 378' ' ' ALA . . . . . 0.448 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -55.96 146.14 23.15 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.362 -0.381 . . . . 0.73999999999999999 111.01 178.588 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 379' ' ' ASN . . . . . 0.502 ' HA ' ' HB2' ' A' ' 364' ' ' ALA . 49.1 m-80 75.56 9.29 3.64 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 123.435 0.694 . . . . 1.49 112.138 179.723 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 62.2 m -72.02 107.03 4.52 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.32 0.581 . . . . 1.8400000000000001 110.774 174.591 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 381' ' ' GLU . . . . . 0.591 ' H ' ' HD3' ' A' ' 318' ' ' LYS . 4.5 tt0 -77.01 99.62 5.35 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.02 -0.991 . . . . 1.03 109.153 177.628 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 83.2 mt -82.46 140.44 33.38 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.167 -0.47 . . . . 0.37 110.878 -173.83 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 25.5 m -117.66 120.57 38.42 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 109.622 -0.51 . . . . 0.27000000000000002 109.622 178.779 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 92.3 m-85 -118.92 113.68 21.4 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.611 -0.268 . . . . 0.32000000000000001 111.168 -176.66 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 385' ' ' ASP . . . . . 0.511 ' O ' ' HA ' ' A' ' 313' ' ' TYR . 23.3 t70 -83.19 104.98 13.79 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 108.428 -0.952 . . . . 1.8 108.428 171.495 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 386' ' ' VAL . . . . . . . . . . . . . 36.0 m -115.27 133.21 62.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-O 121.665 0.745 . . . . 0.31 111.469 -174.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 387' ' ' LYS . . . . . . . . . . . . . 3.3 ptpp? -129.6 126.39 38.35 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.085 -0.961 . . . . 2.5299999999999998 109.841 176.764 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 388' ' ' LEU . . . . . 0.787 HD11 ' HB ' ' A' ' 309' ' ' VAL . 22.3 tp -91.64 127.99 37.3 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 108.279 -1.008 . . . . 0.28000000000000003 108.279 -179.738 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 28.2 m -127.76 -6.18 4.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 C-N-CA 120.77 -0.372 . . . . 0.45000000000000001 111.591 -171.248 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 13.4 p -167.98 171.08 10.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.381 -0.372 . . . . 1.3200000000000001 110.534 179.167 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 391' ' ' MET . . . . . 0.439 ' HE3' ' HB2' ' A' ' 391' ' ' MET . 31.7 ttm -164.45 143.72 7.37 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.9 0.381 . . . . 0.56000000000000005 111.348 -178.232 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 3.2 tppp? . . . . . 0 C--O 1.251 1.133 0 CA-C-O 118.678 -0.677 . . . . 4.9100000000000001 109.257 173.038 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.704 0 N-CA-C 111.816 -0.513 . . . . 11.17 111.816 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -119.42 -17.82 8.68 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.768 0.284 . . . . 9.3699999999999992 111.566 -177.715 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 278' ' ' MET . . . . . . . . . . . . . 15.7 tpt -113.22 118.8 35.67 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.982 0.42 . . . . 7.6699999999999999 111.244 -176.736 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -116.72 165.77 12.9 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.683 -0.689 . . . . 6.3700000000000001 109.337 174.191 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 53.8 mtpt -120.7 81.29 32.84 Favored Pre-proline 0 C--N 1.326 -0.441 0 C-N-CA 120.707 -0.397 . . . . 6.7599999999999998 110.948 -178.41 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -84.66 4.65 6.73 Favored 'Trans proline' 0 C--N 1.347 0.477 0 C-N-CA 123.245 2.63 . . . . 4.7999999999999998 111.455 177.658 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 282' ' ' LYS . . . . . 0.406 ' HE2' ' HB3' ' A' ' 282' ' ' LYS . 48.8 mtpt -75.3 -166.71 0.54 Allowed 'General case' 0 N--CA 1.445 -0.725 0 CA-C-N 114.791 -1.095 . . . . 3.46 111.449 179.308 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.542 HG22 ' HB3' ' A' ' 293' ' ' GLU . 1.9 p -91.49 136.55 33.04 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-N 114.776 -1.102 . . . . 0.76000000000000001 110.016 179.575 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 92.7 mttt -101.45 154.73 18.56 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 110.418 -0.215 . . . . 2.0600000000000001 110.418 179.371 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 59.9 tp -110.43 112.73 24.86 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 109.722 -0.473 . . . . 0.97999999999999998 109.722 176.129 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.738 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 89.4 mt -100.41 -170.97 1.94 Allowed 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.057 -0.52 . . . . 0.80000000000000004 110.924 -178.132 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 287' ' ' GLU . . . . . 0.461 ' HB3' HD13 ' A' ' 347' ' ' ILE . 28.1 tt0 -50.32 136.74 19.64 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 116.011 -0.54 . . . . 2.6400000000000001 111.788 -179.043 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 76.22 -99.42 1.3 Allowed Glycine 0 N--CA 1.445 -0.761 0 C-N-CA 120.755 -0.736 . . . . 1.8400000000000001 111.561 -177.114 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . -151.17 31.91 0.96 Allowed Glycine 0 N--CA 1.447 -0.575 0 N-CA-C 110.736 -0.945 . . . . 0.64000000000000001 110.736 175.873 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 290' ' ' ILE . . . . . 0.738 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 72.6 mt -74.38 121.94 26.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 110.127 -0.324 . . . . 0.41999999999999998 110.127 -176.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 17.9 mt -115.1 139.86 39.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 109.307 -0.627 . . . . 0.93000000000000005 109.307 -178.736 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 292' ' ' ILE . . . . . 0.406 ' O ' ' HA ' ' A' ' 283' ' ' THR . 22.0 pt -136.91 127.02 39.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 C-N-CA 120.816 -0.354 . . . . 0.47999999999999998 110.637 -179.098 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 293' ' ' GLU . . . . . 0.542 ' HB3' HG22 ' A' ' 283' ' ' THR . 16.9 pt-20 -110.87 131.83 54.71 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.09 -0.505 . . . . 2.3100000000000001 109.933 173.271 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -89.64 109.03 20.03 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.186 0.517 . . . . 2.3599999999999999 109.69 -173.106 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 295' ' ' ARG . . . . . 0.799 ' HG3' HG23 ' A' ' 296' ' ' VAL . 21.6 tpt180 -77.89 -54.35 6.42 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.278 -0.874 . . . . 3.5 111.232 -173.807 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.799 HG23 ' HG3' ' A' ' 295' ' ' ARG . 65.0 t -128.63 106.68 14.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 N-CA-C 109.199 -0.667 . . . . 0.69999999999999996 109.199 178.614 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 25.3 m -73.34 114.0 11.05 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.11 0.481 . . . . 1.9299999999999999 111.739 -175.519 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -113.76 171.15 13.65 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.565 -0.743 . . . . 1.04 111.46 178.125 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 26.4 tptp -137.73 127.4 25.25 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.419 0.628 . . . . 4.4900000000000002 111.111 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -170.98 -155.02 10.12 Favored Glycine 0 N--CA 1.44 -1.034 0 N-CA-C 109.966 -1.254 . . . . 1.04 109.966 176.202 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 301' ' ' PRO . . . . . 0.553 ' HB2' ' SD ' ' A' ' 391' ' ' MET . 11.5 Cg_endo -59.48 146.87 93.76 Favored 'Trans proline' 0 CA--C 1.53 0.297 0 C-N-CA 122.305 2.003 . . . . 0.88 110.974 170.342 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 29.1 m80 -106.75 139.09 41.72 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.067 0.46 . . . . 1.49 111.445 -178.448 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 303' ' ' ALA . . . . . 0.438 ' HB2' HG11 ' A' ' 309' ' ' VAL . . . -73.68 142.28 46.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.408 -0.814 . . . . 0.54000000000000004 112.438 -175.497 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 57.6 tttp -150.24 165.52 32.7 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 108.149 -1.056 . . . . 2.8399999999999999 108.149 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 65.8 mttm -62.92 134.94 56.99 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-N 118.203 0.456 . . . . 2.8399999999999999 109.929 174.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 92.23 -6.54 78.49 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 121.087 -0.578 . . . . 0.69999999999999996 111.859 -174.174 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 24.7 m -102.65 145.95 28.91 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.975 -0.379 . . . . 0.40000000000000002 109.975 179.414 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 308' ' ' ARG . . . . . 0.589 ' HB3' ' HG3' ' A' ' 335' ' ' LYS . 11.5 ptp85 -108.86 123.82 49.67 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 109.499 -0.556 . . . . 3.4500000000000002 109.499 179.723 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.832 ' HB ' HD11 ' A' ' 388' ' ' LEU . 34.4 m -110.86 139.17 35.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-O 121.387 0.613 . . . . 0.34000000000000002 111.649 179.477 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 310' ' ' GLY . . . . . 0.412 ' HA2' ' HA ' ' A' ' 333' ' ' VAL . . . -111.05 115.84 4.08 Favored Glycine 0 N--CA 1.444 -0.772 0 N-CA-C 110.189 -1.165 . . . . 0.27000000000000002 110.189 176.858 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 14.2 ptp -133.38 177.75 7.44 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-O 121.498 0.666 . . . . 0.76000000000000001 111.879 -170.498 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 312' ' ' ARG . . . . . 0.424 ' HB3' ' CB ' ' A' ' 327' ' ' THR . 94.1 mtt180 -131.89 144.84 51.15 Favored 'General case' 0 C--N 1.319 -0.717 0 N-CA-C 107.182 -1.414 . . . . 2.5099999999999998 107.182 175.431 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 313' ' ' TYR . . . . . 0.632 ' HB3' HG12 ' A' ' 386' ' ' VAL . 33.6 p90 -159.53 159.27 33.18 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 113.162 0.801 . . . . 0.68000000000000005 113.162 -172.519 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 60.5 t -128.27 113.26 29.5 Favored 'Isoleucine or valine' 0 C--O 1.237 0.423 0 CA-C-N 114.782 -1.099 . . . . 0.34999999999999998 109.024 171.652 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -93.36 116.28 5.14 Favored Glycine 0 C--O 1.239 0.454 0 C-N-CA 121.241 -0.504 . . . . 0.28000000000000003 112.602 -176.44 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 316' ' ' LYS . . . . . 0.726 ' HG2' HG22 ' A' ' 322' ' ' VAL . 26.7 mttp -122.19 154.76 37.03 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-O 121.181 0.515 . . . . 1.9399999999999999 110.885 -177.521 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 317' ' ' LEU . . . . . 0.61 HD21 HG12 ' A' ' 376' ' ' ILE . 69.5 mt -81.04 164.16 22.69 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.202 -0.908 . . . . 0.65000000000000002 109.471 172.481 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 318' ' ' LYS . . . . . 0.452 ' HB2' ' O ' ' A' ' 381' ' ' GLU . 53.2 tptt -60.8 -25.31 66.48 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.074 0.464 . . . . 2.4199999999999999 110.072 175.333 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 74.7 m-20 -75.18 -0.85 20.73 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.82 -0.627 . . . . 2.2000000000000002 111.196 -179.283 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 84.97 10.73 78.11 Favored Glycine 0 C--N 1.334 0.423 0 C-N-CA 120.902 -0.666 . . . . 0.68999999999999995 112.592 178.307 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 321' ' ' LYS . . . . . 0.547 ' HB2' HD12 ' A' ' 317' ' ' LEU . 30.6 mmtp -95.71 125.04 40.01 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.276 -0.268 . . . . 2.4199999999999999 110.276 -179.489 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.726 HG22 ' HG2' ' A' ' 316' ' ' LYS . 50.3 t -83.31 115.36 25.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 110.214 -0.291 . . . . 1.26 110.214 179.221 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 47.7 p90 -91.72 -30.82 16.07 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.919 -0.312 . . . . 0.55000000000000004 111.131 -178.732 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -150.5 153.1 35.23 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 110.025 -0.361 . . . . 1.6799999999999999 110.025 177.531 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 21.0 pttm -163.41 133.32 4.27 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.965 0.412 . . . . 1.99 110.438 -177.08 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 4.1 p30 -155.13 121.44 5.25 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.443 0.639 . . . . 1.9199999999999999 110.119 174.349 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 327' ' ' THR . . . . . 0.424 ' CB ' ' HB3' ' A' ' 312' ' ' ARG . 4.9 t -161.84 -42.51 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.601 -0.727 . . . . 1.6899999999999999 111.485 -175.842 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.44 ' O ' ' HG3' ' A' ' 328' ' ' LYS . 25.1 pttm -79.21 95.1 5.54 Favored 'General case' 0 N--CA 1.454 -0.245 0 CA-C-O 121.568 0.699 . . . . 2.5499999999999998 110.512 -178.344 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.454 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 85.42 -15.36 46.07 Favored Glycine 0 N--CA 1.448 -0.566 0 CA-C-N 115.484 -0.78 . . . . 0.96999999999999997 112.617 179.505 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -104.36 100.59 22.7 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 120.483 0.182 . . . . 2.0800000000000001 111.27 -179.096 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 331' ' ' PRO . . . . . 0.454 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 73.8 Cg_endo -88.06 131.55 2.67 Favored 'Trans proline' 0 N--CA 1.453 -0.888 0 C-N-CA 122.686 2.257 . . . . 0.62 112.027 172.385 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 78.7 t80 -110.28 120.83 43.69 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 109.513 -0.551 . . . . 0.64000000000000001 109.513 177.53 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 333' ' ' VAL . . . . . 0.412 ' HA ' ' HA2' ' A' ' 310' ' ' GLY . 53.2 t -114.49 116.04 51.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.417 -0.356 . . . . 0.38 110.432 -177.402 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.513 ' HZ ' HG21 ' A' ' 349' ' ' VAL . 33.5 p90 -129.0 156.85 43.15 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.832 0.349 . . . . 0.40999999999999998 110.404 178.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 335' ' ' LYS . . . . . 0.589 ' HG3' ' HB3' ' A' ' 308' ' ' ARG . 3.6 mppt? -99.51 135.68 40.56 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.198 -0.456 . . . . 2.5800000000000001 110.604 -179.576 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 9.6 mp -77.03 134.51 38.78 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.42 -0.585 . . . . 0.57999999999999996 109.42 174.105 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 100.72 -1.45 55.51 Favored Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.265 -0.969 . . . . 0.93999999999999995 112.323 -175.544 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 338' ' ' GLN . . . . . 0.439 ' HG2' ' O ' ' A' ' 335' ' ' LYS . 12.1 pt20 -87.94 138.92 31.03 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.673 -0.492 . . . . 2.6200000000000001 109.673 177.371 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -82.17 46.29 3.49 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.614 -0.803 . . . . 0.73999999999999999 112.348 -178.307 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 19.6 mt-10 -121.15 -20.73 6.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.825 0.345 . . . . 2.0899999999999999 110.68 179.209 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 23.0 m -100.49 160.83 3.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 116.416 -0.356 . . . . 0.42999999999999999 110.556 -176.584 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 342' ' ' ILE . . . . . 0.64 HD12 ' HA ' ' A' ' 367' ' ' ALA . 5.2 pt -82.84 159.92 3.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.313 -0.625 . . . . 0.32000000000000001 109.313 175.97 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 343' ' ' LYS . . . . . 0.51 ' HE2' HD11 ' A' ' 347' ' ' ILE . 17.0 mtpt -60.98 -37.31 82.01 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 121.082 -0.247 . . . . 2.9300000000000002 111.648 -173.285 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 344' ' ' GLY . . . . . 0.589 ' HA3' HD13 ' A' ' 362' ' ' ILE . . . -53.29 -35.43 50.18 Favored Glycine 0 CA--C 1.519 0.307 0 C-N-CA 121.003 -0.618 . . . . 0.29999999999999999 112.556 176.575 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 8.0 m95 -73.6 -61.61 1.78 Allowed 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 111.796 0.295 . . . . 0.39000000000000001 111.796 178.531 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -52.8 -36.77 58.82 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-O 120.918 0.39 . . . . 1.75 111.476 -178.387 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 347' ' ' ILE . . . . . 0.51 HD11 ' HE2' ' A' ' 343' ' ' LYS . 74.9 mt -84.48 -48.16 16.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.236 -0.438 . . . . 0.39000000000000001 111.387 -177.474 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -64.7 -33.5 87.39 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 121.039 -0.6 . . . . 0.34000000000000002 113.28 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 349' ' ' VAL . . . . . 0.543 ' O ' ' HB2' ' A' ' 352' ' ' MET . 95.2 t -80.99 -14.24 12.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.016 0.436 . . . . 0.32000000000000001 110.752 179.313 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -64.79 115.74 5.6 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.992 0.425 . . . . 0.46999999999999997 109.954 174.861 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 88.65 21.94 41.72 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.381 -0.914 . . . . 0.39000000000000001 112.183 -176.088 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 352' ' ' MET . . . . . 0.543 ' HB2' ' O ' ' A' ' 349' ' ' VAL . 0.0 OUTLIER -81.08 151.36 28.37 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.109 -0.7 . . . . 1.28 109.109 174.407 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 353' ' ' ALA . . . . . . . . . . . . . . . -121.49 130.63 53.67 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.731 0.3 . . . . 0.55000000000000004 111.35 -176.449 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 98.2 t -57.43 119.43 2.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 116.067 -0.515 . . . . 0.35999999999999999 110.428 174.326 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 107.65 -10.71 38.56 Favored Glycine 0 N--CA 1.448 -0.533 0 C-N-CA 121.065 -0.588 . . . . 0.44 111.965 -177.466 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -104.24 160.41 15.9 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.802 -0.714 . . . . 0.29999999999999999 112.868 -178.812 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 357' ' ' GLU . . . . . 0.567 ' HB2' ' HB3' ' A' ' 387' ' ' LYS . 41.5 tt0 -136.85 134.17 36.63 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 122.773 0.429 . . . . 1.4099999999999999 109.937 178.731 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 358' ' ' ARG . . . . . 0.459 ' HA ' ' H ' ' A' ' 295' ' ' ARG . 4.3 ptp180 -146.65 146.86 30.53 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 121.317 0.58 . . . . 1.3700000000000001 111.298 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 359' ' ' ARG . . . . . . . . . . . . . 35.1 ttm180 -87.79 119.08 27.78 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.111 -0.949 . . . . 2.79 109.909 177.66 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 53.7 mt -98.29 119.67 46.62 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 CA-C-N 115.942 -0.572 . . . . 0.38 109.892 179.65 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 361' ' ' VAL . . . . . . . . . . . . . 74.6 t -103.23 109.09 25.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 115.244 -0.889 . . . . 0.39000000000000001 108.856 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 362' ' ' ILE . . . . . 0.589 HD13 ' HA3' ' A' ' 344' ' ' GLY . 28.8 mt -115.57 107.91 48.09 Favored Pre-proline 0 C--N 1.323 -0.564 0 CA-C-N 116.484 -0.325 . . . . 0.28999999999999998 111.038 -173.313 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 363' ' ' PRO . . . . . 0.488 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 11.6 Cg_endo -56.35 151.48 44.45 Favored 'Trans proline' 0 C--O 1.236 0.425 0 C-N-CA 122.373 2.048 . . . . 0.66000000000000003 111.152 171.377 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 364' ' ' ALA . . . . . . . . . . . . . . . -46.96 -48.95 51.83 Favored Pre-proline 0 CA--C 1.541 0.624 0 N-CA-C 114.126 1.158 . . . . 0.41999999999999998 114.126 -174.137 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 365' ' ' PRO . . . . . 0.488 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 75.5 Cg_exo -51.42 -29.05 29.66 Favored 'Trans proline' 0 C--N 1.365 1.399 0 C-N-CA 122.54 2.16 . . . . 0.69999999999999996 114.05 -176.162 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 366' ' ' TYR . . . . . . . . . . . . . 9.1 m-85 -106.17 4.39 28.94 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 111.917 0.339 . . . . 0.68999999999999995 111.917 -175.357 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 367' ' ' ALA . . . . . 0.688 ' HB1' HD12 ' A' ' 382' ' ' LEU . . . -117.08 -30.21 5.73 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 112.251 0.464 . . . . 0.85999999999999999 112.251 -179.174 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 9.5 m-85 -165.46 -32.46 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 120.941 0.401 . . . . 1.0 110.53 -176.762 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 101.62 -128.79 9.68 Favored Glycine 0 N--CA 1.446 -0.636 0 C-N-CA 120.821 -0.704 . . . . 0.56000000000000005 111.983 177.863 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 21.1 ptmt -108.84 11.02 26.43 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.007 0.432 . . . . 2.7599999999999998 110.538 -179.504 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 51.9 tt0 -85.05 103.15 13.82 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.972 -0.558 . . . . 2.6499999999999999 110.306 -177.179 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 372' ' ' ALA . . . . . . . . . . . . . . . -77.65 94.93 4.48 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.076 0.465 . . . . 1.01 110.919 -179.687 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 80.2 mt -73.91 155.88 88.39 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-N 115.706 -0.679 . . . . 0.93000000000000005 109.599 176.159 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -57.61 114.32 1.9 Allowed 'Trans proline' 0 N--CA 1.46 -0.454 0 C-N-CA 121.664 1.576 . . . . 1.3100000000000001 110.81 173.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 97.62 -29.55 10.8 Favored Glycine 0 CA--C 1.519 0.305 0 C-N-CA 121.034 -0.603 . . . . 0.90000000000000002 112.558 -177.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 376' ' ' ILE . . . . . 0.61 HG12 HD21 ' A' ' 317' ' ' LEU . 25.9 mt -124.45 85.47 55.9 Favored Pre-proline 0 C--N 1.328 -0.347 0 O-C-N 122.808 -0.23 . . . . 0.73999999999999999 110.554 -178.591 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 377' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -75.02 165.73 30.68 Favored 'Trans proline' 0 N--CA 1.46 -0.49 0 C-N-CA 122.666 2.244 . . . . 0.70999999999999996 112.413 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 378' ' ' ALA . . . . . 0.426 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -64.96 159.84 22.06 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.084 -0.507 . . . . 0.73999999999999999 111.595 -178.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 379' ' ' ASN . . . . . 0.426 ' HB2' ' O ' ' A' ' 378' ' ' ALA . 83.3 m-20 73.66 -8.16 1.43 Allowed 'General case' 0 N--CA 1.473 0.676 0 CA-C-N 115.501 -0.772 . . . . 1.49 111.833 179.376 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 48.6 m -70.13 114.3 8.15 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.056 0.455 . . . . 1.8400000000000001 110.928 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 381' ' ' GLU . . . . . 0.452 ' O ' ' HB2' ' A' ' 318' ' ' LYS . 33.0 tt0 -73.5 106.8 5.44 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.549 -0.75 . . . . 1.03 109.862 177.548 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 382' ' ' LEU . . . . . 0.688 HD12 ' HB1' ' A' ' 367' ' ' ALA . 65.9 mt -78.91 141.23 37.78 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.68 0.276 . . . . 0.37 110.394 -178.241 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 24.3 m -123.91 124.85 43.54 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-O 121.002 0.43 . . . . 0.27000000000000002 110.218 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -120.01 112.19 18.84 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.245 -0.434 . . . . 0.32000000000000001 110.932 -178.142 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 385' ' ' ASP . . . . . 0.406 ' O ' ' HA ' ' A' ' 313' ' ' TYR . 72.4 m-20 -86.37 105.4 16.68 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 108.728 -0.841 . . . . 1.8 108.728 174.093 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 386' ' ' VAL . . . . . 0.632 HG12 ' HB3' ' A' ' 313' ' ' TYR . 22.2 m -121.72 136.47 58.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.212 0.53 . . . . 0.31 112.072 -173.64 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 387' ' ' LYS . . . . . 0.567 ' HB3' ' HB2' ' A' ' 357' ' ' GLU . 1.3 ptpp? -123.86 137.28 54.68 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.818 -0.628 . . . . 2.5299999999999998 109.449 170.181 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 388' ' ' LEU . . . . . 0.832 HD11 ' HB ' ' A' ' 309' ' ' VAL . 19.1 tp -95.42 134.28 38.41 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 109.551 -0.537 . . . . 0.28000000000000003 109.551 -177.377 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 30.9 m -127.91 -5.07 4.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 111.955 0.354 . . . . 0.45000000000000001 111.955 -174.146 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 12.5 p -165.68 159.77 16.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.653 -0.248 . . . . 1.3200000000000001 111.093 -178.484 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 391' ' ' MET . . . . . 0.708 ' HG2' ' HG2' ' A' ' 392' ' ' LYS . 41.8 ttm -164.59 155.94 15.4 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.971 -0.559 . . . . 0.56000000000000005 109.832 178.282 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 392' ' ' LYS . . . . . 0.708 ' HG2' ' HG2' ' A' ' 391' ' ' MET . 32.1 mmmt . . . . . 0 C--O 1.247 0.923 0 O-C-N 124.259 0.975 . . . . 4.9100000000000001 111.611 175.154 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.665 0 N-CA-C 111.663 -0.575 . . . . 11.17 111.663 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -109.71 170.28 8.17 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.816 0.341 . . . . 9.3699999999999992 110.673 -179.452 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 278' ' ' MET . . . . . 0.421 ' O ' ' HD2' ' A' ' 282' ' ' LYS . 95.4 mmm -97.79 -39.85 8.83 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.203 -0.453 . . . . 7.6699999999999999 110.001 179.587 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . 62.22 78.0 0.31 Allowed 'General case' 0 C--O 1.236 0.355 0 CA-C-N 115.35 -0.841 . . . . 6.3700000000000001 111.381 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 71.9 mttt 70.67 161.23 0.15 Allowed Pre-proline 0 N--CA 1.468 0.453 0 CA-C-N 115.311 -0.859 . . . . 6.7599999999999998 111.259 177.531 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -62.39 109.95 0.96 Allowed 'Trans proline' 0 C--O 1.235 0.351 0 C-N-CA 122.417 2.078 . . . . 4.7999999999999998 111.638 175.091 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 282' ' ' LYS . . . . . 0.421 ' HD2' ' O ' ' A' ' 278' ' ' MET . 24.8 mtpp -91.18 68.54 6.02 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.446 0.641 . . . . 3.46 110.161 -178.714 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.456 HG22 ' HB2' ' A' ' 293' ' ' GLU . 18.2 p -88.68 150.77 22.84 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.239 -0.892 . . . . 0.76000000000000001 111.679 -178.702 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 284' ' ' LYS . . . . . 0.466 ' O ' ' HA ' ' A' ' 291' ' ' ILE . 92.8 mttt -118.52 144.17 46.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.41 -0.814 . . . . 2.0600000000000001 111.026 -173.497 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 285' ' ' LEU . . . . . 0.547 HD11 ' HA2' ' A' ' 289' ' ' GLY . 56.3 tp -102.8 123.99 47.49 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.466 -0.788 . . . . 0.97999999999999998 110.373 -177.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.461 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 98.6 mt -113.35 -175.74 2.74 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.9 -0.591 . . . . 0.80000000000000004 109.703 178.44 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 287' ' ' GLU . . . . . 0.447 ' HG2' ' OH ' ' A' ' 366' ' ' TYR . 27.6 tt0 -56.73 144.07 34.05 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.178 0.513 . . . . 2.6400000000000001 111.629 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.423 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 72.48 0.32 46.58 Favored Glycine 0 CA--C 1.52 0.352 0 CA-C-N 115.78 -0.646 . . . . 1.8400000000000001 113.806 179.033 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 289' ' ' GLY . . . . . 0.547 ' HA2' HD11 ' A' ' 285' ' ' LEU . . . 95.11 12.37 55.07 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.696 -0.764 . . . . 0.64000000000000001 113.028 179.109 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 290' ' ' ILE . . . . . 0.461 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 71.9 mt -66.62 121.54 15.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 121.253 0.549 . . . . 0.41999999999999998 110.957 -179.071 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.628 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 18.5 mm -104.38 138.96 26.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 115.737 -0.665 . . . . 0.93000000000000005 110.232 178.898 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 292' ' ' ILE . . . . . . . . . . . . . 21.5 pt -127.29 129.36 70.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 120.925 0.393 . . . . 0.47999999999999998 110.685 177.109 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 293' ' ' GLU . . . . . 0.459 ' OE1' ' HD2' ' A' ' 359' ' ' ARG . 24.6 tt0 -118.83 117.96 30.28 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.661 -0.7 . . . . 2.3100000000000001 109.759 177.906 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 294' ' ' ASP . . . . . 0.403 ' OD1' ' HA ' ' A' ' 297' ' ' THR . 0.5 OUTLIER -88.33 96.14 10.46 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.654 -0.869 . . . . 2.3599999999999999 108.654 -178.655 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 295' ' ' ARG . . . . . 0.828 HH22 ' HB3' ' A' ' 385' ' ' ASP . 38.0 ttp180 -76.11 -47.28 25.05 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.598 -0.728 . . . . 3.5 111.587 -171.751 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.736 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 23.3 t -119.03 103.5 14.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 N-CA-C 109.057 -0.719 . . . . 0.69999999999999996 109.057 172.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 297' ' ' THR . . . . . 0.403 ' HA ' ' OD1' ' A' ' 294' ' ' ASP . 32.1 p -62.09 113.32 2.77 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 114.931 -1.031 . . . . 1.9299999999999999 112.197 -174.023 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -119.88 152.02 17.2 Favored Glycine 0 N--CA 1.444 -0.769 0 CA-C-N 115.652 -0.703 . . . . 1.04 111.642 178.003 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -127.74 114.12 16.88 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.759 0.314 . . . . 4.4900000000000002 110.336 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -170.56 -154.6 9.65 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 121.011 -0.614 . . . . 1.04 112.013 -179.414 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 301' ' ' PRO . . . . . 0.592 ' HD2' ' HB ' ' A' ' 354' ' ' VAL . 28.1 Cg_exo -62.33 137.85 67.97 Favored 'Trans proline' 0 C--O 1.233 0.234 0 C-N-CA 122.833 2.355 . . . . 0.88 112.048 178.656 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 302' ' ' HIS . . . . . 0.505 ' HA ' ' O ' ' A' ' 352' ' ' MET . 39.0 m80 -102.5 134.25 46.14 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 120.938 0.399 . . . . 1.49 110.714 178.157 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -69.54 132.41 46.22 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.986 -0.552 . . . . 0.54000000000000004 111.685 -178.558 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 32.6 mmtp -117.19 177.96 4.53 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.042 -0.725 . . . . 2.8399999999999999 109.042 176.105 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 61.4 mttm -68.77 132.24 46.48 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 109.698 -0.482 . . . . 2.8399999999999999 109.698 173.27 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 84.74 7.97 83.43 Favored Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.697 -0.764 . . . . 0.69999999999999996 112.553 -176.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 20.2 m -96.72 147.81 23.53 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 110.286 -0.265 . . . . 0.40000000000000002 110.286 177.381 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 47.4 mtt180 -102.56 130.82 49.52 Favored 'General case' 0 CA--C 1.515 -0.395 0 N-CA-C 108.993 -0.743 . . . . 3.4500000000000002 108.993 178.743 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.836 ' HB ' HD11 ' A' ' 388' ' ' LEU . 19.7 m -130.39 137.75 55.49 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-O 121.125 0.488 . . . . 0.34000000000000002 111.815 -177.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -107.7 120.11 5.98 Favored Glycine 0 N--CA 1.444 -0.789 0 N-CA-C 109.826 -1.31 . . . . 0.27000000000000002 109.826 176.336 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 311' ' ' MET . . . . . 0.599 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 22.9 ptm -140.01 177.04 8.25 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.58 0.705 . . . . 0.76000000000000001 112.212 -171.321 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 312' ' ' ARG . . . . . 0.493 ' HB3' ' HA ' ' A' ' 327' ' ' THR . 20.9 mtm180 -133.64 145.37 49.92 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 107.228 -1.397 . . . . 2.5099999999999998 107.228 174.937 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 313' ' ' TYR . . . . . 0.535 ' CB ' HG12 ' A' ' 386' ' ' VAL . 41.7 p90 -161.57 158.7 26.72 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 113.23 0.826 . . . . 0.68000000000000005 113.23 -173.362 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 47.8 t -125.99 127.08 70.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 114.695 -1.139 . . . . 0.34999999999999998 109.688 174.621 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -96.96 106.73 3.39 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 121.116 -0.564 . . . . 0.28000000000000003 112.139 -179.656 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 316' ' ' LYS . . . . . 0.796 ' HG2' HG22 ' A' ' 322' ' ' VAL . 86.4 mttt -113.07 154.2 26.94 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.282 0.563 . . . . 1.9399999999999999 111.722 -175.328 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 317' ' ' LEU . . . . . 0.431 HD12 ' HB3' ' A' ' 321' ' ' LYS . 88.8 mt -88.84 164.81 15.04 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.639 -0.71 . . . . 0.65000000000000002 109.107 169.682 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 318' ' ' LYS . . . . . . . . . . . . . 37.8 ttpt -66.55 -21.94 66.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.991 0.424 . . . . 2.4199999999999999 110.858 178.928 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 28.1 p30 -83.74 4.72 27.61 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.011 0.434 . . . . 2.2000000000000002 111.028 179.101 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 91.21 -9.5 77.4 Favored Glycine 0 C--N 1.33 0.235 0 C-N-CA 121.252 -0.499 . . . . 0.68999999999999995 113.258 174.673 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 321' ' ' LYS . . . . . 0.431 ' HB3' HD12 ' A' ' 317' ' ' LEU . 22.2 ttmm -77.98 123.55 26.94 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.896 0.379 . . . . 2.4199999999999999 110.37 -179.003 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.796 HG22 ' HG2' ' A' ' 316' ' ' LYS . 67.7 t -85.44 128.49 39.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 116.171 -0.468 . . . . 1.26 110.368 -179.681 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 35.6 p90 -100.81 -35.26 9.5 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.645 -0.422 . . . . 0.55000000000000004 111.587 -179.343 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -146.95 168.55 21.21 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 120.789 -0.364 . . . . 1.6799999999999999 110.108 178.21 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 325' ' ' LYS . . . . . 0.581 ' HD3' ' N ' ' A' ' 325' ' ' LYS . 0.0 OUTLIER -176.55 143.48 0.48 Allowed 'General case' 0 C--O 1.233 0.192 0 CA-C-O 121.247 0.546 . . . . 1.99 111.781 -173.612 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 3.1 p30 -150.73 118.06 6.02 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.576 -0.738 . . . . 1.9199999999999999 109.41 165.601 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 327' ' ' THR . . . . . 0.493 ' HA ' ' HB3' ' A' ' 312' ' ' ARG . 30.7 m -150.7 -55.39 0.15 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.952 -0.567 . . . . 1.6899999999999999 111.169 -175.781 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 34.8 mtmm -72.04 94.21 1.47 Allowed 'General case' 0 C--O 1.235 0.299 0 CA-C-O 120.981 0.42 . . . . 2.5499999999999998 111.272 -177.225 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.506 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 80.24 -10.68 41.0 Favored Glycine 0 N--CA 1.45 -0.422 0 CA-C-N 115.863 -0.608 . . . . 0.96999999999999997 112.971 175.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 25.6 mtpp -103.9 100.7 21.31 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.789 0.294 . . . . 2.0800000000000001 110.955 -177.507 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 331' ' ' PRO . . . . . 0.506 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 64.2 Cg_endo -88.26 136.38 3.41 Favored 'Trans proline' 0 N--CA 1.453 -0.907 0 C-N-CA 122.724 2.282 . . . . 0.62 112.115 172.547 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 75.4 t80 -110.78 122.83 48.8 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.461 -0.57 . . . . 0.64000000000000001 109.461 177.772 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 333' ' ' VAL . . . . . 0.489 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 51.5 t -118.78 115.07 46.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 N-CA-C 110.176 -0.305 . . . . 0.38 110.176 -176.731 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.599 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 23.4 p90 -133.48 172.19 13.06 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.649 0.262 . . . . 0.40999999999999998 110.597 -178.743 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 335' ' ' LYS . . . . . 0.747 ' HD2' ' H ' ' A' ' 335' ' ' LYS . 0.0 OUTLIER -117.29 140.38 49.62 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.335 -0.393 . . . . 2.5800000000000001 110.208 -179.928 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 10.1 mp -79.22 151.03 31.44 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.707 0.289 . . . . 0.57999999999999996 110.646 178.486 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 92.31 9.14 62.14 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.828 -0.701 . . . . 0.93999999999999995 112.007 -176.105 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 338' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -98.17 161.54 13.66 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.796 0.332 . . . . 2.6200000000000001 110.511 -179.687 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -99.82 4.54 57.79 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.852 -0.689 . . . . 0.73999999999999999 112.277 -179.588 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 66.9 mm-40 -73.54 -34.13 65.05 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.904 0.383 . . . . 2.0899999999999999 110.674 178.347 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 34.4 m -100.41 156.47 4.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.988 -0.551 . . . . 0.42999999999999999 110.972 -178.165 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 12.8 pt -71.44 161.91 4.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.471 -0.331 . . . . 0.32000000000000001 110.523 177.734 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.4 -38.45 87.1 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.359 -0.382 . . . . 2.9300000000000002 111.84 -176.738 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -51.56 -36.53 39.41 Favored Glycine 0 C--N 1.331 0.255 0 C-N-CA 121.135 -0.555 . . . . 0.29999999999999999 112.544 175.924 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 9.3 m95 -73.25 -60.3 2.31 Favored 'General case' 0 C--O 1.223 -0.338 0 CA-C-O 120.405 0.145 . . . . 0.39000000000000001 111.067 177.181 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -49.45 -33.87 15.25 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.242 -0.436 . . . . 1.75 112.109 179.774 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 65.9 mt -85.76 -54.96 7.34 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.358 0 CA-C-N 116.638 -0.255 . . . . 0.39000000000000001 111.661 178.55 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -60.97 -36.68 92.6 Favored Glycine 0 CA--C 1.521 0.434 0 C-N-CA 121.585 -0.34 . . . . 0.34000000000000002 113.822 -177.462 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 349' ' ' VAL . . . . . 0.485 HG21 ' HZ ' ' A' ' 334' ' ' PHE . 95.1 t -72.0 -24.96 23.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 120.904 0.383 . . . . 0.32000000000000001 110.691 179.601 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.53 108.71 2.1 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.804 -0.443 . . . . 0.46999999999999997 109.804 175.849 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 107.73 4.67 34.16 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 121.11 -0.567 . . . . 0.39000000000000001 112.216 -175.494 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 352' ' ' MET . . . . . 0.505 ' O ' ' HA ' ' A' ' 302' ' ' HIS . 0.0 OUTLIER -73.03 140.8 47.52 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 109.276 -0.639 . . . . 1.28 109.276 176.158 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 353' ' ' ALA . . . . . 0.46 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -108.08 132.07 53.95 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.732 0.301 . . . . 0.55000000000000004 111.042 -177.353 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 354' ' ' VAL . . . . . 0.592 ' HB ' ' HD2' ' A' ' 301' ' ' PRO . 78.4 t -56.58 116.22 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 120.968 0.414 . . . . 0.35999999999999999 110.551 175.031 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 110.67 -19.31 26.18 Favored Glycine 0 N--CA 1.445 -0.754 0 N-CA-C 111.59 -0.604 . . . . 0.44 111.59 -177.35 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -83.9 148.26 24.47 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 121.168 -0.539 . . . . 0.29999999999999999 112.694 -176.307 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 357' ' ' GLU . . . . . 0.736 ' HB3' ' HB ' ' A' ' 296' ' ' VAL . 5.0 tp10 -126.61 117.94 23.82 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 108.973 -0.751 . . . . 1.4099999999999999 108.973 179.876 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 358' ' ' ARG . . . . . 0.481 ' HG2' ' CE ' ' A' ' 352' ' ' MET . 6.2 ptp180 -145.16 148.44 33.59 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.362 0.601 . . . . 1.3700000000000001 112.303 -173.15 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 359' ' ' ARG . . . . . 0.459 ' HD2' ' OE1' ' A' ' 293' ' ' GLU . 60.2 mtt85 -89.24 128.02 35.81 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.75 -0.659 . . . . 2.79 110.233 171.975 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 57.9 mt -110.97 118.39 57.23 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 N-CA-C 109.201 -0.666 . . . . 0.38 109.201 174.396 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 361' ' ' VAL . . . . . 0.628 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 51.4 t -96.97 117.51 41.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.19 -0.67 . . . . 0.39000000000000001 109.19 178.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 362' ' ' ILE . . . . . . . . . . . . . 65.1 mt -115.01 103.98 54.31 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 116.339 -0.392 . . . . 0.28999999999999998 110.818 -174.241 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 363' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -60.29 160.08 24.52 Favored 'Trans proline' 0 N--CA 1.463 -0.285 0 C-N-CA 122.642 2.228 . . . . 0.66000000000000003 112.007 174.771 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 364' ' ' ALA . . . . . 0.497 ' N ' ' HD2' ' A' ' 365' ' ' PRO . . . -47.23 -51.09 44.34 Favored Pre-proline 0 CA--C 1.539 0.535 0 N-CA-C 114.191 1.182 . . . . 0.41999999999999998 114.191 -176.126 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 365' ' ' PRO . . . . . 0.497 ' HD2' ' N ' ' A' ' 364' ' ' ALA . 16.8 Cg_endo -56.66 -25.87 62.19 Favored 'Trans proline' 0 C--N 1.358 1.078 0 C-N-CA 122.256 1.971 . . . . 0.69999999999999996 114.168 -171.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 366' ' ' TYR . . . . . 0.447 ' OH ' ' HG2' ' A' ' 287' ' ' GLU . 4.1 m-85 -103.36 12.11 35.78 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-O 121.036 0.446 . . . . 0.68999999999999995 111.236 -177.085 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -127.56 -116.43 0.26 Allowed 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 115.664 -0.698 . . . . 0.85999999999999999 110.162 173.515 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 86.2 m-85 -85.51 -14.4 46.07 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.689 0.28 . . . . 1.0 111.712 -177.804 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 62.94 -109.18 2.53 Favored Glycine 0 N--CA 1.452 -0.265 0 CA-C-N 116.183 -0.462 . . . . 0.56000000000000005 113.572 174.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 370' ' ' LYS . . . . . 0.482 ' HA ' ' HB1' ' A' ' 378' ' ' ALA . 58.0 mttm -102.72 8.06 39.58 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 111.722 0.267 . . . . 2.7599999999999998 111.722 -175.763 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 7.4 tp60 -88.83 99.55 12.47 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.964 0.411 . . . . 2.6499999999999999 110.382 179.676 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 372' ' ' ALA . . . . . . . . . . . . . . . -74.31 110.8 8.9 Favored 'General case' 0 N--CA 1.45 -0.441 0 CA-C-N 115.931 -0.577 . . . . 1.01 111.005 178.644 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 71.9 mt -101.37 161.0 24.97 Favored Pre-proline 0 C--N 1.321 -0.641 0 N-CA-C 109.076 -0.713 . . . . 0.93000000000000005 109.076 176.601 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_exo -60.55 114.64 2.22 Favored 'Trans proline' 0 N--CA 1.46 -0.484 0 C-N-CA 121.546 1.498 . . . . 1.3100000000000001 110.96 174.791 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 92.0 -19.87 46.34 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.749 -0.738 . . . . 0.90000000000000002 112.327 -178.559 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 23.6 mt -132.47 78.4 67.71 Favored Pre-proline 0 N--CA 1.465 0.287 0 CA-C-O 120.836 0.35 . . . . 0.73999999999999999 110.512 -179.018 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 377' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_exo -70.72 166.89 27.33 Favored 'Trans proline' 0 N--CA 1.463 -0.319 0 C-N-CA 122.764 2.31 . . . . 0.70999999999999996 113.017 -178.192 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 378' ' ' ALA . . . . . 0.482 ' HB1' ' HA ' ' A' ' 370' ' ' LYS . . . -56.1 151.78 11.65 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.742 -0.663 . . . . 0.73999999999999999 110.846 178.036 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 379' ' ' ASN . . . . . 0.414 ' HA ' ' CB ' ' A' ' 364' ' ' ALA . 84.1 m-20 64.92 32.25 10.83 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.184 0.516 . . . . 1.49 110.306 -178.423 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -77.63 117.02 18.65 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-N 115.643 -0.708 . . . . 1.8400000000000001 111.158 177.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 381' ' ' GLU . . . . . . . . . . . . . 19.3 tt0 -92.05 100.63 13.23 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.031 -0.729 . . . . 1.03 109.031 177.394 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 78.8 mt -94.3 149.53 21.15 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.776 -0.647 . . . . 0.37 112.155 -170.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 29.5 m -127.99 128.43 45.02 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.746 -0.464 . . . . 0.27000000000000002 109.746 176.304 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -119.65 113.09 20.15 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.573 -0.285 . . . . 0.32000000000000001 111.248 -177.885 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 385' ' ' ASP . . . . . 0.828 ' HB3' HH22 ' A' ' 295' ' ' ARG . 1.6 m-20 -79.58 105.33 10.81 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.22 -1.03 . . . . 1.8 108.22 172.267 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 386' ' ' VAL . . . . . 0.591 ' HB ' ' CE ' ' A' ' 311' ' ' MET . 33.8 m -126.09 131.32 71.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.386 0.613 . . . . 0.31 112.456 -171.833 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 387' ' ' LYS . . . . . 0.489 ' HB2' ' CD ' ' A' ' 357' ' ' GLU . 49.9 tttm -126.63 132.07 51.32 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.933 -0.576 . . . . 2.5299999999999998 109.835 175.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 388' ' ' LEU . . . . . 0.836 HD11 ' HB ' ' A' ' 309' ' ' VAL . 23.2 tp -94.67 137.53 33.66 Favored 'General case' 0 C--N 1.319 -0.717 0 N-CA-C 108.992 -0.744 . . . . 0.28000000000000003 108.992 -178.45 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 33.7 m -126.93 -7.09 4.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 111.993 0.368 . . . . 0.45000000000000001 111.993 -174.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 25.2 p -167.5 164.25 14.85 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.701 0.286 . . . . 1.3200000000000001 111.273 -177.498 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 391' ' ' MET . . . . . 0.401 ' HE3' ' HB2' ' A' ' 391' ' ' MET . 39.6 ttm -158.74 147.55 18.66 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.053 -0.521 . . . . 0.56000000000000005 110.337 179.392 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 392' ' ' LYS . . . . . 0.479 ' NZ ' ' HB3' ' A' ' 392' ' ' LYS . 8.3 mtpm? . . . . . 0 C--O 1.248 0.993 0 CA-C-O 118.603 -0.713 . . . . 4.9100000000000001 109.961 177.633 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.765 0 N-CA-C 111.841 -0.504 . . . . 11.17 111.841 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -92.91 164.53 13.28 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 110.27 -0.27 . . . . 9.3699999999999992 110.27 177.667 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 278' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -103.38 156.03 18.04 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 110.054 -0.35 . . . . 7.6699999999999999 110.054 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -130.55 52.88 2.0 Allowed 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.017 0.437 . . . . 6.3700000000000001 110.99 -179.441 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.72 122.18 2.45 Favored Pre-proline 0 C--N 1.325 -0.46 0 CA-C-N 116.142 -0.481 . . . . 6.7599999999999998 110.618 177.62 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -64.79 113.84 2.51 Favored 'Trans proline' 0 C--O 1.233 0.248 0 C-N-CA 122.421 2.081 . . . . 4.7999999999999998 111.569 177.728 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 282' ' ' LYS . . . . . . . . . . . . . 4.4 mtpm? -87.07 97.18 10.59 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.762 -0.458 . . . . 3.46 109.762 -178.533 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 22.3 p -107.67 173.17 6.44 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.133 -0.485 . . . . 0.76000000000000001 111.711 -174.461 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 60.6 mttp -134.33 141.32 46.87 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.779 -0.646 . . . . 2.0600000000000001 109.676 175.562 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 39.3 tp -95.48 122.35 38.12 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 116.184 -0.462 . . . . 0.97999999999999998 111.04 -178.872 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.662 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 98.2 mt -96.35 -170.92 2.18 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.931 -0.577 . . . . 0.80000000000000004 110.599 176.945 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 287' ' ' GLU . . . . . 0.478 ' HG3' ' OH ' ' A' ' 366' ' ' TYR . 6.5 tp10 -52.86 145.21 12.98 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 115.901 -0.59 . . . . 2.6400000000000001 111.551 178.808 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.514 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 72.22 -101.61 1.07 Allowed Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.947 -0.57 . . . . 1.8400000000000001 111.736 -177.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . -148.15 25.57 1.42 Allowed Glycine 0 N--CA 1.444 -0.791 0 N-CA-C 110.214 -1.155 . . . . 0.64000000000000001 110.214 175.808 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 290' ' ' ILE . . . . . 0.662 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 73.1 mt -72.36 124.72 29.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.235 -0.482 . . . . 0.41999999999999998 110.446 -175.731 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.582 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 16.2 mt -107.28 139.39 29.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 116.201 -0.454 . . . . 0.93000000000000005 109.965 -177.217 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 292' ' ' ILE . . . . . . . . . . . . . 14.8 pt -128.06 127.53 67.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 121.176 0.512 . . . . 0.47999999999999998 110.797 177.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 293' ' ' GLU . . . . . 0.435 ' CD ' HH21 ' A' ' 359' ' ' ARG . 30.2 tt0 -114.65 118.26 33.17 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 114.929 -1.032 . . . . 2.3100000000000001 109.123 177.518 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -81.23 114.08 19.79 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.222 -0.591 . . . . 2.3599999999999999 110.06 -174.09 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 295' ' ' ARG . . . . . 0.561 ' HG2' ' HA ' ' A' ' 358' ' ' ARG . 20.3 mmm180 -86.45 -56.08 3.6 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.632 -0.713 . . . . 3.5 110.365 -174.242 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.569 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 96.7 t -124.0 125.01 70.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.908 -0.587 . . . . 0.69999999999999996 109.905 178.745 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 3.9 t -64.1 141.25 58.84 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.284 0.564 . . . . 1.9299999999999999 111.688 -177.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -150.78 142.11 9.28 Favored Glycine 0 N--CA 1.443 -0.89 0 N-CA-C 110.992 -0.843 . . . . 1.04 110.992 176.024 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 51.5 pttt -131.55 117.61 18.99 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.379 0.609 . . . . 4.4900000000000002 110.534 177.188 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -172.01 -154.43 10.03 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.335 -0.848 . . . . 1.04 111.063 -177.688 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 301' ' ' PRO . . . . . 0.463 ' O ' ' HA ' ' A' ' 353' ' ' ALA . 24.6 Cg_exo -62.66 133.53 42.77 Favored 'Trans proline' 0 N--CA 1.462 -0.34 0 C-N-CA 122.356 2.038 . . . . 0.88 111.404 176.282 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 35.9 m80 -95.12 130.15 41.94 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.308 -0.406 . . . . 1.49 110.45 178.474 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 303' ' ' ALA . . . . . 0.496 ' HB2' HG11 ' A' ' 309' ' ' VAL . . . -67.12 133.58 50.1 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.587 -0.733 . . . . 0.54000000000000004 111.434 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 64.4 pttt -132.2 179.13 6.29 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 108.762 -0.829 . . . . 2.8399999999999999 108.762 173.499 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 23.5 ttmm -66.33 135.62 54.63 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 120.587 -0.445 . . . . 2.8399999999999999 110.333 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 92.48 -7.04 77.97 Favored Glycine 0 CA--C 1.521 0.42 0 C-N-CA 121.078 -0.582 . . . . 0.69999999999999996 112.427 -174.774 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 30.3 m -88.97 150.03 23.01 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.716 0.293 . . . . 0.40000000000000002 110.842 -178.484 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 82.2 mtt180 -115.31 102.52 9.93 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 109.468 -0.567 . . . . 3.4500000000000002 109.468 -178.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.802 ' HB ' HD11 ' A' ' 388' ' ' LEU . 35.7 m -102.52 148.26 8.11 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.807 0 CA-C-N 115.592 -0.731 . . . . 0.34000000000000002 112.458 -175.384 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -113.37 118.24 4.46 Favored Glycine 0 N--CA 1.446 -0.69 0 N-CA-C 110.672 -0.971 . . . . 0.27000000000000002 110.672 176.554 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 311' ' ' MET . . . . . 0.5 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 6.8 ptm -139.48 178.49 7.18 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.788 0.804 . . . . 0.76000000000000001 112.434 -172.531 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 55.0 mtt180 -136.06 152.57 51.02 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 113.896 -1.502 . . . . 2.5099999999999998 107.68 176.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 313' ' ' TYR . . . . . 0.559 ' CB ' HG12 ' A' ' 386' ' ' VAL . 32.8 p90 -159.57 158.89 32.54 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 119.556 -0.858 . . . . 0.68000000000000005 113.276 -174.474 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 314' ' ' VAL . . . . . 0.572 HG12 ' HG3' ' A' ' 316' ' ' LYS . 57.9 t -127.02 102.99 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 CA-C-N 114.811 -1.086 . . . . 0.34999999999999998 109.355 171.071 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -87.13 110.32 3.54 Favored Glycine 0 C--O 1.237 0.336 0 N-CA-C 112.082 -0.407 . . . . 0.28000000000000003 112.082 -178.47 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 316' ' ' LYS . . . . . 0.757 ' HG2' ' HB ' ' A' ' 322' ' ' VAL . 33.2 mtmm -126.37 156.03 41.16 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.842 0.353 . . . . 1.9399999999999999 110.92 -174.794 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 317' ' ' LEU . . . . . 0.536 HD12 ' HB3' ' A' ' 321' ' ' LYS . 82.6 mt -81.73 173.33 12.41 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.821 -0.627 . . . . 0.65000000000000002 110.963 177.007 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 318' ' ' LYS . . . . . . . . . . . . . 60.3 tttp -65.26 -22.27 66.84 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.606 -0.724 . . . . 2.4199999999999999 110.674 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 32.6 p-10 -91.67 -1.36 57.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.411 -0.359 . . . . 2.2000000000000002 111.095 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 97.83 -5.31 61.77 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.927 -0.654 . . . . 0.68999999999999995 113.211 178.129 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 321' ' ' LYS . . . . . 0.536 ' HB3' HD12 ' A' ' 317' ' ' LEU . 14.4 tppt? -73.09 111.71 8.45 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.834 0.349 . . . . 2.4199999999999999 110.27 -179.767 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.757 ' HB ' ' HG2' ' A' ' 316' ' ' LYS . 5.4 p -81.4 124.33 38.77 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 116.178 -0.464 . . . . 1.26 110.425 179.034 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 50.4 p90 -102.36 -32.23 10.11 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.908 -0.317 . . . . 0.55000000000000004 111.323 -177.492 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -148.3 132.46 17.35 Favored 'General case' 0 CA--C 1.515 -0.38 0 N-CA-C 109.954 -0.387 . . . . 1.6799999999999999 109.954 -179.203 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 325' ' ' LYS . . . . . 0.414 ' HD3' HG21 ' A' ' 322' ' ' VAL . 59.3 pttt -153.97 134.7 13.67 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.907 0.384 . . . . 1.99 111.449 -174.824 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 326' ' ' ASN . . . . . 0.635 ' HB2' ' HB2' ' A' ' 330' ' ' LYS . 3.9 p30 -146.66 117.08 7.45 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.697 0.76 . . . . 1.9199999999999999 110.322 169.88 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 3.2 p -142.16 -40.83 0.35 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.909 -1.041 . . . . 1.6899999999999999 110.363 179.205 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 21.1 pttp -80.51 101.93 9.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.331 0.586 . . . . 2.5499999999999998 111.432 -178.731 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.514 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 76.04 -13.85 6.88 Favored Glycine 0 N--CA 1.452 -0.237 0 CA-C-N 115.616 -0.72 . . . . 0.96999999999999997 113.633 175.212 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 330' ' ' LYS . . . . . 0.635 ' HB2' ' HB2' ' A' ' 326' ' ' ASN . 27.4 mmmt -103.76 101.52 25.11 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 117.305 0.552 . . . . 2.0800000000000001 111.068 -178.025 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 331' ' ' PRO . . . . . 0.514 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 72.2 Cg_endo -87.83 126.59 2.14 Favored 'Trans proline' 0 N--CA 1.45 -1.042 0 C-N-CA 122.96 2.44 . . . . 0.62 111.826 172.647 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 65.4 t80 -100.04 118.89 37.37 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 110.092 -0.336 . . . . 0.64000000000000001 110.092 179.376 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 333' ' ' VAL . . . . . 0.472 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 61.6 t -119.32 114.82 45.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 N-CA-C 110.119 -0.326 . . . . 0.38 110.119 -178.734 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.5 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 14.1 p90 -131.64 159.38 38.48 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.958 0.409 . . . . 0.40999999999999998 110.201 -179.64 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 335' ' ' LYS . . . . . 0.462 ' HG3' ' HG3' ' A' ' 338' ' ' GLN . 18.2 pttm -99.72 128.92 45.81 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.902 -0.59 . . . . 2.5800000000000001 110.346 177.336 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 10.0 mp -64.54 117.53 7.5 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.484 -0.561 . . . . 0.57999999999999996 109.484 174.645 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 129.36 10.09 3.11 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.774 -0.727 . . . . 0.93999999999999995 111.699 -172.027 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 338' ' ' GLN . . . . . 0.652 ' HB3' ' HG2' ' A' ' 340' ' ' GLU . 91.8 mt-30 -84.35 141.93 30.53 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.962 0.411 . . . . 2.6200000000000001 110.62 176.111 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -96.11 -4.95 59.73 Favored Glycine 0 N--CA 1.448 -0.512 0 N-CA-C 110.857 -0.897 . . . . 0.73999999999999999 110.857 175.194 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 340' ' ' GLU . . . . . 0.652 ' HG2' ' HB3' ' A' ' 338' ' ' GLN . 5.5 pt-20 -84.18 -20.15 32.87 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.078 -0.561 . . . . 2.0899999999999999 110.984 179.21 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 33.4 m -94.06 154.92 3.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 109.524 -0.547 . . . . 0.42999999999999999 109.524 174.797 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 13.4 pt -74.86 154.25 6.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 N-CA-C 110.034 -0.358 . . . . 0.32000000000000001 110.034 179.24 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 343' ' ' LYS . . . . . 0.45 ' HE2' ' HA ' ' A' ' 343' ' ' LYS . 5.7 mmpt? -60.62 -30.69 70.01 Favored 'General case' 0 N--CA 1.464 0.258 0 N-CA-C 111.73 0.27 . . . . 2.9300000000000002 111.73 -174.72 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -55.55 -28.44 51.33 Favored Glycine 0 CA--C 1.521 0.437 0 C-N-CA 121.14 -0.553 . . . . 0.29999999999999999 112.884 174.387 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 8.4 m95 -82.26 -60.96 2.03 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 111.648 0.24 . . . . 0.39000000000000001 111.648 178.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -48.49 -35.73 13.69 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 120.923 0.392 . . . . 1.75 111.73 177.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 62.1 mt -88.51 -51.89 11.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.163 -0.471 . . . . 0.39000000000000001 111.756 179.139 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 348' ' ' GLY . . . . . 0.423 ' HA2' HD13 ' A' ' 286' ' ' LEU . . . -61.08 -36.34 92.17 Favored Glycine 0 C--N 1.331 0.301 0 C-N-CA 121.36 -0.448 . . . . 0.34000000000000002 113.73 -176.797 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 88.6 t -73.66 -23.2 19.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 121.182 0.515 . . . . 0.32000000000000001 110.775 -179.579 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -70.18 105.61 3.0 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.097 0.475 . . . . 0.46999999999999997 110.512 179.357 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 120.9 -2.78 11.81 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.864 -0.684 . . . . 0.39000000000000001 112.303 -176.794 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 352' ' ' MET . . . . . 0.451 ' HG2' ' HD2' ' A' ' 358' ' ' ARG . 69.1 mtp -82.13 144.41 30.77 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.905 0.353 . . . . 1.28 110.622 176.356 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 353' ' ' ALA . . . . . 0.463 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -108.57 147.99 30.97 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.879 -0.6 . . . . 0.55000000000000004 110.682 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 85.7 t -57.7 117.71 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 121.121 0.486 . . . . 0.35999999999999999 110.835 176.048 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 110.67 -27.15 11.58 Favored Glycine 0 N--CA 1.445 -0.752 0 N-CA-C 111.049 -0.82 . . . . 0.44 111.049 -176.761 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -73.99 139.21 25.76 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 121.3 -0.476 . . . . 0.29999999999999999 112.744 -177.162 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 357' ' ' GLU . . . . . 0.709 ' HB2' ' HG3' ' A' ' 387' ' ' LYS . 36.6 tt0 -125.0 133.87 52.82 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 109.063 -0.718 . . . . 1.4099999999999999 109.063 178.358 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 358' ' ' ARG . . . . . 0.561 ' HA ' ' HG2' ' A' ' 295' ' ' ARG . 8.0 ptp180 -155.44 143.89 20.31 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.66 0.743 . . . . 1.3700000000000001 112.294 -178.841 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 359' ' ' ARG . . . . . 0.435 HH21 ' CD ' ' A' ' 293' ' ' GLU . 20.9 ttp85 -86.25 117.95 25.39 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 114.773 -1.103 . . . . 2.79 109.485 177.813 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 50.3 mt -99.73 121.81 50.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.729 -0.669 . . . . 0.38 110.235 -178.31 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 361' ' ' VAL . . . . . 0.582 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 47.7 t -102.45 113.35 38.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 N-CA-C 109.15 -0.685 . . . . 0.39000000000000001 109.15 176.574 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 362' ' ' ILE . . . . . . . . . . . . . 62.1 mt -113.19 101.49 53.53 Favored Pre-proline 0 C--N 1.324 -0.514 0 CA-C-O 120.728 0.299 . . . . 0.28999999999999998 110.987 -175.096 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 363' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -56.43 159.9 12.36 Favored 'Trans proline' 0 C--O 1.237 0.463 0 C-N-CA 122.571 2.181 . . . . 0.66000000000000003 112.41 171.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 364' ' ' ALA . . . . . 0.546 ' HB2' ' HA ' ' A' ' 379' ' ' ASN . . . -47.72 -49.59 56.09 Favored Pre-proline 0 CA--C 1.539 0.547 0 N-CA-C 114.528 1.307 . . . . 0.41999999999999998 114.528 -173.348 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 365' ' ' PRO . . . . . 0.531 ' HD2' ' N ' ' A' ' 364' ' ' ALA . 9.6 Cg_endo -51.03 -32.18 37.81 Favored 'Trans proline' 0 C--N 1.361 1.2 0 C-N-CA 122.567 2.178 . . . . 0.69999999999999996 114.186 -172.832 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 366' ' ' TYR . . . . . 0.514 ' CE2' ' HA3' ' A' ' 288' ' ' GLY . 13.8 m-85 -100.52 12.13 37.97 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.831 -0.348 . . . . 0.68999999999999995 111.841 -175.466 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -127.06 -109.6 0.3 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.441 -0.345 . . . . 0.85999999999999999 110.907 174.799 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 78.8 m-85 -93.59 -15.83 25.0 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 111.977 0.362 . . . . 1.0 111.977 -179.723 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 64.82 -113.91 6.3 Favored Glycine 0 CA--C 1.52 0.388 0 C-N-CA 121.047 -0.597 . . . . 0.56000000000000005 113.691 175.627 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 65.6 mttm -92.1 3.91 54.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.751 0.31 . . . . 2.7599999999999998 111.525 -174.84 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -80.63 99.27 8.06 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.863 0.363 . . . . 2.6499999999999999 111.638 -177.334 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 372' ' ' ALA . . . . . . . . . . . . . . . -78.29 92.48 4.52 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 115.952 -0.567 . . . . 1.01 109.908 171.362 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 30.5 mt -84.0 159.28 60.33 Favored Pre-proline 0 C--N 1.316 -0.885 0 CA-C-N 115.636 -0.711 . . . . 0.93000000000000005 109.342 -179.686 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.55 113.0 1.43 Allowed 'Trans proline' 0 N--CA 1.461 -0.394 0 C-N-CA 121.507 1.472 . . . . 1.3100000000000001 110.684 173.742 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 96.81 -29.92 9.74 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.809 -0.71 . . . . 0.90000000000000002 112.533 -178.496 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 40.0 mt -125.95 88.94 53.38 Favored Pre-proline 0 C--N 1.332 -0.192 0 CA-C-N 116.772 0.286 . . . . 0.73999999999999999 110.279 -179.242 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 377' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_exo -69.58 166.52 27.09 Favored 'Trans proline' 0 N--CA 1.463 -0.3 0 C-N-CA 122.596 2.198 . . . . 0.70999999999999996 113.191 -178.355 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 378' ' ' ALA . . . . . . . . . . . . . . . -61.06 157.32 15.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.202 -0.908 . . . . 0.73999999999999999 111.985 -176.771 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 379' ' ' ASN . . . . . 0.546 ' HA ' ' HB2' ' A' ' 364' ' ' ALA . 18.6 m120 65.69 23.16 11.59 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-N 115.377 -0.828 . . . . 1.49 111.113 177.798 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 59.6 p -66.72 116.43 7.62 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.003 -0.544 . . . . 1.8400000000000001 111.134 179.501 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 381' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -80.37 98.55 7.52 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 108.971 -0.751 . . . . 1.03 108.971 174.541 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 92.6 mt -85.34 136.06 33.63 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.941 0.4 . . . . 0.37 111.248 -176.812 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 32.6 m -118.97 118.54 31.78 Favored 'General case' 0 N--CA 1.444 -0.734 0 N-CA-C 109.93 -0.396 . . . . 0.27000000000000002 109.93 177.824 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -113.16 109.39 18.7 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.867 -0.42 . . . . 0.32000000000000001 109.867 -177.204 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -87.39 104.88 16.85 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 108.034 -1.098 . . . . 1.8 108.034 176.636 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 386' ' ' VAL . . . . . 0.559 HG12 ' CB ' ' A' ' 313' ' ' TYR . 19.9 m -122.89 148.68 26.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 121.563 0.697 . . . . 0.31 112.382 -170.057 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 387' ' ' LYS . . . . . 0.709 ' HG3' ' HB2' ' A' ' 357' ' ' GLU . 46.5 tttm -137.39 129.91 29.83 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.402 -0.817 . . . . 2.5299999999999998 109.652 176.128 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 388' ' ' LEU . . . . . 0.802 HD11 ' HB ' ' A' ' 309' ' ' VAL . 24.6 tp -89.58 134.55 34.08 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.776 -0.824 . . . . 0.28000000000000003 108.776 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 27.5 m -129.36 -3.49 3.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 N-CA-C 112.251 0.463 . . . . 0.45000000000000001 112.251 -174.064 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 10.2 t -168.5 156.67 8.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.69 0.281 . . . . 1.3200000000000001 110.806 -177.506 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 391' ' ' MET . . . . . 0.499 ' HE2' HG12 ' A' ' 309' ' ' VAL . 40.5 ttm -156.33 155.26 31.93 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.229 -0.656 . . . . 0.56000000000000005 109.229 174.401 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 392' ' ' LYS . . . . . 0.42 ' HE2' ' HB2' ' A' ' 392' ' ' LYS . 3.4 ptmm? . . . . . 0 C--O 1.25 1.123 0 CA-C-O 118.654 -0.689 . . . . 4.9100000000000001 110.7 175.486 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.706 0 N-CA-C 112.105 -0.398 . . . . 11.17 112.105 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -145.91 104.63 3.87 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.979 0.419 . . . . 9.3699999999999992 110.879 -179.112 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 278' ' ' MET . . . . . 0.426 ' CE ' ' HA ' ' A' ' 278' ' ' MET . 3.2 tpt -155.2 98.33 1.99 Allowed 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.07 -0.514 . . . . 7.6699999999999999 109.993 176.501 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -142.39 100.63 3.74 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.095 -0.502 . . . . 6.3700000000000001 110.977 179.843 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 54.0 mttp 70.83 140.82 0.08 OUTLIER Pre-proline 0 CA--C 1.535 0.375 0 O-C-N 123.862 0.726 . . . . 6.7599999999999998 112.06 176.117 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -59.41 140.09 92.68 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 123.19 2.593 . . . . 4.7999999999999998 112.693 -178.539 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 282' ' ' LYS . . . . . . . . . . . . . 63.3 mttm -131.94 109.09 9.81 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.703 -0.68 . . . . 3.46 110.537 -179.388 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 15.2 p -106.72 165.6 11.19 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.908 -0.587 . . . . 0.76000000000000001 111.277 -178.884 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 284' ' ' LYS . . . . . 0.573 ' HB2' HG13 ' A' ' 292' ' ' ILE . 72.4 mmtt -130.12 135.94 48.76 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 109.213 -0.662 . . . . 2.0600000000000001 109.213 179.723 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 31.1 tp -104.78 124.16 48.93 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 120.896 0.379 . . . . 0.97999999999999998 110.138 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.786 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 76.7 mt -112.63 -175.21 2.62 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.578 -0.737 . . . . 0.80000000000000004 109.813 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 2.6 tp10 -60.61 147.37 42.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.148 0.499 . . . . 2.6400000000000001 111.336 -177.765 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.595 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 69.37 -1.77 12.17 Favored Glycine 0 N--CA 1.452 -0.297 0 CA-C-N 115.84 -0.618 . . . . 1.8400000000000001 113.648 -179.892 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 97.6 14.8 39.51 Favored Glycine 0 N--CA 1.446 -0.681 0 C-N-CA 120.21 -0.995 . . . . 0.64000000000000001 113.556 -179.274 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 290' ' ' ILE . . . . . 0.786 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 79.5 mt -64.16 122.57 15.31 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.167 0 CA-C-N 117.488 0.644 . . . . 0.41999999999999998 110.507 176.908 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.557 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 80.2 mt -107.36 138.27 34.3 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 N-CA-C 110.355 -0.239 . . . . 0.93000000000000005 110.355 177.08 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 292' ' ' ILE . . . . . 0.573 HG13 ' HB2' ' A' ' 284' ' ' LYS . 23.6 pt -127.02 130.85 71.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 N-CA-C 109.489 -0.56 . . . . 0.47999999999999998 109.489 174.34 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 293' ' ' GLU . . . . . 0.415 ' CD ' HH21 ' A' ' 359' ' ' ARG . 34.3 tt0 -123.43 121.42 35.69 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 115.176 -0.92 . . . . 2.3100000000000001 109.954 -177.139 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 51.9 m-20 -78.3 110.93 13.76 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.712 -0.477 . . . . 2.3599999999999999 109.712 -176.637 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 295' ' ' ARG . . . . . . . . . . . . . 39.1 ttt180 -88.14 -58.24 2.64 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.832 -0.622 . . . . 3.5 110.499 -175.176 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.601 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 58.1 t -128.24 141.36 46.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 110.203 -0.295 . . . . 0.69999999999999996 110.203 177.207 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 9.0 t -96.07 149.84 21.16 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.3 -0.409 . . . . 1.9299999999999999 111.033 -178.197 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -152.93 -164.64 12.65 Favored Glycine 0 C--N 1.331 0.261 0 C-N-CA 121.428 -0.415 . . . . 1.04 112.174 -177.19 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 299' ' ' LYS . . . . . 0.572 ' O ' ' HB1' ' A' ' 353' ' ' ALA . 62.0 tttp -72.78 139.54 47.15 Favored 'General case' 0 CA--C 1.52 -0.211 0 N-CA-C 108.595 -0.891 . . . . 4.4900000000000002 108.595 173.793 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -116.34 80.48 0.3 Allowed Glycine 0 N--CA 1.445 -0.756 0 C-N-CA 119.314 -1.422 . . . . 1.04 115.272 -170.838 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 301' ' ' PRO . . . . . 0.596 ' HD2' ' H ' ' A' ' 354' ' ' VAL . 8.2 Cg_exo -74.57 131.51 14.92 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.036 1.824 . . . . 0.88 108.145 159.9 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 302' ' ' HIS . . . . . 0.439 ' O ' ' HE3' ' A' ' 304' ' ' LYS . 27.4 m80 -85.91 107.35 17.67 Favored 'General case' 0 C--N 1.319 -0.731 0 C-N-CA 120.314 -0.554 . . . . 1.49 111.423 -169.093 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -66.33 109.08 2.55 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.703 -0.681 . . . . 0.54000000000000004 110.375 175.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 304' ' ' LYS . . . . . 0.439 ' HE3' ' O ' ' A' ' 302' ' ' HIS . 11.5 ptpt -127.47 -174.44 3.18 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 116.326 -0.397 . . . . 2.8399999999999999 110.161 -179.171 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.819 ' HG3' ' HA3' ' A' ' 337' ' ' GLY . 62.3 tttm -65.71 124.51 22.6 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.994 0.426 . . . . 2.8399999999999999 111.019 -175.251 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 97.14 -11.24 65.71 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 121.075 -0.583 . . . . 0.69999999999999996 112.81 -178.063 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 307' ' ' THR . . . . . 0.447 ' O ' ' HA ' ' A' ' 335' ' ' LYS . 28.4 m -82.92 142.8 31.16 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 122.881 -0.188 . . . . 0.40000000000000002 110.524 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 22.6 ptt180 -106.78 116.03 31.22 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 121.306 0.574 . . . . 3.4500000000000002 109.583 -178.234 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.783 ' HB ' HD11 ' A' ' 388' ' ' LEU . 31.1 m -113.69 147.8 17.0 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 115.644 -0.707 . . . . 0.34000000000000002 111.918 -177.397 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -116.67 114.19 2.97 Favored Glycine 0 N--CA 1.443 -0.896 0 N-CA-C 110.126 -1.19 . . . . 0.27000000000000002 110.126 174.897 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 311' ' ' MET . . . . . 0.478 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 6.9 ptm -131.65 177.68 7.33 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 121.897 0.856 . . . . 0.76000000000000001 112.488 -172.283 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -138.07 150.31 46.78 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 113.726 -1.579 . . . . 2.5099999999999998 107.794 177.924 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 313' ' ' TYR . . . . . 0.466 ' CB ' HG12 ' A' ' 386' ' ' VAL . 44.3 p90 -156.45 155.33 31.88 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 120.741 -0.384 . . . . 0.68000000000000005 111.375 -169.74 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 314' ' ' VAL . . . . . 0.565 HG11 ' HE3' ' A' ' 316' ' ' LYS . 38.2 t -120.46 105.71 17.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-N 115.587 -0.733 . . . . 0.34999999999999998 109.247 169.206 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -84.82 109.38 3.26 Favored Glycine 0 N--CA 1.445 -0.717 0 CA-C-N 116.088 -0.506 . . . . 0.28000000000000003 112.168 -178.653 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 316' ' ' LYS . . . . . 0.765 ' HG2' HG22 ' A' ' 322' ' ' VAL . 93.6 mttt -123.32 161.05 25.42 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-N 114.929 -0.636 . . . . 1.9399999999999999 110.464 -178.308 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 317' ' ' LEU . . . . . 0.493 HD12 ' HD3' ' A' ' 321' ' ' LYS . 83.6 mt -88.18 165.81 14.81 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 109.392 -0.596 . . . . 0.65000000000000002 109.392 170.899 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 318' ' ' LYS . . . . . 0.907 ' HD2' ' HB3' ' A' ' 381' ' ' GLU . 0.2 OUTLIER -61.15 -19.37 61.46 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.31 -0.405 . . . . 2.4199999999999999 111.633 179.844 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 319' ' ' ASN . . . . . 0.421 ' OD1' ' HB2' ' A' ' 317' ' ' LEU . 28.5 p-10 -90.41 -1.61 57.92 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 116.577 -0.283 . . . . 2.2000000000000002 111.146 -178.575 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 94.5 6.8 60.86 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.505 -0.855 . . . . 0.68999999999999995 113.11 177.836 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 321' ' ' LYS . . . . . 0.493 ' HD3' HD12 ' A' ' 317' ' ' LEU . 63.5 tttp -81.99 118.57 23.09 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.947 0.403 . . . . 2.4199999999999999 110.472 177.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.765 HG22 ' HG2' ' A' ' 316' ' ' LYS . 12.6 t -85.56 129.78 37.39 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 116.115 -0.493 . . . . 1.26 109.948 179.381 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 32.3 p90 -111.48 -43.57 3.66 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 120.528 -0.469 . . . . 0.55000000000000004 111.586 178.508 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -148.07 128.56 14.03 Favored 'General case' 0 CA--C 1.514 -0.431 0 C-N-CA 120.507 -0.477 . . . . 1.6799999999999999 110.958 -177.658 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 325' ' ' LYS . . . . . 0.553 ' HE3' HG11 ' A' ' 322' ' ' VAL . 8.4 pttp -145.75 128.31 16.08 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.092 0.472 . . . . 1.99 110.88 -179.05 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 55.6 m-80 -125.25 116.49 22.06 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.544 -0.753 . . . . 1.9199999999999999 109.055 173.605 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 26.3 m -157.0 -38.89 0.07 Allowed 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.675 -0.693 . . . . 1.6899999999999999 110.155 -177.202 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 29.6 mmmt -75.18 92.74 2.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.788 -0.642 . . . . 2.5499999999999998 110.372 179.589 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.454 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 75.1 -17.7 2.86 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 121.245 -0.502 . . . . 0.96999999999999997 113.606 177.491 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 82.4 mttt -103.37 103.26 34.26 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 117.001 0.401 . . . . 2.0800000000000001 111.571 -175.433 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 331' ' ' PRO . . . . . 0.454 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 98.3 Cg_endo -87.91 145.83 6.6 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 122.825 2.35 . . . . 0.62 112.167 171.698 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 72.3 t80 -111.15 119.51 39.2 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.364 -0.606 . . . . 0.64000000000000001 109.364 175.526 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 46.7 t -111.64 126.3 69.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 120.648 0.261 . . . . 0.38 110.842 -177.236 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.478 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 28.4 p90 -153.54 169.19 23.81 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.34 -0.391 . . . . 0.40999999999999998 110.2 178.415 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 335' ' ' LYS . . . . . 0.49 ' HE2' ' HB3' ' A' ' 338' ' ' GLN . 0.0 OUTLIER -112.77 146.22 39.18 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.152 0.501 . . . . 2.5800000000000001 111.418 177.201 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 10.9 mp -78.35 150.89 33.12 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.853 -0.612 . . . . 0.57999999999999996 110.262 177.661 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 337' ' ' GLY . . . . . 0.819 ' HA3' ' HG3' ' A' ' 305' ' ' LYS . . . 89.12 27.14 24.19 Favored Glycine 0 N--CA 1.445 -0.706 0 C-N-CA 120.739 -0.743 . . . . 0.93999999999999995 112.459 -177.409 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 338' ' ' GLN . . . . . 0.49 ' HB3' ' HE2' ' A' ' 335' ' ' LYS . 3.8 pt20 -118.97 163.06 17.5 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 110.085 -0.339 . . . . 2.6200000000000001 110.085 176.406 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -93.6 2.84 70.79 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.952 -0.642 . . . . 0.73999999999999999 112.329 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -76.43 -24.78 53.96 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.948 0.404 . . . . 2.0899999999999999 110.876 -178.914 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 31.0 m -108.74 152.66 10.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.241 -0.436 . . . . 0.42999999999999999 110.755 -178.734 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 342' ' ' ILE . . . . . 0.502 ' HB ' ' HA ' ' A' ' 367' ' ' ALA . 14.8 pt -70.52 156.24 7.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.858 -0.423 . . . . 0.32000000000000001 109.858 178.457 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -64.48 -32.61 74.32 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.626 -0.261 . . . . 2.9300000000000002 111.396 -175.386 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -53.41 -41.86 63.88 Favored Glycine 0 CA--C 1.523 0.561 0 C-N-CA 120.613 -0.803 . . . . 0.29999999999999999 112.16 173.462 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 7.8 m95 -70.51 -58.42 3.73 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.75 0.309 . . . . 0.39000000000000001 110.489 175.474 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -49.49 -32.27 11.78 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 115.877 -0.601 . . . . 1.75 112.355 -179.308 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 69.2 mt -89.17 -53.21 9.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.501 -0.318 . . . . 0.39000000000000001 111.789 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -64.32 -32.93 85.82 Favored Glycine 0 C--N 1.332 0.307 0 C-N-CA 121.189 -0.529 . . . . 0.34000000000000002 113.664 -177.709 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 89.8 t -78.44 -16.33 13.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.988 0.423 . . . . 0.32000000000000001 111.035 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.01 106.41 1.25 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.235 0.541 . . . . 0.46999999999999997 110.241 178.592 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 98.31 22.33 15.1 Favored Glycine 0 N--CA 1.444 -0.787 0 CA-C-N 115.6 -0.727 . . . . 0.39000000000000001 112.577 -178.234 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 352' ' ' MET . . . . . . . . . . . . . 64.1 mmm -69.22 173.38 5.73 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.562 0.22 . . . . 1.28 110.636 173.308 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 353' ' ' ALA . . . . . 0.572 ' HB1' ' O ' ' A' ' 299' ' ' LYS . . . -135.71 136.61 40.99 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.107 -0.497 . . . . 0.55000000000000004 111.05 -177.605 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 354' ' ' VAL . . . . . 0.596 ' H ' ' HD2' ' A' ' 301' ' ' PRO . 59.4 t -65.76 112.05 1.75 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.202 0 CA-C-O 121.436 0.636 . . . . 0.35999999999999999 109.923 174.856 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 104.56 -24.16 29.45 Favored Glycine 0 N--CA 1.439 -1.134 0 N-CA-C 110.134 -1.186 . . . . 0.44 110.134 -172.7 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -73.85 145.66 35.59 Favored Glycine 0 N--CA 1.444 -0.793 0 N-CA-C 112.04 -0.424 . . . . 0.29999999999999999 112.04 179.874 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 357' ' ' GLU . . . . . 0.724 ' HG3' ' HB2' ' A' ' 387' ' ' LYS . 34.0 tt0 -135.75 131.54 35.68 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 108.238 -1.023 . . . . 1.4099999999999999 108.238 -173.227 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 358' ' ' ARG . . . . . . . . . . . . . 2.1 ptp180 -154.86 148.22 25.06 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.369 0.604 . . . . 1.3700000000000001 112.495 -177.745 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 359' ' ' ARG . . . . . 0.415 HH21 ' CD ' ' A' ' 293' ' ' GLU . 14.8 ttp180 -89.21 114.76 26.11 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.377 -0.829 . . . . 2.79 109.817 176.502 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 65.4 mt -102.67 118.72 49.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 109.955 -0.387 . . . . 0.38 109.955 179.087 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 361' ' ' VAL . . . . . 0.557 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 41.8 t -101.19 111.15 29.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 109.209 -0.663 . . . . 0.39000000000000001 109.209 179.63 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 362' ' ' ILE . . . . . 0.482 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 60.4 mt -108.09 112.48 61.47 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-O 120.985 0.421 . . . . 0.28999999999999998 111.531 -171.402 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 363' ' ' PRO . . . . . 0.557 ' HD2' HG12 ' A' ' 290' ' ' ILE . 33.7 Cg_endo -64.19 155.34 65.73 Favored 'Trans proline' 0 C--O 1.235 0.356 0 C-N-CA 122.902 2.401 . . . . 0.66000000000000003 111.791 175.153 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 364' ' ' ALA . . . . . 0.424 ' CB ' ' HA ' ' A' ' 379' ' ' ASN . . . -51.16 -49.5 81.05 Favored Pre-proline 0 CA--C 1.541 0.598 0 N-CA-C 114.14 1.163 . . . . 0.41999999999999998 114.14 -174.775 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 365' ' ' PRO . . . . . 0.474 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 32.2 Cg_exo -59.0 -24.41 73.22 Favored 'Trans proline' 0 C--N 1.362 1.274 0 C-N-CA 122.176 1.917 . . . . 0.69999999999999996 113.671 -173.056 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 366' ' ' TYR . . . . . 0.595 ' CE2' ' HA3' ' A' ' 288' ' ' GLY . 5.4 m-85 -100.27 10.74 40.79 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.048 0.452 . . . . 0.68999999999999995 111.385 -176.707 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 367' ' ' ALA . . . . . 0.502 ' HA ' ' HB ' ' A' ' 342' ' ' ILE . . . -122.24 -106.04 0.37 Allowed 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.903 -0.59 . . . . 0.85999999999999999 110.406 174.191 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 368' ' ' TYR . . . . . 0.473 ' HB3' ' HB3' ' A' ' 371' ' ' GLN . 96.4 m-85 -92.42 -16.12 26.31 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.642 0.258 . . . . 1.0 111.52 178.38 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 68.53 -110.73 3.56 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.911 -0.661 . . . . 0.56000000000000005 112.669 178.525 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 370' ' ' LYS . . . . . 0.419 ' HA ' ' HB1' ' A' ' 378' ' ' ALA . 48.9 mtpt -101.27 10.18 40.96 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.766 0.317 . . . . 2.7599999999999998 111.174 -177.538 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 371' ' ' GLN . . . . . 0.473 ' HB3' ' HB3' ' A' ' 368' ' ' TYR . 64.5 tt0 -82.58 100.97 10.46 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 120.864 0.364 . . . . 2.6499999999999999 110.572 178.656 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 372' ' ' ALA . . . . . 0.605 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -78.84 107.9 11.89 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.264 -0.426 . . . . 1.01 111.295 178.602 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 83.6 mt -102.47 161.81 22.14 Favored Pre-proline 0 C--N 1.32 -0.691 0 N-CA-C 109.403 -0.592 . . . . 0.93000000000000005 109.403 174.764 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_endo -64.27 114.61 2.74 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 121.592 1.528 . . . . 1.3100000000000001 110.929 172.452 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 96.2 -28.58 12.41 Favored Glycine 0 CA--C 1.521 0.466 0 C-N-CA 120.89 -0.671 . . . . 0.90000000000000002 112.225 -176.665 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 376' ' ' ILE . . . . . 0.547 HG23 HD21 ' A' ' 382' ' ' LEU . 23.0 mt -130.74 77.62 75.27 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 120.701 0.286 . . . . 0.73999999999999999 110.303 179.137 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 377' ' ' PRO . . . . . 0.605 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 73.5 Cg_endo -77.77 167.86 23.26 Favored 'Trans proline' 0 N--CA 1.461 -0.395 0 C-N-CA 122.38 2.054 . . . . 0.70999999999999996 112.805 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 378' ' ' ALA . . . . . 0.419 ' HB1' ' HA ' ' A' ' 370' ' ' LYS . . . -53.07 143.2 18.11 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 116.055 -0.52 . . . . 0.73999999999999999 111.979 -179.72 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 379' ' ' ASN . . . . . 0.424 ' HA ' ' CB ' ' A' ' 364' ' ' ALA . 93.8 m-20 67.95 19.92 9.31 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 115.556 -0.747 . . . . 1.49 112.286 176.356 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 67.1 m -87.2 131.63 34.13 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.332 0.587 . . . . 1.8400000000000001 111.232 176.55 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 381' ' ' GLU . . . . . 0.907 ' HB3' ' HD2' ' A' ' 318' ' ' LYS . 34.1 tt0 -84.71 112.86 20.86 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.999 -1.0 . . . . 1.03 109.93 178.33 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 382' ' ' LEU . . . . . 0.547 HD21 HG23 ' A' ' 376' ' ' ILE . 91.5 mt -89.67 139.49 30.51 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.334 -0.394 . . . . 0.37 110.243 179.765 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 37.8 m -119.33 119.12 33.07 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.322 -0.621 . . . . 0.27000000000000002 109.322 176.553 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -115.13 109.88 18.68 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 121.124 0.488 . . . . 0.32000000000000001 110.444 -177.213 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -87.52 106.92 18.32 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 108.149 -1.056 . . . . 1.8 108.149 174.113 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 386' ' ' VAL . . . . . 0.466 HG12 ' CB ' ' A' ' 313' ' ' TYR . 29.6 m -122.9 148.37 26.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.621 0.724 . . . . 0.31 112.123 -168.873 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 387' ' ' LYS . . . . . 0.724 ' HB2' ' HG3' ' A' ' 357' ' ' GLU . 40.7 tttp -139.05 132.96 30.98 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.74 -1.118 . . . . 2.5299999999999998 109.317 175.222 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 388' ' ' LEU . . . . . 0.783 HD11 ' HB ' ' A' ' 309' ' ' VAL . 30.6 tp -91.98 131.62 37.14 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 108.666 -0.864 . . . . 0.28000000000000003 108.666 -179.178 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 28.9 m -120.01 -4.39 9.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 112.232 0.456 . . . . 0.45000000000000001 112.232 -173.893 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 11.3 t -170.51 152.06 3.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.968 0.413 . . . . 1.3200000000000001 111.154 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 391' ' ' MET . . . . . 0.62 ' HE2' HG12 ' A' ' 309' ' ' VAL . 31.6 ttm -157.25 147.47 20.94 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.747 -0.661 . . . . 0.56000000000000005 109.497 174.626 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 20.8 tptm . . . . . 0 C--O 1.248 0.992 0 CA-C-O 117.88 -1.057 . . . . 4.9100000000000001 111.438 173.471 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.764 0 N-CA-C 111.847 -0.501 . . . . 11.17 111.847 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -87.77 -10.16 51.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.48 0.181 . . . . 9.3699999999999992 111.371 -177.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 278' ' ' MET . . . . . 0.465 ' O ' ' HG3' ' A' ' 280' ' ' LYS . 45.2 mtm 69.06 -1.93 1.95 Allowed 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 123.14 0.576 . . . . 7.6699999999999999 111.357 178.173 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . 63.23 18.55 11.06 Favored 'General case' 0 N--CA 1.463 0.204 0 C-N-CA 123.097 0.559 . . . . 6.3700000000000001 111.302 -176.813 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 280' ' ' LYS . . . . . 0.465 ' HG3' ' O ' ' A' ' 278' ' ' MET . 28.1 mtpp -120.17 144.08 37.06 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 120.613 0.244 . . . . 6.7599999999999998 110.637 -177.036 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 281' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 280' ' ' LYS . 25.8 Cg_exo -63.38 155.42 62.23 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.978 2.452 . . . . 4.7999999999999998 113.286 -177.862 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 282' ' ' LYS . . . . . . . . . . . . . 58.6 mttm -96.11 107.31 19.6 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.807 -0.633 . . . . 3.46 111.001 -178.514 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.963 HG22 ' HG2' ' A' ' 293' ' ' GLU . 31.6 p -109.74 126.36 53.65 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 110.21 -0.292 . . . . 0.76000000000000001 110.21 173.226 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 284' ' ' LYS . . . . . 0.457 ' HB2' HG13 ' A' ' 292' ' ' ILE . 23.8 mmtp -122.03 146.99 46.64 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.94 0.4 . . . . 2.0600000000000001 111.115 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 40.3 tp -103.97 121.17 42.58 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.542 -0.754 . . . . 0.97999999999999998 110.242 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.565 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 94.9 mt -101.78 -169.5 1.69 Allowed 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.978 -0.555 . . . . 0.80000000000000004 110.407 178.048 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -68.37 146.58 53.12 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.702 -0.681 . . . . 2.6400000000000001 110.154 -179.651 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 73.71 10.63 80.23 Favored Glycine 0 CA--C 1.517 0.163 0 C-N-CA 121.102 -0.571 . . . . 1.8400000000000001 113.687 178.869 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 81.44 16.84 72.69 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.63 -0.795 . . . . 0.64000000000000001 112.596 178.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 290' ' ' ILE . . . . . 0.565 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 84.1 mt -69.64 125.76 28.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 N-CA-C 109.94 -0.393 . . . . 0.41999999999999998 109.94 177.82 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.68 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 20.1 mt -104.14 134.91 44.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 N-CA-C 109.286 -0.635 . . . . 0.93000000000000005 109.286 179.386 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 292' ' ' ILE . . . . . 0.457 HG13 ' HB2' ' A' ' 284' ' ' LYS . 18.2 pt -124.13 127.14 73.24 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 CA-C-O 121.112 0.482 . . . . 0.47999999999999998 110.172 177.873 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 293' ' ' GLU . . . . . 0.963 ' HG2' HG22 ' A' ' 283' ' ' THR . 29.4 mt-10 -117.94 114.35 23.07 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.499 -0.773 . . . . 2.3100000000000001 109.469 -179.812 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 294' ' ' ASP . . . . . 0.477 ' C ' ' HE ' ' A' ' 295' ' ' ARG . 8.2 t70 -80.15 135.09 36.22 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 109.255 -0.646 . . . . 2.3599999999999999 109.255 -175.383 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 295' ' ' ARG . . . . . 0.584 ' HG2' ' HA ' ' A' ' 358' ' ' ARG . 1.7 mmp_? -105.76 -60.3 1.65 Allowed 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 110.02 -0.363 . . . . 3.5 110.02 -175.175 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 296' ' ' VAL . . . . . . . . . . . . . 84.0 t -122.2 109.98 25.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 116.039 -0.528 . . . . 0.69999999999999996 109.594 174.486 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 18.1 p -61.93 109.24 1.2 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.522 -0.763 . . . . 1.9299999999999999 111.405 -177.392 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -101.2 171.38 22.32 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.669 -0.776 . . . . 1.04 112.033 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 8.0 tmtm? -145.69 110.58 5.18 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.297 -0.631 . . . . 4.4900000000000002 109.297 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -172.24 -154.25 9.96 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.78 -0.724 . . . . 1.04 111.713 -178.596 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 301' ' ' PRO . . . . . 0.731 ' HD2' ' HB ' ' A' ' 354' ' ' VAL . 24.0 Cg_exo -64.46 134.34 41.16 Favored 'Trans proline' 0 C--O 1.232 0.192 0 C-N-CA 123.129 2.553 . . . . 0.88 112.342 177.28 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 44.4 m-70 -98.32 132.25 43.95 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.317 -0.401 . . . . 1.49 110.048 179.632 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -81.3 143.26 32.37 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 112.487 0.551 . . . . 0.54000000000000004 112.487 -176.009 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -127.26 -178.85 4.6 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.657 -0.701 . . . . 2.8399999999999999 110.041 174.877 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.81 ' HG3' ' HA3' ' A' ' 337' ' ' GLY . 46.7 tttm -68.47 135.49 51.74 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.864 0.364 . . . . 2.8399999999999999 110.342 175.218 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 93.13 -17.83 57.46 Favored Glycine 0 N--CA 1.451 -0.318 0 CA-C-N 116.107 -0.497 . . . . 0.69999999999999996 112.257 -176.517 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 27.0 m -74.83 142.53 44.18 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.729 0.3 . . . . 0.40000000000000002 110.679 -179.236 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 22.0 mtm180 -104.61 103.73 13.44 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 109.04 -0.726 . . . . 3.4500000000000002 109.04 178.58 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.831 ' HB ' HD11 ' A' ' 388' ' ' LEU . 28.4 m -104.35 145.36 13.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 CA-C-N 116.011 -0.54 . . . . 0.34000000000000002 111.567 -177.569 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -111.51 120.68 5.5 Favored Glycine 0 N--CA 1.445 -0.739 0 N-CA-C 109.709 -1.356 . . . . 0.27000000000000002 109.709 176.405 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 311' ' ' MET . . . . . 0.543 ' CE ' ' HB ' ' A' ' 386' ' ' VAL . 22.0 ptm -136.44 176.79 8.38 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.591 0.71 . . . . 0.76000000000000001 112.309 -169.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 312' ' ' ARG . . . . . 0.539 ' HD2' ' HA ' ' A' ' 327' ' ' THR . 12.5 mmt-85 -127.57 151.09 49.34 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 107.303 -1.369 . . . . 2.5099999999999998 107.303 172.887 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 313' ' ' TYR . . . . . 0.474 ' CB ' HG12 ' A' ' 386' ' ' VAL . 51.3 p90 -167.04 158.53 12.39 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.326 0.584 . . . . 0.68000000000000005 111.953 -176.82 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 314' ' ' VAL . . . . . 0.445 HG12 ' HG3' ' A' ' 316' ' ' LYS . 42.6 t -123.15 112.32 33.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.124 -0.944 . . . . 0.34999999999999998 109.559 174.131 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -84.73 105.51 2.86 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 121.073 -0.585 . . . . 0.28000000000000003 111.942 -177.661 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 316' ' ' LYS . . . . . 0.504 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 45.8 mtmt -119.31 154.35 33.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.143 0.497 . . . . 1.9399999999999999 111.681 -176.225 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 78.3 mt -91.15 160.56 15.5 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.811 -0.631 . . . . 0.65000000000000002 109.97 176.152 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 318' ' ' LYS . . . . . 0.665 ' HD2' ' HB3' ' A' ' 381' ' ' GLU . 85.3 tttt -62.4 -18.45 61.64 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-O 121.345 0.593 . . . . 2.4199999999999999 110.138 175.603 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -79.61 -2.03 40.72 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 115.566 -0.743 . . . . 2.2000000000000002 110.788 179.623 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 89.96 -2.91 82.44 Favored Glycine 0 C--N 1.329 0.178 0 C-N-CA 120.648 -0.787 . . . . 0.68999999999999995 112.795 177.364 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -93.83 128.37 40.06 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.691 0.281 . . . . 2.4199999999999999 110.587 -179.073 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.504 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 7.1 p -85.41 136.64 22.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 116.249 -0.432 . . . . 1.26 110.277 177.144 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 42.5 p90 -108.24 -35.67 6.49 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 120.791 -0.364 . . . . 0.55000000000000004 111.36 -179.558 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -147.05 162.28 39.12 Favored 'General case' 0 N--CA 1.464 0.261 0 C-N-CA 120.976 -0.289 . . . . 1.6799999999999999 110.569 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 3.7 ptpp? -164.55 138.72 5.29 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.76 0.314 . . . . 1.99 111.323 -177.136 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 55.0 m-80 -140.58 117.12 10.82 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 108.798 -0.815 . . . . 1.9199999999999999 108.798 173.56 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 327' ' ' THR . . . . . 0.539 ' HA ' ' HD2' ' A' ' 312' ' ' ARG . 5.2 t -160.73 -49.44 0.05 OUTLIER 'General case' 0 C--N 1.324 -0.5 0 C-N-CA 120.859 -0.337 . . . . 1.6899999999999999 111.726 -177.16 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 19.9 pttp -94.77 104.94 16.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.364 0.602 . . . . 2.5499999999999998 110.839 -178.218 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.421 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 87.94 -29.61 5.42 Favored Glycine 0 N--CA 1.45 -0.394 0 CA-C-N 115.409 -0.814 . . . . 0.96999999999999997 112.756 177.49 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 92.3 mttt -102.09 106.49 48.2 Favored Pre-proline 0 C--N 1.326 -0.428 0 CA-C-O 120.735 0.302 . . . . 2.0800000000000001 111.335 -176.791 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 331' ' ' PRO . . . . . 0.421 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 80.3 Cg_endo -87.31 125.72 2.21 Favored 'Trans proline' 0 N--CA 1.448 -1.167 0 C-N-CA 122.765 2.31 . . . . 0.62 111.405 173.126 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 64.7 t80 -103.66 114.36 28.56 Favored 'General case' 0 C--N 1.318 -0.777 0 C-N-CA 120.677 -0.409 . . . . 0.64000000000000001 110.002 179.43 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 333' ' ' VAL . . . . . 0.468 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 58.4 t -115.86 122.61 69.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.767 -0.651 . . . . 0.38 109.868 -178.57 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.466 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 13.2 p90 -138.19 165.87 25.6 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.945 0.403 . . . . 0.40999999999999998 110.229 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 335' ' ' LYS . . . . . 0.548 ' HG3' ' HG3' ' A' ' 338' ' ' GLN . 21.4 pttm -110.08 129.44 55.69 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.977 -0.556 . . . . 2.5800000000000001 110.608 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 9.6 mp -72.44 146.52 46.87 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.849 -0.614 . . . . 0.57999999999999996 111.732 -178.704 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 337' ' ' GLY . . . . . 0.81 ' HA3' ' HG3' ' A' ' 305' ' ' LYS . . . 88.44 25.05 31.75 Favored Glycine 0 N--CA 1.447 -0.614 0 CA-C-N 115.632 -0.713 . . . . 0.93999999999999995 112.769 170.614 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 338' ' ' GLN . . . . . 0.548 ' HG3' ' HG3' ' A' ' 335' ' ' LYS . 48.3 mm-40 -123.09 149.47 44.41 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.732 -0.47 . . . . 2.6200000000000001 109.732 -179.458 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -78.49 43.3 2.31 Favored Glycine 0 CA--C 1.518 0.279 0 C-N-CA 120.875 -0.678 . . . . 0.73999999999999999 112.786 178.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 340' ' ' GLU . . . . . 0.516 ' HG2' ' HB2' ' A' ' 338' ' ' GLN . 10.4 pt-20 -122.29 -3.21 8.97 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.153 0.502 . . . . 2.0899999999999999 110.087 175.647 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 23.9 m -128.49 166.51 25.63 Favored 'Isoleucine or valine' 0 C--O 1.233 0.229 0 CA-C-N 115.47 -0.787 . . . . 0.42999999999999999 109.057 174.335 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 342' ' ' ILE . . . . . 0.739 ' HB ' ' HA ' ' A' ' 367' ' ' ALA . 14.0 pt -82.63 154.35 3.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.325 -0.62 . . . . 0.32000000000000001 109.325 176.397 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 343' ' ' LYS . . . . . 0.424 ' HA ' ' OD2' ' A' ' 346' ' ' ASP . 6.9 mtmm -65.93 -31.39 72.29 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 111.78 0.289 . . . . 2.9300000000000002 111.78 -172.355 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 344' ' ' GLY . . . . . 0.548 ' HA2' HD13 ' A' ' 290' ' ' ILE . . . -54.39 -32.0 51.63 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.69 -0.766 . . . . 0.29999999999999999 111.851 173.031 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 7.2 m95 -76.03 -55.63 5.42 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 111.847 0.314 . . . . 0.39000000000000001 111.847 177.367 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 346' ' ' ASP . . . . . 0.424 ' OD2' ' HA ' ' A' ' 343' ' ' LYS . 0.1 OUTLIER -64.75 -24.32 67.53 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 122.186 -0.321 . . . . 1.75 111.603 -174.844 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 56.8 mt -89.8 -49.4 13.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.631 -0.259 . . . . 0.39000000000000001 111.029 176.546 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -61.49 -36.57 92.76 Favored Glycine 0 CA--C 1.52 0.387 0 C-N-CA 120.982 -0.628 . . . . 0.34000000000000002 113.171 179.345 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 349' ' ' VAL . . . . . 0.489 ' O ' ' HB2' ' A' ' 352' ' ' MET . 95.4 t -78.79 -14.16 13.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.115 0.484 . . . . 0.32000000000000001 110.934 178.602 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -69.87 120.56 15.78 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 109.471 -0.566 . . . . 0.46999999999999997 109.471 176.242 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 85.45 14.05 69.25 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.865 -0.684 . . . . 0.39000000000000001 112.023 -176.591 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 352' ' ' MET . . . . . 0.489 ' HB2' ' O ' ' A' ' 349' ' ' VAL . 0.0 OUTLIER -81.01 137.0 36.07 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 108.867 -0.79 . . . . 1.28 108.867 176.442 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 353' ' ' ALA . . . . . 0.453 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -109.28 130.56 55.49 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.982 0.42 . . . . 0.55000000000000004 111.097 -174.882 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 354' ' ' VAL . . . . . 0.731 ' HB ' ' HD2' ' A' ' 301' ' ' PRO . 95.8 t -54.23 121.03 2.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.906 -0.588 . . . . 0.35999999999999999 111.306 176.686 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 107.52 -8.73 37.74 Favored Glycine 0 N--CA 1.444 -0.797 0 CA-C-N 115.73 -0.668 . . . . 0.44 112.152 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -100.97 154.9 19.22 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.836 -0.697 . . . . 0.29999999999999999 112.571 -178.417 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 357' ' ' GLU . . . . . 0.667 ' HG2' ' HD2' ' A' ' 387' ' ' LYS . 54.0 mt-10 -122.5 130.76 53.39 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.443 -0.577 . . . . 1.4099999999999999 109.443 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 358' ' ' ARG . . . . . 0.584 ' HA ' ' HG2' ' A' ' 295' ' ' ARG . 4.1 ptp180 -156.06 142.24 18.29 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.232 0.539 . . . . 1.3700000000000001 111.094 176.522 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 359' ' ' ARG . . . . . . . . . . . . . 53.9 ttp180 -93.31 133.63 36.35 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.508 -0.769 . . . . 2.79 109.82 -178.86 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 38.8 mt -110.16 119.86 60.01 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-N 116.168 -0.469 . . . . 0.38 110.24 -179.418 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 361' ' ' VAL . . . . . 0.68 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 45.6 t -98.87 112.76 31.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 108.616 -0.883 . . . . 0.39000000000000001 108.616 176.316 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 362' ' ' ILE . . . . . 0.449 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 54.4 mt -112.83 108.0 54.07 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-O 120.7 0.286 . . . . 0.28999999999999998 111.441 -172.127 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 363' ' ' PRO . . . . . 0.631 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 19.4 Cg_endo -59.36 152.09 63.36 Favored 'Trans proline' 0 C--O 1.235 0.35 0 C-N-CA 122.564 2.176 . . . . 0.66000000000000003 111.771 170.798 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 364' ' ' ALA . . . . . . . . . . . . . . . -48.43 -46.8 69.47 Favored Pre-proline 0 CA--C 1.544 0.718 0 N-CA-C 114.077 1.14 . . . . 0.41999999999999998 114.077 -176.544 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 365' ' ' PRO . . . . . 0.631 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 83.7 Cg_exo -49.24 -36.55 37.5 Favored 'Trans proline' 0 C--N 1.361 1.19 0 C-N-CA 122.687 2.258 . . . . 0.69999999999999996 114.068 -177.134 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 366' ' ' TYR . . . . . 0.471 ' HD1' HD11 ' A' ' 290' ' ' ILE . 2.9 m-85 -101.4 8.5 42.18 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.797 -0.361 . . . . 0.68999999999999995 111.158 -176.913 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 367' ' ' ALA . . . . . 0.739 ' HA ' ' HB ' ' A' ' 342' ' ' ILE . . . -110.76 -119.3 0.29 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.162 -0.472 . . . . 0.85999999999999999 109.973 175.107 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 82.6 m-85 -86.92 5.9 34.69 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 121.081 0.467 . . . . 1.0 111.238 178.245 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 67.05 -109.06 2.7 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.909 -0.587 . . . . 0.56000000000000005 112.352 176.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 20.3 pttm -120.71 15.58 11.86 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.774 0.321 . . . . 2.7599999999999998 110.963 -178.823 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 56.3 tp60 -83.18 106.99 15.43 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.947 0.403 . . . . 2.6499999999999999 110.149 178.267 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 372' ' ' ALA . . . . . 0.555 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -75.38 102.03 4.98 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 116.034 -0.53 . . . . 1.01 110.918 179.606 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 76.5 mt -88.9 163.83 33.55 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.706 -0.679 . . . . 0.93000000000000005 109.254 177.35 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -61.77 113.98 2.07 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 121.594 1.529 . . . . 1.3100000000000001 110.69 173.283 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 93.39 -26.66 14.53 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.83 -0.7 . . . . 0.90000000000000002 112.754 -177.881 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 376' ' ' ILE . . . . . 0.448 HG23 HD21 ' A' ' 382' ' ' LEU . 39.6 mt -126.5 81.92 67.29 Favored Pre-proline 0 CA--C 1.532 0.288 0 CA-C-O 120.86 0.362 . . . . 0.73999999999999999 110.978 -178.887 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 377' ' ' PRO . . . . . 0.555 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 56.1 Cg_endo -76.77 167.58 25.09 Favored 'Trans proline' 0 N--CA 1.459 -0.537 0 C-N-CA 122.413 2.075 . . . . 0.70999999999999996 112.457 178.126 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 378' ' ' ALA . . . . . . . . . . . . . . . -54.51 145.89 17.51 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.804 -0.635 . . . . 0.73999999999999999 111.488 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 379' ' ' ASN . . . . . . . . . . . . . 52.5 m-80 73.05 14.25 4.73 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 115.747 -0.661 . . . . 1.49 112.147 176.613 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 66.5 m -78.97 115.03 18.4 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.258 0.551 . . . . 1.8400000000000001 110.45 175.645 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 381' ' ' GLU . . . . . 0.665 ' HB3' ' HD2' ' A' ' 318' ' ' LYS . 33.0 tt0 -74.33 101.47 4.07 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.421 -0.809 . . . . 1.03 108.865 177.38 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 382' ' ' LEU . . . . . 0.448 HD21 HG23 ' A' ' 376' ' ' ILE . 79.4 mt -85.47 142.07 29.48 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 120.714 0.293 . . . . 0.37 110.897 -174.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 18.8 m -121.89 117.22 25.94 Favored 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 109.732 -0.47 . . . . 0.27000000000000002 109.732 178.706 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 384' ' ' PHE . . . . . 0.415 ' CD2' HD12 ' A' ' 362' ' ' ILE . 82.5 m-85 -112.67 109.94 19.77 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 121.094 0.474 . . . . 0.32000000000000001 110.067 -176.81 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -88.5 105.13 17.42 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 108.667 -0.864 . . . . 1.8 108.667 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 386' ' ' VAL . . . . . 0.543 ' HB ' ' CE ' ' A' ' 311' ' ' MET . 12.3 m -124.8 152.07 30.77 Favored 'Isoleucine or valine' 0 C--O 1.235 0.341 0 CA-C-O 121.756 0.788 . . . . 0.31 112.832 -167.208 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 387' ' ' LYS . . . . . 0.667 ' HD2' ' HG2' ' A' ' 357' ' ' GLU . 71.6 tttt -143.7 136.38 27.27 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.1 -0.955 . . . . 2.5299999999999998 109.583 174.541 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 388' ' ' LEU . . . . . 0.831 HD11 ' HB ' ' A' ' 309' ' ' VAL . 30.7 tp -95.94 131.2 42.55 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.729 -0.471 . . . . 0.28000000000000003 109.729 -177.487 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 32.9 m -122.16 -8.96 8.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 N-CA-C 112.226 0.454 . . . . 0.45000000000000001 112.226 -174.202 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 13.9 p -166.94 161.18 14.91 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.003 0.43 . . . . 1.3200000000000001 111.852 -176.013 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 391' ' ' MET . . . . . 0.587 ' HG2' ' HG2' ' A' ' 392' ' ' LYS . 29.9 ttm -151.51 143.37 23.79 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.403 -0.817 . . . . 0.56000000000000005 109.428 176.678 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 392' ' ' LYS . . . . . 0.587 ' HG2' ' HG2' ' A' ' 391' ' ' MET . 19.4 pttp . . . . . 0 C--O 1.248 0.989 0 CA-C-O 117.888 -1.054 . . . . 4.9100000000000001 112.369 179.19 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.873 0 N-CA-C 112.08 -0.408 . . . . 11.17 112.08 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . 57.46 87.14 0.07 Allowed 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 122.996 0.518 . . . . 9.3699999999999992 111.62 -178.624 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 278' ' ' MET . . . . . . . . . . . . . 23.4 ptm -78.8 131.54 36.54 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.203 -0.453 . . . . 7.6699999999999999 110.795 -176.233 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -110.46 118.29 35.88 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.184 -0.462 . . . . 6.3700000000000001 110.232 176.251 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 40.8 ttmt 69.65 90.94 0.08 OUTLIER Pre-proline 0 C--O 1.237 0.435 0 O-C-N 123.728 0.642 . . . . 6.7599999999999998 110.579 -179.774 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -64.61 136.05 48.21 Favored 'Trans proline' 0 C--N 1.349 0.557 0 C-N-CA 123.124 2.549 . . . . 4.7999999999999998 112.274 -178.452 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 282' ' ' LYS . . . . . . . . . . . . . 39.8 mmtm -93.89 80.38 4.16 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.054 0.454 . . . . 3.46 110.465 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.432 HG22 ' HB3' ' A' ' 293' ' ' GLU . 17.9 p -93.71 132.53 37.97 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 115.703 -0.68 . . . . 0.76000000000000001 111.081 -179.765 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 15.1 ptpt -140.68 146.18 37.51 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.2 -0.455 . . . . 2.0600000000000001 110.959 176.527 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 285' ' ' LEU . . . . . 0.54 HD11 ' HA2' ' A' ' 289' ' ' GLY . 22.1 tp -89.5 129.41 35.99 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.294 -0.866 . . . . 0.97999999999999998 111.292 -175.823 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.545 HD11 HD13 ' A' ' 292' ' ' ILE . 81.7 mt -105.62 -166.71 1.24 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.975 -0.557 . . . . 0.80000000000000004 110.284 175.854 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 287' ' ' GLU . . . . . 0.526 ' HG3' ' OH ' ' A' ' 366' ' ' TYR . 8.2 tp10 -51.11 142.0 13.23 Favored 'General case' 0 C--O 1.234 0.28 0 O-C-N 123.706 0.629 . . . . 2.6400000000000001 111.557 -179.832 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 72.67 -99.63 0.93 Allowed Glycine 0 N--CA 1.446 -0.682 0 CA-C-N 115.551 -0.75 . . . . 1.8400000000000001 111.37 -174.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 289' ' ' GLY . . . . . 0.54 ' HA2' HD11 ' A' ' 285' ' ' LEU . . . -153.77 32.91 0.75 Allowed Glycine 0 N--CA 1.443 -0.837 0 N-CA-C 110.428 -1.069 . . . . 0.64000000000000001 110.428 174.138 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 290' ' ' ILE . . . . . 0.511 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 76.9 mt -74.77 124.41 32.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.564 -0.318 . . . . 0.41999999999999998 110.394 -176.14 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.619 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 7.8 mt -104.24 136.45 37.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 N-CA-C 109.651 -0.5 . . . . 0.93000000000000005 109.651 -179.591 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 292' ' ' ILE . . . . . 0.545 HD13 HD11 ' A' ' 286' ' ' LEU . 33.5 pt -133.37 137.28 53.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 120.699 -0.4 . . . . 0.47999999999999998 111.07 179.481 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 293' ' ' GLU . . . . . 0.601 ' CG ' ' HB3' ' A' ' 359' ' ' ARG . 12.1 pt-20 -139.74 143.3 36.92 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.231 -0.895 . . . . 2.3100000000000001 109.709 178.336 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -94.0 139.86 30.42 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 120.996 0.427 . . . . 2.3599999999999999 111.035 179.548 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 295' ' ' ARG . . . . . 0.404 HH11 ' HD2' ' A' ' 295' ' ' ARG . 11.3 mmt85 -114.7 -47.11 2.91 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.569 -0.741 . . . . 3.5 111.414 -174.55 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.57 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 97.6 t -120.9 132.55 70.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.392 -0.367 . . . . 0.69999999999999996 110.414 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 10.3 p -63.5 137.8 58.27 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.845 -0.616 . . . . 1.9299999999999999 112.05 -176.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -165.35 132.77 2.76 Favored Glycine 0 N--CA 1.446 -0.659 0 CA-C-N 115.781 -0.645 . . . . 1.04 111.815 179.294 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 11.1 ptpp? -133.44 116.49 16.07 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.255 0.55 . . . . 4.4900000000000002 109.905 176.909 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -171.55 -154.1 9.6 Favored Glycine 0 N--CA 1.442 -0.918 0 N-CA-C 111.193 -0.763 . . . . 1.04 111.193 -177.232 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 301' ' ' PRO . . . . . 0.441 ' O ' ' HA ' ' A' ' 353' ' ' ALA . 26.2 Cg_exo -61.66 133.01 43.01 Favored 'Trans proline' 0 C--O 1.237 0.443 0 C-N-CA 122.625 2.217 . . . . 0.88 111.472 178.233 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 25.0 m80 -101.47 133.48 46.06 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.247 -0.433 . . . . 1.49 111.298 -177.524 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -64.76 126.5 28.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.503 -0.772 . . . . 0.54000000000000004 111.179 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 38.2 ttpt -136.4 169.77 17.13 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.2 -0.667 . . . . 2.8399999999999999 109.2 -177.225 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 57.0 tttp -63.07 128.2 34.77 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.912 0.386 . . . . 2.8399999999999999 110.18 177.051 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 97.6 -4.91 62.0 Favored Glycine 0 N--CA 1.451 -0.347 0 CA-C-N 115.935 -0.575 . . . . 0.69999999999999996 111.84 -176.756 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 27.4 m -93.74 146.32 23.94 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.708 0.29 . . . . 0.40000000000000002 110.994 -179.363 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 308' ' ' ARG . . . . . 0.504 ' HG2' ' HB3' ' A' ' 335' ' ' LYS . 54.6 mtm180 -110.65 104.12 12.77 Favored 'General case' 0 CA--C 1.516 -0.349 0 N-CA-C 109.346 -0.612 . . . . 3.4500000000000002 109.346 177.822 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.792 ' HB ' HD11 ' A' ' 388' ' ' LEU . 31.5 m -102.65 147.01 9.73 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 CA-C-O 121.349 0.595 . . . . 0.34000000000000002 111.944 -173.457 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -118.02 117.21 3.67 Favored Glycine 0 N--CA 1.446 -0.678 0 N-CA-C 109.669 -1.372 . . . . 0.27000000000000002 109.669 176.068 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 311' ' ' MET . . . . . 0.457 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 21.4 ptm -135.23 177.02 8.14 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.577 0.703 . . . . 0.76000000000000001 112.729 -169.133 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 64.4 mtt180 -134.47 147.63 50.42 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 107.332 -1.359 . . . . 2.5099999999999998 107.332 176.496 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 313' ' ' TYR . . . . . 0.697 ' HB2' HG12 ' A' ' 386' ' ' VAL . 48.6 p90 -164.29 157.92 18.25 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 112.878 0.696 . . . . 0.68000000000000005 112.878 -172.54 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 62.0 t -125.45 116.18 45.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 114.818 -1.083 . . . . 0.34999999999999998 109.44 174.411 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -101.43 116.85 5.67 Favored Glycine 0 C--O 1.24 0.475 0 C-N-CA 120.912 -0.661 . . . . 0.28000000000000003 112.213 -177.587 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 316' ' ' LYS . . . . . 0.536 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 98.3 mttt -119.41 162.42 18.85 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.372 0.606 . . . . 1.9399999999999999 111.058 -178.01 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 63.2 mt -88.04 167.13 13.95 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.02 -0.991 . . . . 0.65000000000000002 109.301 173.389 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 318' ' ' LYS . . . . . 0.52 ' HD3' ' H ' ' A' ' 381' ' ' GLU . 19.3 pttp -66.51 -8.84 29.16 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.38 0.609 . . . . 2.4199999999999999 110.299 175.379 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 13.2 t-20 -86.22 -6.94 58.88 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.678 -0.692 . . . . 2.2000000000000002 110.302 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 96.47 -12.92 66.13 Favored Glycine 0 N--CA 1.451 -0.303 0 CA-C-N 115.833 -0.621 . . . . 0.68999999999999995 112.557 178.553 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 14.4 mmmm -82.94 132.04 35.17 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.681 0.277 . . . . 2.4199999999999999 110.903 -177.825 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.536 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 5.6 p -84.07 134.06 27.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 116.097 -0.501 . . . . 1.26 109.892 177.182 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 34.4 p90 -105.5 -31.73 8.85 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 120.843 -0.343 . . . . 0.55000000000000004 111.424 179.556 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -148.67 151.83 35.62 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 110.062 -0.347 . . . . 1.6799999999999999 110.062 178.274 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 325' ' ' LYS . . . . . 0.599 ' HD3' ' N ' ' A' ' 325' ' ' LYS . 0.0 OUTLIER -160.19 135.24 7.89 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.96 0.41 . . . . 1.99 110.11 -177.908 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 49.0 m-80 -138.51 118.19 13.1 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.512 -0.551 . . . . 1.9199999999999999 109.512 179.415 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 6.6 t -162.26 -43.49 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.576 -0.284 . . . . 1.6899999999999999 110.965 -178.601 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.406 ' O ' ' HG3' ' A' ' 328' ' ' LYS . 6.9 ptpp? -99.51 120.64 39.96 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.862 -0.421 . . . . 2.5499999999999998 109.862 177.167 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.424 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 79.13 -37.18 1.96 Allowed Glycine 0 CA--C 1.52 0.367 0 C-N-CA 121.139 -0.553 . . . . 0.96999999999999997 113.034 178.02 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 32.7 mmtp -103.64 100.58 19.86 Favored Pre-proline 0 C--N 1.33 -0.28 0 N-CA-C 111.801 0.297 . . . . 2.0800000000000001 111.801 -178.906 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 331' ' ' PRO . . . . . 0.424 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 92.4 Cg_endo -87.54 127.4 2.36 Favored 'Trans proline' 0 N--CA 1.45 -1.032 0 C-N-CA 122.456 2.104 . . . . 0.62 110.775 168.144 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 82.9 t80 -102.03 117.63 35.2 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.57 -0.452 . . . . 0.64000000000000001 110.408 -178.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 87.5 t -114.61 122.5 68.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.828 -0.624 . . . . 0.38 110.076 179.343 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.457 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 14.1 p90 -138.49 155.77 48.13 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.713 -0.477 . . . . 0.40999999999999998 109.713 175.325 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 335' ' ' LYS . . . . . 0.504 ' HB3' ' HG2' ' A' ' 308' ' ' ARG . 0.0 OUTLIER -108.99 135.17 50.6 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.306 -0.407 . . . . 2.5800000000000001 111.117 179.861 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 9.5 mp -77.83 110.74 12.98 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.662 -0.699 . . . . 0.57999999999999996 109.471 179.643 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 177.92 -62.72 0.09 OUTLIER Glycine 0 N--CA 1.444 -0.777 0 C-N-CA 120.71 -0.757 . . . . 0.93999999999999995 111.594 -178.271 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 338' ' ' GLN . . . . . . . . . . . . . 20.8 pt20 -96.56 153.13 18.02 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.055 0.455 . . . . 2.6200000000000001 110.598 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -88.84 59.74 3.94 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 121.022 -0.609 . . . . 0.73999999999999999 112.372 -174.785 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 21.8 pt-20 -87.83 -20.82 25.54 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.522 0.677 . . . . 2.0899999999999999 109.62 174.217 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 22.1 m -95.81 167.76 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.084 -0.962 . . . . 0.42999999999999999 108.999 174.129 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 342' ' ' ILE . . . . . 0.598 ' HB ' ' HA ' ' A' ' 367' ' ' ALA . 22.1 pt -71.74 147.49 10.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 N-CA-C 109.13 -0.693 . . . . 0.32000000000000001 109.13 174.168 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 1.3 mtmt -49.92 -40.44 43.33 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 112.724 0.639 . . . . 2.9300000000000002 112.724 -171.718 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -55.64 -25.31 42.79 Favored Glycine 0 CA--C 1.524 0.623 0 C-N-CA 121.333 -0.46 . . . . 0.29999999999999999 113.825 179.014 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 8.2 m95 -74.77 -59.31 2.79 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.915 0.358 . . . . 0.39000000000000001 111.848 -179.501 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -49.68 -36.99 26.95 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-O 121.082 0.468 . . . . 1.75 111.197 177.729 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 60.8 mt -80.55 -52.28 14.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.821 -0.627 . . . . 0.39000000000000001 111.738 -178.529 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -67.83 -35.57 85.25 Favored Glycine 0 CA--C 1.519 0.287 0 C-N-CA 121.192 -0.528 . . . . 0.34000000000000002 113.812 -177.406 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 91.7 t -75.8 -23.97 16.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.699 0.285 . . . . 0.32000000000000001 110.906 -179.077 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.79 96.84 0.3 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.126 0.489 . . . . 0.46999999999999997 110.372 177.724 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 121.49 5.76 9.14 Favored Glycine 0 CA--C 1.52 0.367 0 C-N-CA 121.127 -0.559 . . . . 0.39000000000000001 112.648 -175.696 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 352' ' ' MET . . . . . . . . . . . . . 85.6 mmm -84.99 138.57 32.38 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.68 0.276 . . . . 1.28 110.995 175.882 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 353' ' ' ALA . . . . . 0.441 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -106.19 141.82 36.91 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 116.077 -0.51 . . . . 0.55000000000000004 111.214 -177.865 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 58.9 t -57.49 120.65 3.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.077 -0.511 . . . . 0.35999999999999999 110.4 173.188 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 104.08 -12.11 52.27 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 121.188 -0.53 . . . . 0.44 112.087 179.745 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -102.44 143.5 15.91 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.845 -0.693 . . . . 0.29999999999999999 112.407 -177.347 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 357' ' ' GLU . . . . . 0.57 ' HB3' ' HB ' ' A' ' 296' ' ' VAL . 32.5 tt0 -117.08 133.39 56.06 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 110.192 -0.299 . . . . 1.4099999999999999 110.192 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 358' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -144.81 144.13 30.99 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.213 0.53 . . . . 1.3700000000000001 111.113 -179.088 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 359' ' ' ARG . . . . . 0.624 ' HD2' HG22 ' A' ' 383' ' ' THR . 22.9 tpp85 -88.82 119.35 29.23 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.451 -0.795 . . . . 2.79 110.113 176.255 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 58.3 mt -105.33 121.23 57.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.962 -0.385 . . . . 0.38 109.962 177.418 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 361' ' ' VAL . . . . . 0.619 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 44.7 t -101.88 116.94 46.42 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 N-CA-C 109.471 -0.566 . . . . 0.39000000000000001 109.471 176.793 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 362' ' ' ILE . . . . . 0.51 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 59.0 mt -113.25 109.38 51.74 Favored Pre-proline 0 C--N 1.322 -0.595 0 CA-C-N 116.42 -0.354 . . . . 0.28999999999999998 111.346 -173.495 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 363' ' ' PRO . . . . . 0.529 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 10.2 Cg_endo -53.56 152.35 21.57 Favored 'Trans proline' 0 C--O 1.236 0.401 0 C-N-CA 123.158 2.572 . . . . 0.66000000000000003 112.23 173.098 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 364' ' ' ALA . . . . . 0.405 ' HB3' ' HD3' ' A' ' 365' ' ' PRO . . . -52.09 -49.03 86.71 Favored Pre-proline 0 CA--C 1.542 0.639 0 N-CA-C 113.375 0.88 . . . . 0.41999999999999998 113.375 -175.802 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 365' ' ' PRO . . . . . 0.595 ' HA ' ' HA2' ' A' ' 369' ' ' GLY . 53.4 Cg_exo -53.83 -32.19 65.55 Favored 'Trans proline' 0 C--N 1.364 1.371 0 C-N-CA 122.482 2.121 . . . . 0.69999999999999996 113.754 -177.062 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 366' ' ' TYR . . . . . 0.526 ' OH ' ' HG3' ' A' ' 287' ' ' GLU . 4.9 m-85 -94.66 9.71 37.73 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.217 0.532 . . . . 0.68999999999999995 110.942 -175.622 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 367' ' ' ALA . . . . . 0.598 ' HA ' ' HB ' ' A' ' 342' ' ' ILE . . . -120.1 -109.22 0.35 Allowed 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.592 -0.731 . . . . 0.85999999999999999 109.805 171.58 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 92.3 m-85 -81.58 -12.59 58.71 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 121.003 0.43 . . . . 1.0 111.534 179.404 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 369' ' ' GLY . . . . . 0.595 ' HA2' ' HA ' ' A' ' 365' ' ' PRO . . . 86.63 -114.1 4.02 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.846 -0.692 . . . . 0.56000000000000005 112.789 175.658 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 43.6 mttp -115.05 14.65 17.15 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.012 0.434 . . . . 2.7599999999999998 110.479 -175.454 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 55.3 tp60 -87.81 117.13 26.44 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.003 -0.544 . . . . 2.6499999999999999 110.645 -176.653 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 372' ' ' ALA . . . . . 0.49 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -87.56 98.89 11.66 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.069 -0.514 . . . . 1.01 110.67 177.814 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 76.9 mt -90.05 157.01 46.24 Favored Pre-proline 0 C--N 1.322 -0.619 0 CA-C-N 115.962 -0.563 . . . . 0.93000000000000005 109.951 178.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -61.21 114.25 2.11 Favored 'Trans proline' 0 N--CA 1.459 -0.527 0 C-N-CA 121.803 1.669 . . . . 1.3100000000000001 110.603 171.668 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 96.57 -30.39 8.88 Favored Glycine 0 N--CA 1.448 -0.559 0 CA-C-N 115.879 -0.6 . . . . 0.90000000000000002 112.22 -176.264 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 23.4 mt -129.26 78.26 76.26 Favored Pre-proline 0 C--N 1.329 -0.299 0 N-CA-C 110.145 -0.317 . . . . 0.73999999999999999 110.145 -179.475 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 377' ' ' PRO . . . . . 0.49 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 4.1 Cg_exo -76.86 166.21 27.29 Favored 'Trans proline' 0 N--CA 1.459 -0.54 0 C-N-CA 122.674 2.249 . . . . 0.70999999999999996 112.143 -179.375 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 378' ' ' ALA . . . . . 0.465 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -59.14 152.86 19.38 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.293 -0.412 . . . . 0.73999999999999999 110.695 176.921 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 379' ' ' ASN . . . . . 0.465 ' HB2' ' O ' ' A' ' 378' ' ' ALA . 91.2 m-20 74.95 4.88 4.33 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 123.012 0.525 . . . . 1.49 111.492 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 49.1 m -83.97 94.6 8.31 Favored 'General case' 0 N--CA 1.451 -0.392 0 CA-C-O 121.335 0.588 . . . . 1.8400000000000001 110.127 176.323 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 381' ' ' GLU . . . . . 0.52 ' H ' ' HD3' ' A' ' 318' ' ' LYS . 19.0 tt0 -67.04 112.34 4.33 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 114.972 -1.013 . . . . 1.03 109.617 179.354 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 82.4 mt -78.02 140.98 39.18 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.092 -0.504 . . . . 0.37 110.952 -173.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 383' ' ' THR . . . . . 0.624 HG22 ' HD2' ' A' ' 359' ' ' ARG . 25.1 m -120.19 119.54 33.54 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 109.29 -0.633 . . . . 0.27000000000000002 109.29 -179.182 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -115.63 114.62 25.15 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.05 0.452 . . . . 0.32000000000000001 111.19 -175.888 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 20.8 t70 -91.82 104.47 16.91 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 107.885 -1.154 . . . . 1.8 107.885 174.894 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 386' ' ' VAL . . . . . 0.697 HG12 ' HB2' ' A' ' 313' ' ' TYR . 17.3 m -129.71 147.61 33.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 112.46 0.541 . . . . 0.31 112.46 -167.097 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 387' ' ' LYS . . . . . 0.476 ' HB3' ' HA ' ' A' ' 357' ' ' GLU . 23.7 pttt -144.74 149.91 36.35 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.803 -0.635 . . . . 2.5299999999999998 111.271 170.804 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 388' ' ' LEU . . . . . 0.792 HD11 ' HB ' ' A' ' 309' ' ' VAL . 26.9 tp -99.2 138.4 36.35 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.274 -0.875 . . . . 0.28000000000000003 109.244 -176.702 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 31.8 m -128.83 -8.34 3.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 112.511 0.56 . . . . 0.45000000000000001 112.511 -174.852 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 74.2 m -161.55 157.92 25.57 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.624 0.249 . . . . 1.3200000000000001 110.837 -179.491 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 391' ' ' MET . . . . . . . . . . . . . 39.7 ttm -155.4 132.03 10.5 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-N 116.333 -0.394 . . . . 0.56000000000000005 110.881 -178.888 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 66.6 mttm . . . . . 0 C--O 1.25 1.094 0 CA-C-O 118.432 -0.794 . . . . 4.9100000000000001 109.603 176.781 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.55 0 N-CA-C 111.482 -0.647 . . . . 11.17 111.482 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -143.05 155.8 44.7 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.754 0.311 . . . . 9.3699999999999992 110.521 -178.086 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 278' ' ' MET . . . . . . . . . . . . . 12.2 tpt -96.94 104.41 16.42 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.127 -0.488 . . . . 7.6699999999999999 110.158 179.565 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -90.77 96.79 10.82 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.244 -0.434 . . . . 6.3700000000000001 110.501 -178.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 280' ' ' LYS . . . . . 0.453 ' HA ' ' HD3' ' A' ' 281' ' ' PRO . 35.2 mtmm 70.98 133.32 0.04 OUTLIER Pre-proline 0 N--CA 1.467 0.384 0 O-C-N 124.036 0.835 . . . . 6.7599999999999998 111.375 -177.105 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 281' ' ' PRO . . . . . 0.453 ' HD3' ' HA ' ' A' ' 280' ' ' LYS . 27.3 Cg_exo -62.38 126.76 19.2 Favored 'Trans proline' 0 C--O 1.237 0.427 0 C-N-CA 122.397 2.065 . . . . 4.7999999999999998 111.355 177.37 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 282' ' ' LYS . . . . . . . . . . . . . 27.4 mmtp -90.22 103.76 16.41 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.264 0.554 . . . . 3.46 110.299 -176.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.546 ' HA ' ' O ' ' A' ' 292' ' ' ILE . 24.0 p -111.67 137.02 50.11 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-N 115.451 -0.795 . . . . 0.76000000000000001 111.866 -175.677 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 284' ' ' LYS . . . . . 0.511 ' HB2' ' CG1' ' A' ' 292' ' ' ILE . 13.5 mmmm -110.0 137.94 47.08 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.94 -0.763 . . . . 2.0600000000000001 108.94 174.762 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 285' ' ' LEU . . . . . 0.409 HD11 ' HA2' ' A' ' 289' ' ' GLY . 42.8 tp -100.26 121.71 41.91 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.934 0.397 . . . . 0.97999999999999998 110.59 -178.869 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.66 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 88.3 mt -108.54 -164.56 0.96 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.818 -0.628 . . . . 0.80000000000000004 110.477 -178.621 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -64.64 145.38 56.26 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 116.099 -0.5 . . . . 2.6400000000000001 111.749 -178.533 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.643 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 65.76 8.97 43.49 Favored Glycine 0 C--N 1.329 0.154 0 CA-C-N 115.925 -0.58 . . . . 1.8400000000000001 113.7 177.605 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 289' ' ' GLY . . . . . 0.409 ' HA2' HD11 ' A' ' 285' ' ' LEU . . . 90.95 12.29 60.55 Favored Glycine 0 N--CA 1.441 -0.988 0 C-N-CA 120.516 -0.849 . . . . 0.64000000000000001 113.067 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 290' ' ' ILE . . . . . 0.66 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 94.9 mt -60.67 127.44 20.22 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.139 0 CA-C-N 117.373 0.587 . . . . 0.41999999999999998 110.204 177.526 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.534 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 18.1 mt -113.29 139.82 36.63 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 116.37 -0.377 . . . . 0.93000000000000005 110.181 -178.948 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 292' ' ' ILE . . . . . 0.549 HG22 HG12 ' A' ' 360' ' ' ILE . 22.5 pt -128.34 127.06 66.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 120.891 0.377 . . . . 0.47999999999999998 109.987 175.369 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 293' ' ' GLU . . . . . . . . . . . . . 4.6 tm-20 -105.25 108.44 19.95 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 108.812 -0.81 . . . . 2.3100000000000001 108.812 -179.443 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -78.11 101.55 7.06 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-O 121.156 0.503 . . . . 2.3599999999999999 110.576 -171.195 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 295' ' ' ARG . . . . . 0.434 ' HG3' HG23 ' A' ' 296' ' ' VAL . 6.2 tpt180 -88.08 -59.41 2.25 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.184 -0.916 . . . . 3.5 111.879 -170.314 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.434 HG23 ' HG3' ' A' ' 295' ' ' ARG . 91.9 t -120.34 132.85 68.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.592 -0.277 . . . . 0.69999999999999996 110.77 -178.339 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 6.8 p -92.18 120.55 32.87 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.106 -0.497 . . . . 1.9299999999999999 110.915 178.932 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -126.96 -165.03 11.84 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.691 -0.766 . . . . 1.04 112.788 -175.809 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 299' ' ' LYS . . . . . 0.594 ' O ' ' HB1' ' A' ' 353' ' ' ALA . 74.1 mmtt -73.38 151.75 41.09 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.135 -0.691 . . . . 4.4900000000000002 109.135 177.706 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -119.75 79.72 0.32 Allowed Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 119.316 -1.421 . . . . 1.04 115.074 -168.945 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 301' ' ' PRO . . . . . 0.657 ' HD2' ' H ' ' A' ' 354' ' ' VAL . 2.4 Cg_endo -85.84 133.69 4.35 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 122.735 2.29 . . . . 0.88 109.062 160.234 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 33.6 m170 -92.16 116.46 28.97 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 120.438 -0.505 . . . . 1.49 112.245 -171.628 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -66.24 121.2 14.67 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.413 -0.812 . . . . 0.54000000000000004 110.157 173.14 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 31.9 mtmm -123.12 179.2 4.77 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.468 -0.333 . . . . 2.8399999999999999 110.377 -176.123 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 61.9 tttp -63.9 113.68 3.6 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.391 -0.368 . . . . 2.8399999999999999 110.349 179.618 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 98.62 -7.1 61.16 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.888 -0.673 . . . . 0.69999999999999996 112.547 -179.276 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 307' ' ' THR . . . . . 0.406 ' O ' ' HA ' ' A' ' 335' ' ' LYS . 38.9 m -77.61 145.55 36.72 Favored 'General case' 0 CA--C 1.534 0.346 0 O-C-N 122.776 -0.25 . . . . 0.40000000000000002 110.547 -179.499 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 73.4 mtt180 -105.25 113.87 27.71 Favored 'General case' 0 CA--C 1.519 -0.227 0 N-CA-C 109.565 -0.531 . . . . 3.4500000000000002 109.565 -177.697 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.691 ' HB ' HD11 ' A' ' 388' ' ' LEU . 30.2 m -107.28 139.02 30.44 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 CA-C-O 121.273 0.559 . . . . 0.34000000000000002 111.348 178.498 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -109.88 115.39 4.16 Favored Glycine 0 N--CA 1.445 -0.717 0 N-CA-C 110.23 -1.148 . . . . 0.27000000000000002 110.23 175.278 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 311' ' ' MET . . . . . 0.583 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 22.4 ptm -136.7 177.44 7.85 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.399 0.619 . . . . 0.76000000000000001 112.153 -169.659 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 312' ' ' ARG . . . . . 0.517 ' HD3' ' O ' ' A' ' 327' ' ' THR . 98.9 mtt180 -137.05 147.01 45.89 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 107.677 -1.231 . . . . 2.5099999999999998 107.677 175.341 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 313' ' ' TYR . . . . . 0.42 ' HA ' ' O ' ' A' ' 385' ' ' ASP . 25.2 p90 -161.49 159.93 28.55 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 112.941 0.719 . . . . 0.68000000000000005 112.941 -169.869 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 48.7 t -126.41 120.74 57.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 114.839 -1.073 . . . . 0.34999999999999998 109.68 174.932 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -94.64 106.03 3.36 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.388 -0.434 . . . . 0.28000000000000003 112.19 -177.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 316' ' ' LYS . . . . . 0.556 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 84.3 mttt -114.09 156.31 24.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.064 0.459 . . . . 1.9399999999999999 110.932 -177.038 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 96.5 mt -89.31 163.11 15.49 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.045 -0.525 . . . . 0.65000000000000002 109.585 172.103 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 318' ' ' LYS . . . . . 0.728 ' HD3' ' HB3' ' A' ' 381' ' ' GLU . 61.7 pttt -65.68 -11.55 46.07 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 121.01 0.433 . . . . 2.4199999999999999 111.338 178.405 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 9.0 t30 -87.98 -7.88 56.45 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.083 0.468 . . . . 2.2000000000000002 110.216 178.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 101.17 -15.61 57.69 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 121.09 -0.576 . . . . 0.68999999999999995 112.197 -178.906 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 59.0 tptt -70.89 117.28 12.19 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.644 0.259 . . . . 2.4199999999999999 110.73 -179.272 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.556 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 6.1 p -85.58 131.77 33.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 N-CA-C 110.028 -0.36 . . . . 1.26 110.028 176.819 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 31.6 p90 -106.35 -50.09 3.22 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 120.862 -0.335 . . . . 0.55000000000000004 110.991 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 324' ' ' ASP . . . . . 0.494 ' C ' ' HD3' ' A' ' 325' ' ' LYS . 12.0 t70 -123.86 154.32 39.81 Favored 'General case' 0 CA--C 1.513 -0.446 0 N-CA-C 109.492 -0.559 . . . . 1.6799999999999999 109.492 -179.302 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 325' ' ' LYS . . . . . 0.494 ' HD3' ' C ' ' A' ' 324' ' ' ASP . 0.0 OUTLIER -167.9 131.1 1.61 Allowed 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.959 0.409 . . . . 1.99 111.143 -174.147 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 1.9 p30 -146.52 115.78 7.03 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.684 0.754 . . . . 1.9199999999999999 109.719 170.336 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 327' ' ' THR . . . . . 0.517 ' O ' ' HD3' ' A' ' 312' ' ' ARG . 1.7 p -148.96 -47.17 0.14 Allowed 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 114.935 -1.029 . . . . 1.6899999999999999 110.922 -172.717 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.66 93.34 2.06 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.492 0.663 . . . . 2.5499999999999998 111.534 -178.111 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.487 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 75.37 -11.5 8.96 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 115.508 -0.769 . . . . 0.96999999999999997 113.629 175.288 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 45.9 mtpt -103.25 100.63 18.49 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-N 117.32 0.56 . . . . 2.0800000000000001 111.41 -177.635 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 331' ' ' PRO . . . . . 0.487 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 86.0 Cg_endo -87.76 139.7 4.83 Favored 'Trans proline' 0 N--CA 1.452 -0.953 0 C-N-CA 122.749 2.299 . . . . 0.62 111.854 170.664 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 79.2 t80 -109.84 128.14 55.14 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.253 -0.647 . . . . 0.64000000000000001 109.253 176.359 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 61.9 t -115.22 119.6 62.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 N-CA-C 109.839 -0.43 . . . . 0.38 109.839 -176.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.583 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 21.2 p90 -138.92 166.59 24.07 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.853 -0.425 . . . . 0.40999999999999998 109.853 179.66 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 335' ' ' LYS . . . . . 0.407 ' HG3' ' HB3' ' A' ' 338' ' ' GLN . 58.6 pttt -111.12 140.49 45.62 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.16 -0.473 . . . . 2.5800000000000001 110.403 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 11.2 mp -71.53 139.0 49.32 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.729 -0.471 . . . . 0.57999999999999996 109.729 175.246 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 94.76 5.95 60.99 Favored Glycine 0 N--CA 1.442 -0.93 0 C-N-CA 120.791 -0.719 . . . . 0.93999999999999995 113.002 -174.858 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 338' ' ' GLN . . . . . 0.6 HE21 HG13 ' A' ' 341' ' ' VAL . 13.7 pt20 -85.16 148.86 25.9 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 117.381 0.591 . . . . 2.6200000000000001 109.558 176.165 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -90.37 15.23 60.49 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.75 -0.738 . . . . 0.73999999999999999 114.407 -166.843 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -109.92 -9.07 14.79 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 117.646 0.723 . . . . 2.0899999999999999 111.481 178.397 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 341' ' ' VAL . . . . . 0.6 HG13 HE21 ' A' ' 338' ' ' GLN . 26.3 m -95.71 146.29 7.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 C-N-CA 120.769 -0.372 . . . . 0.42999999999999999 110.144 178.697 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 17.4 pt -73.58 157.1 6.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 109.965 -0.383 . . . . 0.32000000000000001 109.965 178.678 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 343' ' ' LYS . . . . . 0.453 ' HA ' ' HE3' ' A' ' 343' ' ' LYS . 0.0 OUTLIER -62.74 -35.26 79.19 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 111.626 0.232 . . . . 2.9300000000000002 111.626 -175.895 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -52.28 -42.15 55.62 Favored Glycine 0 C--O 1.228 -0.251 0 C-N-CA 120.774 -0.726 . . . . 0.29999999999999999 112.363 174.243 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 4.2 m95 -68.8 -60.34 2.46 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.819 0.342 . . . . 0.39000000000000001 111.043 176.441 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -51.66 -33.97 35.99 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.594 -0.73 . . . . 1.75 112.121 -177.477 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 60.0 mt -85.19 -52.53 12.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 116.4 -0.363 . . . . 0.39000000000000001 111.283 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -60.47 -35.05 87.94 Favored Glycine 0 CA--C 1.524 0.628 0 C-N-CA 121.261 -0.495 . . . . 0.34000000000000002 113.794 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 349' ' ' VAL . . . . . 0.422 ' O ' ' HB2' ' A' ' 352' ' ' MET . 93.1 t -77.68 -18.27 14.05 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 CA-C-O 120.994 0.426 . . . . 0.32000000000000001 111.382 -179.311 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -64.22 100.34 0.33 Allowed 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.157 0.503 . . . . 0.46999999999999997 110.634 177.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 105.52 12.05 27.57 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.914 -0.66 . . . . 0.39000000000000001 112.205 -177.014 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 352' ' ' MET . . . . . 0.422 ' HB2' ' O ' ' A' ' 349' ' ' VAL . 0.0 OUTLIER -66.58 143.89 56.76 Favored 'General case' 0 C--N 1.331 -0.216 0 N-CA-C 109.79 -0.448 . . . . 1.28 109.79 177.675 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 353' ' ' ALA . . . . . 0.594 ' HB1' ' O ' ' A' ' 299' ' ' LYS . . . -104.06 127.06 51.61 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.321 -0.399 . . . . 0.55000000000000004 111.715 -173.082 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 354' ' ' VAL . . . . . 0.657 ' H ' ' HD2' ' A' ' 301' ' ' PRO . 98.3 t -64.84 112.97 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.239 0.542 . . . . 0.35999999999999999 110.743 174.504 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 109.96 -10.88 31.97 Favored Glycine 0 N--CA 1.442 -0.9 0 N-CA-C 111.313 -0.715 . . . . 0.44 111.313 -176.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -101.54 159.77 18.38 Favored Glycine 0 N--CA 1.442 -0.952 0 C-N-CA 121.048 -0.596 . . . . 0.29999999999999999 112.302 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 357' ' ' GLU . . . . . 0.862 ' HB2' ' HD3' ' A' ' 387' ' ' LYS . 43.3 tt0 -135.35 140.97 45.47 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.491 -0.559 . . . . 1.4099999999999999 109.491 -179.505 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 358' ' ' ARG . . . . . . . . . . . . . 5.9 ptp180 -156.2 144.91 20.2 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.026 0.441 . . . . 1.3700000000000001 110.861 177.182 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 359' ' ' ARG . . . . . . . . . . . . . 82.8 mtm180 -91.44 120.02 31.91 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 115.968 -0.56 . . . . 2.79 110.444 179.174 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 360' ' ' ILE . . . . . 0.549 HG12 HG22 ' A' ' 292' ' ' ILE . 62.3 mt -101.68 119.32 49.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-N 115.734 -0.666 . . . . 0.38 110.638 -176.476 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 361' ' ' VAL . . . . . 0.534 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 46.3 t -103.48 112.74 38.09 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 108.972 -0.751 . . . . 0.39000000000000001 108.972 177.025 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 362' ' ' ILE . . . . . . . . . . . . . 57.6 mt -109.74 102.24 49.47 Favored Pre-proline 0 C--N 1.319 -0.723 0 CA-C-N 116.037 -0.528 . . . . 0.28999999999999998 110.999 -174.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 363' ' ' PRO . . . . . 0.472 ' HA ' ' HG3' ' A' ' 381' ' ' GLU . 71.2 Cg_exo -54.39 155.48 16.29 Favored 'Trans proline' 0 N--CA 1.459 -0.559 0 C-N-CA 122.532 2.155 . . . . 0.66000000000000003 112.206 171.231 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 364' ' ' ALA . . . . . 0.547 ' N ' ' HD2' ' A' ' 365' ' ' PRO . . . -46.03 -50.1 37.5 Favored Pre-proline 0 C--N 1.327 -0.41 0 N-CA-C 114.364 1.246 . . . . 0.41999999999999998 114.364 -174.743 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 365' ' ' PRO . . . . . 0.547 ' HD2' ' N ' ' A' ' 364' ' ' ALA . 9.8 Cg_endo -52.53 -31.58 49.58 Favored 'Trans proline' 0 C--N 1.36 1.168 0 C-N-CA 122.685 2.256 . . . . 0.69999999999999996 114.387 -172.144 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 366' ' ' TYR . . . . . 0.643 ' CE2' ' HA3' ' A' ' 288' ' ' GLY . 9.6 m-85 -101.62 13.46 34.86 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-O 121.017 0.437 . . . . 0.68999999999999995 112.035 -176.708 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -126.59 -108.05 0.31 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.963 -0.562 . . . . 0.85999999999999999 110.563 173.744 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 368' ' ' TYR . . . . . 0.406 ' CE2' HD11 ' A' ' 382' ' ' LEU . 40.6 m-85 -84.08 -21.83 31.37 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.821 0.343 . . . . 1.0 111.211 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 70.68 -118.1 7.47 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.841 -0.695 . . . . 0.56000000000000005 112.15 -178.14 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 370' ' ' LYS . . . . . 0.555 ' HA ' ' HB1' ' A' ' 378' ' ' ALA . 19.4 ptmt -101.77 17.39 23.11 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.975 0.416 . . . . 2.7599999999999998 110.735 178.863 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 59.4 tt0 -84.86 102.58 13.2 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.941 -0.572 . . . . 2.6499999999999999 110.154 176.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 372' ' ' ALA . . . . . 0.433 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -81.68 108.25 15.09 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.873 0.368 . . . . 1.01 111.202 177.834 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 86.6 mt -90.02 159.33 42.87 Favored Pre-proline 0 C--N 1.322 -0.626 0 N-CA-C 109.088 -0.708 . . . . 0.93000000000000005 109.088 175.193 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -62.26 114.24 2.25 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 121.656 1.57 . . . . 1.3100000000000001 110.555 172.797 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 96.26 -29.28 10.4 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.67 -0.776 . . . . 0.90000000000000002 112.439 -178.155 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 43.3 mt -128.36 86.66 57.27 Favored Pre-proline 0 C--N 1.332 -0.152 0 N-CA-C 110.011 -0.366 . . . . 0.73999999999999999 110.011 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 377' ' ' PRO . . . . . 0.433 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 83.8 Cg_endo -80.03 168.0 19.37 Favored 'Trans proline' 0 N--CA 1.462 -0.354 0 C-N-CA 122.724 2.283 . . . . 0.70999999999999996 113.017 -176.579 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 378' ' ' ALA . . . . . 0.555 ' HB1' ' HA ' ' A' ' 370' ' ' LYS . . . -52.95 150.16 5.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.5 -0.773 . . . . 0.73999999999999999 111.703 178.73 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 379' ' ' ASN . . . . . 0.434 ' HA ' ' HB2' ' A' ' 364' ' ' ALA . 49.9 m-80 70.91 15.14 6.82 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 115.473 -0.785 . . . . 1.49 111.265 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 21.5 t -76.67 125.98 30.19 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 109.587 -0.523 . . . . 1.8400000000000001 109.587 175.156 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 381' ' ' GLU . . . . . 0.728 ' HB3' ' HD3' ' A' ' 318' ' ' LYS . 27.2 tt0 -102.24 112.57 25.32 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 108.67 -0.863 . . . . 1.03 108.67 -179.01 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 382' ' ' LEU . . . . . 0.406 HD11 ' CE2' ' A' ' 368' ' ' TYR . 75.8 mt -86.26 146.53 26.48 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 116.179 -0.464 . . . . 0.37 111.12 -172.709 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 63.0 m -123.52 122.84 39.24 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.386 -0.598 . . . . 0.27000000000000002 109.386 173.785 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 76.8 m-85 -119.84 111.71 18.32 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 116.483 -0.326 . . . . 0.32000000000000001 111.079 -177.01 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 385' ' ' ASP . . . . . 0.42 ' O ' ' HA ' ' A' ' 313' ' ' TYR . 3.6 m-20 -72.54 104.18 3.77 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 107.924 -1.139 . . . . 1.8 107.924 167.834 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 386' ' ' VAL . . . . . 0.505 ' HB ' ' CE ' ' A' ' 311' ' ' MET . 32.2 m -119.11 135.61 58.97 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.426 0.631 . . . . 0.31 111.012 -176.227 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 387' ' ' LYS . . . . . 0.862 ' HD3' ' HB2' ' A' ' 357' ' ' GLU . 21.6 ttpt -141.32 128.65 21.11 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.296 -0.865 . . . . 2.5299999999999998 109.449 178.44 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 388' ' ' LEU . . . . . 0.691 HD11 ' HB ' ' A' ' 309' ' ' VAL . 22.6 tp -95.04 136.76 34.97 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.932 -0.576 . . . . 0.28000000000000003 109.575 -172.65 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 35.8 m -126.0 -5.0 5.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 N-CA-C 112.392 0.516 . . . . 0.45000000000000001 112.392 -174.654 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 11.3 p -169.15 157.41 7.7 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.816 -0.354 . . . . 1.3200000000000001 111.473 -177.444 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 391' ' ' MET . . . . . 0.55 ' HE2' HG12 ' A' ' 309' ' ' VAL . 34.1 ttm -160.89 139.11 9.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.16 -0.473 . . . . 0.56000000000000005 110.485 177.448 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 18.2 tptm . . . . . 0 C--O 1.246 0.892 0 CA-C-O 117.961 -1.019 . . . . 4.9100000000000001 111.402 175.167 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.616 0 N-CA-C 111.609 -0.597 . . . . 11.17 111.609 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -90.04 -54.98 3.8 Favored 'General case' 0 C--N 1.324 -0.542 0 O-C-N 122.888 -0.184 . . . . 9.3699999999999992 111.203 -176.336 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 278' ' ' MET . . . . . . . . . . . . . 13.7 tpt 61.53 101.23 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.212 0 O-C-N 123.926 0.766 . . . . 7.6699999999999999 109.982 -172.9 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -60.19 -27.86 67.48 Favored 'General case' 0 CA--C 1.515 -0.38 0 CA-C-N 115.977 -0.556 . . . . 6.3700000000000001 112.061 -173.617 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 14.6 tppt? -167.37 108.53 0.61 Allowed Pre-proline 0 C--N 1.31 -1.134 0 CA-C-N 115.451 -0.795 . . . . 6.7599999999999998 109.888 179.259 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_exo -61.93 124.84 15.23 Favored 'Trans proline' 0 C--O 1.235 0.364 0 C-N-CA 122.69 2.26 . . . . 4.7999999999999998 111.726 179.286 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 282' ' ' LYS . . . . . . . . . . . . . 32.4 mmmt -124.78 88.97 2.98 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.85 -0.614 . . . . 3.46 109.588 -176.825 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.456 ' HA ' ' O ' ' A' ' 292' ' ' ILE . 16.9 p -105.91 145.85 30.74 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.651 -0.704 . . . . 0.76000000000000001 111.412 -175.594 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 28.2 mmtp -127.46 139.74 52.61 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.729 -0.669 . . . . 2.0600000000000001 109.629 175.821 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 285' ' ' LEU . . . . . 0.461 HD11 ' HA2' ' A' ' 289' ' ' GLY . 37.6 tp -96.28 121.1 37.71 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.909 -0.587 . . . . 0.97999999999999998 110.217 179.539 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.669 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 95.2 mt -105.83 -171.73 1.96 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.912 -0.586 . . . . 0.80000000000000004 110.378 -179.413 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 287' ' ' GLU . . . . . 0.476 ' HG3' ' OH ' ' A' ' 366' ' ' TYR . 4.9 tp10 -64.51 145.37 56.22 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.889 -0.596 . . . . 2.6400000000000001 111.105 -176.381 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.423 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 70.93 7.19 61.65 Favored Glycine 0 C--N 1.332 0.31 0 C-N-CA 121.055 -0.593 . . . . 1.8400000000000001 113.126 -178.999 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 289' ' ' GLY . . . . . 0.461 ' HA2' HD11 ' A' ' 285' ' ' LEU . . . 84.81 19.93 58.83 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.858 -0.687 . . . . 0.64000000000000001 113.216 -179.613 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 290' ' ' ILE . . . . . 0.669 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 96.1 mt -66.39 126.46 25.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 109.985 -0.376 . . . . 0.41999999999999998 109.985 177.557 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 14.8 mt -110.53 137.14 44.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 N-CA-C 109.726 -0.472 . . . . 0.93000000000000005 109.726 -178.748 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 292' ' ' ILE . . . . . 0.456 ' O ' ' HA ' ' A' ' 283' ' ' THR . 21.7 pt -127.02 128.24 70.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-O 121.054 0.454 . . . . 0.47999999999999998 111.069 179.626 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 293' ' ' GLU . . . . . 0.746 ' HB3' ' HB3' ' A' ' 359' ' ' ARG . 6.6 tp10 -104.62 105.54 15.67 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.177 -1.046 . . . . 2.3100000000000001 108.177 174.223 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -78.02 110.16 12.71 Favored 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 120.562 -0.455 . . . . 2.3599999999999999 109.816 -172.221 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 295' ' ' ARG . . . . . 0.705 ' HB2' ' HG3' ' A' ' 357' ' ' GLU . 14.6 mmm180 -78.05 -59.66 2.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.889 -0.596 . . . . 3.5 110.855 -171.304 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.552 ' HB ' ' HG2' ' A' ' 357' ' ' GLU . 97.8 t -137.16 119.06 18.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 C-N-CA 121.141 -0.223 . . . . 0.69999999999999996 110.626 177.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 14.9 p -68.27 108.04 3.04 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 116.079 -0.51 . . . . 1.9299999999999999 110.494 176.129 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -94.91 157.39 22.17 Favored Glycine 0 N--CA 1.442 -0.926 0 C-N-CA 120.764 -0.731 . . . . 1.04 111.56 178.677 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 18.3 ttpp -115.75 111.03 19.94 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 109.764 -0.458 . . . . 4.4900000000000002 109.764 178.535 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -171.72 -162.39 23.91 Favored Glycine 0 N--CA 1.44 -1.096 0 N-CA-C 111.105 -0.798 . . . . 1.04 111.105 179.742 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 301' ' ' PRO . . . . . 0.435 ' HD2' ' HB ' ' A' ' 354' ' ' VAL . 21.6 Cg_exo -65.76 133.33 33.59 Favored 'Trans proline' 0 N--CA 1.461 -0.394 0 C-N-CA 122.496 2.131 . . . . 0.88 111.661 175.703 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 302' ' ' HIS . . . . . 0.52 ' HA ' ' O ' ' A' ' 352' ' ' MET . 64.4 m80 -89.01 133.69 34.25 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.116 0.484 . . . . 1.49 110.579 -179.706 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 303' ' ' ALA . . . . . 0.44 ' HB2' HG11 ' A' ' 309' ' ' VAL . . . -87.17 129.25 35.02 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.773 -0.649 . . . . 0.54000000000000004 111.621 -177.988 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 59.7 pttt -124.34 -176.3 3.48 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.5 -0.555 . . . . 2.8399999999999999 109.5 174.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.72 ' HG3' ' HA3' ' A' ' 337' ' ' GLY . 50.7 tttm -66.98 133.66 50.4 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.028 0.442 . . . . 2.8399999999999999 110.229 -178.527 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 91.96 -8.91 77.63 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 121.064 -0.589 . . . . 0.69999999999999996 112.669 -176.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 25.6 m -82.06 145.51 30.15 Favored 'General case' 0 CA--C 1.535 0.365 0 CA-C-O 120.688 0.28 . . . . 0.40000000000000002 110.766 -178.689 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 89.6 mtt180 -108.33 103.23 12.35 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-O 121.098 0.475 . . . . 3.4500000000000002 109.771 -178.221 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.901 ' HB ' HD11 ' A' ' 388' ' ' LEU . 32.4 m -112.13 159.83 11.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-N 115.549 -0.751 . . . . 0.34000000000000002 112.244 -175.965 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -123.26 123.55 5.33 Favored Glycine 0 N--CA 1.447 -0.573 0 N-CA-C 110.524 -1.03 . . . . 0.27000000000000002 110.524 176.333 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 10.4 ptp -134.48 178.15 7.21 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.399 0.619 . . . . 0.76000000000000001 111.815 -173.377 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 88.1 mtt180 -137.53 143.4 41.61 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 107.217 -1.401 . . . . 2.5099999999999998 107.217 176.02 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 313' ' ' TYR . . . . . 0.593 ' CB ' HG12 ' A' ' 386' ' ' VAL . 49.4 p90 -162.55 152.16 15.84 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 112.646 0.61 . . . . 0.68000000000000005 112.646 -167.238 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 51.1 t -116.92 119.0 60.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.091 -0.959 . . . . 0.34999999999999998 109.627 173.111 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -97.93 109.15 3.75 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 121.343 -0.456 . . . . 0.28000000000000003 112.261 -178.022 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 316' ' ' LYS . . . . . 0.561 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 56.3 mttm -120.42 162.97 18.62 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.173 0.511 . . . . 1.9399999999999999 111.025 -177.157 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 81.9 mt -86.54 164.54 16.84 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 108.033 -1.099 . . . . 0.65000000000000002 108.033 166.858 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 318' ' ' LYS . . . . . . . . . . . . . 47.7 pttt -64.44 -8.46 13.57 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.483 0.659 . . . . 2.4199999999999999 110.303 173.505 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -79.51 -12.59 59.86 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 115.289 -0.869 . . . . 2.2000000000000002 109.799 176.52 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 95.59 -24.93 27.14 Favored Glycine 0 N--CA 1.453 -0.187 0 N-CA-C 111.572 -0.611 . . . . 0.68999999999999995 111.572 -176.445 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 23.7 ttmm -60.08 120.04 8.96 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.015 -0.593 . . . . 2.4199999999999999 110.831 177.92 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.561 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 5.3 p -88.86 127.22 41.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.133 -0.485 . . . . 1.26 110.201 179.491 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 49.4 p90 -98.88 -27.19 14.02 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.828 -0.349 . . . . 0.55000000000000004 111.16 -178.949 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -155.18 145.79 22.22 Favored 'General case' 0 CA--C 1.514 -0.408 0 N-CA-C 109.981 -0.377 . . . . 1.6799999999999999 109.981 175.599 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 325' ' ' LYS . . . . . 0.487 ' HD3' ' N ' ' A' ' 325' ' ' LYS . 0.0 OUTLIER -149.74 128.7 12.61 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.379 0.609 . . . . 1.99 111.335 -179.257 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 23.6 m-80 -125.21 114.51 19.07 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 107.055 -1.461 . . . . 1.9199999999999999 107.055 174.452 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 10.4 m -155.29 -58.79 0.1 Allowed 'General case' 0 C--N 1.318 -0.803 0 C-N-CA 120.367 -0.533 . . . . 1.6899999999999999 111.784 -168.49 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 9.4 ptmm? -68.05 92.01 0.37 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.288 0.566 . . . . 2.5499999999999998 111.625 -172.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.452 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 63.51 2.77 6.19 Favored Glycine 0 C--N 1.335 0.513 0 CA-C-N 115.582 -0.736 . . . . 0.96999999999999997 113.048 -178.402 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 83.9 tttt -105.63 101.9 35.0 Favored Pre-proline 0 C--N 1.325 -0.47 0 N-CA-C 111.772 0.286 . . . . 2.0800000000000001 111.772 -172.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 331' ' ' PRO . . . . . 0.452 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 95.8 Cg_endo -87.76 161.74 7.7 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 123.067 2.511 . . . . 0.62 112.567 174.289 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 66.4 t80 -134.72 126.45 29.06 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.224 -0.444 . . . . 0.64000000000000001 109.844 174.038 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 333' ' ' VAL . . . . . 0.5 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 59.6 t -109.48 120.91 61.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.556 -0.293 . . . . 0.38 110.363 -177.002 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 22.3 p90 -142.93 160.13 40.93 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.193 0.52 . . . . 0.40999999999999998 111.711 -178.608 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 335' ' ' LYS . . . . . . . . . . . . . 11.2 ttmt -89.34 128.15 35.86 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.309 -0.859 . . . . 2.5800000000000001 110.345 176.881 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 6.8 mp -69.32 136.85 52.38 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.673 0.273 . . . . 0.57999999999999996 110.598 173.813 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 337' ' ' GLY . . . . . 0.72 ' HA3' ' HG3' ' A' ' 305' ' ' LYS . . . 79.08 58.02 3.07 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 121.112 -0.566 . . . . 0.93999999999999995 112.708 178.62 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 338' ' ' GLN . . . . . . . . . . . . . 29.0 pt20 -142.55 161.21 38.64 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.776 -0.453 . . . . 2.6200000000000001 109.776 176.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -81.74 1.39 86.33 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.18 -0.533 . . . . 0.73999999999999999 112.617 -173.797 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 21.0 mm-40 -76.25 -21.66 56.08 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.153 0.501 . . . . 2.0899999999999999 110.307 178.461 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 18.7 m -114.51 166.64 8.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.898 -0.592 . . . . 0.42999999999999999 110.046 -177.317 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 10.4 pt -85.11 154.46 3.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 N-CA-C 109.518 -0.549 . . . . 0.32000000000000001 109.518 175.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 343' ' ' LYS . . . . . 0.622 ' HA ' ' OD1' ' A' ' 346' ' ' ASP . 13.7 mmmm -60.18 -28.54 68.03 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.391 0.515 . . . . 2.9300000000000002 112.391 -172.62 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 344' ' ' GLY . . . . . 0.498 ' HA2' HD13 ' A' ' 290' ' ' ILE . . . -56.27 -31.13 59.15 Favored Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.467 -0.873 . . . . 0.29999999999999999 112.656 174.204 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 9.2 m95 -74.62 -60.65 2.18 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 112.303 0.483 . . . . 0.39000000000000001 112.303 -179.189 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 346' ' ' ASP . . . . . 0.622 ' OD1' ' HA ' ' A' ' 343' ' ' LYS . 8.1 p-10 -64.55 -24.73 67.7 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.634 0.254 . . . . 1.75 111.468 -173.63 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 48.7 mt -84.44 -51.31 14.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 116.318 -0.401 . . . . 0.39000000000000001 111.126 177.347 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -64.28 -36.46 93.25 Favored Glycine 0 CA--C 1.524 0.624 0 C-N-CA 121.032 -0.604 . . . . 0.34000000000000002 113.355 179.599 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 349' ' ' VAL . . . . . 0.511 ' O ' ' HB2' ' A' ' 352' ' ' MET . 77.1 t -80.55 -14.4 12.88 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.88 0.371 . . . . 0.32000000000000001 111.349 -179.218 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -63.2 113.25 3.06 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.957 0.408 . . . . 0.46999999999999997 110.682 177.86 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 96.32 19.57 27.66 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.969 -0.634 . . . . 0.39000000000000001 111.924 -177.048 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 352' ' ' MET . . . . . 0.52 ' O ' ' HA ' ' A' ' 302' ' ' HIS . 0.0 OUTLIER -76.66 155.87 33.06 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.722 -0.473 . . . . 1.28 109.722 174.907 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 353' ' ' ALA . . . . . . . . . . . . . . . -131.04 133.79 46.06 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.671 0.272 . . . . 0.55000000000000004 110.921 -179.435 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 354' ' ' VAL . . . . . 0.435 ' HB ' ' HD2' ' A' ' 301' ' ' PRO . 95.1 t -55.39 114.79 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.976 -0.556 . . . . 0.35999999999999999 110.909 175.733 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 113.83 -8.06 23.72 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.975 -0.631 . . . . 0.44 112.097 -179.019 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -109.79 162.42 12.69 Favored Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.73 -0.747 . . . . 0.29999999999999999 112.785 -179.713 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 357' ' ' GLU . . . . . 0.785 ' HB3' ' HB3' ' A' ' 387' ' ' LYS . 9.6 pt-20 -140.64 145.54 36.74 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 110.172 -0.307 . . . . 1.4099999999999999 110.172 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 358' ' ' ARG . . . . . 0.503 ' HA ' ' HG2' ' A' ' 295' ' ' ARG . 2.8 ptp180 -154.44 145.53 22.75 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.378 0.608 . . . . 1.3700000000000001 111.67 178.393 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 359' ' ' ARG . . . . . 0.746 ' HB3' ' HB3' ' A' ' 293' ' ' GLU . 34.5 ttt180 -86.82 114.46 23.5 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 114.948 -1.024 . . . . 2.79 109.938 -179.707 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 56.1 mt -101.6 117.52 47.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 120.896 0.379 . . . . 0.38 110.46 -178.196 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 361' ' ' VAL . . . . . . . . . . . . . 46.5 t -104.01 112.2 36.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 109.346 -0.612 . . . . 0.39000000000000001 109.346 178.078 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 362' ' ' ILE . . . . . 0.446 HD13 ' HA3' ' A' ' 344' ' ' GLY . 54.5 mt -109.23 106.51 58.78 Favored Pre-proline 0 C--N 1.32 -0.694 0 CA-C-N 116.259 -0.428 . . . . 0.28999999999999998 110.784 -174.181 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 363' ' ' PRO . . . . . 0.515 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 18.4 Cg_endo -58.35 159.53 19.14 Favored 'Trans proline' 0 C--O 1.235 0.372 0 C-N-CA 122.487 2.125 . . . . 0.66000000000000003 111.848 173.327 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 364' ' ' ALA . . . . . 0.405 ' HB3' ' HD3' ' A' ' 365' ' ' PRO . . . -49.37 -50.16 66.69 Favored Pre-proline 0 CA--C 1.538 0.504 0 N-CA-C 114.002 1.112 . . . . 0.41999999999999998 114.002 -174.448 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 365' ' ' PRO . . . . . 0.515 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 77.5 Cg_exo -51.38 -30.9 36.04 Favored 'Trans proline' 0 C--N 1.364 1.368 0 C-N-CA 122.294 1.996 . . . . 0.69999999999999996 114.047 -174.935 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 366' ' ' TYR . . . . . 0.476 ' OH ' ' HG3' ' A' ' 287' ' ' GLU . 3.7 m-85 -102.26 14.13 32.79 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 112.158 0.429 . . . . 0.68999999999999995 112.158 -177.503 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -129.23 -107.57 0.29 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.147 -0.479 . . . . 0.85999999999999999 110.386 173.249 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 32.8 m-85 -87.96 -14.2 39.8 Favored 'General case' 0 N--CA 1.466 0.34 0 N-CA-C 112.09 0.404 . . . . 1.0 112.09 -179.113 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 70.01 -122.96 12.07 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.918 -0.658 . . . . 0.56000000000000005 112.773 178.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 4.7 ptpp? -97.2 4.07 51.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.685 0.279 . . . . 2.7599999999999998 111.12 -178.247 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 88.4 mm-40 -75.36 98.92 3.97 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.085 0.469 . . . . 2.6499999999999999 110.787 -179.261 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 372' ' ' ALA . . . . . . . . . . . . . . . -72.21 90.98 1.26 Allowed 'General case' 0 N--CA 1.447 -0.586 0 CA-C-N 115.695 -0.684 . . . . 1.01 110.454 175.593 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 36.7 mt -74.51 159.24 83.92 Favored Pre-proline 0 C--N 1.323 -0.568 0 CA-C-N 115.516 -0.765 . . . . 0.93000000000000005 109.144 178.844 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -58.63 113.97 1.79 Allowed 'Trans proline' 0 N--CA 1.459 -0.529 0 C-N-CA 121.749 1.633 . . . . 1.3100000000000001 110.721 173.73 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 93.84 -27.76 11.97 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.767 -0.73 . . . . 0.90000000000000002 112.796 -177.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 56.6 mt -125.18 89.41 52.65 Favored Pre-proline 0 C--N 1.327 -0.37 0 CA-C-O 120.71 0.29 . . . . 0.73999999999999999 110.84 -177.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 377' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -72.52 168.09 25.31 Favored 'Trans proline' 0 C--O 1.234 0.276 0 C-N-CA 123.143 2.562 . . . . 0.70999999999999996 113.009 -178.112 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 378' ' ' ALA . . . . . 0.477 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -53.2 155.09 2.81 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.512 -0.767 . . . . 0.73999999999999999 111.212 178.148 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 379' ' ' ASN . . . . . 0.477 ' HB2' ' O ' ' A' ' 378' ' ' ALA . 33.1 m-80 71.97 32.16 1.89 Allowed 'General case' 0 N--CA 1.467 0.419 0 O-C-N 123.805 0.69 . . . . 1.49 109.43 -172.228 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 1.8 p -70.7 87.88 0.7 Allowed 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 114.896 -1.047 . . . . 1.8400000000000001 111.283 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 381' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -80.27 98.91 7.6 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 108.68 -0.859 . . . . 1.03 108.68 174.565 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 67.8 mt -85.96 146.98 26.44 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.0 -0.545 . . . . 0.37 110.292 -176.561 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 28.9 m -124.08 122.68 38.51 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 109.566 -0.531 . . . . 0.27000000000000002 109.566 175.81 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -117.83 110.62 18.0 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.424 -0.353 . . . . 0.32000000000000001 110.429 -178.575 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -84.0 103.81 13.55 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 107.813 -1.18 . . . . 1.8 107.813 172.478 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 386' ' ' VAL . . . . . 0.593 HG12 ' CB ' ' A' ' 313' ' ' TYR . 18.5 m -122.02 149.93 25.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 121.235 0.54 . . . . 0.31 112.185 -170.983 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 387' ' ' LYS . . . . . 0.785 ' HB3' ' HB3' ' A' ' 357' ' ' GLU . 11.1 ptpt -141.6 139.58 33.13 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.686 -0.688 . . . . 2.5299999999999998 110.313 172.35 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 388' ' ' LEU . . . . . 0.901 HD11 ' HB ' ' A' ' 309' ' ' VAL . 31.0 tp -91.53 127.18 36.88 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.766 -0.827 . . . . 0.28000000000000003 108.766 179.566 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 33.3 m -124.77 -10.84 6.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 C-N-CA 120.585 -0.446 . . . . 0.45000000000000001 111.872 -172.676 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 50.0 m -157.96 159.83 36.9 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.844 0.354 . . . . 1.3200000000000001 111.268 -179.33 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 391' ' ' MET . . . . . . . . . . . . . 38.7 ttm -160.32 150.82 18.47 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.339 -0.615 . . . . 0.56000000000000005 109.339 175.354 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 18.5 ptpt . . . . . 0 C--O 1.249 1.067 0 C-N-CA 124.251 1.02 . . . . 4.9100000000000001 112.805 176.866 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.85 0 N-CA-C 111.405 -0.678 . . . . 11.17 111.405 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -97.95 -175.13 3.06 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.579 -0.526 . . . . 9.3699999999999992 109.579 175.142 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 278' ' ' MET . . . . . . . . . . . . . 88.7 mtp -72.62 -64.59 0.93 Allowed 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 109.365 -0.606 . . . . 7.6699999999999999 109.365 176.164 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . 65.78 153.18 0.07 Allowed 'General case' 0 N--CA 1.467 0.38 0 O-C-N 124.088 0.867 . . . . 6.3700000000000001 112.678 176.379 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 84.9 tttt 67.7 127.32 0.03 OUTLIER Pre-proline 0 N--CA 1.466 0.366 0 CA-C-N 115.542 -0.754 . . . . 6.7599999999999998 112.118 176.31 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -67.02 142.62 62.5 Favored 'Trans proline' 0 N--CA 1.461 -0.389 0 C-N-CA 122.335 2.023 . . . . 4.7999999999999998 111.459 176.167 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 282' ' ' LYS . . . . . . . . . . . . . 60.5 mttm -112.87 -175.74 2.74 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.928 -0.397 . . . . 3.46 109.928 179.192 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 2.9 p -90.03 126.6 35.82 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-O 121.351 0.596 . . . . 0.76000000000000001 110.232 178.857 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 284' ' ' LYS . . . . . 0.406 ' HB2' HG13 ' A' ' 292' ' ' ILE . 32.2 mmtp -108.16 130.54 55.12 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 115.652 -0.704 . . . . 2.0600000000000001 110.041 -178.222 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 32.3 tp -95.47 125.44 40.08 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.949 -0.569 . . . . 0.97999999999999998 109.959 179.836 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.759 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 90.4 mt -102.75 -178.12 3.58 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.688 -0.687 . . . . 0.80000000000000004 109.433 179.302 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 14.3 tt0 -66.37 152.04 45.87 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.704 -0.48 . . . . 2.6400000000000001 109.704 179.791 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 72.71 -4.41 21.83 Favored Glycine 0 C--O 1.229 -0.177 0 C-N-CA 120.823 -0.703 . . . . 1.8400000000000001 113.08 -174.265 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 90.33 21.34 38.37 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.504 -0.855 . . . . 0.64000000000000001 113.53 179.547 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 290' ' ' ILE . . . . . 0.759 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 61.9 mt -69.81 133.43 31.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 117.39 0.595 . . . . 0.41999999999999998 110.344 177.828 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.528 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 17.8 mt -113.08 139.49 37.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 C-N-CA 121.106 -0.237 . . . . 0.93000000000000005 110.836 -178.576 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 292' ' ' ILE . . . . . 0.511 ' HB ' ' HD3' ' A' ' 358' ' ' ARG . 17.7 pt -132.08 129.3 60.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 121.151 0.501 . . . . 0.47999999999999998 110.956 177.185 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 293' ' ' GLU . . . . . 0.446 ' C ' ' HG3' ' A' ' 358' ' ' ARG . 4.5 tp10 -125.15 119.21 27.93 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.516 -0.766 . . . . 2.3100000000000001 109.664 178.699 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 294' ' ' ASP . . . . . 0.688 ' OD2' ' HA ' ' A' ' 297' ' ' THR . 6.2 t70 -80.3 96.18 6.56 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.475 -0.565 . . . . 2.3599999999999999 109.475 -175.727 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 295' ' ' ARG . . . . . . . . . . . . . 66.6 ttt180 -69.37 -45.73 68.65 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.784 -0.644 . . . . 3.5 110.146 -175.89 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.598 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 88.8 t -123.4 123.71 68.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 N-CA-C 108.523 -0.917 . . . . 0.69999999999999996 108.523 172.313 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 297' ' ' THR . . . . . 0.688 ' HA ' ' OD2' ' A' ' 294' ' ' ASP . 5.1 t -60.76 109.75 1.13 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.718 0.771 . . . . 1.9299999999999999 110.994 -174.156 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 298' ' ' GLY . . . . . 0.538 ' HA3' ' HA3' ' A' ' 356' ' ' GLY . . . -99.33 111.22 4.16 Favored Glycine 0 N--CA 1.445 -0.708 0 CA-C-N 115.313 -0.858 . . . . 1.04 112.948 -178.036 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 36.9 mmtm -125.39 110.14 13.6 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 108.982 -0.747 . . . . 4.4900000000000002 108.982 173.829 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -173.3 -152.68 8.97 Favored Glycine 0 N--CA 1.447 -0.573 0 N-CA-C 111.218 -0.753 . . . . 1.04 111.218 -174.404 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 301' ' ' PRO . . . . . 0.607 ' O ' ' HA ' ' A' ' 353' ' ' ALA . 32.8 Cg_exo -58.32 132.92 51.66 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.413 2.075 . . . . 0.88 111.312 174.103 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 26.6 m80 -96.63 127.92 43.08 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.941 0.401 . . . . 1.49 111.132 -173.61 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -73.51 117.62 15.49 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.066 -0.516 . . . . 0.54000000000000004 111.056 179.202 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 63.2 mttm -118.9 -179.4 3.8 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.194 -0.457 . . . . 2.8399999999999999 110.583 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 49.7 mtmt -72.68 127.15 31.69 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 109.9 -0.408 . . . . 2.8399999999999999 109.9 179.223 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 94.8 -0.51 64.89 Favored Glycine 0 CA--C 1.518 0.223 0 C-N-CA 120.747 -0.739 . . . . 0.69999999999999996 112.047 -176.906 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 19.8 m -91.29 145.31 24.75 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 110.239 -0.282 . . . . 0.40000000000000002 110.239 177.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 51.4 mtp180 -108.12 106.47 16.69 Favored 'General case' 0 CA--C 1.519 -0.225 0 N-CA-C 109.648 -0.501 . . . . 3.4500000000000002 109.648 178.693 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.914 ' HB ' HD11 ' A' ' 388' ' ' LEU . 32.7 m -106.25 154.11 7.45 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.959 0 CA-C-O 121.086 0.469 . . . . 0.34000000000000002 111.747 -174.09 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -122.74 127.73 6.82 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 110.823 -0.911 . . . . 0.27000000000000002 110.823 177.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 11.9 ptp -135.22 177.01 8.15 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.754 0.788 . . . . 0.76000000000000001 112.789 -173.82 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 44.3 mtm180 -135.96 146.21 47.01 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 107.068 -1.456 . . . . 2.5099999999999998 107.068 173.005 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 313' ' ' TYR . . . . . 0.601 ' HB3' HG12 ' A' ' 386' ' ' VAL . 41.9 p90 -159.13 155.52 27.39 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 113.214 0.82 . . . . 0.68000000000000005 113.214 -168.118 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 58.1 t -122.56 113.24 37.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 114.94 -1.027 . . . . 0.34999999999999998 109.361 170.185 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -97.56 115.64 5.31 Favored Glycine 0 C--O 1.238 0.374 0 C-N-CA 120.85 -0.69 . . . . 0.28000000000000003 112.556 -176.331 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 316' ' ' LYS . . . . . 0.637 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 91.9 mttt -117.86 162.45 18.09 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-O 121.275 0.559 . . . . 1.9399999999999999 110.758 -179.066 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 93.6 mt -90.01 165.89 13.77 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.423 -0.808 . . . . 0.65000000000000002 109.558 173.841 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 318' ' ' LYS . . . . . 0.566 ' HB2' ' HB3' ' A' ' 381' ' ' GLU . 56.9 tttp -59.88 -23.09 63.16 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.22 0.533 . . . . 2.4199999999999999 110.306 176.448 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -70.14 -15.63 62.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.38 -0.827 . . . . 2.2000000000000002 110.894 -179.559 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 98.84 -5.43 59.79 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.51 -0.852 . . . . 0.68999999999999995 112.195 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -91.48 133.28 35.64 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 120.682 0.277 . . . . 2.4199999999999999 110.3 179.004 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.637 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 8.0 p -77.3 140.21 17.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.467 -0.333 . . . . 1.26 110.322 178.575 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 34.9 p90 -103.62 -33.43 8.99 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.54 -0.464 . . . . 0.55000000000000004 110.994 177.636 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -162.7 162.99 27.1 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 121.063 -0.255 . . . . 1.6799999999999999 110.343 175.132 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -159.61 129.63 5.55 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.891 0.377 . . . . 1.99 110.623 -178.33 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 35.1 m-80 -120.56 116.62 25.74 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.606 -0.887 . . . . 1.9199999999999999 108.606 172.874 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.76 -69.25 0.2 Allowed 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.096 -0.502 . . . . 1.6899999999999999 111.76 -174.324 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 24.7 pttm -68.41 97.28 0.74 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.698 0.761 . . . . 2.5499999999999998 111.836 -174.121 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.501 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 86.71 -16.61 45.01 Favored Glycine 0 N--CA 1.446 -0.638 0 CA-C-N 115.269 -0.878 . . . . 0.96999999999999997 113.591 175.375 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 27.6 mmmt -104.83 100.02 21.73 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 117.228 0.514 . . . . 2.0800000000000001 111.471 -175.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 331' ' ' PRO . . . . . 0.501 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 72.1 Cg_endo -87.56 127.86 2.42 Favored 'Trans proline' 0 N--CA 1.455 -0.744 0 C-N-CA 122.883 2.389 . . . . 0.62 111.854 172.809 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 70.6 t80 -102.56 120.55 40.74 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 110.135 -0.321 . . . . 0.64000000000000001 110.135 179.458 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 60.4 t -112.51 122.42 66.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.915 0.388 . . . . 0.38 110.413 -178.154 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 31.1 p90 -139.8 158.76 43.57 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.089 -0.505 . . . . 0.40999999999999998 109.73 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 335' ' ' LYS . . . . . . . . . . . . . 16.9 ptmt -100.15 141.02 33.55 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.214 0.53 . . . . 2.5800000000000001 111.217 179.128 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 11.2 mp -77.34 123.49 26.58 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.769 -0.651 . . . . 0.57999999999999996 109.695 173.864 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 111.79 12.33 14.73 Favored Glycine 0 N--CA 1.446 -0.68 0 C-N-CA 120.683 -0.77 . . . . 0.93999999999999995 111.931 -177.47 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 338' ' ' GLN . . . . . . . . . . . . . 4.0 pt20 -97.91 151.09 20.62 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.963 -0.384 . . . . 2.6200000000000001 109.963 176.912 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -89.28 15.21 58.92 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 121.029 -0.605 . . . . 0.73999999999999999 111.815 -179.047 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -87.32 -15.15 38.83 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.077 0.465 . . . . 2.0899999999999999 110.261 178.298 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 32.6 m -107.24 164.28 4.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.838 -0.619 . . . . 0.42999999999999999 110.575 -177.644 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 342' ' ' ILE . . . . . 0.491 ' HB ' ' HA ' ' A' ' 367' ' ' ALA . 10.0 pt -88.67 165.36 2.06 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 109.718 -0.475 . . . . 0.32000000000000001 109.718 176.546 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 343' ' ' LYS . . . . . 0.413 ' CE ' ' HA ' ' A' ' 343' ' ' LYS . 0.0 OUTLIER -56.11 -37.3 69.22 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 111.908 0.336 . . . . 2.9300000000000002 111.908 -174.644 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 344' ' ' GLY . . . . . 0.587 ' HA2' HD13 ' A' ' 290' ' ' ILE . . . -55.72 -30.84 57.19 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.938 -0.649 . . . . 0.29999999999999999 113.126 177.506 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 345' ' ' TRP . . . . . 0.42 ' CD1' HG12 ' A' ' 342' ' ' ILE . 18.4 m95 -77.83 -61.23 2.06 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 112.506 0.558 . . . . 0.39000000000000001 112.506 -176.886 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -64.23 -20.55 66.11 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.669 0.271 . . . . 1.75 111.41 -175.69 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 71.5 mt -89.41 -55.73 5.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 116.471 -0.332 . . . . 0.39000000000000001 111.685 174.792 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -65.71 -38.55 94.61 Favored Glycine 0 CA--C 1.523 0.59 0 C-N-CA 121.297 -0.478 . . . . 0.34000000000000002 114.135 -177.372 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 83.9 t -75.22 -21.25 16.4 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 CA-C-O 120.953 0.406 . . . . 0.32000000000000001 110.905 -178.612 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.2 104.53 0.93 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.164 0.506 . . . . 0.46999999999999997 110.953 -179.291 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 113.84 0.58 24.31 Favored Glycine 0 N--CA 1.445 -0.712 0 C-N-CA 120.823 -0.704 . . . . 0.39000000000000001 112.851 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 352' ' ' MET . . . . . . . . . . . . . 60.0 mtp -75.37 157.69 33.85 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 117.313 0.557 . . . . 1.28 110.307 174.69 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 353' ' ' ALA . . . . . 0.607 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -123.09 144.58 49.22 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.221 -0.445 . . . . 0.55000000000000004 111.543 -174.861 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 73.4 t -58.2 123.15 9.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.962 -0.563 . . . . 0.35999999999999999 110.357 175.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 104.23 -16.44 49.43 Favored Glycine 0 N--CA 1.446 -0.663 0 C-N-CA 120.831 -0.7 . . . . 0.44 111.528 -177.109 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 356' ' ' GLY . . . . . 0.538 ' HA3' ' HA3' ' A' ' 298' ' ' GLY . . . -87.35 154.29 26.06 Favored Glycine 0 N--CA 1.443 -0.851 0 C-N-CA 120.875 -0.678 . . . . 0.29999999999999999 112.646 179.484 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 357' ' ' GLU . . . . . 0.642 ' HG3' ' HB3' ' A' ' 387' ' ' LYS . 41.2 tt0 -137.87 121.65 17.56 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.951 -0.759 . . . . 1.4099999999999999 108.951 -177.833 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 358' ' ' ARG . . . . . 0.511 ' HD3' ' HB ' ' A' ' 292' ' ' ILE . 35.0 ttm180 -148.41 133.99 18.75 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.071 0.463 . . . . 1.3700000000000001 110.933 -170.883 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 359' ' ' ARG . . . . . 0.408 HH11 ' HD2' ' A' ' 359' ' ' ARG . 31.8 ttp85 -86.02 122.78 30.54 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.717 -0.674 . . . . 2.79 110.459 -179.186 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 360' ' ' ILE . . . . . 0.493 HG12 HG22 ' A' ' 292' ' ' ILE . 56.8 mt -109.52 121.44 62.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.866 -0.606 . . . . 0.38 110.272 -179.646 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 361' ' ' VAL . . . . . 0.528 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 48.6 t -104.19 119.84 53.57 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 N-CA-C 109.256 -0.646 . . . . 0.39000000000000001 109.256 177.699 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 362' ' ' ILE . . . . . 0.491 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 55.9 mt -118.23 100.95 51.7 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-N 116.322 -0.399 . . . . 0.28999999999999998 111.535 -174.092 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 363' ' ' PRO . . . . . 0.526 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 12.3 Cg_endo -56.9 158.12 18.04 Favored 'Trans proline' 0 C--O 1.238 0.498 0 C-N-CA 122.99 2.46 . . . . 0.66000000000000003 112.547 172.127 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 364' ' ' ALA . . . . . 0.489 ' CB ' ' HA ' ' A' ' 379' ' ' ASN . . . -50.18 -47.41 82.07 Favored Pre-proline 0 CA--C 1.539 0.52 0 N-CA-C 114.516 1.302 . . . . 0.41999999999999998 114.516 -173.723 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 365' ' ' PRO . . . . . 0.526 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 82.6 Cg_exo -49.22 -36.55 37.25 Favored 'Trans proline' 0 C--N 1.361 1.231 0 C-N-CA 122.218 1.945 . . . . 0.69999999999999996 113.632 -176.704 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 366' ' ' TYR . . . . . 0.422 ' CD1' HD11 ' A' ' 290' ' ' ILE . 3.6 m-85 -101.31 12.55 37.25 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.761 0.315 . . . . 0.68999999999999995 111.643 -177.097 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 367' ' ' ALA . . . . . 0.491 ' HA ' ' HB ' ' A' ' 342' ' ' ILE . . . -119.31 -112.52 0.33 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.168 -0.469 . . . . 0.85999999999999999 110.505 175.207 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -91.39 -1.88 57.47 Favored 'General case' 0 N--CA 1.464 0.228 0 N-CA-C 112.194 0.442 . . . . 1.0 112.194 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 66.43 -114.97 6.93 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 121.103 -0.57 . . . . 0.56000000000000005 113.65 175.854 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 370' ' ' LYS . . . . . 0.428 ' HE2' ' HB3' ' A' ' 370' ' ' LYS . 14.8 ptpt -112.81 20.31 16.58 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.856 0.36 . . . . 2.7599999999999998 111.502 -174.497 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 27.9 mm-40 -90.14 113.45 25.21 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.29 -0.414 . . . . 2.6499999999999999 110.088 176.596 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 372' ' ' ALA . . . . . 0.447 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -83.51 96.18 8.52 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.175 0.512 . . . . 1.01 111.17 178.827 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 373' ' ' LEU . . . . . 0.5 ' HB3' ' HD2' ' A' ' 374' ' ' PRO . 59.1 mt -80.37 166.67 38.38 Favored Pre-proline 0 C--N 1.32 -0.698 0 CA-C-N 115.562 -0.744 . . . . 0.93000000000000005 109.487 178.728 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 374' ' ' PRO . . . . . 0.5 ' HD2' ' HB3' ' A' ' 373' ' ' LEU . 22.9 Cg_endo -64.33 113.36 2.22 Favored 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 121.514 1.476 . . . . 1.3100000000000001 110.818 172.438 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 90.65 -24.53 16.96 Favored Glycine 0 CA--C 1.519 0.312 0 C-N-CA 120.739 -0.743 . . . . 0.90000000000000002 112.757 -179.003 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 39.8 mt -125.56 83.04 62.47 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.683 0.278 . . . . 0.73999999999999999 110.304 -178.936 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 377' ' ' PRO . . . . . 0.447 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 9.2 Cg_exo -72.59 166.5 29.7 Favored 'Trans proline' 0 N--CA 1.464 -0.253 0 C-N-CA 123.17 2.58 . . . . 0.70999999999999996 113.247 -178.124 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 378' ' ' ALA . . . . . . . . . . . . . . . -55.02 147.55 15.47 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-N 115.557 -0.747 . . . . 0.73999999999999999 111.43 178.898 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 379' ' ' ASN . . . . . 0.489 ' HA ' ' CB ' ' A' ' 364' ' ' ALA . 44.4 m-80 65.54 30.65 10.54 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 115.676 -0.693 . . . . 1.49 111.3 -179.144 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 380' ' ' SER . . . . . 0.424 ' HB2' ' O ' ' A' ' 377' ' ' PRO . 22.2 t -85.41 134.54 34.07 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 116.08 -0.509 . . . . 1.8400000000000001 109.78 175.769 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 381' ' ' GLU . . . . . 0.566 ' HB3' ' HB2' ' A' ' 318' ' ' LYS . 30.7 tt0 -99.43 105.16 17.07 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.305 -0.628 . . . . 1.03 109.305 179.066 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 74.2 mt -84.72 142.09 30.1 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.397 -0.365 . . . . 0.37 110.796 -177.65 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 383' ' ' THR . . . . . 0.471 HG23 HG22 ' A' ' 361' ' ' VAL . 25.7 m -122.39 122.77 39.79 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 109.726 -0.472 . . . . 0.27000000000000002 109.726 177.794 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -117.44 109.59 16.96 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.928 0.394 . . . . 0.32000000000000001 110.32 -178.181 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -88.81 104.4 16.88 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.154 -1.054 . . . . 1.8 108.154 174.254 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 386' ' ' VAL . . . . . 0.601 HG12 ' HB3' ' A' ' 313' ' ' TYR . 20.0 m -125.25 151.37 30.99 Favored 'Isoleucine or valine' 0 C--O 1.232 0.141 0 CA-C-O 121.358 0.599 . . . . 0.31 112.287 -169.131 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 387' ' ' LYS . . . . . 0.642 ' HB3' ' HG3' ' A' ' 357' ' ' GLU . 14.6 ptmm? -139.54 142.21 37.21 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.774 -0.648 . . . . 2.5299999999999998 109.814 172.534 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 388' ' ' LEU . . . . . 0.914 HD11 ' HB ' ' A' ' 309' ' ' VAL . 19.3 tp -93.14 135.43 34.33 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.691 -0.485 . . . . 0.28000000000000003 109.691 -176.471 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 34.7 m -127.53 -6.51 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 N-CA-C 112.268 0.47 . . . . 0.45000000000000001 112.268 -176.442 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 44.1 t -160.57 160.35 31.71 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.528 0.204 . . . . 1.3200000000000001 110.942 -177.784 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 391' ' ' MET . . . . . 0.427 ' HA ' ' HA ' ' A' ' 309' ' ' VAL . 30.9 ttm -165.61 134.1 3.16 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.998 -0.546 . . . . 0.56000000000000005 110.18 179.684 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 63.7 mttp . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.513 -0.756 . . . . 4.9100000000000001 109.716 175.758 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 18.2 p . . . . . 0 N--CA 1.443 -0.79 0 CA-C-O 121.543 0.687 . . . . 0.76 110.896 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 284' ' ' LYS . . . . . 0.408 ' O ' ' HA ' ' A' ' 291' ' ' ILE . 41.8 mtmt -131.55 159.21 38.85 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.519 -0.764 . . . . 2.06 110.414 -174.407 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . 0.513 HD11 ' HA2' ' A' ' 289' ' ' GLY . 42.3 tp -111.93 127.07 55.75 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.217 -0.447 . . . . 0.98 111.987 -170.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.44 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 99.2 mt -108.32 -161.83 0.79 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.839 -0.618 . . . . 0.8 110.309 173.653 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -51.99 140.48 20.15 Favored 'General case' 0 N--CA 1.447 -0.591 0 C-N-CA 123.263 0.625 . . . . 2.64 112.301 179.293 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.487 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 70.4 -102.94 1.08 Allowed Glycine 0 N--CA 1.446 -0.69 0 CA-C-N 115.482 -0.781 . . . . 1.84 111.595 -177.63 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . 0.513 ' HA2' HD11 ' A' ' 285' ' ' LEU . . . -145.92 28.2 1.73 Allowed Glycine 0 N--CA 1.442 -0.948 0 N-CA-C 110.603 -0.999 . . . . 0.64 110.603 176.08 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 290' ' ' ILE . . . . . 0.44 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 75.4 mt -71.14 120.9 19.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.803 0.335 . . . . 0.42 110.733 -177.73 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.408 ' HA ' ' O ' ' A' ' 284' ' ' LYS . 92.1 mt -103.72 138.53 27.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.274 -0.421 . . . . 0.93 110.171 178.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 292' ' ' ILE . . . . . 0.43 HG22 HG12 ' A' ' 360' ' ' ILE . 24.9 pt -124.46 128.21 73.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-O 121.3 0.571 . . . . 0.48 109.864 178.038 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 293' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -114.59 110.78 20.31 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.282 -0.872 . . . . 2.31 109.117 179.538 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 20.7 m-20 -83.83 103.75 13.37 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.386 0.612 . . . . 2.36 109.851 -173.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 295' ' ' ARG . . . . . . . . . . . . . 10.5 mmm180 -76.8 -49.4 15.95 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 114.809 -1.087 . . . . 3.5 110.663 -173.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . . . . . . . . . 97.9 t -118.66 130.09 73.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 115.662 -0.699 . . . . 0.7 110.358 -176.025 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 1.6 m -63.03 107.25 0.97 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.156 -0.475 . . . . 1.93 110.554 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -118.01 116.25 3.39 Favored Glycine 0 N--CA 1.445 -0.759 0 C-N-CA 120.802 -0.713 . . . . 1.04 112.402 -177.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 13.1 tptm -121.9 113.13 19.19 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.575 -0.528 . . . . 4.49 109.575 175.296 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -170.79 -153.71 9.04 Favored Glycine 0 N--CA 1.436 -1.304 0 N-CA-C 111.042 -0.823 . . . . 1.04 111.042 -178.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . 0.428 ' HB2' ' SD ' ' A' ' 391' ' ' MET . 36.8 Cg_exo -60.75 132.7 44.0 Favored 'Trans proline' 0 N--CA 1.461 -0.397 0 C-N-CA 122.6 2.2 . . . . 0.88 111.756 177.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 302' ' ' HIS . . . . . 0.417 ' HA ' ' O ' ' A' ' 352' ' ' MET . 37.3 m80 -88.82 138.44 31.41 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.207 -0.451 . . . . 1.49 110.786 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -85.68 117.37 24.53 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.897 -0.592 . . . . 0.54 111.25 -179.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 21.9 pttp -116.87 -178.54 3.46 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.045 -0.724 . . . . 2.84 109.045 173.15 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 51.4 mttm -68.13 142.4 55.77 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 110.119 -0.326 . . . . 2.84 110.119 176.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 85.29 -7.86 73.79 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 121.085 -0.578 . . . . 0.7 112.225 -175.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 307' ' ' THR . . . . . 0.472 ' O ' ' HA ' ' A' ' 335' ' ' LYS . 87.0 m -89.25 135.47 33.56 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.758 0.314 . . . . 0.4 111.119 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 308' ' ' ARG . . . . . 0.424 HH21 ' C ' ' A' ' 392' ' ' LYS . 73.1 mtm180 -94.24 102.34 14.35 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.687 -0.688 . . . . 3.45 109.903 -177.643 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.869 ' HB ' HD11 ' A' ' 388' ' ' LEU . 34.1 m -103.43 141.54 19.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 CA-C-O 121.426 0.631 . . . . 0.34 111.75 -177.679 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -115.51 121.66 5.34 Favored Glycine 0 N--CA 1.445 -0.759 0 N-CA-C 110.325 -1.11 . . . . 0.27 110.325 177.462 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 13.9 ptp -135.77 177.67 7.65 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.513 0.673 . . . . 0.76 112.304 -173.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -136.65 143.47 43.49 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 106.938 -1.504 . . . . 2.51 106.938 174.157 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 313' ' ' TYR . . . . . 0.509 ' CB ' HG12 ' A' ' 386' ' ' VAL . 18.2 p90 -157.52 157.49 33.92 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 113.39 0.885 . . . . 0.68 113.39 -170.245 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 58.0 t -124.34 120.94 60.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 114.795 -1.093 . . . . 0.35 109.219 173.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -97.86 110.29 3.99 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 120.959 -0.639 . . . . 0.28 112.573 -176.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 316' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -116.15 154.63 29.67 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.177 0.513 . . . . 1.94 110.929 -178.49 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 317' ' ' LEU . . . . . 0.542 HD12 ' HD3' ' A' ' 321' ' ' LYS . 80.1 mt -86.92 170.39 11.66 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.795 -0.639 . . . . 0.65 110.134 171.13 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 318' ' ' LYS . . . . . 0.441 ' HB2' ' HB3' ' A' ' 381' ' ' GLU . 57.7 tttp -59.07 -25.44 63.77 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.14 -0.482 . . . . 2.42 111.298 179.493 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 28.1 p-10 -87.7 -3.04 58.98 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 120.555 0.216 . . . . 2.2 111.267 -178.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 95.52 3.75 61.07 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.775 -0.726 . . . . 0.69 112.7 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 321' ' ' LYS . . . . . 0.542 ' HD3' HD12 ' A' ' 317' ' ' LEU . 53.4 tttp -75.18 113.55 12.65 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.751 0.31 . . . . 2.42 110.259 179.431 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . . . . . . . . . 4.7 p -85.52 119.52 34.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-O 121.287 0.565 . . . . 1.26 110.431 179.222 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 52.2 p90 -110.14 -27.13 9.3 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.072 -0.513 . . . . 0.55 111.284 -177.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -130.88 156.61 44.76 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 108.952 -0.758 . . . . 1.68 108.952 178.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 59.6 pttt -174.44 135.81 0.44 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.099 0.476 . . . . 1.99 111.525 -176.012 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 6.0 p30 -150.35 118.56 6.36 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.68 -0.691 . . . . 1.92 109.316 166.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 29.7 m -140.63 -46.8 0.41 Allowed 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.642 -0.708 . . . . 1.69 110.94 -175.451 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 83.9 mttt -79.66 92.55 5.38 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.79 -0.641 . . . . 2.55 111.259 -173.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.48 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 65.78 7.92 38.05 Favored Glycine 0 CA--C 1.52 0.391 0 CA-C-N 115.853 -0.612 . . . . 0.97 113.742 174.418 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 68.9 mmtt -103.93 100.4 20.26 Favored Pre-proline 0 C--N 1.324 -0.52 0 CA-C-N 116.688 0.244 . . . . 2.08 111.39 -177.29 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 331' ' ' PRO . . . . . 0.48 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 94.1 Cg_endo -88.38 129.54 2.3 Favored 'Trans proline' 0 N--CA 1.453 -0.895 0 C-N-CA 122.839 2.359 . . . . 0.62 112.298 173.199 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -103.74 118.89 37.77 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.956 -0.757 . . . . 0.64 108.956 174.208 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 56.7 t -112.15 125.87 69.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.904 0.383 . . . . 0.38 110.172 -177.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.794 ' HB2' HE22 ' A' ' 338' ' ' GLN . 29.8 p90 -147.31 156.38 42.86 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.835 -0.62 . . . . 0.41 109.511 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 335' ' ' LYS . . . . . 0.472 ' HA ' ' O ' ' A' ' 307' ' ' THR . 0.2 OUTLIER -111.08 142.12 43.65 Favored 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 120.034 -0.667 . . . . 2.58 110.508 177.709 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 9.3 mp -69.84 148.17 49.41 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.851 -0.613 . . . . 0.58 109.91 178.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 103.38 -8.3 52.24 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.7 -0.762 . . . . 0.94 112.942 -178.162 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 338' ' ' GLN . . . . . 0.794 HE22 ' HB2' ' A' ' 334' ' ' PHE . 30.1 pt20 -83.91 160.82 21.02 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.832 0.316 . . . . 2.62 110.215 179.367 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -107.32 21.63 30.59 Favored Glycine 0 CA--C 1.52 0.354 0 C-N-CA 120.485 -0.864 . . . . 0.74 114.307 -172.481 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -114.93 9.56 16.16 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 117.574 0.687 . . . . 2.09 111.093 178.47 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 27.3 m -116.11 146.55 20.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 108.341 -0.985 . . . . 0.43 108.341 172.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 11.4 pt -68.88 151.98 9.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 N-CA-C 109.743 -0.466 . . . . 0.32 109.743 -178.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 343' ' ' LYS . . . . . 0.524 ' HA ' ' HE2' ' A' ' 343' ' ' LYS . 6.2 mmpt? -61.85 -30.38 70.81 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 111.894 0.331 . . . . 2.93 111.894 -172.778 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -54.86 -31.4 54.68 Favored Glycine 0 CA--C 1.521 0.457 0 C-N-CA 120.878 -0.677 . . . . 0.3 112.343 173.647 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 9.3 m95 -77.48 -60.8 2.22 Favored 'General case' 0 C--O 1.22 -0.452 0 CA-C-O 120.531 0.205 . . . . 0.39 111.055 176.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -51.14 -28.87 11.93 Favored 'General case' 0 N--CA 1.47 0.544 0 N-CA-C 112.327 0.491 . . . . 1.75 112.327 -179.336 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 63.6 mt -91.19 -51.17 12.08 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.533 0 N-CA-C 111.946 0.35 . . . . 0.39 111.946 177.523 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -63.95 -31.1 79.68 Favored Glycine 0 CA--C 1.524 0.606 0 C-N-CA 121.282 -0.485 . . . . 0.34 113.758 -178.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 349' ' ' VAL . . . . . 0.546 ' O ' ' HB2' ' A' ' 352' ' ' MET . 90.8 t -79.7 -19.87 12.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 121.024 0.44 . . . . 0.32 110.645 179.704 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -64.6 113.64 3.86 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.373 -0.376 . . . . 0.47 110.132 178.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 97.07 15.17 39.79 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 121.035 -0.603 . . . . 0.39 112.11 -176.634 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 352' ' ' MET . . . . . 0.546 ' HB2' ' O ' ' A' ' 349' ' ' VAL . 0.0 OUTLIER -77.12 154.9 32.78 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 109.296 -0.631 . . . . 1.28 109.296 175.264 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 353' ' ' ALA . . . . . 0.405 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -129.95 134.92 47.77 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.729 0.299 . . . . 0.55 111.166 -177.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 61.4 t -59.85 123.39 12.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.017 -0.538 . . . . 0.36 110.681 177.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 109.47 -12.36 33.2 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 121.136 -0.554 . . . . 0.44 112.022 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -104.89 150.9 17.2 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.761 -0.733 . . . . 0.3 112.737 -179.538 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 357' ' ' GLU . . . . . 0.442 ' CB ' ' HB3' ' A' ' 387' ' ' LYS . 40.0 tt0 -122.44 140.37 52.8 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.247 -0.649 . . . . 1.41 109.247 176.461 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 358' ' ' ARG . . . . . . . . . . . . . 3.1 ptp180 -146.15 137.55 24.71 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.157 0.503 . . . . 1.37 111.178 175.425 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 359' ' ' ARG . . . . . . . . . . . . . 11.9 ttp180 -87.27 117.63 26.16 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.047 -0.723 . . . . 2.79 109.047 174.734 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 360' ' ' ILE . . . . . 0.43 HG12 HG22 ' A' ' 292' ' ' ILE . 65.1 mt -103.17 126.26 57.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-N 115.979 -0.555 . . . . 0.38 110.535 -175.125 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 361' ' ' VAL . . . . . . . . . . . . . 47.7 t -100.73 115.12 41.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 109.175 -0.676 . . . . 0.39 109.175 175.427 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 362' ' ' ILE . . . . . 0.411 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 60.5 mt -110.21 108.97 58.86 Favored Pre-proline 0 C--N 1.322 -0.603 0 CA-C-N 116.447 -0.342 . . . . 0.29 110.689 -175.456 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 363' ' ' PRO . . . . . 0.485 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 35.6 Cg_endo -65.51 162.03 35.75 Favored 'Trans proline' 0 C--O 1.239 0.541 0 C-N-CA 122.42 2.08 . . . . 0.66 111.613 175.432 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 364' ' ' ALA . . . . . . . . . . . . . . . -52.61 -48.89 88.87 Favored Pre-proline 0 CA--C 1.537 0.47 0 N-CA-C 113.85 1.055 . . . . 0.42 113.85 -173.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 365' ' ' PRO . . . . . 0.485 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 74.1 Cg_exo -52.14 -29.74 38.35 Favored 'Trans proline' 0 C--N 1.359 1.09 0 C-N-CA 122.501 2.134 . . . . 0.7 114.212 -175.505 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 366' ' ' TYR . . . . . 0.487 ' CE2' ' HA3' ' A' ' 288' ' ' GLY . 43.1 m-85 -101.05 10.16 41.35 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 112.196 0.443 . . . . 0.69 112.196 -175.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -125.39 -110.81 0.3 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.806 -0.179 . . . . 0.86 110.572 175.484 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -90.02 -22.17 22.01 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.991 0.424 . . . . 1.0 111.317 178.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 70.7 -95.87 0.56 Allowed Glycine 0 N--CA 1.448 -0.51 0 CA-C-N 115.996 -0.547 . . . . 0.56 113.761 175.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 23.4 pttm -109.17 8.12 25.76 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.622 0.248 . . . . 2.76 111.645 -171.625 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 6.3 tp-100 -89.48 120.25 30.63 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.864 0.364 . . . . 2.65 110.56 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 372' ' ' ALA . . . . . 0.794 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -92.47 93.71 8.71 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-O 121.436 0.636 . . . . 1.01 110.592 178.025 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 43.3 mt -81.97 162.99 55.4 Favored Pre-proline 0 C--N 1.318 -0.784 0 CA-C-N 115.373 -0.83 . . . . 0.93 109.079 176.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_exo -61.14 114.97 2.42 Favored 'Trans proline' 0 N--CA 1.462 -0.378 0 C-N-CA 121.478 1.452 . . . . 1.31 110.645 172.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 91.23 -26.63 11.01 Favored Glycine 0 CA--C 1.521 0.413 0 C-N-CA 121.086 -0.578 . . . . 0.9 112.525 -178.457 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 23.5 mt -126.62 81.94 67.66 Favored Pre-proline 0 CA--C 1.533 0.32 0 CA-C-O 120.638 0.256 . . . . 0.74 110.518 -177.118 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 377' ' ' PRO . . . . . 0.794 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 73.5 Cg_endo -80.17 167.85 19.28 Favored 'Trans proline' 0 N--CA 1.463 -0.322 0 C-N-CA 122.693 2.262 . . . . 0.71 113.156 -177.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 378' ' ' ALA . . . . . 0.408 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -49.12 147.25 3.04 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 115.572 -0.74 . . . . 0.74 111.862 178.834 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 379' ' ' ASN . . . . . 0.408 ' HB2' ' O ' ' A' ' 378' ' ' ALA . 42.2 m-80 67.75 33.31 4.94 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 115.712 -0.676 . . . . 1.49 110.688 -175.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 2.4 p -82.29 133.16 35.23 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.922 -0.581 . . . . 1.84 111.42 179.506 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 381' ' ' GLU . . . . . 0.441 ' HB3' ' HB2' ' A' ' 318' ' ' LYS . 32.1 tt0 -104.03 106.64 17.21 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.73 -0.668 . . . . 1.03 109.398 177.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 382' ' ' LEU . . . . . 0.4 HD23 HD23 ' A' ' 317' ' ' LEU . 89.9 mt -86.83 139.97 30.15 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.832 0.349 . . . . 0.37 111.093 -177.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 33.4 m -117.89 117.51 29.49 Favored 'General case' 0 N--CA 1.446 -0.629 0 N-CA-C 109.153 -0.684 . . . . 0.27 109.153 175.645 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 33.9 m-85 -113.69 117.29 31.14 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.214 0.53 . . . . 0.32 111.784 -175.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -85.49 103.82 14.71 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 107.946 -1.131 . . . . 1.8 107.946 172.311 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 386' ' ' VAL . . . . . 0.509 HG12 ' CB ' ' A' ' 313' ' ' TYR . 35.3 m -130.29 141.17 47.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.65 0.738 . . . . 0.31 111.89 -173.159 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 387' ' ' LYS . . . . . 0.442 ' HB3' ' CB ' ' A' ' 357' ' ' GLU . 10.7 pttm -141.07 141.54 34.25 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.148 -0.933 . . . . 2.53 109.747 174.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 388' ' ' LEU . . . . . 0.869 HD11 ' HB ' ' A' ' 309' ' ' VAL . 16.9 tp -94.24 127.35 40.04 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.962 -0.755 . . . . 0.28 108.962 -176.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 34.2 m -125.92 -0.6 4.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 C-N-CA 120.897 -0.321 . . . . 0.45 111.056 -172.094 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 22.9 t -165.15 157.52 15.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.254 -0.43 . . . . 1.32 111.164 179.65 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 391' ' ' MET . . . . . 0.428 ' SD ' ' HB2' ' A' ' 301' ' ' PRO . 39.1 ttm -162.29 132.86 4.85 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.412 -0.813 . . . . 0.56 109.407 175.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 392' ' ' LYS . . . . . 0.424 ' C ' HH21 ' A' ' 308' ' ' ARG . 31.9 mmtp . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.496 -0.764 . . . . 4.91 110.408 -177.64 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.543 HG22 ' HG2' ' A' ' 293' ' ' GLU . 28.3 p . . . . . 0 N--CA 1.449 -0.497 0 CA-C-O 120.894 0.378 . . . . 0.76 111.377 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 43.4 mtpt -127.58 156.98 41.39 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.528 -0.545 . . . . 2.06 109.528 175.037 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 37.7 tp -112.47 119.24 37.53 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.373 -0.376 . . . . 0.98 110.087 -178.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.638 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 92.3 mt -99.37 -170.16 1.87 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.927 -0.579 . . . . 0.8 110.411 178.574 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -50.86 142.93 10.79 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.11 0.481 . . . . 2.64 111.554 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 73.08 -102.74 1.28 Allowed Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 121.069 -0.586 . . . . 1.84 111.9 -178.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . -146.44 28.04 1.65 Allowed Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 110.691 -0.964 . . . . 0.64 110.691 177.184 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 290' ' ' ILE . . . . . 0.638 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 66.2 mt -74.48 125.57 34.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 115.335 -0.432 . . . . 0.42 110.53 -175.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.401 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 8.1 mt -111.12 142.69 22.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 N-CA-C 109.384 -0.599 . . . . 0.93 109.384 -179.024 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 292' ' ' ILE . . . . . . . . . . . . . 18.5 pt -132.8 128.47 57.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 120.859 0.361 . . . . 0.48 111.222 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 293' ' ' GLU . . . . . 0.601 ' HB2' ' HB3' ' A' ' 359' ' ' ARG . 40.0 mt-10 -103.99 131.79 50.88 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.334 -0.848 . . . . 2.31 110.204 175.618 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -79.98 126.48 31.08 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.234 0.54 . . . . 2.36 109.966 175.492 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 295' ' ' ARG . . . . . 0.602 ' HA ' ' HE ' ' A' ' 295' ' ' ARG . 2.6 mmp_? -105.28 -59.23 1.79 Allowed 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.46 -0.57 . . . . 3.5 109.46 175.36 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.644 ' HB ' ' HG2' ' A' ' 357' ' ' GLU . 90.0 t -131.77 105.18 9.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.822 -0.626 . . . . 0.7 109.334 174.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 10.2 t -68.9 138.72 54.89 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.068 0.461 . . . . 1.93 109.827 178.013 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -128.47 161.82 22.17 Favored Glycine 0 N--CA 1.442 -0.959 0 C-N-CA 120.316 -0.945 . . . . 1.04 112.067 -175.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 23.3 tptm -127.26 110.96 13.39 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 109.799 -0.445 . . . . 4.49 109.799 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -171.43 -154.58 9.95 Favored Glycine 0 N--CA 1.441 -0.98 0 N-CA-C 111.381 -0.688 . . . . 1.04 111.381 -178.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . 0.554 ' O ' ' HA ' ' A' ' 353' ' ' ALA . 21.9 Cg_exo -65.12 133.73 36.64 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.988 2.459 . . . . 0.88 111.744 177.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 52.7 m80 -93.32 139.55 30.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.731 0.301 . . . . 1.49 110.35 -179.376 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -74.03 151.73 40.16 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.053 -0.522 . . . . 0.54 111.832 -179.153 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 304' ' ' LYS . . . . . 0.46 ' HG2' ' N ' ' A' ' 305' ' ' LYS . 25.6 ttpp -152.98 169.25 23.35 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 115.855 -0.611 . . . . 2.84 109.387 -178.602 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.46 ' N ' ' HG2' ' A' ' 304' ' ' LYS . 99.4 mttt -64.91 130.94 45.29 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 110.136 -0.32 . . . . 2.84 110.136 176.252 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 92.44 -11.8 71.23 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 121.094 -0.575 . . . . 0.7 111.852 -178.682 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 52.5 m -83.5 140.08 32.52 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 122.457 0.303 . . . . 0.4 110.57 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 50.7 mtt180 -100.68 104.74 16.05 Favored 'General case' 0 CA--C 1.516 -0.36 0 N-CA-C 109.002 -0.74 . . . . 3.45 109.002 -179.514 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.848 ' HB ' HD11 ' A' ' 388' ' ' LEU . 33.7 m -102.12 140.01 21.72 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.915 0 CA-C-O 121.276 0.56 . . . . 0.34 111.14 -176.719 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 310' ' ' GLY . . . . . 0.467 ' HA2' ' HA ' ' A' ' 333' ' ' VAL . . . -115.01 125.85 6.94 Favored Glycine 0 N--CA 1.441 -1.029 0 N-CA-C 110.136 -1.186 . . . . 0.27 110.136 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 13.4 ptp -134.07 177.04 8.05 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-O 121.459 0.647 . . . . 0.76 112.123 -173.75 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 312' ' ' ARG . . . . . 0.776 ' HE ' HG11 ' A' ' 389' ' ' VAL . 72.5 mtm180 -138.25 140.85 39.85 Favored 'General case' 0 C--N 1.317 -0.813 0 N-CA-C 106.995 -1.483 . . . . 2.51 106.995 172.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 313' ' ' TYR . . . . . 0.42 ' CE2' ' HH2' ' A' ' 345' ' ' TRP . 9.8 p90 -158.55 169.53 24.23 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 119.593 -0.843 . . . . 0.68 113.056 -167.404 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 26.2 t -129.42 108.07 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 CA-C-N 114.33 -1.305 . . . . 0.35 109.086 171.234 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -88.28 110.38 3.63 Favored Glycine 0 N--CA 1.447 -0.576 0 N-CA-C 111.761 -0.535 . . . . 0.28 111.761 -177.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 316' ' ' LYS . . . . . 0.86 ' HG2' HG22 ' A' ' 322' ' ' VAL . 51.0 mttp -115.81 164.38 14.46 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.175 0.512 . . . . 1.94 110.831 -176.331 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 94.1 mt -87.95 158.67 18.6 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 107.561 -1.274 . . . . 0.65 107.561 164.702 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 318' ' ' LYS . . . . . 0.801 ' HG2' ' HB3' ' A' ' 381' ' ' GLU . 0.1 OUTLIER -63.29 -8.76 9.25 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.011 0.434 . . . . 2.42 111.232 178.978 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 85.8 m-20 -81.16 -14.55 57.51 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.123 -0.489 . . . . 2.2 110.769 177.059 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 109.55 -18.53 29.79 Favored Glycine 0 CA--C 1.518 0.25 0 C-N-CA 120.806 -0.711 . . . . 0.69 112.853 179.148 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 55.2 mtpt -78.08 138.57 38.83 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.662 0.268 . . . . 2.42 111.249 -176.572 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.86 HG22 ' HG2' ' A' ' 316' ' ' LYS . 47.7 t -97.8 136.84 27.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.123 -0.489 . . . . 1.26 110.466 -176.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -118.21 -24.8 6.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.85 0.357 . . . . 0.55 111.164 179.416 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -140.27 146.83 39.1 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.469 -0.567 . . . . 1.68 109.469 177.173 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 21.0 ptmt -163.25 137.66 6.17 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.041 0.448 . . . . 1.99 111.48 -175.631 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 326' ' ' ASN . . . . . 0.451 ' HB2' ' HB2' ' A' ' 330' ' ' LYS . 5.8 p30 -154.58 128.9 9.05 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.796 -0.638 . . . . 1.92 110.279 170.145 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 327' ' ' THR . . . . . 0.459 ' HA ' ' HD2' ' A' ' 312' ' ' ARG . 7.6 t -163.07 -33.92 0.04 OUTLIER 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.676 -0.693 . . . . 1.69 110.573 -177.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 58.8 mttp -89.29 95.46 10.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.657 -0.247 . . . . 2.55 110.441 177.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.511 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 73.65 -10.33 7.01 Favored Glycine 0 CA--C 1.518 0.275 0 C-N-CA 121.137 -0.554 . . . . 0.97 113.439 177.234 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 330' ' ' LYS . . . . . 0.451 ' HB2' ' HB2' ' A' ' 326' ' ' ASN . 58.7 mttm -103.03 100.74 17.97 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 116.945 0.372 . . . . 2.08 111.291 -177.305 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 331' ' ' PRO . . . . . 0.511 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 87.5 Cg_endo -88.84 143.51 5.05 Favored 'Trans proline' 0 N--CA 1.452 -0.917 0 C-N-CA 122.7 2.267 . . . . 0.62 112.034 170.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 73.8 t80 -116.01 115.65 26.51 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.594 -0.521 . . . . 0.64 109.594 174.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 333' ' ' VAL . . . . . 0.467 ' HA ' ' HA2' ' A' ' 310' ' ' GLY . 42.7 t -114.73 117.08 54.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 120.559 0.218 . . . . 0.38 110.517 -175.375 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.523 ' HZ ' HG21 ' A' ' 349' ' ' VAL . 27.8 p90 -136.18 160.78 37.63 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 110.173 -0.306 . . . . 0.41 110.173 -178.749 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 335' ' ' LYS . . . . . 0.641 ' O ' ' HG2' ' A' ' 338' ' ' GLN . 6.0 ptmt -106.04 134.62 48.88 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.016 0.436 . . . . 2.58 111.513 -179.187 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 10.8 mp -68.82 117.8 10.98 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.332 -0.395 . . . . 0.58 110.174 177.452 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 128.86 -19.27 5.55 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.832 -0.699 . . . . 0.94 112.207 -179.279 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 338' ' ' GLN . . . . . 0.798 HE21 ' HB2' ' A' ' 340' ' ' GLU . 18.8 pt20 -72.53 138.55 47.0 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.836 0.35 . . . . 2.62 110.742 179.883 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -86.65 20.31 24.21 Favored Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 120.931 -0.652 . . . . 0.74 111.56 176.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 340' ' ' GLU . . . . . 0.798 ' HB2' HE21 ' A' ' 338' ' ' GLN . 11.5 mt-10 -89.22 -11.05 44.77 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.287 -0.635 . . . . 2.09 109.287 178.007 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 35.5 m -112.98 173.53 2.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.353 -0.84 . . . . 0.43 109.587 177.386 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 342' ' ' ILE . . . . . 0.57 HD12 ' HA ' ' A' ' 367' ' ' ALA . 8.7 pt -92.81 159.96 2.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 N-CA-C 109.736 -0.468 . . . . 0.32 109.736 178.322 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 343' ' ' LYS . . . . . 0.509 ' HA ' ' HE2' ' A' ' 343' ' ' LYS . 3.4 mmpt? -55.97 -35.73 67.06 Favored 'General case' 0 N--CA 1.467 0.377 0 N-CA-C 112.219 0.451 . . . . 2.93 112.219 -174.78 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 344' ' ' GLY . . . . . 0.428 ' HA3' HD13 ' A' ' 362' ' ' ILE . . . -56.18 -28.74 54.94 Favored Glycine 0 CA--C 1.521 0.446 0 C-N-CA 120.805 -0.712 . . . . 0.3 113.061 177.628 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 345' ' ' TRP . . . . . 0.42 ' HH2' ' CE2' ' A' ' 313' ' ' TYR . 11.2 m95 -79.01 -59.99 2.56 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 112.715 0.635 . . . . 0.39 112.715 -177.063 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 9.0 p-10 -63.92 -22.85 67.11 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 118.046 0.384 . . . . 1.75 111.268 -175.815 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 73.5 mt -86.52 -53.63 9.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.05 -0.523 . . . . 0.39 111.249 176.477 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -64.52 -32.61 84.78 Favored Glycine 0 CA--C 1.523 0.549 0 C-N-CA 121.184 -0.531 . . . . 0.34 113.894 -178.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 349' ' ' VAL . . . . . 0.523 HG21 ' HZ ' ' A' ' 334' ' ' PHE . 93.7 t -80.48 -14.4 12.91 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 CA-C-O 121.047 0.451 . . . . 0.32 111.242 -179.798 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.08 131.67 47.17 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.237 0.541 . . . . 0.47 110.632 178.531 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 79.89 16.15 77.68 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.821 -0.704 . . . . 0.39 112.387 -179.145 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 352' ' ' MET . . . . . 0.408 ' SD ' ' HG2' ' A' ' 358' ' ' ARG . 42.7 mmm -82.6 149.46 27.42 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.643 0.259 . . . . 1.28 110.53 174.238 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 353' ' ' ALA . . . . . 0.554 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -122.84 137.83 54.82 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.031 -0.531 . . . . 0.55 110.491 -179.56 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 354' ' ' VAL . . . . . 0.531 ' HB ' ' HD2' ' A' ' 301' ' ' PRO . 87.6 t -55.33 122.85 5.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.147 -0.479 . . . . 0.36 110.679 176.499 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 111.27 -16.1 27.37 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.927 -0.654 . . . . 0.44 112.175 -178.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -108.37 160.81 13.58 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.692 -0.766 . . . . 0.3 112.439 -178.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 357' ' ' GLU . . . . . 0.845 ' HB3' ' HB2' ' A' ' 387' ' ' LYS . 9.9 pt-20 -139.03 135.91 34.74 Favored 'General case' 0 C--O 1.238 0.462 0 CA-C-O 121.08 0.467 . . . . 1.41 111.171 178.573 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 358' ' ' ARG . . . . . 0.408 ' HG2' ' SD ' ' A' ' 352' ' ' MET . 4.9 ptp180 -132.17 140.46 48.75 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.83 -0.623 . . . . 1.37 109.931 177.445 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 359' ' ' ARG . . . . . 0.601 ' HB3' ' HB2' ' A' ' 293' ' ' GLU . 39.6 ttm180 -86.42 116.15 24.39 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.909 -0.587 . . . . 2.79 109.671 177.086 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 42.2 mt -99.42 117.77 45.05 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 CA-C-N 116.007 -0.542 . . . . 0.38 110.485 -177.536 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 361' ' ' VAL . . . . . 0.401 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 47.2 t -100.52 112.4 33.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 N-CA-C 108.714 -0.847 . . . . 0.39 108.714 175.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 362' ' ' ILE . . . . . 0.462 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 47.9 mt -110.59 109.37 58.04 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 116.073 -0.512 . . . . 0.29 111.67 -171.001 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 363' ' ' PRO . . . . . 0.462 ' HD2' ' HA ' ' A' ' 362' ' ' ILE . 13.8 Cg_endo -57.0 157.22 21.13 Favored 'Trans proline' 0 C--O 1.235 0.357 0 C-N-CA 123.098 2.532 . . . . 0.66 112.185 172.045 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 364' ' ' ALA . . . . . 0.584 ' HB2' ' HA ' ' A' ' 379' ' ' ASN . . . -47.0 -53.8 24.6 Favored Pre-proline 0 CA--C 1.538 0.482 0 N-CA-C 114.051 1.13 . . . . 0.42 114.051 -176.138 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 365' ' ' PRO . . . . . 0.442 ' HD2' ' N ' ' A' ' 364' ' ' ALA . 27.3 Cg_endo -61.6 -15.32 40.98 Favored 'Trans proline' 0 C--N 1.358 1.049 0 C-N-CA 122.2 1.933 . . . . 0.7 114.207 -172.376 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 366' ' ' TYR . . . . . . . . . . . . . 12.2 m-85 -109.25 5.08 23.42 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.794 0.331 . . . . 0.69 111.387 -178.727 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 367' ' ' ALA . . . . . 0.57 ' HA ' HD12 ' A' ' 342' ' ' ILE . . . -119.52 -125.09 0.28 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.435 -0.348 . . . . 0.86 110.41 176.454 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 42.0 m-85 -68.9 -19.02 64.2 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-O 120.562 0.22 . . . . 1.0 111.297 179.232 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 74.96 -117.63 5.41 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.957 -0.639 . . . . 0.56 113.177 177.587 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 370' ' ' LYS . . . . . 0.446 ' HA ' ' HB1' ' A' ' 378' ' ' ALA . 0.0 OUTLIER -111.54 13.57 21.35 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.652 -0.274 . . . . 2.76 111.467 -173.931 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 51.0 tp60 -103.98 108.28 19.55 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.137 0.494 . . . . 2.65 110.875 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 372' ' ' ALA . . . . . 0.41 ' HB1' ' HA ' ' A' ' 377' ' ' PRO . . . -75.42 119.18 19.16 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-N 115.77 -0.65 . . . . 1.01 111.664 178.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 75.3 mt -90.68 160.07 39.48 Favored Pre-proline 0 C--N 1.32 -0.716 0 N-CA-C 108.975 -0.75 . . . . 0.93 108.975 174.309 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -59.6 114.18 1.94 Allowed 'Trans proline' 0 N--CA 1.461 -0.384 0 C-N-CA 121.326 1.351 . . . . 1.31 110.831 173.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 97.2 -29.5 10.65 Favored Glycine 0 CA--C 1.52 0.38 0 C-N-CA 121.129 -0.558 . . . . 0.9 112.768 -177.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 37.7 mt -126.7 94.23 40.56 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.66 0.23 . . . . 0.74 110.461 -178.237 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 377' ' ' PRO . . . . . 0.41 ' HA ' ' HB1' ' A' ' 372' ' ' ALA . 72.1 Cg_endo -75.47 167.36 26.76 Favored 'Trans proline' 0 N--CA 1.461 -0.418 0 C-N-CA 122.51 2.14 . . . . 0.71 112.839 -176.523 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 378' ' ' ALA . . . . . 0.446 ' HB1' ' HA ' ' A' ' 370' ' ' LYS . . . -57.82 152.13 16.45 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.842 -0.617 . . . . 0.74 111.42 178.656 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 379' ' ' ASN . . . . . 0.584 ' HA ' ' HB2' ' A' ' 364' ' ' ALA . 13.6 m120 72.12 14.25 5.68 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 115.714 -0.676 . . . . 1.49 111.962 179.072 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 33.7 m -70.45 112.43 6.74 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.187 0.517 . . . . 1.84 110.861 176.327 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 381' ' ' GLU . . . . . 0.801 ' HB3' ' HG2' ' A' ' 318' ' ' LYS . 40.9 tt0 -72.95 105.11 4.3 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.259 -0.882 . . . . 1.03 109.444 175.236 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 86.6 mt -82.67 148.99 27.61 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.025 -0.534 . . . . 0.37 111.569 -175.687 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 29.4 m -130.57 120.09 23.51 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.589 -0.522 . . . . 0.27 109.589 176.08 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 -121.39 110.45 16.1 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.757 0.313 . . . . 0.32 111.484 -174.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 23.2 m-20 -82.42 103.92 12.34 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 108.375 -0.972 . . . . 1.8 108.375 168.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 386' ' ' VAL . . . . . . . . . . . . . 28.2 m -118.28 128.33 75.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.256 0.551 . . . . 0.31 111.56 -175.533 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 387' ' ' LYS . . . . . 0.845 ' HB2' ' HB3' ' A' ' 357' ' ' GLU . 28.9 ttpt -120.58 131.11 54.49 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.621 -0.718 . . . . 2.53 109.756 175.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 388' ' ' LEU . . . . . 0.848 HD11 ' HB ' ' A' ' 309' ' ' VAL . 17.7 tp -87.43 130.29 34.73 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.33 -0.619 . . . . 0.28 109.33 -174.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 389' ' ' VAL . . . . . 0.776 HG11 ' HE ' ' A' ' 312' ' ' ARG . 17.6 m -121.08 -12.75 8.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 111.997 0.369 . . . . 0.45 111.997 -172.625 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 55.4 p -162.28 170.6 18.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.704 0.288 . . . . 1.32 110.8 -178.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 391' ' ' MET . . . . . 0.432 ' HE3' ' HB2' ' A' ' 391' ' ' MET . 36.8 ttm -169.74 137.94 1.78 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.112 -0.495 . . . . 0.56 110.652 -179.053 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 99.2 mttt . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.35 -0.833 . . . . 4.91 110.265 177.587 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 20.8 p . . . . . 0 N--CA 1.446 -0.626 0 CA-C-O 120.741 0.305 . . . . 0.76 110.991 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 25.5 mtpp -129.98 135.38 48.24 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.879 -0.415 . . . . 2.06 109.879 170.651 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . 0.414 HD11 ' HA2' ' A' ' 289' ' ' GLY . 47.7 tp -94.01 120.77 34.71 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.884 -0.598 . . . . 0.98 109.989 -177.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.609 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 88.3 mt -104.54 -171.95 2.02 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.554 -0.748 . . . . 0.8 110.308 178.433 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 287' ' ' GLU . . . . . 0.65 ' HG3' ' OH ' ' A' ' 366' ' ' TYR . 7.3 tp10 -61.31 145.32 51.83 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.634 -0.712 . . . . 2.64 111.377 -177.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 67.24 17.29 68.03 Favored Glycine 0 CA--C 1.521 0.439 0 C-N-CA 121.171 -0.537 . . . . 1.84 113.967 176.008 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . 0.414 ' HA2' HD11 ' A' ' 285' ' ' LEU . . . 82.06 17.4 69.76 Favored Glycine 0 C--N 1.33 0.197 0 C-N-CA 120.512 -0.851 . . . . 0.64 113.179 178.086 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 290' ' ' ILE . . . . . 0.609 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 87.8 mt -69.62 126.47 29.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 109.813 -0.439 . . . . 0.42 109.813 176.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 10.5 mt -114.81 135.21 55.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 109.448 -0.575 . . . . 0.93 109.448 -179.771 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 292' ' ' ILE . . . . . . . . . . . . . 24.5 pt -124.19 129.64 74.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-O 121.019 0.438 . . . . 0.48 110.563 -177.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 293' ' ' GLU . . . . . . . . . . . . . 25.9 tt0 -107.7 121.18 44.18 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.403 -0.817 . . . . 2.31 109.367 178.033 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -83.19 120.85 26.32 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.352 0.596 . . . . 2.36 109.95 -179.624 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 295' ' ' ARG . . . . . 0.569 ' HD2' ' HB2' ' A' ' 359' ' ' ARG . 68.6 mtp180 -102.06 -50.77 3.56 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.37 -0.377 . . . . 3.5 110.312 -176.768 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.51 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 60.3 t -118.71 115.09 46.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 109.78 -0.452 . . . . 0.7 109.78 174.676 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 20.7 p -81.06 121.52 26.18 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.036 -0.529 . . . . 1.93 111.682 -177.507 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -134.99 173.71 21.46 Favored Glycine 0 N--CA 1.446 -0.654 0 N-CA-C 111.632 -0.587 . . . . 1.04 111.632 179.049 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -151.27 128.17 11.0 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.261 0.553 . . . . 4.49 109.892 174.572 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -172.92 -153.5 9.54 Favored Glycine 0 N--CA 1.443 -0.874 0 N-CA-C 110.869 -0.892 . . . . 1.04 110.869 -177.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_exo -56.64 133.36 57.53 Favored 'Trans proline' 0 N--CA 1.462 -0.372 0 C-N-CA 122.369 2.046 . . . . 0.88 111.017 173.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 302' ' ' HIS . . . . . 0.418 ' HA ' ' O ' ' A' ' 352' ' ' MET . 53.6 m80 -100.48 144.24 29.71 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.42 -0.355 . . . . 1.49 111.033 -176.604 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 303' ' ' ALA . . . . . 0.442 ' HB2' HG11 ' A' ' 309' ' ' VAL . . . -77.39 125.84 29.96 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.832 -0.622 . . . . 0.54 111.382 -179.239 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 304' ' ' LYS . . . . . 0.404 ' O ' ' HB2' ' A' ' 336' ' ' LEU . 98.4 mttt -133.21 179.47 6.18 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.717 -0.674 . . . . 2.84 109.922 176.472 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.942 ' HG3' ' HA3' ' A' ' 337' ' ' GLY . 87.0 tttt -67.39 130.99 44.82 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.839 0.352 . . . . 2.84 110.268 177.03 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 95.99 -26.02 22.7 Favored Glycine 0 N--CA 1.448 -0.542 0 N-CA-C 111.42 -0.672 . . . . 0.7 111.42 -177.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 307' ' ' THR . . . . . 0.628 ' O ' ' HA ' ' A' ' 335' ' ' LYS . 9.7 m -72.51 131.36 42.43 Favored 'General case' 0 N--CA 1.449 -0.52 0 CA-C-N 115.619 -0.291 . . . . 0.4 110.224 178.239 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 308' ' ' ARG . . . . . 0.645 ' HG2' ' HB3' ' A' ' 335' ' ' LYS . 49.6 mtp180 -102.18 104.37 14.95 Favored 'General case' 0 N--CA 1.452 -0.356 0 N-CA-C 108.651 -0.87 . . . . 3.45 108.651 -179.676 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.787 ' HB ' HD11 ' A' ' 388' ' ' LEU . 32.0 m -99.58 140.02 19.88 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-O 121.243 0.544 . . . . 0.34 111.267 -171.034 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -103.79 113.3 4.43 Favored Glycine 0 N--CA 1.442 -0.933 0 CA-C-N 114.956 -1.02 . . . . 0.27 110.646 179.508 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 13.3 ptp -133.62 176.89 8.15 Favored 'General case' 0 N--CA 1.441 -0.92 0 CA-C-O 121.92 0.867 . . . . 0.76 112.273 -173.516 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 49.4 mtp180 -135.46 145.16 46.91 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 113.81 -1.541 . . . . 2.51 106.976 177.174 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 313' ' ' TYR . . . . . 0.511 ' HA ' ' O ' ' A' ' 385' ' ' ASP . 44.9 p90 -161.42 155.63 22.57 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.461 0.648 . . . . 0.68 112.708 -170.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 57.7 t -122.48 120.01 59.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 114.756 -1.111 . . . . 0.35 109.45 175.263 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -101.37 115.23 5.21 Favored Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.83 -0.7 . . . . 0.28 112.461 -177.046 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 316' ' ' LYS . . . . . 0.502 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 62.7 mttm -112.29 151.09 30.08 Favored 'General case' 0 C--N 1.331 -0.221 0 O-C-N 123.946 0.439 . . . . 1.94 111.193 -179.278 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 317' ' ' LEU . . . . . 0.579 HD21 HG12 ' A' ' 376' ' ' ILE . 80.1 mt -84.95 -178.5 6.85 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.505 -0.771 . . . . 0.65 112.114 178.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 318' ' ' LYS . . . . . 0.591 ' HD3' ' H ' ' A' ' 381' ' ' GLU . 49.7 tptt -57.43 -32.59 67.03 Favored 'General case' 0 N--CA 1.461 0.111 0 CA-C-N 115.198 -0.91 . . . . 2.42 110.854 176.82 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 27.0 p-10 -92.7 6.9 45.78 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.078 -0.51 . . . . 2.2 111.368 -177.244 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 88.13 -8.22 79.02 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.638 -0.791 . . . . 0.69 112.641 178.155 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 28.7 tptp -66.25 114.19 5.14 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.028 0.442 . . . . 2.42 110.634 179.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.502 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 4.0 p -68.15 122.44 19.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-N 115.788 -0.642 . . . . 1.26 109.856 175.571 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 323' ' ' PHE . . . . . 0.46 ' HD1' ' HG ' ' A' ' 317' ' ' LEU . 43.1 p90 -100.83 -30.48 11.66 Favored 'General case' 0 C--N 1.322 -0.596 0 C-N-CA 120.738 -0.385 . . . . 0.55 110.794 -178.776 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -149.48 160.08 43.76 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.835 -0.346 . . . . 1.68 110.622 178.719 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 14.8 pttp -166.66 128.42 1.75 Allowed 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.129 -0.487 . . . . 1.99 110.505 -178.38 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -124.82 117.9 25.18 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.947 -0.76 . . . . 1.92 108.947 178.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 2.0 t -164.05 -45.04 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.47 -0.332 . . . . 1.69 111.278 -175.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 12.6 ptmm? -89.44 100.41 13.21 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.317 0.579 . . . . 2.55 110.84 -177.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.473 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 86.28 -26.76 6.03 Favored Glycine 0 N--CA 1.452 -0.292 0 CA-C-N 115.532 -0.758 . . . . 0.97 113.074 178.023 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -103.36 100.78 19.44 Favored Pre-proline 0 C--N 1.329 -0.309 0 N-CA-C 111.729 0.27 . . . . 2.08 111.729 -177.001 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 331' ' ' PRO . . . . . 0.473 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 84.2 Cg_endo -87.79 125.93 2.07 Favored 'Trans proline' 0 N--CA 1.45 -1.078 0 C-N-CA 122.35 2.034 . . . . 0.62 110.342 165.869 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 43.1 t80 -99.92 115.6 30.02 Favored 'General case' 0 C--N 1.321 -0.639 0 C-N-CA 120.486 -0.485 . . . . 0.64 110.107 -177.323 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 333' ' ' VAL . . . . . 0.638 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 47.5 t -111.94 113.17 43.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 116.032 -0.531 . . . . 0.38 109.939 -177.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 30.7 p90 -135.99 149.44 48.86 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.313 -0.403 . . . . 0.41 110.41 -178.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 335' ' ' LYS . . . . . 0.645 ' HB3' ' HG2' ' A' ' 308' ' ' ARG . 12.0 ptmt -92.84 139.22 30.77 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 116.181 -0.463 . . . . 2.58 111.133 177.577 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 336' ' ' LEU . . . . . 0.404 ' HB2' ' O ' ' A' ' 304' ' ' LYS . 9.8 mp -77.64 151.76 34.17 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 109.517 -0.549 . . . . 0.58 109.517 172.267 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 337' ' ' GLY . . . . . 0.942 ' HA3' ' HG3' ' A' ' 305' ' ' LYS . . . 90.78 40.36 5.62 Favored Glycine 0 N--CA 1.446 -0.687 0 C-N-CA 120.698 -0.763 . . . . 0.94 112.577 -177.662 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 338' ' ' GLN . . . . . 0.494 ' HB3' ' HE2' ' A' ' 335' ' ' LYS . 29.7 pt20 -148.26 157.63 43.61 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.454 -0.573 . . . . 2.62 109.454 176.179 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -89.73 20.1 37.3 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.756 -0.735 . . . . 0.74 112.352 -176.223 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -85.18 -15.07 44.92 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.301 0.572 . . . . 2.09 110.012 178.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 25.4 m -123.58 156.78 30.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.843 -0.617 . . . . 0.43 109.855 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 342' ' ' ILE . . . . . 0.456 HD12 ' HA ' ' A' ' 367' ' ' ALA . 11.3 pt -76.79 159.93 5.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 N-CA-C 110.203 -0.295 . . . . 0.32 110.203 -179.826 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 343' ' ' LYS . . . . . 0.478 ' HA ' ' HE2' ' A' ' 343' ' ' LYS . 4.7 mmpt? -63.14 -34.38 77.48 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.19 0.441 . . . . 2.93 112.19 -173.88 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 344' ' ' GLY . . . . . 0.43 ' HA3' HD13 ' A' ' 362' ' ' ILE . . . -54.19 -33.54 52.08 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.72 -0.753 . . . . 0.3 112.383 174.564 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 11.8 m95 -81.23 -59.83 2.5 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 120.584 0.231 . . . . 0.39 110.781 177.568 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 31.5 t70 -48.76 -31.11 6.44 Favored 'General case' 0 CA--C 1.537 0.463 0 CA-C-N 116.193 -0.458 . . . . 1.75 112.107 179.049 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 71.6 mt -93.2 -52.39 9.91 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.404 0 CA-C-N 116.626 -0.261 . . . . 0.39 111.69 178.323 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -63.8 -31.84 82.16 Favored Glycine 0 C--N 1.335 0.505 0 C-N-CA 121.318 -0.468 . . . . 0.34 113.767 -176.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 98.7 t -78.28 -20.52 13.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-O 120.984 0.421 . . . . 0.32 110.812 179.442 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -63.8 118.35 8.21 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.96 0.409 . . . . 0.47 110.163 178.185 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 100.2 0.61 55.89 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.69 -0.766 . . . . 0.39 112.397 -178.017 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 352' ' ' MET . . . . . 0.418 ' O ' ' HA ' ' A' ' 302' ' ' HIS . 58.0 mmm -68.69 139.97 55.42 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.673 0.273 . . . . 1.28 110.668 175.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 353' ' ' ALA . . . . . . . . . . . . . . . -109.69 137.19 47.86 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.877 -0.601 . . . . 0.55 110.819 -178.734 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 68.4 t -56.85 117.19 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.279 -0.419 . . . . 0.36 110.125 173.449 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 111.07 -6.08 28.91 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 121.229 -0.51 . . . . 0.44 112.477 -178.555 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -105.36 154.93 17.11 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.748 -0.739 . . . . 0.3 113.126 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 357' ' ' GLU . . . . . 0.51 ' HB3' ' HB ' ' A' ' 296' ' ' VAL . 25.8 tt0 -132.61 133.53 43.76 Favored 'General case' 0 C--N 1.329 -0.293 0 C-N-CA 122.944 0.498 . . . . 1.41 109.868 -179.486 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 358' ' ' ARG . . . . . . . . . . . . . 5.0 ptp180 -144.48 143.23 30.77 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.094 0.473 . . . . 1.37 111.063 177.598 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 359' ' ' ARG . . . . . 0.569 ' HB2' ' HD2' ' A' ' 295' ' ' ARG . 11.8 ttp180 -93.35 121.47 34.77 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.696 -0.684 . . . . 2.79 109.422 174.551 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 44.9 mt -106.07 127.64 61.06 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-N 116.134 -0.485 . . . . 0.38 110.577 -175.821 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 361' ' ' VAL . . . . . . . . . . . . . 58.8 t -107.16 109.24 27.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 N-CA-C 108.868 -0.79 . . . . 0.39 108.868 175.312 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 362' ' ' ILE . . . . . 0.449 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 51.5 mt -107.11 110.04 63.25 Favored Pre-proline 0 C--N 1.322 -0.598 0 CA-C-N 116.43 -0.35 . . . . 0.29 111.495 -174.255 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 363' ' ' PRO . . . . . 0.498 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 13.2 Cg_endo -57.45 152.83 44.7 Favored 'Trans proline' 0 N--CA 1.46 -0.487 0 C-N-CA 122.641 2.228 . . . . 0.66 111.18 170.4 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 364' ' ' ALA . . . . . 0.502 ' HB2' ' HA ' ' A' ' 379' ' ' ASN . . . -47.93 -49.86 56.59 Favored Pre-proline 0 CA--C 1.537 0.479 0 N-CA-C 113.913 1.079 . . . . 0.42 113.913 -173.87 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 365' ' ' PRO . . . . . 0.498 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 77.6 Cg_exo -49.5 -35.4 36.6 Favored 'Trans proline' 0 C--N 1.36 1.18 0 C-N-CA 122.564 2.176 . . . . 0.7 114.555 -173.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 366' ' ' TYR . . . . . 0.65 ' OH ' ' HG3' ' A' ' 287' ' ' GLU . 3.1 m-85 -101.23 13.82 33.91 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.481 -0.488 . . . . 0.69 112.234 -174.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 367' ' ' ALA . . . . . 0.456 ' HA ' HD12 ' A' ' 342' ' ' ILE . . . -116.58 -105.3 0.4 Allowed 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.306 -0.406 . . . . 0.86 109.926 172.539 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 76.4 m-85 -95.87 4.82 52.48 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.988 0.423 . . . . 1.0 111.158 175.232 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 61.35 -117.4 11.48 Favored Glycine 0 N--CA 1.45 -0.371 0 CA-C-N 115.829 -0.623 . . . . 0.56 113.34 174.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 95.4 mttt -103.14 14.32 32.04 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.686 -0.257 . . . . 2.76 110.778 -176.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 27.8 tp60 -87.27 103.92 15.9 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.355 -0.384 . . . . 2.65 110.773 -177.769 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 372' ' ' ALA . . . . . 0.633 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -74.84 104.15 5.35 Favored 'General case' 0 N--CA 1.45 -0.448 0 CA-C-O 121.077 0.465 . . . . 1.01 110.542 174.517 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 90.2 mt -94.34 162.75 25.22 Favored Pre-proline 0 C--N 1.321 -0.668 0 CA-C-N 115.796 -0.638 . . . . 0.93 109.44 176.589 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_endo -63.15 114.86 2.65 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 121.724 1.616 . . . . 1.31 110.606 170.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 93.83 -30.03 7.93 Favored Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 120.941 -0.647 . . . . 0.9 112.279 -176.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 376' ' ' ILE . . . . . 0.579 HG12 HD21 ' A' ' 317' ' ' LEU . 24.3 mt -128.36 79.92 73.28 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.668 0.27 . . . . 0.74 110.615 -178.524 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 377' ' ' PRO . . . . . 0.633 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 72.5 Cg_endo -75.44 167.96 25.52 Favored 'Trans proline' 0 N--CA 1.463 -0.276 0 C-N-CA 122.379 2.053 . . . . 0.71 112.313 -179.675 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 378' ' ' ALA . . . . . 0.448 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -55.96 146.14 23.15 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.362 -0.381 . . . . 0.74 111.01 178.588 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 379' ' ' ASN . . . . . 0.502 ' HA ' ' HB2' ' A' ' 364' ' ' ALA . 49.1 m-80 75.56 9.29 3.64 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 123.435 0.694 . . . . 1.49 112.138 179.723 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 62.2 m -72.02 107.03 4.52 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.32 0.581 . . . . 1.84 110.774 174.591 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 381' ' ' GLU . . . . . 0.591 ' H ' ' HD3' ' A' ' 318' ' ' LYS . 4.5 tt0 -77.01 99.62 5.35 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.02 -0.991 . . . . 1.03 109.153 177.628 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 83.2 mt -82.46 140.44 33.38 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.167 -0.47 . . . . 0.37 110.878 -173.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 25.5 m -117.66 120.57 38.42 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 109.622 -0.51 . . . . 0.27 109.622 178.779 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 92.3 m-85 -118.92 113.68 21.4 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.611 -0.268 . . . . 0.32 111.168 -176.66 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 385' ' ' ASP . . . . . 0.511 ' O ' ' HA ' ' A' ' 313' ' ' TYR . 23.3 t70 -83.19 104.98 13.79 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 108.428 -0.952 . . . . 1.8 108.428 171.495 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 386' ' ' VAL . . . . . . . . . . . . . 36.0 m -115.27 133.21 62.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-O 121.665 0.745 . . . . 0.31 111.469 -174.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 387' ' ' LYS . . . . . . . . . . . . . 3.3 ptpp? -129.6 126.39 38.35 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.085 -0.961 . . . . 2.53 109.841 176.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 388' ' ' LEU . . . . . 0.787 HD11 ' HB ' ' A' ' 309' ' ' VAL . 22.3 tp -91.64 127.99 37.3 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 108.279 -1.008 . . . . 0.28 108.279 -179.738 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 28.2 m -127.76 -6.18 4.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 C-N-CA 120.77 -0.372 . . . . 0.45 111.591 -171.248 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 13.4 p -167.98 171.08 10.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.381 -0.372 . . . . 1.32 110.534 179.167 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 391' ' ' MET . . . . . 0.439 ' HB2' ' HE3' ' A' ' 391' ' ' MET . 31.7 ttm -164.45 143.72 7.37 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.9 0.381 . . . . 0.56 111.348 -178.232 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 3.2 tppp? . . . . . 0 C--O 1.251 1.133 0 CA-C-O 118.678 -0.677 . . . . 4.91 109.257 173.038 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.542 HG22 ' HB3' ' A' ' 293' ' ' GLU . 1.9 p . . . . . 0 N--CA 1.445 -0.7 0 N-CA-C 110.016 -0.365 . . . . 0.76 110.016 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 92.7 mttt -101.45 154.73 18.56 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 110.418 -0.215 . . . . 2.06 110.418 179.371 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 59.9 tp -110.43 112.73 24.86 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 109.722 -0.473 . . . . 0.98 109.722 176.129 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.738 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 89.4 mt -100.41 -170.97 1.94 Allowed 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.057 -0.52 . . . . 0.8 110.924 -178.132 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 287' ' ' GLU . . . . . 0.461 ' HB3' HD13 ' A' ' 347' ' ' ILE . 28.1 tt0 -50.32 136.74 19.64 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 116.011 -0.54 . . . . 2.64 111.788 -179.043 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 76.22 -99.42 1.3 Allowed Glycine 0 N--CA 1.445 -0.761 0 C-N-CA 120.755 -0.736 . . . . 1.84 111.561 -177.114 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . -151.17 31.91 0.96 Allowed Glycine 0 N--CA 1.447 -0.575 0 N-CA-C 110.736 -0.945 . . . . 0.64 110.736 175.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 290' ' ' ILE . . . . . 0.738 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 72.6 mt -74.38 121.94 26.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 110.127 -0.324 . . . . 0.42 110.127 -176.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 17.9 mt -115.1 139.86 39.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 109.307 -0.627 . . . . 0.93 109.307 -178.736 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 292' ' ' ILE . . . . . 0.406 ' O ' ' HA ' ' A' ' 283' ' ' THR . 22.0 pt -136.91 127.02 39.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 C-N-CA 120.816 -0.354 . . . . 0.48 110.637 -179.098 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 293' ' ' GLU . . . . . 0.542 ' HB3' HG22 ' A' ' 283' ' ' THR . 16.9 pt-20 -110.87 131.83 54.71 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.09 -0.505 . . . . 2.31 109.933 173.271 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -89.64 109.03 20.03 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.186 0.517 . . . . 2.36 109.69 -173.106 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 295' ' ' ARG . . . . . 0.799 ' HG3' HG23 ' A' ' 296' ' ' VAL . 21.6 tpt180 -77.89 -54.35 6.42 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.278 -0.874 . . . . 3.5 111.232 -173.807 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.799 HG23 ' HG3' ' A' ' 295' ' ' ARG . 65.0 t -128.63 106.68 14.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 N-CA-C 109.199 -0.667 . . . . 0.7 109.199 178.614 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 25.3 m -73.34 114.0 11.05 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.11 0.481 . . . . 1.93 111.739 -175.519 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -113.76 171.15 13.65 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.565 -0.743 . . . . 1.04 111.46 178.125 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 26.4 tptp -137.73 127.4 25.25 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.419 0.628 . . . . 4.49 111.111 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -170.98 -155.02 10.12 Favored Glycine 0 N--CA 1.44 -1.034 0 N-CA-C 109.966 -1.254 . . . . 1.04 109.966 176.202 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . 0.553 ' HB2' ' SD ' ' A' ' 391' ' ' MET . 11.5 Cg_endo -59.48 146.87 93.76 Favored 'Trans proline' 0 CA--C 1.53 0.297 0 C-N-CA 122.305 2.003 . . . . 0.88 110.974 170.342 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 29.1 m80 -106.75 139.09 41.72 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.067 0.46 . . . . 1.49 111.445 -178.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 303' ' ' ALA . . . . . 0.438 ' HB2' HG11 ' A' ' 309' ' ' VAL . . . -73.68 142.28 46.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.408 -0.814 . . . . 0.54 112.438 -175.497 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 57.6 tttp -150.24 165.52 32.7 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 108.149 -1.056 . . . . 2.84 108.149 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 65.8 mttm -62.92 134.94 56.99 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-N 118.203 0.456 . . . . 2.84 109.929 174.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 92.23 -6.54 78.49 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 121.087 -0.578 . . . . 0.7 111.859 -174.174 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 24.7 m -102.65 145.95 28.91 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.975 -0.379 . . . . 0.4 109.975 179.414 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 308' ' ' ARG . . . . . 0.589 ' HB3' ' HG3' ' A' ' 335' ' ' LYS . 11.5 ptp85 -108.86 123.82 49.67 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 109.499 -0.556 . . . . 3.45 109.499 179.723 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.832 ' HB ' HD11 ' A' ' 388' ' ' LEU . 34.4 m -110.86 139.17 35.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-O 121.387 0.613 . . . . 0.34 111.649 179.477 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 310' ' ' GLY . . . . . 0.412 ' HA2' ' HA ' ' A' ' 333' ' ' VAL . . . -111.05 115.84 4.08 Favored Glycine 0 N--CA 1.444 -0.772 0 N-CA-C 110.189 -1.165 . . . . 0.27 110.189 176.858 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 14.2 ptp -133.38 177.75 7.44 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-O 121.498 0.666 . . . . 0.76 111.879 -170.498 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 312' ' ' ARG . . . . . 0.424 ' HB3' ' CB ' ' A' ' 327' ' ' THR . 94.1 mtt180 -131.89 144.84 51.15 Favored 'General case' 0 C--N 1.319 -0.717 0 N-CA-C 107.182 -1.414 . . . . 2.51 107.182 175.431 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 313' ' ' TYR . . . . . 0.632 ' HB3' HG12 ' A' ' 386' ' ' VAL . 33.6 p90 -159.53 159.27 33.18 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 113.162 0.801 . . . . 0.68 113.162 -172.519 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 60.5 t -128.27 113.26 29.5 Favored 'Isoleucine or valine' 0 C--O 1.237 0.423 0 CA-C-N 114.782 -1.099 . . . . 0.35 109.024 171.652 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -93.36 116.28 5.14 Favored Glycine 0 C--O 1.239 0.454 0 C-N-CA 121.241 -0.504 . . . . 0.28 112.602 -176.44 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 316' ' ' LYS . . . . . 0.726 ' HG2' HG22 ' A' ' 322' ' ' VAL . 26.7 mttp -122.19 154.76 37.03 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-O 121.181 0.515 . . . . 1.94 110.885 -177.521 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 317' ' ' LEU . . . . . 0.61 HD21 HG12 ' A' ' 376' ' ' ILE . 69.5 mt -81.04 164.16 22.69 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.202 -0.908 . . . . 0.65 109.471 172.481 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 318' ' ' LYS . . . . . 0.452 ' HB2' ' O ' ' A' ' 381' ' ' GLU . 53.2 tptt -60.8 -25.31 66.48 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.074 0.464 . . . . 2.42 110.072 175.333 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 74.7 m-20 -75.18 -0.85 20.73 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.82 -0.627 . . . . 2.2 111.196 -179.283 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 84.97 10.73 78.11 Favored Glycine 0 C--N 1.334 0.423 0 C-N-CA 120.902 -0.666 . . . . 0.69 112.592 178.307 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 321' ' ' LYS . . . . . 0.547 ' HB2' HD12 ' A' ' 317' ' ' LEU . 30.6 mmtp -95.71 125.04 40.01 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.276 -0.268 . . . . 2.42 110.276 -179.489 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.726 HG22 ' HG2' ' A' ' 316' ' ' LYS . 50.3 t -83.31 115.36 25.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 110.214 -0.291 . . . . 1.26 110.214 179.221 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 47.7 p90 -91.72 -30.82 16.07 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.919 -0.312 . . . . 0.55 111.131 -178.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -150.5 153.1 35.23 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 110.025 -0.361 . . . . 1.68 110.025 177.531 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 21.0 pttm -163.41 133.32 4.27 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.965 0.412 . . . . 1.99 110.438 -177.08 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 4.1 p30 -155.13 121.44 5.25 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.443 0.639 . . . . 1.92 110.119 174.349 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 327' ' ' THR . . . . . 0.424 ' CB ' ' HB3' ' A' ' 312' ' ' ARG . 4.9 t -161.84 -42.51 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.601 -0.727 . . . . 1.69 111.485 -175.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.44 ' O ' ' HG3' ' A' ' 328' ' ' LYS . 25.1 pttm -79.21 95.1 5.54 Favored 'General case' 0 N--CA 1.454 -0.245 0 CA-C-O 121.568 0.699 . . . . 2.55 110.512 -178.344 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.454 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 85.42 -15.36 46.07 Favored Glycine 0 N--CA 1.448 -0.566 0 CA-C-N 115.484 -0.78 . . . . 0.97 112.617 179.505 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -104.36 100.59 22.7 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 120.483 0.182 . . . . 2.08 111.27 -179.096 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 331' ' ' PRO . . . . . 0.454 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 73.8 Cg_endo -88.06 131.55 2.67 Favored 'Trans proline' 0 N--CA 1.453 -0.888 0 C-N-CA 122.686 2.257 . . . . 0.62 112.027 172.385 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 78.7 t80 -110.28 120.83 43.69 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 109.513 -0.551 . . . . 0.64 109.513 177.53 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 333' ' ' VAL . . . . . 0.412 ' HA ' ' HA2' ' A' ' 310' ' ' GLY . 53.2 t -114.49 116.04 51.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.417 -0.356 . . . . 0.38 110.432 -177.402 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.513 ' HZ ' HG21 ' A' ' 349' ' ' VAL . 33.5 p90 -129.0 156.85 43.15 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.832 0.349 . . . . 0.41 110.404 178.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 335' ' ' LYS . . . . . 0.589 ' HG3' ' HB3' ' A' ' 308' ' ' ARG . 3.6 mppt? -99.51 135.68 40.56 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.198 -0.456 . . . . 2.58 110.604 -179.576 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 9.6 mp -77.03 134.51 38.78 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.42 -0.585 . . . . 0.58 109.42 174.105 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 100.72 -1.45 55.51 Favored Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.265 -0.969 . . . . 0.94 112.323 -175.544 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 338' ' ' GLN . . . . . 0.439 ' HG2' ' O ' ' A' ' 335' ' ' LYS . 12.1 pt20 -87.94 138.92 31.03 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.673 -0.492 . . . . 2.62 109.673 177.371 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -82.17 46.29 3.49 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.614 -0.803 . . . . 0.74 112.348 -178.307 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 19.6 mt-10 -121.15 -20.73 6.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.825 0.345 . . . . 2.09 110.68 179.209 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 23.0 m -100.49 160.83 3.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 116.416 -0.356 . . . . 0.43 110.556 -176.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 342' ' ' ILE . . . . . 0.64 HD12 ' HA ' ' A' ' 367' ' ' ALA . 5.2 pt -82.84 159.92 3.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.313 -0.625 . . . . 0.32 109.313 175.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 343' ' ' LYS . . . . . 0.51 ' HE2' HD11 ' A' ' 347' ' ' ILE . 17.0 mtpt -60.98 -37.31 82.01 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 121.082 -0.247 . . . . 2.93 111.648 -173.285 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 344' ' ' GLY . . . . . 0.589 ' HA3' HD13 ' A' ' 362' ' ' ILE . . . -53.29 -35.43 50.18 Favored Glycine 0 CA--C 1.519 0.307 0 C-N-CA 121.003 -0.618 . . . . 0.3 112.556 176.575 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 8.0 m95 -73.6 -61.61 1.78 Allowed 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 111.796 0.295 . . . . 0.39 111.796 178.531 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -52.8 -36.77 58.82 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-O 120.918 0.39 . . . . 1.75 111.476 -178.387 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 347' ' ' ILE . . . . . 0.51 HD11 ' HE2' ' A' ' 343' ' ' LYS . 74.9 mt -84.48 -48.16 16.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.236 -0.438 . . . . 0.39 111.387 -177.474 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -64.7 -33.5 87.39 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 121.039 -0.6 . . . . 0.34 113.28 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 349' ' ' VAL . . . . . 0.543 ' O ' ' HB2' ' A' ' 352' ' ' MET . 95.2 t -80.99 -14.24 12.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.016 0.436 . . . . 0.32 110.752 179.313 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -64.79 115.74 5.6 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.992 0.425 . . . . 0.47 109.954 174.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 88.65 21.94 41.72 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.381 -0.914 . . . . 0.39 112.183 -176.088 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 352' ' ' MET . . . . . 0.543 ' HB2' ' O ' ' A' ' 349' ' ' VAL . 0.0 OUTLIER -81.08 151.36 28.37 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.109 -0.7 . . . . 1.28 109.109 174.407 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 353' ' ' ALA . . . . . . . . . . . . . . . -121.49 130.63 53.67 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.731 0.3 . . . . 0.55 111.35 -176.449 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 98.2 t -57.43 119.43 2.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 116.067 -0.515 . . . . 0.36 110.428 174.326 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 107.65 -10.71 38.56 Favored Glycine 0 N--CA 1.448 -0.533 0 C-N-CA 121.065 -0.588 . . . . 0.44 111.965 -177.466 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -104.24 160.41 15.9 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.802 -0.714 . . . . 0.3 112.868 -178.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 357' ' ' GLU . . . . . 0.567 ' HB2' ' HB3' ' A' ' 387' ' ' LYS . 41.5 tt0 -136.85 134.17 36.63 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 122.773 0.429 . . . . 1.41 109.937 178.731 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 358' ' ' ARG . . . . . 0.459 ' HA ' ' H ' ' A' ' 295' ' ' ARG . 4.3 ptp180 -146.65 146.86 30.53 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 121.317 0.58 . . . . 1.37 111.298 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 359' ' ' ARG . . . . . . . . . . . . . 35.1 ttm180 -87.79 119.08 27.78 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.111 -0.949 . . . . 2.79 109.909 177.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 53.7 mt -98.29 119.67 46.62 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 CA-C-N 115.942 -0.572 . . . . 0.38 109.892 179.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 361' ' ' VAL . . . . . . . . . . . . . 74.6 t -103.23 109.09 25.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 115.244 -0.889 . . . . 0.39 108.856 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 362' ' ' ILE . . . . . 0.589 HD13 ' HA3' ' A' ' 344' ' ' GLY . 28.8 mt -115.57 107.91 48.09 Favored Pre-proline 0 C--N 1.323 -0.564 0 CA-C-N 116.484 -0.325 . . . . 0.29 111.038 -173.313 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 363' ' ' PRO . . . . . 0.488 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 11.6 Cg_endo -56.35 151.48 44.45 Favored 'Trans proline' 0 C--O 1.236 0.425 0 C-N-CA 122.373 2.048 . . . . 0.66 111.152 171.377 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 364' ' ' ALA . . . . . . . . . . . . . . . -46.96 -48.95 51.83 Favored Pre-proline 0 CA--C 1.541 0.624 0 N-CA-C 114.126 1.158 . . . . 0.42 114.126 -174.137 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 365' ' ' PRO . . . . . 0.488 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 75.5 Cg_exo -51.42 -29.05 29.66 Favored 'Trans proline' 0 C--N 1.365 1.399 0 C-N-CA 122.54 2.16 . . . . 0.7 114.05 -176.162 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 366' ' ' TYR . . . . . . . . . . . . . 9.1 m-85 -106.17 4.39 28.94 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 111.917 0.339 . . . . 0.69 111.917 -175.357 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 367' ' ' ALA . . . . . 0.688 ' HB1' HD12 ' A' ' 382' ' ' LEU . . . -117.08 -30.21 5.73 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 112.251 0.464 . . . . 0.86 112.251 -179.174 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 9.5 m-85 -165.46 -32.46 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 120.941 0.401 . . . . 1.0 110.53 -176.762 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 101.62 -128.79 9.68 Favored Glycine 0 N--CA 1.446 -0.636 0 C-N-CA 120.821 -0.704 . . . . 0.56 111.983 177.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 21.1 ptmt -108.84 11.02 26.43 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.007 0.432 . . . . 2.76 110.538 -179.504 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 51.9 tt0 -85.05 103.15 13.82 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.972 -0.558 . . . . 2.65 110.306 -177.179 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 372' ' ' ALA . . . . . . . . . . . . . . . -77.65 94.93 4.48 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.076 0.465 . . . . 1.01 110.919 -179.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 80.2 mt -73.91 155.88 88.39 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-N 115.706 -0.679 . . . . 0.93 109.599 176.159 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -57.61 114.32 1.9 Allowed 'Trans proline' 0 N--CA 1.46 -0.454 0 C-N-CA 121.664 1.576 . . . . 1.31 110.81 173.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 97.62 -29.55 10.8 Favored Glycine 0 CA--C 1.519 0.305 0 C-N-CA 121.034 -0.603 . . . . 0.9 112.558 -177.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 376' ' ' ILE . . . . . 0.61 HG12 HD21 ' A' ' 317' ' ' LEU . 25.9 mt -124.45 85.47 55.9 Favored Pre-proline 0 C--N 1.328 -0.347 0 O-C-N 122.808 -0.23 . . . . 0.74 110.554 -178.591 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 377' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -75.02 165.73 30.68 Favored 'Trans proline' 0 N--CA 1.46 -0.49 0 C-N-CA 122.666 2.244 . . . . 0.71 112.413 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 378' ' ' ALA . . . . . 0.426 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -64.96 159.84 22.06 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.084 -0.507 . . . . 0.74 111.595 -178.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 379' ' ' ASN . . . . . 0.426 ' HB2' ' O ' ' A' ' 378' ' ' ALA . 12.3 m120 73.66 -8.16 1.43 Allowed 'General case' 0 N--CA 1.473 0.676 0 CA-C-N 115.501 -0.772 . . . . 1.49 111.833 179.376 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 48.6 m -70.13 114.3 8.15 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.056 0.455 . . . . 1.84 110.928 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 381' ' ' GLU . . . . . 0.452 ' O ' ' HB2' ' A' ' 318' ' ' LYS . 33.0 tt0 -73.5 106.8 5.44 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.549 -0.75 . . . . 1.03 109.862 177.548 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 382' ' ' LEU . . . . . 0.688 HD12 ' HB1' ' A' ' 367' ' ' ALA . 65.9 mt -78.91 141.23 37.78 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.68 0.276 . . . . 0.37 110.394 -178.241 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 24.3 m -123.91 124.85 43.54 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-O 121.002 0.43 . . . . 0.27 110.218 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -120.01 112.19 18.84 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.245 -0.434 . . . . 0.32 110.932 -178.142 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 385' ' ' ASP . . . . . 0.406 ' O ' ' HA ' ' A' ' 313' ' ' TYR . 72.4 m-20 -86.37 105.4 16.68 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 108.728 -0.841 . . . . 1.8 108.728 174.093 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 386' ' ' VAL . . . . . 0.632 HG12 ' HB3' ' A' ' 313' ' ' TYR . 22.2 m -121.72 136.47 58.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.212 0.53 . . . . 0.31 112.072 -173.64 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 387' ' ' LYS . . . . . 0.567 ' HB3' ' HB2' ' A' ' 357' ' ' GLU . 1.3 ptpp? -123.86 137.28 54.68 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.818 -0.628 . . . . 2.53 109.449 170.181 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 388' ' ' LEU . . . . . 0.832 HD11 ' HB ' ' A' ' 309' ' ' VAL . 19.1 tp -95.42 134.28 38.41 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 109.551 -0.537 . . . . 0.28 109.551 -177.377 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 30.9 m -127.91 -5.07 4.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 111.955 0.354 . . . . 0.45 111.955 -174.146 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 12.5 p -165.68 159.77 16.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.653 -0.248 . . . . 1.32 111.093 -178.484 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 391' ' ' MET . . . . . 0.708 ' HG2' ' HG2' ' A' ' 392' ' ' LYS . 41.8 ttm -164.59 155.94 15.4 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.971 -0.559 . . . . 0.56 109.832 178.282 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 392' ' ' LYS . . . . . 0.708 ' HG2' ' HG2' ' A' ' 391' ' ' MET . 32.1 mmmt . . . . . 0 C--O 1.247 0.923 0 O-C-N 124.259 0.975 . . . . 4.91 111.611 175.154 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.456 HG22 ' HB2' ' A' ' 293' ' ' GLU . 18.2 p . . . . . 0 C--O 1.235 0.302 0 CA-C-O 121.091 0.472 . . . . 0.76 111.679 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 284' ' ' LYS . . . . . 0.466 ' O ' ' HA ' ' A' ' 291' ' ' ILE . 92.8 mttt -118.52 144.17 46.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.41 -0.814 . . . . 2.06 111.026 -173.497 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . 0.547 HD11 ' HA2' ' A' ' 289' ' ' GLY . 56.3 tp -102.8 123.99 47.49 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.466 -0.788 . . . . 0.98 110.373 -177.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.461 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 98.6 mt -113.35 -175.74 2.74 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.9 -0.591 . . . . 0.8 109.703 178.44 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 287' ' ' GLU . . . . . 0.447 ' HG2' ' OH ' ' A' ' 366' ' ' TYR . 27.6 tt0 -56.73 144.07 34.05 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.178 0.513 . . . . 2.64 111.629 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.423 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 72.48 0.32 46.58 Favored Glycine 0 CA--C 1.52 0.352 0 CA-C-N 115.78 -0.646 . . . . 1.84 113.806 179.033 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . 0.547 ' HA2' HD11 ' A' ' 285' ' ' LEU . . . 95.11 12.37 55.07 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.696 -0.764 . . . . 0.64 113.028 179.109 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 290' ' ' ILE . . . . . 0.461 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 71.9 mt -66.62 121.54 15.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 121.253 0.549 . . . . 0.42 110.957 -179.071 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.628 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 18.5 mm -104.38 138.96 26.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 115.737 -0.665 . . . . 0.93 110.232 178.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 292' ' ' ILE . . . . . . . . . . . . . 21.5 pt -127.29 129.36 70.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 120.925 0.393 . . . . 0.48 110.685 177.109 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 293' ' ' GLU . . . . . 0.459 ' OE1' ' HD2' ' A' ' 359' ' ' ARG . 24.6 tt0 -118.83 117.96 30.28 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.661 -0.7 . . . . 2.31 109.759 177.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . 0.403 ' OD1' ' HA ' ' A' ' 297' ' ' THR . 0.5 OUTLIER -88.33 96.14 10.46 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.654 -0.869 . . . . 2.36 108.654 -178.655 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 295' ' ' ARG . . . . . 0.828 HH22 ' HB3' ' A' ' 385' ' ' ASP . 38.0 ttp180 -76.11 -47.28 25.05 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.598 -0.728 . . . . 3.5 111.587 -171.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.736 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 23.3 t -119.03 103.5 14.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 N-CA-C 109.057 -0.719 . . . . 0.7 109.057 172.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 297' ' ' THR . . . . . 0.403 ' HA ' ' OD1' ' A' ' 294' ' ' ASP . 32.1 p -62.09 113.32 2.77 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 114.931 -1.031 . . . . 1.93 112.197 -174.023 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -119.88 152.02 17.2 Favored Glycine 0 N--CA 1.444 -0.769 0 CA-C-N 115.652 -0.703 . . . . 1.04 111.642 178.003 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -127.74 114.12 16.88 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.759 0.314 . . . . 4.49 110.336 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -170.56 -154.6 9.65 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 121.011 -0.614 . . . . 1.04 112.013 -179.414 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . 0.592 ' HD2' ' HB ' ' A' ' 354' ' ' VAL . 28.1 Cg_exo -62.33 137.85 67.97 Favored 'Trans proline' 0 C--O 1.233 0.234 0 C-N-CA 122.833 2.355 . . . . 0.88 112.048 178.656 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 302' ' ' HIS . . . . . 0.505 ' HA ' ' O ' ' A' ' 352' ' ' MET . 39.0 m80 -102.5 134.25 46.14 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 120.938 0.399 . . . . 1.49 110.714 178.157 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -69.54 132.41 46.22 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.986 -0.552 . . . . 0.54 111.685 -178.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 32.6 mmtp -117.19 177.96 4.53 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.042 -0.725 . . . . 2.84 109.042 176.105 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 61.4 mttm -68.77 132.24 46.48 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 109.698 -0.482 . . . . 2.84 109.698 173.27 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 84.74 7.97 83.43 Favored Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.697 -0.764 . . . . 0.7 112.553 -176.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 20.2 m -96.72 147.81 23.53 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 110.286 -0.265 . . . . 0.4 110.286 177.381 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 47.4 mtt180 -102.56 130.82 49.52 Favored 'General case' 0 CA--C 1.515 -0.395 0 N-CA-C 108.993 -0.743 . . . . 3.45 108.993 178.743 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.836 ' HB ' HD11 ' A' ' 388' ' ' LEU . 19.7 m -130.39 137.75 55.49 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-O 121.125 0.488 . . . . 0.34 111.815 -177.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -107.7 120.11 5.98 Favored Glycine 0 N--CA 1.444 -0.789 0 N-CA-C 109.826 -1.31 . . . . 0.27 109.826 176.336 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 311' ' ' MET . . . . . 0.599 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 22.9 ptm -140.01 177.04 8.25 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.58 0.705 . . . . 0.76 112.212 -171.321 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 312' ' ' ARG . . . . . 0.493 ' HB3' ' HA ' ' A' ' 327' ' ' THR . 20.9 mtm180 -133.64 145.37 49.92 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 107.228 -1.397 . . . . 2.51 107.228 174.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 313' ' ' TYR . . . . . 0.535 ' CB ' HG12 ' A' ' 386' ' ' VAL . 41.7 p90 -161.57 158.7 26.72 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 113.23 0.826 . . . . 0.68 113.23 -173.362 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 47.8 t -125.99 127.08 70.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 114.695 -1.139 . . . . 0.35 109.688 174.621 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -96.96 106.73 3.39 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 121.116 -0.564 . . . . 0.28 112.139 -179.656 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 316' ' ' LYS . . . . . 0.796 ' HG2' HG22 ' A' ' 322' ' ' VAL . 86.4 mttt -113.07 154.2 26.94 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.282 0.563 . . . . 1.94 111.722 -175.328 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 317' ' ' LEU . . . . . 0.431 HD12 ' HB3' ' A' ' 321' ' ' LYS . 88.8 mt -88.84 164.81 15.04 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.639 -0.71 . . . . 0.65 109.107 169.682 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 318' ' ' LYS . . . . . . . . . . . . . 37.8 ttpt -66.55 -21.94 66.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.991 0.424 . . . . 2.42 110.858 178.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 28.1 p30 -83.74 4.72 27.61 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.011 0.434 . . . . 2.2 111.028 179.101 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 91.21 -9.5 77.4 Favored Glycine 0 C--N 1.33 0.235 0 C-N-CA 121.252 -0.499 . . . . 0.69 113.258 174.673 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 321' ' ' LYS . . . . . 0.431 ' HB3' HD12 ' A' ' 317' ' ' LEU . 22.2 ttmm -77.98 123.55 26.94 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.896 0.379 . . . . 2.42 110.37 -179.003 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.796 HG22 ' HG2' ' A' ' 316' ' ' LYS . 67.7 t -85.44 128.49 39.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 116.171 -0.468 . . . . 1.26 110.368 -179.681 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 35.6 p90 -100.81 -35.26 9.5 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.645 -0.422 . . . . 0.55 111.587 -179.343 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -146.95 168.55 21.21 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 120.789 -0.364 . . . . 1.68 110.108 178.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . 0.581 ' N ' ' HD3' ' A' ' 325' ' ' LYS . 0.0 OUTLIER -176.55 143.48 0.48 Allowed 'General case' 0 C--O 1.233 0.192 0 CA-C-O 121.247 0.546 . . . . 1.99 111.781 -173.612 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 3.1 p30 -150.73 118.06 6.02 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.576 -0.738 . . . . 1.92 109.41 165.601 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 327' ' ' THR . . . . . 0.493 ' HA ' ' HB3' ' A' ' 312' ' ' ARG . 30.7 m -150.7 -55.39 0.15 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.952 -0.567 . . . . 1.69 111.169 -175.781 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 34.8 mtmm -72.04 94.21 1.47 Allowed 'General case' 0 C--O 1.235 0.299 0 CA-C-O 120.981 0.42 . . . . 2.55 111.272 -177.225 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.506 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 80.24 -10.68 41.0 Favored Glycine 0 N--CA 1.45 -0.422 0 CA-C-N 115.863 -0.608 . . . . 0.97 112.971 175.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 25.6 mtpp -103.9 100.7 21.31 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.789 0.294 . . . . 2.08 110.955 -177.507 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 331' ' ' PRO . . . . . 0.506 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 64.2 Cg_endo -88.26 136.38 3.41 Favored 'Trans proline' 0 N--CA 1.453 -0.907 0 C-N-CA 122.724 2.282 . . . . 0.62 112.115 172.547 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 75.4 t80 -110.78 122.83 48.8 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.461 -0.57 . . . . 0.64 109.461 177.772 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 333' ' ' VAL . . . . . 0.489 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 51.5 t -118.78 115.07 46.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 N-CA-C 110.176 -0.305 . . . . 0.38 110.176 -176.731 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.599 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 23.4 p90 -133.48 172.19 13.06 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.649 0.262 . . . . 0.41 110.597 -178.743 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 335' ' ' LYS . . . . . 0.747 ' H ' ' HD2' ' A' ' 335' ' ' LYS . 0.0 OUTLIER -117.29 140.38 49.62 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.335 -0.393 . . . . 2.58 110.208 -179.928 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 10.1 mp -79.22 151.03 31.44 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.707 0.289 . . . . 0.58 110.646 178.486 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 92.31 9.14 62.14 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.828 -0.701 . . . . 0.94 112.007 -176.105 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 338' ' ' GLN . . . . . 0.55 HE22 ' HB2' ' A' ' 334' ' ' PHE . 29.3 pt20 -98.17 161.54 13.66 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.796 0.332 . . . . 2.62 110.511 -179.687 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -99.82 4.54 57.79 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.852 -0.689 . . . . 0.74 112.277 -179.588 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 66.9 mm-40 -73.54 -34.13 65.05 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.904 0.383 . . . . 2.09 110.674 178.347 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 34.4 m -100.41 156.47 4.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.988 -0.551 . . . . 0.43 110.972 -178.165 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 12.8 pt -71.44 161.91 4.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.471 -0.331 . . . . 0.32 110.523 177.734 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.4 -38.45 87.1 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.359 -0.382 . . . . 2.93 111.84 -176.738 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -51.56 -36.53 39.41 Favored Glycine 0 C--N 1.331 0.255 0 C-N-CA 121.135 -0.555 . . . . 0.3 112.544 175.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 9.3 m95 -73.25 -60.3 2.31 Favored 'General case' 0 C--O 1.223 -0.338 0 CA-C-O 120.405 0.145 . . . . 0.39 111.067 177.181 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -49.45 -33.87 15.25 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.242 -0.436 . . . . 1.75 112.109 179.774 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 65.9 mt -85.76 -54.96 7.34 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.358 0 CA-C-N 116.638 -0.255 . . . . 0.39 111.661 178.55 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -60.97 -36.68 92.6 Favored Glycine 0 CA--C 1.521 0.434 0 C-N-CA 121.585 -0.34 . . . . 0.34 113.822 -177.462 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 349' ' ' VAL . . . . . 0.485 HG21 ' HZ ' ' A' ' 334' ' ' PHE . 95.1 t -72.0 -24.96 23.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 120.904 0.383 . . . . 0.32 110.691 179.601 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.53 108.71 2.1 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.804 -0.443 . . . . 0.47 109.804 175.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 107.73 4.67 34.16 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 121.11 -0.567 . . . . 0.39 112.216 -175.494 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 352' ' ' MET . . . . . 0.505 ' O ' ' HA ' ' A' ' 302' ' ' HIS . 0.0 OUTLIER -73.03 140.8 47.52 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 109.276 -0.639 . . . . 1.28 109.276 176.158 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 353' ' ' ALA . . . . . 0.46 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -108.08 132.07 53.95 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.732 0.301 . . . . 0.55 111.042 -177.353 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 354' ' ' VAL . . . . . 0.592 ' HB ' ' HD2' ' A' ' 301' ' ' PRO . 78.4 t -56.58 116.22 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 120.968 0.414 . . . . 0.36 110.551 175.031 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 110.67 -19.31 26.18 Favored Glycine 0 N--CA 1.445 -0.754 0 N-CA-C 111.59 -0.604 . . . . 0.44 111.59 -177.35 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -83.9 148.26 24.47 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 121.168 -0.539 . . . . 0.3 112.694 -176.307 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 357' ' ' GLU . . . . . 0.736 ' HB3' ' HB ' ' A' ' 296' ' ' VAL . 5.0 tp10 -126.61 117.94 23.82 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 108.973 -0.751 . . . . 1.41 108.973 179.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 358' ' ' ARG . . . . . 0.481 ' HG2' ' CE ' ' A' ' 352' ' ' MET . 6.2 ptp180 -145.16 148.44 33.59 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.362 0.601 . . . . 1.37 112.303 -173.15 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 359' ' ' ARG . . . . . 0.459 ' HD2' ' OE1' ' A' ' 293' ' ' GLU . 60.2 mtt85 -89.24 128.02 35.81 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.75 -0.659 . . . . 2.79 110.233 171.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 57.9 mt -110.97 118.39 57.23 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 N-CA-C 109.201 -0.666 . . . . 0.38 109.201 174.396 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 361' ' ' VAL . . . . . 0.628 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 51.4 t -96.97 117.51 41.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.19 -0.67 . . . . 0.39 109.19 178.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 362' ' ' ILE . . . . . . . . . . . . . 65.1 mt -115.01 103.98 54.31 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 116.339 -0.392 . . . . 0.29 110.818 -174.241 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 363' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -60.29 160.08 24.52 Favored 'Trans proline' 0 N--CA 1.463 -0.285 0 C-N-CA 122.642 2.228 . . . . 0.66 112.007 174.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 364' ' ' ALA . . . . . 0.497 ' N ' ' HD2' ' A' ' 365' ' ' PRO . . . -47.23 -51.09 44.34 Favored Pre-proline 0 CA--C 1.539 0.535 0 N-CA-C 114.191 1.182 . . . . 0.42 114.191 -176.126 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 365' ' ' PRO . . . . . 0.497 ' HD2' ' N ' ' A' ' 364' ' ' ALA . 16.8 Cg_endo -56.66 -25.87 62.19 Favored 'Trans proline' 0 C--N 1.358 1.078 0 C-N-CA 122.256 1.971 . . . . 0.7 114.168 -171.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 366' ' ' TYR . . . . . 0.447 ' OH ' ' HG2' ' A' ' 287' ' ' GLU . 4.1 m-85 -103.36 12.11 35.78 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-O 121.036 0.446 . . . . 0.69 111.236 -177.085 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -127.56 -116.43 0.26 Allowed 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 115.664 -0.698 . . . . 0.86 110.162 173.515 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 86.2 m-85 -85.51 -14.4 46.07 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.689 0.28 . . . . 1.0 111.712 -177.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 62.94 -109.18 2.53 Favored Glycine 0 N--CA 1.452 -0.265 0 CA-C-N 116.183 -0.462 . . . . 0.56 113.572 174.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 370' ' ' LYS . . . . . 0.482 ' HA ' ' HB1' ' A' ' 378' ' ' ALA . 58.0 mttm -102.72 8.06 39.58 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 111.722 0.267 . . . . 2.76 111.722 -175.763 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 371' ' ' GLN . . . . . 0.818 ' HA ' HE21 ' A' ' 371' ' ' GLN . 0.0 OUTLIER -88.83 99.55 12.47 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.964 0.411 . . . . 2.65 110.382 179.676 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 372' ' ' ALA . . . . . . . . . . . . . . . -74.31 110.8 8.9 Favored 'General case' 0 N--CA 1.45 -0.441 0 CA-C-N 115.931 -0.577 . . . . 1.01 111.005 178.644 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 71.9 mt -101.37 161.0 24.97 Favored Pre-proline 0 C--N 1.321 -0.641 0 N-CA-C 109.076 -0.713 . . . . 0.93 109.076 176.601 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_exo -60.55 114.64 2.22 Favored 'Trans proline' 0 N--CA 1.46 -0.484 0 C-N-CA 121.546 1.498 . . . . 1.31 110.96 174.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 92.0 -19.87 46.34 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.749 -0.738 . . . . 0.9 112.327 -178.559 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 23.6 mt -132.47 78.4 67.71 Favored Pre-proline 0 N--CA 1.465 0.287 0 CA-C-O 120.836 0.35 . . . . 0.74 110.512 -179.018 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 377' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_exo -70.72 166.89 27.33 Favored 'Trans proline' 0 N--CA 1.463 -0.319 0 C-N-CA 122.764 2.31 . . . . 0.71 113.017 -178.192 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 378' ' ' ALA . . . . . 0.482 ' HB1' ' HA ' ' A' ' 370' ' ' LYS . . . -56.1 151.78 11.65 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.742 -0.663 . . . . 0.74 110.846 178.036 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 379' ' ' ASN . . . . . 0.414 ' HA ' ' CB ' ' A' ' 364' ' ' ALA . 15.0 m120 64.92 32.25 10.83 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.184 0.516 . . . . 1.49 110.306 -178.423 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -77.63 117.02 18.65 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-N 115.643 -0.708 . . . . 1.84 111.158 177.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 381' ' ' GLU . . . . . . . . . . . . . 19.3 tt0 -92.05 100.63 13.23 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.031 -0.729 . . . . 1.03 109.031 177.394 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 78.8 mt -94.3 149.53 21.15 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.776 -0.647 . . . . 0.37 112.155 -170.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 29.5 m -127.99 128.43 45.02 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.746 -0.464 . . . . 0.27 109.746 176.304 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -119.65 113.09 20.15 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.573 -0.285 . . . . 0.32 111.248 -177.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 385' ' ' ASP . . . . . 0.828 ' HB3' HH22 ' A' ' 295' ' ' ARG . 1.6 m-20 -79.58 105.33 10.81 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.22 -1.03 . . . . 1.8 108.22 172.267 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 386' ' ' VAL . . . . . 0.591 ' HB ' ' CE ' ' A' ' 311' ' ' MET . 33.8 m -126.09 131.32 71.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.386 0.613 . . . . 0.31 112.456 -171.833 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 387' ' ' LYS . . . . . 0.489 ' HB2' ' CD ' ' A' ' 357' ' ' GLU . 49.9 tttm -126.63 132.07 51.32 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.933 -0.576 . . . . 2.53 109.835 175.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 388' ' ' LEU . . . . . 0.836 HD11 ' HB ' ' A' ' 309' ' ' VAL . 23.2 tp -94.67 137.53 33.66 Favored 'General case' 0 C--N 1.319 -0.717 0 N-CA-C 108.992 -0.744 . . . . 0.28 108.992 -178.45 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 33.7 m -126.93 -7.09 4.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 111.993 0.368 . . . . 0.45 111.993 -174.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 25.2 p -167.5 164.25 14.85 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.701 0.286 . . . . 1.32 111.273 -177.498 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 391' ' ' MET . . . . . 0.401 ' HE3' ' HB2' ' A' ' 391' ' ' MET . 39.6 ttm -158.74 147.55 18.66 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.053 -0.521 . . . . 0.56 110.337 179.392 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 392' ' ' LYS . . . . . 0.479 ' NZ ' ' HB3' ' A' ' 392' ' ' LYS . 8.3 mtpm? . . . . . 0 C--O 1.248 0.993 0 CA-C-O 118.603 -0.713 . . . . 4.91 109.961 177.633 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 22.3 p . . . . . 0 C--O 1.236 0.366 0 CA-C-O 120.871 0.367 . . . . 0.76 111.711 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 60.6 mttp -134.33 141.32 46.87 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.779 -0.646 . . . . 2.06 109.676 175.562 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 39.3 tp -95.48 122.35 38.12 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 116.184 -0.462 . . . . 0.98 111.04 -178.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.662 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 98.2 mt -96.35 -170.92 2.18 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.931 -0.577 . . . . 0.8 110.599 176.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 287' ' ' GLU . . . . . 0.478 ' HG3' ' OH ' ' A' ' 366' ' ' TYR . 6.5 tp10 -52.86 145.21 12.98 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 115.901 -0.59 . . . . 2.64 111.551 178.808 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.514 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 72.22 -101.61 1.07 Allowed Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.947 -0.57 . . . . 1.84 111.736 -177.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . -148.15 25.57 1.42 Allowed Glycine 0 N--CA 1.444 -0.791 0 N-CA-C 110.214 -1.155 . . . . 0.64 110.214 175.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 290' ' ' ILE . . . . . 0.662 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 73.1 mt -72.36 124.72 29.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.235 -0.482 . . . . 0.42 110.446 -175.731 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.582 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 16.2 mt -107.28 139.39 29.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 116.201 -0.454 . . . . 0.93 109.965 -177.217 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 292' ' ' ILE . . . . . . . . . . . . . 14.8 pt -128.06 127.53 67.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 121.176 0.512 . . . . 0.48 110.797 177.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 293' ' ' GLU . . . . . 0.435 ' CD ' HH21 ' A' ' 359' ' ' ARG . 30.2 tt0 -114.65 118.26 33.17 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 114.929 -1.032 . . . . 2.31 109.123 177.518 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -81.23 114.08 19.79 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.222 -0.591 . . . . 2.36 110.06 -174.09 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 295' ' ' ARG . . . . . 0.561 ' HG2' ' HA ' ' A' ' 358' ' ' ARG . 20.3 mmm180 -86.45 -56.08 3.6 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.632 -0.713 . . . . 3.5 110.365 -174.242 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.569 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 96.7 t -124.0 125.01 70.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.908 -0.587 . . . . 0.7 109.905 178.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 3.9 t -64.1 141.25 58.84 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.284 0.564 . . . . 1.93 111.688 -177.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -150.78 142.11 9.28 Favored Glycine 0 N--CA 1.443 -0.89 0 N-CA-C 110.992 -0.843 . . . . 1.04 110.992 176.024 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 51.5 pttt -131.55 117.61 18.99 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.379 0.609 . . . . 4.49 110.534 177.188 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -172.01 -154.43 10.03 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.335 -0.848 . . . . 1.04 111.063 -177.688 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . 0.463 ' O ' ' HA ' ' A' ' 353' ' ' ALA . 24.6 Cg_exo -62.66 133.53 42.77 Favored 'Trans proline' 0 N--CA 1.462 -0.34 0 C-N-CA 122.356 2.038 . . . . 0.88 111.404 176.282 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 35.9 m80 -95.12 130.15 41.94 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.308 -0.406 . . . . 1.49 110.45 178.474 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 303' ' ' ALA . . . . . 0.496 ' HB2' HG11 ' A' ' 309' ' ' VAL . . . -67.12 133.58 50.1 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.587 -0.733 . . . . 0.54 111.434 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 64.4 pttt -132.2 179.13 6.29 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 108.762 -0.829 . . . . 2.84 108.762 173.499 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 23.5 ttmm -66.33 135.62 54.63 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 120.587 -0.445 . . . . 2.84 110.333 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 92.48 -7.04 77.97 Favored Glycine 0 CA--C 1.521 0.42 0 C-N-CA 121.078 -0.582 . . . . 0.7 112.427 -174.774 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 30.3 m -88.97 150.03 23.01 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.716 0.293 . . . . 0.4 110.842 -178.484 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 82.2 mtt180 -115.31 102.52 9.93 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 109.468 -0.567 . . . . 3.45 109.468 -178.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.802 ' HB ' HD11 ' A' ' 388' ' ' LEU . 35.7 m -102.52 148.26 8.11 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.807 0 CA-C-N 115.592 -0.731 . . . . 0.34 112.458 -175.384 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -113.37 118.24 4.46 Favored Glycine 0 N--CA 1.446 -0.69 0 N-CA-C 110.672 -0.971 . . . . 0.27 110.672 176.554 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 311' ' ' MET . . . . . 0.5 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 6.8 ptm -139.48 178.49 7.18 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.788 0.804 . . . . 0.76 112.434 -172.531 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 55.0 mtt180 -136.06 152.57 51.02 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 113.896 -1.502 . . . . 2.51 107.68 176.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 313' ' ' TYR . . . . . 0.559 ' CB ' HG12 ' A' ' 386' ' ' VAL . 32.8 p90 -159.57 158.89 32.54 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 119.556 -0.858 . . . . 0.68 113.276 -174.474 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . 0.572 HG12 ' HG3' ' A' ' 316' ' ' LYS . 57.9 t -127.02 102.99 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 CA-C-N 114.811 -1.086 . . . . 0.35 109.355 171.071 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -87.13 110.32 3.54 Favored Glycine 0 C--O 1.237 0.336 0 N-CA-C 112.082 -0.407 . . . . 0.28 112.082 -178.47 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 316' ' ' LYS . . . . . 0.757 ' HG2' ' HB ' ' A' ' 322' ' ' VAL . 33.2 mtmm -126.37 156.03 41.16 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.842 0.353 . . . . 1.94 110.92 -174.794 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 317' ' ' LEU . . . . . 0.536 HD12 ' HB3' ' A' ' 321' ' ' LYS . 82.6 mt -81.73 173.33 12.41 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.821 -0.627 . . . . 0.65 110.963 177.007 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 318' ' ' LYS . . . . . . . . . . . . . 60.3 tttp -65.26 -22.27 66.84 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.606 -0.724 . . . . 2.42 110.674 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 32.6 p-10 -91.67 -1.36 57.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.411 -0.359 . . . . 2.2 111.095 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 97.83 -5.31 61.77 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.927 -0.654 . . . . 0.69 113.211 178.129 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 321' ' ' LYS . . . . . 0.536 ' HB3' HD12 ' A' ' 317' ' ' LEU . 14.4 tppt? -73.09 111.71 8.45 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.834 0.349 . . . . 2.42 110.27 -179.767 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.757 ' HB ' ' HG2' ' A' ' 316' ' ' LYS . 5.4 p -81.4 124.33 38.77 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 116.178 -0.464 . . . . 1.26 110.425 179.034 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 50.4 p90 -102.36 -32.23 10.11 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.908 -0.317 . . . . 0.55 111.323 -177.492 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -148.3 132.46 17.35 Favored 'General case' 0 CA--C 1.515 -0.38 0 N-CA-C 109.954 -0.387 . . . . 1.68 109.954 -179.203 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . 0.414 ' HD3' HG21 ' A' ' 322' ' ' VAL . 59.3 pttt -153.97 134.7 13.67 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.907 0.384 . . . . 1.99 111.449 -174.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 326' ' ' ASN . . . . . 0.635 ' HB2' ' HB2' ' A' ' 330' ' ' LYS . 3.9 p30 -146.66 117.08 7.45 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.697 0.76 . . . . 1.92 110.322 169.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 3.2 p -142.16 -40.83 0.35 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.909 -1.041 . . . . 1.69 110.363 179.205 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 21.1 pttp -80.51 101.93 9.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.331 0.586 . . . . 2.55 111.432 -178.731 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.514 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 76.04 -13.85 6.88 Favored Glycine 0 N--CA 1.452 -0.237 0 CA-C-N 115.616 -0.72 . . . . 0.97 113.633 175.212 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 330' ' ' LYS . . . . . 0.635 ' HB2' ' HB2' ' A' ' 326' ' ' ASN . 27.4 mmmt -103.76 101.52 25.11 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 117.305 0.552 . . . . 2.08 111.068 -178.025 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 331' ' ' PRO . . . . . 0.514 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 72.2 Cg_endo -87.83 126.59 2.14 Favored 'Trans proline' 0 N--CA 1.45 -1.042 0 C-N-CA 122.96 2.44 . . . . 0.62 111.826 172.647 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 65.4 t80 -100.04 118.89 37.37 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 110.092 -0.336 . . . . 0.64 110.092 179.376 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 333' ' ' VAL . . . . . 0.472 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 61.6 t -119.32 114.82 45.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 N-CA-C 110.119 -0.326 . . . . 0.38 110.119 -178.734 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.5 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 14.1 p90 -131.64 159.38 38.48 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.958 0.409 . . . . 0.41 110.201 -179.64 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 335' ' ' LYS . . . . . 0.462 ' HG3' ' HG3' ' A' ' 338' ' ' GLN . 18.2 pttm -99.72 128.92 45.81 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.902 -0.59 . . . . 2.58 110.346 177.336 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 10.0 mp -64.54 117.53 7.5 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.484 -0.561 . . . . 0.58 109.484 174.645 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 129.36 10.09 3.11 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.774 -0.727 . . . . 0.94 111.699 -172.027 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 338' ' ' GLN . . . . . 0.652 ' HB3' ' HG2' ' A' ' 340' ' ' GLU . 91.8 mt-30 -84.35 141.93 30.53 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.962 0.411 . . . . 2.62 110.62 176.111 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -96.11 -4.95 59.73 Favored Glycine 0 N--CA 1.448 -0.512 0 N-CA-C 110.857 -0.897 . . . . 0.74 110.857 175.194 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 340' ' ' GLU . . . . . 0.652 ' HG2' ' HB3' ' A' ' 338' ' ' GLN . 5.5 pt-20 -84.18 -20.15 32.87 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.078 -0.561 . . . . 2.09 110.984 179.21 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 33.4 m -94.06 154.92 3.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 109.524 -0.547 . . . . 0.43 109.524 174.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 13.4 pt -74.86 154.25 6.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 N-CA-C 110.034 -0.358 . . . . 0.32 110.034 179.24 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 343' ' ' LYS . . . . . 0.45 ' HA ' ' HE2' ' A' ' 343' ' ' LYS . 5.7 mmpt? -60.62 -30.69 70.01 Favored 'General case' 0 N--CA 1.464 0.258 0 N-CA-C 111.73 0.27 . . . . 2.93 111.73 -174.72 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -55.55 -28.44 51.33 Favored Glycine 0 CA--C 1.521 0.437 0 C-N-CA 121.14 -0.553 . . . . 0.3 112.884 174.387 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 8.4 m95 -82.26 -60.96 2.03 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 111.648 0.24 . . . . 0.39 111.648 178.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -48.49 -35.73 13.69 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 120.923 0.392 . . . . 1.75 111.73 177.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 62.1 mt -88.51 -51.89 11.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.163 -0.471 . . . . 0.39 111.756 179.139 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 348' ' ' GLY . . . . . 0.423 ' HA2' HD13 ' A' ' 286' ' ' LEU . . . -61.08 -36.34 92.17 Favored Glycine 0 C--N 1.331 0.301 0 C-N-CA 121.36 -0.448 . . . . 0.34 113.73 -176.797 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 88.6 t -73.66 -23.2 19.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 121.182 0.515 . . . . 0.32 110.775 -179.579 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -70.18 105.61 3.0 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.097 0.475 . . . . 0.47 110.512 179.357 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 120.9 -2.78 11.81 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.864 -0.684 . . . . 0.39 112.303 -176.794 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 352' ' ' MET . . . . . 0.451 ' HG2' ' HD2' ' A' ' 358' ' ' ARG . 69.1 mtp -82.13 144.41 30.77 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.905 0.353 . . . . 1.28 110.622 176.356 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 353' ' ' ALA . . . . . 0.463 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -108.57 147.99 30.97 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.879 -0.6 . . . . 0.55 110.682 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 85.7 t -57.7 117.71 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 121.121 0.486 . . . . 0.36 110.835 176.048 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 110.67 -27.15 11.58 Favored Glycine 0 N--CA 1.445 -0.752 0 N-CA-C 111.049 -0.82 . . . . 0.44 111.049 -176.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -73.99 139.21 25.76 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 121.3 -0.476 . . . . 0.3 112.744 -177.162 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 357' ' ' GLU . . . . . 0.709 ' HB2' ' HG3' ' A' ' 387' ' ' LYS . 36.6 tt0 -125.0 133.87 52.82 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 109.063 -0.718 . . . . 1.41 109.063 178.358 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 358' ' ' ARG . . . . . 0.561 ' HA ' ' HG2' ' A' ' 295' ' ' ARG . 8.0 ptp180 -155.44 143.89 20.31 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.66 0.743 . . . . 1.37 112.294 -178.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 359' ' ' ARG . . . . . 0.435 HH21 ' CD ' ' A' ' 293' ' ' GLU . 20.9 ttp85 -86.25 117.95 25.39 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 114.773 -1.103 . . . . 2.79 109.485 177.813 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 50.3 mt -99.73 121.81 50.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.729 -0.669 . . . . 0.38 110.235 -178.31 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 361' ' ' VAL . . . . . 0.582 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 47.7 t -102.45 113.35 38.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 N-CA-C 109.15 -0.685 . . . . 0.39 109.15 176.574 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 362' ' ' ILE . . . . . . . . . . . . . 62.1 mt -113.19 101.49 53.53 Favored Pre-proline 0 C--N 1.324 -0.514 0 CA-C-O 120.728 0.299 . . . . 0.29 110.987 -175.096 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 363' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -56.43 159.9 12.36 Favored 'Trans proline' 0 C--O 1.237 0.463 0 C-N-CA 122.571 2.181 . . . . 0.66 112.41 171.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 364' ' ' ALA . . . . . 0.546 ' HB2' ' HA ' ' A' ' 379' ' ' ASN . . . -47.72 -49.59 56.09 Favored Pre-proline 0 CA--C 1.539 0.547 0 N-CA-C 114.528 1.307 . . . . 0.42 114.528 -173.348 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 365' ' ' PRO . . . . . 0.531 ' HD2' ' N ' ' A' ' 364' ' ' ALA . 9.6 Cg_endo -51.03 -32.18 37.81 Favored 'Trans proline' 0 C--N 1.361 1.2 0 C-N-CA 122.567 2.178 . . . . 0.7 114.186 -172.832 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 366' ' ' TYR . . . . . 0.514 ' CE2' ' HA3' ' A' ' 288' ' ' GLY . 13.8 m-85 -100.52 12.13 37.97 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.831 -0.348 . . . . 0.69 111.841 -175.466 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -127.06 -109.6 0.3 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.441 -0.345 . . . . 0.86 110.907 174.799 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 78.8 m-85 -93.59 -15.83 25.0 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 111.977 0.362 . . . . 1.0 111.977 -179.723 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 64.82 -113.91 6.3 Favored Glycine 0 CA--C 1.52 0.388 0 C-N-CA 121.047 -0.597 . . . . 0.56 113.691 175.627 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 65.6 mttm -92.1 3.91 54.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.751 0.31 . . . . 2.76 111.525 -174.84 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -80.63 99.27 8.06 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.863 0.363 . . . . 2.65 111.638 -177.334 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 372' ' ' ALA . . . . . . . . . . . . . . . -78.29 92.48 4.52 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 115.952 -0.567 . . . . 1.01 109.908 171.362 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 30.5 mt -84.0 159.28 60.33 Favored Pre-proline 0 C--N 1.316 -0.885 0 CA-C-N 115.636 -0.711 . . . . 0.93 109.342 -179.686 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.55 113.0 1.43 Allowed 'Trans proline' 0 N--CA 1.461 -0.394 0 C-N-CA 121.507 1.472 . . . . 1.31 110.684 173.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 96.81 -29.92 9.74 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.809 -0.71 . . . . 0.9 112.533 -178.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 40.0 mt -125.95 88.94 53.38 Favored Pre-proline 0 C--N 1.332 -0.192 0 CA-C-N 116.772 0.286 . . . . 0.74 110.279 -179.242 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 377' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_exo -69.58 166.52 27.09 Favored 'Trans proline' 0 N--CA 1.463 -0.3 0 C-N-CA 122.596 2.198 . . . . 0.71 113.191 -178.355 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 378' ' ' ALA . . . . . . . . . . . . . . . -61.06 157.32 15.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.202 -0.908 . . . . 0.74 111.985 -176.771 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 379' ' ' ASN . . . . . 0.546 ' HA ' ' HB2' ' A' ' 364' ' ' ALA . 18.6 m120 65.69 23.16 11.59 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-N 115.377 -0.828 . . . . 1.49 111.113 177.798 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 59.6 p -66.72 116.43 7.62 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.003 -0.544 . . . . 1.84 111.134 179.501 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 381' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -80.37 98.55 7.52 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 108.971 -0.751 . . . . 1.03 108.971 174.541 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 92.6 mt -85.34 136.06 33.63 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.941 0.4 . . . . 0.37 111.248 -176.812 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 32.6 m -118.97 118.54 31.78 Favored 'General case' 0 N--CA 1.444 -0.734 0 N-CA-C 109.93 -0.396 . . . . 0.27 109.93 177.824 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -113.16 109.39 18.7 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.867 -0.42 . . . . 0.32 109.867 -177.204 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -87.39 104.88 16.85 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 108.034 -1.098 . . . . 1.8 108.034 176.636 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 386' ' ' VAL . . . . . 0.559 HG12 ' CB ' ' A' ' 313' ' ' TYR . 19.9 m -122.89 148.68 26.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 121.563 0.697 . . . . 0.31 112.382 -170.057 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 387' ' ' LYS . . . . . 0.709 ' HG3' ' HB2' ' A' ' 357' ' ' GLU . 46.5 tttm -137.39 129.91 29.83 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.402 -0.817 . . . . 2.53 109.652 176.128 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 388' ' ' LEU . . . . . 0.802 HD11 ' HB ' ' A' ' 309' ' ' VAL . 24.6 tp -89.58 134.55 34.08 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.776 -0.824 . . . . 0.28 108.776 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 27.5 m -129.36 -3.49 3.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 N-CA-C 112.251 0.463 . . . . 0.45 112.251 -174.064 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 10.2 t -168.5 156.67 8.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.69 0.281 . . . . 1.32 110.806 -177.506 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 391' ' ' MET . . . . . 0.499 ' HE2' HG12 ' A' ' 309' ' ' VAL . 40.5 ttm -156.33 155.26 31.93 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.229 -0.656 . . . . 0.56 109.229 174.401 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 392' ' ' LYS . . . . . 0.42 ' HE2' ' HB2' ' A' ' 392' ' ' LYS . 3.4 ptmm? . . . . . 0 C--O 1.25 1.123 0 CA-C-O 118.654 -0.689 . . . . 4.91 110.7 175.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 15.2 p . . . . . 0 N--CA 1.452 -0.363 0 CA-C-O 120.778 0.323 . . . . 0.76 111.277 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 284' ' ' LYS . . . . . 0.573 ' HB2' HG13 ' A' ' 292' ' ' ILE . 72.4 mmtt -130.12 135.94 48.76 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 109.213 -0.662 . . . . 2.06 109.213 179.723 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 31.1 tp -104.78 124.16 48.93 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 120.896 0.379 . . . . 0.98 110.138 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.786 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 76.7 mt -112.63 -175.21 2.62 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.578 -0.737 . . . . 0.8 109.813 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 2.6 tp10 -60.61 147.37 42.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.148 0.499 . . . . 2.64 111.336 -177.765 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.595 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 69.37 -1.77 12.17 Favored Glycine 0 N--CA 1.452 -0.297 0 CA-C-N 115.84 -0.618 . . . . 1.84 113.648 -179.892 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 97.6 14.8 39.51 Favored Glycine 0 N--CA 1.446 -0.681 0 C-N-CA 120.21 -0.995 . . . . 0.64 113.556 -179.274 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 290' ' ' ILE . . . . . 0.786 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 79.5 mt -64.16 122.57 15.31 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.167 0 CA-C-N 117.488 0.644 . . . . 0.42 110.507 176.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.557 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 80.2 mt -107.36 138.27 34.3 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 N-CA-C 110.355 -0.239 . . . . 0.93 110.355 177.08 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 292' ' ' ILE . . . . . 0.573 HG13 ' HB2' ' A' ' 284' ' ' LYS . 23.6 pt -127.02 130.85 71.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 N-CA-C 109.489 -0.56 . . . . 0.48 109.489 174.34 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 293' ' ' GLU . . . . . 0.415 ' CD ' HH21 ' A' ' 359' ' ' ARG . 34.3 tt0 -123.43 121.42 35.69 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 115.176 -0.92 . . . . 2.31 109.954 -177.139 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 51.9 m-20 -78.3 110.93 13.76 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.712 -0.477 . . . . 2.36 109.712 -176.637 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 295' ' ' ARG . . . . . . . . . . . . . 39.1 ttt180 -88.14 -58.24 2.64 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.832 -0.622 . . . . 3.5 110.499 -175.176 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.601 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 58.1 t -128.24 141.36 46.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 110.203 -0.295 . . . . 0.7 110.203 177.207 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 9.0 t -96.07 149.84 21.16 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.3 -0.409 . . . . 1.93 111.033 -178.197 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -152.93 -164.64 12.65 Favored Glycine 0 C--N 1.331 0.261 0 C-N-CA 121.428 -0.415 . . . . 1.04 112.174 -177.19 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 299' ' ' LYS . . . . . 0.572 ' O ' ' HB1' ' A' ' 353' ' ' ALA . 62.0 tttp -72.78 139.54 47.15 Favored 'General case' 0 CA--C 1.52 -0.211 0 N-CA-C 108.595 -0.891 . . . . 4.49 108.595 173.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -116.34 80.48 0.3 Allowed Glycine 0 N--CA 1.445 -0.756 0 C-N-CA 119.314 -1.422 . . . . 1.04 115.272 -170.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . 0.596 ' HD2' ' H ' ' A' ' 354' ' ' VAL . 8.2 Cg_exo -74.57 131.51 14.92 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.036 1.824 . . . . 0.88 108.145 159.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 302' ' ' HIS . . . . . 0.439 ' O ' ' HE3' ' A' ' 304' ' ' LYS . 27.4 m80 -85.91 107.35 17.67 Favored 'General case' 0 C--N 1.319 -0.731 0 C-N-CA 120.314 -0.554 . . . . 1.49 111.423 -169.093 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -66.33 109.08 2.55 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.703 -0.681 . . . . 0.54 110.375 175.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 304' ' ' LYS . . . . . 0.439 ' HE3' ' O ' ' A' ' 302' ' ' HIS . 11.5 ptpt -127.47 -174.44 3.18 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 116.326 -0.397 . . . . 2.84 110.161 -179.171 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.819 ' HG3' ' HA3' ' A' ' 337' ' ' GLY . 62.3 tttm -65.71 124.51 22.6 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.994 0.426 . . . . 2.84 111.019 -175.251 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 97.14 -11.24 65.71 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 121.075 -0.583 . . . . 0.7 112.81 -178.063 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 307' ' ' THR . . . . . 0.447 ' O ' ' HA ' ' A' ' 335' ' ' LYS . 28.4 m -82.92 142.8 31.16 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 122.881 -0.188 . . . . 0.4 110.524 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 22.6 ptt180 -106.78 116.03 31.22 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 121.306 0.574 . . . . 3.45 109.583 -178.234 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.783 ' HB ' HD11 ' A' ' 388' ' ' LEU . 31.1 m -113.69 147.8 17.0 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 115.644 -0.707 . . . . 0.34 111.918 -177.397 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -116.67 114.19 2.97 Favored Glycine 0 N--CA 1.443 -0.896 0 N-CA-C 110.126 -1.19 . . . . 0.27 110.126 174.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 311' ' ' MET . . . . . 0.478 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 6.9 ptm -131.65 177.68 7.33 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 121.897 0.856 . . . . 0.76 112.488 -172.283 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -138.07 150.31 46.78 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 113.726 -1.579 . . . . 2.51 107.794 177.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 313' ' ' TYR . . . . . 0.466 ' CB ' HG12 ' A' ' 386' ' ' VAL . 44.3 p90 -156.45 155.33 31.88 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 120.741 -0.384 . . . . 0.68 111.375 -169.74 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . 0.565 HG11 ' HE3' ' A' ' 316' ' ' LYS . 38.2 t -120.46 105.71 17.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-N 115.587 -0.733 . . . . 0.35 109.247 169.206 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -84.82 109.38 3.26 Favored Glycine 0 N--CA 1.445 -0.717 0 CA-C-N 116.088 -0.506 . . . . 0.28 112.168 -178.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 316' ' ' LYS . . . . . 0.765 ' HG2' HG22 ' A' ' 322' ' ' VAL . 93.6 mttt -123.32 161.05 25.42 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-N 114.929 -0.636 . . . . 1.94 110.464 -178.308 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 317' ' ' LEU . . . . . 0.493 HD12 ' HD3' ' A' ' 321' ' ' LYS . 83.6 mt -88.18 165.81 14.81 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 109.392 -0.596 . . . . 0.65 109.392 170.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 318' ' ' LYS . . . . . 0.907 ' HD2' ' HB3' ' A' ' 381' ' ' GLU . 0.2 OUTLIER -61.15 -19.37 61.46 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.31 -0.405 . . . . 2.42 111.633 179.844 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 319' ' ' ASN . . . . . 0.421 ' OD1' ' HB2' ' A' ' 317' ' ' LEU . 28.5 p-10 -90.41 -1.61 57.92 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 116.577 -0.283 . . . . 2.2 111.146 -178.575 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 94.5 6.8 60.86 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.505 -0.855 . . . . 0.69 113.11 177.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 321' ' ' LYS . . . . . 0.493 ' HD3' HD12 ' A' ' 317' ' ' LEU . 63.5 tttp -81.99 118.57 23.09 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.947 0.403 . . . . 2.42 110.472 177.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.765 HG22 ' HG2' ' A' ' 316' ' ' LYS . 12.6 t -85.56 129.78 37.39 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 116.115 -0.493 . . . . 1.26 109.948 179.381 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 32.3 p90 -111.48 -43.57 3.66 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 120.528 -0.469 . . . . 0.55 111.586 178.508 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -148.07 128.56 14.03 Favored 'General case' 0 CA--C 1.514 -0.431 0 C-N-CA 120.507 -0.477 . . . . 1.68 110.958 -177.658 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . 0.553 ' HE3' HG11 ' A' ' 322' ' ' VAL . 8.4 pttp -145.75 128.31 16.08 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.092 0.472 . . . . 1.99 110.88 -179.05 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 55.6 m-80 -125.25 116.49 22.06 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.544 -0.753 . . . . 1.92 109.055 173.605 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 26.3 m -157.0 -38.89 0.07 Allowed 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.675 -0.693 . . . . 1.69 110.155 -177.202 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 29.6 mmmt -75.18 92.74 2.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.788 -0.642 . . . . 2.55 110.372 179.589 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.454 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 75.1 -17.7 2.86 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 121.245 -0.502 . . . . 0.97 113.606 177.491 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 82.4 mttt -103.37 103.26 34.26 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 117.001 0.401 . . . . 2.08 111.571 -175.433 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 331' ' ' PRO . . . . . 0.454 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 98.3 Cg_endo -87.91 145.83 6.6 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 122.825 2.35 . . . . 0.62 112.167 171.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 72.3 t80 -111.15 119.51 39.2 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.364 -0.606 . . . . 0.64 109.364 175.526 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 46.7 t -111.64 126.3 69.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 120.648 0.261 . . . . 0.38 110.842 -177.236 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.66 ' HB2' HE22 ' A' ' 338' ' ' GLN . 28.4 p90 -153.54 169.19 23.81 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.34 -0.391 . . . . 0.41 110.2 178.415 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 335' ' ' LYS . . . . . 0.49 ' HE2' ' HB3' ' A' ' 338' ' ' GLN . 0.0 OUTLIER -112.77 146.22 39.18 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.152 0.501 . . . . 2.58 111.418 177.201 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 10.9 mp -78.35 150.89 33.12 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.853 -0.612 . . . . 0.58 110.262 177.661 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 337' ' ' GLY . . . . . 0.819 ' HA3' ' HG3' ' A' ' 305' ' ' LYS . . . 89.12 27.14 24.19 Favored Glycine 0 N--CA 1.445 -0.706 0 C-N-CA 120.739 -0.743 . . . . 0.94 112.459 -177.409 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 338' ' ' GLN . . . . . 0.66 HE22 ' HB2' ' A' ' 334' ' ' PHE . 30.2 pt20 -118.97 163.06 17.5 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 110.085 -0.339 . . . . 2.62 110.085 176.406 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -93.6 2.84 70.79 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.952 -0.642 . . . . 0.74 112.329 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -76.43 -24.78 53.96 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.948 0.404 . . . . 2.09 110.876 -178.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 31.0 m -108.74 152.66 10.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.241 -0.436 . . . . 0.43 110.755 -178.734 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 342' ' ' ILE . . . . . 0.502 ' HB ' ' HA ' ' A' ' 367' ' ' ALA . 14.8 pt -70.52 156.24 7.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.858 -0.423 . . . . 0.32 109.858 178.457 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -64.48 -32.61 74.32 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.626 -0.261 . . . . 2.93 111.396 -175.386 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -53.41 -41.86 63.88 Favored Glycine 0 CA--C 1.523 0.561 0 C-N-CA 120.613 -0.803 . . . . 0.3 112.16 173.462 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 7.8 m95 -70.51 -58.42 3.73 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.75 0.309 . . . . 0.39 110.489 175.474 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -49.49 -32.27 11.78 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 115.877 -0.601 . . . . 1.75 112.355 -179.308 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 69.2 mt -89.17 -53.21 9.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.501 -0.318 . . . . 0.39 111.789 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -64.32 -32.93 85.82 Favored Glycine 0 C--N 1.332 0.307 0 C-N-CA 121.189 -0.529 . . . . 0.34 113.664 -177.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 89.8 t -78.44 -16.33 13.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.988 0.423 . . . . 0.32 111.035 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.01 106.41 1.25 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.235 0.541 . . . . 0.47 110.241 178.592 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 98.31 22.33 15.1 Favored Glycine 0 N--CA 1.444 -0.787 0 CA-C-N 115.6 -0.727 . . . . 0.39 112.577 -178.234 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 352' ' ' MET . . . . . . . . . . . . . 64.1 mmm -69.22 173.38 5.73 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.562 0.22 . . . . 1.28 110.636 173.308 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 353' ' ' ALA . . . . . 0.572 ' HB1' ' O ' ' A' ' 299' ' ' LYS . . . -135.71 136.61 40.99 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.107 -0.497 . . . . 0.55 111.05 -177.605 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 354' ' ' VAL . . . . . 0.596 ' H ' ' HD2' ' A' ' 301' ' ' PRO . 59.4 t -65.76 112.05 1.75 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.202 0 CA-C-O 121.436 0.636 . . . . 0.36 109.923 174.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 104.56 -24.16 29.45 Favored Glycine 0 N--CA 1.439 -1.134 0 N-CA-C 110.134 -1.186 . . . . 0.44 110.134 -172.7 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -73.85 145.66 35.59 Favored Glycine 0 N--CA 1.444 -0.793 0 N-CA-C 112.04 -0.424 . . . . 0.3 112.04 179.874 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 357' ' ' GLU . . . . . 0.724 ' HG3' ' HB2' ' A' ' 387' ' ' LYS . 34.0 tt0 -135.75 131.54 35.68 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 108.238 -1.023 . . . . 1.41 108.238 -173.227 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 358' ' ' ARG . . . . . . . . . . . . . 2.1 ptp180 -154.86 148.22 25.06 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.369 0.604 . . . . 1.37 112.495 -177.745 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 359' ' ' ARG . . . . . 0.415 HH21 ' CD ' ' A' ' 293' ' ' GLU . 14.8 ttp180 -89.21 114.76 26.11 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.377 -0.829 . . . . 2.79 109.817 176.502 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 65.4 mt -102.67 118.72 49.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 109.955 -0.387 . . . . 0.38 109.955 179.087 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 361' ' ' VAL . . . . . 0.557 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 41.8 t -101.19 111.15 29.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 109.209 -0.663 . . . . 0.39 109.209 179.63 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 362' ' ' ILE . . . . . 0.482 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 60.4 mt -108.09 112.48 61.47 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-O 120.985 0.421 . . . . 0.29 111.531 -171.402 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 363' ' ' PRO . . . . . 0.557 ' HD2' HG12 ' A' ' 290' ' ' ILE . 33.7 Cg_endo -64.19 155.34 65.73 Favored 'Trans proline' 0 C--O 1.235 0.356 0 C-N-CA 122.902 2.401 . . . . 0.66 111.791 175.153 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 364' ' ' ALA . . . . . 0.424 ' CB ' ' HA ' ' A' ' 379' ' ' ASN . . . -51.16 -49.5 81.05 Favored Pre-proline 0 CA--C 1.541 0.598 0 N-CA-C 114.14 1.163 . . . . 0.42 114.14 -174.775 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 365' ' ' PRO . . . . . 0.474 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 32.2 Cg_exo -59.0 -24.41 73.22 Favored 'Trans proline' 0 C--N 1.362 1.274 0 C-N-CA 122.176 1.917 . . . . 0.7 113.671 -173.056 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 366' ' ' TYR . . . . . 0.595 ' CE2' ' HA3' ' A' ' 288' ' ' GLY . 5.4 m-85 -100.27 10.74 40.79 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.048 0.452 . . . . 0.69 111.385 -176.707 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 367' ' ' ALA . . . . . 0.502 ' HA ' ' HB ' ' A' ' 342' ' ' ILE . . . -122.24 -106.04 0.37 Allowed 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.903 -0.59 . . . . 0.86 110.406 174.191 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 368' ' ' TYR . . . . . 0.473 ' HB3' ' HB3' ' A' ' 371' ' ' GLN . 96.4 m-85 -92.42 -16.12 26.31 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.642 0.258 . . . . 1.0 111.52 178.38 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 68.53 -110.73 3.56 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.911 -0.661 . . . . 0.56 112.669 178.525 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 370' ' ' LYS . . . . . 0.419 ' HA ' ' HB1' ' A' ' 378' ' ' ALA . 48.9 mtpt -101.27 10.18 40.96 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.766 0.317 . . . . 2.76 111.174 -177.538 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 371' ' ' GLN . . . . . 0.473 ' HB3' ' HB3' ' A' ' 368' ' ' TYR . 64.5 tt0 -82.58 100.97 10.46 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 120.864 0.364 . . . . 2.65 110.572 178.656 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 372' ' ' ALA . . . . . 0.605 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -78.84 107.9 11.89 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.264 -0.426 . . . . 1.01 111.295 178.602 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 83.6 mt -102.47 161.81 22.14 Favored Pre-proline 0 C--N 1.32 -0.691 0 N-CA-C 109.403 -0.592 . . . . 0.93 109.403 174.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_endo -64.27 114.61 2.74 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 121.592 1.528 . . . . 1.31 110.929 172.452 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 96.2 -28.58 12.41 Favored Glycine 0 CA--C 1.521 0.466 0 C-N-CA 120.89 -0.671 . . . . 0.9 112.225 -176.665 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 376' ' ' ILE . . . . . 0.547 HG23 HD21 ' A' ' 382' ' ' LEU . 23.0 mt -130.74 77.62 75.27 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 120.701 0.286 . . . . 0.74 110.303 179.137 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 377' ' ' PRO . . . . . 0.605 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 73.5 Cg_endo -77.77 167.86 23.26 Favored 'Trans proline' 0 N--CA 1.461 -0.395 0 C-N-CA 122.38 2.054 . . . . 0.71 112.805 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 378' ' ' ALA . . . . . 0.419 ' HB1' ' HA ' ' A' ' 370' ' ' LYS . . . -53.07 143.2 18.11 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 116.055 -0.52 . . . . 0.74 111.979 -179.72 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 379' ' ' ASN . . . . . 0.424 ' HA ' ' CB ' ' A' ' 364' ' ' ALA . 12.3 m120 67.95 19.92 9.31 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 115.556 -0.747 . . . . 1.49 112.286 176.356 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 67.1 m -87.2 131.63 34.13 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.332 0.587 . . . . 1.84 111.232 176.55 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 381' ' ' GLU . . . . . 0.907 ' HB3' ' HD2' ' A' ' 318' ' ' LYS . 34.1 tt0 -84.71 112.86 20.86 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.999 -1.0 . . . . 1.03 109.93 178.33 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 382' ' ' LEU . . . . . 0.547 HD21 HG23 ' A' ' 376' ' ' ILE . 91.5 mt -89.67 139.49 30.51 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.334 -0.394 . . . . 0.37 110.243 179.765 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 37.8 m -119.33 119.12 33.07 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.322 -0.621 . . . . 0.27 109.322 176.553 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -115.13 109.88 18.68 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 121.124 0.488 . . . . 0.32 110.444 -177.213 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -87.52 106.92 18.32 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 108.149 -1.056 . . . . 1.8 108.149 174.113 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 386' ' ' VAL . . . . . 0.466 HG12 ' CB ' ' A' ' 313' ' ' TYR . 29.6 m -122.9 148.37 26.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.621 0.724 . . . . 0.31 112.123 -168.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 387' ' ' LYS . . . . . 0.724 ' HB2' ' HG3' ' A' ' 357' ' ' GLU . 40.7 tttp -139.05 132.96 30.98 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.74 -1.118 . . . . 2.53 109.317 175.222 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 388' ' ' LEU . . . . . 0.783 HD11 ' HB ' ' A' ' 309' ' ' VAL . 30.6 tp -91.98 131.62 37.14 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 108.666 -0.864 . . . . 0.28 108.666 -179.178 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 28.9 m -120.01 -4.39 9.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 112.232 0.456 . . . . 0.45 112.232 -173.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 11.3 t -170.51 152.06 3.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.968 0.413 . . . . 1.32 111.154 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 391' ' ' MET . . . . . 0.62 ' HE2' HG12 ' A' ' 309' ' ' VAL . 31.6 ttm -157.25 147.47 20.94 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.747 -0.661 . . . . 0.56 109.497 174.626 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 20.8 tptm . . . . . 0 C--O 1.248 0.992 0 CA-C-O 117.88 -1.057 . . . . 4.91 111.438 173.471 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.963 HG22 ' HG2' ' A' ' 293' ' ' GLU . 31.6 p . . . . . 0 N--CA 1.455 -0.201 0 N-CA-C 110.21 -0.292 . . . . 0.76 110.21 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 284' ' ' LYS . . . . . 0.457 ' HB2' HG13 ' A' ' 292' ' ' ILE . 23.8 mmtp -122.03 146.99 46.64 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.94 0.4 . . . . 2.06 111.115 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 40.3 tp -103.97 121.17 42.58 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.542 -0.754 . . . . 0.98 110.242 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.565 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 94.9 mt -101.78 -169.5 1.69 Allowed 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.978 -0.555 . . . . 0.8 110.407 178.048 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -68.37 146.58 53.12 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.702 -0.681 . . . . 2.64 110.154 -179.651 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 73.71 10.63 80.23 Favored Glycine 0 CA--C 1.517 0.163 0 C-N-CA 121.102 -0.571 . . . . 1.84 113.687 178.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 81.44 16.84 72.69 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.63 -0.795 . . . . 0.64 112.596 178.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 290' ' ' ILE . . . . . 0.565 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 84.1 mt -69.64 125.76 28.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 N-CA-C 109.94 -0.393 . . . . 0.42 109.94 177.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.68 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 20.1 mt -104.14 134.91 44.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 N-CA-C 109.286 -0.635 . . . . 0.93 109.286 179.386 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 292' ' ' ILE . . . . . 0.457 HG13 ' HB2' ' A' ' 284' ' ' LYS . 18.2 pt -124.13 127.14 73.24 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 CA-C-O 121.112 0.482 . . . . 0.48 110.172 177.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 293' ' ' GLU . . . . . 0.963 ' HG2' HG22 ' A' ' 283' ' ' THR . 29.4 mt-10 -117.94 114.35 23.07 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.499 -0.773 . . . . 2.31 109.469 -179.812 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . 0.477 ' C ' ' HE ' ' A' ' 295' ' ' ARG . 8.2 t70 -80.15 135.09 36.22 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 109.255 -0.646 . . . . 2.36 109.255 -175.383 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 295' ' ' ARG . . . . . 0.584 ' HG2' ' HA ' ' A' ' 358' ' ' ARG . 1.7 mmp_? -105.76 -60.3 1.65 Allowed 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 110.02 -0.363 . . . . 3.5 110.02 -175.175 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . . . . . . . . . 84.0 t -122.2 109.98 25.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 116.039 -0.528 . . . . 0.7 109.594 174.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 18.1 p -61.93 109.24 1.2 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.522 -0.763 . . . . 1.93 111.405 -177.392 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -101.2 171.38 22.32 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.669 -0.776 . . . . 1.04 112.033 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 8.0 tmtm? -145.69 110.58 5.18 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.297 -0.631 . . . . 4.49 109.297 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -172.24 -154.25 9.96 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.78 -0.724 . . . . 1.04 111.713 -178.596 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . 0.731 ' HD2' ' HB ' ' A' ' 354' ' ' VAL . 24.0 Cg_exo -64.46 134.34 41.16 Favored 'Trans proline' 0 C--O 1.232 0.192 0 C-N-CA 123.129 2.553 . . . . 0.88 112.342 177.28 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 44.4 m-70 -98.32 132.25 43.95 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.317 -0.401 . . . . 1.49 110.048 179.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -81.3 143.26 32.37 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 112.487 0.551 . . . . 0.54 112.487 -176.009 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -127.26 -178.85 4.6 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.657 -0.701 . . . . 2.84 110.041 174.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.81 ' HG3' ' HA3' ' A' ' 337' ' ' GLY . 46.7 tttm -68.47 135.49 51.74 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.864 0.364 . . . . 2.84 110.342 175.218 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 93.13 -17.83 57.46 Favored Glycine 0 N--CA 1.451 -0.318 0 CA-C-N 116.107 -0.497 . . . . 0.7 112.257 -176.517 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 27.0 m -74.83 142.53 44.18 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.729 0.3 . . . . 0.4 110.679 -179.236 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 22.0 mtm180 -104.61 103.73 13.44 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 109.04 -0.726 . . . . 3.45 109.04 178.58 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.831 ' HB ' HD11 ' A' ' 388' ' ' LEU . 28.4 m -104.35 145.36 13.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 CA-C-N 116.011 -0.54 . . . . 0.34 111.567 -177.569 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -111.51 120.68 5.5 Favored Glycine 0 N--CA 1.445 -0.739 0 N-CA-C 109.709 -1.356 . . . . 0.27 109.709 176.405 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 311' ' ' MET . . . . . 0.543 ' CE ' ' HB ' ' A' ' 386' ' ' VAL . 22.0 ptm -136.44 176.79 8.38 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.591 0.71 . . . . 0.76 112.309 -169.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 312' ' ' ARG . . . . . 0.539 ' HD2' ' HA ' ' A' ' 327' ' ' THR . 12.5 mmt-85 -127.57 151.09 49.34 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 107.303 -1.369 . . . . 2.51 107.303 172.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 313' ' ' TYR . . . . . 0.474 ' CB ' HG12 ' A' ' 386' ' ' VAL . 51.3 p90 -167.04 158.53 12.39 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.326 0.584 . . . . 0.68 111.953 -176.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . 0.445 HG12 ' HG3' ' A' ' 316' ' ' LYS . 42.6 t -123.15 112.32 33.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.124 -0.944 . . . . 0.35 109.559 174.131 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -84.73 105.51 2.86 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 121.073 -0.585 . . . . 0.28 111.942 -177.661 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 316' ' ' LYS . . . . . 0.504 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 45.8 mtmt -119.31 154.35 33.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.143 0.497 . . . . 1.94 111.681 -176.225 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 78.3 mt -91.15 160.56 15.5 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.811 -0.631 . . . . 0.65 109.97 176.152 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 318' ' ' LYS . . . . . 0.665 ' HD2' ' HB3' ' A' ' 381' ' ' GLU . 85.3 tttt -62.4 -18.45 61.64 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-O 121.345 0.593 . . . . 2.42 110.138 175.603 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -79.61 -2.03 40.72 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 115.566 -0.743 . . . . 2.2 110.788 179.623 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 89.96 -2.91 82.44 Favored Glycine 0 C--N 1.329 0.178 0 C-N-CA 120.648 -0.787 . . . . 0.69 112.795 177.364 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -93.83 128.37 40.06 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.691 0.281 . . . . 2.42 110.587 -179.073 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.504 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 7.1 p -85.41 136.64 22.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 116.249 -0.432 . . . . 1.26 110.277 177.144 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 42.5 p90 -108.24 -35.67 6.49 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 120.791 -0.364 . . . . 0.55 111.36 -179.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -147.05 162.28 39.12 Favored 'General case' 0 N--CA 1.464 0.261 0 C-N-CA 120.976 -0.289 . . . . 1.68 110.569 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 3.7 ptpp? -164.55 138.72 5.29 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.76 0.314 . . . . 1.99 111.323 -177.136 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 55.0 m-80 -140.58 117.12 10.82 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 108.798 -0.815 . . . . 1.92 108.798 173.56 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 327' ' ' THR . . . . . 0.539 ' HA ' ' HD2' ' A' ' 312' ' ' ARG . 5.2 t -160.73 -49.44 0.05 OUTLIER 'General case' 0 C--N 1.324 -0.5 0 C-N-CA 120.859 -0.337 . . . . 1.69 111.726 -177.16 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 19.9 pttp -94.77 104.94 16.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.364 0.602 . . . . 2.55 110.839 -178.218 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.421 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 87.94 -29.61 5.42 Favored Glycine 0 N--CA 1.45 -0.394 0 CA-C-N 115.409 -0.814 . . . . 0.97 112.756 177.49 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 92.3 mttt -102.09 106.49 48.2 Favored Pre-proline 0 C--N 1.326 -0.428 0 CA-C-O 120.735 0.302 . . . . 2.08 111.335 -176.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 331' ' ' PRO . . . . . 0.421 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 80.3 Cg_endo -87.31 125.72 2.21 Favored 'Trans proline' 0 N--CA 1.448 -1.167 0 C-N-CA 122.765 2.31 . . . . 0.62 111.405 173.126 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 64.7 t80 -103.66 114.36 28.56 Favored 'General case' 0 C--N 1.318 -0.777 0 C-N-CA 120.677 -0.409 . . . . 0.64 110.002 179.43 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 333' ' ' VAL . . . . . 0.468 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 58.4 t -115.86 122.61 69.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.767 -0.651 . . . . 0.38 109.868 -178.57 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.466 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 13.2 p90 -138.19 165.87 25.6 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.945 0.403 . . . . 0.41 110.229 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 335' ' ' LYS . . . . . 0.548 ' HG3' ' HG3' ' A' ' 338' ' ' GLN . 21.4 pttm -110.08 129.44 55.69 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.977 -0.556 . . . . 2.58 110.608 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 9.6 mp -72.44 146.52 46.87 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.849 -0.614 . . . . 0.58 111.732 -178.704 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 337' ' ' GLY . . . . . 0.81 ' HA3' ' HG3' ' A' ' 305' ' ' LYS . . . 88.44 25.05 31.75 Favored Glycine 0 N--CA 1.447 -0.614 0 CA-C-N 115.632 -0.713 . . . . 0.94 112.769 170.614 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 338' ' ' GLN . . . . . 0.548 ' HG3' ' HG3' ' A' ' 335' ' ' LYS . 48.3 mm-40 -123.09 149.47 44.41 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.732 -0.47 . . . . 2.62 109.732 -179.458 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -78.49 43.3 2.31 Favored Glycine 0 CA--C 1.518 0.279 0 C-N-CA 120.875 -0.678 . . . . 0.74 112.786 178.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 340' ' ' GLU . . . . . 0.516 ' HG2' ' HB2' ' A' ' 338' ' ' GLN . 10.4 pt-20 -122.29 -3.21 8.97 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.153 0.502 . . . . 2.09 110.087 175.647 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 23.9 m -128.49 166.51 25.63 Favored 'Isoleucine or valine' 0 C--O 1.233 0.229 0 CA-C-N 115.47 -0.787 . . . . 0.43 109.057 174.335 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 342' ' ' ILE . . . . . 0.739 ' HB ' ' HA ' ' A' ' 367' ' ' ALA . 14.0 pt -82.63 154.35 3.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.325 -0.62 . . . . 0.32 109.325 176.397 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 343' ' ' LYS . . . . . 0.424 ' HA ' ' OD2' ' A' ' 346' ' ' ASP . 6.9 mtmm -65.93 -31.39 72.29 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 111.78 0.289 . . . . 2.93 111.78 -172.355 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 344' ' ' GLY . . . . . 0.548 ' HA2' HD13 ' A' ' 290' ' ' ILE . . . -54.39 -32.0 51.63 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.69 -0.766 . . . . 0.3 111.851 173.031 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 7.2 m95 -76.03 -55.63 5.42 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 111.847 0.314 . . . . 0.39 111.847 177.367 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 346' ' ' ASP . . . . . 0.424 ' OD2' ' HA ' ' A' ' 343' ' ' LYS . 0.1 OUTLIER -64.75 -24.32 67.53 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 122.186 -0.321 . . . . 1.75 111.603 -174.844 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 56.8 mt -89.8 -49.4 13.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.631 -0.259 . . . . 0.39 111.029 176.546 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -61.49 -36.57 92.76 Favored Glycine 0 CA--C 1.52 0.387 0 C-N-CA 120.982 -0.628 . . . . 0.34 113.171 179.345 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 349' ' ' VAL . . . . . 0.489 ' O ' ' HB2' ' A' ' 352' ' ' MET . 95.4 t -78.79 -14.16 13.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.115 0.484 . . . . 0.32 110.934 178.602 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -69.87 120.56 15.78 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 109.471 -0.566 . . . . 0.47 109.471 176.242 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 85.45 14.05 69.25 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.865 -0.684 . . . . 0.39 112.023 -176.591 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 352' ' ' MET . . . . . 0.489 ' HB2' ' O ' ' A' ' 349' ' ' VAL . 0.0 OUTLIER -81.01 137.0 36.07 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 108.867 -0.79 . . . . 1.28 108.867 176.442 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 353' ' ' ALA . . . . . 0.453 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -109.28 130.56 55.49 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.982 0.42 . . . . 0.55 111.097 -174.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 354' ' ' VAL . . . . . 0.731 ' HB ' ' HD2' ' A' ' 301' ' ' PRO . 95.8 t -54.23 121.03 2.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.906 -0.588 . . . . 0.36 111.306 176.686 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 107.52 -8.73 37.74 Favored Glycine 0 N--CA 1.444 -0.797 0 CA-C-N 115.73 -0.668 . . . . 0.44 112.152 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -100.97 154.9 19.22 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.836 -0.697 . . . . 0.3 112.571 -178.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 357' ' ' GLU . . . . . 0.667 ' HG2' ' HD2' ' A' ' 387' ' ' LYS . 54.0 mt-10 -122.5 130.76 53.39 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.443 -0.577 . . . . 1.41 109.443 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 358' ' ' ARG . . . . . 0.584 ' HA ' ' HG2' ' A' ' 295' ' ' ARG . 4.1 ptp180 -156.06 142.24 18.29 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.232 0.539 . . . . 1.37 111.094 176.522 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 359' ' ' ARG . . . . . . . . . . . . . 53.9 ttp180 -93.31 133.63 36.35 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.508 -0.769 . . . . 2.79 109.82 -178.86 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 38.8 mt -110.16 119.86 60.01 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-N 116.168 -0.469 . . . . 0.38 110.24 -179.418 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 361' ' ' VAL . . . . . 0.68 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 45.6 t -98.87 112.76 31.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 108.616 -0.883 . . . . 0.39 108.616 176.316 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 362' ' ' ILE . . . . . 0.449 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 54.4 mt -112.83 108.0 54.07 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-O 120.7 0.286 . . . . 0.29 111.441 -172.127 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 363' ' ' PRO . . . . . 0.631 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 19.4 Cg_endo -59.36 152.09 63.36 Favored 'Trans proline' 0 C--O 1.235 0.35 0 C-N-CA 122.564 2.176 . . . . 0.66 111.771 170.798 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 364' ' ' ALA . . . . . . . . . . . . . . . -48.43 -46.8 69.47 Favored Pre-proline 0 CA--C 1.544 0.718 0 N-CA-C 114.077 1.14 . . . . 0.42 114.077 -176.544 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 365' ' ' PRO . . . . . 0.631 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 83.7 Cg_exo -49.24 -36.55 37.5 Favored 'Trans proline' 0 C--N 1.361 1.19 0 C-N-CA 122.687 2.258 . . . . 0.7 114.068 -177.134 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 366' ' ' TYR . . . . . 0.471 ' HD1' HD11 ' A' ' 290' ' ' ILE . 2.9 m-85 -101.4 8.5 42.18 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.797 -0.361 . . . . 0.69 111.158 -176.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 367' ' ' ALA . . . . . 0.739 ' HA ' ' HB ' ' A' ' 342' ' ' ILE . . . -110.76 -119.3 0.29 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.162 -0.472 . . . . 0.86 109.973 175.107 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 82.6 m-85 -86.92 5.9 34.69 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 121.081 0.467 . . . . 1.0 111.238 178.245 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 67.05 -109.06 2.7 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.909 -0.587 . . . . 0.56 112.352 176.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 20.3 pttm -120.71 15.58 11.86 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.774 0.321 . . . . 2.76 110.963 -178.823 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 8.7 tp-100 -83.18 106.99 15.43 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.947 0.403 . . . . 2.65 110.149 178.267 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 372' ' ' ALA . . . . . 0.555 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -75.38 102.03 4.98 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 116.034 -0.53 . . . . 1.01 110.918 179.606 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 76.5 mt -88.9 163.83 33.55 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.706 -0.679 . . . . 0.93 109.254 177.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -61.77 113.98 2.07 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 121.594 1.529 . . . . 1.31 110.69 173.283 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 93.39 -26.66 14.53 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.83 -0.7 . . . . 0.9 112.754 -177.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 376' ' ' ILE . . . . . 0.448 HG23 HD21 ' A' ' 382' ' ' LEU . 39.6 mt -126.5 81.92 67.29 Favored Pre-proline 0 CA--C 1.532 0.288 0 CA-C-O 120.86 0.362 . . . . 0.74 110.978 -178.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 377' ' ' PRO . . . . . 0.555 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 56.1 Cg_endo -76.77 167.58 25.09 Favored 'Trans proline' 0 N--CA 1.459 -0.537 0 C-N-CA 122.413 2.075 . . . . 0.71 112.457 178.126 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 378' ' ' ALA . . . . . . . . . . . . . . . -54.51 145.89 17.51 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.804 -0.635 . . . . 0.74 111.488 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 379' ' ' ASN . . . . . . . . . . . . . 52.5 m-80 73.05 14.25 4.73 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 115.747 -0.661 . . . . 1.49 112.147 176.613 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 66.5 m -78.97 115.03 18.4 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.258 0.551 . . . . 1.84 110.45 175.645 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 381' ' ' GLU . . . . . 0.665 ' HB3' ' HD2' ' A' ' 318' ' ' LYS . 33.0 tt0 -74.33 101.47 4.07 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.421 -0.809 . . . . 1.03 108.865 177.38 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 382' ' ' LEU . . . . . 0.448 HD21 HG23 ' A' ' 376' ' ' ILE . 79.4 mt -85.47 142.07 29.48 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 120.714 0.293 . . . . 0.37 110.897 -174.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 18.8 m -121.89 117.22 25.94 Favored 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 109.732 -0.47 . . . . 0.27 109.732 178.706 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 384' ' ' PHE . . . . . 0.415 ' CD2' HD12 ' A' ' 362' ' ' ILE . 82.5 m-85 -112.67 109.94 19.77 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 121.094 0.474 . . . . 0.32 110.067 -176.81 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -88.5 105.13 17.42 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 108.667 -0.864 . . . . 1.8 108.667 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 386' ' ' VAL . . . . . 0.543 ' HB ' ' CE ' ' A' ' 311' ' ' MET . 12.3 m -124.8 152.07 30.77 Favored 'Isoleucine or valine' 0 C--O 1.235 0.341 0 CA-C-O 121.756 0.788 . . . . 0.31 112.832 -167.208 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 387' ' ' LYS . . . . . 0.667 ' HD2' ' HG2' ' A' ' 357' ' ' GLU . 71.6 tttt -143.7 136.38 27.27 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.1 -0.955 . . . . 2.53 109.583 174.541 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 388' ' ' LEU . . . . . 0.831 HD11 ' HB ' ' A' ' 309' ' ' VAL . 30.7 tp -95.94 131.2 42.55 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.729 -0.471 . . . . 0.28 109.729 -177.487 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 32.9 m -122.16 -8.96 8.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 N-CA-C 112.226 0.454 . . . . 0.45 112.226 -174.202 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 13.9 p -166.94 161.18 14.91 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.003 0.43 . . . . 1.32 111.852 -176.013 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 391' ' ' MET . . . . . 0.587 ' HG2' ' HG2' ' A' ' 392' ' ' LYS . 29.9 ttm -151.51 143.37 23.79 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.403 -0.817 . . . . 0.56 109.428 176.678 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 392' ' ' LYS . . . . . 0.587 ' HG2' ' HG2' ' A' ' 391' ' ' MET . 19.4 pttp . . . . . 0 C--O 1.248 0.989 0 CA-C-O 117.888 -1.054 . . . . 4.91 112.369 179.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.432 HG22 ' HB3' ' A' ' 293' ' ' GLU . 17.9 p . . . . . 0 N--CA 1.444 -0.733 0 CA-C-O 120.999 0.428 . . . . 0.76 111.081 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 15.1 ptpt -140.68 146.18 37.51 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.2 -0.455 . . . . 2.06 110.959 176.527 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . 0.54 HD11 ' HA2' ' A' ' 289' ' ' GLY . 22.1 tp -89.5 129.41 35.99 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.294 -0.866 . . . . 0.98 111.292 -175.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.545 HD11 HD13 ' A' ' 292' ' ' ILE . 81.7 mt -105.62 -166.71 1.24 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.975 -0.557 . . . . 0.8 110.284 175.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 287' ' ' GLU . . . . . 0.526 ' HG3' ' OH ' ' A' ' 366' ' ' TYR . 8.2 tp10 -51.11 142.0 13.23 Favored 'General case' 0 C--O 1.234 0.28 0 O-C-N 123.706 0.629 . . . . 2.64 111.557 -179.832 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 72.67 -99.63 0.93 Allowed Glycine 0 N--CA 1.446 -0.682 0 CA-C-N 115.551 -0.75 . . . . 1.84 111.37 -174.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . 0.54 ' HA2' HD11 ' A' ' 285' ' ' LEU . . . -153.77 32.91 0.75 Allowed Glycine 0 N--CA 1.443 -0.837 0 N-CA-C 110.428 -1.069 . . . . 0.64 110.428 174.138 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 290' ' ' ILE . . . . . 0.511 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 76.9 mt -74.77 124.41 32.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.564 -0.318 . . . . 0.42 110.394 -176.14 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.619 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 7.8 mt -104.24 136.45 37.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 N-CA-C 109.651 -0.5 . . . . 0.93 109.651 -179.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 292' ' ' ILE . . . . . 0.545 HD13 HD11 ' A' ' 286' ' ' LEU . 33.5 pt -133.37 137.28 53.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 120.699 -0.4 . . . . 0.48 111.07 179.481 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 293' ' ' GLU . . . . . 0.601 ' CG ' ' HB3' ' A' ' 359' ' ' ARG . 12.1 pt-20 -139.74 143.3 36.92 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.231 -0.895 . . . . 2.31 109.709 178.336 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -94.0 139.86 30.42 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 120.996 0.427 . . . . 2.36 111.035 179.548 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 295' ' ' ARG . . . . . 0.404 HH11 ' HD2' ' A' ' 295' ' ' ARG . 11.3 mmt85 -114.7 -47.11 2.91 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.569 -0.741 . . . . 3.5 111.414 -174.55 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.57 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 97.6 t -120.9 132.55 70.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.392 -0.367 . . . . 0.7 110.414 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 10.3 p -63.5 137.8 58.27 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.845 -0.616 . . . . 1.93 112.05 -176.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -165.35 132.77 2.76 Favored Glycine 0 N--CA 1.446 -0.659 0 CA-C-N 115.781 -0.645 . . . . 1.04 111.815 179.294 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 11.1 ptpp? -133.44 116.49 16.07 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.255 0.55 . . . . 4.49 109.905 176.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -171.55 -154.1 9.6 Favored Glycine 0 N--CA 1.442 -0.918 0 N-CA-C 111.193 -0.763 . . . . 1.04 111.193 -177.232 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . 0.441 ' O ' ' HA ' ' A' ' 353' ' ' ALA . 26.2 Cg_exo -61.66 133.01 43.01 Favored 'Trans proline' 0 C--O 1.237 0.443 0 C-N-CA 122.625 2.217 . . . . 0.88 111.472 178.233 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 25.0 m80 -101.47 133.48 46.06 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.247 -0.433 . . . . 1.49 111.298 -177.524 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -64.76 126.5 28.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.503 -0.772 . . . . 0.54 111.179 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 38.2 ttpt -136.4 169.77 17.13 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.2 -0.667 . . . . 2.84 109.2 -177.225 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 57.0 tttp -63.07 128.2 34.77 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.912 0.386 . . . . 2.84 110.18 177.051 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 97.6 -4.91 62.0 Favored Glycine 0 N--CA 1.451 -0.347 0 CA-C-N 115.935 -0.575 . . . . 0.7 111.84 -176.756 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 27.4 m -93.74 146.32 23.94 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.708 0.29 . . . . 0.4 110.994 -179.363 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 308' ' ' ARG . . . . . 0.504 ' HG2' ' HB3' ' A' ' 335' ' ' LYS . 54.6 mtm180 -110.65 104.12 12.77 Favored 'General case' 0 CA--C 1.516 -0.349 0 N-CA-C 109.346 -0.612 . . . . 3.45 109.346 177.822 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.792 ' HB ' HD11 ' A' ' 388' ' ' LEU . 31.5 m -102.65 147.01 9.73 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 CA-C-O 121.349 0.595 . . . . 0.34 111.944 -173.457 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -118.02 117.21 3.67 Favored Glycine 0 N--CA 1.446 -0.678 0 N-CA-C 109.669 -1.372 . . . . 0.27 109.669 176.068 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 311' ' ' MET . . . . . 0.457 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 21.4 ptm -135.23 177.02 8.14 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.577 0.703 . . . . 0.76 112.729 -169.133 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 64.4 mtt180 -134.47 147.63 50.42 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 107.332 -1.359 . . . . 2.51 107.332 176.496 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 313' ' ' TYR . . . . . 0.697 ' HB2' HG12 ' A' ' 386' ' ' VAL . 48.6 p90 -164.29 157.92 18.25 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 112.878 0.696 . . . . 0.68 112.878 -172.54 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 62.0 t -125.45 116.18 45.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 114.818 -1.083 . . . . 0.35 109.44 174.411 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -101.43 116.85 5.67 Favored Glycine 0 C--O 1.24 0.475 0 C-N-CA 120.912 -0.661 . . . . 0.28 112.213 -177.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 316' ' ' LYS . . . . . 0.536 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 98.3 mttt -119.41 162.42 18.85 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.372 0.606 . . . . 1.94 111.058 -178.01 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 63.2 mt -88.04 167.13 13.95 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.02 -0.991 . . . . 0.65 109.301 173.389 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 318' ' ' LYS . . . . . 0.52 ' HD3' ' H ' ' A' ' 381' ' ' GLU . 19.3 pttp -66.51 -8.84 29.16 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.38 0.609 . . . . 2.42 110.299 175.379 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 319' ' ' ASN . . . . . 0.495 HD22 ' HG2' ' A' ' 321' ' ' LYS . 8.3 t30 -86.22 -6.94 58.88 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.678 -0.692 . . . . 2.2 110.302 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 96.47 -12.92 66.13 Favored Glycine 0 N--CA 1.451 -0.303 0 CA-C-N 115.833 -0.621 . . . . 0.69 112.557 178.553 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 321' ' ' LYS . . . . . 0.495 ' HG2' HD22 ' A' ' 319' ' ' ASN . 14.4 mmmm -82.94 132.04 35.17 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.681 0.277 . . . . 2.42 110.903 -177.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.536 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 5.6 p -84.07 134.06 27.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 116.097 -0.501 . . . . 1.26 109.892 177.182 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 34.4 p90 -105.5 -31.73 8.85 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 120.843 -0.343 . . . . 0.55 111.424 179.556 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -148.67 151.83 35.62 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 110.062 -0.347 . . . . 1.68 110.062 178.274 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . 0.599 ' N ' ' HD3' ' A' ' 325' ' ' LYS . 0.0 OUTLIER -160.19 135.24 7.89 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.96 0.41 . . . . 1.99 110.11 -177.908 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 49.0 m-80 -138.51 118.19 13.1 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.512 -0.551 . . . . 1.92 109.512 179.415 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 6.6 t -162.26 -43.49 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.576 -0.284 . . . . 1.69 110.965 -178.601 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.406 ' O ' ' HG3' ' A' ' 328' ' ' LYS . 6.9 ptpp? -99.51 120.64 39.96 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.862 -0.421 . . . . 2.55 109.862 177.167 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.424 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 79.13 -37.18 1.96 Allowed Glycine 0 CA--C 1.52 0.367 0 C-N-CA 121.139 -0.553 . . . . 0.97 113.034 178.02 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 32.7 mmtp -103.64 100.58 19.86 Favored Pre-proline 0 C--N 1.33 -0.28 0 N-CA-C 111.801 0.297 . . . . 2.08 111.801 -178.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 331' ' ' PRO . . . . . 0.424 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 92.4 Cg_endo -87.54 127.4 2.36 Favored 'Trans proline' 0 N--CA 1.45 -1.032 0 C-N-CA 122.456 2.104 . . . . 0.62 110.775 168.144 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 82.9 t80 -102.03 117.63 35.2 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.57 -0.452 . . . . 0.64 110.408 -178.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 87.5 t -114.61 122.5 68.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.828 -0.624 . . . . 0.38 110.076 179.343 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.457 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 14.1 p90 -138.49 155.77 48.13 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.713 -0.477 . . . . 0.41 109.713 175.325 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 335' ' ' LYS . . . . . 0.504 ' HB3' ' HG2' ' A' ' 308' ' ' ARG . 0.0 OUTLIER -108.99 135.17 50.6 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.306 -0.407 . . . . 2.58 111.117 179.861 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 9.5 mp -77.83 110.74 12.98 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.662 -0.699 . . . . 0.58 109.471 179.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 177.92 -62.72 0.09 OUTLIER Glycine 0 N--CA 1.444 -0.777 0 C-N-CA 120.71 -0.757 . . . . 0.94 111.594 -178.271 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 338' ' ' GLN . . . . . . . . . . . . . 20.8 pt20 -96.56 153.13 18.02 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.055 0.455 . . . . 2.62 110.598 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -88.84 59.74 3.94 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 121.022 -0.609 . . . . 0.74 112.372 -174.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 21.8 pt-20 -87.83 -20.82 25.54 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.522 0.677 . . . . 2.09 109.62 174.217 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 22.1 m -95.81 167.76 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.084 -0.962 . . . . 0.43 108.999 174.129 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 342' ' ' ILE . . . . . 0.598 ' HB ' ' HA ' ' A' ' 367' ' ' ALA . 22.1 pt -71.74 147.49 10.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 N-CA-C 109.13 -0.693 . . . . 0.32 109.13 174.168 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 1.3 mtmt -49.92 -40.44 43.33 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 112.724 0.639 . . . . 2.93 112.724 -171.718 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -55.64 -25.31 42.79 Favored Glycine 0 CA--C 1.524 0.623 0 C-N-CA 121.333 -0.46 . . . . 0.3 113.825 179.014 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 8.2 m95 -74.77 -59.31 2.79 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.915 0.358 . . . . 0.39 111.848 -179.501 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -49.68 -36.99 26.95 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-O 121.082 0.468 . . . . 1.75 111.197 177.729 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 60.8 mt -80.55 -52.28 14.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.821 -0.627 . . . . 0.39 111.738 -178.529 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -67.83 -35.57 85.25 Favored Glycine 0 CA--C 1.519 0.287 0 C-N-CA 121.192 -0.528 . . . . 0.34 113.812 -177.406 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 91.7 t -75.8 -23.97 16.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.699 0.285 . . . . 0.32 110.906 -179.077 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.79 96.84 0.3 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.126 0.489 . . . . 0.47 110.372 177.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 121.49 5.76 9.14 Favored Glycine 0 CA--C 1.52 0.367 0 C-N-CA 121.127 -0.559 . . . . 0.39 112.648 -175.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 352' ' ' MET . . . . . . . . . . . . . 85.6 mmm -84.99 138.57 32.38 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.68 0.276 . . . . 1.28 110.995 175.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 353' ' ' ALA . . . . . 0.441 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -106.19 141.82 36.91 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 116.077 -0.51 . . . . 0.55 111.214 -177.865 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 58.9 t -57.49 120.65 3.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.077 -0.511 . . . . 0.36 110.4 173.188 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 104.08 -12.11 52.27 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 121.188 -0.53 . . . . 0.44 112.087 179.745 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -102.44 143.5 15.91 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.845 -0.693 . . . . 0.3 112.407 -177.347 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 357' ' ' GLU . . . . . 0.57 ' HB3' ' HB ' ' A' ' 296' ' ' VAL . 32.5 tt0 -117.08 133.39 56.06 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 110.192 -0.299 . . . . 1.41 110.192 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 358' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -144.81 144.13 30.99 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.213 0.53 . . . . 1.37 111.113 -179.088 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 359' ' ' ARG . . . . . 0.624 ' HD2' HG22 ' A' ' 383' ' ' THR . 22.9 tpp85 -88.82 119.35 29.23 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.451 -0.795 . . . . 2.79 110.113 176.255 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 58.3 mt -105.33 121.23 57.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.962 -0.385 . . . . 0.38 109.962 177.418 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 361' ' ' VAL . . . . . 0.619 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 44.7 t -101.88 116.94 46.42 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 N-CA-C 109.471 -0.566 . . . . 0.39 109.471 176.793 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 362' ' ' ILE . . . . . 0.51 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 59.0 mt -113.25 109.38 51.74 Favored Pre-proline 0 C--N 1.322 -0.595 0 CA-C-N 116.42 -0.354 . . . . 0.29 111.346 -173.495 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 363' ' ' PRO . . . . . 0.529 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 10.2 Cg_endo -53.56 152.35 21.57 Favored 'Trans proline' 0 C--O 1.236 0.401 0 C-N-CA 123.158 2.572 . . . . 0.66 112.23 173.098 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 364' ' ' ALA . . . . . 0.405 ' HB3' ' HD3' ' A' ' 365' ' ' PRO . . . -52.09 -49.03 86.71 Favored Pre-proline 0 CA--C 1.542 0.639 0 N-CA-C 113.375 0.88 . . . . 0.42 113.375 -175.802 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 365' ' ' PRO . . . . . 0.595 ' HA ' ' HA2' ' A' ' 369' ' ' GLY . 53.4 Cg_exo -53.83 -32.19 65.55 Favored 'Trans proline' 0 C--N 1.364 1.371 0 C-N-CA 122.482 2.121 . . . . 0.7 113.754 -177.062 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 366' ' ' TYR . . . . . 0.526 ' OH ' ' HG3' ' A' ' 287' ' ' GLU . 4.9 m-85 -94.66 9.71 37.73 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.217 0.532 . . . . 0.69 110.942 -175.622 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 367' ' ' ALA . . . . . 0.598 ' HA ' ' HB ' ' A' ' 342' ' ' ILE . . . -120.1 -109.22 0.35 Allowed 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.592 -0.731 . . . . 0.86 109.805 171.58 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 92.3 m-85 -81.58 -12.59 58.71 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 121.003 0.43 . . . . 1.0 111.534 179.404 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 369' ' ' GLY . . . . . 0.595 ' HA2' ' HA ' ' A' ' 365' ' ' PRO . . . 86.63 -114.1 4.02 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.846 -0.692 . . . . 0.56 112.789 175.658 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 43.6 mttp -115.05 14.65 17.15 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.012 0.434 . . . . 2.76 110.479 -175.454 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 8.5 tp-100 -87.81 117.13 26.44 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.003 -0.544 . . . . 2.65 110.645 -176.653 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 372' ' ' ALA . . . . . 0.49 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -87.56 98.89 11.66 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.069 -0.514 . . . . 1.01 110.67 177.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 76.9 mt -90.05 157.01 46.24 Favored Pre-proline 0 C--N 1.322 -0.619 0 CA-C-N 115.962 -0.563 . . . . 0.93 109.951 178.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -61.21 114.25 2.11 Favored 'Trans proline' 0 N--CA 1.459 -0.527 0 C-N-CA 121.803 1.669 . . . . 1.31 110.603 171.668 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 96.57 -30.39 8.88 Favored Glycine 0 N--CA 1.448 -0.559 0 CA-C-N 115.879 -0.6 . . . . 0.9 112.22 -176.264 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 23.4 mt -129.26 78.26 76.26 Favored Pre-proline 0 C--N 1.329 -0.299 0 N-CA-C 110.145 -0.317 . . . . 0.74 110.145 -179.475 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 377' ' ' PRO . . . . . 0.49 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 4.1 Cg_exo -76.86 166.21 27.29 Favored 'Trans proline' 0 N--CA 1.459 -0.54 0 C-N-CA 122.674 2.249 . . . . 0.71 112.143 -179.375 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 378' ' ' ALA . . . . . 0.465 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -59.14 152.86 19.38 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.293 -0.412 . . . . 0.74 110.695 176.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 379' ' ' ASN . . . . . 0.465 ' HB2' ' O ' ' A' ' 378' ' ' ALA . 16.8 m120 74.95 4.88 4.33 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 123.012 0.525 . . . . 1.49 111.492 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 49.1 m -83.97 94.6 8.31 Favored 'General case' 0 N--CA 1.451 -0.392 0 CA-C-O 121.335 0.588 . . . . 1.84 110.127 176.323 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 381' ' ' GLU . . . . . 0.52 ' H ' ' HD3' ' A' ' 318' ' ' LYS . 19.0 tt0 -67.04 112.34 4.33 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 114.972 -1.013 . . . . 1.03 109.617 179.354 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 82.4 mt -78.02 140.98 39.18 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.092 -0.504 . . . . 0.37 110.952 -173.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 383' ' ' THR . . . . . 0.624 HG22 ' HD2' ' A' ' 359' ' ' ARG . 25.1 m -120.19 119.54 33.54 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 109.29 -0.633 . . . . 0.27 109.29 -179.182 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -115.63 114.62 25.15 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.05 0.452 . . . . 0.32 111.19 -175.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 20.8 t70 -91.82 104.47 16.91 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 107.885 -1.154 . . . . 1.8 107.885 174.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 386' ' ' VAL . . . . . 0.697 HG12 ' HB2' ' A' ' 313' ' ' TYR . 17.3 m -129.71 147.61 33.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 112.46 0.541 . . . . 0.31 112.46 -167.097 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 387' ' ' LYS . . . . . 0.476 ' HB3' ' HA ' ' A' ' 357' ' ' GLU . 23.7 pttt -144.74 149.91 36.35 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.803 -0.635 . . . . 2.53 111.271 170.804 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 388' ' ' LEU . . . . . 0.792 HD11 ' HB ' ' A' ' 309' ' ' VAL . 26.9 tp -99.2 138.4 36.35 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.274 -0.875 . . . . 0.28 109.244 -176.702 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 31.8 m -128.83 -8.34 3.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 112.511 0.56 . . . . 0.45 112.511 -174.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 74.2 m -161.55 157.92 25.57 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.624 0.249 . . . . 1.32 110.837 -179.491 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 391' ' ' MET . . . . . . . . . . . . . 39.7 ttm -155.4 132.03 10.5 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-N 116.333 -0.394 . . . . 0.56 110.881 -178.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 66.6 mttm . . . . . 0 C--O 1.25 1.094 0 CA-C-O 118.432 -0.794 . . . . 4.91 109.603 176.781 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.546 ' HA ' ' O ' ' A' ' 292' ' ' ILE . 24.0 p . . . . . 0 N--CA 1.443 -0.807 0 CA-C-O 120.958 0.408 . . . . 0.76 111.866 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 284' ' ' LYS . . . . . 0.511 ' HB2' ' CG1' ' A' ' 292' ' ' ILE . 13.5 mmmm -110.0 137.94 47.08 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.94 -0.763 . . . . 2.06 108.94 174.762 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . 0.409 HD11 ' HA2' ' A' ' 289' ' ' GLY . 42.8 tp -100.26 121.71 41.91 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.934 0.397 . . . . 0.98 110.59 -178.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.66 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 88.3 mt -108.54 -164.56 0.96 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.818 -0.628 . . . . 0.8 110.477 -178.621 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -64.64 145.38 56.26 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 116.099 -0.5 . . . . 2.64 111.749 -178.533 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.643 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 65.76 8.97 43.49 Favored Glycine 0 C--N 1.329 0.154 0 CA-C-N 115.925 -0.58 . . . . 1.84 113.7 177.605 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . 0.409 ' HA2' HD11 ' A' ' 285' ' ' LEU . . . 90.95 12.29 60.55 Favored Glycine 0 N--CA 1.441 -0.988 0 C-N-CA 120.516 -0.849 . . . . 0.64 113.067 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 290' ' ' ILE . . . . . 0.66 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 94.9 mt -60.67 127.44 20.22 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.139 0 CA-C-N 117.373 0.587 . . . . 0.42 110.204 177.526 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.534 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 18.1 mt -113.29 139.82 36.63 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 116.37 -0.377 . . . . 0.93 110.181 -178.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 292' ' ' ILE . . . . . 0.549 HG22 HG12 ' A' ' 360' ' ' ILE . 22.5 pt -128.34 127.06 66.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 120.891 0.377 . . . . 0.48 109.987 175.369 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 293' ' ' GLU . . . . . . . . . . . . . 4.6 tm-20 -105.25 108.44 19.95 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 108.812 -0.81 . . . . 2.31 108.812 -179.443 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -78.11 101.55 7.06 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-O 121.156 0.503 . . . . 2.36 110.576 -171.195 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 295' ' ' ARG . . . . . 0.434 ' HG3' HG23 ' A' ' 296' ' ' VAL . 6.2 tpt180 -88.08 -59.41 2.25 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.184 -0.916 . . . . 3.5 111.879 -170.314 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.434 HG23 ' HG3' ' A' ' 295' ' ' ARG . 91.9 t -120.34 132.85 68.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.592 -0.277 . . . . 0.7 110.77 -178.339 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 6.8 p -92.18 120.55 32.87 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.106 -0.497 . . . . 1.93 110.915 178.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -126.96 -165.03 11.84 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.691 -0.766 . . . . 1.04 112.788 -175.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 299' ' ' LYS . . . . . 0.594 ' O ' ' HB1' ' A' ' 353' ' ' ALA . 74.1 mmtt -73.38 151.75 41.09 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.135 -0.691 . . . . 4.49 109.135 177.706 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -119.75 79.72 0.32 Allowed Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 119.316 -1.421 . . . . 1.04 115.074 -168.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . 0.657 ' HD2' ' H ' ' A' ' 354' ' ' VAL . 2.4 Cg_endo -85.84 133.69 4.35 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 122.735 2.29 . . . . 0.88 109.062 160.234 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 33.6 m170 -92.16 116.46 28.97 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 120.438 -0.505 . . . . 1.49 112.245 -171.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -66.24 121.2 14.67 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.413 -0.812 . . . . 0.54 110.157 173.14 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 31.9 mtmm -123.12 179.2 4.77 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.468 -0.333 . . . . 2.84 110.377 -176.123 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 61.9 tttp -63.9 113.68 3.6 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.391 -0.368 . . . . 2.84 110.349 179.618 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 98.62 -7.1 61.16 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.888 -0.673 . . . . 0.7 112.547 -179.276 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 307' ' ' THR . . . . . 0.406 ' O ' ' HA ' ' A' ' 335' ' ' LYS . 38.9 m -77.61 145.55 36.72 Favored 'General case' 0 CA--C 1.534 0.346 0 O-C-N 122.776 -0.25 . . . . 0.4 110.547 -179.499 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 73.4 mtt180 -105.25 113.87 27.71 Favored 'General case' 0 CA--C 1.519 -0.227 0 N-CA-C 109.565 -0.531 . . . . 3.45 109.565 -177.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.691 ' HB ' HD11 ' A' ' 388' ' ' LEU . 30.2 m -107.28 139.02 30.44 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 CA-C-O 121.273 0.559 . . . . 0.34 111.348 178.498 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -109.88 115.39 4.16 Favored Glycine 0 N--CA 1.445 -0.717 0 N-CA-C 110.23 -1.148 . . . . 0.27 110.23 175.278 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 311' ' ' MET . . . . . 0.583 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 22.4 ptm -136.7 177.44 7.85 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.399 0.619 . . . . 0.76 112.153 -169.659 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 312' ' ' ARG . . . . . 0.517 ' HD3' ' O ' ' A' ' 327' ' ' THR . 98.9 mtt180 -137.05 147.01 45.89 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 107.677 -1.231 . . . . 2.51 107.677 175.341 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 313' ' ' TYR . . . . . 0.42 ' HA ' ' O ' ' A' ' 385' ' ' ASP . 25.2 p90 -161.49 159.93 28.55 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 112.941 0.719 . . . . 0.68 112.941 -169.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 48.7 t -126.41 120.74 57.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 114.839 -1.073 . . . . 0.35 109.68 174.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -94.64 106.03 3.36 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.388 -0.434 . . . . 0.28 112.19 -177.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 316' ' ' LYS . . . . . 0.556 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 84.3 mttt -114.09 156.31 24.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.064 0.459 . . . . 1.94 110.932 -177.038 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 96.5 mt -89.31 163.11 15.49 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.045 -0.525 . . . . 0.65 109.585 172.103 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 318' ' ' LYS . . . . . 0.728 ' HD3' ' HB3' ' A' ' 381' ' ' GLU . 61.7 pttt -65.68 -11.55 46.07 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 121.01 0.433 . . . . 2.42 111.338 178.405 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 9.0 t30 -87.98 -7.88 56.45 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.083 0.468 . . . . 2.2 110.216 178.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 101.17 -15.61 57.69 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 121.09 -0.576 . . . . 0.69 112.197 -178.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 59.0 tptt -70.89 117.28 12.19 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.644 0.259 . . . . 2.42 110.73 -179.272 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.556 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 6.1 p -85.58 131.77 33.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 N-CA-C 110.028 -0.36 . . . . 1.26 110.028 176.819 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 31.6 p90 -106.35 -50.09 3.22 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 120.862 -0.335 . . . . 0.55 110.991 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 324' ' ' ASP . . . . . 0.494 ' C ' ' HD3' ' A' ' 325' ' ' LYS . 12.0 t70 -123.86 154.32 39.81 Favored 'General case' 0 CA--C 1.513 -0.446 0 N-CA-C 109.492 -0.559 . . . . 1.68 109.492 -179.302 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . 0.494 ' HD3' ' C ' ' A' ' 324' ' ' ASP . 0.0 OUTLIER -167.9 131.1 1.61 Allowed 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.959 0.409 . . . . 1.99 111.143 -174.147 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 1.9 p30 -146.52 115.78 7.03 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.684 0.754 . . . . 1.92 109.719 170.336 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 327' ' ' THR . . . . . 0.517 ' O ' ' HD3' ' A' ' 312' ' ' ARG . 1.7 p -148.96 -47.17 0.14 Allowed 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 114.935 -1.029 . . . . 1.69 110.922 -172.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.66 93.34 2.06 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.492 0.663 . . . . 2.55 111.534 -178.111 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.487 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 75.37 -11.5 8.96 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 115.508 -0.769 . . . . 0.97 113.629 175.288 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 45.9 mtpt -103.25 100.63 18.49 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-N 117.32 0.56 . . . . 2.08 111.41 -177.635 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 331' ' ' PRO . . . . . 0.487 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 86.0 Cg_endo -87.76 139.7 4.83 Favored 'Trans proline' 0 N--CA 1.452 -0.953 0 C-N-CA 122.749 2.299 . . . . 0.62 111.854 170.664 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 79.2 t80 -109.84 128.14 55.14 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.253 -0.647 . . . . 0.64 109.253 176.359 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 61.9 t -115.22 119.6 62.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 N-CA-C 109.839 -0.43 . . . . 0.38 109.839 -176.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.583 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 21.2 p90 -138.92 166.59 24.07 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.853 -0.425 . . . . 0.41 109.853 179.66 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 335' ' ' LYS . . . . . 0.407 ' HG3' ' HB3' ' A' ' 338' ' ' GLN . 58.6 pttt -111.12 140.49 45.62 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.16 -0.473 . . . . 2.58 110.403 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 11.2 mp -71.53 139.0 49.32 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.729 -0.471 . . . . 0.58 109.729 175.246 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 94.76 5.95 60.99 Favored Glycine 0 N--CA 1.442 -0.93 0 C-N-CA 120.791 -0.719 . . . . 0.94 113.002 -174.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 338' ' ' GLN . . . . . 0.6 HE21 HG13 ' A' ' 341' ' ' VAL . 13.7 pt20 -85.16 148.86 25.9 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 117.381 0.591 . . . . 2.62 109.558 176.165 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -90.37 15.23 60.49 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.75 -0.738 . . . . 0.74 114.407 -166.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -109.92 -9.07 14.79 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 117.646 0.723 . . . . 2.09 111.481 178.397 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 341' ' ' VAL . . . . . 0.6 HG13 HE21 ' A' ' 338' ' ' GLN . 26.3 m -95.71 146.29 7.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 C-N-CA 120.769 -0.372 . . . . 0.43 110.144 178.697 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 17.4 pt -73.58 157.1 6.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 109.965 -0.383 . . . . 0.32 109.965 178.678 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 343' ' ' LYS . . . . . 0.453 ' HA ' ' HE3' ' A' ' 343' ' ' LYS . 0.0 OUTLIER -62.74 -35.26 79.19 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 111.626 0.232 . . . . 2.93 111.626 -175.895 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -52.28 -42.15 55.62 Favored Glycine 0 C--O 1.228 -0.251 0 C-N-CA 120.774 -0.726 . . . . 0.3 112.363 174.243 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 4.2 m95 -68.8 -60.34 2.46 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.819 0.342 . . . . 0.39 111.043 176.441 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -51.66 -33.97 35.99 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.594 -0.73 . . . . 1.75 112.121 -177.477 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 60.0 mt -85.19 -52.53 12.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 116.4 -0.363 . . . . 0.39 111.283 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -60.47 -35.05 87.94 Favored Glycine 0 CA--C 1.524 0.628 0 C-N-CA 121.261 -0.495 . . . . 0.34 113.794 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 349' ' ' VAL . . . . . 0.422 ' O ' ' HB2' ' A' ' 352' ' ' MET . 93.1 t -77.68 -18.27 14.05 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 CA-C-O 120.994 0.426 . . . . 0.32 111.382 -179.311 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -64.22 100.34 0.33 Allowed 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.157 0.503 . . . . 0.47 110.634 177.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 105.52 12.05 27.57 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.914 -0.66 . . . . 0.39 112.205 -177.014 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 352' ' ' MET . . . . . 0.422 ' HB2' ' O ' ' A' ' 349' ' ' VAL . 0.0 OUTLIER -66.58 143.89 56.76 Favored 'General case' 0 C--N 1.331 -0.216 0 N-CA-C 109.79 -0.448 . . . . 1.28 109.79 177.675 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 353' ' ' ALA . . . . . 0.594 ' HB1' ' O ' ' A' ' 299' ' ' LYS . . . -104.06 127.06 51.61 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.321 -0.399 . . . . 0.55 111.715 -173.082 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 354' ' ' VAL . . . . . 0.657 ' H ' ' HD2' ' A' ' 301' ' ' PRO . 98.3 t -64.84 112.97 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.239 0.542 . . . . 0.36 110.743 174.504 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 109.96 -10.88 31.97 Favored Glycine 0 N--CA 1.442 -0.9 0 N-CA-C 111.313 -0.715 . . . . 0.44 111.313 -176.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -101.54 159.77 18.38 Favored Glycine 0 N--CA 1.442 -0.952 0 C-N-CA 121.048 -0.596 . . . . 0.3 112.302 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 357' ' ' GLU . . . . . 0.862 ' HB2' ' HD3' ' A' ' 387' ' ' LYS . 43.3 tt0 -135.35 140.97 45.47 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.491 -0.559 . . . . 1.41 109.491 -179.505 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 358' ' ' ARG . . . . . . . . . . . . . 5.9 ptp180 -156.2 144.91 20.2 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.026 0.441 . . . . 1.37 110.861 177.182 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 359' ' ' ARG . . . . . . . . . . . . . 82.8 mtm180 -91.44 120.02 31.91 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 115.968 -0.56 . . . . 2.79 110.444 179.174 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 360' ' ' ILE . . . . . 0.549 HG12 HG22 ' A' ' 292' ' ' ILE . 62.3 mt -101.68 119.32 49.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-N 115.734 -0.666 . . . . 0.38 110.638 -176.476 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 361' ' ' VAL . . . . . 0.534 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 46.3 t -103.48 112.74 38.09 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 108.972 -0.751 . . . . 0.39 108.972 177.025 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 362' ' ' ILE . . . . . . . . . . . . . 57.6 mt -109.74 102.24 49.47 Favored Pre-proline 0 C--N 1.319 -0.723 0 CA-C-N 116.037 -0.528 . . . . 0.29 110.999 -174.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 363' ' ' PRO . . . . . 0.472 ' HA ' ' HG3' ' A' ' 381' ' ' GLU . 71.2 Cg_exo -54.39 155.48 16.29 Favored 'Trans proline' 0 N--CA 1.459 -0.559 0 C-N-CA 122.532 2.155 . . . . 0.66 112.206 171.231 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 364' ' ' ALA . . . . . 0.547 ' N ' ' HD2' ' A' ' 365' ' ' PRO . . . -46.03 -50.1 37.5 Favored Pre-proline 0 C--N 1.327 -0.41 0 N-CA-C 114.364 1.246 . . . . 0.42 114.364 -174.743 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 365' ' ' PRO . . . . . 0.547 ' HD2' ' N ' ' A' ' 364' ' ' ALA . 9.8 Cg_endo -52.53 -31.58 49.58 Favored 'Trans proline' 0 C--N 1.36 1.168 0 C-N-CA 122.685 2.256 . . . . 0.7 114.387 -172.144 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 366' ' ' TYR . . . . . 0.643 ' CE2' ' HA3' ' A' ' 288' ' ' GLY . 9.6 m-85 -101.62 13.46 34.86 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-O 121.017 0.437 . . . . 0.69 112.035 -176.708 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -126.59 -108.05 0.31 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.963 -0.562 . . . . 0.86 110.563 173.744 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 368' ' ' TYR . . . . . 0.406 ' CE2' HD11 ' A' ' 382' ' ' LEU . 40.6 m-85 -84.08 -21.83 31.37 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.821 0.343 . . . . 1.0 111.211 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 70.68 -118.1 7.47 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.841 -0.695 . . . . 0.56 112.15 -178.14 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 370' ' ' LYS . . . . . 0.555 ' HA ' ' HB1' ' A' ' 378' ' ' ALA . 19.4 ptmt -101.77 17.39 23.11 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.975 0.416 . . . . 2.76 110.735 178.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 59.4 tt0 -84.86 102.58 13.2 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.941 -0.572 . . . . 2.65 110.154 176.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 372' ' ' ALA . . . . . 0.433 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -81.68 108.25 15.09 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.873 0.368 . . . . 1.01 111.202 177.834 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 86.6 mt -90.02 159.33 42.87 Favored Pre-proline 0 C--N 1.322 -0.626 0 N-CA-C 109.088 -0.708 . . . . 0.93 109.088 175.193 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -62.26 114.24 2.25 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 121.656 1.57 . . . . 1.31 110.555 172.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 96.26 -29.28 10.4 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.67 -0.776 . . . . 0.9 112.439 -178.155 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 43.3 mt -128.36 86.66 57.27 Favored Pre-proline 0 C--N 1.332 -0.152 0 N-CA-C 110.011 -0.366 . . . . 0.74 110.011 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 377' ' ' PRO . . . . . 0.433 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 83.8 Cg_endo -80.03 168.0 19.37 Favored 'Trans proline' 0 N--CA 1.462 -0.354 0 C-N-CA 122.724 2.283 . . . . 0.71 113.017 -176.579 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 378' ' ' ALA . . . . . 0.555 ' HB1' ' HA ' ' A' ' 370' ' ' LYS . . . -52.95 150.16 5.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.5 -0.773 . . . . 0.74 111.703 178.73 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 379' ' ' ASN . . . . . 0.434 ' HA ' ' HB2' ' A' ' 364' ' ' ALA . 49.9 m-80 70.91 15.14 6.82 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 115.473 -0.785 . . . . 1.49 111.265 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 21.5 t -76.67 125.98 30.19 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 109.587 -0.523 . . . . 1.84 109.587 175.156 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 381' ' ' GLU . . . . . 0.728 ' HB3' ' HD3' ' A' ' 318' ' ' LYS . 27.2 tt0 -102.24 112.57 25.32 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 108.67 -0.863 . . . . 1.03 108.67 -179.01 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 382' ' ' LEU . . . . . 0.406 HD11 ' CE2' ' A' ' 368' ' ' TYR . 75.8 mt -86.26 146.53 26.48 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 116.179 -0.464 . . . . 0.37 111.12 -172.709 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 63.0 m -123.52 122.84 39.24 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.386 -0.598 . . . . 0.27 109.386 173.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 76.8 m-85 -119.84 111.71 18.32 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 116.483 -0.326 . . . . 0.32 111.079 -177.01 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 385' ' ' ASP . . . . . 0.42 ' O ' ' HA ' ' A' ' 313' ' ' TYR . 3.6 m-20 -72.54 104.18 3.77 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 107.924 -1.139 . . . . 1.8 107.924 167.834 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 386' ' ' VAL . . . . . 0.505 ' HB ' ' CE ' ' A' ' 311' ' ' MET . 32.2 m -119.11 135.61 58.97 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.426 0.631 . . . . 0.31 111.012 -176.227 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 387' ' ' LYS . . . . . 0.862 ' HD3' ' HB2' ' A' ' 357' ' ' GLU . 21.6 ttpt -141.32 128.65 21.11 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.296 -0.865 . . . . 2.53 109.449 178.44 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 388' ' ' LEU . . . . . 0.691 HD11 ' HB ' ' A' ' 309' ' ' VAL . 22.6 tp -95.04 136.76 34.97 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.932 -0.576 . . . . 0.28 109.575 -172.65 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 35.8 m -126.0 -5.0 5.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 N-CA-C 112.392 0.516 . . . . 0.45 112.392 -174.654 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 11.3 p -169.15 157.41 7.7 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.816 -0.354 . . . . 1.32 111.473 -177.444 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 391' ' ' MET . . . . . 0.55 ' HE2' HG12 ' A' ' 309' ' ' VAL . 34.1 ttm -160.89 139.11 9.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.16 -0.473 . . . . 0.56 110.485 177.448 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 18.2 tptm . . . . . 0 C--O 1.246 0.892 0 CA-C-O 117.961 -1.019 . . . . 4.91 111.402 175.167 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.456 ' HA ' ' O ' ' A' ' 292' ' ' ILE . 16.9 p . . . . . 0 N--CA 1.444 -0.729 0 CA-C-O 121.083 0.468 . . . . 0.76 111.412 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 28.2 mmtp -127.46 139.74 52.61 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.729 -0.669 . . . . 2.06 109.629 175.821 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . 0.461 HD11 ' HA2' ' A' ' 289' ' ' GLY . 37.6 tp -96.28 121.1 37.71 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.909 -0.587 . . . . 0.98 110.217 179.539 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.669 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 95.2 mt -105.83 -171.73 1.96 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.912 -0.586 . . . . 0.8 110.378 -179.413 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 287' ' ' GLU . . . . . 0.476 ' HG3' ' OH ' ' A' ' 366' ' ' TYR . 4.9 tp10 -64.51 145.37 56.22 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.889 -0.596 . . . . 2.64 111.105 -176.381 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.423 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 70.93 7.19 61.65 Favored Glycine 0 C--N 1.332 0.31 0 C-N-CA 121.055 -0.593 . . . . 1.84 113.126 -178.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . 0.461 ' HA2' HD11 ' A' ' 285' ' ' LEU . . . 84.81 19.93 58.83 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.858 -0.687 . . . . 0.64 113.216 -179.613 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 290' ' ' ILE . . . . . 0.669 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 96.1 mt -66.39 126.46 25.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 109.985 -0.376 . . . . 0.42 109.985 177.557 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 14.8 mt -110.53 137.14 44.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 N-CA-C 109.726 -0.472 . . . . 0.93 109.726 -178.748 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 292' ' ' ILE . . . . . 0.456 ' O ' ' HA ' ' A' ' 283' ' ' THR . 21.7 pt -127.02 128.24 70.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-O 121.054 0.454 . . . . 0.48 111.069 179.626 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 293' ' ' GLU . . . . . 0.746 ' HB3' ' HB3' ' A' ' 359' ' ' ARG . 6.6 tp10 -104.62 105.54 15.67 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.177 -1.046 . . . . 2.31 108.177 174.223 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -78.02 110.16 12.71 Favored 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 120.562 -0.455 . . . . 2.36 109.816 -172.221 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 295' ' ' ARG . . . . . 0.705 ' HB2' ' HG3' ' A' ' 357' ' ' GLU . 14.6 mmm180 -78.05 -59.66 2.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.889 -0.596 . . . . 3.5 110.855 -171.304 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.552 ' HB ' ' HG2' ' A' ' 357' ' ' GLU . 97.8 t -137.16 119.06 18.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 C-N-CA 121.141 -0.223 . . . . 0.7 110.626 177.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 14.9 p -68.27 108.04 3.04 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 116.079 -0.51 . . . . 1.93 110.494 176.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -94.91 157.39 22.17 Favored Glycine 0 N--CA 1.442 -0.926 0 C-N-CA 120.764 -0.731 . . . . 1.04 111.56 178.677 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 18.3 ttpp -115.75 111.03 19.94 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 109.764 -0.458 . . . . 4.49 109.764 178.535 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -171.72 -162.39 23.91 Favored Glycine 0 N--CA 1.44 -1.096 0 N-CA-C 111.105 -0.798 . . . . 1.04 111.105 179.742 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . 0.435 ' HD2' ' HB ' ' A' ' 354' ' ' VAL . 21.6 Cg_exo -65.76 133.33 33.59 Favored 'Trans proline' 0 N--CA 1.461 -0.394 0 C-N-CA 122.496 2.131 . . . . 0.88 111.661 175.703 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 302' ' ' HIS . . . . . 0.52 ' HA ' ' O ' ' A' ' 352' ' ' MET . 64.4 m80 -89.01 133.69 34.25 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.116 0.484 . . . . 1.49 110.579 -179.706 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 303' ' ' ALA . . . . . 0.44 ' HB2' HG11 ' A' ' 309' ' ' VAL . . . -87.17 129.25 35.02 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.773 -0.649 . . . . 0.54 111.621 -177.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 59.7 pttt -124.34 -176.3 3.48 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.5 -0.555 . . . . 2.84 109.5 174.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.72 ' HG3' ' HA3' ' A' ' 337' ' ' GLY . 50.7 tttm -66.98 133.66 50.4 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.028 0.442 . . . . 2.84 110.229 -178.527 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 91.96 -8.91 77.63 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 121.064 -0.589 . . . . 0.7 112.669 -176.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 25.6 m -82.06 145.51 30.15 Favored 'General case' 0 CA--C 1.535 0.365 0 CA-C-O 120.688 0.28 . . . . 0.4 110.766 -178.689 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 89.6 mtt180 -108.33 103.23 12.35 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-O 121.098 0.475 . . . . 3.45 109.771 -178.221 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.901 ' HB ' HD11 ' A' ' 388' ' ' LEU . 32.4 m -112.13 159.83 11.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-N 115.549 -0.751 . . . . 0.34 112.244 -175.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -123.26 123.55 5.33 Favored Glycine 0 N--CA 1.447 -0.573 0 N-CA-C 110.524 -1.03 . . . . 0.27 110.524 176.333 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 10.4 ptp -134.48 178.15 7.21 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.399 0.619 . . . . 0.76 111.815 -173.377 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 88.1 mtt180 -137.53 143.4 41.61 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 107.217 -1.401 . . . . 2.51 107.217 176.02 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 313' ' ' TYR . . . . . 0.593 ' CB ' HG12 ' A' ' 386' ' ' VAL . 49.4 p90 -162.55 152.16 15.84 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 112.646 0.61 . . . . 0.68 112.646 -167.238 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 51.1 t -116.92 119.0 60.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.091 -0.959 . . . . 0.35 109.627 173.111 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -97.93 109.15 3.75 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 121.343 -0.456 . . . . 0.28 112.261 -178.022 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 316' ' ' LYS . . . . . 0.561 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 56.3 mttm -120.42 162.97 18.62 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.173 0.511 . . . . 1.94 111.025 -177.157 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 81.9 mt -86.54 164.54 16.84 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 108.033 -1.099 . . . . 0.65 108.033 166.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 318' ' ' LYS . . . . . . . . . . . . . 47.7 pttt -64.44 -8.46 13.57 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.483 0.659 . . . . 2.42 110.303 173.505 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -79.51 -12.59 59.86 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 115.289 -0.869 . . . . 2.2 109.799 176.52 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 95.59 -24.93 27.14 Favored Glycine 0 N--CA 1.453 -0.187 0 N-CA-C 111.572 -0.611 . . . . 0.69 111.572 -176.445 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 23.7 ttmm -60.08 120.04 8.96 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.015 -0.593 . . . . 2.42 110.831 177.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.561 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 5.3 p -88.86 127.22 41.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.133 -0.485 . . . . 1.26 110.201 179.491 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 49.4 p90 -98.88 -27.19 14.02 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.828 -0.349 . . . . 0.55 111.16 -178.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -155.18 145.79 22.22 Favored 'General case' 0 CA--C 1.514 -0.408 0 N-CA-C 109.981 -0.377 . . . . 1.68 109.981 175.599 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . 0.487 ' N ' ' HD3' ' A' ' 325' ' ' LYS . 0.0 OUTLIER -149.74 128.7 12.61 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.379 0.609 . . . . 1.99 111.335 -179.257 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 23.6 m-80 -125.21 114.51 19.07 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 107.055 -1.461 . . . . 1.92 107.055 174.452 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 10.4 m -155.29 -58.79 0.1 Allowed 'General case' 0 C--N 1.318 -0.803 0 C-N-CA 120.367 -0.533 . . . . 1.69 111.784 -168.49 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 9.4 ptmm? -68.05 92.01 0.37 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.288 0.566 . . . . 2.55 111.625 -172.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.452 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 63.51 2.77 6.19 Favored Glycine 0 C--N 1.335 0.513 0 CA-C-N 115.582 -0.736 . . . . 0.97 113.048 -178.402 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 83.9 tttt -105.63 101.9 35.0 Favored Pre-proline 0 C--N 1.325 -0.47 0 N-CA-C 111.772 0.286 . . . . 2.08 111.772 -172.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 331' ' ' PRO . . . . . 0.452 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 95.8 Cg_endo -87.76 161.74 7.7 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 123.067 2.511 . . . . 0.62 112.567 174.289 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 66.4 t80 -134.72 126.45 29.06 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.224 -0.444 . . . . 0.64 109.844 174.038 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 333' ' ' VAL . . . . . 0.5 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 59.6 t -109.48 120.91 61.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.556 -0.293 . . . . 0.38 110.363 -177.002 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 22.3 p90 -142.93 160.13 40.93 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.193 0.52 . . . . 0.41 111.711 -178.608 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 335' ' ' LYS . . . . . . . . . . . . . 11.2 ttmt -89.34 128.15 35.86 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.309 -0.859 . . . . 2.58 110.345 176.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 6.8 mp -69.32 136.85 52.38 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.673 0.273 . . . . 0.58 110.598 173.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 337' ' ' GLY . . . . . 0.72 ' HA3' ' HG3' ' A' ' 305' ' ' LYS . . . 79.08 58.02 3.07 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 121.112 -0.566 . . . . 0.94 112.708 178.62 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 338' ' ' GLN . . . . . . . . . . . . . 29.0 pt20 -142.55 161.21 38.64 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.776 -0.453 . . . . 2.62 109.776 176.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -81.74 1.39 86.33 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.18 -0.533 . . . . 0.74 112.617 -173.797 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 21.0 mm-40 -76.25 -21.66 56.08 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.153 0.501 . . . . 2.09 110.307 178.461 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 18.7 m -114.51 166.64 8.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.898 -0.592 . . . . 0.43 110.046 -177.317 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 10.4 pt -85.11 154.46 3.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 N-CA-C 109.518 -0.549 . . . . 0.32 109.518 175.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 343' ' ' LYS . . . . . 0.622 ' HA ' ' OD1' ' A' ' 346' ' ' ASP . 13.7 mmmm -60.18 -28.54 68.03 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.391 0.515 . . . . 2.93 112.391 -172.62 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 344' ' ' GLY . . . . . 0.498 ' HA2' HD13 ' A' ' 290' ' ' ILE . . . -56.27 -31.13 59.15 Favored Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.467 -0.873 . . . . 0.3 112.656 174.204 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 9.2 m95 -74.62 -60.65 2.18 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 112.303 0.483 . . . . 0.39 112.303 -179.189 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 346' ' ' ASP . . . . . 0.622 ' OD1' ' HA ' ' A' ' 343' ' ' LYS . 8.1 p-10 -64.55 -24.73 67.7 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.634 0.254 . . . . 1.75 111.468 -173.63 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 48.7 mt -84.44 -51.31 14.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 116.318 -0.401 . . . . 0.39 111.126 177.347 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -64.28 -36.46 93.25 Favored Glycine 0 CA--C 1.524 0.624 0 C-N-CA 121.032 -0.604 . . . . 0.34 113.355 179.599 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 349' ' ' VAL . . . . . 0.511 ' O ' ' HB2' ' A' ' 352' ' ' MET . 77.1 t -80.55 -14.4 12.88 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.88 0.371 . . . . 0.32 111.349 -179.218 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -63.2 113.25 3.06 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.957 0.408 . . . . 0.47 110.682 177.86 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 96.32 19.57 27.66 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.969 -0.634 . . . . 0.39 111.924 -177.048 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 352' ' ' MET . . . . . 0.52 ' O ' ' HA ' ' A' ' 302' ' ' HIS . 0.0 OUTLIER -76.66 155.87 33.06 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.722 -0.473 . . . . 1.28 109.722 174.907 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 353' ' ' ALA . . . . . . . . . . . . . . . -131.04 133.79 46.06 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.671 0.272 . . . . 0.55 110.921 -179.435 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 354' ' ' VAL . . . . . 0.435 ' HB ' ' HD2' ' A' ' 301' ' ' PRO . 95.1 t -55.39 114.79 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.976 -0.556 . . . . 0.36 110.909 175.733 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 113.83 -8.06 23.72 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.975 -0.631 . . . . 0.44 112.097 -179.019 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -109.79 162.42 12.69 Favored Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.73 -0.747 . . . . 0.3 112.785 -179.713 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 357' ' ' GLU . . . . . 0.785 ' HB3' ' HB3' ' A' ' 387' ' ' LYS . 9.6 pt-20 -140.64 145.54 36.74 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 110.172 -0.307 . . . . 1.41 110.172 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 358' ' ' ARG . . . . . 0.503 ' HA ' ' HG2' ' A' ' 295' ' ' ARG . 2.8 ptp180 -154.44 145.53 22.75 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.378 0.608 . . . . 1.37 111.67 178.393 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 359' ' ' ARG . . . . . 0.746 ' HB3' ' HB3' ' A' ' 293' ' ' GLU . 34.5 ttt180 -86.82 114.46 23.5 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 114.948 -1.024 . . . . 2.79 109.938 -179.707 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 56.1 mt -101.6 117.52 47.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 120.896 0.379 . . . . 0.38 110.46 -178.196 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 361' ' ' VAL . . . . . . . . . . . . . 46.5 t -104.01 112.2 36.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 109.346 -0.612 . . . . 0.39 109.346 178.078 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 362' ' ' ILE . . . . . 0.446 HD13 ' HA3' ' A' ' 344' ' ' GLY . 54.5 mt -109.23 106.51 58.78 Favored Pre-proline 0 C--N 1.32 -0.694 0 CA-C-N 116.259 -0.428 . . . . 0.29 110.784 -174.181 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 363' ' ' PRO . . . . . 0.515 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 18.4 Cg_endo -58.35 159.53 19.14 Favored 'Trans proline' 0 C--O 1.235 0.372 0 C-N-CA 122.487 2.125 . . . . 0.66 111.848 173.327 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 364' ' ' ALA . . . . . 0.405 ' HB3' ' HD3' ' A' ' 365' ' ' PRO . . . -49.37 -50.16 66.69 Favored Pre-proline 0 CA--C 1.538 0.504 0 N-CA-C 114.002 1.112 . . . . 0.42 114.002 -174.448 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 365' ' ' PRO . . . . . 0.515 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 77.5 Cg_exo -51.38 -30.9 36.04 Favored 'Trans proline' 0 C--N 1.364 1.368 0 C-N-CA 122.294 1.996 . . . . 0.7 114.047 -174.935 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 366' ' ' TYR . . . . . 0.476 ' OH ' ' HG3' ' A' ' 287' ' ' GLU . 3.7 m-85 -102.26 14.13 32.79 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 112.158 0.429 . . . . 0.69 112.158 -177.503 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -129.23 -107.57 0.29 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.147 -0.479 . . . . 0.86 110.386 173.249 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 32.8 m-85 -87.96 -14.2 39.8 Favored 'General case' 0 N--CA 1.466 0.34 0 N-CA-C 112.09 0.404 . . . . 1.0 112.09 -179.113 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 70.01 -122.96 12.07 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.918 -0.658 . . . . 0.56 112.773 178.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 4.7 ptpp? -97.2 4.07 51.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.685 0.279 . . . . 2.76 111.12 -178.247 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 15.8 mm100 -75.36 98.92 3.97 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.085 0.469 . . . . 2.65 110.787 -179.261 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 372' ' ' ALA . . . . . . . . . . . . . . . -72.21 90.98 1.26 Allowed 'General case' 0 N--CA 1.447 -0.586 0 CA-C-N 115.695 -0.684 . . . . 1.01 110.454 175.593 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 36.7 mt -74.51 159.24 83.92 Favored Pre-proline 0 C--N 1.323 -0.568 0 CA-C-N 115.516 -0.765 . . . . 0.93 109.144 178.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -58.63 113.97 1.79 Allowed 'Trans proline' 0 N--CA 1.459 -0.529 0 C-N-CA 121.749 1.633 . . . . 1.31 110.721 173.73 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 93.84 -27.76 11.97 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.767 -0.73 . . . . 0.9 112.796 -177.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 56.6 mt -125.18 89.41 52.65 Favored Pre-proline 0 C--N 1.327 -0.37 0 CA-C-O 120.71 0.29 . . . . 0.74 110.84 -177.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 377' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -72.52 168.09 25.31 Favored 'Trans proline' 0 C--O 1.234 0.276 0 C-N-CA 123.143 2.562 . . . . 0.71 113.009 -178.112 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 378' ' ' ALA . . . . . 0.477 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -53.2 155.09 2.81 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.512 -0.767 . . . . 0.74 111.212 178.148 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 379' ' ' ASN . . . . . 0.477 ' HB2' ' O ' ' A' ' 378' ' ' ALA . 33.1 m-80 71.97 32.16 1.89 Allowed 'General case' 0 N--CA 1.467 0.419 0 O-C-N 123.805 0.69 . . . . 1.49 109.43 -172.228 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 1.8 p -70.7 87.88 0.7 Allowed 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 114.896 -1.047 . . . . 1.84 111.283 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 381' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -80.27 98.91 7.6 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 108.68 -0.859 . . . . 1.03 108.68 174.565 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 67.8 mt -85.96 146.98 26.44 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.0 -0.545 . . . . 0.37 110.292 -176.561 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 28.9 m -124.08 122.68 38.51 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 109.566 -0.531 . . . . 0.27 109.566 175.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -117.83 110.62 18.0 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.424 -0.353 . . . . 0.32 110.429 -178.575 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -84.0 103.81 13.55 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 107.813 -1.18 . . . . 1.8 107.813 172.478 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 386' ' ' VAL . . . . . 0.593 HG12 ' CB ' ' A' ' 313' ' ' TYR . 18.5 m -122.02 149.93 25.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 121.235 0.54 . . . . 0.31 112.185 -170.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 387' ' ' LYS . . . . . 0.785 ' HB3' ' HB3' ' A' ' 357' ' ' GLU . 11.1 ptpt -141.6 139.58 33.13 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.686 -0.688 . . . . 2.53 110.313 172.35 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 388' ' ' LEU . . . . . 0.901 HD11 ' HB ' ' A' ' 309' ' ' VAL . 31.0 tp -91.53 127.18 36.88 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.766 -0.827 . . . . 0.28 108.766 179.566 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 33.3 m -124.77 -10.84 6.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 C-N-CA 120.585 -0.446 . . . . 0.45 111.872 -172.676 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 50.0 m -157.96 159.83 36.9 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.844 0.354 . . . . 1.32 111.268 -179.33 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 391' ' ' MET . . . . . . . . . . . . . 38.7 ttm -160.32 150.82 18.47 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.339 -0.615 . . . . 0.56 109.339 175.354 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 18.5 ptpt . . . . . 0 C--O 1.249 1.067 0 C-N-CA 124.251 1.02 . . . . 4.91 112.805 176.866 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 2.9 p . . . . . 0 N--CA 1.444 -0.768 0 CA-C-O 121.351 0.596 . . . . 0.76 110.232 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 284' ' ' LYS . . . . . 0.406 ' HB2' HG13 ' A' ' 292' ' ' ILE . 32.2 mmtp -108.16 130.54 55.12 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 115.652 -0.704 . . . . 2.06 110.041 -178.222 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 32.3 tp -95.47 125.44 40.08 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.949 -0.569 . . . . 0.98 109.959 179.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.759 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 90.4 mt -102.75 -178.12 3.58 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.688 -0.687 . . . . 0.8 109.433 179.302 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 14.3 tt0 -66.37 152.04 45.87 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.704 -0.48 . . . . 2.64 109.704 179.791 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 72.71 -4.41 21.83 Favored Glycine 0 C--O 1.229 -0.177 0 C-N-CA 120.823 -0.703 . . . . 1.84 113.08 -174.265 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 90.33 21.34 38.37 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.504 -0.855 . . . . 0.64 113.53 179.547 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 290' ' ' ILE . . . . . 0.759 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 61.9 mt -69.81 133.43 31.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 117.39 0.595 . . . . 0.42 110.344 177.828 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.528 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 17.8 mt -113.08 139.49 37.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 C-N-CA 121.106 -0.237 . . . . 0.93 110.836 -178.576 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 292' ' ' ILE . . . . . 0.511 ' HB ' ' HD3' ' A' ' 358' ' ' ARG . 17.7 pt -132.08 129.3 60.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 121.151 0.501 . . . . 0.48 110.956 177.185 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 293' ' ' GLU . . . . . 0.446 ' C ' ' HG3' ' A' ' 358' ' ' ARG . 4.5 tp10 -125.15 119.21 27.93 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.516 -0.766 . . . . 2.31 109.664 178.699 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . 0.688 ' OD2' ' HA ' ' A' ' 297' ' ' THR . 6.2 t70 -80.3 96.18 6.56 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.475 -0.565 . . . . 2.36 109.475 -175.727 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 295' ' ' ARG . . . . . . . . . . . . . 66.6 ttt180 -69.37 -45.73 68.65 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.784 -0.644 . . . . 3.5 110.146 -175.89 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.598 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 88.8 t -123.4 123.71 68.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 N-CA-C 108.523 -0.917 . . . . 0.7 108.523 172.313 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 297' ' ' THR . . . . . 0.688 ' HA ' ' OD2' ' A' ' 294' ' ' ASP . 5.1 t -60.76 109.75 1.13 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.718 0.771 . . . . 1.93 110.994 -174.156 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 298' ' ' GLY . . . . . 0.538 ' HA3' ' HA3' ' A' ' 356' ' ' GLY . . . -99.33 111.22 4.16 Favored Glycine 0 N--CA 1.445 -0.708 0 CA-C-N 115.313 -0.858 . . . . 1.04 112.948 -178.036 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 36.9 mmtm -125.39 110.14 13.6 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 108.982 -0.747 . . . . 4.49 108.982 173.829 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -173.3 -152.68 8.97 Favored Glycine 0 N--CA 1.447 -0.573 0 N-CA-C 111.218 -0.753 . . . . 1.04 111.218 -174.404 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . 0.607 ' O ' ' HA ' ' A' ' 353' ' ' ALA . 32.8 Cg_exo -58.32 132.92 51.66 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.413 2.075 . . . . 0.88 111.312 174.103 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 26.6 m80 -96.63 127.92 43.08 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.941 0.401 . . . . 1.49 111.132 -173.61 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -73.51 117.62 15.49 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.066 -0.516 . . . . 0.54 111.056 179.202 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 63.2 mttm -118.9 -179.4 3.8 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.194 -0.457 . . . . 2.84 110.583 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 49.7 mtmt -72.68 127.15 31.69 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 109.9 -0.408 . . . . 2.84 109.9 179.223 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 94.8 -0.51 64.89 Favored Glycine 0 CA--C 1.518 0.223 0 C-N-CA 120.747 -0.739 . . . . 0.7 112.047 -176.906 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 19.8 m -91.29 145.31 24.75 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 110.239 -0.282 . . . . 0.4 110.239 177.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 51.4 mtp180 -108.12 106.47 16.69 Favored 'General case' 0 CA--C 1.519 -0.225 0 N-CA-C 109.648 -0.501 . . . . 3.45 109.648 178.693 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.914 ' HB ' HD11 ' A' ' 388' ' ' LEU . 32.7 m -106.25 154.11 7.45 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.959 0 CA-C-O 121.086 0.469 . . . . 0.34 111.747 -174.09 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -122.74 127.73 6.82 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 110.823 -0.911 . . . . 0.27 110.823 177.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 11.9 ptp -135.22 177.01 8.15 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.754 0.788 . . . . 0.76 112.789 -173.82 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 44.3 mtm180 -135.96 146.21 47.01 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 107.068 -1.456 . . . . 2.51 107.068 173.005 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 313' ' ' TYR . . . . . 0.601 ' HB3' HG12 ' A' ' 386' ' ' VAL . 41.9 p90 -159.13 155.52 27.39 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 113.214 0.82 . . . . 0.68 113.214 -168.118 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 58.1 t -122.56 113.24 37.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 114.94 -1.027 . . . . 0.35 109.361 170.185 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -97.56 115.64 5.31 Favored Glycine 0 C--O 1.238 0.374 0 C-N-CA 120.85 -0.69 . . . . 0.28 112.556 -176.331 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 316' ' ' LYS . . . . . 0.637 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 91.9 mttt -117.86 162.45 18.09 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-O 121.275 0.559 . . . . 1.94 110.758 -179.066 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 93.6 mt -90.01 165.89 13.77 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.423 -0.808 . . . . 0.65 109.558 173.841 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 318' ' ' LYS . . . . . 0.566 ' HB2' ' HB3' ' A' ' 381' ' ' GLU . 56.9 tttp -59.88 -23.09 63.16 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.22 0.533 . . . . 2.42 110.306 176.448 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -70.14 -15.63 62.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.38 -0.827 . . . . 2.2 110.894 -179.559 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 98.84 -5.43 59.79 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.51 -0.852 . . . . 0.69 112.195 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -91.48 133.28 35.64 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 120.682 0.277 . . . . 2.42 110.3 179.004 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.637 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 8.0 p -77.3 140.21 17.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.467 -0.333 . . . . 1.26 110.322 178.575 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 34.9 p90 -103.62 -33.43 8.99 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.54 -0.464 . . . . 0.55 110.994 177.636 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -162.7 162.99 27.1 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 121.063 -0.255 . . . . 1.68 110.343 175.132 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -159.61 129.63 5.55 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.891 0.377 . . . . 1.99 110.623 -178.33 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 35.1 m-80 -120.56 116.62 25.74 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.606 -0.887 . . . . 1.92 108.606 172.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.76 -69.25 0.2 Allowed 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.096 -0.502 . . . . 1.69 111.76 -174.324 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 24.7 pttm -68.41 97.28 0.74 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.698 0.761 . . . . 2.55 111.836 -174.121 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.501 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 86.71 -16.61 45.01 Favored Glycine 0 N--CA 1.446 -0.638 0 CA-C-N 115.269 -0.878 . . . . 0.97 113.591 175.375 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 27.6 mmmt -104.83 100.02 21.73 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 117.228 0.514 . . . . 2.08 111.471 -175.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 331' ' ' PRO . . . . . 0.501 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 72.1 Cg_endo -87.56 127.86 2.42 Favored 'Trans proline' 0 N--CA 1.455 -0.744 0 C-N-CA 122.883 2.389 . . . . 0.62 111.854 172.809 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 70.6 t80 -102.56 120.55 40.74 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 110.135 -0.321 . . . . 0.64 110.135 179.458 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 60.4 t -112.51 122.42 66.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.915 0.388 . . . . 0.38 110.413 -178.154 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 31.1 p90 -139.8 158.76 43.57 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.089 -0.505 . . . . 0.41 109.73 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 335' ' ' LYS . . . . . . . . . . . . . 16.9 ptmt -100.15 141.02 33.55 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.214 0.53 . . . . 2.58 111.217 179.128 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 11.2 mp -77.34 123.49 26.58 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.769 -0.651 . . . . 0.58 109.695 173.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 111.79 12.33 14.73 Favored Glycine 0 N--CA 1.446 -0.68 0 C-N-CA 120.683 -0.77 . . . . 0.94 111.931 -177.47 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 338' ' ' GLN . . . . . 0.729 HE21 HG13 ' A' ' 341' ' ' VAL . 13.2 pt20 -97.91 151.09 20.62 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.963 -0.384 . . . . 2.62 109.963 176.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -89.28 15.21 58.92 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 121.029 -0.605 . . . . 0.74 111.815 -179.047 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -87.32 -15.15 38.83 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.077 0.465 . . . . 2.09 110.261 178.298 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 341' ' ' VAL . . . . . 0.729 HG13 HE21 ' A' ' 338' ' ' GLN . 32.6 m -107.24 164.28 4.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.838 -0.619 . . . . 0.43 110.575 -177.644 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 342' ' ' ILE . . . . . 0.491 ' HB ' ' HA ' ' A' ' 367' ' ' ALA . 10.0 pt -88.67 165.36 2.06 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 109.718 -0.475 . . . . 0.32 109.718 176.546 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 343' ' ' LYS . . . . . 0.413 ' HA ' ' CE ' ' A' ' 343' ' ' LYS . 0.0 OUTLIER -56.11 -37.3 69.22 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 111.908 0.336 . . . . 2.93 111.908 -174.644 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 344' ' ' GLY . . . . . 0.587 ' HA2' HD13 ' A' ' 290' ' ' ILE . . . -55.72 -30.84 57.19 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.938 -0.649 . . . . 0.3 113.126 177.506 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 345' ' ' TRP . . . . . 0.42 ' CD1' HG12 ' A' ' 342' ' ' ILE . 18.4 m95 -77.83 -61.23 2.06 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 112.506 0.558 . . . . 0.39 112.506 -176.886 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -64.23 -20.55 66.11 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.669 0.271 . . . . 1.75 111.41 -175.69 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 71.5 mt -89.41 -55.73 5.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 116.471 -0.332 . . . . 0.39 111.685 174.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -65.71 -38.55 94.61 Favored Glycine 0 CA--C 1.523 0.59 0 C-N-CA 121.297 -0.478 . . . . 0.34 114.135 -177.372 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 83.9 t -75.22 -21.25 16.4 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 CA-C-O 120.953 0.406 . . . . 0.32 110.905 -178.612 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.2 104.53 0.93 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.164 0.506 . . . . 0.47 110.953 -179.291 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 113.84 0.58 24.31 Favored Glycine 0 N--CA 1.445 -0.712 0 C-N-CA 120.823 -0.704 . . . . 0.39 112.851 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 352' ' ' MET . . . . . . . . . . . . . 60.0 mtp -75.37 157.69 33.85 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 117.313 0.557 . . . . 1.28 110.307 174.69 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 353' ' ' ALA . . . . . 0.607 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -123.09 144.58 49.22 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.221 -0.445 . . . . 0.55 111.543 -174.861 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 73.4 t -58.2 123.15 9.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.962 -0.563 . . . . 0.36 110.357 175.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 104.23 -16.44 49.43 Favored Glycine 0 N--CA 1.446 -0.663 0 C-N-CA 120.831 -0.7 . . . . 0.44 111.528 -177.109 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 356' ' ' GLY . . . . . 0.538 ' HA3' ' HA3' ' A' ' 298' ' ' GLY . . . -87.35 154.29 26.06 Favored Glycine 0 N--CA 1.443 -0.851 0 C-N-CA 120.875 -0.678 . . . . 0.3 112.646 179.484 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 357' ' ' GLU . . . . . 0.642 ' HG3' ' HB3' ' A' ' 387' ' ' LYS . 41.2 tt0 -137.87 121.65 17.56 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.951 -0.759 . . . . 1.41 108.951 -177.833 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 358' ' ' ARG . . . . . 0.511 ' HD3' ' HB ' ' A' ' 292' ' ' ILE . 35.0 ttm180 -148.41 133.99 18.75 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.071 0.463 . . . . 1.37 110.933 -170.883 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 359' ' ' ARG . . . . . 0.408 HH11 ' HD2' ' A' ' 359' ' ' ARG . 31.8 ttp85 -86.02 122.78 30.54 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.717 -0.674 . . . . 2.79 110.459 -179.186 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 360' ' ' ILE . . . . . 0.493 HG12 HG22 ' A' ' 292' ' ' ILE . 56.8 mt -109.52 121.44 62.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.866 -0.606 . . . . 0.38 110.272 -179.646 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 361' ' ' VAL . . . . . 0.528 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 48.6 t -104.19 119.84 53.57 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 N-CA-C 109.256 -0.646 . . . . 0.39 109.256 177.699 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 362' ' ' ILE . . . . . 0.491 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 55.9 mt -118.23 100.95 51.7 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-N 116.322 -0.399 . . . . 0.29 111.535 -174.092 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 363' ' ' PRO . . . . . 0.526 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 12.3 Cg_endo -56.9 158.12 18.04 Favored 'Trans proline' 0 C--O 1.238 0.498 0 C-N-CA 122.99 2.46 . . . . 0.66 112.547 172.127 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 364' ' ' ALA . . . . . 0.489 ' CB ' ' HA ' ' A' ' 379' ' ' ASN . . . -50.18 -47.41 82.07 Favored Pre-proline 0 CA--C 1.539 0.52 0 N-CA-C 114.516 1.302 . . . . 0.42 114.516 -173.723 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 365' ' ' PRO . . . . . 0.526 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 82.6 Cg_exo -49.22 -36.55 37.25 Favored 'Trans proline' 0 C--N 1.361 1.231 0 C-N-CA 122.218 1.945 . . . . 0.7 113.632 -176.704 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 366' ' ' TYR . . . . . 0.422 ' CD1' HD11 ' A' ' 290' ' ' ILE . 3.6 m-85 -101.31 12.55 37.25 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.761 0.315 . . . . 0.69 111.643 -177.097 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 367' ' ' ALA . . . . . 0.491 ' HA ' ' HB ' ' A' ' 342' ' ' ILE . . . -119.31 -112.52 0.33 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.168 -0.469 . . . . 0.86 110.505 175.207 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -91.39 -1.88 57.47 Favored 'General case' 0 N--CA 1.464 0.228 0 N-CA-C 112.194 0.442 . . . . 1.0 112.194 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 66.43 -114.97 6.93 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 121.103 -0.57 . . . . 0.56 113.65 175.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 370' ' ' LYS . . . . . 0.428 ' HE2' ' HB3' ' A' ' 370' ' ' LYS . 14.8 ptpt -112.81 20.31 16.58 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.856 0.36 . . . . 2.76 111.502 -174.497 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 27.9 mm-40 -90.14 113.45 25.21 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.29 -0.414 . . . . 2.65 110.088 176.596 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 372' ' ' ALA . . . . . 0.447 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -83.51 96.18 8.52 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.175 0.512 . . . . 1.01 111.17 178.827 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 373' ' ' LEU . . . . . 0.5 ' HB3' ' HD2' ' A' ' 374' ' ' PRO . 59.1 mt -80.37 166.67 38.38 Favored Pre-proline 0 C--N 1.32 -0.698 0 CA-C-N 115.562 -0.744 . . . . 0.93 109.487 178.728 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 374' ' ' PRO . . . . . 0.5 ' HD2' ' HB3' ' A' ' 373' ' ' LEU . 22.9 Cg_endo -64.33 113.36 2.22 Favored 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 121.514 1.476 . . . . 1.31 110.818 172.438 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 90.65 -24.53 16.96 Favored Glycine 0 CA--C 1.519 0.312 0 C-N-CA 120.739 -0.743 . . . . 0.9 112.757 -179.003 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 39.8 mt -125.56 83.04 62.47 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.683 0.278 . . . . 0.74 110.304 -178.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 377' ' ' PRO . . . . . 0.447 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 9.2 Cg_exo -72.59 166.5 29.7 Favored 'Trans proline' 0 N--CA 1.464 -0.253 0 C-N-CA 123.17 2.58 . . . . 0.71 113.247 -178.124 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 378' ' ' ALA . . . . . . . . . . . . . . . -55.02 147.55 15.47 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-N 115.557 -0.747 . . . . 0.74 111.43 178.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 379' ' ' ASN . . . . . 0.489 ' HA ' ' CB ' ' A' ' 364' ' ' ALA . 44.4 m-80 65.54 30.65 10.54 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 115.676 -0.693 . . . . 1.49 111.3 -179.144 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 380' ' ' SER . . . . . 0.424 ' HB2' ' O ' ' A' ' 377' ' ' PRO . 22.2 t -85.41 134.54 34.07 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 116.08 -0.509 . . . . 1.84 109.78 175.769 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 381' ' ' GLU . . . . . 0.566 ' HB3' ' HB2' ' A' ' 318' ' ' LYS . 30.7 tt0 -99.43 105.16 17.07 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.305 -0.628 . . . . 1.03 109.305 179.066 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 74.2 mt -84.72 142.09 30.1 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.397 -0.365 . . . . 0.37 110.796 -177.65 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 383' ' ' THR . . . . . 0.471 HG23 HG22 ' A' ' 361' ' ' VAL . 25.7 m -122.39 122.77 39.79 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 109.726 -0.472 . . . . 0.27 109.726 177.794 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -117.44 109.59 16.96 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.928 0.394 . . . . 0.32 110.32 -178.181 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -88.81 104.4 16.88 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.154 -1.054 . . . . 1.8 108.154 174.254 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 386' ' ' VAL . . . . . 0.601 HG12 ' HB3' ' A' ' 313' ' ' TYR . 20.0 m -125.25 151.37 30.99 Favored 'Isoleucine or valine' 0 C--O 1.232 0.141 0 CA-C-O 121.358 0.599 . . . . 0.31 112.287 -169.131 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 387' ' ' LYS . . . . . 0.642 ' HB3' ' HG3' ' A' ' 357' ' ' GLU . 14.6 ptmm? -139.54 142.21 37.21 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.774 -0.648 . . . . 2.53 109.814 172.534 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 388' ' ' LEU . . . . . 0.914 HD11 ' HB ' ' A' ' 309' ' ' VAL . 19.3 tp -93.14 135.43 34.33 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.691 -0.485 . . . . 0.28 109.691 -176.471 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 34.7 m -127.53 -6.51 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 N-CA-C 112.268 0.47 . . . . 0.45 112.268 -176.442 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 44.1 t -160.57 160.35 31.71 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.528 0.204 . . . . 1.32 110.942 -177.784 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 391' ' ' MET . . . . . 0.427 ' HA ' ' HA ' ' A' ' 309' ' ' VAL . 30.9 ttm -165.61 134.1 3.16 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.998 -0.546 . . . . 0.56 110.18 179.684 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 63.7 mttp . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.513 -0.756 . . . . 4.91 109.716 175.758 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 1.45 0 N-CA-C 111.946 -0.462 . . . . 11.17 111.946 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -135.91 129.22 31.91 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 110.026 -0.361 . . . . 9.37 110.026 179.391 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 278' ' ' MET . . . . . . . . . . . . . 23.1 ttt -90.1 96.06 10.49 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.109 0.481 . . . . 7.67 110.818 -177.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -99.67 4.41 45.59 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.743 -0.662 . . . . 6.37 110.301 174.567 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 35.4 ttmt 56.51 84.14 0.21 Allowed Pre-proline 0 C--O 1.236 0.366 0 CA-C-N 114.898 -1.046 . . . . 6.76 110.999 -179.429 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -74.94 62.41 5.8 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 123.34 2.693 . . . . 4.8 112.148 -179.013 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 282' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -139.55 -165.27 1.84 Allowed 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.501 -0.772 . . . . 3.46 109.619 178.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 18.2 p -91.04 131.5 36.59 Favored 'General case' 0 C--N 1.31 -1.123 0 CA-C-N 115.437 -0.801 . . . . 0.76 110.896 178.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 284' ' ' LYS . . . . . 0.408 ' O ' ' HA ' ' A' ' 291' ' ' ILE . 41.8 mtmt -131.55 159.21 38.85 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.519 -0.764 . . . . 2.06 110.414 -174.407 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . 0.513 HD11 ' HA2' ' A' ' 289' ' ' GLY . 42.3 tp -111.93 127.07 55.75 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.217 -0.447 . . . . 0.98 111.987 -170.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.44 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 99.2 mt -108.32 -161.83 0.79 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.839 -0.618 . . . . 0.8 110.309 173.653 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -51.99 140.48 20.15 Favored 'General case' 0 N--CA 1.447 -0.591 0 C-N-CA 123.263 0.625 . . . . 2.64 112.301 179.293 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.487 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 70.4 -102.94 1.08 Allowed Glycine 0 N--CA 1.446 -0.69 0 CA-C-N 115.482 -0.781 . . . . 1.84 111.595 -177.63 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . 0.513 ' HA2' HD11 ' A' ' 285' ' ' LEU . . . -145.92 28.2 1.73 Allowed Glycine 0 N--CA 1.442 -0.948 0 N-CA-C 110.603 -0.999 . . . . 0.64 110.603 176.08 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 290' ' ' ILE . . . . . 0.44 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 75.4 mt -71.14 120.9 19.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.803 0.335 . . . . 0.42 110.733 -177.73 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.408 ' HA ' ' O ' ' A' ' 284' ' ' LYS . 92.1 mt -103.72 138.53 27.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.274 -0.421 . . . . 0.93 110.171 178.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 292' ' ' ILE . . . . . 0.43 HG22 HG12 ' A' ' 360' ' ' ILE . 24.9 pt -124.46 128.21 73.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-O 121.3 0.571 . . . . 0.48 109.864 178.038 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 293' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -114.59 110.78 20.31 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.282 -0.872 . . . . 2.31 109.117 179.538 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 20.7 m-20 -83.83 103.75 13.37 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.386 0.612 . . . . 2.36 109.851 -173.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 295' ' ' ARG . . . . . . . . . . . . . 10.5 mmm180 -76.8 -49.4 15.95 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 114.809 -1.087 . . . . 3.5 110.663 -173.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . . . . . . . . . 97.9 t -118.66 130.09 73.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 115.662 -0.699 . . . . 0.7 110.358 -176.025 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 1.6 m -63.03 107.25 0.97 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.156 -0.475 . . . . 1.93 110.554 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -118.01 116.25 3.39 Favored Glycine 0 N--CA 1.445 -0.759 0 C-N-CA 120.802 -0.713 . . . . 1.04 112.402 -177.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 13.1 tptm -121.9 113.13 19.19 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.575 -0.528 . . . . 4.49 109.575 175.296 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -170.79 -153.71 9.04 Favored Glycine 0 N--CA 1.436 -1.304 0 N-CA-C 111.042 -0.823 . . . . 1.04 111.042 -178.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . 0.428 ' HB2' ' SD ' ' A' ' 391' ' ' MET . 36.8 Cg_exo -60.75 132.7 44.0 Favored 'Trans proline' 0 N--CA 1.461 -0.397 0 C-N-CA 122.6 2.2 . . . . 0.88 111.756 177.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 302' ' ' HIS . . . . . 0.417 ' HA ' ' O ' ' A' ' 352' ' ' MET . 37.3 m80 -88.82 138.44 31.41 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.207 -0.451 . . . . 1.49 110.786 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -85.68 117.37 24.53 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.897 -0.592 . . . . 0.54 111.25 -179.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 21.9 pttp -116.87 -178.54 3.46 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.045 -0.724 . . . . 2.84 109.045 173.15 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 51.4 mttm -68.13 142.4 55.77 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 110.119 -0.326 . . . . 2.84 110.119 176.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 85.29 -7.86 73.79 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 121.085 -0.578 . . . . 0.7 112.225 -175.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 307' ' ' THR . . . . . 0.472 ' O ' ' HA ' ' A' ' 335' ' ' LYS . 87.0 m -89.25 135.47 33.56 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.758 0.314 . . . . 0.4 111.119 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . 0.424 HH21 ' C ' ' A' ' 392' ' ' LYS . 73.1 mtm180 -94.24 102.34 14.35 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.687 -0.688 . . . . 3.45 109.903 -177.643 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.869 ' HB ' HD11 ' A' ' 388' ' ' LEU . 34.1 m -103.43 141.54 19.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 CA-C-O 121.426 0.631 . . . . 0.34 111.75 -177.679 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -115.51 121.66 5.34 Favored Glycine 0 N--CA 1.445 -0.759 0 N-CA-C 110.325 -1.11 . . . . 0.27 110.325 177.462 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 13.9 ptp -135.77 177.67 7.65 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.513 0.673 . . . . 0.76 112.304 -173.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -136.65 143.47 43.49 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 106.938 -1.504 . . . . 2.51 106.938 174.157 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 313' ' ' TYR . . . . . 0.509 ' CB ' HG12 ' A' ' 386' ' ' VAL . 18.2 p90 -157.52 157.49 33.92 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 113.39 0.885 . . . . 0.68 113.39 -170.245 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 58.0 t -124.34 120.94 60.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 114.795 -1.093 . . . . 0.35 109.219 173.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -97.86 110.29 3.99 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 120.959 -0.639 . . . . 0.28 112.573 -176.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 316' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -116.15 154.63 29.67 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.177 0.513 . . . . 1.94 110.929 -178.49 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 317' ' ' LEU . . . . . 0.542 HD12 ' HD3' ' A' ' 321' ' ' LYS . 80.1 mt -86.92 170.39 11.66 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.795 -0.639 . . . . 0.65 110.134 171.13 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 318' ' ' LYS . . . . . 0.441 ' HB2' ' HB3' ' A' ' 381' ' ' GLU . 57.7 tttp -59.07 -25.44 63.77 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.14 -0.482 . . . . 2.42 111.298 179.493 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 28.1 p-10 -87.7 -3.04 58.98 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 120.555 0.216 . . . . 2.2 111.267 -178.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 95.52 3.75 61.07 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.775 -0.726 . . . . 0.69 112.7 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 321' ' ' LYS . . . . . 0.542 ' HD3' HD12 ' A' ' 317' ' ' LEU . 53.4 tttp -75.18 113.55 12.65 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.751 0.31 . . . . 2.42 110.259 179.431 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . . . . . . . . . 4.7 p -85.52 119.52 34.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-O 121.287 0.565 . . . . 1.26 110.431 179.222 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 52.2 p90 -110.14 -27.13 9.3 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.072 -0.513 . . . . 0.55 111.284 -177.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -130.88 156.61 44.76 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 108.952 -0.758 . . . . 1.68 108.952 178.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 59.6 pttt -174.44 135.81 0.44 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.099 0.476 . . . . 1.99 111.525 -176.012 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 6.0 p30 -150.35 118.56 6.36 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.68 -0.691 . . . . 1.92 109.316 166.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 29.7 m -140.63 -46.8 0.41 Allowed 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.642 -0.708 . . . . 1.69 110.94 -175.451 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 83.9 mttt -79.66 92.55 5.38 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.79 -0.641 . . . . 2.55 111.259 -173.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.48 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 65.78 7.92 38.05 Favored Glycine 0 CA--C 1.52 0.391 0 CA-C-N 115.853 -0.612 . . . . 0.97 113.742 174.418 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 68.9 mmtt -103.93 100.4 20.26 Favored Pre-proline 0 C--N 1.324 -0.52 0 CA-C-N 116.688 0.244 . . . . 2.08 111.39 -177.29 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 331' ' ' PRO . . . . . 0.48 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 94.1 Cg_endo -88.38 129.54 2.3 Favored 'Trans proline' 0 N--CA 1.453 -0.895 0 C-N-CA 122.839 2.359 . . . . 0.62 112.298 173.199 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -103.74 118.89 37.77 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.956 -0.757 . . . . 0.64 108.956 174.208 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 56.7 t -112.15 125.87 69.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.904 0.383 . . . . 0.38 110.172 -177.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.794 ' HB2' HE22 ' A' ' 338' ' ' GLN . 29.8 p90 -147.31 156.38 42.86 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.835 -0.62 . . . . 0.41 109.511 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 335' ' ' LYS . . . . . 0.472 ' HA ' ' O ' ' A' ' 307' ' ' THR . 0.2 OUTLIER -111.08 142.12 43.65 Favored 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 120.034 -0.667 . . . . 2.58 110.508 177.709 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 9.3 mp -69.84 148.17 49.41 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.851 -0.613 . . . . 0.58 109.91 178.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 103.38 -8.3 52.24 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.7 -0.762 . . . . 0.94 112.942 -178.162 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 338' ' ' GLN . . . . . 0.794 HE22 ' HB2' ' A' ' 334' ' ' PHE . 30.1 pt20 -83.91 160.82 21.02 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.832 0.316 . . . . 2.62 110.215 179.367 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -107.32 21.63 30.59 Favored Glycine 0 CA--C 1.52 0.354 0 C-N-CA 120.485 -0.864 . . . . 0.74 114.307 -172.481 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -114.93 9.56 16.16 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 117.574 0.687 . . . . 2.09 111.093 178.47 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 27.3 m -116.11 146.55 20.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 108.341 -0.985 . . . . 0.43 108.341 172.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 11.4 pt -68.88 151.98 9.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 N-CA-C 109.743 -0.466 . . . . 0.32 109.743 -178.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . 0.524 ' HA ' ' HE2' ' A' ' 343' ' ' LYS . 6.2 mmpt? -61.85 -30.38 70.81 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 111.894 0.331 . . . . 2.93 111.894 -172.778 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -54.86 -31.4 54.68 Favored Glycine 0 CA--C 1.521 0.457 0 C-N-CA 120.878 -0.677 . . . . 0.3 112.343 173.647 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 9.3 m95 -77.48 -60.8 2.22 Favored 'General case' 0 C--O 1.22 -0.452 0 CA-C-O 120.531 0.205 . . . . 0.39 111.055 176.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -51.14 -28.87 11.93 Favored 'General case' 0 N--CA 1.47 0.544 0 N-CA-C 112.327 0.491 . . . . 1.75 112.327 -179.336 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 63.6 mt -91.19 -51.17 12.08 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.533 0 N-CA-C 111.946 0.35 . . . . 0.39 111.946 177.523 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -63.95 -31.1 79.68 Favored Glycine 0 CA--C 1.524 0.606 0 C-N-CA 121.282 -0.485 . . . . 0.34 113.758 -178.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 349' ' ' VAL . . . . . 0.546 ' O ' ' HB2' ' A' ' 352' ' ' MET . 90.8 t -79.7 -19.87 12.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 121.024 0.44 . . . . 0.32 110.645 179.704 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -64.6 113.64 3.86 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.373 -0.376 . . . . 0.47 110.132 178.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 97.07 15.17 39.79 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 121.035 -0.603 . . . . 0.39 112.11 -176.634 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 352' ' ' MET . . . . . 0.546 ' HB2' ' O ' ' A' ' 349' ' ' VAL . 0.0 OUTLIER -77.12 154.9 32.78 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 109.296 -0.631 . . . . 1.28 109.296 175.264 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 353' ' ' ALA . . . . . 0.405 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -129.95 134.92 47.77 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.729 0.299 . . . . 0.55 111.166 -177.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 61.4 t -59.85 123.39 12.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.017 -0.538 . . . . 0.36 110.681 177.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 109.47 -12.36 33.2 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 121.136 -0.554 . . . . 0.44 112.022 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -104.89 150.9 17.2 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.761 -0.733 . . . . 0.3 112.737 -179.538 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 357' ' ' GLU . . . . . 0.442 ' CB ' ' HB3' ' A' ' 387' ' ' LYS . 40.0 tt0 -122.44 140.37 52.8 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.247 -0.649 . . . . 1.41 109.247 176.461 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 358' ' ' ARG . . . . . . . . . . . . . 3.1 ptp180 -146.15 137.55 24.71 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.157 0.503 . . . . 1.37 111.178 175.425 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 359' ' ' ARG . . . . . . . . . . . . . 11.9 ttp180 -87.27 117.63 26.16 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.047 -0.723 . . . . 2.79 109.047 174.734 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 360' ' ' ILE . . . . . 0.43 HG12 HG22 ' A' ' 292' ' ' ILE . 65.1 mt -103.17 126.26 57.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-N 115.979 -0.555 . . . . 0.38 110.535 -175.125 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 361' ' ' VAL . . . . . . . . . . . . . 47.7 t -100.73 115.12 41.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 109.175 -0.676 . . . . 0.39 109.175 175.427 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 362' ' ' ILE . . . . . 0.411 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 60.5 mt -110.21 108.97 58.86 Favored Pre-proline 0 C--N 1.322 -0.603 0 CA-C-N 116.447 -0.342 . . . . 0.29 110.689 -175.456 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 363' ' ' PRO . . . . . 0.485 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 35.6 Cg_endo -65.51 162.03 35.75 Favored 'Trans proline' 0 C--O 1.239 0.541 0 C-N-CA 122.42 2.08 . . . . 0.66 111.613 175.432 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 364' ' ' ALA . . . . . . . . . . . . . . . -52.61 -48.89 88.87 Favored Pre-proline 0 CA--C 1.537 0.47 0 N-CA-C 113.85 1.055 . . . . 0.42 113.85 -173.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 365' ' ' PRO . . . . . 0.485 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 74.1 Cg_exo -52.14 -29.74 38.35 Favored 'Trans proline' 0 C--N 1.359 1.09 0 C-N-CA 122.501 2.134 . . . . 0.7 114.212 -175.505 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 366' ' ' TYR . . . . . 0.487 ' CE2' ' HA3' ' A' ' 288' ' ' GLY . 43.1 m-85 -101.05 10.16 41.35 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 112.196 0.443 . . . . 0.69 112.196 -175.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -125.39 -110.81 0.3 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.806 -0.179 . . . . 0.86 110.572 175.484 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -90.02 -22.17 22.01 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.991 0.424 . . . . 1.0 111.317 178.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 70.7 -95.87 0.56 Allowed Glycine 0 N--CA 1.448 -0.51 0 CA-C-N 115.996 -0.547 . . . . 0.56 113.761 175.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 23.4 pttm -109.17 8.12 25.76 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.622 0.248 . . . . 2.76 111.645 -171.625 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 6.3 tp-100 -89.48 120.25 30.63 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.864 0.364 . . . . 2.65 110.56 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 372' ' ' ALA . . . . . 0.794 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -92.47 93.71 8.71 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-O 121.436 0.636 . . . . 1.01 110.592 178.025 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 43.3 mt -81.97 162.99 55.4 Favored Pre-proline 0 C--N 1.318 -0.784 0 CA-C-N 115.373 -0.83 . . . . 0.93 109.079 176.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_exo -61.14 114.97 2.42 Favored 'Trans proline' 0 N--CA 1.462 -0.378 0 C-N-CA 121.478 1.452 . . . . 1.31 110.645 172.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 91.23 -26.63 11.01 Favored Glycine 0 CA--C 1.521 0.413 0 C-N-CA 121.086 -0.578 . . . . 0.9 112.525 -178.457 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 23.5 mt -126.62 81.94 67.66 Favored Pre-proline 0 CA--C 1.533 0.32 0 CA-C-O 120.638 0.256 . . . . 0.74 110.518 -177.118 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 377' ' ' PRO . . . . . 0.794 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 73.5 Cg_endo -80.17 167.85 19.28 Favored 'Trans proline' 0 N--CA 1.463 -0.322 0 C-N-CA 122.693 2.262 . . . . 0.71 113.156 -177.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 378' ' ' ALA . . . . . 0.408 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -49.12 147.25 3.04 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 115.572 -0.74 . . . . 0.74 111.862 178.834 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 379' ' ' ASN . . . . . 0.408 ' HB2' ' O ' ' A' ' 378' ' ' ALA . 42.2 m-80 67.75 33.31 4.94 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 115.712 -0.676 . . . . 1.49 110.688 -175.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 2.4 p -82.29 133.16 35.23 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.922 -0.581 . . . . 1.84 111.42 179.506 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 381' ' ' GLU . . . . . 0.441 ' HB3' ' HB2' ' A' ' 318' ' ' LYS . 32.1 tt0 -104.03 106.64 17.21 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.73 -0.668 . . . . 1.03 109.398 177.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 382' ' ' LEU . . . . . 0.4 HD23 HD23 ' A' ' 317' ' ' LEU . 89.9 mt -86.83 139.97 30.15 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.832 0.349 . . . . 0.37 111.093 -177.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 33.4 m -117.89 117.51 29.49 Favored 'General case' 0 N--CA 1.446 -0.629 0 N-CA-C 109.153 -0.684 . . . . 0.27 109.153 175.645 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 33.9 m-85 -113.69 117.29 31.14 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.214 0.53 . . . . 0.32 111.784 -175.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -85.49 103.82 14.71 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 107.946 -1.131 . . . . 1.8 107.946 172.311 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 386' ' ' VAL . . . . . 0.509 HG12 ' CB ' ' A' ' 313' ' ' TYR . 35.3 m -130.29 141.17 47.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.65 0.738 . . . . 0.31 111.89 -173.159 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 387' ' ' LYS . . . . . 0.442 ' HB3' ' CB ' ' A' ' 357' ' ' GLU . 10.7 pttm -141.07 141.54 34.25 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.148 -0.933 . . . . 2.53 109.747 174.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 388' ' ' LEU . . . . . 0.869 HD11 ' HB ' ' A' ' 309' ' ' VAL . 16.9 tp -94.24 127.35 40.04 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.962 -0.755 . . . . 0.28 108.962 -176.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 34.2 m -125.92 -0.6 4.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 C-N-CA 120.897 -0.321 . . . . 0.45 111.056 -172.094 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 22.9 t -165.15 157.52 15.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.254 -0.43 . . . . 1.32 111.164 179.65 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 391' ' ' MET . . . . . 0.428 ' SD ' ' HB2' ' A' ' 301' ' ' PRO . 39.1 ttm -162.29 132.86 4.85 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.412 -0.813 . . . . 0.56 109.407 175.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 392' ' ' LYS . . . . . 0.424 ' C ' HH21 ' A' ' 308' ' ' ARG . 31.9 mmtp . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.496 -0.764 . . . . 4.91 110.408 -177.64 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.581 0 N-CA-C 111.992 -0.443 . . . . 11.17 111.992 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -129.56 166.75 19.08 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.788 0.328 . . . . 9.37 110.626 -178.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 278' ' ' MET . . . . . . . . . . . . . 28.2 ttt -78.36 92.31 4.55 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.15 -0.477 . . . . 7.67 110.268 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -126.41 83.74 2.2 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.045 -0.525 . . . . 6.37 110.612 178.645 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 45.6 mttp -142.78 151.39 56.6 Favored Pre-proline 0 C--N 1.322 -0.63 0 CA-C-N 115.567 -0.742 . . . . 6.76 110.156 -178.691 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_exo -57.29 136.3 75.44 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 122.792 2.328 . . . . 4.8 112.309 179.597 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 282' ' ' LYS . . . . . . . . . . . . . 30.1 mtmm -79.19 98.11 6.47 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.005 -0.543 . . . . 3.46 110.639 -177.277 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.543 HG22 ' HG2' ' A' ' 293' ' ' GLU . 28.3 p -101.4 153.9 19.28 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.682 -0.69 . . . . 0.76 111.377 -178.745 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 43.4 mtpt -127.58 156.98 41.39 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.528 -0.545 . . . . 2.06 109.528 175.037 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 37.7 tp -112.47 119.24 37.53 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.373 -0.376 . . . . 0.98 110.087 -178.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.638 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 92.3 mt -99.37 -170.16 1.87 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.927 -0.579 . . . . 0.8 110.411 178.574 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -50.86 142.93 10.79 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.11 0.481 . . . . 2.64 111.554 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 73.08 -102.74 1.28 Allowed Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 121.069 -0.586 . . . . 1.84 111.9 -178.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . -146.44 28.04 1.65 Allowed Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 110.691 -0.964 . . . . 0.64 110.691 177.184 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 290' ' ' ILE . . . . . 0.638 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 66.2 mt -74.48 125.57 34.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 115.335 -0.432 . . . . 0.42 110.53 -175.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.401 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 8.1 mt -111.12 142.69 22.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 N-CA-C 109.384 -0.599 . . . . 0.93 109.384 -179.024 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 292' ' ' ILE . . . . . . . . . . . . . 18.5 pt -132.8 128.47 57.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 120.859 0.361 . . . . 0.48 111.222 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 293' ' ' GLU . . . . . 0.601 ' HB2' ' HB3' ' A' ' 359' ' ' ARG . 40.0 mt-10 -103.99 131.79 50.88 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.334 -0.848 . . . . 2.31 110.204 175.618 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -79.98 126.48 31.08 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.234 0.54 . . . . 2.36 109.966 175.492 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 295' ' ' ARG . . . . . 0.602 ' HA ' ' HE ' ' A' ' 295' ' ' ARG . 2.6 mmp_? -105.28 -59.23 1.79 Allowed 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.46 -0.57 . . . . 3.5 109.46 175.36 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.644 ' HB ' ' HG2' ' A' ' 357' ' ' GLU . 90.0 t -131.77 105.18 9.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.822 -0.626 . . . . 0.7 109.334 174.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 10.2 t -68.9 138.72 54.89 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.068 0.461 . . . . 1.93 109.827 178.013 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -128.47 161.82 22.17 Favored Glycine 0 N--CA 1.442 -0.959 0 C-N-CA 120.316 -0.945 . . . . 1.04 112.067 -175.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 23.3 tptm -127.26 110.96 13.39 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 109.799 -0.445 . . . . 4.49 109.799 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -171.43 -154.58 9.95 Favored Glycine 0 N--CA 1.441 -0.98 0 N-CA-C 111.381 -0.688 . . . . 1.04 111.381 -178.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . 0.554 ' O ' ' HA ' ' A' ' 353' ' ' ALA . 21.9 Cg_exo -65.12 133.73 36.64 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.988 2.459 . . . . 0.88 111.744 177.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 52.7 m80 -93.32 139.55 30.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.731 0.301 . . . . 1.49 110.35 -179.376 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -74.03 151.73 40.16 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.053 -0.522 . . . . 0.54 111.832 -179.153 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . 0.46 ' HG2' ' N ' ' A' ' 305' ' ' LYS . 25.6 ttpp -152.98 169.25 23.35 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 115.855 -0.611 . . . . 2.84 109.387 -178.602 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.46 ' N ' ' HG2' ' A' ' 304' ' ' LYS . 99.4 mttt -64.91 130.94 45.29 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 110.136 -0.32 . . . . 2.84 110.136 176.252 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 92.44 -11.8 71.23 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 121.094 -0.575 . . . . 0.7 111.852 -178.682 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 52.5 m -83.5 140.08 32.52 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 122.457 0.303 . . . . 0.4 110.57 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 50.7 mtt180 -100.68 104.74 16.05 Favored 'General case' 0 CA--C 1.516 -0.36 0 N-CA-C 109.002 -0.74 . . . . 3.45 109.002 -179.514 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.848 ' HB ' HD11 ' A' ' 388' ' ' LEU . 33.7 m -102.12 140.01 21.72 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.915 0 CA-C-O 121.276 0.56 . . . . 0.34 111.14 -176.719 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 310' ' ' GLY . . . . . 0.467 ' HA2' ' HA ' ' A' ' 333' ' ' VAL . . . -115.01 125.85 6.94 Favored Glycine 0 N--CA 1.441 -1.029 0 N-CA-C 110.136 -1.186 . . . . 0.27 110.136 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 13.4 ptp -134.07 177.04 8.05 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-O 121.459 0.647 . . . . 0.76 112.123 -173.75 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 312' ' ' ARG . . . . . 0.776 ' HE ' HG11 ' A' ' 389' ' ' VAL . 72.5 mtm180 -138.25 140.85 39.85 Favored 'General case' 0 C--N 1.317 -0.813 0 N-CA-C 106.995 -1.483 . . . . 2.51 106.995 172.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 313' ' ' TYR . . . . . 0.42 ' CE2' ' HH2' ' A' ' 345' ' ' TRP . 9.8 p90 -158.55 169.53 24.23 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 119.593 -0.843 . . . . 0.68 113.056 -167.404 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 26.2 t -129.42 108.07 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 CA-C-N 114.33 -1.305 . . . . 0.35 109.086 171.234 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -88.28 110.38 3.63 Favored Glycine 0 N--CA 1.447 -0.576 0 N-CA-C 111.761 -0.535 . . . . 0.28 111.761 -177.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 316' ' ' LYS . . . . . 0.86 ' HG2' HG22 ' A' ' 322' ' ' VAL . 51.0 mttp -115.81 164.38 14.46 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.175 0.512 . . . . 1.94 110.831 -176.331 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 94.1 mt -87.95 158.67 18.6 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 107.561 -1.274 . . . . 0.65 107.561 164.702 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 318' ' ' LYS . . . . . 0.801 ' HG2' ' HB3' ' A' ' 381' ' ' GLU . 0.1 OUTLIER -63.29 -8.76 9.25 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.011 0.434 . . . . 2.42 111.232 178.978 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 85.8 m-20 -81.16 -14.55 57.51 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.123 -0.489 . . . . 2.2 110.769 177.059 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 109.55 -18.53 29.79 Favored Glycine 0 CA--C 1.518 0.25 0 C-N-CA 120.806 -0.711 . . . . 0.69 112.853 179.148 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 55.2 mtpt -78.08 138.57 38.83 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.662 0.268 . . . . 2.42 111.249 -176.572 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.86 HG22 ' HG2' ' A' ' 316' ' ' LYS . 47.7 t -97.8 136.84 27.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.123 -0.489 . . . . 1.26 110.466 -176.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -118.21 -24.8 6.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.85 0.357 . . . . 0.55 111.164 179.416 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -140.27 146.83 39.1 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.469 -0.567 . . . . 1.68 109.469 177.173 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 21.0 ptmt -163.25 137.66 6.17 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.041 0.448 . . . . 1.99 111.48 -175.631 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 326' ' ' ASN . . . . . 0.451 ' HB2' ' HB2' ' A' ' 330' ' ' LYS . 5.8 p30 -154.58 128.9 9.05 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.796 -0.638 . . . . 1.92 110.279 170.145 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 327' ' ' THR . . . . . 0.459 ' HA ' ' HD2' ' A' ' 312' ' ' ARG . 7.6 t -163.07 -33.92 0.04 OUTLIER 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.676 -0.693 . . . . 1.69 110.573 -177.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 58.8 mttp -89.29 95.46 10.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.657 -0.247 . . . . 2.55 110.441 177.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.511 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 73.65 -10.33 7.01 Favored Glycine 0 CA--C 1.518 0.275 0 C-N-CA 121.137 -0.554 . . . . 0.97 113.439 177.234 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 330' ' ' LYS . . . . . 0.451 ' HB2' ' HB2' ' A' ' 326' ' ' ASN . 58.7 mttm -103.03 100.74 17.97 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 116.945 0.372 . . . . 2.08 111.291 -177.305 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 331' ' ' PRO . . . . . 0.511 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 87.5 Cg_endo -88.84 143.51 5.05 Favored 'Trans proline' 0 N--CA 1.452 -0.917 0 C-N-CA 122.7 2.267 . . . . 0.62 112.034 170.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 73.8 t80 -116.01 115.65 26.51 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.594 -0.521 . . . . 0.64 109.594 174.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 333' ' ' VAL . . . . . 0.467 ' HA ' ' HA2' ' A' ' 310' ' ' GLY . 42.7 t -114.73 117.08 54.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 120.559 0.218 . . . . 0.38 110.517 -175.375 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.523 ' HZ ' HG21 ' A' ' 349' ' ' VAL . 27.8 p90 -136.18 160.78 37.63 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 110.173 -0.306 . . . . 0.41 110.173 -178.749 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 335' ' ' LYS . . . . . 0.641 ' O ' ' HG2' ' A' ' 338' ' ' GLN . 6.0 ptmt -106.04 134.62 48.88 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.016 0.436 . . . . 2.58 111.513 -179.187 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 10.8 mp -68.82 117.8 10.98 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.332 -0.395 . . . . 0.58 110.174 177.452 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 128.86 -19.27 5.55 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.832 -0.699 . . . . 0.94 112.207 -179.279 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 338' ' ' GLN . . . . . 0.798 HE21 ' HB2' ' A' ' 340' ' ' GLU . 18.8 pt20 -72.53 138.55 47.0 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.836 0.35 . . . . 2.62 110.742 179.883 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -86.65 20.31 24.21 Favored Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 120.931 -0.652 . . . . 0.74 111.56 176.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 340' ' ' GLU . . . . . 0.798 ' HB2' HE21 ' A' ' 338' ' ' GLN . 11.5 mt-10 -89.22 -11.05 44.77 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.287 -0.635 . . . . 2.09 109.287 178.007 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 35.5 m -112.98 173.53 2.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.353 -0.84 . . . . 0.43 109.587 177.386 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 342' ' ' ILE . . . . . 0.57 HD12 ' HA ' ' A' ' 367' ' ' ALA . 8.7 pt -92.81 159.96 2.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 N-CA-C 109.736 -0.468 . . . . 0.32 109.736 178.322 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . 0.509 ' HA ' ' HE2' ' A' ' 343' ' ' LYS . 3.4 mmpt? -55.97 -35.73 67.06 Favored 'General case' 0 N--CA 1.467 0.377 0 N-CA-C 112.219 0.451 . . . . 2.93 112.219 -174.78 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 344' ' ' GLY . . . . . 0.428 ' HA3' HD13 ' A' ' 362' ' ' ILE . . . -56.18 -28.74 54.94 Favored Glycine 0 CA--C 1.521 0.446 0 C-N-CA 120.805 -0.712 . . . . 0.3 113.061 177.628 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 345' ' ' TRP . . . . . 0.42 ' HH2' ' CE2' ' A' ' 313' ' ' TYR . 11.2 m95 -79.01 -59.99 2.56 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 112.715 0.635 . . . . 0.39 112.715 -177.063 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 9.0 p-10 -63.92 -22.85 67.11 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 118.046 0.384 . . . . 1.75 111.268 -175.815 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 73.5 mt -86.52 -53.63 9.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.05 -0.523 . . . . 0.39 111.249 176.477 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -64.52 -32.61 84.78 Favored Glycine 0 CA--C 1.523 0.549 0 C-N-CA 121.184 -0.531 . . . . 0.34 113.894 -178.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 349' ' ' VAL . . . . . 0.523 HG21 ' HZ ' ' A' ' 334' ' ' PHE . 93.7 t -80.48 -14.4 12.91 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 CA-C-O 121.047 0.451 . . . . 0.32 111.242 -179.798 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.08 131.67 47.17 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.237 0.541 . . . . 0.47 110.632 178.531 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 79.89 16.15 77.68 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.821 -0.704 . . . . 0.39 112.387 -179.145 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 352' ' ' MET . . . . . 0.408 ' SD ' ' HG2' ' A' ' 358' ' ' ARG . 42.7 mmm -82.6 149.46 27.42 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.643 0.259 . . . . 1.28 110.53 174.238 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 353' ' ' ALA . . . . . 0.554 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -122.84 137.83 54.82 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.031 -0.531 . . . . 0.55 110.491 -179.56 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 354' ' ' VAL . . . . . 0.531 ' HB ' ' HD2' ' A' ' 301' ' ' PRO . 87.6 t -55.33 122.85 5.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.147 -0.479 . . . . 0.36 110.679 176.499 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 111.27 -16.1 27.37 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.927 -0.654 . . . . 0.44 112.175 -178.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -108.37 160.81 13.58 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.692 -0.766 . . . . 0.3 112.439 -178.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 357' ' ' GLU . . . . . 0.845 ' HB3' ' HB2' ' A' ' 387' ' ' LYS . 9.9 pt-20 -139.03 135.91 34.74 Favored 'General case' 0 C--O 1.238 0.462 0 CA-C-O 121.08 0.467 . . . . 1.41 111.171 178.573 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 358' ' ' ARG . . . . . 0.408 ' HG2' ' SD ' ' A' ' 352' ' ' MET . 4.9 ptp180 -132.17 140.46 48.75 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.83 -0.623 . . . . 1.37 109.931 177.445 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 359' ' ' ARG . . . . . 0.601 ' HB3' ' HB2' ' A' ' 293' ' ' GLU . 39.6 ttm180 -86.42 116.15 24.39 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.909 -0.587 . . . . 2.79 109.671 177.086 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 42.2 mt -99.42 117.77 45.05 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 CA-C-N 116.007 -0.542 . . . . 0.38 110.485 -177.536 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 361' ' ' VAL . . . . . 0.401 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 47.2 t -100.52 112.4 33.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 N-CA-C 108.714 -0.847 . . . . 0.39 108.714 175.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 362' ' ' ILE . . . . . 0.462 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 47.9 mt -110.59 109.37 58.04 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 116.073 -0.512 . . . . 0.29 111.67 -171.001 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 363' ' ' PRO . . . . . 0.462 ' HD2' ' HA ' ' A' ' 362' ' ' ILE . 13.8 Cg_endo -57.0 157.22 21.13 Favored 'Trans proline' 0 C--O 1.235 0.357 0 C-N-CA 123.098 2.532 . . . . 0.66 112.185 172.045 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 364' ' ' ALA . . . . . 0.584 ' HB2' ' HA ' ' A' ' 379' ' ' ASN . . . -47.0 -53.8 24.6 Favored Pre-proline 0 CA--C 1.538 0.482 0 N-CA-C 114.051 1.13 . . . . 0.42 114.051 -176.138 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 365' ' ' PRO . . . . . 0.442 ' HD2' ' N ' ' A' ' 364' ' ' ALA . 27.3 Cg_endo -61.6 -15.32 40.98 Favored 'Trans proline' 0 C--N 1.358 1.049 0 C-N-CA 122.2 1.933 . . . . 0.7 114.207 -172.376 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 366' ' ' TYR . . . . . . . . . . . . . 12.2 m-85 -109.25 5.08 23.42 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.794 0.331 . . . . 0.69 111.387 -178.727 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 367' ' ' ALA . . . . . 0.57 ' HA ' HD12 ' A' ' 342' ' ' ILE . . . -119.52 -125.09 0.28 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.435 -0.348 . . . . 0.86 110.41 176.454 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 42.0 m-85 -68.9 -19.02 64.2 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-O 120.562 0.22 . . . . 1.0 111.297 179.232 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 74.96 -117.63 5.41 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.957 -0.639 . . . . 0.56 113.177 177.587 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 370' ' ' LYS . . . . . 0.446 ' HA ' ' HB1' ' A' ' 378' ' ' ALA . 0.0 OUTLIER -111.54 13.57 21.35 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.652 -0.274 . . . . 2.76 111.467 -173.931 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 51.0 tp60 -103.98 108.28 19.55 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.137 0.494 . . . . 2.65 110.875 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 372' ' ' ALA . . . . . 0.41 ' HB1' ' HA ' ' A' ' 377' ' ' PRO . . . -75.42 119.18 19.16 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-N 115.77 -0.65 . . . . 1.01 111.664 178.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 75.3 mt -90.68 160.07 39.48 Favored Pre-proline 0 C--N 1.32 -0.716 0 N-CA-C 108.975 -0.75 . . . . 0.93 108.975 174.309 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -59.6 114.18 1.94 Allowed 'Trans proline' 0 N--CA 1.461 -0.384 0 C-N-CA 121.326 1.351 . . . . 1.31 110.831 173.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 97.2 -29.5 10.65 Favored Glycine 0 CA--C 1.52 0.38 0 C-N-CA 121.129 -0.558 . . . . 0.9 112.768 -177.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 37.7 mt -126.7 94.23 40.56 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.66 0.23 . . . . 0.74 110.461 -178.237 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 377' ' ' PRO . . . . . 0.41 ' HA ' ' HB1' ' A' ' 372' ' ' ALA . 72.1 Cg_endo -75.47 167.36 26.76 Favored 'Trans proline' 0 N--CA 1.461 -0.418 0 C-N-CA 122.51 2.14 . . . . 0.71 112.839 -176.523 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 378' ' ' ALA . . . . . 0.446 ' HB1' ' HA ' ' A' ' 370' ' ' LYS . . . -57.82 152.13 16.45 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.842 -0.617 . . . . 0.74 111.42 178.656 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 379' ' ' ASN . . . . . 0.584 ' HA ' ' HB2' ' A' ' 364' ' ' ALA . 13.6 m120 72.12 14.25 5.68 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 115.714 -0.676 . . . . 1.49 111.962 179.072 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 33.7 m -70.45 112.43 6.74 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.187 0.517 . . . . 1.84 110.861 176.327 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 381' ' ' GLU . . . . . 0.801 ' HB3' ' HG2' ' A' ' 318' ' ' LYS . 40.9 tt0 -72.95 105.11 4.3 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.259 -0.882 . . . . 1.03 109.444 175.236 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 86.6 mt -82.67 148.99 27.61 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.025 -0.534 . . . . 0.37 111.569 -175.687 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 29.4 m -130.57 120.09 23.51 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.589 -0.522 . . . . 0.27 109.589 176.08 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 -121.39 110.45 16.1 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.757 0.313 . . . . 0.32 111.484 -174.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 23.2 m-20 -82.42 103.92 12.34 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 108.375 -0.972 . . . . 1.8 108.375 168.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 386' ' ' VAL . . . . . . . . . . . . . 28.2 m -118.28 128.33 75.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.256 0.551 . . . . 0.31 111.56 -175.533 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 387' ' ' LYS . . . . . 0.845 ' HB2' ' HB3' ' A' ' 357' ' ' GLU . 28.9 ttpt -120.58 131.11 54.49 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.621 -0.718 . . . . 2.53 109.756 175.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 388' ' ' LEU . . . . . 0.848 HD11 ' HB ' ' A' ' 309' ' ' VAL . 17.7 tp -87.43 130.29 34.73 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.33 -0.619 . . . . 0.28 109.33 -174.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 389' ' ' VAL . . . . . 0.776 HG11 ' HE ' ' A' ' 312' ' ' ARG . 17.6 m -121.08 -12.75 8.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 111.997 0.369 . . . . 0.45 111.997 -172.625 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 55.4 p -162.28 170.6 18.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.704 0.288 . . . . 1.32 110.8 -178.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 391' ' ' MET . . . . . 0.432 ' HE3' ' HB2' ' A' ' 391' ' ' MET . 36.8 ttm -169.74 137.94 1.78 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.112 -0.495 . . . . 0.56 110.652 -179.053 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 99.2 mttt . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.35 -0.833 . . . . 4.91 110.265 177.587 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.622 0 N-CA-C 112.36 -0.296 . . . . 11.17 112.36 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -88.12 -40.67 13.58 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 111.669 0.248 . . . . 9.37 111.669 -177.241 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 278' ' ' MET . . . . . . . . . . . . . 16.6 tpt 66.54 96.29 0.06 Allowed 'General case' 0 N--CA 1.465 0.275 0 CA-C-O 121.518 0.675 . . . . 7.67 111.101 -178.36 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -120.35 23.29 10.97 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.773 -0.649 . . . . 6.37 110.613 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -100.37 133.78 21.16 Favored Pre-proline 0 C--N 1.321 -0.637 0 CA-C-N 115.809 -0.632 . . . . 6.76 110.251 -177.208 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 69.0 Cg_endo -74.5 153.51 44.48 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 122.762 2.308 . . . . 4.8 113.166 -176.209 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 282' ' ' LYS . . . . . 0.501 ' HD3' ' HA ' ' A' ' 282' ' ' LYS . 64.8 mmtt -156.97 23.47 0.32 Allowed 'General case' 0 CA--C 1.503 -0.844 0 CA-C-N 115.389 -0.823 . . . . 3.46 110.189 177.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 20.8 p -157.01 126.29 6.02 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 114.532 -1.213 . . . . 0.76 110.991 -175.373 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 25.5 mtpp -129.98 135.38 48.24 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.879 -0.415 . . . . 2.06 109.879 170.651 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . 0.414 HD11 ' HA2' ' A' ' 289' ' ' GLY . 47.7 tp -94.01 120.77 34.71 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.884 -0.598 . . . . 0.98 109.989 -177.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.609 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 88.3 mt -104.54 -171.95 2.02 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.554 -0.748 . . . . 0.8 110.308 178.433 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 287' ' ' GLU . . . . . 0.65 ' HG3' ' OH ' ' A' ' 366' ' ' TYR . 7.3 tp10 -61.31 145.32 51.83 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.634 -0.712 . . . . 2.64 111.377 -177.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 67.24 17.29 68.03 Favored Glycine 0 CA--C 1.521 0.439 0 C-N-CA 121.171 -0.537 . . . . 1.84 113.967 176.008 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . 0.414 ' HA2' HD11 ' A' ' 285' ' ' LEU . . . 82.06 17.4 69.76 Favored Glycine 0 C--N 1.33 0.197 0 C-N-CA 120.512 -0.851 . . . . 0.64 113.179 178.086 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 290' ' ' ILE . . . . . 0.609 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 87.8 mt -69.62 126.47 29.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 109.813 -0.439 . . . . 0.42 109.813 176.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 10.5 mt -114.81 135.21 55.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 109.448 -0.575 . . . . 0.93 109.448 -179.771 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 292' ' ' ILE . . . . . . . . . . . . . 24.5 pt -124.19 129.64 74.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-O 121.019 0.438 . . . . 0.48 110.563 -177.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 293' ' ' GLU . . . . . . . . . . . . . 25.9 tt0 -107.7 121.18 44.18 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.403 -0.817 . . . . 2.31 109.367 178.033 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -83.19 120.85 26.32 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.352 0.596 . . . . 2.36 109.95 -179.624 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 295' ' ' ARG . . . . . 0.569 ' HD2' ' HB2' ' A' ' 359' ' ' ARG . 68.6 mtp180 -102.06 -50.77 3.56 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.37 -0.377 . . . . 3.5 110.312 -176.768 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.51 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 60.3 t -118.71 115.09 46.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 109.78 -0.452 . . . . 0.7 109.78 174.676 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 20.7 p -81.06 121.52 26.18 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.036 -0.529 . . . . 1.93 111.682 -177.507 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -134.99 173.71 21.46 Favored Glycine 0 N--CA 1.446 -0.654 0 N-CA-C 111.632 -0.587 . . . . 1.04 111.632 179.049 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -151.27 128.17 11.0 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.261 0.553 . . . . 4.49 109.892 174.572 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -172.92 -153.5 9.54 Favored Glycine 0 N--CA 1.443 -0.874 0 N-CA-C 110.869 -0.892 . . . . 1.04 110.869 -177.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_exo -56.64 133.36 57.53 Favored 'Trans proline' 0 N--CA 1.462 -0.372 0 C-N-CA 122.369 2.046 . . . . 0.88 111.017 173.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 302' ' ' HIS . . . . . 0.418 ' HA ' ' O ' ' A' ' 352' ' ' MET . 53.6 m80 -100.48 144.24 29.71 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.42 -0.355 . . . . 1.49 111.033 -176.604 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 303' ' ' ALA . . . . . 0.442 ' HB2' HG11 ' A' ' 309' ' ' VAL . . . -77.39 125.84 29.96 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.832 -0.622 . . . . 0.54 111.382 -179.239 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . 0.404 ' O ' ' HB2' ' A' ' 336' ' ' LEU . 98.4 mttt -133.21 179.47 6.18 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.717 -0.674 . . . . 2.84 109.922 176.472 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.942 ' HG3' ' HA3' ' A' ' 337' ' ' GLY . 87.0 tttt -67.39 130.99 44.82 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.839 0.352 . . . . 2.84 110.268 177.03 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 95.99 -26.02 22.7 Favored Glycine 0 N--CA 1.448 -0.542 0 N-CA-C 111.42 -0.672 . . . . 0.7 111.42 -177.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 307' ' ' THR . . . . . 0.628 ' O ' ' HA ' ' A' ' 335' ' ' LYS . 9.7 m -72.51 131.36 42.43 Favored 'General case' 0 N--CA 1.449 -0.52 0 CA-C-N 115.619 -0.291 . . . . 0.4 110.224 178.239 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . 0.645 ' HG2' ' HB3' ' A' ' 335' ' ' LYS . 49.6 mtp180 -102.18 104.37 14.95 Favored 'General case' 0 N--CA 1.452 -0.356 0 N-CA-C 108.651 -0.87 . . . . 3.45 108.651 -179.676 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.787 ' HB ' HD11 ' A' ' 388' ' ' LEU . 32.0 m -99.58 140.02 19.88 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-O 121.243 0.544 . . . . 0.34 111.267 -171.034 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -103.79 113.3 4.43 Favored Glycine 0 N--CA 1.442 -0.933 0 CA-C-N 114.956 -1.02 . . . . 0.27 110.646 179.508 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 13.3 ptp -133.62 176.89 8.15 Favored 'General case' 0 N--CA 1.441 -0.92 0 CA-C-O 121.92 0.867 . . . . 0.76 112.273 -173.516 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 49.4 mtp180 -135.46 145.16 46.91 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 113.81 -1.541 . . . . 2.51 106.976 177.174 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 313' ' ' TYR . . . . . 0.511 ' HA ' ' O ' ' A' ' 385' ' ' ASP . 44.9 p90 -161.42 155.63 22.57 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.461 0.648 . . . . 0.68 112.708 -170.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 57.7 t -122.48 120.01 59.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 114.756 -1.111 . . . . 0.35 109.45 175.263 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -101.37 115.23 5.21 Favored Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.83 -0.7 . . . . 0.28 112.461 -177.046 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 316' ' ' LYS . . . . . 0.502 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 62.7 mttm -112.29 151.09 30.08 Favored 'General case' 0 C--N 1.331 -0.221 0 O-C-N 123.946 0.439 . . . . 1.94 111.193 -179.278 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 317' ' ' LEU . . . . . 0.579 HD21 HG12 ' A' ' 376' ' ' ILE . 80.1 mt -84.95 -178.5 6.85 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.505 -0.771 . . . . 0.65 112.114 178.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 318' ' ' LYS . . . . . 0.591 ' HD3' ' H ' ' A' ' 381' ' ' GLU . 49.7 tptt -57.43 -32.59 67.03 Favored 'General case' 0 N--CA 1.461 0.111 0 CA-C-N 115.198 -0.91 . . . . 2.42 110.854 176.82 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 27.0 p-10 -92.7 6.9 45.78 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.078 -0.51 . . . . 2.2 111.368 -177.244 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 88.13 -8.22 79.02 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.638 -0.791 . . . . 0.69 112.641 178.155 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 28.7 tptp -66.25 114.19 5.14 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.028 0.442 . . . . 2.42 110.634 179.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.502 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 4.0 p -68.15 122.44 19.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-N 115.788 -0.642 . . . . 1.26 109.856 175.571 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 323' ' ' PHE . . . . . 0.46 ' HD1' ' HG ' ' A' ' 317' ' ' LEU . 43.1 p90 -100.83 -30.48 11.66 Favored 'General case' 0 C--N 1.322 -0.596 0 C-N-CA 120.738 -0.385 . . . . 0.55 110.794 -178.776 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -149.48 160.08 43.76 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.835 -0.346 . . . . 1.68 110.622 178.719 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 14.8 pttp -166.66 128.42 1.75 Allowed 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.129 -0.487 . . . . 1.99 110.505 -178.38 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -124.82 117.9 25.18 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.947 -0.76 . . . . 1.92 108.947 178.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 2.0 t -164.05 -45.04 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.47 -0.332 . . . . 1.69 111.278 -175.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 12.6 ptmm? -89.44 100.41 13.21 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.317 0.579 . . . . 2.55 110.84 -177.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.473 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 86.28 -26.76 6.03 Favored Glycine 0 N--CA 1.452 -0.292 0 CA-C-N 115.532 -0.758 . . . . 0.97 113.074 178.023 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -103.36 100.78 19.44 Favored Pre-proline 0 C--N 1.329 -0.309 0 N-CA-C 111.729 0.27 . . . . 2.08 111.729 -177.001 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 331' ' ' PRO . . . . . 0.473 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 84.2 Cg_endo -87.79 125.93 2.07 Favored 'Trans proline' 0 N--CA 1.45 -1.078 0 C-N-CA 122.35 2.034 . . . . 0.62 110.342 165.869 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 43.1 t80 -99.92 115.6 30.02 Favored 'General case' 0 C--N 1.321 -0.639 0 C-N-CA 120.486 -0.485 . . . . 0.64 110.107 -177.323 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 333' ' ' VAL . . . . . 0.638 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 47.5 t -111.94 113.17 43.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 116.032 -0.531 . . . . 0.38 109.939 -177.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 30.7 p90 -135.99 149.44 48.86 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.313 -0.403 . . . . 0.41 110.41 -178.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 335' ' ' LYS . . . . . 0.645 ' HB3' ' HG2' ' A' ' 308' ' ' ARG . 12.0 ptmt -92.84 139.22 30.77 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 116.181 -0.463 . . . . 2.58 111.133 177.577 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 336' ' ' LEU . . . . . 0.404 ' HB2' ' O ' ' A' ' 304' ' ' LYS . 9.8 mp -77.64 151.76 34.17 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 109.517 -0.549 . . . . 0.58 109.517 172.267 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 337' ' ' GLY . . . . . 0.942 ' HA3' ' HG3' ' A' ' 305' ' ' LYS . . . 90.78 40.36 5.62 Favored Glycine 0 N--CA 1.446 -0.687 0 C-N-CA 120.698 -0.763 . . . . 0.94 112.577 -177.662 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 338' ' ' GLN . . . . . 0.494 ' HB3' ' HE2' ' A' ' 335' ' ' LYS . 29.7 pt20 -148.26 157.63 43.61 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.454 -0.573 . . . . 2.62 109.454 176.179 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -89.73 20.1 37.3 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.756 -0.735 . . . . 0.74 112.352 -176.223 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -85.18 -15.07 44.92 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.301 0.572 . . . . 2.09 110.012 178.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 25.4 m -123.58 156.78 30.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.843 -0.617 . . . . 0.43 109.855 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 342' ' ' ILE . . . . . 0.456 HD12 ' HA ' ' A' ' 367' ' ' ALA . 11.3 pt -76.79 159.93 5.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 N-CA-C 110.203 -0.295 . . . . 0.32 110.203 -179.826 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . 0.478 ' HA ' ' HE2' ' A' ' 343' ' ' LYS . 4.7 mmpt? -63.14 -34.38 77.48 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.19 0.441 . . . . 2.93 112.19 -173.88 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 344' ' ' GLY . . . . . 0.43 ' HA3' HD13 ' A' ' 362' ' ' ILE . . . -54.19 -33.54 52.08 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.72 -0.753 . . . . 0.3 112.383 174.564 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 11.8 m95 -81.23 -59.83 2.5 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 120.584 0.231 . . . . 0.39 110.781 177.568 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 31.5 t70 -48.76 -31.11 6.44 Favored 'General case' 0 CA--C 1.537 0.463 0 CA-C-N 116.193 -0.458 . . . . 1.75 112.107 179.049 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 71.6 mt -93.2 -52.39 9.91 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.404 0 CA-C-N 116.626 -0.261 . . . . 0.39 111.69 178.323 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -63.8 -31.84 82.16 Favored Glycine 0 C--N 1.335 0.505 0 C-N-CA 121.318 -0.468 . . . . 0.34 113.767 -176.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 98.7 t -78.28 -20.52 13.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-O 120.984 0.421 . . . . 0.32 110.812 179.442 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -63.8 118.35 8.21 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.96 0.409 . . . . 0.47 110.163 178.185 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 100.2 0.61 55.89 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.69 -0.766 . . . . 0.39 112.397 -178.017 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 352' ' ' MET . . . . . 0.418 ' O ' ' HA ' ' A' ' 302' ' ' HIS . 58.0 mmm -68.69 139.97 55.42 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.673 0.273 . . . . 1.28 110.668 175.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 353' ' ' ALA . . . . . . . . . . . . . . . -109.69 137.19 47.86 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.877 -0.601 . . . . 0.55 110.819 -178.734 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 68.4 t -56.85 117.19 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.279 -0.419 . . . . 0.36 110.125 173.449 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 111.07 -6.08 28.91 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 121.229 -0.51 . . . . 0.44 112.477 -178.555 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -105.36 154.93 17.11 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.748 -0.739 . . . . 0.3 113.126 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 357' ' ' GLU . . . . . 0.51 ' HB3' ' HB ' ' A' ' 296' ' ' VAL . 25.8 tt0 -132.61 133.53 43.76 Favored 'General case' 0 C--N 1.329 -0.293 0 C-N-CA 122.944 0.498 . . . . 1.41 109.868 -179.486 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 358' ' ' ARG . . . . . . . . . . . . . 5.0 ptp180 -144.48 143.23 30.77 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.094 0.473 . . . . 1.37 111.063 177.598 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 359' ' ' ARG . . . . . 0.569 ' HB2' ' HD2' ' A' ' 295' ' ' ARG . 11.8 ttp180 -93.35 121.47 34.77 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.696 -0.684 . . . . 2.79 109.422 174.551 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 44.9 mt -106.07 127.64 61.06 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-N 116.134 -0.485 . . . . 0.38 110.577 -175.821 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 361' ' ' VAL . . . . . . . . . . . . . 58.8 t -107.16 109.24 27.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 N-CA-C 108.868 -0.79 . . . . 0.39 108.868 175.312 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 362' ' ' ILE . . . . . 0.449 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 51.5 mt -107.11 110.04 63.25 Favored Pre-proline 0 C--N 1.322 -0.598 0 CA-C-N 116.43 -0.35 . . . . 0.29 111.495 -174.255 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 363' ' ' PRO . . . . . 0.498 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 13.2 Cg_endo -57.45 152.83 44.7 Favored 'Trans proline' 0 N--CA 1.46 -0.487 0 C-N-CA 122.641 2.228 . . . . 0.66 111.18 170.4 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 364' ' ' ALA . . . . . 0.502 ' HB2' ' HA ' ' A' ' 379' ' ' ASN . . . -47.93 -49.86 56.59 Favored Pre-proline 0 CA--C 1.537 0.479 0 N-CA-C 113.913 1.079 . . . . 0.42 113.913 -173.87 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 365' ' ' PRO . . . . . 0.498 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 77.6 Cg_exo -49.5 -35.4 36.6 Favored 'Trans proline' 0 C--N 1.36 1.18 0 C-N-CA 122.564 2.176 . . . . 0.7 114.555 -173.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 366' ' ' TYR . . . . . 0.65 ' OH ' ' HG3' ' A' ' 287' ' ' GLU . 3.1 m-85 -101.23 13.82 33.91 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.481 -0.488 . . . . 0.69 112.234 -174.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 367' ' ' ALA . . . . . 0.456 ' HA ' HD12 ' A' ' 342' ' ' ILE . . . -116.58 -105.3 0.4 Allowed 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.306 -0.406 . . . . 0.86 109.926 172.539 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 76.4 m-85 -95.87 4.82 52.48 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.988 0.423 . . . . 1.0 111.158 175.232 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 61.35 -117.4 11.48 Favored Glycine 0 N--CA 1.45 -0.371 0 CA-C-N 115.829 -0.623 . . . . 0.56 113.34 174.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 95.4 mttt -103.14 14.32 32.04 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.686 -0.257 . . . . 2.76 110.778 -176.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 27.8 tp60 -87.27 103.92 15.9 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.355 -0.384 . . . . 2.65 110.773 -177.769 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 372' ' ' ALA . . . . . 0.633 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -74.84 104.15 5.35 Favored 'General case' 0 N--CA 1.45 -0.448 0 CA-C-O 121.077 0.465 . . . . 1.01 110.542 174.517 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 90.2 mt -94.34 162.75 25.22 Favored Pre-proline 0 C--N 1.321 -0.668 0 CA-C-N 115.796 -0.638 . . . . 0.93 109.44 176.589 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_endo -63.15 114.86 2.65 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 121.724 1.616 . . . . 1.31 110.606 170.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 93.83 -30.03 7.93 Favored Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 120.941 -0.647 . . . . 0.9 112.279 -176.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 376' ' ' ILE . . . . . 0.579 HG12 HD21 ' A' ' 317' ' ' LEU . 24.3 mt -128.36 79.92 73.28 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.668 0.27 . . . . 0.74 110.615 -178.524 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 377' ' ' PRO . . . . . 0.633 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 72.5 Cg_endo -75.44 167.96 25.52 Favored 'Trans proline' 0 N--CA 1.463 -0.276 0 C-N-CA 122.379 2.053 . . . . 0.71 112.313 -179.675 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 378' ' ' ALA . . . . . 0.448 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -55.96 146.14 23.15 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.362 -0.381 . . . . 0.74 111.01 178.588 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 379' ' ' ASN . . . . . 0.502 ' HA ' ' HB2' ' A' ' 364' ' ' ALA . 49.1 m-80 75.56 9.29 3.64 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 123.435 0.694 . . . . 1.49 112.138 179.723 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 62.2 m -72.02 107.03 4.52 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.32 0.581 . . . . 1.84 110.774 174.591 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 381' ' ' GLU . . . . . 0.591 ' H ' ' HD3' ' A' ' 318' ' ' LYS . 4.5 tt0 -77.01 99.62 5.35 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.02 -0.991 . . . . 1.03 109.153 177.628 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 83.2 mt -82.46 140.44 33.38 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.167 -0.47 . . . . 0.37 110.878 -173.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 25.5 m -117.66 120.57 38.42 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 109.622 -0.51 . . . . 0.27 109.622 178.779 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 92.3 m-85 -118.92 113.68 21.4 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.611 -0.268 . . . . 0.32 111.168 -176.66 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 385' ' ' ASP . . . . . 0.511 ' O ' ' HA ' ' A' ' 313' ' ' TYR . 23.3 t70 -83.19 104.98 13.79 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 108.428 -0.952 . . . . 1.8 108.428 171.495 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 386' ' ' VAL . . . . . . . . . . . . . 36.0 m -115.27 133.21 62.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-O 121.665 0.745 . . . . 0.31 111.469 -174.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 387' ' ' LYS . . . . . . . . . . . . . 3.3 ptpp? -129.6 126.39 38.35 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.085 -0.961 . . . . 2.53 109.841 176.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 388' ' ' LEU . . . . . 0.787 HD11 ' HB ' ' A' ' 309' ' ' VAL . 22.3 tp -91.64 127.99 37.3 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 108.279 -1.008 . . . . 0.28 108.279 -179.738 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 28.2 m -127.76 -6.18 4.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 C-N-CA 120.77 -0.372 . . . . 0.45 111.591 -171.248 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 13.4 p -167.98 171.08 10.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.381 -0.372 . . . . 1.32 110.534 179.167 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 391' ' ' MET . . . . . 0.439 ' HB2' ' HE3' ' A' ' 391' ' ' MET . 31.7 ttm -164.45 143.72 7.37 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.9 0.381 . . . . 0.56 111.348 -178.232 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 3.2 tppp? . . . . . 0 C--O 1.251 1.133 0 CA-C-O 118.678 -0.677 . . . . 4.91 109.257 173.038 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.704 0 N-CA-C 111.816 -0.513 . . . . 11.17 111.816 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -119.42 -17.82 8.68 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.768 0.284 . . . . 9.37 111.566 -177.715 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 278' ' ' MET . . . . . . . . . . . . . 15.7 tpt -113.22 118.8 35.67 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.982 0.42 . . . . 7.67 111.244 -176.736 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -116.72 165.77 12.9 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.683 -0.689 . . . . 6.37 109.337 174.191 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 53.8 mtpt -120.7 81.29 32.84 Favored Pre-proline 0 C--N 1.326 -0.441 0 C-N-CA 120.707 -0.397 . . . . 6.76 110.948 -178.41 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -84.66 4.65 6.73 Favored 'Trans proline' 0 C--N 1.347 0.477 0 C-N-CA 123.245 2.63 . . . . 4.8 111.455 177.658 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 282' ' ' LYS . . . . . 0.406 ' HE2' ' HB3' ' A' ' 282' ' ' LYS . 48.8 mtpt -75.3 -166.71 0.54 Allowed 'General case' 0 N--CA 1.445 -0.725 0 CA-C-N 114.791 -1.095 . . . . 3.46 111.449 179.308 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.542 HG22 ' HB3' ' A' ' 293' ' ' GLU . 1.9 p -91.49 136.55 33.04 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-N 114.776 -1.102 . . . . 0.76 110.016 179.575 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 92.7 mttt -101.45 154.73 18.56 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 110.418 -0.215 . . . . 2.06 110.418 179.371 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 59.9 tp -110.43 112.73 24.86 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 109.722 -0.473 . . . . 0.98 109.722 176.129 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.738 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 89.4 mt -100.41 -170.97 1.94 Allowed 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.057 -0.52 . . . . 0.8 110.924 -178.132 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 287' ' ' GLU . . . . . 0.461 ' HB3' HD13 ' A' ' 347' ' ' ILE . 28.1 tt0 -50.32 136.74 19.64 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 116.011 -0.54 . . . . 2.64 111.788 -179.043 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 76.22 -99.42 1.3 Allowed Glycine 0 N--CA 1.445 -0.761 0 C-N-CA 120.755 -0.736 . . . . 1.84 111.561 -177.114 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . -151.17 31.91 0.96 Allowed Glycine 0 N--CA 1.447 -0.575 0 N-CA-C 110.736 -0.945 . . . . 0.64 110.736 175.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 290' ' ' ILE . . . . . 0.738 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 72.6 mt -74.38 121.94 26.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 110.127 -0.324 . . . . 0.42 110.127 -176.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 17.9 mt -115.1 139.86 39.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 109.307 -0.627 . . . . 0.93 109.307 -178.736 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 292' ' ' ILE . . . . . 0.406 ' O ' ' HA ' ' A' ' 283' ' ' THR . 22.0 pt -136.91 127.02 39.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 C-N-CA 120.816 -0.354 . . . . 0.48 110.637 -179.098 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 293' ' ' GLU . . . . . 0.542 ' HB3' HG22 ' A' ' 283' ' ' THR . 16.9 pt-20 -110.87 131.83 54.71 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.09 -0.505 . . . . 2.31 109.933 173.271 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -89.64 109.03 20.03 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.186 0.517 . . . . 2.36 109.69 -173.106 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 295' ' ' ARG . . . . . 0.799 ' HG3' HG23 ' A' ' 296' ' ' VAL . 21.6 tpt180 -77.89 -54.35 6.42 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.278 -0.874 . . . . 3.5 111.232 -173.807 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.799 HG23 ' HG3' ' A' ' 295' ' ' ARG . 65.0 t -128.63 106.68 14.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 N-CA-C 109.199 -0.667 . . . . 0.7 109.199 178.614 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 25.3 m -73.34 114.0 11.05 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.11 0.481 . . . . 1.93 111.739 -175.519 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -113.76 171.15 13.65 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.565 -0.743 . . . . 1.04 111.46 178.125 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 26.4 tptp -137.73 127.4 25.25 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.419 0.628 . . . . 4.49 111.111 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -170.98 -155.02 10.12 Favored Glycine 0 N--CA 1.44 -1.034 0 N-CA-C 109.966 -1.254 . . . . 1.04 109.966 176.202 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . 0.553 ' HB2' ' SD ' ' A' ' 391' ' ' MET . 11.5 Cg_endo -59.48 146.87 93.76 Favored 'Trans proline' 0 CA--C 1.53 0.297 0 C-N-CA 122.305 2.003 . . . . 0.88 110.974 170.342 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 29.1 m80 -106.75 139.09 41.72 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.067 0.46 . . . . 1.49 111.445 -178.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 303' ' ' ALA . . . . . 0.438 ' HB2' HG11 ' A' ' 309' ' ' VAL . . . -73.68 142.28 46.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.408 -0.814 . . . . 0.54 112.438 -175.497 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 57.6 tttp -150.24 165.52 32.7 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 108.149 -1.056 . . . . 2.84 108.149 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 65.8 mttm -62.92 134.94 56.99 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-N 118.203 0.456 . . . . 2.84 109.929 174.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 92.23 -6.54 78.49 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 121.087 -0.578 . . . . 0.7 111.859 -174.174 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 24.7 m -102.65 145.95 28.91 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.975 -0.379 . . . . 0.4 109.975 179.414 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . 0.589 ' HB3' ' HG3' ' A' ' 335' ' ' LYS . 11.5 ptp85 -108.86 123.82 49.67 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 109.499 -0.556 . . . . 3.45 109.499 179.723 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.832 ' HB ' HD11 ' A' ' 388' ' ' LEU . 34.4 m -110.86 139.17 35.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-O 121.387 0.613 . . . . 0.34 111.649 179.477 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 310' ' ' GLY . . . . . 0.412 ' HA2' ' HA ' ' A' ' 333' ' ' VAL . . . -111.05 115.84 4.08 Favored Glycine 0 N--CA 1.444 -0.772 0 N-CA-C 110.189 -1.165 . . . . 0.27 110.189 176.858 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 14.2 ptp -133.38 177.75 7.44 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-O 121.498 0.666 . . . . 0.76 111.879 -170.498 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 312' ' ' ARG . . . . . 0.424 ' HB3' ' CB ' ' A' ' 327' ' ' THR . 94.1 mtt180 -131.89 144.84 51.15 Favored 'General case' 0 C--N 1.319 -0.717 0 N-CA-C 107.182 -1.414 . . . . 2.51 107.182 175.431 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 313' ' ' TYR . . . . . 0.632 ' HB3' HG12 ' A' ' 386' ' ' VAL . 33.6 p90 -159.53 159.27 33.18 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 113.162 0.801 . . . . 0.68 113.162 -172.519 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 60.5 t -128.27 113.26 29.5 Favored 'Isoleucine or valine' 0 C--O 1.237 0.423 0 CA-C-N 114.782 -1.099 . . . . 0.35 109.024 171.652 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -93.36 116.28 5.14 Favored Glycine 0 C--O 1.239 0.454 0 C-N-CA 121.241 -0.504 . . . . 0.28 112.602 -176.44 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 316' ' ' LYS . . . . . 0.726 ' HG2' HG22 ' A' ' 322' ' ' VAL . 26.7 mttp -122.19 154.76 37.03 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-O 121.181 0.515 . . . . 1.94 110.885 -177.521 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 317' ' ' LEU . . . . . 0.61 HD21 HG12 ' A' ' 376' ' ' ILE . 69.5 mt -81.04 164.16 22.69 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.202 -0.908 . . . . 0.65 109.471 172.481 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 318' ' ' LYS . . . . . 0.452 ' HB2' ' O ' ' A' ' 381' ' ' GLU . 53.2 tptt -60.8 -25.31 66.48 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.074 0.464 . . . . 2.42 110.072 175.333 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 74.7 m-20 -75.18 -0.85 20.73 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.82 -0.627 . . . . 2.2 111.196 -179.283 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 84.97 10.73 78.11 Favored Glycine 0 C--N 1.334 0.423 0 C-N-CA 120.902 -0.666 . . . . 0.69 112.592 178.307 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 321' ' ' LYS . . . . . 0.547 ' HB2' HD12 ' A' ' 317' ' ' LEU . 30.6 mmtp -95.71 125.04 40.01 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.276 -0.268 . . . . 2.42 110.276 -179.489 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.726 HG22 ' HG2' ' A' ' 316' ' ' LYS . 50.3 t -83.31 115.36 25.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 110.214 -0.291 . . . . 1.26 110.214 179.221 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 47.7 p90 -91.72 -30.82 16.07 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.919 -0.312 . . . . 0.55 111.131 -178.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -150.5 153.1 35.23 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 110.025 -0.361 . . . . 1.68 110.025 177.531 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 21.0 pttm -163.41 133.32 4.27 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.965 0.412 . . . . 1.99 110.438 -177.08 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 4.1 p30 -155.13 121.44 5.25 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.443 0.639 . . . . 1.92 110.119 174.349 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 327' ' ' THR . . . . . 0.424 ' CB ' ' HB3' ' A' ' 312' ' ' ARG . 4.9 t -161.84 -42.51 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.601 -0.727 . . . . 1.69 111.485 -175.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.44 ' O ' ' HG3' ' A' ' 328' ' ' LYS . 25.1 pttm -79.21 95.1 5.54 Favored 'General case' 0 N--CA 1.454 -0.245 0 CA-C-O 121.568 0.699 . . . . 2.55 110.512 -178.344 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.454 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 85.42 -15.36 46.07 Favored Glycine 0 N--CA 1.448 -0.566 0 CA-C-N 115.484 -0.78 . . . . 0.97 112.617 179.505 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -104.36 100.59 22.7 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 120.483 0.182 . . . . 2.08 111.27 -179.096 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 331' ' ' PRO . . . . . 0.454 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 73.8 Cg_endo -88.06 131.55 2.67 Favored 'Trans proline' 0 N--CA 1.453 -0.888 0 C-N-CA 122.686 2.257 . . . . 0.62 112.027 172.385 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 78.7 t80 -110.28 120.83 43.69 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 109.513 -0.551 . . . . 0.64 109.513 177.53 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 333' ' ' VAL . . . . . 0.412 ' HA ' ' HA2' ' A' ' 310' ' ' GLY . 53.2 t -114.49 116.04 51.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.417 -0.356 . . . . 0.38 110.432 -177.402 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.513 ' HZ ' HG21 ' A' ' 349' ' ' VAL . 33.5 p90 -129.0 156.85 43.15 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.832 0.349 . . . . 0.41 110.404 178.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 335' ' ' LYS . . . . . 0.589 ' HG3' ' HB3' ' A' ' 308' ' ' ARG . 3.6 mppt? -99.51 135.68 40.56 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.198 -0.456 . . . . 2.58 110.604 -179.576 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 9.6 mp -77.03 134.51 38.78 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.42 -0.585 . . . . 0.58 109.42 174.105 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 100.72 -1.45 55.51 Favored Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.265 -0.969 . . . . 0.94 112.323 -175.544 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 338' ' ' GLN . . . . . 0.439 ' HG2' ' O ' ' A' ' 335' ' ' LYS . 12.1 pt20 -87.94 138.92 31.03 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.673 -0.492 . . . . 2.62 109.673 177.371 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -82.17 46.29 3.49 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.614 -0.803 . . . . 0.74 112.348 -178.307 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 19.6 mt-10 -121.15 -20.73 6.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.825 0.345 . . . . 2.09 110.68 179.209 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 23.0 m -100.49 160.83 3.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 116.416 -0.356 . . . . 0.43 110.556 -176.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 342' ' ' ILE . . . . . 0.64 HD12 ' HA ' ' A' ' 367' ' ' ALA . 5.2 pt -82.84 159.92 3.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.313 -0.625 . . . . 0.32 109.313 175.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . 0.51 ' HE2' HD11 ' A' ' 347' ' ' ILE . 17.0 mtpt -60.98 -37.31 82.01 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 121.082 -0.247 . . . . 2.93 111.648 -173.285 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 344' ' ' GLY . . . . . 0.589 ' HA3' HD13 ' A' ' 362' ' ' ILE . . . -53.29 -35.43 50.18 Favored Glycine 0 CA--C 1.519 0.307 0 C-N-CA 121.003 -0.618 . . . . 0.3 112.556 176.575 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 8.0 m95 -73.6 -61.61 1.78 Allowed 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 111.796 0.295 . . . . 0.39 111.796 178.531 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -52.8 -36.77 58.82 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-O 120.918 0.39 . . . . 1.75 111.476 -178.387 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 347' ' ' ILE . . . . . 0.51 HD11 ' HE2' ' A' ' 343' ' ' LYS . 74.9 mt -84.48 -48.16 16.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.236 -0.438 . . . . 0.39 111.387 -177.474 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -64.7 -33.5 87.39 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 121.039 -0.6 . . . . 0.34 113.28 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 349' ' ' VAL . . . . . 0.543 ' O ' ' HB2' ' A' ' 352' ' ' MET . 95.2 t -80.99 -14.24 12.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.016 0.436 . . . . 0.32 110.752 179.313 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -64.79 115.74 5.6 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.992 0.425 . . . . 0.47 109.954 174.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 88.65 21.94 41.72 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.381 -0.914 . . . . 0.39 112.183 -176.088 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 352' ' ' MET . . . . . 0.543 ' HB2' ' O ' ' A' ' 349' ' ' VAL . 0.0 OUTLIER -81.08 151.36 28.37 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.109 -0.7 . . . . 1.28 109.109 174.407 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 353' ' ' ALA . . . . . . . . . . . . . . . -121.49 130.63 53.67 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.731 0.3 . . . . 0.55 111.35 -176.449 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 98.2 t -57.43 119.43 2.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 116.067 -0.515 . . . . 0.36 110.428 174.326 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 107.65 -10.71 38.56 Favored Glycine 0 N--CA 1.448 -0.533 0 C-N-CA 121.065 -0.588 . . . . 0.44 111.965 -177.466 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -104.24 160.41 15.9 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.802 -0.714 . . . . 0.3 112.868 -178.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 357' ' ' GLU . . . . . 0.567 ' HB2' ' HB3' ' A' ' 387' ' ' LYS . 41.5 tt0 -136.85 134.17 36.63 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 122.773 0.429 . . . . 1.41 109.937 178.731 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 358' ' ' ARG . . . . . 0.459 ' HA ' ' H ' ' A' ' 295' ' ' ARG . 4.3 ptp180 -146.65 146.86 30.53 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 121.317 0.58 . . . . 1.37 111.298 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 359' ' ' ARG . . . . . . . . . . . . . 35.1 ttm180 -87.79 119.08 27.78 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.111 -0.949 . . . . 2.79 109.909 177.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 53.7 mt -98.29 119.67 46.62 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 CA-C-N 115.942 -0.572 . . . . 0.38 109.892 179.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 361' ' ' VAL . . . . . . . . . . . . . 74.6 t -103.23 109.09 25.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 115.244 -0.889 . . . . 0.39 108.856 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 362' ' ' ILE . . . . . 0.589 HD13 ' HA3' ' A' ' 344' ' ' GLY . 28.8 mt -115.57 107.91 48.09 Favored Pre-proline 0 C--N 1.323 -0.564 0 CA-C-N 116.484 -0.325 . . . . 0.29 111.038 -173.313 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 363' ' ' PRO . . . . . 0.488 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 11.6 Cg_endo -56.35 151.48 44.45 Favored 'Trans proline' 0 C--O 1.236 0.425 0 C-N-CA 122.373 2.048 . . . . 0.66 111.152 171.377 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 364' ' ' ALA . . . . . . . . . . . . . . . -46.96 -48.95 51.83 Favored Pre-proline 0 CA--C 1.541 0.624 0 N-CA-C 114.126 1.158 . . . . 0.42 114.126 -174.137 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 365' ' ' PRO . . . . . 0.488 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 75.5 Cg_exo -51.42 -29.05 29.66 Favored 'Trans proline' 0 C--N 1.365 1.399 0 C-N-CA 122.54 2.16 . . . . 0.7 114.05 -176.162 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 366' ' ' TYR . . . . . . . . . . . . . 9.1 m-85 -106.17 4.39 28.94 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 111.917 0.339 . . . . 0.69 111.917 -175.357 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 367' ' ' ALA . . . . . 0.688 ' HB1' HD12 ' A' ' 382' ' ' LEU . . . -117.08 -30.21 5.73 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 112.251 0.464 . . . . 0.86 112.251 -179.174 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 9.5 m-85 -165.46 -32.46 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 120.941 0.401 . . . . 1.0 110.53 -176.762 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 101.62 -128.79 9.68 Favored Glycine 0 N--CA 1.446 -0.636 0 C-N-CA 120.821 -0.704 . . . . 0.56 111.983 177.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 21.1 ptmt -108.84 11.02 26.43 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.007 0.432 . . . . 2.76 110.538 -179.504 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 51.9 tt0 -85.05 103.15 13.82 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.972 -0.558 . . . . 2.65 110.306 -177.179 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 372' ' ' ALA . . . . . . . . . . . . . . . -77.65 94.93 4.48 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.076 0.465 . . . . 1.01 110.919 -179.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 80.2 mt -73.91 155.88 88.39 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-N 115.706 -0.679 . . . . 0.93 109.599 176.159 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -57.61 114.32 1.9 Allowed 'Trans proline' 0 N--CA 1.46 -0.454 0 C-N-CA 121.664 1.576 . . . . 1.31 110.81 173.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 97.62 -29.55 10.8 Favored Glycine 0 CA--C 1.519 0.305 0 C-N-CA 121.034 -0.603 . . . . 0.9 112.558 -177.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 376' ' ' ILE . . . . . 0.61 HG12 HD21 ' A' ' 317' ' ' LEU . 25.9 mt -124.45 85.47 55.9 Favored Pre-proline 0 C--N 1.328 -0.347 0 O-C-N 122.808 -0.23 . . . . 0.74 110.554 -178.591 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 377' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -75.02 165.73 30.68 Favored 'Trans proline' 0 N--CA 1.46 -0.49 0 C-N-CA 122.666 2.244 . . . . 0.71 112.413 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 378' ' ' ALA . . . . . 0.426 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -64.96 159.84 22.06 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.084 -0.507 . . . . 0.74 111.595 -178.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 379' ' ' ASN . . . . . 0.426 ' HB2' ' O ' ' A' ' 378' ' ' ALA . 12.3 m120 73.66 -8.16 1.43 Allowed 'General case' 0 N--CA 1.473 0.676 0 CA-C-N 115.501 -0.772 . . . . 1.49 111.833 179.376 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 48.6 m -70.13 114.3 8.15 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.056 0.455 . . . . 1.84 110.928 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 381' ' ' GLU . . . . . 0.452 ' O ' ' HB2' ' A' ' 318' ' ' LYS . 33.0 tt0 -73.5 106.8 5.44 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.549 -0.75 . . . . 1.03 109.862 177.548 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 382' ' ' LEU . . . . . 0.688 HD12 ' HB1' ' A' ' 367' ' ' ALA . 65.9 mt -78.91 141.23 37.78 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.68 0.276 . . . . 0.37 110.394 -178.241 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 24.3 m -123.91 124.85 43.54 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-O 121.002 0.43 . . . . 0.27 110.218 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -120.01 112.19 18.84 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.245 -0.434 . . . . 0.32 110.932 -178.142 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 385' ' ' ASP . . . . . 0.406 ' O ' ' HA ' ' A' ' 313' ' ' TYR . 72.4 m-20 -86.37 105.4 16.68 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 108.728 -0.841 . . . . 1.8 108.728 174.093 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 386' ' ' VAL . . . . . 0.632 HG12 ' HB3' ' A' ' 313' ' ' TYR . 22.2 m -121.72 136.47 58.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.212 0.53 . . . . 0.31 112.072 -173.64 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 387' ' ' LYS . . . . . 0.567 ' HB3' ' HB2' ' A' ' 357' ' ' GLU . 1.3 ptpp? -123.86 137.28 54.68 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.818 -0.628 . . . . 2.53 109.449 170.181 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 388' ' ' LEU . . . . . 0.832 HD11 ' HB ' ' A' ' 309' ' ' VAL . 19.1 tp -95.42 134.28 38.41 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 109.551 -0.537 . . . . 0.28 109.551 -177.377 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 30.9 m -127.91 -5.07 4.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 111.955 0.354 . . . . 0.45 111.955 -174.146 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 12.5 p -165.68 159.77 16.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.653 -0.248 . . . . 1.32 111.093 -178.484 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 391' ' ' MET . . . . . 0.708 ' HG2' ' HG2' ' A' ' 392' ' ' LYS . 41.8 ttm -164.59 155.94 15.4 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.971 -0.559 . . . . 0.56 109.832 178.282 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 392' ' ' LYS . . . . . 0.708 ' HG2' ' HG2' ' A' ' 391' ' ' MET . 32.1 mmmt . . . . . 0 C--O 1.247 0.923 0 O-C-N 124.259 0.975 . . . . 4.91 111.611 175.154 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.665 0 N-CA-C 111.663 -0.575 . . . . 11.17 111.663 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -109.71 170.28 8.17 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.816 0.341 . . . . 9.37 110.673 -179.452 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 278' ' ' MET . . . . . 0.421 ' O ' ' HD2' ' A' ' 282' ' ' LYS . 95.4 mmm -97.79 -39.85 8.83 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.203 -0.453 . . . . 7.67 110.001 179.587 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . 62.22 78.0 0.31 Allowed 'General case' 0 C--O 1.236 0.355 0 CA-C-N 115.35 -0.841 . . . . 6.37 111.381 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 71.9 mttt 70.67 161.23 0.15 Allowed Pre-proline 0 N--CA 1.468 0.453 0 CA-C-N 115.311 -0.859 . . . . 6.76 111.259 177.531 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -62.39 109.95 0.96 Allowed 'Trans proline' 0 C--O 1.235 0.351 0 C-N-CA 122.417 2.078 . . . . 4.8 111.638 175.091 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 282' ' ' LYS . . . . . 0.421 ' HD2' ' O ' ' A' ' 278' ' ' MET . 24.8 mtpp -91.18 68.54 6.02 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.446 0.641 . . . . 3.46 110.161 -178.714 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.456 HG22 ' HB2' ' A' ' 293' ' ' GLU . 18.2 p -88.68 150.77 22.84 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.239 -0.892 . . . . 0.76 111.679 -178.702 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 284' ' ' LYS . . . . . 0.466 ' O ' ' HA ' ' A' ' 291' ' ' ILE . 92.8 mttt -118.52 144.17 46.23 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.41 -0.814 . . . . 2.06 111.026 -173.497 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . 0.547 HD11 ' HA2' ' A' ' 289' ' ' GLY . 56.3 tp -102.8 123.99 47.49 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.466 -0.788 . . . . 0.98 110.373 -177.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.461 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 98.6 mt -113.35 -175.74 2.74 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.9 -0.591 . . . . 0.8 109.703 178.44 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 287' ' ' GLU . . . . . 0.447 ' HG2' ' OH ' ' A' ' 366' ' ' TYR . 27.6 tt0 -56.73 144.07 34.05 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.178 0.513 . . . . 2.64 111.629 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.423 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 72.48 0.32 46.58 Favored Glycine 0 CA--C 1.52 0.352 0 CA-C-N 115.78 -0.646 . . . . 1.84 113.806 179.033 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . 0.547 ' HA2' HD11 ' A' ' 285' ' ' LEU . . . 95.11 12.37 55.07 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.696 -0.764 . . . . 0.64 113.028 179.109 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 290' ' ' ILE . . . . . 0.461 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 71.9 mt -66.62 121.54 15.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 121.253 0.549 . . . . 0.42 110.957 -179.071 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.628 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 18.5 mm -104.38 138.96 26.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 115.737 -0.665 . . . . 0.93 110.232 178.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 292' ' ' ILE . . . . . . . . . . . . . 21.5 pt -127.29 129.36 70.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 120.925 0.393 . . . . 0.48 110.685 177.109 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 293' ' ' GLU . . . . . 0.459 ' OE1' ' HD2' ' A' ' 359' ' ' ARG . 24.6 tt0 -118.83 117.96 30.28 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.661 -0.7 . . . . 2.31 109.759 177.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . 0.403 ' OD1' ' HA ' ' A' ' 297' ' ' THR . 0.5 OUTLIER -88.33 96.14 10.46 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.654 -0.869 . . . . 2.36 108.654 -178.655 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 295' ' ' ARG . . . . . 0.828 HH22 ' HB3' ' A' ' 385' ' ' ASP . 38.0 ttp180 -76.11 -47.28 25.05 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.598 -0.728 . . . . 3.5 111.587 -171.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.736 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 23.3 t -119.03 103.5 14.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 N-CA-C 109.057 -0.719 . . . . 0.7 109.057 172.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 297' ' ' THR . . . . . 0.403 ' HA ' ' OD1' ' A' ' 294' ' ' ASP . 32.1 p -62.09 113.32 2.77 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 114.931 -1.031 . . . . 1.93 112.197 -174.023 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -119.88 152.02 17.2 Favored Glycine 0 N--CA 1.444 -0.769 0 CA-C-N 115.652 -0.703 . . . . 1.04 111.642 178.003 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -127.74 114.12 16.88 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.759 0.314 . . . . 4.49 110.336 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -170.56 -154.6 9.65 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 121.011 -0.614 . . . . 1.04 112.013 -179.414 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . 0.592 ' HD2' ' HB ' ' A' ' 354' ' ' VAL . 28.1 Cg_exo -62.33 137.85 67.97 Favored 'Trans proline' 0 C--O 1.233 0.234 0 C-N-CA 122.833 2.355 . . . . 0.88 112.048 178.656 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 302' ' ' HIS . . . . . 0.505 ' HA ' ' O ' ' A' ' 352' ' ' MET . 39.0 m80 -102.5 134.25 46.14 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 120.938 0.399 . . . . 1.49 110.714 178.157 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -69.54 132.41 46.22 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.986 -0.552 . . . . 0.54 111.685 -178.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 32.6 mmtp -117.19 177.96 4.53 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.042 -0.725 . . . . 2.84 109.042 176.105 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 61.4 mttm -68.77 132.24 46.48 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 109.698 -0.482 . . . . 2.84 109.698 173.27 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 84.74 7.97 83.43 Favored Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.697 -0.764 . . . . 0.7 112.553 -176.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 20.2 m -96.72 147.81 23.53 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 110.286 -0.265 . . . . 0.4 110.286 177.381 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 47.4 mtt180 -102.56 130.82 49.52 Favored 'General case' 0 CA--C 1.515 -0.395 0 N-CA-C 108.993 -0.743 . . . . 3.45 108.993 178.743 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.836 ' HB ' HD11 ' A' ' 388' ' ' LEU . 19.7 m -130.39 137.75 55.49 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-O 121.125 0.488 . . . . 0.34 111.815 -177.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -107.7 120.11 5.98 Favored Glycine 0 N--CA 1.444 -0.789 0 N-CA-C 109.826 -1.31 . . . . 0.27 109.826 176.336 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 311' ' ' MET . . . . . 0.599 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 22.9 ptm -140.01 177.04 8.25 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.58 0.705 . . . . 0.76 112.212 -171.321 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 312' ' ' ARG . . . . . 0.493 ' HB3' ' HA ' ' A' ' 327' ' ' THR . 20.9 mtm180 -133.64 145.37 49.92 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 107.228 -1.397 . . . . 2.51 107.228 174.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 313' ' ' TYR . . . . . 0.535 ' CB ' HG12 ' A' ' 386' ' ' VAL . 41.7 p90 -161.57 158.7 26.72 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 113.23 0.826 . . . . 0.68 113.23 -173.362 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 47.8 t -125.99 127.08 70.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 114.695 -1.139 . . . . 0.35 109.688 174.621 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -96.96 106.73 3.39 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 121.116 -0.564 . . . . 0.28 112.139 -179.656 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 316' ' ' LYS . . . . . 0.796 ' HG2' HG22 ' A' ' 322' ' ' VAL . 86.4 mttt -113.07 154.2 26.94 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.282 0.563 . . . . 1.94 111.722 -175.328 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 317' ' ' LEU . . . . . 0.431 HD12 ' HB3' ' A' ' 321' ' ' LYS . 88.8 mt -88.84 164.81 15.04 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.639 -0.71 . . . . 0.65 109.107 169.682 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 318' ' ' LYS . . . . . . . . . . . . . 37.8 ttpt -66.55 -21.94 66.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.991 0.424 . . . . 2.42 110.858 178.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 28.1 p30 -83.74 4.72 27.61 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.011 0.434 . . . . 2.2 111.028 179.101 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 91.21 -9.5 77.4 Favored Glycine 0 C--N 1.33 0.235 0 C-N-CA 121.252 -0.499 . . . . 0.69 113.258 174.673 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 321' ' ' LYS . . . . . 0.431 ' HB3' HD12 ' A' ' 317' ' ' LEU . 22.2 ttmm -77.98 123.55 26.94 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.896 0.379 . . . . 2.42 110.37 -179.003 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.796 HG22 ' HG2' ' A' ' 316' ' ' LYS . 67.7 t -85.44 128.49 39.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 116.171 -0.468 . . . . 1.26 110.368 -179.681 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 35.6 p90 -100.81 -35.26 9.5 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.645 -0.422 . . . . 0.55 111.587 -179.343 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -146.95 168.55 21.21 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 120.789 -0.364 . . . . 1.68 110.108 178.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . 0.581 ' N ' ' HD3' ' A' ' 325' ' ' LYS . 0.0 OUTLIER -176.55 143.48 0.48 Allowed 'General case' 0 C--O 1.233 0.192 0 CA-C-O 121.247 0.546 . . . . 1.99 111.781 -173.612 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 3.1 p30 -150.73 118.06 6.02 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.576 -0.738 . . . . 1.92 109.41 165.601 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 327' ' ' THR . . . . . 0.493 ' HA ' ' HB3' ' A' ' 312' ' ' ARG . 30.7 m -150.7 -55.39 0.15 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.952 -0.567 . . . . 1.69 111.169 -175.781 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 34.8 mtmm -72.04 94.21 1.47 Allowed 'General case' 0 C--O 1.235 0.299 0 CA-C-O 120.981 0.42 . . . . 2.55 111.272 -177.225 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.506 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 80.24 -10.68 41.0 Favored Glycine 0 N--CA 1.45 -0.422 0 CA-C-N 115.863 -0.608 . . . . 0.97 112.971 175.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 25.6 mtpp -103.9 100.7 21.31 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.789 0.294 . . . . 2.08 110.955 -177.507 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 331' ' ' PRO . . . . . 0.506 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 64.2 Cg_endo -88.26 136.38 3.41 Favored 'Trans proline' 0 N--CA 1.453 -0.907 0 C-N-CA 122.724 2.282 . . . . 0.62 112.115 172.547 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 75.4 t80 -110.78 122.83 48.8 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.461 -0.57 . . . . 0.64 109.461 177.772 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 333' ' ' VAL . . . . . 0.489 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 51.5 t -118.78 115.07 46.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 N-CA-C 110.176 -0.305 . . . . 0.38 110.176 -176.731 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.599 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 23.4 p90 -133.48 172.19 13.06 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.649 0.262 . . . . 0.41 110.597 -178.743 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 335' ' ' LYS . . . . . 0.747 ' H ' ' HD2' ' A' ' 335' ' ' LYS . 0.0 OUTLIER -117.29 140.38 49.62 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.335 -0.393 . . . . 2.58 110.208 -179.928 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 10.1 mp -79.22 151.03 31.44 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.707 0.289 . . . . 0.58 110.646 178.486 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 92.31 9.14 62.14 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.828 -0.701 . . . . 0.94 112.007 -176.105 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 338' ' ' GLN . . . . . 0.55 HE22 ' HB2' ' A' ' 334' ' ' PHE . 29.3 pt20 -98.17 161.54 13.66 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.796 0.332 . . . . 2.62 110.511 -179.687 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -99.82 4.54 57.79 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.852 -0.689 . . . . 0.74 112.277 -179.588 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 66.9 mm-40 -73.54 -34.13 65.05 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.904 0.383 . . . . 2.09 110.674 178.347 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 34.4 m -100.41 156.47 4.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.988 -0.551 . . . . 0.43 110.972 -178.165 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 12.8 pt -71.44 161.91 4.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.471 -0.331 . . . . 0.32 110.523 177.734 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.4 -38.45 87.1 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.359 -0.382 . . . . 2.93 111.84 -176.738 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -51.56 -36.53 39.41 Favored Glycine 0 C--N 1.331 0.255 0 C-N-CA 121.135 -0.555 . . . . 0.3 112.544 175.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 9.3 m95 -73.25 -60.3 2.31 Favored 'General case' 0 C--O 1.223 -0.338 0 CA-C-O 120.405 0.145 . . . . 0.39 111.067 177.181 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -49.45 -33.87 15.25 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.242 -0.436 . . . . 1.75 112.109 179.774 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 65.9 mt -85.76 -54.96 7.34 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.358 0 CA-C-N 116.638 -0.255 . . . . 0.39 111.661 178.55 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -60.97 -36.68 92.6 Favored Glycine 0 CA--C 1.521 0.434 0 C-N-CA 121.585 -0.34 . . . . 0.34 113.822 -177.462 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 349' ' ' VAL . . . . . 0.485 HG21 ' HZ ' ' A' ' 334' ' ' PHE . 95.1 t -72.0 -24.96 23.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 120.904 0.383 . . . . 0.32 110.691 179.601 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.53 108.71 2.1 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.804 -0.443 . . . . 0.47 109.804 175.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 107.73 4.67 34.16 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 121.11 -0.567 . . . . 0.39 112.216 -175.494 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 352' ' ' MET . . . . . 0.505 ' O ' ' HA ' ' A' ' 302' ' ' HIS . 0.0 OUTLIER -73.03 140.8 47.52 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 109.276 -0.639 . . . . 1.28 109.276 176.158 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 353' ' ' ALA . . . . . 0.46 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -108.08 132.07 53.95 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.732 0.301 . . . . 0.55 111.042 -177.353 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 354' ' ' VAL . . . . . 0.592 ' HB ' ' HD2' ' A' ' 301' ' ' PRO . 78.4 t -56.58 116.22 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 120.968 0.414 . . . . 0.36 110.551 175.031 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 110.67 -19.31 26.18 Favored Glycine 0 N--CA 1.445 -0.754 0 N-CA-C 111.59 -0.604 . . . . 0.44 111.59 -177.35 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -83.9 148.26 24.47 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 121.168 -0.539 . . . . 0.3 112.694 -176.307 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 357' ' ' GLU . . . . . 0.736 ' HB3' ' HB ' ' A' ' 296' ' ' VAL . 5.0 tp10 -126.61 117.94 23.82 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 108.973 -0.751 . . . . 1.41 108.973 179.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 358' ' ' ARG . . . . . 0.481 ' HG2' ' CE ' ' A' ' 352' ' ' MET . 6.2 ptp180 -145.16 148.44 33.59 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.362 0.601 . . . . 1.37 112.303 -173.15 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 359' ' ' ARG . . . . . 0.459 ' HD2' ' OE1' ' A' ' 293' ' ' GLU . 60.2 mtt85 -89.24 128.02 35.81 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.75 -0.659 . . . . 2.79 110.233 171.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 57.9 mt -110.97 118.39 57.23 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 N-CA-C 109.201 -0.666 . . . . 0.38 109.201 174.396 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 361' ' ' VAL . . . . . 0.628 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 51.4 t -96.97 117.51 41.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.19 -0.67 . . . . 0.39 109.19 178.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 362' ' ' ILE . . . . . . . . . . . . . 65.1 mt -115.01 103.98 54.31 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 116.339 -0.392 . . . . 0.29 110.818 -174.241 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 363' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -60.29 160.08 24.52 Favored 'Trans proline' 0 N--CA 1.463 -0.285 0 C-N-CA 122.642 2.228 . . . . 0.66 112.007 174.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 364' ' ' ALA . . . . . 0.497 ' N ' ' HD2' ' A' ' 365' ' ' PRO . . . -47.23 -51.09 44.34 Favored Pre-proline 0 CA--C 1.539 0.535 0 N-CA-C 114.191 1.182 . . . . 0.42 114.191 -176.126 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 365' ' ' PRO . . . . . 0.497 ' HD2' ' N ' ' A' ' 364' ' ' ALA . 16.8 Cg_endo -56.66 -25.87 62.19 Favored 'Trans proline' 0 C--N 1.358 1.078 0 C-N-CA 122.256 1.971 . . . . 0.7 114.168 -171.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 366' ' ' TYR . . . . . 0.447 ' OH ' ' HG2' ' A' ' 287' ' ' GLU . 4.1 m-85 -103.36 12.11 35.78 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-O 121.036 0.446 . . . . 0.69 111.236 -177.085 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -127.56 -116.43 0.26 Allowed 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 115.664 -0.698 . . . . 0.86 110.162 173.515 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 86.2 m-85 -85.51 -14.4 46.07 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.689 0.28 . . . . 1.0 111.712 -177.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 62.94 -109.18 2.53 Favored Glycine 0 N--CA 1.452 -0.265 0 CA-C-N 116.183 -0.462 . . . . 0.56 113.572 174.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 370' ' ' LYS . . . . . 0.482 ' HA ' ' HB1' ' A' ' 378' ' ' ALA . 58.0 mttm -102.72 8.06 39.58 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 111.722 0.267 . . . . 2.76 111.722 -175.763 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 371' ' ' GLN . . . . . 0.818 ' HA ' HE21 ' A' ' 371' ' ' GLN . 0.0 OUTLIER -88.83 99.55 12.47 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.964 0.411 . . . . 2.65 110.382 179.676 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 372' ' ' ALA . . . . . . . . . . . . . . . -74.31 110.8 8.9 Favored 'General case' 0 N--CA 1.45 -0.441 0 CA-C-N 115.931 -0.577 . . . . 1.01 111.005 178.644 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 71.9 mt -101.37 161.0 24.97 Favored Pre-proline 0 C--N 1.321 -0.641 0 N-CA-C 109.076 -0.713 . . . . 0.93 109.076 176.601 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_exo -60.55 114.64 2.22 Favored 'Trans proline' 0 N--CA 1.46 -0.484 0 C-N-CA 121.546 1.498 . . . . 1.31 110.96 174.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 92.0 -19.87 46.34 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.749 -0.738 . . . . 0.9 112.327 -178.559 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 23.6 mt -132.47 78.4 67.71 Favored Pre-proline 0 N--CA 1.465 0.287 0 CA-C-O 120.836 0.35 . . . . 0.74 110.512 -179.018 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 377' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_exo -70.72 166.89 27.33 Favored 'Trans proline' 0 N--CA 1.463 -0.319 0 C-N-CA 122.764 2.31 . . . . 0.71 113.017 -178.192 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 378' ' ' ALA . . . . . 0.482 ' HB1' ' HA ' ' A' ' 370' ' ' LYS . . . -56.1 151.78 11.65 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.742 -0.663 . . . . 0.74 110.846 178.036 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 379' ' ' ASN . . . . . 0.414 ' HA ' ' CB ' ' A' ' 364' ' ' ALA . 15.0 m120 64.92 32.25 10.83 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.184 0.516 . . . . 1.49 110.306 -178.423 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -77.63 117.02 18.65 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-N 115.643 -0.708 . . . . 1.84 111.158 177.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 381' ' ' GLU . . . . . . . . . . . . . 19.3 tt0 -92.05 100.63 13.23 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.031 -0.729 . . . . 1.03 109.031 177.394 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 78.8 mt -94.3 149.53 21.15 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.776 -0.647 . . . . 0.37 112.155 -170.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 29.5 m -127.99 128.43 45.02 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.746 -0.464 . . . . 0.27 109.746 176.304 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -119.65 113.09 20.15 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.573 -0.285 . . . . 0.32 111.248 -177.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 385' ' ' ASP . . . . . 0.828 ' HB3' HH22 ' A' ' 295' ' ' ARG . 1.6 m-20 -79.58 105.33 10.81 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.22 -1.03 . . . . 1.8 108.22 172.267 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 386' ' ' VAL . . . . . 0.591 ' HB ' ' CE ' ' A' ' 311' ' ' MET . 33.8 m -126.09 131.32 71.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.386 0.613 . . . . 0.31 112.456 -171.833 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 387' ' ' LYS . . . . . 0.489 ' HB2' ' CD ' ' A' ' 357' ' ' GLU . 49.9 tttm -126.63 132.07 51.32 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.933 -0.576 . . . . 2.53 109.835 175.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 388' ' ' LEU . . . . . 0.836 HD11 ' HB ' ' A' ' 309' ' ' VAL . 23.2 tp -94.67 137.53 33.66 Favored 'General case' 0 C--N 1.319 -0.717 0 N-CA-C 108.992 -0.744 . . . . 0.28 108.992 -178.45 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 33.7 m -126.93 -7.09 4.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 111.993 0.368 . . . . 0.45 111.993 -174.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 25.2 p -167.5 164.25 14.85 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.701 0.286 . . . . 1.32 111.273 -177.498 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 391' ' ' MET . . . . . 0.401 ' HE3' ' HB2' ' A' ' 391' ' ' MET . 39.6 ttm -158.74 147.55 18.66 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.053 -0.521 . . . . 0.56 110.337 179.392 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 392' ' ' LYS . . . . . 0.479 ' NZ ' ' HB3' ' A' ' 392' ' ' LYS . 8.3 mtpm? . . . . . 0 C--O 1.248 0.993 0 CA-C-O 118.603 -0.713 . . . . 4.91 109.961 177.633 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.765 0 N-CA-C 111.841 -0.504 . . . . 11.17 111.841 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -92.91 164.53 13.28 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 110.27 -0.27 . . . . 9.37 110.27 177.667 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 278' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -103.38 156.03 18.04 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 110.054 -0.35 . . . . 7.67 110.054 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -130.55 52.88 2.0 Allowed 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.017 0.437 . . . . 6.37 110.99 -179.441 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.72 122.18 2.45 Favored Pre-proline 0 C--N 1.325 -0.46 0 CA-C-N 116.142 -0.481 . . . . 6.76 110.618 177.62 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -64.79 113.84 2.51 Favored 'Trans proline' 0 C--O 1.233 0.248 0 C-N-CA 122.421 2.081 . . . . 4.8 111.569 177.728 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 282' ' ' LYS . . . . . . . . . . . . . 4.4 mtpm? -87.07 97.18 10.59 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.762 -0.458 . . . . 3.46 109.762 -178.533 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 22.3 p -107.67 173.17 6.44 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.133 -0.485 . . . . 0.76 111.711 -174.461 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 60.6 mttp -134.33 141.32 46.87 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.779 -0.646 . . . . 2.06 109.676 175.562 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 39.3 tp -95.48 122.35 38.12 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 116.184 -0.462 . . . . 0.98 111.04 -178.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.662 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 98.2 mt -96.35 -170.92 2.18 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.931 -0.577 . . . . 0.8 110.599 176.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 287' ' ' GLU . . . . . 0.478 ' HG3' ' OH ' ' A' ' 366' ' ' TYR . 6.5 tp10 -52.86 145.21 12.98 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 115.901 -0.59 . . . . 2.64 111.551 178.808 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.514 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 72.22 -101.61 1.07 Allowed Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.947 -0.57 . . . . 1.84 111.736 -177.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . -148.15 25.57 1.42 Allowed Glycine 0 N--CA 1.444 -0.791 0 N-CA-C 110.214 -1.155 . . . . 0.64 110.214 175.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 290' ' ' ILE . . . . . 0.662 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 73.1 mt -72.36 124.72 29.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.235 -0.482 . . . . 0.42 110.446 -175.731 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.582 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 16.2 mt -107.28 139.39 29.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 116.201 -0.454 . . . . 0.93 109.965 -177.217 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 292' ' ' ILE . . . . . . . . . . . . . 14.8 pt -128.06 127.53 67.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 121.176 0.512 . . . . 0.48 110.797 177.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 293' ' ' GLU . . . . . 0.435 ' CD ' HH21 ' A' ' 359' ' ' ARG . 30.2 tt0 -114.65 118.26 33.17 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 114.929 -1.032 . . . . 2.31 109.123 177.518 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -81.23 114.08 19.79 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.222 -0.591 . . . . 2.36 110.06 -174.09 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 295' ' ' ARG . . . . . 0.561 ' HG2' ' HA ' ' A' ' 358' ' ' ARG . 20.3 mmm180 -86.45 -56.08 3.6 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.632 -0.713 . . . . 3.5 110.365 -174.242 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.569 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 96.7 t -124.0 125.01 70.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.908 -0.587 . . . . 0.7 109.905 178.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 3.9 t -64.1 141.25 58.84 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.284 0.564 . . . . 1.93 111.688 -177.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -150.78 142.11 9.28 Favored Glycine 0 N--CA 1.443 -0.89 0 N-CA-C 110.992 -0.843 . . . . 1.04 110.992 176.024 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 51.5 pttt -131.55 117.61 18.99 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.379 0.609 . . . . 4.49 110.534 177.188 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -172.01 -154.43 10.03 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.335 -0.848 . . . . 1.04 111.063 -177.688 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . 0.463 ' O ' ' HA ' ' A' ' 353' ' ' ALA . 24.6 Cg_exo -62.66 133.53 42.77 Favored 'Trans proline' 0 N--CA 1.462 -0.34 0 C-N-CA 122.356 2.038 . . . . 0.88 111.404 176.282 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 35.9 m80 -95.12 130.15 41.94 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.308 -0.406 . . . . 1.49 110.45 178.474 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 303' ' ' ALA . . . . . 0.496 ' HB2' HG11 ' A' ' 309' ' ' VAL . . . -67.12 133.58 50.1 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.587 -0.733 . . . . 0.54 111.434 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 64.4 pttt -132.2 179.13 6.29 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 108.762 -0.829 . . . . 2.84 108.762 173.499 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 23.5 ttmm -66.33 135.62 54.63 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 120.587 -0.445 . . . . 2.84 110.333 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 92.48 -7.04 77.97 Favored Glycine 0 CA--C 1.521 0.42 0 C-N-CA 121.078 -0.582 . . . . 0.7 112.427 -174.774 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 30.3 m -88.97 150.03 23.01 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.716 0.293 . . . . 0.4 110.842 -178.484 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 82.2 mtt180 -115.31 102.52 9.93 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 109.468 -0.567 . . . . 3.45 109.468 -178.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.802 ' HB ' HD11 ' A' ' 388' ' ' LEU . 35.7 m -102.52 148.26 8.11 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.807 0 CA-C-N 115.592 -0.731 . . . . 0.34 112.458 -175.384 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -113.37 118.24 4.46 Favored Glycine 0 N--CA 1.446 -0.69 0 N-CA-C 110.672 -0.971 . . . . 0.27 110.672 176.554 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 311' ' ' MET . . . . . 0.5 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 6.8 ptm -139.48 178.49 7.18 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.788 0.804 . . . . 0.76 112.434 -172.531 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 55.0 mtt180 -136.06 152.57 51.02 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 113.896 -1.502 . . . . 2.51 107.68 176.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 313' ' ' TYR . . . . . 0.559 ' CB ' HG12 ' A' ' 386' ' ' VAL . 32.8 p90 -159.57 158.89 32.54 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 119.556 -0.858 . . . . 0.68 113.276 -174.474 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . 0.572 HG12 ' HG3' ' A' ' 316' ' ' LYS . 57.9 t -127.02 102.99 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 CA-C-N 114.811 -1.086 . . . . 0.35 109.355 171.071 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -87.13 110.32 3.54 Favored Glycine 0 C--O 1.237 0.336 0 N-CA-C 112.082 -0.407 . . . . 0.28 112.082 -178.47 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 316' ' ' LYS . . . . . 0.757 ' HG2' ' HB ' ' A' ' 322' ' ' VAL . 33.2 mtmm -126.37 156.03 41.16 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.842 0.353 . . . . 1.94 110.92 -174.794 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 317' ' ' LEU . . . . . 0.536 HD12 ' HB3' ' A' ' 321' ' ' LYS . 82.6 mt -81.73 173.33 12.41 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.821 -0.627 . . . . 0.65 110.963 177.007 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 318' ' ' LYS . . . . . . . . . . . . . 60.3 tttp -65.26 -22.27 66.84 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.606 -0.724 . . . . 2.42 110.674 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 32.6 p-10 -91.67 -1.36 57.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.411 -0.359 . . . . 2.2 111.095 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 97.83 -5.31 61.77 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.927 -0.654 . . . . 0.69 113.211 178.129 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 321' ' ' LYS . . . . . 0.536 ' HB3' HD12 ' A' ' 317' ' ' LEU . 14.4 tppt? -73.09 111.71 8.45 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.834 0.349 . . . . 2.42 110.27 -179.767 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.757 ' HB ' ' HG2' ' A' ' 316' ' ' LYS . 5.4 p -81.4 124.33 38.77 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 116.178 -0.464 . . . . 1.26 110.425 179.034 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 50.4 p90 -102.36 -32.23 10.11 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.908 -0.317 . . . . 0.55 111.323 -177.492 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -148.3 132.46 17.35 Favored 'General case' 0 CA--C 1.515 -0.38 0 N-CA-C 109.954 -0.387 . . . . 1.68 109.954 -179.203 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . 0.414 ' HD3' HG21 ' A' ' 322' ' ' VAL . 59.3 pttt -153.97 134.7 13.67 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.907 0.384 . . . . 1.99 111.449 -174.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 326' ' ' ASN . . . . . 0.635 ' HB2' ' HB2' ' A' ' 330' ' ' LYS . 3.9 p30 -146.66 117.08 7.45 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.697 0.76 . . . . 1.92 110.322 169.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 3.2 p -142.16 -40.83 0.35 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.909 -1.041 . . . . 1.69 110.363 179.205 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 21.1 pttp -80.51 101.93 9.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.331 0.586 . . . . 2.55 111.432 -178.731 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.514 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 76.04 -13.85 6.88 Favored Glycine 0 N--CA 1.452 -0.237 0 CA-C-N 115.616 -0.72 . . . . 0.97 113.633 175.212 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 330' ' ' LYS . . . . . 0.635 ' HB2' ' HB2' ' A' ' 326' ' ' ASN . 27.4 mmmt -103.76 101.52 25.11 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 117.305 0.552 . . . . 2.08 111.068 -178.025 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 331' ' ' PRO . . . . . 0.514 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 72.2 Cg_endo -87.83 126.59 2.14 Favored 'Trans proline' 0 N--CA 1.45 -1.042 0 C-N-CA 122.96 2.44 . . . . 0.62 111.826 172.647 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 65.4 t80 -100.04 118.89 37.37 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 110.092 -0.336 . . . . 0.64 110.092 179.376 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 333' ' ' VAL . . . . . 0.472 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 61.6 t -119.32 114.82 45.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 N-CA-C 110.119 -0.326 . . . . 0.38 110.119 -178.734 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.5 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 14.1 p90 -131.64 159.38 38.48 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.958 0.409 . . . . 0.41 110.201 -179.64 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 335' ' ' LYS . . . . . 0.462 ' HG3' ' HG3' ' A' ' 338' ' ' GLN . 18.2 pttm -99.72 128.92 45.81 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.902 -0.59 . . . . 2.58 110.346 177.336 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 10.0 mp -64.54 117.53 7.5 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.484 -0.561 . . . . 0.58 109.484 174.645 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 129.36 10.09 3.11 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.774 -0.727 . . . . 0.94 111.699 -172.027 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 338' ' ' GLN . . . . . 0.652 ' HB3' ' HG2' ' A' ' 340' ' ' GLU . 91.8 mt-30 -84.35 141.93 30.53 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.962 0.411 . . . . 2.62 110.62 176.111 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -96.11 -4.95 59.73 Favored Glycine 0 N--CA 1.448 -0.512 0 N-CA-C 110.857 -0.897 . . . . 0.74 110.857 175.194 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 340' ' ' GLU . . . . . 0.652 ' HG2' ' HB3' ' A' ' 338' ' ' GLN . 5.5 pt-20 -84.18 -20.15 32.87 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.078 -0.561 . . . . 2.09 110.984 179.21 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 33.4 m -94.06 154.92 3.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 109.524 -0.547 . . . . 0.43 109.524 174.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 13.4 pt -74.86 154.25 6.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 N-CA-C 110.034 -0.358 . . . . 0.32 110.034 179.24 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . 0.45 ' HA ' ' HE2' ' A' ' 343' ' ' LYS . 5.7 mmpt? -60.62 -30.69 70.01 Favored 'General case' 0 N--CA 1.464 0.258 0 N-CA-C 111.73 0.27 . . . . 2.93 111.73 -174.72 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -55.55 -28.44 51.33 Favored Glycine 0 CA--C 1.521 0.437 0 C-N-CA 121.14 -0.553 . . . . 0.3 112.884 174.387 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 8.4 m95 -82.26 -60.96 2.03 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 111.648 0.24 . . . . 0.39 111.648 178.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -48.49 -35.73 13.69 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 120.923 0.392 . . . . 1.75 111.73 177.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 62.1 mt -88.51 -51.89 11.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.163 -0.471 . . . . 0.39 111.756 179.139 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 348' ' ' GLY . . . . . 0.423 ' HA2' HD13 ' A' ' 286' ' ' LEU . . . -61.08 -36.34 92.17 Favored Glycine 0 C--N 1.331 0.301 0 C-N-CA 121.36 -0.448 . . . . 0.34 113.73 -176.797 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 88.6 t -73.66 -23.2 19.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 121.182 0.515 . . . . 0.32 110.775 -179.579 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -70.18 105.61 3.0 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.097 0.475 . . . . 0.47 110.512 179.357 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 120.9 -2.78 11.81 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.864 -0.684 . . . . 0.39 112.303 -176.794 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 352' ' ' MET . . . . . 0.451 ' HG2' ' HD2' ' A' ' 358' ' ' ARG . 69.1 mtp -82.13 144.41 30.77 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.905 0.353 . . . . 1.28 110.622 176.356 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 353' ' ' ALA . . . . . 0.463 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -108.57 147.99 30.97 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.879 -0.6 . . . . 0.55 110.682 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 85.7 t -57.7 117.71 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 121.121 0.486 . . . . 0.36 110.835 176.048 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 110.67 -27.15 11.58 Favored Glycine 0 N--CA 1.445 -0.752 0 N-CA-C 111.049 -0.82 . . . . 0.44 111.049 -176.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -73.99 139.21 25.76 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 121.3 -0.476 . . . . 0.3 112.744 -177.162 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 357' ' ' GLU . . . . . 0.709 ' HB2' ' HG3' ' A' ' 387' ' ' LYS . 36.6 tt0 -125.0 133.87 52.82 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 109.063 -0.718 . . . . 1.41 109.063 178.358 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 358' ' ' ARG . . . . . 0.561 ' HA ' ' HG2' ' A' ' 295' ' ' ARG . 8.0 ptp180 -155.44 143.89 20.31 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.66 0.743 . . . . 1.37 112.294 -178.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 359' ' ' ARG . . . . . 0.435 HH21 ' CD ' ' A' ' 293' ' ' GLU . 20.9 ttp85 -86.25 117.95 25.39 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 114.773 -1.103 . . . . 2.79 109.485 177.813 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 50.3 mt -99.73 121.81 50.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.729 -0.669 . . . . 0.38 110.235 -178.31 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 361' ' ' VAL . . . . . 0.582 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 47.7 t -102.45 113.35 38.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 N-CA-C 109.15 -0.685 . . . . 0.39 109.15 176.574 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 362' ' ' ILE . . . . . . . . . . . . . 62.1 mt -113.19 101.49 53.53 Favored Pre-proline 0 C--N 1.324 -0.514 0 CA-C-O 120.728 0.299 . . . . 0.29 110.987 -175.096 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 363' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -56.43 159.9 12.36 Favored 'Trans proline' 0 C--O 1.237 0.463 0 C-N-CA 122.571 2.181 . . . . 0.66 112.41 171.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 364' ' ' ALA . . . . . 0.546 ' HB2' ' HA ' ' A' ' 379' ' ' ASN . . . -47.72 -49.59 56.09 Favored Pre-proline 0 CA--C 1.539 0.547 0 N-CA-C 114.528 1.307 . . . . 0.42 114.528 -173.348 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 365' ' ' PRO . . . . . 0.531 ' HD2' ' N ' ' A' ' 364' ' ' ALA . 9.6 Cg_endo -51.03 -32.18 37.81 Favored 'Trans proline' 0 C--N 1.361 1.2 0 C-N-CA 122.567 2.178 . . . . 0.7 114.186 -172.832 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 366' ' ' TYR . . . . . 0.514 ' CE2' ' HA3' ' A' ' 288' ' ' GLY . 13.8 m-85 -100.52 12.13 37.97 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.831 -0.348 . . . . 0.69 111.841 -175.466 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -127.06 -109.6 0.3 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.441 -0.345 . . . . 0.86 110.907 174.799 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 78.8 m-85 -93.59 -15.83 25.0 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 111.977 0.362 . . . . 1.0 111.977 -179.723 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 64.82 -113.91 6.3 Favored Glycine 0 CA--C 1.52 0.388 0 C-N-CA 121.047 -0.597 . . . . 0.56 113.691 175.627 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 65.6 mttm -92.1 3.91 54.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.751 0.31 . . . . 2.76 111.525 -174.84 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -80.63 99.27 8.06 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.863 0.363 . . . . 2.65 111.638 -177.334 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 372' ' ' ALA . . . . . . . . . . . . . . . -78.29 92.48 4.52 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 115.952 -0.567 . . . . 1.01 109.908 171.362 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 30.5 mt -84.0 159.28 60.33 Favored Pre-proline 0 C--N 1.316 -0.885 0 CA-C-N 115.636 -0.711 . . . . 0.93 109.342 -179.686 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.55 113.0 1.43 Allowed 'Trans proline' 0 N--CA 1.461 -0.394 0 C-N-CA 121.507 1.472 . . . . 1.31 110.684 173.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 96.81 -29.92 9.74 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.809 -0.71 . . . . 0.9 112.533 -178.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 40.0 mt -125.95 88.94 53.38 Favored Pre-proline 0 C--N 1.332 -0.192 0 CA-C-N 116.772 0.286 . . . . 0.74 110.279 -179.242 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 377' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_exo -69.58 166.52 27.09 Favored 'Trans proline' 0 N--CA 1.463 -0.3 0 C-N-CA 122.596 2.198 . . . . 0.71 113.191 -178.355 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 378' ' ' ALA . . . . . . . . . . . . . . . -61.06 157.32 15.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.202 -0.908 . . . . 0.74 111.985 -176.771 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 379' ' ' ASN . . . . . 0.546 ' HA ' ' HB2' ' A' ' 364' ' ' ALA . 18.6 m120 65.69 23.16 11.59 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-N 115.377 -0.828 . . . . 1.49 111.113 177.798 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 59.6 p -66.72 116.43 7.62 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.003 -0.544 . . . . 1.84 111.134 179.501 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 381' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -80.37 98.55 7.52 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 108.971 -0.751 . . . . 1.03 108.971 174.541 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 92.6 mt -85.34 136.06 33.63 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.941 0.4 . . . . 0.37 111.248 -176.812 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 32.6 m -118.97 118.54 31.78 Favored 'General case' 0 N--CA 1.444 -0.734 0 N-CA-C 109.93 -0.396 . . . . 0.27 109.93 177.824 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -113.16 109.39 18.7 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.867 -0.42 . . . . 0.32 109.867 -177.204 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -87.39 104.88 16.85 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 108.034 -1.098 . . . . 1.8 108.034 176.636 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 386' ' ' VAL . . . . . 0.559 HG12 ' CB ' ' A' ' 313' ' ' TYR . 19.9 m -122.89 148.68 26.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 121.563 0.697 . . . . 0.31 112.382 -170.057 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 387' ' ' LYS . . . . . 0.709 ' HG3' ' HB2' ' A' ' 357' ' ' GLU . 46.5 tttm -137.39 129.91 29.83 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.402 -0.817 . . . . 2.53 109.652 176.128 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 388' ' ' LEU . . . . . 0.802 HD11 ' HB ' ' A' ' 309' ' ' VAL . 24.6 tp -89.58 134.55 34.08 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.776 -0.824 . . . . 0.28 108.776 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 27.5 m -129.36 -3.49 3.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 N-CA-C 112.251 0.463 . . . . 0.45 112.251 -174.064 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 10.2 t -168.5 156.67 8.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.69 0.281 . . . . 1.32 110.806 -177.506 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 391' ' ' MET . . . . . 0.499 ' HE2' HG12 ' A' ' 309' ' ' VAL . 40.5 ttm -156.33 155.26 31.93 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.229 -0.656 . . . . 0.56 109.229 174.401 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 392' ' ' LYS . . . . . 0.42 ' HE2' ' HB2' ' A' ' 392' ' ' LYS . 3.4 ptmm? . . . . . 0 C--O 1.25 1.123 0 CA-C-O 118.654 -0.689 . . . . 4.91 110.7 175.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.706 0 N-CA-C 112.105 -0.398 . . . . 11.17 112.105 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -145.91 104.63 3.87 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.979 0.419 . . . . 9.37 110.879 -179.112 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 278' ' ' MET . . . . . 0.426 ' HA ' ' CE ' ' A' ' 278' ' ' MET . 3.2 tpt -155.2 98.33 1.99 Allowed 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.07 -0.514 . . . . 7.67 109.993 176.501 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -142.39 100.63 3.74 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.095 -0.502 . . . . 6.37 110.977 179.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 54.0 mttp 70.83 140.82 0.08 OUTLIER Pre-proline 0 CA--C 1.535 0.375 0 O-C-N 123.862 0.726 . . . . 6.76 112.06 176.117 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -59.41 140.09 92.68 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 123.19 2.593 . . . . 4.8 112.693 -178.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 282' ' ' LYS . . . . . . . . . . . . . 63.3 mttm -131.94 109.09 9.81 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.703 -0.68 . . . . 3.46 110.537 -179.388 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 15.2 p -106.72 165.6 11.19 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.908 -0.587 . . . . 0.76 111.277 -178.884 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 284' ' ' LYS . . . . . 0.573 ' HB2' HG13 ' A' ' 292' ' ' ILE . 72.4 mmtt -130.12 135.94 48.76 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 109.213 -0.662 . . . . 2.06 109.213 179.723 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 31.1 tp -104.78 124.16 48.93 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 120.896 0.379 . . . . 0.98 110.138 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.786 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 76.7 mt -112.63 -175.21 2.62 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.578 -0.737 . . . . 0.8 109.813 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 2.6 tp10 -60.61 147.37 42.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.148 0.499 . . . . 2.64 111.336 -177.765 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.595 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 69.37 -1.77 12.17 Favored Glycine 0 N--CA 1.452 -0.297 0 CA-C-N 115.84 -0.618 . . . . 1.84 113.648 -179.892 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 97.6 14.8 39.51 Favored Glycine 0 N--CA 1.446 -0.681 0 C-N-CA 120.21 -0.995 . . . . 0.64 113.556 -179.274 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 290' ' ' ILE . . . . . 0.786 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 79.5 mt -64.16 122.57 15.31 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.167 0 CA-C-N 117.488 0.644 . . . . 0.42 110.507 176.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.557 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 80.2 mt -107.36 138.27 34.3 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 N-CA-C 110.355 -0.239 . . . . 0.93 110.355 177.08 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 292' ' ' ILE . . . . . 0.573 HG13 ' HB2' ' A' ' 284' ' ' LYS . 23.6 pt -127.02 130.85 71.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 N-CA-C 109.489 -0.56 . . . . 0.48 109.489 174.34 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 293' ' ' GLU . . . . . 0.415 ' CD ' HH21 ' A' ' 359' ' ' ARG . 34.3 tt0 -123.43 121.42 35.69 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 115.176 -0.92 . . . . 2.31 109.954 -177.139 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 51.9 m-20 -78.3 110.93 13.76 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.712 -0.477 . . . . 2.36 109.712 -176.637 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 295' ' ' ARG . . . . . . . . . . . . . 39.1 ttt180 -88.14 -58.24 2.64 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.832 -0.622 . . . . 3.5 110.499 -175.176 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.601 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 58.1 t -128.24 141.36 46.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 110.203 -0.295 . . . . 0.7 110.203 177.207 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 9.0 t -96.07 149.84 21.16 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.3 -0.409 . . . . 1.93 111.033 -178.197 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -152.93 -164.64 12.65 Favored Glycine 0 C--N 1.331 0.261 0 C-N-CA 121.428 -0.415 . . . . 1.04 112.174 -177.19 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . 0.572 ' O ' ' HB1' ' A' ' 353' ' ' ALA . 62.0 tttp -72.78 139.54 47.15 Favored 'General case' 0 CA--C 1.52 -0.211 0 N-CA-C 108.595 -0.891 . . . . 4.49 108.595 173.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -116.34 80.48 0.3 Allowed Glycine 0 N--CA 1.445 -0.756 0 C-N-CA 119.314 -1.422 . . . . 1.04 115.272 -170.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . 0.596 ' HD2' ' H ' ' A' ' 354' ' ' VAL . 8.2 Cg_exo -74.57 131.51 14.92 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.036 1.824 . . . . 0.88 108.145 159.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 302' ' ' HIS . . . . . 0.439 ' O ' ' HE3' ' A' ' 304' ' ' LYS . 27.4 m80 -85.91 107.35 17.67 Favored 'General case' 0 C--N 1.319 -0.731 0 C-N-CA 120.314 -0.554 . . . . 1.49 111.423 -169.093 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -66.33 109.08 2.55 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.703 -0.681 . . . . 0.54 110.375 175.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . 0.439 ' HE3' ' O ' ' A' ' 302' ' ' HIS . 11.5 ptpt -127.47 -174.44 3.18 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 116.326 -0.397 . . . . 2.84 110.161 -179.171 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.819 ' HG3' ' HA3' ' A' ' 337' ' ' GLY . 62.3 tttm -65.71 124.51 22.6 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.994 0.426 . . . . 2.84 111.019 -175.251 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 97.14 -11.24 65.71 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 121.075 -0.583 . . . . 0.7 112.81 -178.063 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 307' ' ' THR . . . . . 0.447 ' O ' ' HA ' ' A' ' 335' ' ' LYS . 28.4 m -82.92 142.8 31.16 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 122.881 -0.188 . . . . 0.4 110.524 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 22.6 ptt180 -106.78 116.03 31.22 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 121.306 0.574 . . . . 3.45 109.583 -178.234 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.783 ' HB ' HD11 ' A' ' 388' ' ' LEU . 31.1 m -113.69 147.8 17.0 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 115.644 -0.707 . . . . 0.34 111.918 -177.397 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -116.67 114.19 2.97 Favored Glycine 0 N--CA 1.443 -0.896 0 N-CA-C 110.126 -1.19 . . . . 0.27 110.126 174.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 311' ' ' MET . . . . . 0.478 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 6.9 ptm -131.65 177.68 7.33 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 121.897 0.856 . . . . 0.76 112.488 -172.283 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -138.07 150.31 46.78 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 113.726 -1.579 . . . . 2.51 107.794 177.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 313' ' ' TYR . . . . . 0.466 ' CB ' HG12 ' A' ' 386' ' ' VAL . 44.3 p90 -156.45 155.33 31.88 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 120.741 -0.384 . . . . 0.68 111.375 -169.74 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . 0.565 HG11 ' HE3' ' A' ' 316' ' ' LYS . 38.2 t -120.46 105.71 17.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-N 115.587 -0.733 . . . . 0.35 109.247 169.206 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -84.82 109.38 3.26 Favored Glycine 0 N--CA 1.445 -0.717 0 CA-C-N 116.088 -0.506 . . . . 0.28 112.168 -178.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 316' ' ' LYS . . . . . 0.765 ' HG2' HG22 ' A' ' 322' ' ' VAL . 93.6 mttt -123.32 161.05 25.42 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-N 114.929 -0.636 . . . . 1.94 110.464 -178.308 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 317' ' ' LEU . . . . . 0.493 HD12 ' HD3' ' A' ' 321' ' ' LYS . 83.6 mt -88.18 165.81 14.81 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 109.392 -0.596 . . . . 0.65 109.392 170.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 318' ' ' LYS . . . . . 0.907 ' HD2' ' HB3' ' A' ' 381' ' ' GLU . 0.2 OUTLIER -61.15 -19.37 61.46 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.31 -0.405 . . . . 2.42 111.633 179.844 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 319' ' ' ASN . . . . . 0.421 ' OD1' ' HB2' ' A' ' 317' ' ' LEU . 28.5 p-10 -90.41 -1.61 57.92 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 116.577 -0.283 . . . . 2.2 111.146 -178.575 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 94.5 6.8 60.86 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.505 -0.855 . . . . 0.69 113.11 177.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 321' ' ' LYS . . . . . 0.493 ' HD3' HD12 ' A' ' 317' ' ' LEU . 63.5 tttp -81.99 118.57 23.09 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.947 0.403 . . . . 2.42 110.472 177.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.765 HG22 ' HG2' ' A' ' 316' ' ' LYS . 12.6 t -85.56 129.78 37.39 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 116.115 -0.493 . . . . 1.26 109.948 179.381 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 32.3 p90 -111.48 -43.57 3.66 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 120.528 -0.469 . . . . 0.55 111.586 178.508 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -148.07 128.56 14.03 Favored 'General case' 0 CA--C 1.514 -0.431 0 C-N-CA 120.507 -0.477 . . . . 1.68 110.958 -177.658 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . 0.553 ' HE3' HG11 ' A' ' 322' ' ' VAL . 8.4 pttp -145.75 128.31 16.08 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.092 0.472 . . . . 1.99 110.88 -179.05 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 55.6 m-80 -125.25 116.49 22.06 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.544 -0.753 . . . . 1.92 109.055 173.605 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 26.3 m -157.0 -38.89 0.07 Allowed 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.675 -0.693 . . . . 1.69 110.155 -177.202 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 29.6 mmmt -75.18 92.74 2.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.788 -0.642 . . . . 2.55 110.372 179.589 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.454 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 75.1 -17.7 2.86 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 121.245 -0.502 . . . . 0.97 113.606 177.491 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 82.4 mttt -103.37 103.26 34.26 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 117.001 0.401 . . . . 2.08 111.571 -175.433 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 331' ' ' PRO . . . . . 0.454 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 98.3 Cg_endo -87.91 145.83 6.6 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 122.825 2.35 . . . . 0.62 112.167 171.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 72.3 t80 -111.15 119.51 39.2 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.364 -0.606 . . . . 0.64 109.364 175.526 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 46.7 t -111.64 126.3 69.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 120.648 0.261 . . . . 0.38 110.842 -177.236 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.66 ' HB2' HE22 ' A' ' 338' ' ' GLN . 28.4 p90 -153.54 169.19 23.81 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.34 -0.391 . . . . 0.41 110.2 178.415 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 335' ' ' LYS . . . . . 0.49 ' HE2' ' HB3' ' A' ' 338' ' ' GLN . 0.0 OUTLIER -112.77 146.22 39.18 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.152 0.501 . . . . 2.58 111.418 177.201 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 10.9 mp -78.35 150.89 33.12 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.853 -0.612 . . . . 0.58 110.262 177.661 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 337' ' ' GLY . . . . . 0.819 ' HA3' ' HG3' ' A' ' 305' ' ' LYS . . . 89.12 27.14 24.19 Favored Glycine 0 N--CA 1.445 -0.706 0 C-N-CA 120.739 -0.743 . . . . 0.94 112.459 -177.409 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 338' ' ' GLN . . . . . 0.66 HE22 ' HB2' ' A' ' 334' ' ' PHE . 30.2 pt20 -118.97 163.06 17.5 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 110.085 -0.339 . . . . 2.62 110.085 176.406 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -93.6 2.84 70.79 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.952 -0.642 . . . . 0.74 112.329 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -76.43 -24.78 53.96 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.948 0.404 . . . . 2.09 110.876 -178.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 31.0 m -108.74 152.66 10.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.241 -0.436 . . . . 0.43 110.755 -178.734 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 342' ' ' ILE . . . . . 0.502 ' HB ' ' HA ' ' A' ' 367' ' ' ALA . 14.8 pt -70.52 156.24 7.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.858 -0.423 . . . . 0.32 109.858 178.457 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -64.48 -32.61 74.32 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.626 -0.261 . . . . 2.93 111.396 -175.386 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -53.41 -41.86 63.88 Favored Glycine 0 CA--C 1.523 0.561 0 C-N-CA 120.613 -0.803 . . . . 0.3 112.16 173.462 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 7.8 m95 -70.51 -58.42 3.73 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.75 0.309 . . . . 0.39 110.489 175.474 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -49.49 -32.27 11.78 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 115.877 -0.601 . . . . 1.75 112.355 -179.308 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 69.2 mt -89.17 -53.21 9.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.501 -0.318 . . . . 0.39 111.789 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -64.32 -32.93 85.82 Favored Glycine 0 C--N 1.332 0.307 0 C-N-CA 121.189 -0.529 . . . . 0.34 113.664 -177.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 89.8 t -78.44 -16.33 13.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.988 0.423 . . . . 0.32 111.035 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.01 106.41 1.25 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.235 0.541 . . . . 0.47 110.241 178.592 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 98.31 22.33 15.1 Favored Glycine 0 N--CA 1.444 -0.787 0 CA-C-N 115.6 -0.727 . . . . 0.39 112.577 -178.234 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 352' ' ' MET . . . . . . . . . . . . . 64.1 mmm -69.22 173.38 5.73 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.562 0.22 . . . . 1.28 110.636 173.308 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 353' ' ' ALA . . . . . 0.572 ' HB1' ' O ' ' A' ' 299' ' ' LYS . . . -135.71 136.61 40.99 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.107 -0.497 . . . . 0.55 111.05 -177.605 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 354' ' ' VAL . . . . . 0.596 ' H ' ' HD2' ' A' ' 301' ' ' PRO . 59.4 t -65.76 112.05 1.75 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.202 0 CA-C-O 121.436 0.636 . . . . 0.36 109.923 174.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 104.56 -24.16 29.45 Favored Glycine 0 N--CA 1.439 -1.134 0 N-CA-C 110.134 -1.186 . . . . 0.44 110.134 -172.7 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -73.85 145.66 35.59 Favored Glycine 0 N--CA 1.444 -0.793 0 N-CA-C 112.04 -0.424 . . . . 0.3 112.04 179.874 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 357' ' ' GLU . . . . . 0.724 ' HG3' ' HB2' ' A' ' 387' ' ' LYS . 34.0 tt0 -135.75 131.54 35.68 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 108.238 -1.023 . . . . 1.41 108.238 -173.227 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 358' ' ' ARG . . . . . . . . . . . . . 2.1 ptp180 -154.86 148.22 25.06 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.369 0.604 . . . . 1.37 112.495 -177.745 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 359' ' ' ARG . . . . . 0.415 HH21 ' CD ' ' A' ' 293' ' ' GLU . 14.8 ttp180 -89.21 114.76 26.11 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.377 -0.829 . . . . 2.79 109.817 176.502 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 65.4 mt -102.67 118.72 49.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 109.955 -0.387 . . . . 0.38 109.955 179.087 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 361' ' ' VAL . . . . . 0.557 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 41.8 t -101.19 111.15 29.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 109.209 -0.663 . . . . 0.39 109.209 179.63 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 362' ' ' ILE . . . . . 0.482 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 60.4 mt -108.09 112.48 61.47 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-O 120.985 0.421 . . . . 0.29 111.531 -171.402 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 363' ' ' PRO . . . . . 0.557 ' HD2' HG12 ' A' ' 290' ' ' ILE . 33.7 Cg_endo -64.19 155.34 65.73 Favored 'Trans proline' 0 C--O 1.235 0.356 0 C-N-CA 122.902 2.401 . . . . 0.66 111.791 175.153 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 364' ' ' ALA . . . . . 0.424 ' CB ' ' HA ' ' A' ' 379' ' ' ASN . . . -51.16 -49.5 81.05 Favored Pre-proline 0 CA--C 1.541 0.598 0 N-CA-C 114.14 1.163 . . . . 0.42 114.14 -174.775 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 365' ' ' PRO . . . . . 0.474 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 32.2 Cg_exo -59.0 -24.41 73.22 Favored 'Trans proline' 0 C--N 1.362 1.274 0 C-N-CA 122.176 1.917 . . . . 0.7 113.671 -173.056 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 366' ' ' TYR . . . . . 0.595 ' CE2' ' HA3' ' A' ' 288' ' ' GLY . 5.4 m-85 -100.27 10.74 40.79 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.048 0.452 . . . . 0.69 111.385 -176.707 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 367' ' ' ALA . . . . . 0.502 ' HA ' ' HB ' ' A' ' 342' ' ' ILE . . . -122.24 -106.04 0.37 Allowed 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.903 -0.59 . . . . 0.86 110.406 174.191 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 368' ' ' TYR . . . . . 0.473 ' HB3' ' HB3' ' A' ' 371' ' ' GLN . 96.4 m-85 -92.42 -16.12 26.31 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.642 0.258 . . . . 1.0 111.52 178.38 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 68.53 -110.73 3.56 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.911 -0.661 . . . . 0.56 112.669 178.525 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 370' ' ' LYS . . . . . 0.419 ' HA ' ' HB1' ' A' ' 378' ' ' ALA . 48.9 mtpt -101.27 10.18 40.96 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.766 0.317 . . . . 2.76 111.174 -177.538 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 371' ' ' GLN . . . . . 0.473 ' HB3' ' HB3' ' A' ' 368' ' ' TYR . 64.5 tt0 -82.58 100.97 10.46 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 120.864 0.364 . . . . 2.65 110.572 178.656 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 372' ' ' ALA . . . . . 0.605 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -78.84 107.9 11.89 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.264 -0.426 . . . . 1.01 111.295 178.602 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 83.6 mt -102.47 161.81 22.14 Favored Pre-proline 0 C--N 1.32 -0.691 0 N-CA-C 109.403 -0.592 . . . . 0.93 109.403 174.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_endo -64.27 114.61 2.74 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 121.592 1.528 . . . . 1.31 110.929 172.452 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 96.2 -28.58 12.41 Favored Glycine 0 CA--C 1.521 0.466 0 C-N-CA 120.89 -0.671 . . . . 0.9 112.225 -176.665 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 376' ' ' ILE . . . . . 0.547 HG23 HD21 ' A' ' 382' ' ' LEU . 23.0 mt -130.74 77.62 75.27 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 120.701 0.286 . . . . 0.74 110.303 179.137 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 377' ' ' PRO . . . . . 0.605 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 73.5 Cg_endo -77.77 167.86 23.26 Favored 'Trans proline' 0 N--CA 1.461 -0.395 0 C-N-CA 122.38 2.054 . . . . 0.71 112.805 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 378' ' ' ALA . . . . . 0.419 ' HB1' ' HA ' ' A' ' 370' ' ' LYS . . . -53.07 143.2 18.11 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 116.055 -0.52 . . . . 0.74 111.979 -179.72 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 379' ' ' ASN . . . . . 0.424 ' HA ' ' CB ' ' A' ' 364' ' ' ALA . 12.3 m120 67.95 19.92 9.31 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 115.556 -0.747 . . . . 1.49 112.286 176.356 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 67.1 m -87.2 131.63 34.13 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.332 0.587 . . . . 1.84 111.232 176.55 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 381' ' ' GLU . . . . . 0.907 ' HB3' ' HD2' ' A' ' 318' ' ' LYS . 34.1 tt0 -84.71 112.86 20.86 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.999 -1.0 . . . . 1.03 109.93 178.33 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 382' ' ' LEU . . . . . 0.547 HD21 HG23 ' A' ' 376' ' ' ILE . 91.5 mt -89.67 139.49 30.51 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.334 -0.394 . . . . 0.37 110.243 179.765 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 37.8 m -119.33 119.12 33.07 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.322 -0.621 . . . . 0.27 109.322 176.553 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -115.13 109.88 18.68 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 121.124 0.488 . . . . 0.32 110.444 -177.213 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -87.52 106.92 18.32 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 108.149 -1.056 . . . . 1.8 108.149 174.113 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 386' ' ' VAL . . . . . 0.466 HG12 ' CB ' ' A' ' 313' ' ' TYR . 29.6 m -122.9 148.37 26.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.621 0.724 . . . . 0.31 112.123 -168.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 387' ' ' LYS . . . . . 0.724 ' HB2' ' HG3' ' A' ' 357' ' ' GLU . 40.7 tttp -139.05 132.96 30.98 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.74 -1.118 . . . . 2.53 109.317 175.222 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 388' ' ' LEU . . . . . 0.783 HD11 ' HB ' ' A' ' 309' ' ' VAL . 30.6 tp -91.98 131.62 37.14 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 108.666 -0.864 . . . . 0.28 108.666 -179.178 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 28.9 m -120.01 -4.39 9.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 112.232 0.456 . . . . 0.45 112.232 -173.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 11.3 t -170.51 152.06 3.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.968 0.413 . . . . 1.32 111.154 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 391' ' ' MET . . . . . 0.62 ' HE2' HG12 ' A' ' 309' ' ' VAL . 31.6 ttm -157.25 147.47 20.94 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.747 -0.661 . . . . 0.56 109.497 174.626 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 20.8 tptm . . . . . 0 C--O 1.248 0.992 0 CA-C-O 117.88 -1.057 . . . . 4.91 111.438 173.471 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.764 0 N-CA-C 111.847 -0.501 . . . . 11.17 111.847 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -87.77 -10.16 51.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.48 0.181 . . . . 9.37 111.371 -177.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 278' ' ' MET . . . . . 0.465 ' O ' ' HG3' ' A' ' 280' ' ' LYS . 45.2 mtm 69.06 -1.93 1.95 Allowed 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 123.14 0.576 . . . . 7.67 111.357 178.173 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . 63.23 18.55 11.06 Favored 'General case' 0 N--CA 1.463 0.204 0 C-N-CA 123.097 0.559 . . . . 6.37 111.302 -176.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . 0.465 ' HG3' ' O ' ' A' ' 278' ' ' MET . 28.1 mtpp -120.17 144.08 37.06 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 120.613 0.244 . . . . 6.76 110.637 -177.036 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 281' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 280' ' ' LYS . 25.8 Cg_exo -63.38 155.42 62.23 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.978 2.452 . . . . 4.8 113.286 -177.862 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 282' ' ' LYS . . . . . . . . . . . . . 58.6 mttm -96.11 107.31 19.6 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.807 -0.633 . . . . 3.46 111.001 -178.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.963 HG22 ' HG2' ' A' ' 293' ' ' GLU . 31.6 p -109.74 126.36 53.65 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 110.21 -0.292 . . . . 0.76 110.21 173.226 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 284' ' ' LYS . . . . . 0.457 ' HB2' HG13 ' A' ' 292' ' ' ILE . 23.8 mmtp -122.03 146.99 46.64 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.94 0.4 . . . . 2.06 111.115 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 40.3 tp -103.97 121.17 42.58 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.542 -0.754 . . . . 0.98 110.242 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.565 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 94.9 mt -101.78 -169.5 1.69 Allowed 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.978 -0.555 . . . . 0.8 110.407 178.048 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -68.37 146.58 53.12 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.702 -0.681 . . . . 2.64 110.154 -179.651 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 73.71 10.63 80.23 Favored Glycine 0 CA--C 1.517 0.163 0 C-N-CA 121.102 -0.571 . . . . 1.84 113.687 178.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 81.44 16.84 72.69 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.63 -0.795 . . . . 0.64 112.596 178.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 290' ' ' ILE . . . . . 0.565 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 84.1 mt -69.64 125.76 28.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 N-CA-C 109.94 -0.393 . . . . 0.42 109.94 177.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.68 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 20.1 mt -104.14 134.91 44.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 N-CA-C 109.286 -0.635 . . . . 0.93 109.286 179.386 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 292' ' ' ILE . . . . . 0.457 HG13 ' HB2' ' A' ' 284' ' ' LYS . 18.2 pt -124.13 127.14 73.24 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 CA-C-O 121.112 0.482 . . . . 0.48 110.172 177.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 293' ' ' GLU . . . . . 0.963 ' HG2' HG22 ' A' ' 283' ' ' THR . 29.4 mt-10 -117.94 114.35 23.07 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.499 -0.773 . . . . 2.31 109.469 -179.812 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . 0.477 ' C ' ' HE ' ' A' ' 295' ' ' ARG . 8.2 t70 -80.15 135.09 36.22 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 109.255 -0.646 . . . . 2.36 109.255 -175.383 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 295' ' ' ARG . . . . . 0.584 ' HG2' ' HA ' ' A' ' 358' ' ' ARG . 1.7 mmp_? -105.76 -60.3 1.65 Allowed 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 110.02 -0.363 . . . . 3.5 110.02 -175.175 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . . . . . . . . . 84.0 t -122.2 109.98 25.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 116.039 -0.528 . . . . 0.7 109.594 174.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 18.1 p -61.93 109.24 1.2 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.522 -0.763 . . . . 1.93 111.405 -177.392 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -101.2 171.38 22.32 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.669 -0.776 . . . . 1.04 112.033 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 8.0 tmtm? -145.69 110.58 5.18 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.297 -0.631 . . . . 4.49 109.297 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -172.24 -154.25 9.96 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.78 -0.724 . . . . 1.04 111.713 -178.596 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . 0.731 ' HD2' ' HB ' ' A' ' 354' ' ' VAL . 24.0 Cg_exo -64.46 134.34 41.16 Favored 'Trans proline' 0 C--O 1.232 0.192 0 C-N-CA 123.129 2.553 . . . . 0.88 112.342 177.28 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 44.4 m-70 -98.32 132.25 43.95 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.317 -0.401 . . . . 1.49 110.048 179.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -81.3 143.26 32.37 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 112.487 0.551 . . . . 0.54 112.487 -176.009 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -127.26 -178.85 4.6 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.657 -0.701 . . . . 2.84 110.041 174.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.81 ' HG3' ' HA3' ' A' ' 337' ' ' GLY . 46.7 tttm -68.47 135.49 51.74 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.864 0.364 . . . . 2.84 110.342 175.218 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 93.13 -17.83 57.46 Favored Glycine 0 N--CA 1.451 -0.318 0 CA-C-N 116.107 -0.497 . . . . 0.7 112.257 -176.517 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 27.0 m -74.83 142.53 44.18 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.729 0.3 . . . . 0.4 110.679 -179.236 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 22.0 mtm180 -104.61 103.73 13.44 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 109.04 -0.726 . . . . 3.45 109.04 178.58 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.831 ' HB ' HD11 ' A' ' 388' ' ' LEU . 28.4 m -104.35 145.36 13.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 CA-C-N 116.011 -0.54 . . . . 0.34 111.567 -177.569 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -111.51 120.68 5.5 Favored Glycine 0 N--CA 1.445 -0.739 0 N-CA-C 109.709 -1.356 . . . . 0.27 109.709 176.405 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 311' ' ' MET . . . . . 0.543 ' CE ' ' HB ' ' A' ' 386' ' ' VAL . 22.0 ptm -136.44 176.79 8.38 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.591 0.71 . . . . 0.76 112.309 -169.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 312' ' ' ARG . . . . . 0.539 ' HD2' ' HA ' ' A' ' 327' ' ' THR . 12.5 mmt-85 -127.57 151.09 49.34 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 107.303 -1.369 . . . . 2.51 107.303 172.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 313' ' ' TYR . . . . . 0.474 ' CB ' HG12 ' A' ' 386' ' ' VAL . 51.3 p90 -167.04 158.53 12.39 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.326 0.584 . . . . 0.68 111.953 -176.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . 0.445 HG12 ' HG3' ' A' ' 316' ' ' LYS . 42.6 t -123.15 112.32 33.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.124 -0.944 . . . . 0.35 109.559 174.131 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -84.73 105.51 2.86 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 121.073 -0.585 . . . . 0.28 111.942 -177.661 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 316' ' ' LYS . . . . . 0.504 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 45.8 mtmt -119.31 154.35 33.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.143 0.497 . . . . 1.94 111.681 -176.225 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 78.3 mt -91.15 160.56 15.5 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.811 -0.631 . . . . 0.65 109.97 176.152 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 318' ' ' LYS . . . . . 0.665 ' HD2' ' HB3' ' A' ' 381' ' ' GLU . 85.3 tttt -62.4 -18.45 61.64 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-O 121.345 0.593 . . . . 2.42 110.138 175.603 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -79.61 -2.03 40.72 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 115.566 -0.743 . . . . 2.2 110.788 179.623 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 89.96 -2.91 82.44 Favored Glycine 0 C--N 1.329 0.178 0 C-N-CA 120.648 -0.787 . . . . 0.69 112.795 177.364 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -93.83 128.37 40.06 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.691 0.281 . . . . 2.42 110.587 -179.073 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.504 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 7.1 p -85.41 136.64 22.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 116.249 -0.432 . . . . 1.26 110.277 177.144 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 42.5 p90 -108.24 -35.67 6.49 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 120.791 -0.364 . . . . 0.55 111.36 -179.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -147.05 162.28 39.12 Favored 'General case' 0 N--CA 1.464 0.261 0 C-N-CA 120.976 -0.289 . . . . 1.68 110.569 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 3.7 ptpp? -164.55 138.72 5.29 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.76 0.314 . . . . 1.99 111.323 -177.136 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 55.0 m-80 -140.58 117.12 10.82 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 108.798 -0.815 . . . . 1.92 108.798 173.56 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 327' ' ' THR . . . . . 0.539 ' HA ' ' HD2' ' A' ' 312' ' ' ARG . 5.2 t -160.73 -49.44 0.05 OUTLIER 'General case' 0 C--N 1.324 -0.5 0 C-N-CA 120.859 -0.337 . . . . 1.69 111.726 -177.16 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 19.9 pttp -94.77 104.94 16.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.364 0.602 . . . . 2.55 110.839 -178.218 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.421 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 87.94 -29.61 5.42 Favored Glycine 0 N--CA 1.45 -0.394 0 CA-C-N 115.409 -0.814 . . . . 0.97 112.756 177.49 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 92.3 mttt -102.09 106.49 48.2 Favored Pre-proline 0 C--N 1.326 -0.428 0 CA-C-O 120.735 0.302 . . . . 2.08 111.335 -176.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 331' ' ' PRO . . . . . 0.421 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 80.3 Cg_endo -87.31 125.72 2.21 Favored 'Trans proline' 0 N--CA 1.448 -1.167 0 C-N-CA 122.765 2.31 . . . . 0.62 111.405 173.126 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 64.7 t80 -103.66 114.36 28.56 Favored 'General case' 0 C--N 1.318 -0.777 0 C-N-CA 120.677 -0.409 . . . . 0.64 110.002 179.43 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 333' ' ' VAL . . . . . 0.468 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 58.4 t -115.86 122.61 69.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.767 -0.651 . . . . 0.38 109.868 -178.57 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.466 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 13.2 p90 -138.19 165.87 25.6 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.945 0.403 . . . . 0.41 110.229 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 335' ' ' LYS . . . . . 0.548 ' HG3' ' HG3' ' A' ' 338' ' ' GLN . 21.4 pttm -110.08 129.44 55.69 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.977 -0.556 . . . . 2.58 110.608 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 9.6 mp -72.44 146.52 46.87 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.849 -0.614 . . . . 0.58 111.732 -178.704 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 337' ' ' GLY . . . . . 0.81 ' HA3' ' HG3' ' A' ' 305' ' ' LYS . . . 88.44 25.05 31.75 Favored Glycine 0 N--CA 1.447 -0.614 0 CA-C-N 115.632 -0.713 . . . . 0.94 112.769 170.614 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 338' ' ' GLN . . . . . 0.548 ' HG3' ' HG3' ' A' ' 335' ' ' LYS . 48.3 mm-40 -123.09 149.47 44.41 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.732 -0.47 . . . . 2.62 109.732 -179.458 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -78.49 43.3 2.31 Favored Glycine 0 CA--C 1.518 0.279 0 C-N-CA 120.875 -0.678 . . . . 0.74 112.786 178.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 340' ' ' GLU . . . . . 0.516 ' HG2' ' HB2' ' A' ' 338' ' ' GLN . 10.4 pt-20 -122.29 -3.21 8.97 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.153 0.502 . . . . 2.09 110.087 175.647 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 23.9 m -128.49 166.51 25.63 Favored 'Isoleucine or valine' 0 C--O 1.233 0.229 0 CA-C-N 115.47 -0.787 . . . . 0.43 109.057 174.335 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 342' ' ' ILE . . . . . 0.739 ' HB ' ' HA ' ' A' ' 367' ' ' ALA . 14.0 pt -82.63 154.35 3.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.325 -0.62 . . . . 0.32 109.325 176.397 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . 0.424 ' HA ' ' OD2' ' A' ' 346' ' ' ASP . 6.9 mtmm -65.93 -31.39 72.29 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 111.78 0.289 . . . . 2.93 111.78 -172.355 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 344' ' ' GLY . . . . . 0.548 ' HA2' HD13 ' A' ' 290' ' ' ILE . . . -54.39 -32.0 51.63 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.69 -0.766 . . . . 0.3 111.851 173.031 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 7.2 m95 -76.03 -55.63 5.42 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 111.847 0.314 . . . . 0.39 111.847 177.367 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 346' ' ' ASP . . . . . 0.424 ' OD2' ' HA ' ' A' ' 343' ' ' LYS . 0.1 OUTLIER -64.75 -24.32 67.53 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 122.186 -0.321 . . . . 1.75 111.603 -174.844 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 56.8 mt -89.8 -49.4 13.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.631 -0.259 . . . . 0.39 111.029 176.546 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -61.49 -36.57 92.76 Favored Glycine 0 CA--C 1.52 0.387 0 C-N-CA 120.982 -0.628 . . . . 0.34 113.171 179.345 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 349' ' ' VAL . . . . . 0.489 ' O ' ' HB2' ' A' ' 352' ' ' MET . 95.4 t -78.79 -14.16 13.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.115 0.484 . . . . 0.32 110.934 178.602 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -69.87 120.56 15.78 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 109.471 -0.566 . . . . 0.47 109.471 176.242 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 85.45 14.05 69.25 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.865 -0.684 . . . . 0.39 112.023 -176.591 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 352' ' ' MET . . . . . 0.489 ' HB2' ' O ' ' A' ' 349' ' ' VAL . 0.0 OUTLIER -81.01 137.0 36.07 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 108.867 -0.79 . . . . 1.28 108.867 176.442 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 353' ' ' ALA . . . . . 0.453 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -109.28 130.56 55.49 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.982 0.42 . . . . 0.55 111.097 -174.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 354' ' ' VAL . . . . . 0.731 ' HB ' ' HD2' ' A' ' 301' ' ' PRO . 95.8 t -54.23 121.03 2.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.906 -0.588 . . . . 0.36 111.306 176.686 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 107.52 -8.73 37.74 Favored Glycine 0 N--CA 1.444 -0.797 0 CA-C-N 115.73 -0.668 . . . . 0.44 112.152 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -100.97 154.9 19.22 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.836 -0.697 . . . . 0.3 112.571 -178.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 357' ' ' GLU . . . . . 0.667 ' HG2' ' HD2' ' A' ' 387' ' ' LYS . 54.0 mt-10 -122.5 130.76 53.39 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.443 -0.577 . . . . 1.41 109.443 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 358' ' ' ARG . . . . . 0.584 ' HA ' ' HG2' ' A' ' 295' ' ' ARG . 4.1 ptp180 -156.06 142.24 18.29 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.232 0.539 . . . . 1.37 111.094 176.522 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 359' ' ' ARG . . . . . . . . . . . . . 53.9 ttp180 -93.31 133.63 36.35 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.508 -0.769 . . . . 2.79 109.82 -178.86 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 38.8 mt -110.16 119.86 60.01 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-N 116.168 -0.469 . . . . 0.38 110.24 -179.418 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 361' ' ' VAL . . . . . 0.68 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 45.6 t -98.87 112.76 31.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 108.616 -0.883 . . . . 0.39 108.616 176.316 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 362' ' ' ILE . . . . . 0.449 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 54.4 mt -112.83 108.0 54.07 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-O 120.7 0.286 . . . . 0.29 111.441 -172.127 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 363' ' ' PRO . . . . . 0.631 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 19.4 Cg_endo -59.36 152.09 63.36 Favored 'Trans proline' 0 C--O 1.235 0.35 0 C-N-CA 122.564 2.176 . . . . 0.66 111.771 170.798 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 364' ' ' ALA . . . . . . . . . . . . . . . -48.43 -46.8 69.47 Favored Pre-proline 0 CA--C 1.544 0.718 0 N-CA-C 114.077 1.14 . . . . 0.42 114.077 -176.544 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 365' ' ' PRO . . . . . 0.631 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 83.7 Cg_exo -49.24 -36.55 37.5 Favored 'Trans proline' 0 C--N 1.361 1.19 0 C-N-CA 122.687 2.258 . . . . 0.7 114.068 -177.134 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 366' ' ' TYR . . . . . 0.471 ' HD1' HD11 ' A' ' 290' ' ' ILE . 2.9 m-85 -101.4 8.5 42.18 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.797 -0.361 . . . . 0.69 111.158 -176.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 367' ' ' ALA . . . . . 0.739 ' HA ' ' HB ' ' A' ' 342' ' ' ILE . . . -110.76 -119.3 0.29 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.162 -0.472 . . . . 0.86 109.973 175.107 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 82.6 m-85 -86.92 5.9 34.69 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 121.081 0.467 . . . . 1.0 111.238 178.245 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 67.05 -109.06 2.7 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.909 -0.587 . . . . 0.56 112.352 176.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 20.3 pttm -120.71 15.58 11.86 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.774 0.321 . . . . 2.76 110.963 -178.823 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 8.7 tp-100 -83.18 106.99 15.43 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.947 0.403 . . . . 2.65 110.149 178.267 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 372' ' ' ALA . . . . . 0.555 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -75.38 102.03 4.98 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 116.034 -0.53 . . . . 1.01 110.918 179.606 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 76.5 mt -88.9 163.83 33.55 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.706 -0.679 . . . . 0.93 109.254 177.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -61.77 113.98 2.07 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 121.594 1.529 . . . . 1.31 110.69 173.283 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 93.39 -26.66 14.53 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.83 -0.7 . . . . 0.9 112.754 -177.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 376' ' ' ILE . . . . . 0.448 HG23 HD21 ' A' ' 382' ' ' LEU . 39.6 mt -126.5 81.92 67.29 Favored Pre-proline 0 CA--C 1.532 0.288 0 CA-C-O 120.86 0.362 . . . . 0.74 110.978 -178.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 377' ' ' PRO . . . . . 0.555 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 56.1 Cg_endo -76.77 167.58 25.09 Favored 'Trans proline' 0 N--CA 1.459 -0.537 0 C-N-CA 122.413 2.075 . . . . 0.71 112.457 178.126 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 378' ' ' ALA . . . . . . . . . . . . . . . -54.51 145.89 17.51 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.804 -0.635 . . . . 0.74 111.488 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 379' ' ' ASN . . . . . . . . . . . . . 52.5 m-80 73.05 14.25 4.73 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 115.747 -0.661 . . . . 1.49 112.147 176.613 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 66.5 m -78.97 115.03 18.4 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.258 0.551 . . . . 1.84 110.45 175.645 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 381' ' ' GLU . . . . . 0.665 ' HB3' ' HD2' ' A' ' 318' ' ' LYS . 33.0 tt0 -74.33 101.47 4.07 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.421 -0.809 . . . . 1.03 108.865 177.38 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 382' ' ' LEU . . . . . 0.448 HD21 HG23 ' A' ' 376' ' ' ILE . 79.4 mt -85.47 142.07 29.48 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 120.714 0.293 . . . . 0.37 110.897 -174.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 18.8 m -121.89 117.22 25.94 Favored 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 109.732 -0.47 . . . . 0.27 109.732 178.706 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 384' ' ' PHE . . . . . 0.415 ' CD2' HD12 ' A' ' 362' ' ' ILE . 82.5 m-85 -112.67 109.94 19.77 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 121.094 0.474 . . . . 0.32 110.067 -176.81 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -88.5 105.13 17.42 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 108.667 -0.864 . . . . 1.8 108.667 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 386' ' ' VAL . . . . . 0.543 ' HB ' ' CE ' ' A' ' 311' ' ' MET . 12.3 m -124.8 152.07 30.77 Favored 'Isoleucine or valine' 0 C--O 1.235 0.341 0 CA-C-O 121.756 0.788 . . . . 0.31 112.832 -167.208 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 387' ' ' LYS . . . . . 0.667 ' HD2' ' HG2' ' A' ' 357' ' ' GLU . 71.6 tttt -143.7 136.38 27.27 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.1 -0.955 . . . . 2.53 109.583 174.541 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 388' ' ' LEU . . . . . 0.831 HD11 ' HB ' ' A' ' 309' ' ' VAL . 30.7 tp -95.94 131.2 42.55 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.729 -0.471 . . . . 0.28 109.729 -177.487 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 32.9 m -122.16 -8.96 8.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 N-CA-C 112.226 0.454 . . . . 0.45 112.226 -174.202 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 13.9 p -166.94 161.18 14.91 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.003 0.43 . . . . 1.32 111.852 -176.013 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 391' ' ' MET . . . . . 0.587 ' HG2' ' HG2' ' A' ' 392' ' ' LYS . 29.9 ttm -151.51 143.37 23.79 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.403 -0.817 . . . . 0.56 109.428 176.678 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 392' ' ' LYS . . . . . 0.587 ' HG2' ' HG2' ' A' ' 391' ' ' MET . 19.4 pttp . . . . . 0 C--O 1.248 0.989 0 CA-C-O 117.888 -1.054 . . . . 4.91 112.369 179.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.873 0 N-CA-C 112.08 -0.408 . . . . 11.17 112.08 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . 57.46 87.14 0.07 Allowed 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 122.996 0.518 . . . . 9.37 111.62 -178.624 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 278' ' ' MET . . . . . . . . . . . . . 23.4 ptm -78.8 131.54 36.54 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.203 -0.453 . . . . 7.67 110.795 -176.233 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -110.46 118.29 35.88 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.184 -0.462 . . . . 6.37 110.232 176.251 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 40.8 ttmt 69.65 90.94 0.08 OUTLIER Pre-proline 0 C--O 1.237 0.435 0 O-C-N 123.728 0.642 . . . . 6.76 110.579 -179.774 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -64.61 136.05 48.21 Favored 'Trans proline' 0 C--N 1.349 0.557 0 C-N-CA 123.124 2.549 . . . . 4.8 112.274 -178.452 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 282' ' ' LYS . . . . . . . . . . . . . 39.8 mmtm -93.89 80.38 4.16 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.054 0.454 . . . . 3.46 110.465 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.432 HG22 ' HB3' ' A' ' 293' ' ' GLU . 17.9 p -93.71 132.53 37.97 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 115.703 -0.68 . . . . 0.76 111.081 -179.765 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 15.1 ptpt -140.68 146.18 37.51 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.2 -0.455 . . . . 2.06 110.959 176.527 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . 0.54 HD11 ' HA2' ' A' ' 289' ' ' GLY . 22.1 tp -89.5 129.41 35.99 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.294 -0.866 . . . . 0.98 111.292 -175.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.545 HD11 HD13 ' A' ' 292' ' ' ILE . 81.7 mt -105.62 -166.71 1.24 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.975 -0.557 . . . . 0.8 110.284 175.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 287' ' ' GLU . . . . . 0.526 ' HG3' ' OH ' ' A' ' 366' ' ' TYR . 8.2 tp10 -51.11 142.0 13.23 Favored 'General case' 0 C--O 1.234 0.28 0 O-C-N 123.706 0.629 . . . . 2.64 111.557 -179.832 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 72.67 -99.63 0.93 Allowed Glycine 0 N--CA 1.446 -0.682 0 CA-C-N 115.551 -0.75 . . . . 1.84 111.37 -174.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . 0.54 ' HA2' HD11 ' A' ' 285' ' ' LEU . . . -153.77 32.91 0.75 Allowed Glycine 0 N--CA 1.443 -0.837 0 N-CA-C 110.428 -1.069 . . . . 0.64 110.428 174.138 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 290' ' ' ILE . . . . . 0.511 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 76.9 mt -74.77 124.41 32.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.564 -0.318 . . . . 0.42 110.394 -176.14 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.619 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 7.8 mt -104.24 136.45 37.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 N-CA-C 109.651 -0.5 . . . . 0.93 109.651 -179.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 292' ' ' ILE . . . . . 0.545 HD13 HD11 ' A' ' 286' ' ' LEU . 33.5 pt -133.37 137.28 53.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 120.699 -0.4 . . . . 0.48 111.07 179.481 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 293' ' ' GLU . . . . . 0.601 ' CG ' ' HB3' ' A' ' 359' ' ' ARG . 12.1 pt-20 -139.74 143.3 36.92 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.231 -0.895 . . . . 2.31 109.709 178.336 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -94.0 139.86 30.42 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 120.996 0.427 . . . . 2.36 111.035 179.548 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 295' ' ' ARG . . . . . 0.404 HH11 ' HD2' ' A' ' 295' ' ' ARG . 11.3 mmt85 -114.7 -47.11 2.91 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.569 -0.741 . . . . 3.5 111.414 -174.55 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.57 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 97.6 t -120.9 132.55 70.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.392 -0.367 . . . . 0.7 110.414 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 10.3 p -63.5 137.8 58.27 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.845 -0.616 . . . . 1.93 112.05 -176.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -165.35 132.77 2.76 Favored Glycine 0 N--CA 1.446 -0.659 0 CA-C-N 115.781 -0.645 . . . . 1.04 111.815 179.294 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 11.1 ptpp? -133.44 116.49 16.07 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.255 0.55 . . . . 4.49 109.905 176.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -171.55 -154.1 9.6 Favored Glycine 0 N--CA 1.442 -0.918 0 N-CA-C 111.193 -0.763 . . . . 1.04 111.193 -177.232 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . 0.441 ' O ' ' HA ' ' A' ' 353' ' ' ALA . 26.2 Cg_exo -61.66 133.01 43.01 Favored 'Trans proline' 0 C--O 1.237 0.443 0 C-N-CA 122.625 2.217 . . . . 0.88 111.472 178.233 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 25.0 m80 -101.47 133.48 46.06 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.247 -0.433 . . . . 1.49 111.298 -177.524 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -64.76 126.5 28.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.503 -0.772 . . . . 0.54 111.179 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 38.2 ttpt -136.4 169.77 17.13 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.2 -0.667 . . . . 2.84 109.2 -177.225 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 57.0 tttp -63.07 128.2 34.77 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.912 0.386 . . . . 2.84 110.18 177.051 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 97.6 -4.91 62.0 Favored Glycine 0 N--CA 1.451 -0.347 0 CA-C-N 115.935 -0.575 . . . . 0.7 111.84 -176.756 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 27.4 m -93.74 146.32 23.94 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.708 0.29 . . . . 0.4 110.994 -179.363 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . 0.504 ' HG2' ' HB3' ' A' ' 335' ' ' LYS . 54.6 mtm180 -110.65 104.12 12.77 Favored 'General case' 0 CA--C 1.516 -0.349 0 N-CA-C 109.346 -0.612 . . . . 3.45 109.346 177.822 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.792 ' HB ' HD11 ' A' ' 388' ' ' LEU . 31.5 m -102.65 147.01 9.73 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 CA-C-O 121.349 0.595 . . . . 0.34 111.944 -173.457 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -118.02 117.21 3.67 Favored Glycine 0 N--CA 1.446 -0.678 0 N-CA-C 109.669 -1.372 . . . . 0.27 109.669 176.068 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 311' ' ' MET . . . . . 0.457 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 21.4 ptm -135.23 177.02 8.14 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.577 0.703 . . . . 0.76 112.729 -169.133 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 64.4 mtt180 -134.47 147.63 50.42 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 107.332 -1.359 . . . . 2.51 107.332 176.496 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 313' ' ' TYR . . . . . 0.697 ' HB2' HG12 ' A' ' 386' ' ' VAL . 48.6 p90 -164.29 157.92 18.25 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 112.878 0.696 . . . . 0.68 112.878 -172.54 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 62.0 t -125.45 116.18 45.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 114.818 -1.083 . . . . 0.35 109.44 174.411 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -101.43 116.85 5.67 Favored Glycine 0 C--O 1.24 0.475 0 C-N-CA 120.912 -0.661 . . . . 0.28 112.213 -177.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 316' ' ' LYS . . . . . 0.536 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 98.3 mttt -119.41 162.42 18.85 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.372 0.606 . . . . 1.94 111.058 -178.01 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 63.2 mt -88.04 167.13 13.95 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.02 -0.991 . . . . 0.65 109.301 173.389 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 318' ' ' LYS . . . . . 0.52 ' HD3' ' H ' ' A' ' 381' ' ' GLU . 19.3 pttp -66.51 -8.84 29.16 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.38 0.609 . . . . 2.42 110.299 175.379 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 319' ' ' ASN . . . . . 0.495 HD22 ' HG2' ' A' ' 321' ' ' LYS . 8.3 t30 -86.22 -6.94 58.88 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.678 -0.692 . . . . 2.2 110.302 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 96.47 -12.92 66.13 Favored Glycine 0 N--CA 1.451 -0.303 0 CA-C-N 115.833 -0.621 . . . . 0.69 112.557 178.553 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 321' ' ' LYS . . . . . 0.495 ' HG2' HD22 ' A' ' 319' ' ' ASN . 14.4 mmmm -82.94 132.04 35.17 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.681 0.277 . . . . 2.42 110.903 -177.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.536 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 5.6 p -84.07 134.06 27.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 116.097 -0.501 . . . . 1.26 109.892 177.182 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 34.4 p90 -105.5 -31.73 8.85 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 120.843 -0.343 . . . . 0.55 111.424 179.556 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -148.67 151.83 35.62 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 110.062 -0.347 . . . . 1.68 110.062 178.274 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . 0.599 ' N ' ' HD3' ' A' ' 325' ' ' LYS . 0.0 OUTLIER -160.19 135.24 7.89 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.96 0.41 . . . . 1.99 110.11 -177.908 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 49.0 m-80 -138.51 118.19 13.1 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.512 -0.551 . . . . 1.92 109.512 179.415 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 6.6 t -162.26 -43.49 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.576 -0.284 . . . . 1.69 110.965 -178.601 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.406 ' O ' ' HG3' ' A' ' 328' ' ' LYS . 6.9 ptpp? -99.51 120.64 39.96 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.862 -0.421 . . . . 2.55 109.862 177.167 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.424 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 79.13 -37.18 1.96 Allowed Glycine 0 CA--C 1.52 0.367 0 C-N-CA 121.139 -0.553 . . . . 0.97 113.034 178.02 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 32.7 mmtp -103.64 100.58 19.86 Favored Pre-proline 0 C--N 1.33 -0.28 0 N-CA-C 111.801 0.297 . . . . 2.08 111.801 -178.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 331' ' ' PRO . . . . . 0.424 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 92.4 Cg_endo -87.54 127.4 2.36 Favored 'Trans proline' 0 N--CA 1.45 -1.032 0 C-N-CA 122.456 2.104 . . . . 0.62 110.775 168.144 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 82.9 t80 -102.03 117.63 35.2 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.57 -0.452 . . . . 0.64 110.408 -178.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 87.5 t -114.61 122.5 68.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.828 -0.624 . . . . 0.38 110.076 179.343 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.457 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 14.1 p90 -138.49 155.77 48.13 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.713 -0.477 . . . . 0.41 109.713 175.325 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 335' ' ' LYS . . . . . 0.504 ' HB3' ' HG2' ' A' ' 308' ' ' ARG . 0.0 OUTLIER -108.99 135.17 50.6 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.306 -0.407 . . . . 2.58 111.117 179.861 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 9.5 mp -77.83 110.74 12.98 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.662 -0.699 . . . . 0.58 109.471 179.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 177.92 -62.72 0.09 OUTLIER Glycine 0 N--CA 1.444 -0.777 0 C-N-CA 120.71 -0.757 . . . . 0.94 111.594 -178.271 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 338' ' ' GLN . . . . . . . . . . . . . 20.8 pt20 -96.56 153.13 18.02 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.055 0.455 . . . . 2.62 110.598 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -88.84 59.74 3.94 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 121.022 -0.609 . . . . 0.74 112.372 -174.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 21.8 pt-20 -87.83 -20.82 25.54 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.522 0.677 . . . . 2.09 109.62 174.217 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 22.1 m -95.81 167.76 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.084 -0.962 . . . . 0.43 108.999 174.129 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 342' ' ' ILE . . . . . 0.598 ' HB ' ' HA ' ' A' ' 367' ' ' ALA . 22.1 pt -71.74 147.49 10.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 N-CA-C 109.13 -0.693 . . . . 0.32 109.13 174.168 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 1.3 mtmt -49.92 -40.44 43.33 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 112.724 0.639 . . . . 2.93 112.724 -171.718 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -55.64 -25.31 42.79 Favored Glycine 0 CA--C 1.524 0.623 0 C-N-CA 121.333 -0.46 . . . . 0.3 113.825 179.014 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 8.2 m95 -74.77 -59.31 2.79 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.915 0.358 . . . . 0.39 111.848 -179.501 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -49.68 -36.99 26.95 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-O 121.082 0.468 . . . . 1.75 111.197 177.729 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 60.8 mt -80.55 -52.28 14.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.821 -0.627 . . . . 0.39 111.738 -178.529 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -67.83 -35.57 85.25 Favored Glycine 0 CA--C 1.519 0.287 0 C-N-CA 121.192 -0.528 . . . . 0.34 113.812 -177.406 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 91.7 t -75.8 -23.97 16.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.699 0.285 . . . . 0.32 110.906 -179.077 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.79 96.84 0.3 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.126 0.489 . . . . 0.47 110.372 177.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 121.49 5.76 9.14 Favored Glycine 0 CA--C 1.52 0.367 0 C-N-CA 121.127 -0.559 . . . . 0.39 112.648 -175.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 352' ' ' MET . . . . . . . . . . . . . 85.6 mmm -84.99 138.57 32.38 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.68 0.276 . . . . 1.28 110.995 175.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 353' ' ' ALA . . . . . 0.441 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -106.19 141.82 36.91 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 116.077 -0.51 . . . . 0.55 111.214 -177.865 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 58.9 t -57.49 120.65 3.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.077 -0.511 . . . . 0.36 110.4 173.188 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 104.08 -12.11 52.27 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 121.188 -0.53 . . . . 0.44 112.087 179.745 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -102.44 143.5 15.91 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.845 -0.693 . . . . 0.3 112.407 -177.347 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 357' ' ' GLU . . . . . 0.57 ' HB3' ' HB ' ' A' ' 296' ' ' VAL . 32.5 tt0 -117.08 133.39 56.06 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 110.192 -0.299 . . . . 1.41 110.192 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 358' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -144.81 144.13 30.99 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.213 0.53 . . . . 1.37 111.113 -179.088 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 359' ' ' ARG . . . . . 0.624 ' HD2' HG22 ' A' ' 383' ' ' THR . 22.9 tpp85 -88.82 119.35 29.23 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.451 -0.795 . . . . 2.79 110.113 176.255 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 58.3 mt -105.33 121.23 57.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.962 -0.385 . . . . 0.38 109.962 177.418 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 361' ' ' VAL . . . . . 0.619 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 44.7 t -101.88 116.94 46.42 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 N-CA-C 109.471 -0.566 . . . . 0.39 109.471 176.793 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 362' ' ' ILE . . . . . 0.51 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 59.0 mt -113.25 109.38 51.74 Favored Pre-proline 0 C--N 1.322 -0.595 0 CA-C-N 116.42 -0.354 . . . . 0.29 111.346 -173.495 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 363' ' ' PRO . . . . . 0.529 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 10.2 Cg_endo -53.56 152.35 21.57 Favored 'Trans proline' 0 C--O 1.236 0.401 0 C-N-CA 123.158 2.572 . . . . 0.66 112.23 173.098 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 364' ' ' ALA . . . . . 0.405 ' HB3' ' HD3' ' A' ' 365' ' ' PRO . . . -52.09 -49.03 86.71 Favored Pre-proline 0 CA--C 1.542 0.639 0 N-CA-C 113.375 0.88 . . . . 0.42 113.375 -175.802 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 365' ' ' PRO . . . . . 0.595 ' HA ' ' HA2' ' A' ' 369' ' ' GLY . 53.4 Cg_exo -53.83 -32.19 65.55 Favored 'Trans proline' 0 C--N 1.364 1.371 0 C-N-CA 122.482 2.121 . . . . 0.7 113.754 -177.062 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 366' ' ' TYR . . . . . 0.526 ' OH ' ' HG3' ' A' ' 287' ' ' GLU . 4.9 m-85 -94.66 9.71 37.73 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.217 0.532 . . . . 0.69 110.942 -175.622 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 367' ' ' ALA . . . . . 0.598 ' HA ' ' HB ' ' A' ' 342' ' ' ILE . . . -120.1 -109.22 0.35 Allowed 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.592 -0.731 . . . . 0.86 109.805 171.58 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 92.3 m-85 -81.58 -12.59 58.71 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 121.003 0.43 . . . . 1.0 111.534 179.404 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 369' ' ' GLY . . . . . 0.595 ' HA2' ' HA ' ' A' ' 365' ' ' PRO . . . 86.63 -114.1 4.02 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.846 -0.692 . . . . 0.56 112.789 175.658 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 43.6 mttp -115.05 14.65 17.15 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.012 0.434 . . . . 2.76 110.479 -175.454 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 8.5 tp-100 -87.81 117.13 26.44 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.003 -0.544 . . . . 2.65 110.645 -176.653 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 372' ' ' ALA . . . . . 0.49 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -87.56 98.89 11.66 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.069 -0.514 . . . . 1.01 110.67 177.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 76.9 mt -90.05 157.01 46.24 Favored Pre-proline 0 C--N 1.322 -0.619 0 CA-C-N 115.962 -0.563 . . . . 0.93 109.951 178.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -61.21 114.25 2.11 Favored 'Trans proline' 0 N--CA 1.459 -0.527 0 C-N-CA 121.803 1.669 . . . . 1.31 110.603 171.668 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 96.57 -30.39 8.88 Favored Glycine 0 N--CA 1.448 -0.559 0 CA-C-N 115.879 -0.6 . . . . 0.9 112.22 -176.264 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 23.4 mt -129.26 78.26 76.26 Favored Pre-proline 0 C--N 1.329 -0.299 0 N-CA-C 110.145 -0.317 . . . . 0.74 110.145 -179.475 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 377' ' ' PRO . . . . . 0.49 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 4.1 Cg_exo -76.86 166.21 27.29 Favored 'Trans proline' 0 N--CA 1.459 -0.54 0 C-N-CA 122.674 2.249 . . . . 0.71 112.143 -179.375 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 378' ' ' ALA . . . . . 0.465 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -59.14 152.86 19.38 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.293 -0.412 . . . . 0.74 110.695 176.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 379' ' ' ASN . . . . . 0.465 ' HB2' ' O ' ' A' ' 378' ' ' ALA . 16.8 m120 74.95 4.88 4.33 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 123.012 0.525 . . . . 1.49 111.492 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 49.1 m -83.97 94.6 8.31 Favored 'General case' 0 N--CA 1.451 -0.392 0 CA-C-O 121.335 0.588 . . . . 1.84 110.127 176.323 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 381' ' ' GLU . . . . . 0.52 ' H ' ' HD3' ' A' ' 318' ' ' LYS . 19.0 tt0 -67.04 112.34 4.33 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 114.972 -1.013 . . . . 1.03 109.617 179.354 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 82.4 mt -78.02 140.98 39.18 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.092 -0.504 . . . . 0.37 110.952 -173.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 383' ' ' THR . . . . . 0.624 HG22 ' HD2' ' A' ' 359' ' ' ARG . 25.1 m -120.19 119.54 33.54 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 109.29 -0.633 . . . . 0.27 109.29 -179.182 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -115.63 114.62 25.15 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.05 0.452 . . . . 0.32 111.19 -175.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 20.8 t70 -91.82 104.47 16.91 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 107.885 -1.154 . . . . 1.8 107.885 174.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 386' ' ' VAL . . . . . 0.697 HG12 ' HB2' ' A' ' 313' ' ' TYR . 17.3 m -129.71 147.61 33.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 112.46 0.541 . . . . 0.31 112.46 -167.097 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 387' ' ' LYS . . . . . 0.476 ' HB3' ' HA ' ' A' ' 357' ' ' GLU . 23.7 pttt -144.74 149.91 36.35 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.803 -0.635 . . . . 2.53 111.271 170.804 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 388' ' ' LEU . . . . . 0.792 HD11 ' HB ' ' A' ' 309' ' ' VAL . 26.9 tp -99.2 138.4 36.35 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.274 -0.875 . . . . 0.28 109.244 -176.702 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 31.8 m -128.83 -8.34 3.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 112.511 0.56 . . . . 0.45 112.511 -174.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 74.2 m -161.55 157.92 25.57 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.624 0.249 . . . . 1.32 110.837 -179.491 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 391' ' ' MET . . . . . . . . . . . . . 39.7 ttm -155.4 132.03 10.5 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-N 116.333 -0.394 . . . . 0.56 110.881 -178.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 66.6 mttm . . . . . 0 C--O 1.25 1.094 0 CA-C-O 118.432 -0.794 . . . . 4.91 109.603 176.781 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.55 0 N-CA-C 111.482 -0.647 . . . . 11.17 111.482 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -143.05 155.8 44.7 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.754 0.311 . . . . 9.37 110.521 -178.086 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 278' ' ' MET . . . . . . . . . . . . . 12.2 tpt -96.94 104.41 16.42 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.127 -0.488 . . . . 7.67 110.158 179.565 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -90.77 96.79 10.82 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.244 -0.434 . . . . 6.37 110.501 -178.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . 0.453 ' HA ' ' HD3' ' A' ' 281' ' ' PRO . 35.2 mtmm 70.98 133.32 0.04 OUTLIER Pre-proline 0 N--CA 1.467 0.384 0 O-C-N 124.036 0.835 . . . . 6.76 111.375 -177.105 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 281' ' ' PRO . . . . . 0.453 ' HD3' ' HA ' ' A' ' 280' ' ' LYS . 27.3 Cg_exo -62.38 126.76 19.2 Favored 'Trans proline' 0 C--O 1.237 0.427 0 C-N-CA 122.397 2.065 . . . . 4.8 111.355 177.37 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 282' ' ' LYS . . . . . . . . . . . . . 27.4 mmtp -90.22 103.76 16.41 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.264 0.554 . . . . 3.46 110.299 -176.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.546 ' HA ' ' O ' ' A' ' 292' ' ' ILE . 24.0 p -111.67 137.02 50.11 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-N 115.451 -0.795 . . . . 0.76 111.866 -175.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 284' ' ' LYS . . . . . 0.511 ' HB2' ' CG1' ' A' ' 292' ' ' ILE . 13.5 mmmm -110.0 137.94 47.08 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.94 -0.763 . . . . 2.06 108.94 174.762 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . 0.409 HD11 ' HA2' ' A' ' 289' ' ' GLY . 42.8 tp -100.26 121.71 41.91 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.934 0.397 . . . . 0.98 110.59 -178.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.66 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 88.3 mt -108.54 -164.56 0.96 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.818 -0.628 . . . . 0.8 110.477 -178.621 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -64.64 145.38 56.26 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 116.099 -0.5 . . . . 2.64 111.749 -178.533 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.643 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 65.76 8.97 43.49 Favored Glycine 0 C--N 1.329 0.154 0 CA-C-N 115.925 -0.58 . . . . 1.84 113.7 177.605 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . 0.409 ' HA2' HD11 ' A' ' 285' ' ' LEU . . . 90.95 12.29 60.55 Favored Glycine 0 N--CA 1.441 -0.988 0 C-N-CA 120.516 -0.849 . . . . 0.64 113.067 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 290' ' ' ILE . . . . . 0.66 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 94.9 mt -60.67 127.44 20.22 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.139 0 CA-C-N 117.373 0.587 . . . . 0.42 110.204 177.526 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.534 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 18.1 mt -113.29 139.82 36.63 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 116.37 -0.377 . . . . 0.93 110.181 -178.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 292' ' ' ILE . . . . . 0.549 HG22 HG12 ' A' ' 360' ' ' ILE . 22.5 pt -128.34 127.06 66.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 120.891 0.377 . . . . 0.48 109.987 175.369 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 293' ' ' GLU . . . . . . . . . . . . . 4.6 tm-20 -105.25 108.44 19.95 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 108.812 -0.81 . . . . 2.31 108.812 -179.443 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -78.11 101.55 7.06 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-O 121.156 0.503 . . . . 2.36 110.576 -171.195 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 295' ' ' ARG . . . . . 0.434 ' HG3' HG23 ' A' ' 296' ' ' VAL . 6.2 tpt180 -88.08 -59.41 2.25 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.184 -0.916 . . . . 3.5 111.879 -170.314 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.434 HG23 ' HG3' ' A' ' 295' ' ' ARG . 91.9 t -120.34 132.85 68.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.592 -0.277 . . . . 0.7 110.77 -178.339 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 6.8 p -92.18 120.55 32.87 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.106 -0.497 . . . . 1.93 110.915 178.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -126.96 -165.03 11.84 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.691 -0.766 . . . . 1.04 112.788 -175.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . 0.594 ' O ' ' HB1' ' A' ' 353' ' ' ALA . 74.1 mmtt -73.38 151.75 41.09 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.135 -0.691 . . . . 4.49 109.135 177.706 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -119.75 79.72 0.32 Allowed Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 119.316 -1.421 . . . . 1.04 115.074 -168.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . 0.657 ' HD2' ' H ' ' A' ' 354' ' ' VAL . 2.4 Cg_endo -85.84 133.69 4.35 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 122.735 2.29 . . . . 0.88 109.062 160.234 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 33.6 m170 -92.16 116.46 28.97 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 120.438 -0.505 . . . . 1.49 112.245 -171.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -66.24 121.2 14.67 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.413 -0.812 . . . . 0.54 110.157 173.14 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 31.9 mtmm -123.12 179.2 4.77 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.468 -0.333 . . . . 2.84 110.377 -176.123 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 61.9 tttp -63.9 113.68 3.6 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.391 -0.368 . . . . 2.84 110.349 179.618 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 98.62 -7.1 61.16 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.888 -0.673 . . . . 0.7 112.547 -179.276 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 307' ' ' THR . . . . . 0.406 ' O ' ' HA ' ' A' ' 335' ' ' LYS . 38.9 m -77.61 145.55 36.72 Favored 'General case' 0 CA--C 1.534 0.346 0 O-C-N 122.776 -0.25 . . . . 0.4 110.547 -179.499 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 73.4 mtt180 -105.25 113.87 27.71 Favored 'General case' 0 CA--C 1.519 -0.227 0 N-CA-C 109.565 -0.531 . . . . 3.45 109.565 -177.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.691 ' HB ' HD11 ' A' ' 388' ' ' LEU . 30.2 m -107.28 139.02 30.44 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 CA-C-O 121.273 0.559 . . . . 0.34 111.348 178.498 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -109.88 115.39 4.16 Favored Glycine 0 N--CA 1.445 -0.717 0 N-CA-C 110.23 -1.148 . . . . 0.27 110.23 175.278 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 311' ' ' MET . . . . . 0.583 ' SD ' ' HE2' ' A' ' 334' ' ' PHE . 22.4 ptm -136.7 177.44 7.85 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.399 0.619 . . . . 0.76 112.153 -169.659 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 312' ' ' ARG . . . . . 0.517 ' HD3' ' O ' ' A' ' 327' ' ' THR . 98.9 mtt180 -137.05 147.01 45.89 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 107.677 -1.231 . . . . 2.51 107.677 175.341 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 313' ' ' TYR . . . . . 0.42 ' HA ' ' O ' ' A' ' 385' ' ' ASP . 25.2 p90 -161.49 159.93 28.55 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 112.941 0.719 . . . . 0.68 112.941 -169.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 48.7 t -126.41 120.74 57.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 114.839 -1.073 . . . . 0.35 109.68 174.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -94.64 106.03 3.36 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.388 -0.434 . . . . 0.28 112.19 -177.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 316' ' ' LYS . . . . . 0.556 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 84.3 mttt -114.09 156.31 24.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.064 0.459 . . . . 1.94 110.932 -177.038 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 96.5 mt -89.31 163.11 15.49 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.045 -0.525 . . . . 0.65 109.585 172.103 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 318' ' ' LYS . . . . . 0.728 ' HD3' ' HB3' ' A' ' 381' ' ' GLU . 61.7 pttt -65.68 -11.55 46.07 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 121.01 0.433 . . . . 2.42 111.338 178.405 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 9.0 t30 -87.98 -7.88 56.45 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.083 0.468 . . . . 2.2 110.216 178.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 101.17 -15.61 57.69 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 121.09 -0.576 . . . . 0.69 112.197 -178.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 59.0 tptt -70.89 117.28 12.19 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.644 0.259 . . . . 2.42 110.73 -179.272 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.556 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 6.1 p -85.58 131.77 33.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 N-CA-C 110.028 -0.36 . . . . 1.26 110.028 176.819 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 31.6 p90 -106.35 -50.09 3.22 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 120.862 -0.335 . . . . 0.55 110.991 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 324' ' ' ASP . . . . . 0.494 ' C ' ' HD3' ' A' ' 325' ' ' LYS . 12.0 t70 -123.86 154.32 39.81 Favored 'General case' 0 CA--C 1.513 -0.446 0 N-CA-C 109.492 -0.559 . . . . 1.68 109.492 -179.302 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . 0.494 ' HD3' ' C ' ' A' ' 324' ' ' ASP . 0.0 OUTLIER -167.9 131.1 1.61 Allowed 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.959 0.409 . . . . 1.99 111.143 -174.147 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 1.9 p30 -146.52 115.78 7.03 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.684 0.754 . . . . 1.92 109.719 170.336 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 327' ' ' THR . . . . . 0.517 ' O ' ' HD3' ' A' ' 312' ' ' ARG . 1.7 p -148.96 -47.17 0.14 Allowed 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 114.935 -1.029 . . . . 1.69 110.922 -172.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.66 93.34 2.06 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.492 0.663 . . . . 2.55 111.534 -178.111 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.487 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 75.37 -11.5 8.96 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 115.508 -0.769 . . . . 0.97 113.629 175.288 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 45.9 mtpt -103.25 100.63 18.49 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-N 117.32 0.56 . . . . 2.08 111.41 -177.635 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 331' ' ' PRO . . . . . 0.487 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 86.0 Cg_endo -87.76 139.7 4.83 Favored 'Trans proline' 0 N--CA 1.452 -0.953 0 C-N-CA 122.749 2.299 . . . . 0.62 111.854 170.664 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 79.2 t80 -109.84 128.14 55.14 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.253 -0.647 . . . . 0.64 109.253 176.359 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 61.9 t -115.22 119.6 62.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 N-CA-C 109.839 -0.43 . . . . 0.38 109.839 -176.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.583 ' HE2' ' SD ' ' A' ' 311' ' ' MET . 21.2 p90 -138.92 166.59 24.07 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.853 -0.425 . . . . 0.41 109.853 179.66 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 335' ' ' LYS . . . . . 0.407 ' HG3' ' HB3' ' A' ' 338' ' ' GLN . 58.6 pttt -111.12 140.49 45.62 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.16 -0.473 . . . . 2.58 110.403 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 11.2 mp -71.53 139.0 49.32 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.729 -0.471 . . . . 0.58 109.729 175.246 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 94.76 5.95 60.99 Favored Glycine 0 N--CA 1.442 -0.93 0 C-N-CA 120.791 -0.719 . . . . 0.94 113.002 -174.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 338' ' ' GLN . . . . . 0.6 HE21 HG13 ' A' ' 341' ' ' VAL . 13.7 pt20 -85.16 148.86 25.9 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 117.381 0.591 . . . . 2.62 109.558 176.165 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -90.37 15.23 60.49 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.75 -0.738 . . . . 0.74 114.407 -166.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -109.92 -9.07 14.79 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 117.646 0.723 . . . . 2.09 111.481 178.397 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 341' ' ' VAL . . . . . 0.6 HG13 HE21 ' A' ' 338' ' ' GLN . 26.3 m -95.71 146.29 7.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 C-N-CA 120.769 -0.372 . . . . 0.43 110.144 178.697 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 17.4 pt -73.58 157.1 6.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 109.965 -0.383 . . . . 0.32 109.965 178.678 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . 0.453 ' HA ' ' HE3' ' A' ' 343' ' ' LYS . 0.0 OUTLIER -62.74 -35.26 79.19 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 111.626 0.232 . . . . 2.93 111.626 -175.895 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 344' ' ' GLY . . . . . . . . . . . . . . . -52.28 -42.15 55.62 Favored Glycine 0 C--O 1.228 -0.251 0 C-N-CA 120.774 -0.726 . . . . 0.3 112.363 174.243 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 4.2 m95 -68.8 -60.34 2.46 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.819 0.342 . . . . 0.39 111.043 176.441 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -51.66 -33.97 35.99 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.594 -0.73 . . . . 1.75 112.121 -177.477 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 60.0 mt -85.19 -52.53 12.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 116.4 -0.363 . . . . 0.39 111.283 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -60.47 -35.05 87.94 Favored Glycine 0 CA--C 1.524 0.628 0 C-N-CA 121.261 -0.495 . . . . 0.34 113.794 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 349' ' ' VAL . . . . . 0.422 ' O ' ' HB2' ' A' ' 352' ' ' MET . 93.1 t -77.68 -18.27 14.05 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 CA-C-O 120.994 0.426 . . . . 0.32 111.382 -179.311 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -64.22 100.34 0.33 Allowed 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.157 0.503 . . . . 0.47 110.634 177.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 105.52 12.05 27.57 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.914 -0.66 . . . . 0.39 112.205 -177.014 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 352' ' ' MET . . . . . 0.422 ' HB2' ' O ' ' A' ' 349' ' ' VAL . 0.0 OUTLIER -66.58 143.89 56.76 Favored 'General case' 0 C--N 1.331 -0.216 0 N-CA-C 109.79 -0.448 . . . . 1.28 109.79 177.675 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 353' ' ' ALA . . . . . 0.594 ' HB1' ' O ' ' A' ' 299' ' ' LYS . . . -104.06 127.06 51.61 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.321 -0.399 . . . . 0.55 111.715 -173.082 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 354' ' ' VAL . . . . . 0.657 ' H ' ' HD2' ' A' ' 301' ' ' PRO . 98.3 t -64.84 112.97 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.239 0.542 . . . . 0.36 110.743 174.504 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 109.96 -10.88 31.97 Favored Glycine 0 N--CA 1.442 -0.9 0 N-CA-C 111.313 -0.715 . . . . 0.44 111.313 -176.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -101.54 159.77 18.38 Favored Glycine 0 N--CA 1.442 -0.952 0 C-N-CA 121.048 -0.596 . . . . 0.3 112.302 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 357' ' ' GLU . . . . . 0.862 ' HB2' ' HD3' ' A' ' 387' ' ' LYS . 43.3 tt0 -135.35 140.97 45.47 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.491 -0.559 . . . . 1.41 109.491 -179.505 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 358' ' ' ARG . . . . . . . . . . . . . 5.9 ptp180 -156.2 144.91 20.2 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.026 0.441 . . . . 1.37 110.861 177.182 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 359' ' ' ARG . . . . . . . . . . . . . 82.8 mtm180 -91.44 120.02 31.91 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 115.968 -0.56 . . . . 2.79 110.444 179.174 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 360' ' ' ILE . . . . . 0.549 HG12 HG22 ' A' ' 292' ' ' ILE . 62.3 mt -101.68 119.32 49.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-N 115.734 -0.666 . . . . 0.38 110.638 -176.476 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 361' ' ' VAL . . . . . 0.534 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 46.3 t -103.48 112.74 38.09 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 108.972 -0.751 . . . . 0.39 108.972 177.025 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 362' ' ' ILE . . . . . . . . . . . . . 57.6 mt -109.74 102.24 49.47 Favored Pre-proline 0 C--N 1.319 -0.723 0 CA-C-N 116.037 -0.528 . . . . 0.29 110.999 -174.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 363' ' ' PRO . . . . . 0.472 ' HA ' ' HG3' ' A' ' 381' ' ' GLU . 71.2 Cg_exo -54.39 155.48 16.29 Favored 'Trans proline' 0 N--CA 1.459 -0.559 0 C-N-CA 122.532 2.155 . . . . 0.66 112.206 171.231 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 364' ' ' ALA . . . . . 0.547 ' N ' ' HD2' ' A' ' 365' ' ' PRO . . . -46.03 -50.1 37.5 Favored Pre-proline 0 C--N 1.327 -0.41 0 N-CA-C 114.364 1.246 . . . . 0.42 114.364 -174.743 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 365' ' ' PRO . . . . . 0.547 ' HD2' ' N ' ' A' ' 364' ' ' ALA . 9.8 Cg_endo -52.53 -31.58 49.58 Favored 'Trans proline' 0 C--N 1.36 1.168 0 C-N-CA 122.685 2.256 . . . . 0.7 114.387 -172.144 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 366' ' ' TYR . . . . . 0.643 ' CE2' ' HA3' ' A' ' 288' ' ' GLY . 9.6 m-85 -101.62 13.46 34.86 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-O 121.017 0.437 . . . . 0.69 112.035 -176.708 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -126.59 -108.05 0.31 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.963 -0.562 . . . . 0.86 110.563 173.744 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 368' ' ' TYR . . . . . 0.406 ' CE2' HD11 ' A' ' 382' ' ' LEU . 40.6 m-85 -84.08 -21.83 31.37 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.821 0.343 . . . . 1.0 111.211 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 70.68 -118.1 7.47 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.841 -0.695 . . . . 0.56 112.15 -178.14 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 370' ' ' LYS . . . . . 0.555 ' HA ' ' HB1' ' A' ' 378' ' ' ALA . 19.4 ptmt -101.77 17.39 23.11 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.975 0.416 . . . . 2.76 110.735 178.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 59.4 tt0 -84.86 102.58 13.2 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.941 -0.572 . . . . 2.65 110.154 176.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 372' ' ' ALA . . . . . 0.433 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -81.68 108.25 15.09 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.873 0.368 . . . . 1.01 111.202 177.834 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 86.6 mt -90.02 159.33 42.87 Favored Pre-proline 0 C--N 1.322 -0.626 0 N-CA-C 109.088 -0.708 . . . . 0.93 109.088 175.193 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -62.26 114.24 2.25 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 121.656 1.57 . . . . 1.31 110.555 172.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 96.26 -29.28 10.4 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.67 -0.776 . . . . 0.9 112.439 -178.155 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 43.3 mt -128.36 86.66 57.27 Favored Pre-proline 0 C--N 1.332 -0.152 0 N-CA-C 110.011 -0.366 . . . . 0.74 110.011 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 377' ' ' PRO . . . . . 0.433 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 83.8 Cg_endo -80.03 168.0 19.37 Favored 'Trans proline' 0 N--CA 1.462 -0.354 0 C-N-CA 122.724 2.283 . . . . 0.71 113.017 -176.579 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 378' ' ' ALA . . . . . 0.555 ' HB1' ' HA ' ' A' ' 370' ' ' LYS . . . -52.95 150.16 5.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.5 -0.773 . . . . 0.74 111.703 178.73 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 379' ' ' ASN . . . . . 0.434 ' HA ' ' HB2' ' A' ' 364' ' ' ALA . 49.9 m-80 70.91 15.14 6.82 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 115.473 -0.785 . . . . 1.49 111.265 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 21.5 t -76.67 125.98 30.19 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 109.587 -0.523 . . . . 1.84 109.587 175.156 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 381' ' ' GLU . . . . . 0.728 ' HB3' ' HD3' ' A' ' 318' ' ' LYS . 27.2 tt0 -102.24 112.57 25.32 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 108.67 -0.863 . . . . 1.03 108.67 -179.01 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 382' ' ' LEU . . . . . 0.406 HD11 ' CE2' ' A' ' 368' ' ' TYR . 75.8 mt -86.26 146.53 26.48 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 116.179 -0.464 . . . . 0.37 111.12 -172.709 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 63.0 m -123.52 122.84 39.24 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.386 -0.598 . . . . 0.27 109.386 173.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 76.8 m-85 -119.84 111.71 18.32 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 116.483 -0.326 . . . . 0.32 111.079 -177.01 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 385' ' ' ASP . . . . . 0.42 ' O ' ' HA ' ' A' ' 313' ' ' TYR . 3.6 m-20 -72.54 104.18 3.77 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 107.924 -1.139 . . . . 1.8 107.924 167.834 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 386' ' ' VAL . . . . . 0.505 ' HB ' ' CE ' ' A' ' 311' ' ' MET . 32.2 m -119.11 135.61 58.97 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.426 0.631 . . . . 0.31 111.012 -176.227 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 387' ' ' LYS . . . . . 0.862 ' HD3' ' HB2' ' A' ' 357' ' ' GLU . 21.6 ttpt -141.32 128.65 21.11 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.296 -0.865 . . . . 2.53 109.449 178.44 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 388' ' ' LEU . . . . . 0.691 HD11 ' HB ' ' A' ' 309' ' ' VAL . 22.6 tp -95.04 136.76 34.97 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.932 -0.576 . . . . 0.28 109.575 -172.65 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 35.8 m -126.0 -5.0 5.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 N-CA-C 112.392 0.516 . . . . 0.45 112.392 -174.654 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 11.3 p -169.15 157.41 7.7 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.816 -0.354 . . . . 1.32 111.473 -177.444 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 391' ' ' MET . . . . . 0.55 ' HE2' HG12 ' A' ' 309' ' ' VAL . 34.1 ttm -160.89 139.11 9.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.16 -0.473 . . . . 0.56 110.485 177.448 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 18.2 tptm . . . . . 0 C--O 1.246 0.892 0 CA-C-O 117.961 -1.019 . . . . 4.91 111.402 175.167 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.616 0 N-CA-C 111.609 -0.597 . . . . 11.17 111.609 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -90.04 -54.98 3.8 Favored 'General case' 0 C--N 1.324 -0.542 0 O-C-N 122.888 -0.184 . . . . 9.37 111.203 -176.336 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 278' ' ' MET . . . . . . . . . . . . . 13.7 tpt 61.53 101.23 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.212 0 O-C-N 123.926 0.766 . . . . 7.67 109.982 -172.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -60.19 -27.86 67.48 Favored 'General case' 0 CA--C 1.515 -0.38 0 CA-C-N 115.977 -0.556 . . . . 6.37 112.061 -173.617 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 14.6 tppt? -167.37 108.53 0.61 Allowed Pre-proline 0 C--N 1.31 -1.134 0 CA-C-N 115.451 -0.795 . . . . 6.76 109.888 179.259 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_exo -61.93 124.84 15.23 Favored 'Trans proline' 0 C--O 1.235 0.364 0 C-N-CA 122.69 2.26 . . . . 4.8 111.726 179.286 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 282' ' ' LYS . . . . . . . . . . . . . 32.4 mmmt -124.78 88.97 2.98 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.85 -0.614 . . . . 3.46 109.588 -176.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.456 ' HA ' ' O ' ' A' ' 292' ' ' ILE . 16.9 p -105.91 145.85 30.74 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.651 -0.704 . . . . 0.76 111.412 -175.594 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 284' ' ' LYS . . . . . . . . . . . . . 28.2 mmtp -127.46 139.74 52.61 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.729 -0.669 . . . . 2.06 109.629 175.821 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . 0.461 HD11 ' HA2' ' A' ' 289' ' ' GLY . 37.6 tp -96.28 121.1 37.71 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.909 -0.587 . . . . 0.98 110.217 179.539 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.669 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 95.2 mt -105.83 -171.73 1.96 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.912 -0.586 . . . . 0.8 110.378 -179.413 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 287' ' ' GLU . . . . . 0.476 ' HG3' ' OH ' ' A' ' 366' ' ' TYR . 4.9 tp10 -64.51 145.37 56.22 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.889 -0.596 . . . . 2.64 111.105 -176.381 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.423 ' HA3' ' CE2' ' A' ' 366' ' ' TYR . . . 70.93 7.19 61.65 Favored Glycine 0 C--N 1.332 0.31 0 C-N-CA 121.055 -0.593 . . . . 1.84 113.126 -178.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . 0.461 ' HA2' HD11 ' A' ' 285' ' ' LEU . . . 84.81 19.93 58.83 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.858 -0.687 . . . . 0.64 113.216 -179.613 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 290' ' ' ILE . . . . . 0.669 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 96.1 mt -66.39 126.46 25.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 109.985 -0.376 . . . . 0.42 109.985 177.557 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 14.8 mt -110.53 137.14 44.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 N-CA-C 109.726 -0.472 . . . . 0.93 109.726 -178.748 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 292' ' ' ILE . . . . . 0.456 ' O ' ' HA ' ' A' ' 283' ' ' THR . 21.7 pt -127.02 128.24 70.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-O 121.054 0.454 . . . . 0.48 111.069 179.626 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 293' ' ' GLU . . . . . 0.746 ' HB3' ' HB3' ' A' ' 359' ' ' ARG . 6.6 tp10 -104.62 105.54 15.67 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.177 -1.046 . . . . 2.31 108.177 174.223 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -78.02 110.16 12.71 Favored 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 120.562 -0.455 . . . . 2.36 109.816 -172.221 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 295' ' ' ARG . . . . . 0.705 ' HB2' ' HG3' ' A' ' 357' ' ' GLU . 14.6 mmm180 -78.05 -59.66 2.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.889 -0.596 . . . . 3.5 110.855 -171.304 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.552 ' HB ' ' HG2' ' A' ' 357' ' ' GLU . 97.8 t -137.16 119.06 18.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 C-N-CA 121.141 -0.223 . . . . 0.7 110.626 177.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 297' ' ' THR . . . . . . . . . . . . . 14.9 p -68.27 108.04 3.04 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 116.079 -0.51 . . . . 1.93 110.494 176.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 298' ' ' GLY . . . . . . . . . . . . . . . -94.91 157.39 22.17 Favored Glycine 0 N--CA 1.442 -0.926 0 C-N-CA 120.764 -0.731 . . . . 1.04 111.56 178.677 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 18.3 ttpp -115.75 111.03 19.94 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 109.764 -0.458 . . . . 4.49 109.764 178.535 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -171.72 -162.39 23.91 Favored Glycine 0 N--CA 1.44 -1.096 0 N-CA-C 111.105 -0.798 . . . . 1.04 111.105 179.742 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . 0.435 ' HD2' ' HB ' ' A' ' 354' ' ' VAL . 21.6 Cg_exo -65.76 133.33 33.59 Favored 'Trans proline' 0 N--CA 1.461 -0.394 0 C-N-CA 122.496 2.131 . . . . 0.88 111.661 175.703 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 302' ' ' HIS . . . . . 0.52 ' HA ' ' O ' ' A' ' 352' ' ' MET . 64.4 m80 -89.01 133.69 34.25 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.116 0.484 . . . . 1.49 110.579 -179.706 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 303' ' ' ALA . . . . . 0.44 ' HB2' HG11 ' A' ' 309' ' ' VAL . . . -87.17 129.25 35.02 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.773 -0.649 . . . . 0.54 111.621 -177.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 59.7 pttt -124.34 -176.3 3.48 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.5 -0.555 . . . . 2.84 109.5 174.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.72 ' HG3' ' HA3' ' A' ' 337' ' ' GLY . 50.7 tttm -66.98 133.66 50.4 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.028 0.442 . . . . 2.84 110.229 -178.527 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 91.96 -8.91 77.63 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 121.064 -0.589 . . . . 0.7 112.669 -176.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 25.6 m -82.06 145.51 30.15 Favored 'General case' 0 CA--C 1.535 0.365 0 CA-C-O 120.688 0.28 . . . . 0.4 110.766 -178.689 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 89.6 mtt180 -108.33 103.23 12.35 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-O 121.098 0.475 . . . . 3.45 109.771 -178.221 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.901 ' HB ' HD11 ' A' ' 388' ' ' LEU . 32.4 m -112.13 159.83 11.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-N 115.549 -0.751 . . . . 0.34 112.244 -175.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -123.26 123.55 5.33 Favored Glycine 0 N--CA 1.447 -0.573 0 N-CA-C 110.524 -1.03 . . . . 0.27 110.524 176.333 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 10.4 ptp -134.48 178.15 7.21 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.399 0.619 . . . . 0.76 111.815 -173.377 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 88.1 mtt180 -137.53 143.4 41.61 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 107.217 -1.401 . . . . 2.51 107.217 176.02 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 313' ' ' TYR . . . . . 0.593 ' CB ' HG12 ' A' ' 386' ' ' VAL . 49.4 p90 -162.55 152.16 15.84 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 112.646 0.61 . . . . 0.68 112.646 -167.238 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 51.1 t -116.92 119.0 60.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.091 -0.959 . . . . 0.35 109.627 173.111 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -97.93 109.15 3.75 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 121.343 -0.456 . . . . 0.28 112.261 -178.022 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 316' ' ' LYS . . . . . 0.561 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 56.3 mttm -120.42 162.97 18.62 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.173 0.511 . . . . 1.94 111.025 -177.157 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 81.9 mt -86.54 164.54 16.84 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 108.033 -1.099 . . . . 0.65 108.033 166.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 318' ' ' LYS . . . . . . . . . . . . . 47.7 pttt -64.44 -8.46 13.57 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.483 0.659 . . . . 2.42 110.303 173.505 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -79.51 -12.59 59.86 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 115.289 -0.869 . . . . 2.2 109.799 176.52 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 95.59 -24.93 27.14 Favored Glycine 0 N--CA 1.453 -0.187 0 N-CA-C 111.572 -0.611 . . . . 0.69 111.572 -176.445 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 23.7 ttmm -60.08 120.04 8.96 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.015 -0.593 . . . . 2.42 110.831 177.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.561 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 5.3 p -88.86 127.22 41.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.133 -0.485 . . . . 1.26 110.201 179.491 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 49.4 p90 -98.88 -27.19 14.02 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.828 -0.349 . . . . 0.55 111.16 -178.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -155.18 145.79 22.22 Favored 'General case' 0 CA--C 1.514 -0.408 0 N-CA-C 109.981 -0.377 . . . . 1.68 109.981 175.599 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . 0.487 ' N ' ' HD3' ' A' ' 325' ' ' LYS . 0.0 OUTLIER -149.74 128.7 12.61 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.379 0.609 . . . . 1.99 111.335 -179.257 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 23.6 m-80 -125.21 114.51 19.07 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 107.055 -1.461 . . . . 1.92 107.055 174.452 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 10.4 m -155.29 -58.79 0.1 Allowed 'General case' 0 C--N 1.318 -0.803 0 C-N-CA 120.367 -0.533 . . . . 1.69 111.784 -168.49 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 9.4 ptmm? -68.05 92.01 0.37 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.288 0.566 . . . . 2.55 111.625 -172.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.452 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 63.51 2.77 6.19 Favored Glycine 0 C--N 1.335 0.513 0 CA-C-N 115.582 -0.736 . . . . 0.97 113.048 -178.402 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 83.9 tttt -105.63 101.9 35.0 Favored Pre-proline 0 C--N 1.325 -0.47 0 N-CA-C 111.772 0.286 . . . . 2.08 111.772 -172.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 331' ' ' PRO . . . . . 0.452 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 95.8 Cg_endo -87.76 161.74 7.7 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 123.067 2.511 . . . . 0.62 112.567 174.289 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 66.4 t80 -134.72 126.45 29.06 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.224 -0.444 . . . . 0.64 109.844 174.038 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 333' ' ' VAL . . . . . 0.5 ' HA ' ' O ' ' A' ' 309' ' ' VAL . 59.6 t -109.48 120.91 61.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.556 -0.293 . . . . 0.38 110.363 -177.002 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 22.3 p90 -142.93 160.13 40.93 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.193 0.52 . . . . 0.41 111.711 -178.608 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 335' ' ' LYS . . . . . . . . . . . . . 11.2 ttmt -89.34 128.15 35.86 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.309 -0.859 . . . . 2.58 110.345 176.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 6.8 mp -69.32 136.85 52.38 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.673 0.273 . . . . 0.58 110.598 173.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 337' ' ' GLY . . . . . 0.72 ' HA3' ' HG3' ' A' ' 305' ' ' LYS . . . 79.08 58.02 3.07 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 121.112 -0.566 . . . . 0.94 112.708 178.62 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 338' ' ' GLN . . . . . . . . . . . . . 29.0 pt20 -142.55 161.21 38.64 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.776 -0.453 . . . . 2.62 109.776 176.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -81.74 1.39 86.33 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.18 -0.533 . . . . 0.74 112.617 -173.797 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 21.0 mm-40 -76.25 -21.66 56.08 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.153 0.501 . . . . 2.09 110.307 178.461 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 341' ' ' VAL . . . . . . . . . . . . . 18.7 m -114.51 166.64 8.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.898 -0.592 . . . . 0.43 110.046 -177.317 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 342' ' ' ILE . . . . . . . . . . . . . 10.4 pt -85.11 154.46 3.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 N-CA-C 109.518 -0.549 . . . . 0.32 109.518 175.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . 0.622 ' HA ' ' OD1' ' A' ' 346' ' ' ASP . 13.7 mmmm -60.18 -28.54 68.03 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.391 0.515 . . . . 2.93 112.391 -172.62 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 344' ' ' GLY . . . . . 0.498 ' HA2' HD13 ' A' ' 290' ' ' ILE . . . -56.27 -31.13 59.15 Favored Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.467 -0.873 . . . . 0.3 112.656 174.204 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 345' ' ' TRP . . . . . . . . . . . . . 9.2 m95 -74.62 -60.65 2.18 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 112.303 0.483 . . . . 0.39 112.303 -179.189 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 346' ' ' ASP . . . . . 0.622 ' OD1' ' HA ' ' A' ' 343' ' ' LYS . 8.1 p-10 -64.55 -24.73 67.7 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.634 0.254 . . . . 1.75 111.468 -173.63 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 48.7 mt -84.44 -51.31 14.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 116.318 -0.401 . . . . 0.39 111.126 177.347 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -64.28 -36.46 93.25 Favored Glycine 0 CA--C 1.524 0.624 0 C-N-CA 121.032 -0.604 . . . . 0.34 113.355 179.599 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 349' ' ' VAL . . . . . 0.511 ' O ' ' HB2' ' A' ' 352' ' ' MET . 77.1 t -80.55 -14.4 12.88 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.88 0.371 . . . . 0.32 111.349 -179.218 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -63.2 113.25 3.06 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.957 0.408 . . . . 0.47 110.682 177.86 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 96.32 19.57 27.66 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.969 -0.634 . . . . 0.39 111.924 -177.048 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 352' ' ' MET . . . . . 0.52 ' O ' ' HA ' ' A' ' 302' ' ' HIS . 0.0 OUTLIER -76.66 155.87 33.06 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.722 -0.473 . . . . 1.28 109.722 174.907 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 353' ' ' ALA . . . . . . . . . . . . . . . -131.04 133.79 46.06 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.671 0.272 . . . . 0.55 110.921 -179.435 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 354' ' ' VAL . . . . . 0.435 ' HB ' ' HD2' ' A' ' 301' ' ' PRO . 95.1 t -55.39 114.79 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.976 -0.556 . . . . 0.36 110.909 175.733 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 113.83 -8.06 23.72 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.975 -0.631 . . . . 0.44 112.097 -179.019 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 356' ' ' GLY . . . . . . . . . . . . . . . -109.79 162.42 12.69 Favored Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.73 -0.747 . . . . 0.3 112.785 -179.713 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 357' ' ' GLU . . . . . 0.785 ' HB3' ' HB3' ' A' ' 387' ' ' LYS . 9.6 pt-20 -140.64 145.54 36.74 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 110.172 -0.307 . . . . 1.41 110.172 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 358' ' ' ARG . . . . . 0.503 ' HA ' ' HG2' ' A' ' 295' ' ' ARG . 2.8 ptp180 -154.44 145.53 22.75 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.378 0.608 . . . . 1.37 111.67 178.393 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 359' ' ' ARG . . . . . 0.746 ' HB3' ' HB3' ' A' ' 293' ' ' GLU . 34.5 ttt180 -86.82 114.46 23.5 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 114.948 -1.024 . . . . 2.79 109.938 -179.707 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 360' ' ' ILE . . . . . . . . . . . . . 56.1 mt -101.6 117.52 47.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 120.896 0.379 . . . . 0.38 110.46 -178.196 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 361' ' ' VAL . . . . . . . . . . . . . 46.5 t -104.01 112.2 36.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 109.346 -0.612 . . . . 0.39 109.346 178.078 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 362' ' ' ILE . . . . . 0.446 HD13 ' HA3' ' A' ' 344' ' ' GLY . 54.5 mt -109.23 106.51 58.78 Favored Pre-proline 0 C--N 1.32 -0.694 0 CA-C-N 116.259 -0.428 . . . . 0.29 110.784 -174.181 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 363' ' ' PRO . . . . . 0.515 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 18.4 Cg_endo -58.35 159.53 19.14 Favored 'Trans proline' 0 C--O 1.235 0.372 0 C-N-CA 122.487 2.125 . . . . 0.66 111.848 173.327 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 364' ' ' ALA . . . . . 0.405 ' HB3' ' HD3' ' A' ' 365' ' ' PRO . . . -49.37 -50.16 66.69 Favored Pre-proline 0 CA--C 1.538 0.504 0 N-CA-C 114.002 1.112 . . . . 0.42 114.002 -174.448 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 365' ' ' PRO . . . . . 0.515 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 77.5 Cg_exo -51.38 -30.9 36.04 Favored 'Trans proline' 0 C--N 1.364 1.368 0 C-N-CA 122.294 1.996 . . . . 0.7 114.047 -174.935 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 366' ' ' TYR . . . . . 0.476 ' OH ' ' HG3' ' A' ' 287' ' ' GLU . 3.7 m-85 -102.26 14.13 32.79 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 112.158 0.429 . . . . 0.69 112.158 -177.503 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 367' ' ' ALA . . . . . . . . . . . . . . . -129.23 -107.57 0.29 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.147 -0.479 . . . . 0.86 110.386 173.249 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 32.8 m-85 -87.96 -14.2 39.8 Favored 'General case' 0 N--CA 1.466 0.34 0 N-CA-C 112.09 0.404 . . . . 1.0 112.09 -179.113 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 70.01 -122.96 12.07 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.918 -0.658 . . . . 0.56 112.773 178.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 370' ' ' LYS . . . . . . . . . . . . . 4.7 ptpp? -97.2 4.07 51.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.685 0.279 . . . . 2.76 111.12 -178.247 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 15.8 mm100 -75.36 98.92 3.97 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.085 0.469 . . . . 2.65 110.787 -179.261 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 372' ' ' ALA . . . . . . . . . . . . . . . -72.21 90.98 1.26 Allowed 'General case' 0 N--CA 1.447 -0.586 0 CA-C-N 115.695 -0.684 . . . . 1.01 110.454 175.593 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 373' ' ' LEU . . . . . . . . . . . . . 36.7 mt -74.51 159.24 83.92 Favored Pre-proline 0 C--N 1.323 -0.568 0 CA-C-N 115.516 -0.765 . . . . 0.93 109.144 178.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 374' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -58.63 113.97 1.79 Allowed 'Trans proline' 0 N--CA 1.459 -0.529 0 C-N-CA 121.749 1.633 . . . . 1.31 110.721 173.73 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 93.84 -27.76 11.97 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.767 -0.73 . . . . 0.9 112.796 -177.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 56.6 mt -125.18 89.41 52.65 Favored Pre-proline 0 C--N 1.327 -0.37 0 CA-C-O 120.71 0.29 . . . . 0.74 110.84 -177.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 377' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -72.52 168.09 25.31 Favored 'Trans proline' 0 C--O 1.234 0.276 0 C-N-CA 123.143 2.562 . . . . 0.71 113.009 -178.112 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 378' ' ' ALA . . . . . 0.477 ' O ' ' HB2' ' A' ' 379' ' ' ASN . . . -53.2 155.09 2.81 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.512 -0.767 . . . . 0.74 111.212 178.148 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 379' ' ' ASN . . . . . 0.477 ' HB2' ' O ' ' A' ' 378' ' ' ALA . 33.1 m-80 71.97 32.16 1.89 Allowed 'General case' 0 N--CA 1.467 0.419 0 O-C-N 123.805 0.69 . . . . 1.49 109.43 -172.228 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 380' ' ' SER . . . . . . . . . . . . . 1.8 p -70.7 87.88 0.7 Allowed 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 114.896 -1.047 . . . . 1.84 111.283 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 381' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -80.27 98.91 7.6 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 108.68 -0.859 . . . . 1.03 108.68 174.565 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 67.8 mt -85.96 146.98 26.44 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.0 -0.545 . . . . 0.37 110.292 -176.561 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 383' ' ' THR . . . . . . . . . . . . . 28.9 m -124.08 122.68 38.51 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 109.566 -0.531 . . . . 0.27 109.566 175.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -117.83 110.62 18.0 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.424 -0.353 . . . . 0.32 110.429 -178.575 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -84.0 103.81 13.55 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 107.813 -1.18 . . . . 1.8 107.813 172.478 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 386' ' ' VAL . . . . . 0.593 HG12 ' CB ' ' A' ' 313' ' ' TYR . 18.5 m -122.02 149.93 25.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 121.235 0.54 . . . . 0.31 112.185 -170.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 387' ' ' LYS . . . . . 0.785 ' HB3' ' HB3' ' A' ' 357' ' ' GLU . 11.1 ptpt -141.6 139.58 33.13 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.686 -0.688 . . . . 2.53 110.313 172.35 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 388' ' ' LEU . . . . . 0.901 HD11 ' HB ' ' A' ' 309' ' ' VAL . 31.0 tp -91.53 127.18 36.88 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.766 -0.827 . . . . 0.28 108.766 179.566 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 33.3 m -124.77 -10.84 6.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 C-N-CA 120.585 -0.446 . . . . 0.45 111.872 -172.676 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 50.0 m -157.96 159.83 36.9 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.844 0.354 . . . . 1.32 111.268 -179.33 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 391' ' ' MET . . . . . . . . . . . . . 38.7 ttm -160.32 150.82 18.47 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.339 -0.615 . . . . 0.56 109.339 175.354 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 18.5 ptpt . . . . . 0 C--O 1.249 1.067 0 C-N-CA 124.251 1.02 . . . . 4.91 112.805 176.866 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 276' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.85 0 N-CA-C 111.405 -0.678 . . . . 11.17 111.405 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 277' ' ' ALA . . . . . . . . . . . . . . . -97.95 -175.13 3.06 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.579 -0.526 . . . . 9.37 109.579 175.142 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 278' ' ' MET . . . . . . . . . . . . . 88.7 mtp -72.62 -64.59 0.93 Allowed 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 109.365 -0.606 . . . . 7.67 109.365 176.164 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . 65.78 153.18 0.07 Allowed 'General case' 0 N--CA 1.467 0.38 0 O-C-N 124.088 0.867 . . . . 6.37 112.678 176.379 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 280' ' ' LYS . . . . . . . . . . . . . 84.9 tttt 67.7 127.32 0.03 OUTLIER Pre-proline 0 N--CA 1.466 0.366 0 CA-C-N 115.542 -0.754 . . . . 6.76 112.118 176.31 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 281' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -67.02 142.62 62.5 Favored 'Trans proline' 0 N--CA 1.461 -0.389 0 C-N-CA 122.335 2.023 . . . . 4.8 111.459 176.167 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 282' ' ' LYS . . . . . . . . . . . . . 60.5 mttm -112.87 -175.74 2.74 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.928 -0.397 . . . . 3.46 109.928 179.192 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 2.9 p -90.03 126.6 35.82 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-O 121.351 0.596 . . . . 0.76 110.232 178.857 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 284' ' ' LYS . . . . . 0.406 ' HB2' HG13 ' A' ' 292' ' ' ILE . 32.2 mmtp -108.16 130.54 55.12 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 115.652 -0.704 . . . . 2.06 110.041 -178.222 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 32.3 tp -95.47 125.44 40.08 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.949 -0.569 . . . . 0.98 109.959 179.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.759 ' HB2' ' HB ' ' A' ' 290' ' ' ILE . 90.4 mt -102.75 -178.12 3.58 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.688 -0.687 . . . . 0.8 109.433 179.302 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 287' ' ' GLU . . . . . . . . . . . . . 14.3 tt0 -66.37 152.04 45.87 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.704 -0.48 . . . . 2.64 109.704 179.791 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 72.71 -4.41 21.83 Favored Glycine 0 C--O 1.229 -0.177 0 C-N-CA 120.823 -0.703 . . . . 1.84 113.08 -174.265 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 90.33 21.34 38.37 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.504 -0.855 . . . . 0.64 113.53 179.547 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 290' ' ' ILE . . . . . 0.759 ' HB ' ' HB2' ' A' ' 286' ' ' LEU . 61.9 mt -69.81 133.43 31.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 117.39 0.595 . . . . 0.42 110.344 177.828 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.528 ' HB ' ' HB ' ' A' ' 361' ' ' VAL . 17.8 mt -113.08 139.49 37.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 C-N-CA 121.106 -0.237 . . . . 0.93 110.836 -178.576 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 292' ' ' ILE . . . . . 0.511 ' HB ' ' HD3' ' A' ' 358' ' ' ARG . 17.7 pt -132.08 129.3 60.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 121.151 0.501 . . . . 0.48 110.956 177.185 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 293' ' ' GLU . . . . . 0.446 ' C ' ' HG3' ' A' ' 358' ' ' ARG . 4.5 tp10 -125.15 119.21 27.93 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.516 -0.766 . . . . 2.31 109.664 178.699 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . 0.688 ' OD2' ' HA ' ' A' ' 297' ' ' THR . 6.2 t70 -80.3 96.18 6.56 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.475 -0.565 . . . . 2.36 109.475 -175.727 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 295' ' ' ARG . . . . . . . . . . . . . 66.6 ttt180 -69.37 -45.73 68.65 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.784 -0.644 . . . . 3.5 110.146 -175.89 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.598 ' HB ' ' HB3' ' A' ' 357' ' ' GLU . 88.8 t -123.4 123.71 68.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 N-CA-C 108.523 -0.917 . . . . 0.7 108.523 172.313 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 297' ' ' THR . . . . . 0.688 ' HA ' ' OD2' ' A' ' 294' ' ' ASP . 5.1 t -60.76 109.75 1.13 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.718 0.771 . . . . 1.93 110.994 -174.156 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 298' ' ' GLY . . . . . 0.538 ' HA3' ' HA3' ' A' ' 356' ' ' GLY . . . -99.33 111.22 4.16 Favored Glycine 0 N--CA 1.445 -0.708 0 CA-C-N 115.313 -0.858 . . . . 1.04 112.948 -178.036 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 36.9 mmtm -125.39 110.14 13.6 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 108.982 -0.747 . . . . 4.49 108.982 173.829 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 300' ' ' GLY . . . . . . . . . . . . . . . -173.3 -152.68 8.97 Favored Glycine 0 N--CA 1.447 -0.573 0 N-CA-C 111.218 -0.753 . . . . 1.04 111.218 -174.404 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . 0.607 ' O ' ' HA ' ' A' ' 353' ' ' ALA . 32.8 Cg_exo -58.32 132.92 51.66 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.413 2.075 . . . . 0.88 111.312 174.103 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 302' ' ' HIS . . . . . . . . . . . . . 26.6 m80 -96.63 127.92 43.08 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.941 0.401 . . . . 1.49 111.132 -173.61 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 303' ' ' ALA . . . . . . . . . . . . . . . -73.51 117.62 15.49 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.066 -0.516 . . . . 0.54 111.056 179.202 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 63.2 mttm -118.9 -179.4 3.8 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.194 -0.457 . . . . 2.84 110.583 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . . . . . . . . . 49.7 mtmt -72.68 127.15 31.69 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 109.9 -0.408 . . . . 2.84 109.9 179.223 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 306' ' ' GLY . . . . . . . . . . . . . . . 94.8 -0.51 64.89 Favored Glycine 0 CA--C 1.518 0.223 0 C-N-CA 120.747 -0.739 . . . . 0.7 112.047 -176.906 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 307' ' ' THR . . . . . . . . . . . . . 19.8 m -91.29 145.31 24.75 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 110.239 -0.282 . . . . 0.4 110.239 177.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 51.4 mtp180 -108.12 106.47 16.69 Favored 'General case' 0 CA--C 1.519 -0.225 0 N-CA-C 109.648 -0.501 . . . . 3.45 109.648 178.693 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.914 ' HB ' HD11 ' A' ' 388' ' ' LEU . 32.7 m -106.25 154.11 7.45 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.959 0 CA-C-O 121.086 0.469 . . . . 0.34 111.747 -174.09 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -122.74 127.73 6.82 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 110.823 -0.911 . . . . 0.27 110.823 177.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 311' ' ' MET . . . . . . . . . . . . . 11.9 ptp -135.22 177.01 8.15 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.754 0.788 . . . . 0.76 112.789 -173.82 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 312' ' ' ARG . . . . . . . . . . . . . 44.3 mtm180 -135.96 146.21 47.01 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 107.068 -1.456 . . . . 2.51 107.068 173.005 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 313' ' ' TYR . . . . . 0.601 ' HB3' HG12 ' A' ' 386' ' ' VAL . 41.9 p90 -159.13 155.52 27.39 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 113.214 0.82 . . . . 0.68 113.214 -168.118 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 58.1 t -122.56 113.24 37.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 114.94 -1.027 . . . . 0.35 109.361 170.185 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -97.56 115.64 5.31 Favored Glycine 0 C--O 1.238 0.374 0 C-N-CA 120.85 -0.69 . . . . 0.28 112.556 -176.331 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 316' ' ' LYS . . . . . 0.637 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 91.9 mttt -117.86 162.45 18.09 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-O 121.275 0.559 . . . . 1.94 110.758 -179.066 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 317' ' ' LEU . . . . . . . . . . . . . 93.6 mt -90.01 165.89 13.77 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.423 -0.808 . . . . 0.65 109.558 173.841 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 318' ' ' LYS . . . . . 0.566 ' HB2' ' HB3' ' A' ' 381' ' ' GLU . 56.9 tttp -59.88 -23.09 63.16 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.22 0.533 . . . . 2.42 110.306 176.448 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 319' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -70.14 -15.63 62.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.38 -0.827 . . . . 2.2 110.894 -179.559 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 320' ' ' GLY . . . . . . . . . . . . . . . 98.84 -5.43 59.79 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.51 -0.852 . . . . 0.69 112.195 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 321' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -91.48 133.28 35.64 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 120.682 0.277 . . . . 2.42 110.3 179.004 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.637 ' HA ' ' HA ' ' A' ' 316' ' ' LYS . 8.0 p -77.3 140.21 17.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.467 -0.333 . . . . 1.26 110.322 178.575 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 323' ' ' PHE . . . . . . . . . . . . . 34.9 p90 -103.62 -33.43 8.99 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.54 -0.464 . . . . 0.55 110.994 177.636 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 324' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -162.7 162.99 27.1 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 121.063 -0.255 . . . . 1.68 110.343 175.132 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -159.61 129.63 5.55 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.891 0.377 . . . . 1.99 110.623 -178.33 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 326' ' ' ASN . . . . . . . . . . . . . 35.1 m-80 -120.56 116.62 25.74 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.606 -0.887 . . . . 1.92 108.606 172.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 327' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.76 -69.25 0.2 Allowed 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.096 -0.502 . . . . 1.69 111.76 -174.324 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 24.7 pttm -68.41 97.28 0.74 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.698 0.761 . . . . 2.55 111.836 -174.121 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.501 ' O ' ' HD3' ' A' ' 331' ' ' PRO . . . 86.71 -16.61 45.01 Favored Glycine 0 N--CA 1.446 -0.638 0 CA-C-N 115.269 -0.878 . . . . 0.97 113.591 175.375 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 330' ' ' LYS . . . . . . . . . . . . . 27.6 mmmt -104.83 100.02 21.73 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 117.228 0.514 . . . . 2.08 111.471 -175.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 331' ' ' PRO . . . . . 0.501 ' HD3' ' O ' ' A' ' 329' ' ' GLY . 72.1 Cg_endo -87.56 127.86 2.42 Favored 'Trans proline' 0 N--CA 1.455 -0.744 0 C-N-CA 122.883 2.389 . . . . 0.62 111.854 172.809 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 332' ' ' PHE . . . . . . . . . . . . . 70.6 t80 -102.56 120.55 40.74 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 110.135 -0.321 . . . . 0.64 110.135 179.458 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 333' ' ' VAL . . . . . . . . . . . . . 60.4 t -112.51 122.42 66.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.915 0.388 . . . . 0.38 110.413 -178.154 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 31.1 p90 -139.8 158.76 43.57 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.089 -0.505 . . . . 0.41 109.73 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 335' ' ' LYS . . . . . . . . . . . . . 16.9 ptmt -100.15 141.02 33.55 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.214 0.53 . . . . 2.58 111.217 179.128 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 336' ' ' LEU . . . . . . . . . . . . . 11.2 mp -77.34 123.49 26.58 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.769 -0.651 . . . . 0.58 109.695 173.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 337' ' ' GLY . . . . . . . . . . . . . . . 111.79 12.33 14.73 Favored Glycine 0 N--CA 1.446 -0.68 0 C-N-CA 120.683 -0.77 . . . . 0.94 111.931 -177.47 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 338' ' ' GLN . . . . . 0.729 HE21 HG13 ' A' ' 341' ' ' VAL . 13.2 pt20 -97.91 151.09 20.62 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.963 -0.384 . . . . 2.62 109.963 176.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 339' ' ' GLY . . . . . . . . . . . . . . . -89.28 15.21 58.92 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 121.029 -0.605 . . . . 0.74 111.815 -179.047 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 340' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -87.32 -15.15 38.83 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.077 0.465 . . . . 2.09 110.261 178.298 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 341' ' ' VAL . . . . . 0.729 HG13 HE21 ' A' ' 338' ' ' GLN . 32.6 m -107.24 164.28 4.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.838 -0.619 . . . . 0.43 110.575 -177.644 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 342' ' ' ILE . . . . . 0.491 ' HB ' ' HA ' ' A' ' 367' ' ' ALA . 10.0 pt -88.67 165.36 2.06 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 109.718 -0.475 . . . . 0.32 109.718 176.546 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . 0.413 ' HA ' ' CE ' ' A' ' 343' ' ' LYS . 0.0 OUTLIER -56.11 -37.3 69.22 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 111.908 0.336 . . . . 2.93 111.908 -174.644 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 344' ' ' GLY . . . . . 0.587 ' HA2' HD13 ' A' ' 290' ' ' ILE . . . -55.72 -30.84 57.19 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.938 -0.649 . . . . 0.3 113.126 177.506 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 345' ' ' TRP . . . . . 0.42 ' CD1' HG12 ' A' ' 342' ' ' ILE . 18.4 m95 -77.83 -61.23 2.06 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 112.506 0.558 . . . . 0.39 112.506 -176.886 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 346' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -64.23 -20.55 66.11 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.669 0.271 . . . . 1.75 111.41 -175.69 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 347' ' ' ILE . . . . . . . . . . . . . 71.5 mt -89.41 -55.73 5.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 116.471 -0.332 . . . . 0.39 111.685 174.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 348' ' ' GLY . . . . . . . . . . . . . . . -65.71 -38.55 94.61 Favored Glycine 0 CA--C 1.523 0.59 0 C-N-CA 121.297 -0.478 . . . . 0.34 114.135 -177.372 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 349' ' ' VAL . . . . . . . . . . . . . 83.9 t -75.22 -21.25 16.4 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 CA-C-O 120.953 0.406 . . . . 0.32 110.905 -178.612 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 350' ' ' ALA . . . . . . . . . . . . . . . -65.2 104.53 0.93 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.164 0.506 . . . . 0.47 110.953 -179.291 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 351' ' ' GLY . . . . . . . . . . . . . . . 113.84 0.58 24.31 Favored Glycine 0 N--CA 1.445 -0.712 0 C-N-CA 120.823 -0.704 . . . . 0.39 112.851 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 352' ' ' MET . . . . . . . . . . . . . 60.0 mtp -75.37 157.69 33.85 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 117.313 0.557 . . . . 1.28 110.307 174.69 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 353' ' ' ALA . . . . . 0.607 ' HA ' ' O ' ' A' ' 301' ' ' PRO . . . -123.09 144.58 49.22 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.221 -0.445 . . . . 0.55 111.543 -174.861 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 354' ' ' VAL . . . . . . . . . . . . . 73.4 t -58.2 123.15 9.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.962 -0.563 . . . . 0.36 110.357 175.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 104.23 -16.44 49.43 Favored Glycine 0 N--CA 1.446 -0.663 0 C-N-CA 120.831 -0.7 . . . . 0.44 111.528 -177.109 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 356' ' ' GLY . . . . . 0.538 ' HA3' ' HA3' ' A' ' 298' ' ' GLY . . . -87.35 154.29 26.06 Favored Glycine 0 N--CA 1.443 -0.851 0 C-N-CA 120.875 -0.678 . . . . 0.3 112.646 179.484 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 357' ' ' GLU . . . . . 0.642 ' HG3' ' HB3' ' A' ' 387' ' ' LYS . 41.2 tt0 -137.87 121.65 17.56 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.951 -0.759 . . . . 1.41 108.951 -177.833 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 358' ' ' ARG . . . . . 0.511 ' HD3' ' HB ' ' A' ' 292' ' ' ILE . 35.0 ttm180 -148.41 133.99 18.75 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.071 0.463 . . . . 1.37 110.933 -170.883 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 359' ' ' ARG . . . . . 0.408 HH11 ' HD2' ' A' ' 359' ' ' ARG . 31.8 ttp85 -86.02 122.78 30.54 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.717 -0.674 . . . . 2.79 110.459 -179.186 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 360' ' ' ILE . . . . . 0.493 HG12 HG22 ' A' ' 292' ' ' ILE . 56.8 mt -109.52 121.44 62.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.866 -0.606 . . . . 0.38 110.272 -179.646 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 361' ' ' VAL . . . . . 0.528 ' HB ' ' HB ' ' A' ' 291' ' ' ILE . 48.6 t -104.19 119.84 53.57 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 N-CA-C 109.256 -0.646 . . . . 0.39 109.256 177.699 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 362' ' ' ILE . . . . . 0.491 ' HA ' ' HD2' ' A' ' 363' ' ' PRO . 55.9 mt -118.23 100.95 51.7 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-N 116.322 -0.399 . . . . 0.29 111.535 -174.092 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 363' ' ' PRO . . . . . 0.526 ' HB2' ' HD2' ' A' ' 365' ' ' PRO . 12.3 Cg_endo -56.9 158.12 18.04 Favored 'Trans proline' 0 C--O 1.238 0.498 0 C-N-CA 122.99 2.46 . . . . 0.66 112.547 172.127 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 364' ' ' ALA . . . . . 0.489 ' CB ' ' HA ' ' A' ' 379' ' ' ASN . . . -50.18 -47.41 82.07 Favored Pre-proline 0 CA--C 1.539 0.52 0 N-CA-C 114.516 1.302 . . . . 0.42 114.516 -173.723 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 365' ' ' PRO . . . . . 0.526 ' HD2' ' HB2' ' A' ' 363' ' ' PRO . 82.6 Cg_exo -49.22 -36.55 37.25 Favored 'Trans proline' 0 C--N 1.361 1.231 0 C-N-CA 122.218 1.945 . . . . 0.7 113.632 -176.704 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 366' ' ' TYR . . . . . 0.422 ' CD1' HD11 ' A' ' 290' ' ' ILE . 3.6 m-85 -101.31 12.55 37.25 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.761 0.315 . . . . 0.69 111.643 -177.097 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 367' ' ' ALA . . . . . 0.491 ' HA ' ' HB ' ' A' ' 342' ' ' ILE . . . -119.31 -112.52 0.33 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.168 -0.469 . . . . 0.86 110.505 175.207 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 368' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -91.39 -1.88 57.47 Favored 'General case' 0 N--CA 1.464 0.228 0 N-CA-C 112.194 0.442 . . . . 1.0 112.194 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 369' ' ' GLY . . . . . . . . . . . . . . . 66.43 -114.97 6.93 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 121.103 -0.57 . . . . 0.56 113.65 175.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 370' ' ' LYS . . . . . 0.428 ' HE2' ' HB3' ' A' ' 370' ' ' LYS . 14.8 ptpt -112.81 20.31 16.58 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.856 0.36 . . . . 2.76 111.502 -174.497 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 371' ' ' GLN . . . . . . . . . . . . . 27.9 mm-40 -90.14 113.45 25.21 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.29 -0.414 . . . . 2.65 110.088 176.596 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 372' ' ' ALA . . . . . 0.447 ' HA ' ' HA ' ' A' ' 377' ' ' PRO . . . -83.51 96.18 8.52 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.175 0.512 . . . . 1.01 111.17 178.827 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 373' ' ' LEU . . . . . 0.5 ' HB3' ' HD2' ' A' ' 374' ' ' PRO . 59.1 mt -80.37 166.67 38.38 Favored Pre-proline 0 C--N 1.32 -0.698 0 CA-C-N 115.562 -0.744 . . . . 0.93 109.487 178.728 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 374' ' ' PRO . . . . . 0.5 ' HD2' ' HB3' ' A' ' 373' ' ' LEU . 22.9 Cg_endo -64.33 113.36 2.22 Favored 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 121.514 1.476 . . . . 1.31 110.818 172.438 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 375' ' ' GLY . . . . . . . . . . . . . . . 90.65 -24.53 16.96 Favored Glycine 0 CA--C 1.519 0.312 0 C-N-CA 120.739 -0.743 . . . . 0.9 112.757 -179.003 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 376' ' ' ILE . . . . . . . . . . . . . 39.8 mt -125.56 83.04 62.47 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.683 0.278 . . . . 0.74 110.304 -178.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 377' ' ' PRO . . . . . 0.447 ' HA ' ' HA ' ' A' ' 372' ' ' ALA . 9.2 Cg_exo -72.59 166.5 29.7 Favored 'Trans proline' 0 N--CA 1.464 -0.253 0 C-N-CA 123.17 2.58 . . . . 0.71 113.247 -178.124 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 378' ' ' ALA . . . . . . . . . . . . . . . -55.02 147.55 15.47 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-N 115.557 -0.747 . . . . 0.74 111.43 178.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 379' ' ' ASN . . . . . 0.489 ' HA ' ' CB ' ' A' ' 364' ' ' ALA . 44.4 m-80 65.54 30.65 10.54 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 115.676 -0.693 . . . . 1.49 111.3 -179.144 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 380' ' ' SER . . . . . 0.424 ' HB2' ' O ' ' A' ' 377' ' ' PRO . 22.2 t -85.41 134.54 34.07 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 116.08 -0.509 . . . . 1.84 109.78 175.769 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 381' ' ' GLU . . . . . 0.566 ' HB3' ' HB2' ' A' ' 318' ' ' LYS . 30.7 tt0 -99.43 105.16 17.07 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.305 -0.628 . . . . 1.03 109.305 179.066 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 382' ' ' LEU . . . . . . . . . . . . . 74.2 mt -84.72 142.09 30.1 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.397 -0.365 . . . . 0.37 110.796 -177.65 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 383' ' ' THR . . . . . 0.471 HG23 HG22 ' A' ' 361' ' ' VAL . 25.7 m -122.39 122.77 39.79 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 109.726 -0.472 . . . . 0.27 109.726 177.794 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 384' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -117.44 109.59 16.96 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.928 0.394 . . . . 0.32 110.32 -178.181 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 385' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -88.81 104.4 16.88 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.154 -1.054 . . . . 1.8 108.154 174.254 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 386' ' ' VAL . . . . . 0.601 HG12 ' HB3' ' A' ' 313' ' ' TYR . 20.0 m -125.25 151.37 30.99 Favored 'Isoleucine or valine' 0 C--O 1.232 0.141 0 CA-C-O 121.358 0.599 . . . . 0.31 112.287 -169.131 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 387' ' ' LYS . . . . . 0.642 ' HB3' ' HG3' ' A' ' 357' ' ' GLU . 14.6 ptmm? -139.54 142.21 37.21 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.774 -0.648 . . . . 2.53 109.814 172.534 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 388' ' ' LEU . . . . . 0.914 HD11 ' HB ' ' A' ' 309' ' ' VAL . 19.3 tp -93.14 135.43 34.33 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.691 -0.485 . . . . 0.28 109.691 -176.471 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 34.7 m -127.53 -6.51 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 N-CA-C 112.268 0.47 . . . . 0.45 112.268 -176.442 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 44.1 t -160.57 160.35 31.71 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.528 0.204 . . . . 1.32 110.942 -177.784 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 391' ' ' MET . . . . . 0.427 ' HA ' ' HA ' ' A' ' 309' ' ' VAL . 30.9 ttm -165.61 134.1 3.16 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.998 -0.546 . . . . 0.56 110.18 179.684 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 392' ' ' LYS . . . . . . . . . . . . . 63.7 mttp . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.513 -0.756 . . . . 4.91 109.716 175.758 . . . . . . . . 0 0 . 1 stop_ save_